%PDF-1.3
%
51 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
13 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
32 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
56 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
28 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
33 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
36 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
49 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
53 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
57 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
93 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
3 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
103 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
27 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
84 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
68 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
89 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
42 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
25 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
71 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
76 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
10 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
5 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
60 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
66 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
80 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
17 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
87 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
31 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
58 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
96 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
79 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
54 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
9 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
44 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
11 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
52 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
83 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
22 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
102 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
30 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
18 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
61 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
35 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
100 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
94 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
21 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
47 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
59 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
16 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
97 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
23 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
19 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
40 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
105 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
15 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
62 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
20 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
95 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
101 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
90 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
77 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
45 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
46 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
67 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
92 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
14 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
88 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
50 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
64 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
72 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
98 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
81 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
78 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
85 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
38 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
106 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
48 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
4 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
65 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
69 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
41 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
39 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
63 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
86 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
104 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
7 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
26 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
74 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
12 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
37 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
70 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
75 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
8 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
73 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
99 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
1 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
55 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
82 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
43 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
24 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
91 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
34 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
29 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
6 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
108 0 obj
<>stream
Atypon Systems, Inc.; modified using iText 4.2.0 by 1T3XT
Arbortext Advanced Print Publisher 9.0.114/W
2016-05-01T10:45:53-07:00
2016-04-06T17:38:26+05:30
application/pdf
JWH-2016-29006-abstracts-ver9-Abstracts_3P 1..35
uuid:2d31f448-e410-437d-8149-ce26fb84f477
uuid:89c2f213-63ff-43f6-8593-ad5fd125cd97
endstream
endobj
109 0 obj
<>stream
x+ |
endstream
endobj
110 0 obj
<>stream
xS**T0T0 BifU !D. ss
endstream
endobj
111 0 obj
<>stream
x+ |
endstream
endobj
112 0 obj
<>stream
xS**T0T0 Bih]D. r^j
endstream
endobj
113 0 obj
<>stream
x+ |
endstream
endobj
114 0 obj
<>stream
xS**T0T0 Bia]%D. u]
endstream
endobj
115 0 obj
<>stream
x+ |
endstream
endobj
116 0 obj
<>stream
xS**T0T0 Bid]%D. rs
endstream
endobj
117 0 obj
<>stream
x+ |
endstream
endobj
118 0 obj
<>stream
xS**T0T0 Bib] D. qjj
endstream
endobj
119 0 obj
<>stream
x+ |
endstream
endobj
120 0 obj
<>stream
xS**T0T0 Bij]D. rs
endstream
endobj
121 0 obj
<>stream
x+ |
endstream
endobj
122 0 obj
<>stream
xS**T0T0 Bil]D. pa
endstream
endobj
123 0 obj
<>stream
x+ |
endstream
endobj
124 0 obj
<>stream
xS**T0T0 Bii]D. u`
endstream
endobj
125 0 obj
<>stream
x+ |
endstream
endobj
126 0 obj
<>stream
xS**T0T0 BiiU !D2
endstream
endobj
127 0 obj
<>stream
x+ |
endstream
endobj
128 0 obj
<>stream
xS**T0T0 BiUD* 8
endstream
endobj
129 0 obj
<>stream
x+ |
endstream
endobj
130 0 obj
<>stream
xS**T0T0 Bid]D. qdj
endstream
endobj
131 0 obj
<>stream
x+ |
endstream
endobj
132 0 obj
<>stream
xS**T0T0 Bij]%D. t|
endstream
endobj
133 0 obj
<>stream
x+ |
endstream
endobj
134 0 obj
<>stream
xS**T0T0 Bia]D. t|
endstream
endobj
135 0 obj
<>stream
x+ |
endstream
endobj
136 0 obj
<>stream
xS**T0T0 Bin]9D. t
|
endstream
endobj
137 0 obj
<>stream
x+ |
endstream
endobj
138 0 obj
<>stream
xS**T0T0 Bia]1D. rs
endstream
endobj
139 0 obj
<>stream
x+ |
endstream
endobj
140 0 obj
<>stream
xS**T0T0 Bif]D. t
|
endstream
endobj
141 0 obj
<>stream
x+ |
endstream
endobj
142 0 obj
<>stream
xS**T0T0 Bin]D. u
|
endstream
endobj
143 0 obj
<>stream
x+ |
endstream
endobj
144 0 obj
<>stream
xS**T0T0 Bii])D. t|
endstream
endobj
145 0 obj
<>stream
x+ |
endstream
endobj
146 0 obj
<>stream
xS**T0T0 Bih]9D. qaj
endstream
endobj
147 0 obj
<>stream
x+ |
endstream
endobj
148 0 obj
<>stream
xS**T0T0 Bib]9D. rs
endstream
endobj
149 0 obj
<>stream
x+ |
endstream
endobj
150 0 obj
<>stream
xS**T0T0 BiU !D. _e1
endstream
endobj
151 0 obj
<>stream
x+ |
endstream
endobj
152 0 obj
<>stream
xS**T0T0 Bil])D. qgj
endstream
endobj
153 0 obj
<>stream
x+ |
endstream
endobj
154 0 obj
<>stream
xS**T0T0 BiUD* :
endstream
endobj
155 0 obj
<>stream
x+ |
endstream
endobj
156 0 obj
<>stream
xS**T0T0 Bij]1D. qmj
endstream
endobj
157 0 obj
<>stream
x+ |
endstream
endobj
158 0 obj
<>stream
xS**T0T0 Bif])D. rs
endstream
endobj
159 0 obj
<>stream
x+ |
endstream
endobj
160 0 obj
<>stream
xS**T0T0 Bin] D. rs
endstream
endobj
161 0 obj
<>stream
x+ |
endstream
endobj
162 0 obj
<>stream
xS**T0T0 Bih`C D2
endstream
endobj
163 0 obj
<>stream
x+ |
endstream
endobj
164 0 obj
<>stream
xS**T0T0 BilU !D. rej
endstream
endobj
165 0 obj
<>stream
x+ |
endstream
endobj
166 0 obj
<>stream
xS**T0T0 Bil]D. rs
endstream
endobj
167 0 obj
<>stream
x+ |
endstream
endobj
168 0 obj
<>stream
xS**T0T0 Bif]D. qpj
endstream
endobj
169 0 obj
<>stream
x+ |
endstream
endobj
170 0 obj
<>stream
xS**T0T0 Bii]D. rs
endstream
endobj
171 0 obj
<>stream
x+ |
endstream
endobj
172 0 obj
<>stream
xS**T0T0 BiU)D* 9V
endstream
endobj
173 0 obj
<>stream
x+ |
endstream
endobj
174 0 obj
<>stream
xS**T0T0 Bih] D. pa
endstream
endobj
175 0 obj
<>stream
x+ |
endstream
endobj
176 0 obj
<>stream
xS**T0T0 Bib]D. ss
endstream
endobj
177 0 obj
<>stream
x+ |
endstream
endobj
178 0 obj
<>stream
xS**T0T0 Bid]1D. pa
endstream
endobj
180 0 obj
<>stream
/GS1 gs
BT
/F3 1 Tf
9.2982 0 0 9.2982 62.022 638.5888 Tm
0 0 0 rg
0 Tc
0 Tw
(01.)Tj
9.843 0 0 9.843 82.9417 638.5888 Tm
[(Prevalence)-288.7(and)-279.4(Risk)-281.5(Factor)-280.8(Prole)-286.6(for)-280.9(Human)]TJ
0 -1.1116 TD
[(Papillomavirus)-283.8(Infection)-282.5(Among)-283.8(Uyghur)-284.8(Women)]TJ
T*
[(in)-278.6(Xinjiang)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 62.022 600.151 Tm
[(Guzalnur)-334.8(Abliz,)-333.8(Fatima)-338.9(Mijit,)-332.3(Tangnur)-331.4(Ablimit,)-334.1(Hua)-334.9(Li,)]TJ
0 -1.128 TD
[(Ling)-336.6(Lu,)-331(Avagul)-334.3(Yuksal,)-333.5(Tunsahan)-332.4(Abdurehym)]TJ
/F5 1 Tf
0 -1.7682 TD
[(5th)-334.8(Department)-332.5(of)-334.8(Gynecology,)-334.7(Afliated)-339.2(Tumor)-332.7(Hospital)-334.3(of)]TJ
0 -1.1219 TD
[(Xinjiang)-335.5(Medical)-332.8(University,)-340(Urumqi,)-330.7(China)]TJ
/F3 1 Tf
.9999 -2.3047 TD
(Background:)Tj
/F4 1 Tf
5.9448 0 TD
[(In)-343.8(China,)-343.7(the)-345.1(prevalence)-345.9(of)-343.8(cervical)-347.3(cancer)-342.3(is)]TJ
-6.9447 -1.128 TD
[(very)-213.8(high)-212.8(among)-210.9(the)-217(Uyghurs,)-210.1(an)-217.6(ethnic)-214.6(minority)-213.5(in)-212.8(the)-210.9(Xinjiang)]TJ
0 -1.1219 TD
[(region.)-371.8(When)-368(cervical)-371.7(cancer)-366.6(is)-370.5(diagnosed)-366.6(in)-371.4(Uyghur)-363.5(women,)]TJ
0 -1.128 TD
[(about)-326.7(8090%)-325.3(of)-325.5(cases)-327.9(are)-327.8(at)-326.8(advanced)-327.6(stages,)-323.1(beyond)-327.2(the)-326.8(op-)]TJ
0 -1.1219 TD
[(portunity)-287.2(for)-291.2(operation.)-284(Thus,)-287.5(in)-292.1(the)-284.1(present)-289.8(study,)-291.2(we)-286.1(explored)]TJ
0 -1.128 TD
[(factors)-450.7(that)-442.1(may)-448.7(contribute)-448.1(to)-444.5(the)-448.7(high)-444.5(incidence)-448.6(of)-447.4(cervical)]TJ
0 -1.1219 TD
[(cancer)-421.5(in)-414.1(Uyghur)-418.3(women)-413.6(to)-414.1(provide)-420.5(a)-412.7(theoretical)-425.5(basis)-416.5(for)-413.2(a)]TJ
0 -1.128 TD
[(future)-532.7(project)-534(regarding)-536.8(comprehensive)-529.2(cervical)-536.3(cancer)-537.4(pre-)]TJ
0 -1.1219 TD
[(vention)-301.8(and)-296.8(control)-304.2(in)-298.2(Xinjiang.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.9387 0 TD
[(To)-434.7(investigate)-430.2(the)-436.5(current)-433.2(status)-428.2(of)-435.2(HPV)-432.6(in-)]TJ
-6.9386 -1.1219 TD
[(fection)-296.2(and)-296.8(its)-296.8(risk)-293.6(factors)-298.2(within)-298.6(rural)-294.9(Uyghur)-296.4(women)-291.6(in)-298.2(order)]TJ
0 -1.128 TD
[(to)-298.2(provide)-304.7(guidance)-298.5(for)-303.4(cervical)-298.5(cancer)-305.7(prevention)-302.2(in)-298.2(Xinjiang.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Material/Methods:)Tj
/F4 1 Tf
8.4812 0 TD
[(A)-403.9(s)0(u)19.2(r)0(v)22.1(e)0(y)-394.4(o)12.2(f)-404.8(H)0(P)20.1(V)-403.9(in)18.8(fe)17.9(ct)20.7(i)12.7(o)0(n)-396.3(f)0(a)17.9(c)14.1(to)18.8(rs)-391.7(wa)18.7(s)]TJ
-9.4811 -1.128 TD
[(co)20.2(nd)18.3(u)12.2(c)0(t)20.7(e)0(d)-248.1(o)0(n)-249.9(6)12.2(0)12.2(0)0(0)-249.9(s)13.1(ex)20.2(ua)20.2(ll)19.3(y)-256.1(a)0(c)16(t)12.7(iv)18.9(e)-260.3(U)0(y)22.9(g)0(h)18.3(u)12.2(r)-258.4(w)0(o)22.9(m)0(e)14.7(n)-256.1(a)14.1(g)0(e)14.1(d)-256.1(2)12.2(1)-256.1(t)12.7(o)-256.1(60)]TJ
0 -1.1219 TD
[(y)12.2(e)0(a)16(r)0(s)-190.5(i)12.7(n)-201.2(K)0(a)18.7(r)0(a)17.8(k)12.2(ax)-187.1(Co)19.7(un)18.3(ty)-188.5(o)12.2(f)-203.6(t)12.7(h)12.2(e)-205.4(H)0(o)22.9(t)0(a)20.7(n)-201.2(re)17.8(g)12.2(i)0(o)18.8(n)-195.1(be)14.1(t)12.7(w)0(e)18.7(e)0(n)-187.1(J)0(u)19.2(n)0(e)-193.2(1)12.2(5)-201.2(a)14.1(nd)]TJ
0 -1.128 TD
[(No)16.8(v)12.2(e)0(m)20.8(b)0(e)20.2(r)-343.8(15)18.3(,)-341.4(2)0(0)18.3(1)12.2(3.)-335.3(Th)22.6(e)-345.6(p)0(a)20.2(r)0(t)16.5(i)12.7(ci)14.6(p)12.2(a)0(n)20.2(t)0(s)-333.9(w)0(e)18.7(r)0(e)-335.8(a)0(l)20.7(s)0(o)-334.4(t)12.7(es)15(t)12.7(e)0(d)-333.4(f)0(o)16(r)-343.8(HP)20.1(V)]TJ
0 -1.1219 TD
[(in)18.8(fe)17.8(c)14.1(t)0(i)19.3(o)0(n)18.3(.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Results:)Tj
/F4 1 Tf
3.7437 0 TD
[(Th)16.5(e)-296.9(o)12.2(v)12.2(e)0(r)17.8(a)0(l)14.6(l)-292.1(HP)14(V)-294.1(i)0(n)18.8(f)0(e)17.8(c)0(t)20.7(i)0(o)18.8(n)-298.7(ra)23.9(te)-290.2(wa)18.7(s)-297.9(8)0(.)18.3(4)12.2(2%)16(.)-292.7(H)0(P)20.1(V)-300.2(in)18.8(-)]TJ
-4.7436 -1.1219 TD
[(fe)17.8(ct)20.7(io)18.8(n)-286.5(r)0(a)17.8(t)12.7(e)-284.7(w)0(a)18.7(s)-291.8(h)12.2(i)12.7(gh)18.3(er)-274.8(in)-279.9(wo)22.9(me)20.7(n)-286.5(w)0(h)16.8(o)-286.5(we)18.7(re)-274.8(o)12.2(l)0(d)18.8(e)0(r)-280.9(t)12.7(h)12.2(a)0(n)-278.5(4)12.2(5)-286.5(y)0(e)20.2(a)0(r)17.8(s)0(.)]TJ
0 -1.128 TD
[(Th)16.5(e)-205.4(l)0(o)18.8(g)12.2(is)19.7(ti)19.3(c)-211.5(r)0(e)17.8(g)12.2(re)17.8(s)13.1(s)0(i)19.7(o)0(n)-201.2(m)12.8(od)18.3(el)-198.8(s)13.1(h)0(o)18.3(w)0(e)18.7(d)-207.3(th)18.8(at)-198.8(wo)16.8(m)12.8(e)0(n)-199.3(w)0(h)16.8(o)-207.3(h)12.2(a)0(d)-199.3(a)-211.5(l)12.7(o)12.2(ng)]TJ
T*
[(in)18.8(t)12.7(e)0(r)17.8(v)0(a)20.2(l)-560.4(b)12.2(e)0(t)14.6(w)0(e)18.7(e)14.1(n)-560.9(s)13.1(ho)18.3(we)18.7(rs)-550.2(\(O)20.6(R)]TJ
/F2 1 Tf
12.859 0 TD
(=)Tj
/F4 1 Tf
.5427 0 TD
[(4)12.2(.)12.2(3)0(5)18.3(8)12.2(\),)-551.1(wi)17.3(t)12.7(h)-560.9(e)14.1(d)0(u)18.3(c)0(a)16(t)12.7(io)18.8(n)-560.9(l)12.7(ev)20.2(el)20.7(s)]TJ
-13.4016 -1.1219 TD
[(o)12.2(f)-471.8(j)12.7(u)12.2(ni)18.8(or)-459.6(co)20.2(l)12.7(l)0(e)14.6(g)12.2(e)-467.6(a)0(n)20.2(d)-469.5(ab)20.2(o)12.2(v)0(e)-461.5(\()0(O)20.6(R)]TJ
/F2 1 Tf
13.8162 0 TD
(=)Tj
/F4 1 Tf
.5427 0 TD
[(3.)18.3(3)12.2(6)0(9)18.3(\))0(;)-459.1(p)12.2(ar)17.8(t)12.7(i)0(c)14.6(i)12.7(p)12.2(a)0(t)14.6(i)12.7(ng)-457.2(in)-456.7(fr)19.7(e-)]TJ
-14.3589 -1.128 TD
[(q)12.2(u)0(e)14.1(n)12.2(t)-401.9(i)12.7(nt)18.8(er)17.8(co)20.2(u)12.2(r)0(s)16.8(e)-400.5(\(O)20.6(R)]TJ
/F2 1 Tf
9.036 0 TD
(=)Tj
/F4 1 Tf
.5427 0 TD
[(2)12.2(.)12.2(2)0(2)18.3(2)12.2(\),)-392.6(u)12.2(s)0(e)-393.5(o)12.2(f)-404.8(o)12.2(ra)17.8(l)-401.9(c)0(o)20.2(n)12.2(tr)16.5(a)14.1(c)0(e)16(p)12.2(ti)19.3(ve)20.2(s)-401.5(\()0(O)14.5(R)]TJ
/F2 1 Tf
15.7978 0 TD
(=)Tj
/F4 1 Tf
-25.3765 -1.1219 TD
.011 Tc
[(2.0)11(7)-7.2(1)-1.2(\),)-299.9(cleaned)-299.9(their)-296.2(v)-1.2(agin)11(a)-11.5(s)-299.1(\(OR)]TJ
/F2 1 Tf
14.0357 0 TD
0 Tc
(=)Tj
/F4 1 Tf
.5609 0 TD
[(1)-12.2(.)0(6)-18.2(0)-12.2(8)-12.2(\))-8.4(,)-310.9(u)-12.2(se)-320.4(of)-319.4(i)-11.7(n)-12.2(tr)-20.1(a)-10.3(-)-8.4(u)-12.2(t)-11.7(e)-10.3(r)-14.5(in)-17.7(e)]TJ
-14.5967 -1.128 TD
.011 Tc
[(devices)-585.6(\(OR)]TJ
/F2 1 Tf
5.4204 0 TD
0 Tc
(=)Tj
/F4 1 Tf
.567 0 TD
.0123 Tc
[(1)12.3(.)-6(467)12.3(\))-8.3(,)-585.2(wh)12.3(o)-5.9(s)1(e)-589.4(h)12.3(u)-5.9(s)1(band)12.3(s)-596.5(w)4.7(ere)-589.4(s)1(m)12.3(o)-5.4(kers)-584.3(\(OR)]TJ
/F2 1 Tf
19.4013 0 TD
0 Tc
(=)Tj
/F4 1 Tf
-25.3887 -1.1219 TD
.0119 Tc
[(1.3)11.9(7)-6.3(7)-.3(\))-295.3(w)-1.8(ere)-297.2(a)1.6(t)-298.5(h)-.3(igh)11.9(e)-4.5(r)-301.4(r)3.5(isk)-299(o)-.3(f)-301.4(H)4.3(PV)-300.5(infect)11.9(i)-5.3(on.)]TJ
/F3 1 Tf
.9999 -1.128 TD
0 Tc
(Conclusions:)Tj
/F4 1 Tf
5.8106 0 TD
[(Our)-326.9(ndings)-318.4(suggested)-329.2(that)-320.2(women)-328.2(older)-323(than)]TJ
-6.8106 -1.1219 TD
[(45)-359.7(should)-364.3(be)-357.8(screened)-365.7(and)-363.9(monitored)-358.5(closely.)-366.1(Meanwhile,)-365.7(ed-)]TJ
0 -1.128 TD
[(ucation)-446.3(include)-452.4(improving)-445.7(womens)-445.5(bad)-449.2(health)-446.3(habits,)-453.4(advo-)]TJ
0 -1.1219 TD
[(cating)-239(for)-242.5(condom)-235.2(use,)-241.1(persuading)-240.9(their)-243.3(spouses)-239.3(to)-237.2(quit)-236.7(smoking)]TJ
0 -1.128 TD
[(should)-297.3(be)-302.9(emphasized.)]TJ
/F3 1 Tf
0 -4.5485 TD
(02.)Tj
9.843 0 0 9.843 82.9417 185.2157 Tm
[(The)-281.8(Importance)-285.7(of)-278.6(Adding)-283.6(Vitamin)-280.4(D)-284.2(Status)]TJ
0 -1.1116 TD
[(\(25OHD\))-281.7(to)-278.6(the)-286.5(Allostatic)-283.9(Load)-281.7(Index)-276.9(in)]TJ
0 -1.1174 TD
[(Reproductive)-283.3(Aged)-282.7(Women)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 62.022 146.7212 Tm
[(Eynav)-335.2(Accortt)]TJ
/F5 1 Tf
0 -1.7682 TD
[(Cedars-Sinai)-337.6(Medical)-332.8(Center,)-334.8(Los)-331.2(Angeles,)-338(California)]TJ
/F3 1 Tf
.9999 -2.3047 TD
(Background:)Tj
/F4 1 Tf
5.9448 0 TD
[(Allostatic)-347.8(load)-345.1(\(AL\))-343.3(is)-340(an)-345.6(index)-345(of)-343.8(multi-sys-)]TJ
-6.9447 -1.1219 TD
[(tem)-375(physiological)-371.1()52.5(wear-and-tear,)49.4()-374.3(operationalizing)-370(emergent)]TJ
0 -1.128 TD
[(chronic)-266.2(disease)-266.4(risk)-269.2(and)-266.3(predicting)-265.1(morbidity)-262.3(and)-266.3(mortality.)-266(AL)]TJ
0 -1.1219 TD
[(has)-466.7(been)-471.7(proposed)-468.9(as)-466.7(an)-467.6(organizing)-472.9(framework)-467.5(for)-468.1(studying)]TJ
0 -1.128 TD
[(pregnancy)-289.2(outcomes;)-292.4(however,)-292.6(little)-294.2(data)-288.3(exists.)-287.9(A)-294.1(recent)-288.8(study)]TJ
0 -1.1219 TD
[(showed)-584(that)-582.3(pregnancy)-581.8(complications)-588.2(were)-585.4(associated)-587.1(with)]TJ
26.9984 62.5938 TD
[(higher)-310.8(AL)-314.3(in)-310.4(2,448)-304.7(mothers.)-309.4(Additional)-314.4(AL)-308.2(biomarkers)-309.8(for)-309.5(the)]TJ
0 -1.1219 TD
[(study)-303.4(of)-301.1(pregnancy)-301.4(would)-299.6(be)-296.8(valuable.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.8167 0 TD
[(We)-307.1(hypothesized)-309.3(that)-308(including)-307.3(vitamin)-313(D)-306.3(de-)]TJ
-6.8167 -1.1219 TD
[(ciency)-429.5(\(serum)-434.2(25\(OH\))-428.3(D)]TJ
/F2 1 Tf
11.231 0 TD
(<)Tj
/F4 1 Tf
.7195 0 TD
[(20)-164.6(ng/ml\))-427.5(in)-426.2(an)-431(AL)-424(index)-430.4(would)]TJ
-11.9505 -1.128 TD
[(better)-302.3(predict)-302.3(adverse)-306.7(pregnancy)-301.4(outcomes.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Material/Methods:)Tj
/F4 1 Tf
8.4507 0 TD
[(The)-377.9(Community)-380.5(Child)-375.5(Health)-380.7(Network)]TJ
-9.4506 -1.128 TD
[(\(CCHN\))-376.8(is)-370.5(a)-370(community-based)-371.5(participatory)-374.8(research)-374.2(network)]TJ
0 -1.1219 TD
[(\(5)-465.7(sites\))-467.1(that)-460.4(enrolled)-466.9(a)-467.6(large)-461.4(cohort)-463.2(of)-465.7(women)-462.4(at)-467.1(birth)-464.6(and)]TJ
0 -1.128 TD
[(followed)-409.3(them)-405.5(for)-401(two)-409.4(years)-406.2(with)-402.8(interviews,)-406(ultrasound,)-406.9(and)]TJ
0 -1.1219 TD
[(biomarkers)-364.7(\(10)-362(AL)-356.9(components\).)-362.3(A)-361.2(composite)-359.5(of)-362.1(ve)-360.7(adverse)]TJ
0 -1.128 TD
[(pregnancy)-679.4(outcomes,)-683.1(abstracted)-681.7(from)-674.8(patient)-683.6(charts)-680(\(birth)]TJ
0 -1.1219 TD
[(weight,)-303.3(preterm)-304.6(birth,)-300(preeclampsia,)-307.4(gestational)-302.2(diabetes)-303.3(or)-301.1(hy-)]TJ
0 -1.128 TD
[(pertension\),)-261(was)-260.9(created.)-262.5(Vitamin)-259.6(D)-257.6(status)-263.6(was)-260.9(measured)-257.3(2439)]TJ
0 -1.1219 TD
[(weeks)-472.4(postpartum)-467.4(in)-468.9(a)-467.6(sample)-469.8(of)-471.8(123)-469.4(women)-468.5(from)-467.5(the)-467(Los)]TJ
0 -1.128 TD
[(Angeles)-307.2(site.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Results:)Tj
/F4 1 Tf
3.8107 0 TD
[(28%)-374.2(\(34\))-376.6(experienced)-376.3(one)-376.1(or)-374.2(more)-377.9(of)-374.3(the)-375.6(ve)-372.8(ad-)]TJ
-4.8107 -1.128 TD
[(verse)-491.5(outcomes.)-488(Vitamin)-491.3(D)-489.3(status)-489.1(was)-486.5(signicantly,)-489.8(but)-487.2(not)]TJ
0 -1.1219 TD
[(strongly,)-372.2(inversely)-368.5(correlated)-367.9(with)-372.3(6)-365.8(o)0(f)-368.2(the)-363.4(10)-371.9(AL)-369.1(biomarkers)]TJ
0 -1.128 TD
[(\(Spearmans)-344.2(r)]TJ
/F2 1 Tf
5.9021 0 TD
.3321 Tc
(=-)Tj
/F4 1 Tf
1.6036 0 TD
0 Tc
[(0.16)-335.3(to)]TJ
/F2 1 Tf
3.3657 0 TD
(-)Tj
/F4 1 Tf
.7195 0 TD
[(0.33,)-335.2(p)]TJ
/F2 1 Tf
2.9998 0 TD
(<)Tj
/F4 1 Tf
.7195 0 TD
[(0.05\).)-337.6(Logistic)-332.8(regression)]TJ
-15.31 -1.1219 TD
[(results,)-296.4(controlling)-297(for)-297.3(maternal)-293.8(age)-294.9(and)-296.8(race,)-295.4(showed)-297.4(that)-295.8(high)]TJ
0 -1.128 TD
[(AL)-363(signicantly)-361.8(predicted)-361.4(the)-357.3(composite)-365.6(outcome.)-354.8(Adding)-360.6(vi-)]TJ
0 -1.1219 TD
[(tamin)-368.4(D)-361.2(status)-367.2(as)-363.1(an)-363.9(11th)-359.1(component)-366.9(improved)-359(the)-363.4(prediction)]TJ
0 -1.128 TD
[(based)-208.7(on)-201.1(t)-203.5(statistics)-210.4(\(Delta)-206.3(\(-2LogL\))]TJ
/F2 1 Tf
14.993 0 TD
(=)Tj
/F4 1 Tf
.7195 0 TD
[(4.251,)-207.2(p)]TJ
/F2 1 Tf
3.3717 0 TD
(=)Tj
/F4 1 Tf
.7195 0 TD
[(0.034\),)-203.4(and)-205.3(the)]TJ
-19.8037 -1.1219 TD
[(Akaike)-606.8(Information)-601(Criterion)-603.4(was)-602.3(smaller)-605.8(\(improved\))-601.5(with)]TJ
0 -1.128 TD
[(25\(OH\))-306.4(D)-300.2(a)0(s)-296(a)0(n)-302.9(added)-301(predictor.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Conclusions:)Tj
/F4 1 Tf
5.7618 0 TD
[(Results)-268.3(suggest)-270.1(that)-271.4(including)-264.7(25\(OH\))-269.8(D)-269.7(i)0(n)-273.8(the)]TJ
-6.7618 -1.1219 TD
[(AL)-326.4(score)-326.9(is)-327.8(a)-327.3(valuable)-322.4(addition)-325.7(identifying)-327.5(postpartum)-327.1(women)]TJ
0 -1.128 TD
[(who)-458.7(might)-461.7(develop)-459(adverse)-459.1(pregnancy)-459.9(outcomes)-457.6(in)-456.7(the)-454.8(next)]TJ
0 -1.1219 TD
[(pregnancy.)-234.3(Future)-228.3(work)-229.4(focuses)-234.5(on)-231.6(whether)-231.1(adding)-229.2(25\(OH\))-227.1(D)-233.2(t)0(o)]TJ
0 -1.128 TD
[(AL)-381.3(improves)-376.4(prediction)-381(of)-374.2(early)-376(risk)-379(for)-376.6(other)-377.9(specic)-379.8(condi-)]TJ
0 -1.1219 TD
[(tions)-302.9(such)-302(as)-302.1(maternal)-299.9(cardiovascular)-304.1(disease.)]TJ
/F3 1 Tf
0 -3.8168 TD
(03.)Tj
9.843 0 0 9.843 333.9779 289.3038 Tm
[(Male)-284.4(Partners)-284.9(Involvement)-285.8(in)-278.6(Pregnancy)-285(Related)]TJ
0 -1.1116 TD
[(Care)-284.1(Among)-283.8(Married)-284.1(Men)-283(in)-278.6(Ibadan,)-280.1(Nigeria)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 313.0582 261.8078 Tm
[(Ayodeji)-339.9(Adebayo)]TJ
6.9735 0 0 6.198 379.7857 265.9464 Tm
(1)Tj
9.2982 0 0 9.2982 383.3007 261.8078 Tm
[(,)-329.2(Olayinka)-338(Falade-Fatila)]TJ
6.9735 0 0 6.198 475.2565 265.9464 Tm
(2)Tj
/F5 1 Tf
-23.2592 -2.6526 TD
(1)Tj
9.2982 0 0 9.2982 316.5731 245.3669 Tm
[(University)-340(of)-328.7(Ibadan,)-331.5(Ibadan,)-337.6(Nigeria)]TJ
6.9735 0 0 6.198 313.0582 239.0173 Tm
(2)Tj
9.2982 0 0 9.2982 316.5731 234.8787 Tm
[(University)-340(College)-335.1(Hospital,)-328.2(Ibadan,)-337.6(Nigeria)]TJ
/F3 1 Tf
.6219 -2.2986 TD
(Background:)Tj
/F4 1 Tf
5.8838 0 TD
[(Maternal)-281.2(death)-276.1(remains)-277(a)-278.6(public)-277.4(health)-281.7(burden)]TJ
-6.8837 -1.128 TD
[(in)-255.5(the)-247.5(developing)-251.1(countries)-252.6(including)-252.5(Nigeria.)-255(The)-249.9(major)-249.3(causes)]TJ
T*
[(are)-419.3(pregnancy)-417.2(related)-422.4(and)-412.7(lack)-416.4(of)-416.9(male)-421.9(involvement)-414.6(in)-414.1(preg-)]TJ
0 -1.1219 TD
[(nancy)-343.7(related)-343.1(care)-344.2(\(PRC\))-346.2(is)-340(one)-339.5(of)-343.8(the)-339(contributory)-342.5(factors.)-340.9(In)]TJ
0 -1.128 TD
[(Nigeria,)-553.8(most)-552.9(studies)-556.2(on)-548.7(male)-550(involvement)-554.9(are)-553.4(focused)-552.4(on)]TJ
0 -1.1219 TD
[(family)-303.7(planning)-301.8(services.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Objective\(s\):)Tj
/F4 1 Tf
6.1582 0 TD
[(This)-652.8(study)-644.8(was)-651.1(carried)-650.8(out)-651.8(to)-645.8(assess)-651.2(the)]TJ
-7.1581 -1.1219 TD
[(knowledge)-271.4(and)-266.3(involvement)-274.4(of)-264.5(male)-269.5(partners)-267.7(in)-273.8(PRC)-268.3(in)-267.7(Ibadan,)]TJ
0 -1.128 TD
(Nigeria.)Tj
/F3 1 Tf
.9999 -1.1219 TD
(Material/Methods:)Tj
/F4 1 Tf
8.4934 0 TD
[(A)-410(d)12.2(es)21.1(cr)17.8(i)12.7(p)0(t)18.8(i)0(v)18.9(e)-412.7(c)14.1(r)0(o)16(s)13.1(s)-407.6(s)0(e)15(c)0(t)20.7(i)0(o)18.8(n)12.2(al)-400(st)19.7(u)12.2(d)0(y)-402.4(w)0(a)18.7(s)]TJ
-9.4933 -1.128 TD
[(co)14.1(n)12.2(d)12.2(u)0(c)20.2(t)0(e)14.6(d)-237.8(am)20.8(on)18.3(g)-237.8(3)0(6)18.3(7)-243.9(m)12.8(a)0(r)17.8(r)0(i)22.6(e)0(d)-235.9(m)12.7(en)-229.8(in)-231.1(an)-229.8(ur)16(b)12.2(a)0(n)-229.8(c)0(o)20.2(m)0(m)19.4(u)0(n)18.3(i)12.7(ty)-231.1(us)19.2(in)18.8(g)]TJ
0 -1.1219 TD
[(a)-534.6(s)13.1(em)14.6(i)12.7(-)0(s)16.8(t)12.7(ru)22.1(ct)14.6(u)12.2(r)0(e)17.8(d)12.2(,)-530.4(i)12.7(nt)18.8(er)17.8(v)12.2(i)0(e)14.6(w)0(e)18.7(r)0(-)19.7(a)14.1(dm)18.9(in)18.8(is)19.7(te)20.7(re)17.8(d)-530.4(q)12.2(ue)20.2(st)19.7(io)18.8(nn)18.3(ai)20.7(re)17.8(.)-530.4(R)0(e)21.6(-)]TJ
0 -1.128 TD
[(sp)19.2(on)18.3(se)21.1(s)-322.3(t)12.7(o)-323.1(q)12.2(ue)20.2(st)19.7(io)18.8(n)12.2(s)-322.3(o)12.2(n)-323.1(k)12.2(n)0(o)18.3(w)0(l)17.3(e)14.1(dg)18.3(e)-321.2(o)12.2(f)-319.4(P)0(R)16.8(C)-321.7(we)24.8(re)-311.4(co)20.2(nv)18.3(er)17.9(t)12.7(e)0(d)-315.1(t)12.7(o)-323.1(a)]TJ
0 -1.1219 TD
[(33)18.3(-p)22.1(oi)18.8(nt)-316.5(sc)15(a)14.1(l)0(e)14.6(.)-323.1(Sc)17.3(o)12.2(r)0(e)17.8(s)-328.4(g)12.2(r)0(e)17.8(a)0(t)20.7(e)0(r)-317.5(t)0(h)18.8(a)0(n)-321.2(o)12.2(r)-325.5(e)0(q)20.2(u)0(a)20.2(l)-328.7(to)-316.5(th)18.8(e)-327.3(m)12.8(ea)16(n)-329.2(k)12.2(n)12.2(o)0(w)16.8(l)12.7(-)]TJ
0 -1.128 TD
[(ed)14.1(g)12.2(e)-260.3(sc)15(o)12.2(r)0(e)-256.5(\()0(2)22.1(6)12.2(.2)18.3(\))-264.5(w)0(a)18.7(s)-261.3(ca)16(t)12.7(e)0(g)20.2(o)12.2(ri)16.5(ze)16(d)-262.1(a)14.1(s)-267.4(g)12.2(o)12.2(o)0(d)-256(k)12.2(n)12.2(o)0(w)16.8(l)12.7(ed)14.1(g)12.2(e)0(.)-254.2(S)0(i)22.1(m)12.8(il)19.3(ar)17.8(ly)18.9(,)]TJ
0 -1.1219 TD
[(re)17.8(sp)19.2(on)18.3(s)13.1(e)0(s)-314.3(t)12.7(o)-323.1(i)12.7(n)12.2(v)0(o)18.4(l)12.7(ve)14.1(m)12.8(e)0(n)20.2(t)-322.6(i)12.7(n)-317(PR)16.9(C)-321.7(q)12.2(u)12.2(e)0(s)15(t)12.7(io)18.9(n)12.2(s)-322.3(we)18.7(re)-311.4(c)14.1(o)0(n)18.3(v)12.2(er)17.9(te)20.7(d)-323.1(t)12.7(o)-323.1(a)]TJ
/F6 1 Tf
8.9663 0 0 8.9663 299.9054 34.2425 Tm
(A-2)Tj
ET
endstream
endobj
190 0 obj
<>stream
hbd`ab`ddpqpvL)0su6If!#wޯX-8}s~AeQfzFF4 @1%?)U!$5X3/9 ($5EOA1'G!dBBPjqjQP#5,$39Q!X!Q(1%57([!?M'3/ U]!1/E?H!483%3(3X `dcfPb`eddbǾl|?|/[+Cc#jflY,Dž]N~o߶快~&}!}.~OۑIߍؾ{8 l| ol
endstream
endobj
193 0 obj
<>stream
/GS1 gs
BT
/F4 1 Tf
9.2982 0 0 9.2982 59.7543 725.5557 Tm
0 0 0 rg
0 Tc
0 Tw
[(24)18.3(-p)22.1(oi)18.8(nt)-206.7(s)13.1(c)0(a)16(l)12.7(e)-211.5(w)0(i)17.3(t)0(h)-206.7(s)13.1(co)20.2(re)17.8(s)-212.5(g)12.2(re)17.8(at)20.7(er)-207.8(t)12.7(h)0(a)20.2(n)-213.4(or)-203.5(eq)20.2(ua)20.2(l)-212.9(t)0(o)-206.7(t)12.7(he)-205.4(m)12.8(e)0(a)16(n)-213.4(\(1)22.1(5.)18.3(1)12.2(\))]TJ
0 -1.128 TD
[(cl)14.6(a)14.1(s)0(s)13.9(i)12.7(e)17.3(d)-426.8(a)0(s)-424(g)12.2(oo)18.3(d)-432.9(i)12.7(n)12.2(v)0(o)18.3(l)12.7(ve)14.1(m)12.8(e)0(n)20.2(t)0(.)-420.2(D)0(a)18.7(t)0(a)-424.4(w)0(e)18.7(r)0(e)-421.1(a)0(n)20.2(a)0(l)20.7(y)0(z)20.2(e)0(d)-424.9(u)12.2(si)19.7(n)12.2(g)-432.9(d)12.2(e)0(-)]TJ
0 -1.1219 TD
[(sc)15(ri)22.6(pt)18.8(i)12.7(v)0(e)-363.9(s)13.1(ta)14.6(t)12.7(i)12.7(s)0(t)19.7(i)0(c)14.6(s)-365(an)14.1(d)-365.8(a)0(s)21.1(s)0(o)19.2(c)0(i)20.7(a)0(t)14.6(i)12.7(on)-359.7(b)12.2(e)0(t)14.6(w)0(e)18.7(e)14.1(n)-371.9(q)12.2(ua)20.2(li)19.3(ta)14.6(t)12.7(i)12.7(v)0(e)-363.9(v)12.2(ar)17.8(i)12.7(a)0(b)20.2(l)0(e)14.6(s)]TJ
0 -1.128 TD
[(wa)18.7(s)-291.8(e)0(s)21.1(t)0(a)14.6(b)12.2(li)19.4(sh)19.2(ed)-278.5(us)19.2(in)18.8(g)-286.5(C)0(h)19.7(i)0(-)16.5(s)13.1(qu)18.3(ar)17.8(e)-290.8(t)12.7(es)15(t)-286(a)0(t)-284.1(p)]TJ
/F2 1 Tf
16.6331 0 TD
(=)Tj
/F4 1 Tf
.5426 0 TD
-.0122 Tc
[(0.)-12.2(0)6.1(5)0(.)]TJ
/F3 1 Tf
-16.1758 -1.1219 TD
0 Tc
(Results:)Tj
/F4 1 Tf
3.7132 0 TD
[(Th)16.5(e)-260.3(m)0(e)14.7(a)14.1(n)-268.2(a)0(g)20.2(e)-266.4(o)12.2(f)-270.6(re)23.9(sp)19.2(on)18.3(d)12.2(e)0(n)20.2(t)0(s)-260.8(w)0(a)18.7(s)-261.3(37)18.3(.)12.2(5)-268.2(\()]TJ
/F2 1 Tf
16.1636 0 TD
()Tj
/F4 1 Tf
.7073 0 TD
[(7.)18.3(5)12.2(\))-264.5(ye)14.1(a)14.1(r)0(s)16.8(.)]TJ
-21.5841 -1.128 TD
-.0135 Tc
[(A)-13.5(b)3.3(ov)-13.5(e)-438.4(t)-13.5(w)3.8(o)-1.3(-)-13.5(t)3(hi)-13.5(rd)-446.4(\()-13.5(6)2.5(8.7)-13.5(%\))-448.7(ha)-13.5(d)-438.4(s)-13.5(eco)-13.5(n)4.8(da)-13.5(r)4.3(y)-452.5(ed)-13.5(u)4.8(c)-13.5(ati)-13.5(o)5.3(n)-446.4(a)-13.5(n)6.7(d)-452.5(92)-13.5(.)4.8(6)-1.3(%)]TJ
0 -1.1219 TD
0 Tc
[(ea)16(rn)22.1(ed)-235.9(a)-242(m)0(o)18.9(n)12.2(th)18.8(l)12.7(y)-243.9(in)18.8(co)20.2(me)-235.3(o)12.2(f)-246.2(N5)22.9(0)12.2(,)-243.9(0)12.2(0)0(0)-237.7(o)12.2(r)-240.1(l)0(e)14.6(s)13.1(s.)-230.8(Si)16(x)12.2(t)0(y)18.8(-)0(t)22.6(h)0(r)16(e)0(e)-234(p)12.2(er)17.8(ce)22.1(nt)]TJ
0 -1.128 TD
[(ha)14.1(d)-292.6(g)0(o)18.3(o)12.2(d)-298.7(k)12.2(no)18.3(wl)17.3(e)14.1(d)0(g)18.3(e)-296.9(of)-288.9(PR)16.8(C)13.6(.)-298.7(Ov)16.8(e)14.1(r)0(a)17.8(l)0(l)19.3(,)-298.7(5)12.2(6)12.2(.)0(9)18.3(%)-301.1(h)12.2(a)0(d)-284.6(g)0(o)18.3(o)12.2(d)-298.7(i)0(n)18.9(v)12.2(ol)18.8(v)12.2(e)0(-)]TJ
0 -1.1219 TD
[(me)14.7(n)12.2(t)-347(i)12.7(n)-347.5(PR)22.9(C;)-339.5(1)12.2(9)0(.)18.3(6)12.2(%)-349.9(a)14.1(nd)-335.3(19)18.3(.)12.2(9)0(%)-337.6(f)0(o)22.1(l)0(l)19.3(o)0(w)16.8(e)0(d)-333.4(t)0(h)18.8(e)0(i)20.7(r)-349.9(p)12.2(a)0(r)17.8(t)12.7(ne)20.2(rs)-336.8(fo)16(r)-343.8(a)0(n)20.2(-)]TJ
0 -1.128 TD
[(te)14.6(n)12.2(a)0(t)20.7(a)0(l)-192.7(c)0(a)16(r)0(e)-195.6(\()0(A)20.6(N)0(C)18.2(\))-203.6(v)12.2(i)12.7(si)19.7(ts)-193.7(an)20.2(d)-207.3(p)12.2(o)12.2(s)0(t)19.7(-)0(n)16(a)14.1(ta)14.6(l)-200.7(c)0(l)20.7(i)0(n)18.8(i)0(c)-192.7(\()0(P)19.2(N)0(C)18.2(\))-203.6(re)17.9(s)13.1(p)12.2(ec)16(ti)19.3(v)12.2(e)0(l)14.6(y)12.2(.)]TJ
0 -1.1219 TD
[(A)-367.3(h)12.2(i)12.7(g)0(h)18.3(e)0(r)-354.1(p)12.2(ro)22.1(po)18.3(rt)16.5(i)12.7(o)12.2(n)-365.8(o)12.2(f)-362.1(r)0(e)17.8(s)13.1(po)18.3(n)12.2(d)0(e)20.2(n)0(t)18.8(s)-365(wi)23.4(th)-353.1(go)18.3(o)12.2(d)-365.8(k)12.2(n)12.2(o)0(w)16.8(l)12.7(ed)20.2(ge)-351.7(we)18.7(re)]TJ
0 -1.128 TD
[(in)18.8(vo)18.3(l)12.7(v)0(e)20.2(d)-542.6(i)12.7(n)-536.5(ac)16(co)20.2(mp)18.9(an)20.2(y)12.2(i)0(n)18.8(g)-536.5(th)18.8(ei)20.7(r)-538.9(p)0(a)20.2(r)0(t)16.5(n)12.2(er)17.8(s)-535.7(f)0(o)16(r)-538.9(AN)21.4(C)-541.2(v)12.2(i)12.7(s)0(i)19.7(t)0(s)-529.1(\()0(p)]TJ
/F2 1 Tf
25.3277 0 TD
(=)Tj
/F4 1 Tf
-25.3277 -1.1219 TD
[(0.)18.3(0)12.2(0)0(8)18.3(\))0(,)-368.2(P)15.4(NC)-365.9(cl)14.6(i)12.7(n)12.2(ic)-369.5(\(p)]TJ
/F2 1 Tf
8.8165 0 TD
(=)Tj
/F4 1 Tf
.5427 0 TD
[(0)12.2(.)0(0)18.3(1)12.2(4\))16(,)-371.9(l)0(a)20.7(b)0(o)18.3(r)-374.3(wa)18.7(rd)-368.2(\(p)]TJ
/F2 1 Tf
8.7007 0 TD
(=)Tj
/F4 1 Tf
.5427 0 TD
[(0)12.2(.)12.2(0)0(5)18.3(0)12.2(\))-380.4(a)14.1(nd)-365.8(ar)17.8(r)-8.4(a)-16.4(n-)]TJ
-18.6025 -1.128 TD
.0117 Tc
[(ging)-463.9(means)-469.1(o)11.7(f)-478.4(c)1.4(om)11.7(municatio)11.7(n)-476(f)3.3(or)-466.2(their)-466.2(p)-.5(artners)-469.1(i)0(n)-463.9(c)1.4(ase)-462(o)-.5(f)]TJ
T*
.0125 Tc
[(em)12.5(e)-9.4(r)4.1(gencies)-413.4(\()4.1(p)]TJ
/F2 1 Tf
6.4081 0 TD
0 Tc
(<)Tj
/F4 1 Tf
.5609 0 TD
.0111 Tc
[(0.0)11.1(0)-7.1(1)-1.1(\).)-415.7(Jo)11.1(b)-421.7(d)-1.1(emand)11.1(,)-421.8(social)-415.2(sti)11.1(g)-6.6(ma)-413.8(and)-415.7(l)11.1(o)-6.6(n)-1.1(g)]TJ
-6.9691 -1.1219 TD
-.0125 Tc
[(w)-12.5(a)6.2(it)-12.5(i)6.8(n)-.3(g)-305.1(t)-12.5(i)6.8(m).3(e)-309.4(w)-12.5(e)6.2(r)-12.5(e)-293.4(r)-12.5(e)5.3(a)1.6(s)-12.5(o)6.7(ns)-304.3(h)-12.5(i)6.3(ghl)-12.5(i)6.8(g)-.3(h)-12.5(t)6.3(e)-12.5(d)-297.1(f)-12.5(o)9.6(r)-301.4(t)-12.5(h)6.3(e)-12.5(i)8.2(r)-307.5(non-)-12.5(invol)-12.5(v)6.3(e)-12.5(m)8.3(e)-12.5(n)7.7(t)]TJ
0 -1.128 TD
0 Tc
[(in)-279.9(PR)22.9(C.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Conclusions:)Tj
/F4 1 Tf
5.8472 0 TD
[(The)-353.5(study)-358.3(revealed)-360(gaps)-356.9(in)-353.1(male)-360.9(partners)-355.4(in-)]TJ
-6.8471 -1.128 TD
[(volvement)-366.4(in)-365.3(pregnancy)-362.3(related)-367.5(care.)-368.6(This)-366.2(informed)-361.4(a)-363.9(need)-368.1(to)]TJ
0 -1.1219 TD
[(advocate)-223.5(for)-224.2(a)-217.6(change)-225.9(in)-218.9(focus)-219(of)-221.8(reproductive)-223.4(health)-220.7(program)-221.7(to)]TJ
0 -1.128 TD
[(accommodate)-305.8(men.)]TJ
/F3 1 Tf
0 -2.9815 TD
(04.)Tj
9.843 0 0 9.843 80.674 488.5794 Tm
[(Mental)-286.4(Health)-279.6(Problems)-283.9(of)-278.6(Women)]TJ
0 -1.1116 TD
[(of)-284.4(Reproductive)-283.3(Age)-281.8(in)-278.6(a)-283.3(Rural)-284(Community)]TJ
0 -1.1174 TD
[(of)-284.4(South-West)-283.2(Nigeria)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 59.7543 450.0849 Tm
[(Ayodeji)-333.8(Adebayo)]TJ
6.9735 0 0 6.198 126.4819 454.2235 Tm
(1)Tj
9.2982 0 0 9.2982 129.9968 450.0849 Tm
[(,)-329.2(Tolulope)-334.1(Soyanwo)]TJ
6.9735 0 0 6.198 206.759 454.2235 Tm
(2)Tj
/F5 1 Tf
-21.0804 -2.6526 TD
(1)Tj
9.2982 0 0 9.2982 63.2693 433.644 Tm
[(University)-333.9(of)-334.8(Ibadan,)-331.5(Ibadan,)-337.6(Nigeria)]TJ
6.9735 0 0 6.198 59.7543 427.2944 Tm
(2)Tj
9.2982 0 0 9.2982 63.2693 423.2125 Tm
[(University)-333.9(College)-335.1(Hospital,)-334.3(Ibadan,)-337.6(Nigeria)]TJ
/F3 1 Tf
.6219 -2.3047 TD
(Background:)Tj
/F4 1 Tf
5.9387 0 TD
[(Mental)-335.7(health)-336.5(is)-333.9(a)-333.4(component)-336.4(of)-331.6(reproductive)]TJ
-6.9386 -1.128 TD
[(health)-214.6(which)-212.4(is)-212(generally)-215(and)-211.4(is)-212(still)-210.4(not)-212.8(given)-210.9(priority)-210.3(in)-212.8(low)-214.3(and)]TJ
0 -1.1219 TD
[(middle)-362.3(income)-360.9(countries.)-362.4(In)-362.1(Nigeria,)-358.7(efforts)-363.5(to)-359.2(improve)-359(wom-)]TJ
0 -1.128 TD
[(ens)-304.4(health)-306(have)-301(focused)-308.6(on)-298.7(issues)-305.9(related)-306.5(to)-298.2(reproduction)-304.6(such)]TJ
0 -1.1219 TD
[(as)-210.6(family)-206.1(planning)-210.3(and)-205.3(fertility)-207.4(while)-205.8(womens)-207.8(mental)-208(health)-208.5(has)]TJ
0 -1.128 TD
[(been)-301(relatively)-305.4(neglected.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Objective\(s\):)Tj
/F4 1 Tf
6.0179 0 TD
[(This)-506.5(study)-510.7(was)-510.9(conducted)-505.8(to)-511.6(determine)-507.2(the)]TJ
-7.0179 -1.128 TD
[(prevalence)-449.5(and)-443.1(predictors)-444(of)-441.3(mental)-439.7(health)-446.3(problems)-443.5(in)-438.4(non-)]TJ
0 -1.1219 TD
[(pregnant)-205.2(reproductive)-205.1(age)-203.5(women)-206.3(in)-200.6(a)-205.4(rural)-203.4(setting)-209(of)-203.5(south-west)]TJ
0 -1.128 TD
(Nigeria.)Tj
/F3 1 Tf
.9999 -1.1219 TD
(Material/Methods:)Tj
/F4 1 Tf
8.3836 0 TD
[(A)-318.5(community)-312.9(based)-312.3(cross-sectional)-316(sur-)]TJ
-9.3836 -1.128 TD
[(vey)-296.8(was)-297.5(conducted)-292.4(using)-297.3(a)-296.9(cluster)-295.4(sampling)-294.3(technique)-298(to)-292.1(select)]TJ
0 -1.1219 TD
[(283)-292.6(non-pregnant)-286.8(women)-291.6(aged)-294.9(1549)-286.4(years.)-290.3(Mental)-293(health)-287.8(was)]TJ
0 -1.128 TD
[(assessed)-301.7(based)-294(on)-292.6(respondents)-297.3(experience)-303.2(of)-295(any)-290.7(symptoms)-295.3(of)]TJ
0 -1.1219 TD
[(depression)-459.6(and)-455.3(anxiety.)-458.4(Data)-460.5(was)-456(analyzed)-455.2(using)-455.8(descriptive)]TJ
0 -1.128 TD
[(statistics,)-314.1(Chi-square)-315.1(and)-309(multivariate)-310.5(logistic)-312.1(regression)-315.6(at)-308.5(5%)]TJ
0 -1.1219 TD
[(level)-306.1(of)-295(signicance.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Results:)Tj
/F4 1 Tf
3.9205 0 TD
[(The)-487.7(mean)-483.4(age)-483.9(of)-484(the)-485.3(respondents)-483.9(was)-486.5(25.6)]TJ
/F2 1 Tf
18.8281 0 TD
()Tj
/F4 1 Tf
.7195 0 TD
(7.8)Tj
-24.468 -1.1219 TD
[(years)-253.7(with)-256.5(the)-253.6(highest)-252.2(proportion)-247.4(\(57.1%\))-256.9(between)-251.3(1524)-249.9(years.)]TJ
0 -1.128 TD
[(The)-231.6(prevalence)-236.1(of)-234(depression)-227.9(and)-235.8(anxiety)-232.9(was)-230.4(28.9%)-227.8(each)-232.1(while)]TJ
T*
[(19.8%)-374.2(experienced)-376.3(both.)-371.3(Gynecological)-376.3(conditions)-373.5(was)-376.7(a)-370(pre-)]TJ
0 -1.1219 TD
[(dictor)-505.4(of)-496.2(anxiety)-501.1(\(OR)-502.4(2.7;)-499.4(95%)-496.1(CI)-500.9(1.35.6\))-496.1(while)-504.6(previous)]TJ
0 -1.128 TD
[(history)-329.6(of)-325.5(miscarriage)-329.9(was)-327.9(a)-327.3(predictor)-322.9(of)-325.5(depression)-331.5(\(OR)-325.6(10.5;)]TJ
0 -1.1219 TD
[(95%)-301(CI)-299.7(1.0108.8\).)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Conclusions:)Tj
/F4 1 Tf
5.9082 0 TD
[(Thi)-7.4(s)-480.8(study)-486.3(showe)-10.8(d)-481.6(that)-484.8(men)-9.7(tal)-484.8(hea)-8.4(lth)-480.6(pr)-8.4(ob-)]TJ
-6.9081 -1.1219 TD
[(le)-9.8(ms)-376.6(are)-382.7(quit)-11.1(e)-376.1(p)0(r)-8.4(evale)-12(nt)-377.5(in)-383.6(women)-383.1(of)-380.3(repr)-8.9(oduc)-10.2(tive)-381.1(ag)-10.3(e)-376.1(gro)-8.4(up)]TJ
0 -1.128 TD
[(in)-450.6(the)-454.8(stud)-10.7(y)-445.1(s)0(e)-9.4(tting.)-455.6(Ther)-8.3(e)-449.3(i)0(s)-449.8(a)-449.3(nee)-8.4(d)-451.2(for)-449.8(repr)-8.9(oduc)-10.2(tive)-454.3(hea)-8.4(lth)]TJ
0 -1.1219 TD
[(poli)-11.1(ces)-464.8(in)-456.7(Nige)-11.2(ria)-457.2(to)-462.8(recog)-10.7(nize)-465.1(ment)-9.2(al)-454.9(hea)-8.4(lth)-462.3(pro)-8.4(blems)-465.6(as)-454.5(a)]TJ
0 -1.128 TD
[(con)-10.2(tri)-7.4(butor)-404.2(to)-395.8(the)-406.1(burd)-8.4(en)-400.5(of)-398.6(dise)-8.9(ases)-403(in)-401.9(wome)-11.2(n)-396.3(and)-400.5(inte)-9.2(grate)]TJ
0 -1.1219 TD
[(it)-480.6(into)-480.6(repr)-8.9(oduc)-10.2(tive)-484.8(health)-482.9(se)-9.4(rvice)-10.2(s.)-474.7(Th)-7.9(ere)-480.2(is)-480.3(also)-478.3(a)-479.8(nee)-8.4(d)-469.5(t)0(o)]TJ
0 -1.128 TD
[(pr)-8.4(omote)-375(publi)-11.1(c)-370(hea)-8.4(lth)-370.8(inte)-9.2(rvent)-12.1(ions)-370.5(to)-371.4(ta)-9.8(rget)-371.8(wo)-7.5(men)-369.4(with)-378.4(gy-)]TJ
0 -1.1219 TD
[(nec)-8.4(olog)-11.6(ical)-391.5(con)-10.2(diti)-10.6(ons)-389.3(and)-388.3(w)-7.6(h)0(o)-384.1(e)0(x)-10.3(perie)-10.2(nce)-392.5(misc)-8.3(arr)-8.9(iag)-9.7(e)-382.2(t)0(o)-389.7(ef-)]TJ
0 -1.128 TD
[(fec)-10.7(tive)-9.2(ly)-371.4(reduc)-10.7(e)-363.9(the)-375.6(bur)-8.4(den)-370(of)-368.2(ment)-9.2(al)-369.5(hea)-8.4(lth)-370.8(pro)-8.4(blem)-9.2(s)-365(amo)-9.7(ng)]TJ
0 -1.1219 TD
[(the)-369.5(popul)-11.6(atio)-9.2(n.)]TJ
/F3 1 Tf
27.0045 71.9468 TD
(05.)Tj
9.843 0 0 9.843 331.7668 725.5557 Tm
[(Experience)-282.6(and)-279.4(Disclo)-8.7(sure)-277.1(of)-284.4(Sexual)-278.3(Assault)]TJ
0 -1.1174 TD
[(among)-277.1(Undergraduates)-290.8(in)-278.6(a)-277.6(Tertiary)-284.1(Institution)]TJ
0 -1.1116 TD
[(in)-278.6(South-West)-283.2(Nigeria:)-282.9(A)-284.2(Gender-Based)-284.4(Analysis)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 310.8472 687.0613 Tm
[(Adebola)-332.4(Adejimi)]TJ
6.9735 0 0 6.198 376.1007 691.1998 Tm
(1)Tj
9.2982 0 0 9.2982 379.559 687.0613 Tm
[(,)-335.3(Olukemi)-333.3(Sabageh)]TJ
6.9735 0 0 6.198 452.296 691.1998 Tm
(1)Tj
9.2982 0 0 9.2982 455.8109 687.0613 Tm
(,)Tj
-15.5905 -1.128 TD
[(Oluwatimileyin)-336.8(Adedokun)]TJ
6.9735 0 0 6.198 411.2503 680.7117 Tm
(2)Tj
/F5 1 Tf
-14.3978 -2.6526 TD
(1)Tj
9.2982 0 0 9.2982 314.3054 660.1321 Tm
[(Department)-338.6(of)-334.8(Community)-333.9(Medicine,)-337(Ladoke)-334.3(Akintola)]TJ
-.3719 -1.1219 TD
[(University)-333.9(of)-334.8(Technology)-331.8(\(LAUTECH\),)-338.7(LAUTECH)-334(Teaching)]TJ
0 -1.128 TD
[(Hospital,)-334.3(Osogbo,)-329.7(Osun)-335.9(State,)-332.3(Nigeria,)]TJ
6.9735 0 0 6.198 310.8472 632.9195 Tm
(2)Tj
9.2982 0 0 9.2982 314.3054 628.7809 Tm
[(Ladoke)-334.3(Akintola)-333.6(University)-340(of)-334.8(Technology)-331.8(\(LAUTECH\),)]TJ
-.3719 -1.128 TD
[(Osogbo,)-329.7(Osun)-335.9(State,)-332.3(Nigeria)]TJ
/F3 1 Tf
.9999 -2.2986 TD
(Background:)Tj
/F4 1 Tf
5.9265 0 TD
[(Sexual)-327.7(violence,)-328.5(including)-325.6(sexual)-330.1(assault,)-328.7(is)-327.8(a)]TJ
-6.9264 -1.128 TD
[(signicant)-435.5(public)-436(health)-434.1(problem)-438.3(on)-432.8(university)-436.9(campuses)-437(but)]TJ
0 -1.1219 TD
[(this)-235.8(may)-241.4(be)-235.9(seen)-239.2(as)-235(a)-242(private)-235.2(issue)-239.7(and)-241.9(it)-236.7(may)-235.3(be)-235.9(under-reported.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.8716 0 TD
[(The)-365.7(objective)-370.7(of)-368.2(this)-363.9(study)-370.4(was)-364.5(to)-365.3(assess)-370.7(and)]TJ
-6.8715 -1.1219 TD
[(compare)-288.7(the)-290.2(experience)-297.1(and)-290.7(disclosure)-288.3(of)-288.9(sexual)-293.5(assault)-292.1(among)]TJ
0 -1.128 TD
[(male)-275.6(and)-272.4(female)-276(undergraduates)-282.1(in)-273.8(Ladoke)-272.3(Akintola)-278.4(University)]TJ
0 -1.1219 TD
[(o)12.2(f)-258.4(Te)18.4(ch)20.2(no)18.3(lo)18.8(g)12.2(y)-262.1(\(L)20.2(AU)21.4(TE)14.6(C)13.6(H)0(\))20.6(,)-262.2(Og)16.8(b)12.2(o)12.2(m)0(o)18.9(s)0(o)19.2(,)-256.1(So)15.5(u)12.2(t)0(h)18.9(-)0(w)20.6(e)0(s)21.1(t)0(e)14.6(r)0(n)-246.2(N)0(i)17.3(g)12.2(er)17.8(ia)20.7(.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Material/Methods:)Tj
/F4 1 Tf
8.4507 0 TD
[(A)-385.6(cross)-388.9(sectional)-388.1(study)-382.6(of)-386.4(1538)-384(under-)]TJ
-9.4506 -1.128 TD
[(graduates)-592.7(who)-598.9(were)-597.5(selected)-594.1(using)-596(a)-595.6(multi-stage)-592.5(sampling)]TJ
0 -1.1219 TD
[(technique)-468.7(was)-468.2(conducted.)-463.1(A)-471(pre-tested)-466.5(and)-467.5(self-administered)]TJ
0 -1.128 TD
[(questionnaire)-262.3(on)-262.1(the)-265.8(experience)-266.6(and)-260.2(disclosure)-264(of)-264.5(sexual)-263(assault)]TJ
0 -1.1219 TD
[(was)-327.9(used)-326.4(in)-328.7(data)-324.9(collection.)-333.5(Chi)-327.3(square)-326.9(test)-331.5(was)-327.9(used)-326.4(to)-328.7(assess)]TJ
0 -1.128 TD
[(associations)-282.7(between)-287.9(categorical)-283.9(variables)-287.3(and)-278.5(the)-284.1(predictors)-285.5(of)]TJ
0 -1.1219 TD
[(experience)-467.8(and)-467.5(disclosure)-471.3(of)-465.7(sexual)-464.2(assault)-469(were)-469.5(determined)]TJ
0 -1.128 TD
[(using)-297.3(logistic)-299.9(regression)-303.4(at)-302.4(a)-303(level)-300(of)-301.1(signicance)-298.1(of)-301.1(5%.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Results:)Tj
/F4 1 Tf
3.6888 0 TD
[(The)-256(mean)-251.7(age)-258.4(was)-254.8(21.9)]TJ
/F2 1 Tf
9.786 0 TD
()Tj
/F4 1 Tf
.8841 0 TD
[(2.6)-249.9(years)-259.8(and)-254.1(58.4%)-252.2(were)]TJ
-15.3588 -1.128 TD
[(female.)-257.7(The)-262.1(prevalence)-260.5(of)-258.4(sexual)-263(assault)-261.7(one)-254.1(year)-260.7(preceding)-264.3(the)]TJ
0 -1.1219 TD
[(study)-248.5(was)-248.7(9.4%)-246.1(and)-248(14.6%)-252.2(among)-247.5(male)-245.1(and)-254.1(female)-245.5(respondents)]TJ
0 -1.128 TD
[(respectively.)-242.2(About)-244.8(36.7%)-240(of)-246.2(male)-245.1(and)-241.9(44.3%)-240(of)-240.1(female)-245.5(victims)]TJ
0 -1.1219 TD
[(shared)-253.7(their)-249.4(experience)-260.5(of)-246.2(sexual)-256.9(assaults)-254.7(with)-250.4(someone,)-256.9(mainly)]TJ
0 -1.128 TD
[(with)-524.8(informal)-519.4(support)-525.2(providers)-519.6(such)-527.6(as)-521.6(friends)-525.7(and)-522.4(family)]TJ
0 -1.1219 TD
[(members.)-277(Majority)-278.4(\(90.1%\))-275.2(did)-279.9(not)-273.8(disclose)-279.9(their)-273.7(experience)-284.9(of)]TJ
0 -1.128 TD
[(sexual)-269.1(assaults)-279.1(to)-267.7(a)-272.5(formal)-276.1(support)-269.1(system.)-269.6(Signicantly,)-274.1(higher)]TJ
0 -1.1219 TD
[(proportions)-313.6(of)-313.3(female)-318.7(respondents)-313.2(and)-315.1(those)-313.7(with)-317.4(any)-315.1(previous)]TJ
0 -1.128 TD
[(history)-219.8(of)-221.8(sexual)-220.3(intercourse)-222.6(experienced)-223.9(sexual)-226.4(assault)-219(one)-223.6(year)]TJ
0 -1.1219 TD
[(preceding)-428.9(the)-424.4(study.)-425.3(However,)-428.2(age,)-429.1(marital)-429.3(status)-428.2(and)-424.8(sexual)]TJ
0 -1.128 TD
[(orientation)-240.2(were)-243.9(not)-243.3(signicantly)-246(associated)-245.6(with)-238.2(the)-241.4(experience)]TJ
0 -1.1219 TD
[(or)-441.3(disclosure)-446.9(sexual)-445.9(assaults.)-449.8(Respondents)-443.6(with)-445.5(any)-443.1(previous)]TJ
0 -1.128 TD
[(history)-457.6(of)-453.5(sexual)-458.1(intercourse)-460.4(were)-457.3(more)-457.2(likely)-453.8(to)-456.7(experience)]TJ
0 -1.1219 TD
[(sexual)-299.6(assault)-298.2([Odds)-295.6(Ratio)-300.5(\(OR\):)-296.9(5.1)-298.7(\(95%)-297.3(Condence)-300.5(Interval)]TJ
0 -1.128 TD
[(\(CI\):)-511.2(1.8614.06\)].)-510.5(Females)-513.5(were)-512.2(more)-512(likely)-514.7(to)-505.5(experience)]TJ
0 -1.1219 TD
[([OR:)-203.1(1.5)-195(\(95%)-199.7(CI:)-201.6(1.072.08\)])-199.6(and)-199.3(to)-200.6(disclose)-206.8([OR:)-197(1.8)-201.1(\(95%)-199.7(CI:)]TJ
0 -1.128 TD
[(1.052.93\)])-504.5(sexual)-513(assaults.)-510.8(Disclosure)-509.3(of)-508.4(sexual)-506.9(assaults)-510.8(to)]TJ
0 -1.1219 TD
[(someone)-299.6(was)-303.6(associated)-300.5(with)-299.2(increasing)-305.6(years)-302.5(of)-301.1(study.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Conclusions:)Tj
/F4 1 Tf
5.8289 0 TD
[(Sexual)-346(assault)-347(was)-346.2(quite)-344.5(prevalent)-349.2(among)-345(un-)]TJ
-6.8289 -1.1219 TD
[(dergraduates)-373.6(in)-371.4(LAUTECH,)-374.3(Ogbomoso,)-371.8(Nigeria)-377(and)-376.1(affecting)]TJ
0 -1.128 TD
[(more)-268.1(females)-269.1(than)-265.8(males.)-268.6(The)-268.2(high)-267.7(non-disclosure)-272.3(rate)-266.3(can)-270.5(be)-266.3(a)]TJ
0 -1.1219 TD
[(barrier)-344.1(to)-340.9(the)-345.1(success)-339.2(of)-343.8(sexual)-342.3(assault)-347(preventive)-343(efforts.)-345.2(Tar-)]TJ
0 -1.128 TD
[(geted)-489.5(gender-based)-490(preventive)-483.3(interventions)-489.3(and)-491.9(policies)-487.6(are)]TJ
0 -1.1219 TD
[(needed)-299.1(to)-298.2(address)-307.7(these)-299.6(problems)-297.2(in)-304.3(the)-296.3(institution.)]TJ
/F3 1 Tf
0 -2.7072 TD
(06.)Tj
9.843 0 0 9.843 331.7668 163.7858 Tm
[(Improving)-282.5(Osteoporosis)-281.1(Screening)-284.9(at)-284.4(MacNeal)]TJ
0 -1.1116 TD
[(Family)-279.8(Medicine)-285.2(Center)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 310.8472 136.2897 Tm
[(Mirtha)-333.8(Aguilar)-336.2(Alvarado)]TJ
6.9735 0 0 6.198 405.5243 140.4283 Tm
(1)Tj
9.2982 0 0 9.2982 409.0392 136.2897 Tm
[(,)-329.2(Amy)-336.2(Harrison)]TJ
6.9735 0 0 6.198 468.6802 140.4283 Tm
(2)Tj
/F5 1 Tf
-22.6332 -2.6526 TD
(1)Tj
9.2982 0 0 9.2982 314.3054 119.8488 Tm
[(MacNeal)-338(Hospital,)-334.3(Gwinnett)-331.9(Medical)-338.9(Center,)-334.8(Lawrenceville,)]TJ
-.3719 -1.128 TD
(Georgia)Tj
6.9735 0 0 6.198 310.8472 103.0677 Tm
(2)Tj
9.2982 0 0 9.2982 314.3054 98.9291 Tm
[(MacNeal)-338(Hospital,)-334.3(Berwyn,)-337.2(Illinois)]TJ
/F3 1 Tf
.628 -2.3047 TD
(Background:)Tj
/F4 1 Tf
5.9143 0 TD
[(The)-310.8(number)-310.8(of)-313.3(women)-309.9(above)-313.2(65)-310.9(years)-314.7(old)-316.5(re-)]TJ
-6.9142 -1.128 TD
[(ceiving)-336.5(osteoporosis)-332(screening)-342.7(remains)-338(low.)-330.2(3,)-335.3(1,)-335.3(16.)-335.3(Informa-)]TJ
0 -1.1219 TD
[(tion)-334.2(about)-338.9(the)-339(status)-336.7(for)-340(this)-333.4(test)-337.6(at)-339(MacNeal)-340(Family)-340.8(Medicine)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 59.7543 749.7069 Tm
(ABSTRACTS)Tj
53.1188 0 TD
(A-3)Tj
ET
endstream
endobj
197 0 obj
<>stream
/GS1 gs
BT
/F4 1 Tf
9.2982 0 0 9.2982 62.022 725.5557 Tm
0 0 0 rg
0 Tc
0 Tw
[(Center)-216.1(is)-212(limited)-214.9(and)-217.5(no)-213.3(specic)-215.2(interventions)-214.9(were)-213.4(developed)-219.2(in)]TJ
0 -1.128 TD
[(the)-302.4(past)-301.5(to)-298.2(improve)-298.1(this)-302.9(service.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.8838 0 TD
[(1.)-378(To)-379.8(obtain)-375(baseline)-382.5(data)-379.8(about)-375.5(osteoporosis)]TJ
-6.8837 -1.128 TD
[(screening)-336.6(rates)-332.5(in)-334.8(our)-331.5(practice.)-335.1(2.)-335.3(To)-331(improve)-334.6(the)-332.9(osteoporosis)]TJ
0 -1.1219 TD
[(screening)-391.5(rates)-387.4(in)-389.7(female)-391.9(patients)-390(aged)-386.4(65)-390.2(to)-383.6(80)-390.2(years)-387.9(old)-389.6(by)]TJ
0 -1.128 TD
[(reaching)-374.1(patients)-377.8(with)-378.4(reminder)-371.7(by)-378(a)-376.1(phone)-369.9(call)-379.3(and)-376.1(a)-370(mailed)]TJ
0 -1.1219 TD
[(reminder)-231.5(along)-235.3(with)-226(a)-235.9(mailed)-232.4(order)-228.3(for)-230.3(bone)-235.8(mineral)-228.6(density)-233.9(test)]TJ
0 -1.128 TD
(\(BMD\).)Tj
/F3 1 Tf
.9999 -1.1219 TD
(Material/Methods:)Tj
/F4 1 Tf
8.4324 0 TD
[(A)-367.3(non-randomized)-363.6(prospective)-366.5(pre-post)]TJ
-9.4324 -1.128 TD
[(intervention)-307.3(study)-303.4(was)-309.7(completed.)-303.6(Women)-306.5(aged)-307.1(65)-304.8(to)-304.3(80)-304.8(years)]TJ
0 -1.1219 TD
[(old)-261.6(who)-257.5(received)-262.4(services)-262.6(between)-263.5(October)-261.6(1st)-260.8(2012)-262.1(to)-255.5(October)]TJ
0 -1.128 TD
[(31st)-394.9(2014)-390.1(at)-400(MacNeal)-394.9(Family)-395.6(Medicine)-394.7(Center)-399(were)-390.2(selected)]TJ
0 -1.1219 TD
[(from)-601.6(the)-595.1(electronic)-602.8(medical)-602.4(record.)-598.4(A)-599(baseline)-602(of)-593.7(women)]TJ
0 -1.128 TD
.0117 Tc
[(screened)-433.4(for)-435.7(o)11.7(s)-5.7(t)0(eoporosis)-432.5(was)-438.6(e)1.4(stabli)11.7(shed.)-439.5(P)2.8(atients)-432.5(w)-2(ho)-433.4(did)]TJ
T*
[(not)-280.5(have)-279.2(bon)11.6(e)-291.3(d)-.6(ensit)11.6(y)-292.7(t)11.6(e)-10.4(st)-280.5(were)-285.3(selected)-281(an)11.6(d)-293.2(r)3.2(ecei)11.6(v)-6.1(ed)-287.1(a)-279.2(pho)11.6(n)-6.6(e)]TJ
0 -1.1219 TD
.0109 Tc
[(call)-305.6(r)-3.6(emin)10.9(d)-7.3(e).6(r)-308.5(f)2.5(ollowed)-306.1(b)-1.3(y)-306.1(a)-310.3(m)10.9(a)-11(i)10.9(l)-6.3(ed)-306.1(remin)10.9(d)-7.3(er)-308.5(and)-306.1(a).6(n)-306.1(o)-1.3(rder)-308.5(for)]TJ
0 -1.128 TD
.012 Tc
[(the)-388.5(t).3(est.)-390.4(Pre)-388.5(a)-4.4(n)12(d)-396.5(post)-389.9(i).3(nt)12(e)-10(r)3.6(venti)12(o)-5.7(n)-390.4(r)-2.5(esul)12(ts)-395.6(were)-388.5(obtain)12(e)-10.5(d)-390.4(a)1.7(nd)]TJ
0 -1.1219 TD
.0109 Tc
(compared.)Tj
/F3 1 Tf
.9999 -1.128 TD
0 Tc
(Results:)Tj
/F4 1 Tf
4.012 0 TD
[(Ninety)-571.6(three)-577.2(of)-569.4(two)-574.1(hundred)-573.5(thirty)-573.9(four)-577.8(\(40%\))]TJ
-5.0119 -1.1219 TD
[(females)-372.7(of)-368.2(aged)-368.1(65)-371.9(to)-365.3(80)-371.9(years)-369.6(old)-371.3(had)-363.9(BMD)-371.1(prior)-370(to)-371.4(our)-368.1(in-)]TJ
0 -1.128 TD
[(tervention)-326.1(and)-327.3(of)-325.5(these)-330.1(53%)-325.4(had)-327.3(the)-320.7(diagnosis)-330.5(of)-325.5(osteoporosis.)]TJ
0 -1.1219 TD
[(Phone)-317.9(calls)-323.5(followed)-323.9(by)-317(a)-321.2(mailed)-323.8(reminder)-322.9(letter)-320.1(and)-321.2(order)-319.8(for)]TJ
0 -1.128 TD
[(BMD)-358.9(testing)-355.3(increased)-365.2(the)-357.3(percentage)-358.1(of)-356(women)-358.7(with)-360.1(the)-357.3(test)]TJ
0 -1.1219 TD
[(done)-302.9(from)-296.8(40)-298.7(to)-304.3(48%.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Conclusions:)Tj
/F4 1 Tf
5.7679 0 TD
[(At)-281.4(baseline,)-285(the)-284.1(percentage)-284.9(of)-282.8(females)-287.4(aged)-282.7(65)]TJ
-6.7679 -1.1219 TD
[(to)-328.7(in)-328.7(the)-326.8(Family)-328.6(Medicine)-327.6(Center)-325.8(who)-330.7(had)-327.3(a)-327.3(screening)-330.5(test)-325.4(for)]TJ
0 -1.128 TD
[(osteoporosis)-234.4(is)-230.3(48%.)-234(The)-231.6(percentage)-236.1(of)-234(female)-233.4(with)-232.1(diagnosis)-233(of)]TJ
0 -1.1219 TD
[(osteoporosis)-204(in)-206.7(the)-204.8(Center)-210(is)-205.9(elevated)-204.7(compared)-209.4(to)-200.7(those)-204(found)-209.5(in)]TJ
0 -1.128 TD
[(the)-235.3(National)-233.8(Health)-240.5(Osteoporosis)-229.8(Survey.)-234.9(A)-233.2(phone)-235.8(call)-239(followed)]TJ
0 -1.1219 TD
[(by)-243.8(a)-248.1(mailed)-250.6(reminder)-243.7(letter)-247(and)-248(an)-248.1(order)-246.6(for)-242.5(BDM)-249.2(test)-246.2(increased)]TJ
0 -1.128 TD
[(the)-406.1(rate)-406.5(of)-404.7(osteoporosis)-405.2(screening,)-403.7(however)-408.5(did)-401.8(not)-407.9(reach)-405.1(the)]TJ
0 -1.1219 TD
[(expected)-302.7(percentage.)]TJ
/F3 1 Tf
0 -4.1095 TD
(07.)Tj
9.843 0 0 9.843 82.9417 363.0613 Tm
[(Gender)-281.7(Differences)-289.2(in)-278.6(Authorship)-283(Collaboration)]TJ
0 -1.1174 TD
[(Patterns:)-283.7(The)-281.8(Experience)-288.4(of)-278.6(a)-283.3(Dental)-279.3(School)]TJ
0 -1.1116 TD
[(in)-278.6(a)-283.3(Developing)-284.9(Country)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 62.022 324.5668 Tm
[(Maha)-336.7(ElTantawi)]TJ
6.9735 0 0 6.198 125.2346 328.7054 Tm
(1)Tj
9.2982 0 0 9.2982 128.7496 324.5668 Tm
[(,)-335.3(Amr)-332.5(Fathy)]TJ
6.9735 0 0 6.198 175.5212 328.7054 Tm
(2)Tj
9.2982 0 0 9.2982 178.9795 324.5668 Tm
[(,)-335.3(Mohamed)-336.1(Alsa)]TJ
6.9735 0 0 6.198 247.4645 328.7054 Tm
(3)Tj
9.2982 0 0 9.2982 250.9228 324.5668 Tm
(,)Tj
-20.3158 -1.128 TD
[(Asim)-334.9(Al-Ansari)]TJ
6.9735 0 0 6.198 122.4566 318.2173 Tm
(1)Tj
/F5 1 Tf
-8.6663 -2.6526 TD
(1)Tj
9.2982 0 0 9.2982 65.537 297.6377 Tm
[(College)-280.3(of)-286(Dentistry,)-280.9(University)-285.1(of)-286(Dammam,)-280.2(Dammam,)-286.3(Saudi)]TJ
-.378 -1.1219 TD
(Arabia)Tj
6.9735 0 0 6.198 62.022 280.8566 Tm
(2)Tj
9.2982 0 0 9.2982 65.537 276.718 Tm
[(Faculty)-332.3(of)-334.8(Engineering,)-331.3(Alexandria)-337.4(University,)-340(Alexandria,)]TJ
-.378 -1.1219 TD
(Egypt)Tj
6.9735 0 0 6.198 62.022 259.937 Tm
(3)Tj
9.2982 0 0 9.2982 65.537 255.7984 Tm
[(Faculty)-265.2(of)-261.6(Dentistry,)-262.6(Alexandria)-264.3(University,)-266.8(Alexandria,)-264.3(Egypt)]TJ
/F3 1 Tf
.6219 -2.2986 TD
(Background:)Tj
/F4 1 Tf
6.1947 0 TD
[(Faculty)-589.4(members)-590.3(involvement)-591.5(in)-590.9(research)]TJ
-7.1947 -1.128 TD
[(ensures)-265(timely)-270.3(transfer)-270.1(of)-264.5(knowledge)-265.3(and)-266.3(helps)-264.9(train)-267.6(students)-269.6(in)]TJ
0 -1.1219 TD
[(the)-351.2(use)-350.8(of)-349.9(the)-351.2(evidence-based)-349.2(approach.)-356.3(Less)-345.7(publications)-352.8(and)]TJ
0 -1.128 TD
[(citations)-273.6(signify)-268.6(a)-266.4(problem)-273.7(in)-267.7(research)-270.6(translation)-269.9(and)-272.4(reect)-273.3(on)]TJ
T*
[(the)-302.4(faculties)-301.4(ability)-300.8(to)-298.2(fulll)-302.4(their)-304.2(role.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Objective\(s\):)Tj
/F4 1 Tf
6.085 0 TD
[(To)-581(assess)-578(gender)-577.7(differences)-577.2(in)-578.7(authorship)]TJ
-7.0849 -1.128 TD
[(collaboration)-360.2(patterns)-356.3(among)-357.2(a)-357.8(group)-349.8(of)-356(faculty)-357.2(members)-362.4(in)-353.1(a)]TJ
0 -1.1219 TD
[(dental)-300(school)-301.5(in)-298.2(a)-303(developing)-299.9(country.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Material/Methods:)Tj
/F4 1 Tf
8.4324 0 TD
-.0129 Tc
[(A)-313.1(d)-.7(ata)-12.9(b)7.3(ase)-315.9(w)3.9(a)-12.9(s)-302.8(developed)-317.7(t)-.2(o)-311.6(i)-.2(nclude)-309.8(the)]TJ
-9.4324 -1.1219 TD
-.0128 Tc
[(publications)-548.5(of)-551.7(fac)-12.8(u)13.5(lty)-549.3(me)-12.8(m)8(b)5.5(e)-12.8(r)11.1(s)-548.5(a)-12.8(t)-540.8(t)-.1(he)-547.4(F)-12.8(a)10.6(culty)-549.3(of)-545.6(D)-12.8(e)12(ntistr)-12.8(y)9.3(,)]TJ
0 -1.128 TD
[(A)-12.8(l)10.6(exandria)-462.1(U)-12.8(n)16.2(ive)-12.8(r)11.1(sity,)-457.9(E)-12.8(g)15.9(ypt)-457.4(w)-12.8(h)10.1(o)-457.9(p)-.6(u)5.5(b)-.6(lish)-457.9(i)-.1(nter)-12.8(n)9.3(a)1.3(tionally.)-457.9(T)3.7(he)]TJ
0 -1.1219 TD
[(appr)-12.8(o)15.4(v)-.6(a)-12.8(l)-455.5(of)-460.2(the)-468.2(R).8(esea)-12.8(r)11.1(c)-12.8(h)-456(E)3.7(thics)-469.2(C).8(ommittee)-462.1(w)-12.8(a)12(s)-469.2(o)5.5(b)-.6(ta)-12.8(i)7.9(n)5.5(e)-12.8(d)7.4(.)-464(I)3.1(n-)]TJ
0 -1.128 TD
0 Tc
[(fo)28.2(rm)22.6(a)14.1(t)12.7(i)12.7(o)12.2(n)-182.9(w)16.8(as)-174(c)14.1(o)12.2(l)12.7(l)12.7(e)14.1(c)14.1(t)12.7(ed)-168.8(ab)20.2(o)18.3(u)12.2(t)-182.4(e)14.1(ac)22.1(h)-182.9(f)15.9(ac)22.1(u)12.2(l)12.7(t)12.7(y)-176.8(m)12.8(e)0(m)20.7(b)18.3(er)23.9(s)-172.2(i)12.7(n)12.2(t)12.7(e)14.1(r)15.9(n)12.2(at)20.7(i)12.7(o)18.3(n)12.2(a)0(l)]TJ
0 -1.1219 TD
-.0131 Tc
[(publications,)-281.4(h)-.9(is/her)-277.6(c)-13.1(o)7.1(-authors)-286.6(a)1(nd)-281.3(their)-277.6(h)-.9(-)-13.1(i)9.5(nd)5.2(e)-13.1(x)7.1(.)-281.4(S)2.3(ocial)-280.8(n)-.9(e)-13.1(t)7.6(wor)-13.1(k)]TJ
0 -1.128 TD
[(ana)-13.1(l)7.6(y)5.2(s)0(is)-237.8(\(S)-13.1(N)13.1(A)-13.1(\))-224.2(w)-13.1(a)11.7(s)-237.8(u)5.2(s)-13.1(e)8(d)-232.6(to)-232.6(a)-13.1(n)13.2(a)-13.1(l)7.6(yze)-236.8(c)1(o-a)-13.1(u)13.2(thor)-13.1(s)9.8(h)-.9(ip)-232.6(netw)-13.1(o)15.9(r)-13.1(k)9(.)-232.6(U)-13.1(s)10.7(ing)]TJ
0 -1.1219 TD
0 Tc
[(Ge)24.8(p)12.2(h)12.2(i)-328.7(s)13.1(o)12.2(ft)22.6(w)16.8(a)0(r)23.9(e)14.1(,)-335.3(n)12.2(e)14.1(t)12.7(wo)29(rk)22.1(s)13.1()-331.6(p)12.2(a)14.1(r)15.9(a)0(m)20.8(e)14.1(t)12.7(e)14.1(rs)-318.5(we)24.8(re)-317.5(ca)22.1(l)12.7(c)14.1(u)12.2(l)12.7(a)14.1(t)12.7(ed)-321.2(i)12.7(n)12.2(c)14.1(l)12.7(u)12.2(d)12.2(i)12.7(n)12.2(g)]TJ
0 -1.128 TD
-.0129 Tc
[(number)-326.2(o)-.7(f)-332.3(n)-.7(o)5.4(d)-.7(e)-12.9(s)-321.1(\(co-)-12.9(a)11(u)-.7(thors\))-332.3(and)-329.9(e)1.2(dges)-329.1(\()3(c)-12.9(o)7.3(l)5.9(l)-.2(a)-12.9(b)7.3(o)5.4(r)-12.9(a)11(tions\))-12.9(,)-314(degr)-12.9(e)11(e)]TJ
0 -1.1219 TD
-.0131 Tc
[(\()-13.1(n)15.1(umber)-259.3(o)-.9(f)-253.2(c)1(ollabora)-13.1(t)7.6(ors)-256.1(a)1(n)-257(a)1(uthor)-253.2(is)-256.1(connecte)-13.1(d)-242.9(to\),)-257(netw)-13.1(o)9.8(r)2.8(k)-257(d)-.9(en-)]TJ
26.9984 71.9468 TD
[(s)-13(i)6.7(t)5.8(y)-372.7(\()-13(r)12.8(atio)-372.7(of)-369(a)-13(c)9.1(tual)-372.2(to)-366.6(potential)-372.2(c)-13(o)13.3(lla)-13(b)7.2(o)5.3(r)-13(a)10.9(tions\),)-372.7(number)-369(o)-.8(f)-369(c)-13(o)7.2(n)5.3(-)]TJ
0 -1.128 TD
[(ne)-13(c)9.1(t)-.3(ed)-183.7(components)-182.8(\()2.9(co-)-13(a)10.9(uthorship)-183.7(groups\))-180(a)1.1(nd)-183.7(aver)-13(a)10.9(g)-.8(e)-181.8(p)-.8(ath)-183.7(l)-.3(ength)]TJ
0 -1.1219 TD
-.0129 Tc
[(\()-12.9(a)11(ver)-12.9(a)11(ge)-352.4(nu)5.4(mber)-350.6(of)-350.6(authors)-353.5(c)1.2(on)5.4(ne)-12.9(c)9.2(ting)-348.2(t)-.2(w)-12.9(o)-337.5(co-a)-12.9(u)13.4(t)-.2(hor)-12.9(s)10(\))3(.)-348.2(G)-12.9(e)11.9(nder)]TJ
0 -1.128 TD
0 Tc
[(d)12.2(i)12.7(ff)25.8(er)23.9(e)14.1(n)12.2(ce)22.1(s)-236.9(w)0(e)24.8(r)0(e)-226(c)14.1(o)12.2(m)12.8(p)12.2(a)14.1(re)23.9(d)-237.8(u)12.2(s)13.1(i)12.7(n)18.3(g)-237.8(t)12.7(h)12.2(e)-235.9(S)0(N)20.1(A)16.8(-g)22.1(e)14.1(n)12.2(e)14.1(r)0(a)23.9(t)12.7(e)14.1(d)-237.8(s)13.1(t)12.7(a)14.1(t)12.7(i)12.7(s)13.1(t)12.7(i)12.7(c)0(s)21.1(.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Results:)Tj
/F4 1 Tf
3.762 0 TD
[(A)-324.6(total)-325.7(of)-319.4(421)-323.1(co-authors)-328.6(were)-323.2(included)-324.3(in)-322.6(the)-326.8(net-)]TJ
-4.7619 -1.128 TD
[(work.)-339.1(Women)-337(faculty)-332.8(members)-338(formed)-337.5(15.9%)-337.6(of)-331.6(authors)-334.3(pub-)]TJ
0 -1.1219 TD
[(lishing)-357.2(internationally)-359.2(with)-360.1(the)-357.3(network)-355(including)-362.2(publications)]TJ
0 -1.128 TD
[(that)-558(were)-554.9(cited)-556.1(7464)-554.7(times.)-556.5(Exclusively)-556.4(male)-556.1(collaboration)]TJ
0 -1.1219 TD
[(produced)-266.7(70.1%)-264.4(of)-264.5(all)-271.4(network)-263.5(citations)-267.5(and)-266.3(exclusively)-266.1(female)]TJ
0 -1.128 TD
[(collaborations)-371.6(produced)-370.3(5.8%.)-368.1(Same)-370.4(gender)-370.4(collaborations)-371.6(re-)]TJ
0 -1.1219 TD
[(sulted)-477.8(in)-468.9(fewer)-478(collaborators)-472(per)-469.9(author)-475.4(among)-473(women)-474.6(than)]TJ
0 -1.128 TD
[(among)-363.3(men)-363.3(\(degree)]TJ
/F2 1 Tf
8.1885 0 TD
(=)Tj
/F4 1 Tf
.5548 0 TD
[(2.567)-359.6(and)-357.8(5.119\).)-361.9(Subnetworks)-356.9(including)]TJ
-8.7434 -1.1219 TD
[(only)-267.7(women)-267.2(faculty)-265.7(members)-270.9(were)-268.3(fewer)-264.5(and)-266.3(denser)-265.9(than)-265.8(those)]TJ
0 -1.128 TD
[(formed)-258.3(by)-249.9(men)-247.5(only.)-255.5(Most)-247.7(authors)-255.1(with)-250.4(high)-255.5(h-index)-249.8(were)-256.1(men.)]TJ
T*
[(However,)-373.4(some)-368.6(women)-364.8(with)-366.2(high)-365.2(h-index)-365.6(formed)-368(the)-369.5(nucleus)]TJ
0 -1.1219 TD
[(of)-362.1(research)-368.1(groups)-361.1(that)-362.9(were)-365.9(mostly)-363.3(formed)-361.9(of)-362.1(men)-363.3(with)-360.1(high)]TJ
0 -1.128 TD
[(h-index)-304.7(with)-299.2(few)-300.7(connections.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Conclusions:)Tj
/F4 1 Tf
5.9326 0 TD
[(Women)-440.7(formed)-435.1(a)-443.2(smaller)-441.2(portion)-440.2(of)-441.3(authors)]TJ
-6.9325 -1.128 TD
[(publishing)-326.6(internationally)-322.6(and)-321.2(had)-321.2(fewer)-325.5(citations)-328.5(whether)-322.6(col-)]TJ
0 -1.1219 TD
[(laborating)-252.9(exclusively)-253.9(with)-250.4(women)-249(or)-246.2(with)-250.4(a)-254.2(mix)-248.9(of)-246.2(women)-255.1(and)]TJ
0 -1.128 TD
[(men.)-241.4(The)-237.7(co-authorship)-236.6(patterns)-240.5(of)-234(women)-236.8(faculty)-241.3(at)-235.4(this)-235.8(school)]TJ
0 -1.1219 TD
[(may)-460.9(be)-461.5(responsible)-465.1(for)-455.9(their)-462.8(lower)-464.8(impact)-458(on)-463.3(research.)-459.6(Pro-)]TJ
0 -1.128 TD
[(moting)-272.7(opportunities)-271.7(for)-266.8(international)-274.4(collaborations)-274(potentially)]TJ
0 -1.1219 TD
[(reduces)-251.8(the)-241.4(gap)-248(in)-243.3(number)-243.7(of)-246.2(publications)-249.2(and)-241.9(citations)-249.2(between)]TJ
0 -1.128 TD
[(men)-302.4(and)-302.9(women)-297.7(faculty)-302.3(members.)]TJ
/F3 1 Tf
0 -4.1644 TD
(08.)Tj
9.843 0 0 9.843 333.9779 435.7416 Tm
[(Impact)-284.9(of)-278.6(a)-283.3(Prenatal)-283(Labor)-278.3(Pain)-282(Management)]TJ
0 -1.1116 TD
[(Educational)-284.8(Intervention)-286.8(in)-278.6(Primiparous)-287.2(Women)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 313.0582 408.2455 Tm
[(Patricia)-339.4(L.)-331.1(Antoine)]TJ
/F5 1 Tf
0 -1.7682 TD
[(Old)-336.3(Dominion)-337.1(University,)-333.9(Norfolk,)-336.2(Virginia)]TJ
/F3 1 Tf
.9999 -2.3047 TD
(Background:)Tj
/F4 1 Tf
5.8106 0 TD
[(The)-213.3(pain)-210.9(that)-210.4(women)-206.3(experience)-211.7(during)-209(labor)-213.3(is)]TJ
-6.8106 -1.1219 TD
[(extreme)-404.1(yet)-400(the)-400(education)-401.7(and)-400.5(preparation)-400.3(of)-398.6(the)-400(primiparous)]TJ
0 -1.128 TD
[(woman)-322.1(for)-321.7(that)-326.3(experience)-321.5(is)-321.7(inadequate.)-320.5(The)-323(consequences)-324(of)]TJ
0 -1.1219 TD
[(this)-510.2(may)-515.8(lead)-507.8(to)-511.6(anesthetic)-514.3(and)-510.2(obstetric)-508.2(complications)-515(and)]TJ
0 -1.128 TD
[(dissatisfaction,)-369.3(specically,)-370.8(with)-366.2(their)-365.2(pain)-369.4(management)-368.7(expe-)]TJ
0 -1.1219 TD
[(rience,)-307(and)-296.8(the)-302.4(overall)-302.3(childbirth)-303.1(experience.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.7557 0 TD
[(Ev)16.5(a)14.1(l)0(u)18.8(a)14.1(te)20.7(d)-237.8(t)12.7(he)-229.8(i)12.7(m)12.8(pa)20.2(ct)-229.3(o)12.2(f)-234(th)18.8(e)-235.9(p)12.2(re)17.8(n)12.2(a)0(t)20.7(a)0(l)-229.3(e)14.1(du)18.3(c)14.1(a)0(t)20.7(i)0(o)18.9(n)12.2(al)]TJ
-6.7557 -1.1219 TD
.0115 Tc
[(pro)11.5(g)-6.7(ram)-396.5(o)-.7(n)-397(l)-.2(abo)11.5(r)-405.4(pain)-397(management)-396.5(in)-397(changin)11.5(g)-409.2(k)11.5(n)-6.7(owledge,)]TJ
0 -1.128 TD
[(perceptio)11.5(n)-6.7(s).2(,)-336(a)1.2(nd)-329.9(likelih)11.5(o)-6.7(o)-.7(d)-336(t)11.5(o)-341.6(c)1.2(hoo)11.5(s)-5.9(e)-334.1(e)-4.9(a)1.2(rly)-336(p)-.7(ain)-329.9(m)-.1(anagement)]TJ
0 -1.1219 TD
.0112 Tc
[(in)-299.7(primiparous)-298.9(women.)]TJ
/F3 1 Tf
.9999 -1.128 TD
0 Tc
(Material/Methods:)Tj
/F4 1 Tf
8.4263 0 TD
[(A)-355.1(Quasi-experimental)-352.8(design)-356.4(was)-352.3(used.)]TJ
-9.4263 -1.1219 TD
[(Fifty-three)-254.5(subjects)-255.5(participated)-254.7(in)-255.5(this)-254.1(project.)-253.5(The)-249.9(intervention)]TJ
0 -1.128 TD
[(occurred)-413.5(during)-410.2(already)-410.7(existing)-410.2(prenatal)-410.2(classes.)-411.9(Participants)]TJ
0 -1.1219 TD
[(were)-372(primiparous)-366.1(women)-364.8(ages)-373.3(1840)-365.7(who)-361.2(were)-371.9(able)-367.6(to)-365.3(speak)]TJ
0 -1.128 TD
[(and)-449.2(write)-446(English.)-438.8(They)-445(participated)-449.9(once)-441.2(in)-444.5(a)-449.3(prenatal)-440.6(pain)]TJ
0 -1.1219 TD
[(management)-222.4(program.)-215.6(The)-219.4(method)-216.4(was)-218.2(repeated)-219.8(over)-219.9(a)-217.6(12-week)]TJ
0 -1.128 TD
[(period)-249.8(with)-250.4(different)-252.1(participants)-249.7(in)-243.3(subsequent)-249.9(prenatal)-251.6(classes.)]TJ
T*
[(Outcomes)-306.6(were)-298.8(assessed)-301.7(pre)-305.3(and)-296.8(post)-303.4(intervention.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Results:)Tj
/F4 1 Tf
3.7803 0 TD
[(There)-341.8(were)-341.5(no)-341.4(statistically)-342.5(signicant)-338(difference)-346.4(in)]TJ
-4.7802 -1.128 TD
[(pre)-530.9(and)-522.4(post)-529(likelihood)-526.3(to)-523.8(consider)-527.5(early)-522.4(pain)-528(management)]TJ
0 -1.1219 TD
(\(p)Tj
/F2 1 Tf
.8353 0 TD
(=)Tj
/F4 1 Tf
.5548 0 TD
[(.084\))-252.2(or)-258.4(likelihood)-251.9(to)-255.5(request)-259.3(an)-254.2(epidural)-253.5(\(p)]TJ
/F2 1 Tf
17.5172 0 TD
(=)Tj
/F4 1 Tf
.5548 0 TD
[(.533\).)-252.2(48.1%)-252.2(of)]TJ
-19.4622 -1.128 TD
[(participants)-463.1(perceived)-463.6(labor)-463.3(pain)-460.9(as)-460.6(being)-460.9(severe)-465.2(and)-455.3(52.8%)]TJ
0 -1.1219 TD
[(believed)-237.1(that)-234.8(they)-229.2(would)-232.6(be)-229.8(able)-233.4(to)-231.1(handle)-233.4(the)-235.3(pain)-229.2(of)-234(childbirth.)]TJ
0 -1.128 TD
[(Pre)-356.9(and)-357.8(post)-352.2(mean)-355.4(knowledge)-356.8(scores)-356.5(were)-359.8(statistically)-354.7(signi-)]TJ
0 -1.1219 TD
[(cant)-306.6(\(5.25)-294.9(versus)-303.5(8.96\).)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Conclusions:)Tj
/F4 1 Tf
6.1826 0 TD
[(Education)-691.9(and)-693.1(preparation)-699(of)-691.3(primiparous)]TJ
-7.1825 -1.1219 TD
[(women)-316(are)-309.5(needed)-311.3(early)-315(during)-306.6(the)-314.6(pregnancy)-313.6(concerning)-307(pain)]TJ
0 -1.128 TD
[(management)-441.9(options)-437(in)-438.4(addition)-435.4(to)-438.4(natural)-436.4(childbirth)-437.2(classes.)]TJ
0 -1.1219 TD
[(Also)-335.4(this)-327.3(study)-327.8(needs)-330.6(to)-328.7(be)-327.3(conducted)-335.1(with)-329.6(a)-327.3(larger)-329.6(number)-329.1(of)]TJ
0 -1.128 TD
[(participants)-353.3(that)-344.6(includes)-347.8(a)-345.6(more)-347.4(diverse)-344.6(group)-349.8(of)-343.8(primiparous)]TJ
0 -1.1219 TD
(women.)Tj
/F3 1 Tf
8.9663 0 0 8.9663 62.022 749.6502 Tm
(A-4)Tj
48.6864 0 TD
(ABSTRACTS)Tj
ET
endstream
endobj
201 0 obj
<>stream
/GS1 gs
BT
/F3 1 Tf
9.2982 0 0 9.2982 59.7543 725.5557 Tm
0 0 0 rg
0 Tc
0 Tw
(09.)Tj
9.843 0 0 9.843 80.674 725.5557 Tm
[(The)-281.8(Early)-284.3(Start)-282.9(Program)-283(Experience:)-283.7(Cigarette)]TJ
0 -1.1174 TD
[(Smoking)-284.9(During)-279.2(Pregnancy)-285(and)-279.4(Links)-282.6(to)-278.6(Other)]TJ
0 -1.1116 TD
[(Substance)-287.8(Use)-281.6(and)-279.4(Maternal)-284.1(and)-279.4(Neonatal)]TJ
T*
(Outcomes)Tj
/F4 1 Tf
9.2982 0 0 9.2982 59.7543 676.1195 Tm
[(Mary)-334.9(Anne)-334.9(Armstrong)]TJ
6.9735 0 0 6.198 146.5511 680.2581 Tm
(1)Tj
9.2982 0 0 9.2982 150.0094 676.1195 Tm
[(,)-335.3(Lue-Yen)-337.1(Tucker)]TJ
6.9735 0 0 6.198 218.0976 680.2581 Tm
(1)Tj
9.2982 0 0 9.2982 221.5558 676.1195 Tm
[(,)-335.3(Cosette)-334.3(Taillac)]TJ
6.9735 0 0 6.198 284.1448 680.2581 Tm
(1)Tj
9.2982 0 0 9.2982 287.6031 676.1195 Tm
(,)Tj
-24.5046 -1.128 TD
[(Amy)-336.2(Conway)]TJ
6.9735 0 0 6.198 112.422 669.7699 Tm
(1)Tj
9.2982 0 0 9.2982 115.937 665.6313 Tm
[(,)-335.3(Nancy)-333(Goler)]TJ
6.9735 0 0 6.198 169.9653 669.7699 Tm
(3)Tj
/F5 1 Tf
-15.8042 -2.6526 TD
(1)Tj
9.2982 0 0 9.2982 63.2693 649.1904 Tm
[(Kaiser)-262.7(Permanente,)-258.3(Division)-265.3(of)-255.5(Research,)-262.6(Oakland,)-261.1(California)]TJ
6.9735 0 0 6.198 59.7543 642.8975 Tm
(2)Tj
9.2982 0 0 9.2982 63.2693 638.7589 Tm
[(Kaiser)-335.8(Permanente,)-337.6(Oakland,)-334.3(California)]TJ
6.9735 0 0 6.198 59.7543 632.4093 Tm
(3)Tj
9.2982 0 0 9.2982 63.2693 628.2707 Tm
[(Kaiser)-335.8(Permanente,)-337.6(OB/GYN)-334.9(Vallejo,)-333.6(Oakland,)-334.3(California)]TJ
/F3 1 Tf
.6219 -2.3047 TD
(Background:)Tj
/F4 1 Tf
5.9021 0 TD
[(Cigarette)-298.5(smoking)-296.7(during)-300.5(pregnancy)-301.4(is)-297.4(related)]TJ
-6.902 -1.1219 TD
[(to)-450.6(adverse)-446.9(maternal)-446.2(and)-449.2(infant)-444.4(outcomes.)-445.4(Kaiser)-449.8(Permanente)]TJ
0 -1.128 TD
[(No)22.9(rt)22.6(h)12.2(e)0(r)23.9(n)-292.6(C)13.6(a)0(l)20.7(i)12.7(fo)22.1(r)15.9(n)12.2(ia)-278(\(K)20.6(PN)20.1(C)13.6(\))-288.9(h)12.2(a)14.1(s)-291.8(a)-290.8(we)24.8(l)12.7(l)12.7(-)0(e)17.8(s)13.1(t)12.7(a)0(b)20.2(l)12.7(i)12.7(s)13.1(h)12.2(e)0(d)-278.5(p)12.2(re)23.9(n)12.2(a)0(t)20.7(a)14.1(l)-292.1(s)13.1(u)12.2(b)12.2(-)]TJ
0 -1.1219 TD
[(st)19.7(a)14.1(n)12.2(ce)-307.2(a)14.1(b)12.2(u)12.2(s)13.1(e)-315.1(s)0(c)21.1(r)0(e)23.9(e)0(n)20.2(i)12.7(n)12.2(g)-310.9(an)20.2(d)-310.9(t)12.7(re)17.8(a)14.1(t)12.7(m)12.8(e)0(n)20.2(t)-316.5(p)12.2(r)15.9(o)12.2(g)12.2(r)0(a)17.8(m)-310.4(ca)22.1(l)12.7(l)12.7(e)0(d)-302.9(E)0(a)18.4(r)15.9(l)12.7(y)-317(S)15.4(t)0(a)20.7(r)0(t)]TJ
0 -1.128 TD
-.0132 Tc
[(\()-13.2(E)7(S\))-344.8(w)-13.2(h)9.7(ich)-342.4(i)-.5(de)-13.2(n)7(ti)-13.2(e)10.2(s)-341.6(w)-13.2(o)9.7(me)-13.2(n)-328.3(w)-13.2(h)9.7(o)-342.4(smoke)-13.2(d)-328.3(c)-13.2(i)7.5(g)-1(ar)-13.2(e)4.6(ttes)-341.6(b)-1(e)-13.2(f)4.6(ore)-340.5(a)-13.2(n)7(d)]TJ
0 -1.1219 TD
-.0197 Tc
[(d)-7.5(u)-7.5(r)-19.7(in)-7.5(g)-312.3(p)-7.5(re)-19.7(gn)-7.5(a)-5.6(n)-19.7(cy)-7.5(.)]TJ
/F3 1 Tf
.9999 -1.128 TD
0 Tc
(Objective\(s\):)Tj
/F4 1 Tf
5.835 0 TD
[(\(1\))-321.7(To)-318.8(compare)-325.3(the)-326.8(estimated)-320.5(rate)-327.3(of)-319.4(cigarette)]TJ
-6.8349 -1.1219 TD
[(smoking)-260.1(during)-257.8(pregnancy)-258.7(in)-261.6(KPNC)-260.5(to)-255.5(California)-266.1(and)-254.1(US)-260.4(rates.)]TJ
0 -1.128 TD
[(\(2\))-205.9(Determine)-203.8(if)-196.9(women)-206.3(screened)-201.1(as)-204.5()58.6(smoker)-202.5(only)53.1()-203.6(but)-200.6(upon)-201.1(ES)]TJ
0 -1.1219 TD
[(assessment)-258(were)-256.1(also)-252.8(positive)-251.6(for)-248.6(alcohol/other)-256.6(drugs)-251.4(had)-254.1(worse)]TJ
0 -1.128 TD
[(outcomes)-268.5(than)-265.8(women)-267.2(screened)-268.2(as)-271.6()58.6(smoker)-269.6(only)53.1()-264.5(but)-267.7(were)-268.3(not)]TJ
0 -1.1219 TD
[(positive)-300.4(for)-303.4(alcohol/other)-299.3(drugs.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Material/Methods:)Tj
/F4 1 Tf
8.5056 0 TD
[(Of)-412.3(3)12.2(4)0(5)18.3(,)12.2(54)18.3(3)-420.7(w)0(o)16.8(m)12.8(en)-418.8(wh)22.9(o)-420.7(c)0(o)14.1(m)12.8(p)12.2(l)0(e)14.6(t)12.7(ed)-412.7(ES)]TJ
-9.5055 -1.1219 TD
[(Sc)17.3(re)17.8(en)20.2(i)12.7(n)0(g)-438.9(Q)0(u)22.9(e)0(s)21.1(t)0(i)19.3(o)0(n)18.3(n)12.2(ai)14.6(re)23.9(s)-450.3(b)12.2(et)20.7(we)18.7(en)-437.1(0)12.2(2)12.2(/)0(0)18.8(1)0(/)18.8(1)12.2(99)18.3(9)12.2()0(1)18.3(2)12.2(/3)18.8(1)12.2(/)0(2)18.8(0)0(1)18.3(4)-445.1(an)20.2(d)]TJ
0 -1.128 TD
[(ha)14.1(d)-469.5(a)-467.6(li)19.3(ve)-461.5(bi)18.8(rt)16.5(h)-469.5(o)12.2(r)-471.8(i)12.7(nt)18.8(ra)17.8(-u)22.1(te)14.6(ri)22.6(n)12.2(e)-473.7(fe)17.8(t)12.7(a)0(l)-461(d)0(e)20.2(m)0(i)19.4(s)0(e)15(,)-469.5(3)12.2(,)0(9)18.3(9)12.2(5)-469.5(i)0(n)18.8(d)0(i)18.8(c)0(a)16(t)12.7(ed)]TJ
0 -1.1219 TD
.0178 Tc
[()52()3.3(smo)5.6(k)-.5(er)-240.6(o)5.6(n)-.5(ly)5.6()52()-240.6(d)5.6(u)-.5(ring)-238.3(p)5.6(r)-2.8(eg)5.6(nancy)5.6(.)-238.3(A)-239.7(c)1.4(ont)6.1(ro)5.6(l)-243.9(g)5.6(roup)-238.3(o)5.6(f)-240.6(22)5.6(1,7)5.6(96)]TJ
0 -1.128 TD
.0176 Tc
[(non)5.4(-smok)5.4(e)1.2(rs)6.3(,)-494.5(non)5.4(-sub)5.4(stance)-492.7(us)6.3(ers)-493.7(w)3.9(as)-499.8(i)5.9(d)-.7(ent)5.9(i)-.2(ed)-494.5(\()3.1(tot)5.9(a)-4.9(l)-494(c)1.2(o)5.4(-)]TJ
0 -1.1219 TD
.017 Tc
(hort)Tj
/F2 1 Tf
1.6828 0 TD
0 Tc
(=)Tj
/F4 1 Tf
.567 0 TD
.0132 Tc
[(22)-5.1(5)-5.1(,)1(7)-5.1(9)1(1)-5.1(\))-1.3(.)-377(T)-6.9(he)-375.1()47.4()-1.3(s)-4.2(m)-4.5(ok)-5.1(ers)-376.1(o)-5.1(nl)-4.6(y)-5.1()53.5()-379.4(w)-.5(er)-7.4(e)-375.1(s)-4.2(ub)-5.1(di)-4.6(v)-5.1(i)-4.6(ded)-377(i)-4.6(nt)-4.6(o)-377(5)]TJ
-2.2499 -1.128 TD
.0173 Tc
[(grou)5.1(ps)-311.1(based)-311.9(o)5.1(n)-311.9(a).9(ssess)6(ment)-311.4(resul)5.6(t)-.5(s)-311.1(a).9(nd)-311.9(t)5.6(r)-3.3(eat)5.6(ment)-311.4(st)5.6(atus.)-305.8(T)-2.8(h)5.1(e)]TJ
0 -1.1219 TD
0 Tc
[(gro)16(ups)-188.1(wer)16.4(e)-199.3(com)14.7(par)17.9(ed)-193.2(on)-195.1(nu)12.3(mer)12.3(ou)12.2(s)-194.2(out)12.8(co)14.1(mes)15.5(,)-201.2(i)0(n)12.8(clu)14.7(di)12.7(ng)-195.1(pre)17.9(ter)12.3(m)]TJ
0 -1.128 TD
[(del)14.6(ive)14.6(ry,)-301.1(lo)12.7(w)-312.4(b)0(i)12.7(rth)-300.6(we)12.6(ig)12.8(ht,)-298.2(assi)16.4(st)13.6(ed)-309(ve)14.1(nti)13.3(lat)15.2(io)12.8(n,)-304.8(pl)12.7(ace)11.8(nt)12.7(al)-308.5(ab)14.1(rup)16(-)]TJ
0 -1.1219 TD
[(tio)13.3(n,)-317(an)14.1(d)-323.1(int)13.3(ra)11.8(-ut)16.5(eri)12.3(ne)-315.1(fe)11.8(tal)-314.1(dem)14.7(is)13.6(e,)-321.2(us)13.1(ing)-310.4(Chi)14.1(-sq)16.8(uar)11.8(ed)-315.1(tes)15.5(ts)-315.7(and)]TJ
0 -1.128 TD
[(log)12.8(is)13.6(tic)-289.7(re)11.8(gre)17.9(ssi)14.5(on)12.2(.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Results:)Tj
/F4 1 Tf
3.6644 0 TD
[(In)-203.5(20)18.3(0)12.2(3)0(,)-207.3(t)0(h)18.8(e)-217.6(es)21.1(ti)19.3(ma)20.7(te)14.6(d)-213.4(s)0(m)19.7(o)0(k)18.3(i)12.7(ng)-207.3(ra)17.8(t)12.7(e)-217.6(du)18.3(ri)22.6(ng)-207.3(pr)16(e)14.1(g)0(n)18.3(a)0(n)20.2(c)0(y)]TJ
-4.6644 -1.1219 TD
.0119 Tc
[(in)-366.1(Californ)11.9(i)-5.8(a)-370.3(w)4.3(as)-365.2(8.7%)-362.3(vs)-365.2(10)11.9(.)-6.4(7)-.3(%)-362.3(i).2(n)-366.1(t).2(he)-364.2(US.)-366.1(T)4(he)-364.2(KPNC)-364.7(rat)11.9(e)]TJ
0 -1.128 TD
.0115 Tc
[(was)-219.3(5)-.7(.)11.5(6)-6.8(%.)-220.2(Am)11.5(o)-6.2(n)-.7(g)-214.1(t)-.2(he)-218.3(assessed)-220.2()57.9(sm)11.5(o)-6.2(kers)-213.2(only)11.5()45.8(,)-220.2(38)11.5(%)-222.5(a)-4.9(d)11.5(m)-6.2(itted)]TJ
0 -1.1219 TD
0 Tc
[(to)-286(al)20.7(co)20.2(ho)18.3(l)12.7(/)0(d)18.8(r)0(u)22.1(g)-298.7(u)12.2(s)13.1(e)-296.9(a)0(t)-290.2(a)0(s)21.1(s)13.1(es)15(s)13.1(m)12.8(en)20.2(t.)-286(Th)16.5(e)-296.9(u)12.2(n)12.2(a)0(d)20.2(j)12.7(us)19.2(t)12.7(e)0(d)-290.7(r)0(a)23.9(t)0(e)20.7(s)-297.9(fo)22.1(r)-301.1(m)12.8(o)12.2(s)0(t)]TJ
0 -1.128 TD
[(ou)18.3(t)12.7(c)0(o)20.2(m)12.8(es)-363.1(we)18.7(re)-360.2(l)12.7(o)12.2(we)18.7(r)-374.3(i)12.7(n)-371.9(t)12.7(h)12.2(e)-370(tr)16.5(e)14.1(a)0(t)20.7(e)0(d)-363.9()64.7(s)22.9(m)12.8(o)0(k)18.3(e)0(r)-360.2(o)12.2(n)12.2(l)0(y)18.8()64.7()-368.2(g)0(r)22.1(o)0(u)18.3(p)-371.9(wh)22.9(o)]TJ
0 -1.1219 TD
[(as)21.1(se)15(s)13.1(s)13.1(e)0(d)-394.4(p)12.2(o)12.2(s)0(i)19.7(t)12.7(iv)18.8(e)-400.5(f)0(o)22.1(r)-404.8(a)14.1(l)0(c)20.7(o)0(h)18.3(o)12.2(l)12.7(/)0(o)18.9(t)12.7(h)12.2(e)0(r)-396.8(d)12.2(ru)22.1(g)12.2(s)-401.5(co)20.2(m)12.8(p)12.2(ar)17.8(ed)-388.3(to)-389.7(bo)18.3(t)12.7(h)-402.4(t)12.7(h)12.2(e)]TJ
0 -1.128 TD
[(un)18.3(t)12.7(r)0(e)17.8(a)14.1(te)20.7(d)-298.7()64.7(s)16.8(m)12.8(o)12.2(ke)20.2(rs)-288(o)12.2(n)0(l)18.8(y)12.2()64.7()-301.1(wh)22.9(o)-298.7(u)12.2(se)21.1(d)-298.7(a)0(l)20.7(c)0(o)20.2(h)12.2(ol)18.8(/)12.7(o)0(t)18.8(h)12.2(er)-287(dr)16(u)12.2(g)12.2(s)-297.9(an)20.2(d)-298.7(t)12.7(h)12.2(e)]TJ
0 -1.1219 TD
[(co)20.2(n)21.6(rm)22.6(ed)-284.6()64.7()0(s)22.9(m)12.8(ok)18.3(e)14.1(r)0(s)-281.9(o)12.2(n)12.2(l)0(y)18.8()64.7()-288.9(r)0(e)17.8(g)12.2(ar)17.8(d)12.2(l)12.7(es)21.1(s)-291.8(o)12.2(f)-288.9(t)0(r)22.6(e)0(a)16(t)12.7(m)12.8(e)0(n)20.2(t)0(.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Conclusions:)Tj
/F4 1 Tf
5.7314 0 TD
[(The)-237.7(cigarette)-243.1(smoking)-235.7(rate)-241.9(during)-239.5(pregnancy)-240.4(in)]TJ
-6.7313 -1.1219 TD
[(KPNC)-303.2(is)-303.5(signicantly)-300.8(lower)-306.2(than)-302.4(both)-298.2(US)-303.1(and)-302.9(California)-302.7(rates.)]TJ
0 -1.128 TD
[(Re)15.5(c)14.1(e)0(i)20.7(v)0(i)18.8(n)12.2(g)-323.1(t)12.7(re)17.8(a)14.1(t)0(m)19.4(e)0(n)20.2(t)-322.6(wa)24.8(s)-322.3(t)12.7(he)-315.1(k)12.2(e)14.1(y)-323.1(f)0(a)17.8(c)14.1(to)18.8(r)-319.4(r)0(e)17.8(l)12.7(at)20.7(ed)-309(to)-310.4(l)12.7(o)0(w)16.9(e)14.1(r)-325.5(r)0(a)23.9(t)0(e)20.7(s)-322.3(o)12.2(f)]TJ
0 -1.1219 TD
[(ad)20.2(ve)20.2(rs)16.8(e)-211.5(o)12.2(ut)18.8(co)20.2(m)12.8(e)0(s)21.1(.)-213.4()58.6()15.9(Sm)16(o)12.2(k)12.2(e)0(r)17.8(s)-212.5(o)12.2(n)12.2(l)0(y)18.9()64.7()-215.7(w)0(h)22.9(o)-213.4(us)19.2(ed)-205.4(a)14.1(l)0(c)20.7(o)0(h)18.3(o)12.2(l/)19.3(o)12.2(t)12.7(he)20.2(r)-215.7(d)12.2(ru)16(g)12.2(s)]TJ
0 -1.128 TD
[(ma)20.7(y)-451.2(h)12.2(a)14.1(v)0(e)-437.1(r)0(e)17.8(c)0(e)22.1(i)0(v)18.8(e)14.1(d)-451.2(m)12.8(o)12.2(r)0(e)-439.4(t)12.7(re)17.8(a)14.1(t)0(m)19.4(e)0(n)20.2(t)-444.6(if)-434.7(th)18.9(ei)20.7(r)-447.4(s)13.1(u)12.2(b)0(s)19.2(t)12.7(an)20.2(ce)-441.3(u)12.2(s)13.1(e)-449.3(w)0(a)18.7(s)]TJ
0 -1.1219 TD
[(co)20.2(ns)19.2(i)12.7(d)0(e)20.2(r)0(e)17.8(d)-286.5(mo)18.9(re)-280.9(s)13.1(e)0(v)20.2(e)0(r)23.9(e)-290.8(th)18.9(an)-278.5(t)12.7(h)0(a)20.2(t)-292.1(o)12.2(f)-288.9(co)20.2(n)12.2()0(r)19.2(m)12.8(ed)-278.5()64.7()0(s)16.8(m)12.8(o)12.2(k)12.2(e)0(r)17.9(s)-291.8(o)12.2(n)12.2(l)12.7(y)70.8(.)]TJ
/F3 1 Tf
0 -3.7254 TD
(10.)Tj
9.843 0 0 9.843 80.674 195.6472 Tm
[(Sex-Differences)-288.8(in)-284.4(Outcomes)-283.8(After)-279.3(Transcatheter)]TJ
0 -1.1116 TD
[(Aortic)-286.4(Valve)-278.4(Replacement:)-290.3(A)-278.4(Systematic)]TJ
T*
[(Literature)-287.3(Review)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 59.7543 157.2094 Tm
[(Yasameen)-254.6(Azarbaijani,)-250.7(Kathryn)-245.2(OCallaghan,)-251.7(William)-249.6(Sanders,)]TJ
0 -1.128 TD
[(Changfu)-334.3(Wu,)-333.4(John)-334.4(Laschinger,)-338.4(Danica)-336.7(Marinac)-330.5(Dabic,)]TJ
0 -1.1219 TD
[(Christopher)-334.7(Ronk,)-333.9(David)-334.3(Strauss,)-336.3(Daniel)-331.9(Canos,)]TJ
0 -1.128 TD
[(Robbert)-333.8(Zusterzeel)]TJ
/F5 1 Tf
0 -1.7682 TD
[(FDA,)-334.4(Silver)-335.7(Spring,)-333.8(Maryland)]TJ
/F3 1 Tf
.9999 -2.3047 TD
(Background:)Tj
/F4 1 Tf
5.9387 0 TD
[(Aortic)-330.1(stenosis)-335.8(is)-333.9(a)-333.4(common)-332.3(valvular)-332.8(disease,)]TJ
-6.9386 -1.1219 TD
[(especially)-331.3(in)-328.7(the)-326.8(aging)-326.7(population)-325.6(of)-325.5(Western)-330.5(countries.)-325.8(While)]TJ
0 -1.128 TD
[(surgical)-344.1(aortic)-345(valve)-343.2(replacement)-344.8(is)-340(the)-345.1(predominant)-344.4(treatment)]TJ
0 -1.1219 TD
[(for)-449.8(patients)-451(with)-445.5(symptomatic)-449.9(severe)-446.9(aortic)-448.7(stenosis,)-451.7(30%)-447.4(to)]TJ
27.0045 71.9468 TD
.0122 Tc
[(40)12.2(%)-374.2(o)0(f)-368.2(p)12.2(a)-10.3(t).5(i)12.2(e)-9.8(n)12.2(t)-5.5(s)-371(a)1.9(re)-370(no)12.2(t)-377.5(e)1.9(lig)12.2(i)-5.5(b)0(le)-363.9(for)-362.1(s).9(urg)12.2(e)-4.2(ry)-365.8(due)-363.9(to)-365.8(ad)12.2(v)-6(a)1.9(nced)]TJ
0 -1.128 TD
.0116 Tc
[(age,)-220.1(severe)-218.2(left)-219.6(ventricular)-222.4(dysfun)11.6(c)-10.9(t)11.6(i)-5.6(on,)-220.1(or)-222.4(ot)11.6(h)-6.1(e)1.3(r)-222.4(c)-4.8(o)11.6(m)-6.1(orbidi)11.6(ties.)]TJ
0 -1.1219 TD
0 Tc
[(Tr)20.2(a)14.1(n)0(s)19.2(c)0(a)22.1(t)0(h)18.8(e)0(t)20.7(e)0(r)-293.1(a)0(o)20.2(r)0(t)22.6(i)0(c)-296.3(v)12.2(al)20.7(ve)-296.8(re)17.8(p)12.2(l)12.7(ac)16(e)14.1(m)0(e)20.7(n)12.2(t)-310.4(\()15.9(TA)15(VR)24.3(\))-307.2(h)12.2(as)-296(b)12.2(e)0(e)22.1(n)-304.8(sh)19.2(o)12.2(w)0(n)]TJ
0 -1.128 TD
[(t)12.7(o)-597.5(b)12.2(e)-595.6(a)14.1(n)-597.5(al)20.7(t)12.7(e)0(r)17.8(n)12.2(at)20.7(iv)18.8(e)-595.6(t)12.7(h)12.2(e)0(r)17.8(a)14.1(pe)20.2(ut)18.8(i)12.7(c)-595.6(ap)20.2(p)12.2(r)0(o)22.1(a)0(c)16(h)-591.4(fo)22.1(r)-599.9(t)12.7(h)12.2(e)0(s)21.1(e)-595.6(p)12.2(a)0(t)20.7(i)0(e)14.6(n)12.2(t)12.7(s)]TJ
0 -1.1219 TD
[(s)13.1(h)12.2(ow)16.8(i)12.7(n)12.2(g)-408.5(b)12.2(et)20.7(te)20.7(r)-410.9(o)12.2(r)-410.9(e)0(q)20.2(u)12.2(al)-400(re)23.9(su)19.2(l)12.7(t)0(s)-401(c)14.1(om)18.9(p)12.2(a)0(r)17.8(e)14.1(d)-408.5(t)0(o)-401.9(s)13.1(u)12.2(r)0(g)22.1(i)0(c)20.7(a)0(l)-400(v)12.2(al)20.7(ve)-400.5(re)17.8(-)]TJ
0 -1.128 TD
[(p)12.2(l)12.7(ac)16(e)14.1(m)0(e)20.7(n)0(t)18.8(.)-268.3(Ho)22.9(we)18.7(v)12.2(e)0(r)23.9(,)-268.3(t)12.7(h)0(e)-260.2(e)14.1(ff)19.7(ec)22.1(ts)-260.8(o)12.2(f)-264.5(s)13.1(e)0(x)-260.3(o)12.2(n)-268.2(o)12.2(u)12.2(t)12.7(co)20.2(me)20.7(s)-267.4(a)0(f)17.8(t)12.7(er)-256.5(TA)21.1(VR)]TJ
0 -1.1219 TD
[(re)23.9(ma)20.7(in)-279.9(t)12.7(o)-292.6(b)12.2(e)-290.8(el)20.7(u)12.2(c)0(i)20.7(d)0(a)20.2(t)0(e)20.7(d)12.2(.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.8777 0 TD
[(We)-374.2(gathered)-374.1(and)-370(compared)-374.1(all)-369(previously)-376.4(re-)]TJ
-6.8776 -1.1219 TD
[(ported)-402.3(sex-specic)-409.9(data)-404.2(on)-402.4(effectiveness)-407(and)-406.6(safety)-405.6(outcomes)]TJ
0 -1.128 TD
[(after)-299.1(TAVR.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Material/Methods:)Tj
/F4 1 Tf
8.3166 0 TD
[(We)-246.2(conducted)-249.7(a)-248.1(search)-251.8(in)-249.4(PUBMED)-249.2(and)]TJ
-9.3165 -1.128 TD
[(EMBASE)-353.2(using)-346.1(the)-351.2(following)-349.7(key)-351.7(words:)-349.9(transcatheter)-360.9(aortic)]TJ
0 -1.1219 TD
[(valve)-489.5(replacement,)-493.5(transcatheter)-488.9(aortic)-491.3(valve)-489.5(implantation,)]TJ
0 -1.128 TD
[(sex)-353.2(differences,)-360.1(gender,)-356.8(sex)-353.2(characteristics.)-363.7(Selected)-360(pub-)]TJ
T*
[(lications)-310.2(consisted)-304.3(of)-307.2(original)-309.7(reports)-312.3(that)-308(included)-306(sex-specic)]TJ
0 -1.1219 TD
[(data)-215.1(on)-213.3(outcomes)-213.7(after)-219.9(TAVR)-210.7(and)-217.5(were)-213.4(written)-219.8(in)-212.8(English.)-213.2(From)]TJ
0 -1.128 TD
[(the)-314.6(publications)-316.2(we)-316.6(collected)-313.9(information)-317.6(on)-317(sex-specic)-318.4(base-)]TJ
0 -1.1219 TD
[(line)-558(features,)-558.5(procedural)-559.3(characteristics)-562.6(and)-552.9(post)-559.5(procedural)]TJ
0 -1.128 TD
[(outcomes)-262.5(after)-262.5(TAVR.)-265.5(We)-264.4(used)-265.4(mortality,)-259.9(valve)-263.9(complications,)]TJ
0 -1.1219 TD
[(cerebrovascular)-768.5(complications,)-765(vascular)-769.5(complications)-765(and)]TJ
0 -1.128 TD
[(other)-298.6(outcomes)-299(as)-302.1(our)-301.1(main)-301.9(endpoints.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Results:)Tj
/F4 1 Tf
3.8595 0 TD
[(After)-430.5(in-)-428.6(and)-430.9(exclusion)-427.1(criteria)-430.3(were)-432.9(applied,)-428(our)]TJ
-4.8595 -1.128 TD
[(search)-361.6(resulted)-368.5(in)-359.2(25)-365.8(publications.)-365(At)-360.7(baseline,)-364.2(men)-363.3(had)-363.9(more)]TJ
0 -1.1219 TD
[(comorbidities)-214.4(than)-217(women,)-218.5(especially)-215.5(in)-212.8(terms)-218(of)-215.7(pre-procedural)]TJ
0 -1.128 TD
[(cardiovascular)-334.6(disease)-339.5(and)-333.4(cardiac)-335.6(interventions.)-336.9(Women)-337(were)]TJ
0 -1.1219 TD
[(older,)-402.3(had)-400.5(higher)-402.3(aortic)-399.9(valve)-404.1(gradients)-399(and)-406.6(a)-400.5(higher)-402.3(ejection)]TJ
0 -1.128 TD
[(fraction.)-548.5(While)-549.9(there)-552.8(were)-554.9(no)-548.7(signicant)-551.4(sex-differences)-552.4(in)]TJ
0 -1.1219 TD
[(mortality)-302.6(rates)-308.1(at)-302.4(30)-304.8(days,)-302(most)-302.9(studies)-306.2(reported)-305.2(better)-308.4(survival)]TJ
0 -1.128 TD
[(in)-365.3(women)-364.8(at)-369.5(mid-)-367.1(and)-363.9(long-term)-366.9(follow)-368.5(up)-365.8(with)-366.2(hazard)-368.5(ratios)]TJ
0 -1.1219 TD
-.013 Tc
[(\()-13(f)6.7(or)-253.1(w)-13(o)3.8(me)-13(n)-248.9(c)1.1(om)-13(p)5.9(a)-13(r)4.8(e)1.1(d)-256.9(t)-.3(o)-256.9(m)-13(e)7.7(n)-13(\))-247(r)-13(a)4.8(ngin)-13(g)-250.7(fr)-13(om)-256.3(0.27)-256.9(\()-13(9)9.1(5%)-259.2(C)-13(I)10.4(:)-256.4(0)-13(.)5.3(09)]TJ
0 -1.128 TD
-.0122 Tc
[(0.84)-12.2(\))-496.2(t).5(o)-506(0.9)-12.2(1)-493.8(\()-12.2(9)9.9(5)-12.2(%)-496.2(C)1.4(I)-12.2(:)-495.7(0.7)-12.2(5)6.1(1.1)-12.2(0)6.1(\))-12.2(.)-490.1(O)-12.2(t)5.1(h)0(e)-12.2(r)-494.3(ou)-12.2(t)6.6(c)-12.2(o)8(m).6(e)-12.2(s)-497.2(inc)-12.2(l)8.5(ud)-12.2(e)8(d)]TJ
0 -1.1219 TD
.0117 Tc
[(aortic)-315.6(reg)11.7(u)-6.5(rg)11.7(i)-6(t)0(ation)11.7(,)-323.6(which)-317.5(w)4.1(as)-316.7(the)-315.6(m).1(ost)-317(c)1.4(omm)11.7(o)-6(n)-317.5(v)-.5(alve)-315.6(com-)]TJ
0 -1.128 TD
.0121 Tc
[(pl)12.1(icat)12.1(ion.)-426.9(At)-426.4(30)-426.9(days)-426(of)-423.1(fol)12.1(l)-5.1(ow)-428.4(up)12.1(,)-433(a)1.8(ort)12.1(i)-5.1(c)-431.1(r)3.7(egurgitatio)12.1(n)-432.9(w)-1.6(as)]TJ
0 -1.1219 TD
0 Tc
[(m)12.8(o)12.2(re)-201.7(pr)22.1(ev)20.2(al)20.7(en)20.2(t)-212.9(a)0(m)20.8(o)12.2(n)12.2(g)-213.4(m)12.7(e)0(n)-205.4(\()0(1)22.1(2)12.2(%)22.1(2)12.2(4)0(%)-203.5(a)0(n)20.2(d)-207.3(7)18.3(1)12.2(9)12.2(%)-215.7(i)12.7(n)-207.3(wo)16.8(m)12.8(e)0(n)-199.3(a)0(n)20.2(d)]TJ
0 -1.128 TD
[(m)12.8(e)0(n)20.2(,)-268.3(re)17.8(s)13.1(p)12.2(ec)16(t)12.7(i)12.7(v)12.2(el)14.6(y)12.2(\))0(.)-258.4(S)15.4(tr)16.5(o)12.2(k)12.2(e)-266.4(ra)17.8(t)12.7(e)0(s)-259.4(w)0(e)18.7(r)0(e)-256.5(s)0(i)19.7(m)12.7(il)19.3(ar)-262.6(a)14.1(t)-267.7(30)-256(da)20.2(ys)-261.3(\(w)20.6(o)12.2(m)12.7(en)20.2(:)]TJ
0 -1.1219 TD
[(1)12.2(%)0()22.1(7)12.2(%)-465.7(a)0(n)20.2(d)-463.4(m)12.8(e)0(n)20.2(:)-469(1)12.2(%)0()22.1(5)12.2(%\))19.7(.)-463.4(W)0(o)20.2(m)12.8(en)-455.4(al)20.7(so)-456.4(h)12.2(a)0(d)-455.4(h)12.2(i)12.7(g)0(h)18.4(e)0(r)-451.6(r)0(a)17.8(t)12.7(es)-454.5(of)]TJ
0 -1.128 TD
[(v)12.2(a)0(s)21.1(c)0(u)20.2(l)12.7(ar)-323.6(co)20.2(m)12.8(p)12.2(li)19.3(ca)22.1(ti)19.3(o)12.2(n)0(s)-322.3(a)0(t)-320.7(3)12.2(0)-329.2(d)12.2(ay)20.2(s,)-322.3(ra)23.9(ng)18.3(i)12.7(n)12.2(g)-335.3(f)0(r)25.8(o)0(m)-322.6(6)12.2(%)22.1(2)12.2(0)0(%)-319.3(c)0(o)20.2(m)0(-)]TJ
0 -1.1219 TD
-.0125 Tc
[(pa)-12.5(r)5.3(e)1.6(d)-274.6(t).2(o)-268.6(2)-12.5(%14%)-270.9(i)-12.5(n)-261.9(me)-12.5(n)-266.7(a)1.6(nd)-274.6(hig)-12.5(h)5.8(e)-12.5(r)-262.9(ble)-12.5(e)3.5(ding)-274.6(r)-12.5(a)11.4(t)-12.5(e)2.1(s)-267.7(r)-12.5(a)5.3(ngi)-12.5(n)6.4(g)-268.6(f)-12.5(r)7.2(om)]TJ
0 -1.128 TD
0 Tc
[(1)12.2(0)12.2(%)0()22.1(4)0(4)18.3(%)-325.5(co)20.2(m)12.8(p)0(a)20.2(r)0(e)17.8(d)-329.2(t)12.7(o)-329.2(8)12.2(%)0()22.1(2)12.2(5%)-319.3(i)12.7(n)-329.2(me)20.7(n.)-317(My)19.2(o)12.2(c)0(a)16(r)15.9(di)18.8(al)-320.7(i)12.7(n)12.2(fa)17.8(rc)23.9(ti)19.3(o)12.2(n)]TJ
0 -1.1219 TD
[(wa)18.7(s)-316.2(s)13.1(im)19.4(i)12.7(l)0(a)20.7(r)-319.4(be)20.2(tw)17.3(e)14.1(e)0(n)-309(t)0(h)18.8(e)-315.2(se)21.1(xe)20.2(s)-322.3(a)14.1(s)-322.3(w)0(e)18.7(l)12.7(l)-316.5(a)0(s)-308.2(t)0(a)20.7(m)0(p)18.9(o)12.2(n)12.2(a)0(d)20.2(e)0(,)-309(k)12.2(id)18.8(n)12.2(e)0(y)-309(i)12.7(n-)]TJ
0 -1.128 TD
[(j)12.7(u)12.2(ry)22.1(/f)16.5(a)14.1(i)0(l)19.3(u)12.2(re)-384.6(an)20.2(d)-390.2(s)0(e)21.1(p)12.2(si)19.7(s.)-383.2(Pe)23.4(rm)16.5(a)14.1(n)0(e)20.2(n)12.2(t)-395.8(p)12.2(ac)22.1(em)20.7(ak)20.2(er)-384.6(i)12.7(m)0(p)18.9(l)12.7(an)20.2(t)12.7(a)0(t)20.7(i)0(o)18.8(n)-390.2(wa)18.7(s)]TJ
0 -1.1219 TD
[(m)12.8(o)12.2(re)-293.1(fr)19.7(eq)20.2(u)12.2(e)0(n)20.2(t)-304.3(am)20.7(o)12.2(n)0(g)-292.6(m)0(e)20.7(n)-304.8(wi)17.3(t)12.7(h)-304.8(ra)23.9(te)20.7(s)-310.1(f)15.9(ro)16(m)-298.2(1)0(0)18.3(%)0()22.1(2)12.2(5)12.2(%)-307.2(i)12.7(n)-304.8(wo)22.9(me)20.8(n)]TJ
0 -1.128 TD
[(a)14.1(n)0(d)-280.4(1)12.2(5%)22.1(3)18.3(1)12.2(%)-288.9(i)12.7(n)-292.6(m)12.8(e)0(n)20.2(.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Conclusions:)Tj
/F4 1 Tf
5.7862 0 TD
[(In)-301.1(this)-296.8(systematic)-307.5(literature)-301.7(review)-304.3(we)-298.3(found)-301(a)]TJ
-6.7862 -1.128 TD
[(better)-284(survival)-278.9(in)-286(women)-279.4(compared)-282.6(to)-286(men)-278(after)-286.9(TAVR)-283.8(at)-278(mid-)]TJ
0 -1.1219 TD
[(and)-260.2(long-term)-257.2(follow)-264.9(up.)-256(However,)-263.6(in)-261.6(general)-258.3(women)-261.2(had)-260.2(more)]TJ
0 -1.128 TD
[(vascular)-367.1(complications)-368.7(and)-363.9(bleeding,)-367(but)-365.3(less)-367.8(aortic)-363.3(regurgita-)]TJ
0 -1.1219 TD
[(tion)-505(and)-504.1(pacemaker)-504.4(implantations;)-503.7(stroke)-505.1(rates)-509.3(were)-506.1(similar)]TJ
0 -1.128 TD
[(between)-452.5(women)-456.3(and)-455.3(men.)-454.8(These)-454.4(ndings)-458.6(may)-454.8(partly)-450.5(be)-455.4(ex-)]TJ
T*
[(plained)-440.2(by)-438.9(better)-442.6(baseline)-443.5(characteristics)-446.7(and)-443.1(less)-440.9(valve)-440.7(mis-)]TJ
0 -1.1219 TD
[(match)-208.5(in)-212.8(women)-212.4(compared)-215.5(to)-206.7(men.)-217(Results)-213.4(should)-205.8(be)-211.5(interpreted)]TJ
0 -1.128 TD
[(with)-402.8(caution)-409.7(as)-405.7(most)-406.5(measures)-408.9(only)-401.8(include)-409.7(raw)-404.3(percentages.)]TJ
0 -1.1219 TD
[(Future)-319.8(studies)-324.5(including)-319.5(a)-321.2(larger)-323.5(sample)-323.5(of)-319.4(patients,)-322.9(preferably)]TJ
0 -1.128 TD
[(based)-355(on)-359.7(individual-patient)-358.6(data)-355.4(meta-analysis,)-362.7(are)-358.3(required)-353.9(to)]TJ
0 -1.1219 TD
[(conrm)-301.4(and)-296.8(thoroughly)-299.9(evaluate)-302.2(these)-305.7(preliminary)-297.5(ndings.)]TJ
/F3 1 Tf
0 -3.0364 TD
(11.)Tj
9.843 0 0 9.843 331.7668 132.4346 Tm
[(How)-281.9(to)-278.6(get)-280.9(Gender)-281.7(Medicine)-285.2(into)-280.8(the)]TJ
0 -1.1174 TD
[(Doctors)-282.5(Ofce)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 310.8472 104.8819 Tm
[(Angelika)-331.9(Bader,)-338.6(Margarethe)-337.1(Hochleitner)]TJ
/F5 1 Tf
0 -1.7682 TD
[(Medical)-332.8(University)-340(of)-328.7(Innsbruck,)-338.1(Innsbruck,)-332(Austria)]TJ
/F3 1 Tf
.9999 -2.3047 TD
(Background:)Tj
/F4 1 Tf
5.957 0 TD
[(In)-356(Austria,)-359.7(all)-356.8(diplomas)-355.3(in)-359.2(post-graduate)-356.7(pro-)]TJ
-6.9569 -1.1219 TD
.0158 Tc
[(grammes)-428.4(a)-.6(re)-427.4(awarded)-423.2(b)-2.5(y)-423.2(t)-2(he)-427.4(Au)]TJ
14.2491 0 TD
.0162 Tc
[(strian)-422.8(Medical)-428.4(Association)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 59.7543 749.7069 Tm
0 Tc
(ABSTRACTS)Tj
53.1188 0 TD
(A-5)Tj
ET
endstream
endobj
205 0 obj
<>stream
/GS1 gs
BT
/F4 1 Tf
9.2982 0 0 9.2982 62.022 725.5557 Tm
0 0 0 rg
.0163 Tc
0 Tw
[(\(the)-390.3(licensing)-386.1(authority)-386.1(in)-386.1(this)-391.3(case)-390.3(i)4.6(s)-391.3(t)-1.5(he)-390.3(Austrian)-386.1(Medical)]TJ
0 -1.128 TD
.0174 Tc
[(As)6.1(sociat)5.7(ion)5.2(\))-3.2(.)-360.6(T)3.4(here)-364.8(are)-364.8(t)5.7(wo)-360.6(ty)5.2(pes)-359.7(o)-.9(f)-363(p)5.2(ost-g)5.2(r)-3.2(ad)5.2(uate)-358.7(dip)5.2(l)-.4(om)5.8(a:)]TJ
0 -1.1219 TD
0 Tc
[(sp)19.2(e)14.1(c)0(i)20.7(a)0(l)20.7(i)0(s)19.7(a)0(t)20.7(i)0(o)18.8(n)-371.9(\(s)22.9(ur)16(g)12.2(e)14.1(ry)16(,)-371.9(c)14.1(ar)17.8(d)12.2(i)0(o)18.8(l)12.7(o)12.2(g)0(y)18.3(,)-371.9(et)20.7(c.)20.2(\))-374.3(a)0(n)20.2(d)-371.9(d)12.2(i)0(p)18.8(l)12.7(o)12.2(m)0(a)-363.4(f)0(o)22.1(r)-374.3(cr)17.8(o)12.2(s)0(s)20(-)]TJ
0 -1.128 TD
[(cu)20.2(t)12.7(t)0(i)19.4(n)12.2(g)-292.6(d)12.2(i)12.7(s)0(c)21.1(i)0(p)18.8(l)12.7(in)18.8(es)-277.7(\(s)16.8(p)12.2(o)12.2(r)0(t)22.6(s)-291.8(m)12.8(e)0(d)20.2(i)12.7(ci)20.7(ne)20.2(,)-292.7(g)12.2(er)17.8(i)12.7(a)0(t)20.7(r)0(i)22.6(c)0(s)21.1(\))0(.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.7314 0 TD
[(To)-221.3(get)-223.1(Gender)-225.6(Medicine)-224(into)-218.4(the)-223.1(doctors)-226.9(ofce)]TJ
-6.7313 -1.128 TD
[(\(family)-226.8(doctors)-224.6(and)-223.6(all)-228.7(doctors)-224.6(in)-225(private)-223(practice\))-227.7(we)-225.2(decided)-231.5(to)]TJ
0 -1.1219 TD
[(set)-368.6(up)-371.9(a)-370(diploma)-368.3(programme)-371.6(for)-370.5(Gender)-371.9(Medicine)-370.3(that)-375(would)]TJ
0 -1.128 TD
[(give)-485.3(family)-486.6(doctors)-486.7(and)-485.8(all)-484.8(specialists)-489.5(a)-485.9(diploma)-490.3(in)-481.1(Gender)]TJ
0 -1.1219 TD
[(Medicine)-352(to)-353.1(demonstrate)-353.8(to)-353.1(their)-353(patients)-353.4(that)-350.7(they)-351.2(take)-355.4(an)-351.7(in-)]TJ
0 -1.128 TD
[(terest)-301.5(in)-304.3(and)-296.8(have)-301(knowledge)-301.9(of)-301.1(Gender)-298.7(Medicine.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Material/Methods:)Tj
/F4 1 Tf
8.6458 0 TD
[(At)-574.1(our)-575.4(request)-576.3(the)-576.8(Austrian)-579.2(Medical)]TJ
-9.6458 -1.128 TD
[(Association)-506.4(agreed)-508.8(to)-511.6(set)-502.8(up)-506(a)-510.3(diploma)-502.5(program)-508.2(in)-505.5(Gender)]TJ
0 -1.1219 TD
[(Medicine.)-309.3(We)-313.2(developed)-304.6(a)-309.1(course)-308.6(in)-310.4(Gender)-310.9(Medicine)-309.3(consist-)]TJ
0 -1.128 TD
[(ing)-377.4(of)-374.3(10)-378(modules)-380.2(of)-374.2(16)-378(hours)-379.4(each)-378.4(running)-373.6(three)-382.1(or)-374.2(four)-376.6(se-)]TJ
T*
[(mesters,)-300.6(just)-302.9(as)-302.1(for)-297.3(many)-302.4(other)-298.6(diploma)-301.3(courses.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Results:)Tj
/F4 1 Tf
3.9266 0 TD
.0163 Tc
[(The)-487.9(A)2.6(us)5(tria)6(n)-489.7(M)-1.1(edical)-483.1(As)5(sociation)-489.7(s)-1.1(tarted)-489.7(a)-487.9(d)4.1(i-)]TJ
-4.9265 -1.128 TD
.0141 Tc
[(p)-4.2(l)2.4(o)-4.2(m)2.5(a)-319.3(p)1.9(ro)-4.2(gram)-3.6(me)-319.3(for)-317.5(G).4(en)-4.2(der)-317.5(M)2.8(ed)-4.2(ici)-3.7(n)1.9(e)-319.3(i)2.4(n)-315.1(2)-4.2(01)-4.2(5.)-315.1(Th)-4.2(e)-313.2(g)-4.2(oal)-320.7(o)1.9(f)]TJ
0 -1.1219 TD
.0135 Tc
[(t)-4.3(h)1.3(e)-319.9(c)-2.9(ou)-4.8(rs)-3.9(e)-319.9(i)1.8(s)-3.9(:)-321.3(kn)-4.8(owl)-4.3(e)-2.9(dg)-4.8(e)-319.9(o)1.3(f)-318.1(G)-6.3(ender)-324.2(M)2.2(ed)-4.8(ici)-4.3(n)1.3(e)-319.9(o)-4.8(n)-315.7(t)-4.3(he)-319.9(b)-4.8(a)3.2(s)-3.9(i)-4.3(s)-321(o)1.3(f)]TJ
0 -1.128 TD
.0154 Tc
[(evidence-based)-521.1(k)3.2(nowledge)-525.3(s)4.1(h)-2.9(ou)]TJ
13.9199 0 TD
.0148 Tc
[(ld)-527.8(be)-525.9(incorporated)-521.7(into)-521.7(all)]TJ
-13.9199 -1.1219 TD
.0157 Tc
[(aspects)-434.6(o)3.5(f)-431.7(m)4.1(edicine,)-429.4(i.e.)-429.4(prev)]TJ
12.7858 0 TD
[(ention,)-429.4(d)3.5(iagnosis,)-429.4(therapy)-429.4(a)-.7(nd)]TJ
-12.7858 -1.128 TD
.0173 Tc
[(reha)7(bi)5.6(lit)5.6(ati)5.6(o)-1(n)5.1(.)-281.4(Ess)6(e).9(nt)5.6(ial)-280.9(c).9(o)5.1(n)5.1(t)]TJ
11.9505 0 TD
.0154 Tc
[(ents)-282.5(are:)-282.8(Womens)-282.5(H)1.7(ealth/Mens)]TJ
-11.9505 -1.1219 TD
.0157 Tc
[(Health,)-386.7(s)4.4(exuality)-386.7(and)-386.7(r)1.2(eproduct)]TJ
13.426 0 TD
.0134 Tc
[(io)-4.9(n,)-389(cardi)-4.4(ol)-4.4(og)-4.9(y,)-389(p)-4.9(h)1.2(arm)-4.3(acol)-4.4(o)1.2(-)]TJ
-13.426 -1.128 TD
.0181 Tc
[(gy)5.9(,)-341.6(e)1.7(nd)5.9(oc)7.8(ri)6.4(no)5.9(lo)5.9(g)5.9(y)-.2(/)6.4(m).4(et)6.4(abo)5.9(l).3(i)6.4(s).7(m,)]TJ
13.3711 0 TD
.0172 Tc
[(d)5(i)-.6(ab)5(etes)-341.7(mel)5.5(l)-.6(i)5.5(t)-.6(u)5(s)-.2(,)-342.5(lip)5(id)-342.5(me)6.9(ta-)]TJ
-13.3711 -1.1219 TD
.0175 Tc
[(bo)5.3(li)5.8(c)-462.3(d)-.8(i)5.8(s).1(o)5.3(r)3(ders,)-458.1(o)-.8(s)6.2(t)-.3(eo)5.3(po)5.3(ros)6.2(i)-.3(s,)-458.1(we)7.2(ig)5.3(ht)5.8(,)-464.2(p)-.8(s)6.2(y)-.8(ch)5.3(iat)5.8(r)3(y,)-458.1(add)5.3(i)-.3(ct)5.8(io)5.3(n,)]TJ
0 -1.128 TD
.0136 Tc
[(em)-4.1(er)-7(gency)-577.8(m)-4.1(edi)-4.2(c)-2.8(in)-4.7(e,)-577.8(gas)-3.8(t)-4.2(roent)-4.2(e)-2.8(rol)-4.2(o)1.4(g)-4.7(y)1.4(,)-583.9(n)1.4(eph)-4.7(r)-.9(ol)-4.2(og)-4.7(y,)-577.8(p)-4.7(h)1.4(y)-4.7(s)2.3(i)-4.2(-)]TJ
0 -1.1219 TD
.0154 Tc
[(cia)5.1(n)-2.9(-patient)-471.8(communication,)-472.4(pr)]TJ
13.4504 0 TD
.0146 Tc
[(e)4.3(v)-3.7(ention,)-473.2(p)-3.7(ublic)-477.4(h)2.4(ealth.)-479.3(T).6(he)]TJ
-13.4504 -1.128 TD
.0133 Tc
[(d)-5(i)1.6(p)-5(l)1.6(o)-5(m)1.7(a)-484.8(p)1.1(r)-7.3(ogram)-4.4(me)-484.8(i)-4.5(n)-480.5(G)-6.5(e)-3.1(nder)-482.9(M)-4.1(edi)-4.5(c)-3.1(in)-5(e)-484.8(c)-3.1(oncl)-4.5(u)1.1(d)-5(e)-3.1(s)-479.7(w)-6.5(it)-4.5(h)-480.5(a)]TJ
0 -1.1219 TD
.0152 Tc
[(pres)3.9(entation)-320.1(and)-326.2(a)-324.3(nal)-325.7(paper.)-326.2(The)-324.3(d)-3.1(iploma)-324.3(in)-320.1(Gender)-322.5(M)-2.2(edi-)]TJ
0 -1.128 TD
.0154 Tc
[(cine)-391.2(is)-392.2(granted)-393.1(t)-2.4(o)-387(p)-2.9(hys)4.1(i)-2.4(cians)-392.2(w)]TJ
13.4321 0 TD
.0158 Tc
[(ho)-392.7(success)4.5(f)1.3(ully)-392.7(conc)5.5(lude)-390.8(the)]TJ
-13.4321 -1.1219 TD
.0179 Tc
[(mo)5.7(du)5.7(le)7.6(s)-298.3(a)1.5(nd)-293(th)5.7(e)-297.2(e)1.5(xam)6.3(i).1(n)5.7(a)1.5(ti)6.2(on)5.7(s.)]TJ
/F3 1 Tf
.9999 -1.128 TD
0 Tc
(Conclusions:)Tj
/F4 1 Tf
5.8594 0 TD
[(Th)16.5(e)-321.2(d)0(i)18.8(p)12.2(lo)18.8(ma)-314.6(in)-316.5(Ge)18.7(n)12.2(d)12.2(e)0(r)-317.5(M)13.1(ed)14.1(i)12.7(c)0(i)20.7(n)0(e)-315.1(p)12.2(er)17.8(mi)19.4(ts)-315.7(p)12.2(h)0(y)18.3(-)]TJ
-6.8593 -1.1219 TD
[(si)19.7(ci)20.7(an)14.1(s)-377.1(t)12.7(o)-384.1(a)0(c)22.1(q)0(u)18.3(i)12.7(re)-372.4(a)-382.2(g)12.2(en)20.2(er)17.8(al)-369.5(un)18.3(d)12.2(e)0(r)17.8(s)0(t)19.7(a)0(n)20.2(d)0(i)18.8(n)12.2(g)-384.1(o)12.2(f)-380.4(G)0(e)18.7(n)12.2(de)20.2(r)-380.4(M)0(e)15(d)12.2(ic)20.7(in)18.8(e)]TJ
0 -1.128 TD
[(an)20.2(d)-341.4(h)12.2(ow)-336.8(t)12.7(o)-341.4(i)12.7(n)0(c)14.1(o)12.2(rp)22.1(or)16(a)14.1(t)0(e)-332.9(G)0(e)18.7(n)0(d)18.3(e)0(r)-329.7(M)0(e)15(d)12.2(i)12.7(c)0(i)14.6(n)12.2(e)-339.5(a)0(s)15(p)12.2(ec)16(t)12.7(s)-340.6(in)18.8(to)-334.8(a)14.1(l)0(l)-334.3(m)12.8(ed)20.2(i-)]TJ
0 -1.1219 TD
[(ca)16(l)-176.3(d)12.2(is)19.7(ci)14.6(p)12.2(l)0(i)19.3(n)12.2(es)-174(a)14.1(n)0(d)-170.7(i)0(t)-169.7(d)12.2(em)14.7(o)12.2(n)12.2(s)0(t)19.7(r)0(a)17.8(t)0(e)20.7(s)-182(t)12.7(h)0(i)18.8(s)-182(k)12.2(n)12.2(o)0(w)16.8(l)12.7(ed)20.2(ge)-174.9(t)12.7(o)-176.8(th)18.9(ei)20.7(r)-179.2(p)0(a)14.1(t)12.7(ie)20.7(nt)18.8(s.)]TJ
/F3 1 Tf
0 -4.1644 TD
(12.)Tj
9.843 0 0 9.843 82.9417 341.6314 Tm
[(Experience)-288.4(of)-278.6(Intimate)-281.5(Partner)-288.7(Violence)]TJ
0 -1.1116 TD
[(Among)-283.8(Urban)-277.9(Women)-285.1(in)-278.6(Southwestern)-287.4(Nigeria)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 62.022 314.0786 Tm
[(Mary)-334.9(Balogun)]TJ
/F5 1 Tf
0 -1.7682 TD
[(Department)-338.6(of)-328.7(Community)-340(Medicine,)-330.9(College)-335.1(of)-334.8(Medicine,)]TJ
0 -1.1219 TD
[(University)-340(of)-328.7(Ibadan,)-331.5(Nigeria,)-336.2(Ibadan,)-331.5(Nigeria)]TJ
/F3 1 Tf
.9999 -2.3047 TD
(Background:)Tj
/F4 1 Tf
6.1947 0 TD
-.0199 Tc
[(Intimate)-542.4(P)1.6(artner)-546.6(Violenc)-5.8(e)-542.4(is)-543.4(widespread)-544.2(and)]TJ
-7.1947 -1.1219 TD
-.0189 Tc
[(deeply)-329.8(in)5.5(grained)-329.8(a)1.3(nd)-329.8(has)-329(s).3(eri)6(ous)-329(imp)5.5(a)-4.8(cts)-329(o)5.5(n)-335.9(w)4(omen)5.5(s)-329(health)-329.8(and)]TJ
0 -1.128 TD
-.0187 Tc
[(well)6.2(-bein)5.7(g)-.4(.)-232.1(I)-2.8(n)-232.1(N)4.2(igeri)6.2(a)-4.6(,)-232.1(s).5(tu)5.7(dies)-231.2(th)]TJ
12.5358 0 TD
-.02 Tc
[(at)-239(have)-237.6(addressed)-233.4(I)-4.1(ntimate)-237.6(P)1.5(artner)]TJ
-12.5358 -1.1219 TD
-.0185 Tc
[(Vi)6.4(olence)-156.8(\(IPV\))-155(to)-152.6(wo)5.9(men)-152.6(h)-.2(ave)-156.8(f)3.5(ocu)5.9(s).7(ed)-152.6(m)6.4(a)-4.4(i)6.4(n)-.2(ly)-152.6(on)-152.6(ph)5.9(ysical)-152.1(viol)6.4(en)5.9(ce.)]TJ
/F3 1 Tf
.9999 -1.128 TD
0 Tc
(Objective\(s\):)Tj
/F4 1 Tf
5.8045 0 TD
[(The)-298.7(purpose)-298.2(of)-295(the)-296.3(study)-297.3(was)-297.5(to)-298.2(determine)-299.9(the)]TJ
-6.8045 -1.1219 TD
[(prevalence,)-272.7(types)-264.9(and)-266.3(factors)-267.7(associated)-270(with)-268.7(experience)-266.6(of)-270.6(IPV)]TJ
0 -1.128 TD
[(among)-302.3(urban)-305.2(women)-303.8(in)-304.3(Southwestern)-299.6(Nigeria.)-309.9(Attitude)-302.3(to)-304.3(wife)]TJ
T*
[(beating)-299.9(was)-303.6(also)-301.5(assessed.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Material/Methods:)Tj
/F4 1 Tf
8.2983 0 TD
-.0132 Tc
[(300)-190(u)-13.2(r)2.8(ba)-13.2(n)-182(w)-13.2(o)9.7(m)-13.2(en)-190(ag)-13.2(ed)-190(be)-13.2(t)7.5(w)-13.2(e)5.5(e)-13.2(n)-182(1)-1(5)-190(a)-13.2(n)7(d)-190(4)-13.2(9)]TJ
-9.2982 -1.128 TD
0 Tc
[(y)12.2(e)0(a)16(r)0(s)-153.9(s)13.1(el)14.6(e)14.1(c)0(t)14.6(e)14.1(d)-164.6(u)12.2(si)19.7(ng)-152.4(m)12.8(u)0(l)18.8(t)0(i)19.3(s)0(t)19.7(a)0(g)20.2(e)-162.7(sa)15(m)12.8(p)12.2(li)19.3(ng)-152.4(me)20.7(th)18.8(od)-152.4(we)18.7(re)-152.9(i)12.7(n)0(t)18.8(e)0(r)17.8(v)12.2(ie)14.6(we)18.7(d)]TJ
0 -1.1219 TD
[(u)12.2(s)0(i)19.7(n)0(g)-243.8(s)13.1(em)14.7(i)-249.5(s)13.1(tr)16.5(u)12.2(c)0(t)20.7(u)0(r)16(e)14.1(d)-250(i)0(n)18.8(t)0(e)20.7(r)0(v)16(i)12.7(ew)18.7(er)-244.3(a)14.1(d)0(m)18.9(i)0(n)18.8(i)0(s)19.7(t)0(e)20.7(r)0(e)17.8(d)-250(q)12.2(u)0(e)14.1(s)13.1(ti)19.3(o)12.2(n)0(n)18.3(a)0(i)20.7(r)0(e)17.8(.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Results:)Tj
/F4 1 Tf
3.8473 0 TD
[(Li)17(fe)17.8(t)12.7(i)0(m)19.4(e)-363.9(pr)16(e)14.1(v)0(a)14.1(l)12.7(en)20.2(ce)-355.9(o)12.2(f)-368.2(IP)25.3(V)-367.3(w)0(a)18.7(s)-365(7)12.2(0)12.2(.)0(0)18.3(%)0(,)-355.9(c)14.1(on)18.3(tr)16.5(o)12.2(l)12.7(li)19.3(ng)]TJ
-4.8473 -1.1219 TD
[(b)12.2(e)0(h)14.1(a)14.1(v)0(i)18.8(o)12.2(r)-441.3(w)0(a)18.7(s)-438.1(57)18.3(.)12.2(7)0(%)16(,)-432.9(ps)19.2(yc)20.2(ho)18.3(lo)18.9(g)12.2(i)0(c)14.6(a)14.1(l)-438.5(v)0(i)18.8(o)0(l)18.8(e)0(n)20.2(c)0(e)-429.1()0(3)18.3(3)12.2(.7)18.3(%,)-429.1(p)12.2(h)0(y)18.3(s)13.1(ic)14.6(a)14.1(l)]TJ
0 -1.128 TD
-.0132 Tc
[(vi)-13.2(o)5.6(l)-13.2(e)7.5(n)-13.2(ce)-261.3()-13.2(1)5.1(3.)-13.2(7)5.1(%)-13.2(,)-253.3(a)-13.2(nd)-263.2(se)-13.2(xua)-13.2(l)-254.7(v)-13.2(i)5.6(ol)-13.2(enc)-13.2(e)-259.4(16)-13.2(.)5.1(4)-1(%)-13.2(.)-259.4(Pr)-13.2(e)4.6(d)-13.2(i)5.6(c)-13.2(t)7.5(o)-13.2(rs)-262.3(of)-265.5(c)-13.2(o).9(n-)]TJ
0 -1.1219 TD
0 Tc
[(tr)16.5(o)12.2(l)12.7(li)19.3(ng)-414.6(be)20.2(ha)20.2(vi)18.8(or)-416.9(we)18.7(re)-415.1(y)12.2(o)0(u)18.3(n)12.2(g)-426.8(a)0(g)20.2(e)-424.9(o)12.2(f)-423.1(wo)16.8(m)12.8(e)0(n)-418.8(\()0(2)22.1(5)12.2(3)18.3(4)-158.5(y)12.2(rs)16.8(\))-423.1(\()0(O)20.6(R)]TJ
/F2 1 Tf
25.3521 0 TD
(=)Tj
/F4 1 Tf
-25.3521 -1.128 TD
[(2)12.2(.)0(0)18.3(;)-505.5(9)12.2(5)12.2(%)0(C)17.4(I)-502.3(1)12.2(.)0(1)18.3()12.2(3.)18.3(9)12.2(\))-502.3(an)20.2(d)-506(h)12.2(is)19.7(to)18.9(ry)-490.1(of)-496.2(p)12.2(a)0(r)17.8(t)12.7(ne)20.2(r)19.7(s)-505.2(i)12.7(nv)18.3(o)12.2(l)0(v)18.9(e)0(m)14.7(e)14.1(nt)-493.3(in)]TJ
0 -1.1219 TD
[(p)12.2(h)0(y)18.3(s)0(i)19.7(c)0(a)16(l)-255.6(g)21.6(h)12.2(t)-255.6(\(O)14.5(R)]TJ
/F2 1 Tf
7.2739 0 TD
(=)Tj
/F4 1 Tf
.5427 0 TD
[(8.)18.3(2)12.2(;)-255.6(95)18.3(%)-258.4(C)13.6(I)-258.4(1)12.2(.1)18.3()12.2(6)0(5)18.3(.)12.2(4\))16(.)-256.1(P)15.4(re)17.8(di)18.8(ct)20.7(or)16(s)-255.2(o)12.2(f)-258.4(p)12.2(hy)18.3(s)13.1(i)0(c)14.6(a)14.1(l)]TJ
-7.8166 -1.128 TD
[(v)12.2(i)0(o)18.8(l)0(e)20.7(n)0(c)14.1(e)-351.7(we)18.7(re)-348(p)12.2(a)0(r)17.8(t)12.7(n)12.2(e)0(r)17.8()0(s)-349(a)14.1(lc)14.6(o)12.2(h)12.2(o)0(l)-347(c)14.1(on)18.3(su)19.2(m)12.8(p)0(t)18.8(i)0(o)18.8(n)-353.6(\(O)20.6(R)]TJ
/F2 1 Tf
20.1634 0 TD
(=)Tj
/F4 1 Tf
.5427 0 TD
[(3)12.2(.)12.2(2)0(;)-347(9)12.2(5%)-343.7(CI)]TJ
-20.7061 -1.1219 TD
[(1)12.2(.)0(4)18.3()12.2(7.)18.3(2)12.2(\))-404.8(an)14.1(d)-402.4(h)12.2(is)19.7(to)18.8(ry)-392.5(of)-398.6(p)12.2(a)0(r)17.8(t)12.7(ne)20.2(r)19.7(s)-407.6(i)12.7(nv)18.3(o)12.2(l)0(v)18.8(e)0(m)20.8(e)0(n)14.1(t)-401.9(in)-395.8(p)12.2(h)0(y)18.3(s)13.1(ic)14.6(a)14.1(l)-408(g)21.6(h)12.2(t)]TJ
0 -1.128 TD
[(\(O)20.6(R)]TJ
/F2 1 Tf
1.6889 0 TD
(=)Tj
/F4 1 Tf
.5427 0 TD
-.0124 Tc
[(4.)-12.4(5)5.9(;)-335(95%)-337.9(CI)-337.9(1.2)-12.4()5.9(1)-.2(7)-12.4(.)5.9(3\))-12.4(.)-325.7(H)-12.4(a)6.3(v)-.2(i)-12.4(n)6.4(g)-335.5(f)-12.4(e)5.4(w)-12.4(e)6.3(r)-331.8(c)-12.4(h)7.8(i)-12.4(l)6.9(dr)-12.4(e)5.4(n)-335.5(\()]TJ
/F2 1 Tf
19.3891 0 TD
0 Tc
()Tj
/F4 1 Tf
.7134 0 TD
[(2)12.2(\))-319.4(\(O)20.6(R)]TJ
/F2 1 Tf
2.8291 0 TD
(=)Tj
/F4 1 Tf
-25.1631 -1.1219 TD
[(4)12.2(.)0(6)18.3(;)-389.7(95)18.3(%)-392.5(C)13.6(I)-392.6(1)12.2(.6)18.3(1)18.3(6)12.2(.)0(0)18.3(\))-392.6(a)14.1(n)0(d)-384.1(h)12.2(is)19.7(to)18.9(ry)-380.3(o)12.2(f)-392.6(pa)20.2(rt)16.5(n)12.2(e)0(r)17.8()0(s)-379.5(i)0(n)18.8(v)12.2(ol)18.8(ve)20.2(me)14.6(n)12.2(t)-389.7(in)]TJ
26.9984 71.9468 TD
[(ph)18.3(y)12.2(s)0(i)13.6(c)14.1(al)-168.3(g)15.5(h)12.2(t)-176.3(we)18.7(re)-171.2(p)12.2(r)0(e)17.9(d)12.2(ic)14.6(t)12.7(o)12.2(rs)-172.2(o)12.2(f)-179.2(s)13.1(e)0(x)14.1(u)12.2(al)-168.3(v)12.2(i)0(o)18.8(l)0(e)20.7(n)0(c)14.1(e)-174.9(\(O)20.6(R)]TJ
/F2 1 Tf
20.517 0 TD
(=)Tj
/F4 1 Tf
.5427 0 TD
[(8)12.2(.)0(4)18.3(;)-176.3(95)18.3(%)-179.1(C)13.6(I)]TJ
-21.0597 -1.128 TD
[(1.)18.3(4)12.2()0(5)18.3(1)0(.)18.3(8)12.2(\).)-154.8(Ab)16.8(o)12.2(u)12.2(t)-170.2(2)12.2(3)12.2(.)0(4)18.3(%)-166.9(o)12.2(f)-167(wo)22.9(me)14.6(n)-164.6(j)12.7(us)19.2(ti)19.3(e)17.3(d)-164.6(w)0(i)23.4(f)0(e)-159(b)12.2(ea)16(t)12.7(i)0(n)18.8(g)12.2(.)-170.7(T)0(h)22.6(e)-168.8(m)12.8(o)12.2(st)]TJ
0 -1.1219 TD
[(co)14.1(m)12.8(m)12.8(o)0(n)-384.1(r)0(e)23.9(a)0(s)15(o)12.2(n)-390.2(f)0(o)22.1(r)-392.6(j)12.7(u)12.2(st)19.7(i)16(c)14.1(a)0(t)14.6(i)12.7(on)-378(wa)18.7(s)-389.3(t)0(h)18.9(a)0(t)-381.7(t)12.7(he)-382.2(wo)22.9(ma)20.8(n)-390.2(h)0(a)20.2(d)-390.2(b)12.2(e)0(e)16(n)]TJ
0 -1.128 TD
[(un)18.3(fa)17.8(i)12.7(t)0(h)18.8(f)0(u)16(l)-249.5(\(2)22.1(2)12.2(%)0(\))19.7(.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Conclusions:)Tj
/F4 1 Tf
5.8045 0 TD
[(IPV)-311.5(and)-309(its)-315.1(different)-313.1(types)-313.7(is)-309.6(a)-315.2(common)-314(expe-)]TJ
-6.8045 -1.128 TD
[(rience)-410.7(among)-406(Nigerian)-413.5(urban)-402.8(women.)-413.6(Different)-406.1(strategies)-407.9(are)]TJ
0 -1.1219 TD
[(needed)-305.2(to)-298.2(prevent)-302.8(and)-302.9(reduce)-301.5(IPV.)]TJ
/F3 1 Tf
0 -3.579 TD
(13.)Tj
9.843 0 0 9.843 333.9779 629.5179 Tm
[(Sex)-280.8(Differences)-289.2(in)-278.6(Recent)-287.2(Mental)-280.7(Health)]TJ
0 -1.1116 TD
[(Disorders)-284.6(Among)-283.8(Military)-283.3(Sexual)-284.1(Trauma)]TJ
T*
[(Victims)-287.3(Using)-282.6(Data)-281.7(from)-277.3(a)-283.3(National)-280.5(Veteran)]TJ
0 -1.1174 TD
[(Health)-285.4(Survey)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 313.0582 580.0817 Tm
[(Shannon)-336.2(Barth,)-333.8(Erin)-332.9(Dursa,)-336.4(Robert)-333.8(Bossarte,)]TJ
0 -1.1219 TD
[(Aaron)-337.2(Schneiderman)]TJ
/F5 1 Tf
0 -1.7682 TD
[(Department)-338.6(of)-334.8(Veterans)-331(Affairs,)-339.9(Washington,)-329.5(District)]TJ
0 -1.128 TD
[(of)-334.8(Columbia)]TJ
/F3 1 Tf
.9999 -2.3047 TD
(Background:)Tj
/F4 1 Tf
5.8106 0 TD
[(Since)-205.8(2002,)-207.2(the)-204.8(Department)-209.9(of)-209.6(Veterans)-204(Affairs)]TJ
-6.8106 -1.1219 TD
[(\(VA\))-464.9(has)-460.6(conducted)-463.1(universal)-459.9(military)-461.2(sexual)-464.2(trauma)-460.8(\(MST\))]TJ
0 -1.128 TD
[(screening)-464.7(for)-462(all)-460.4(veterans)-464.7(utilizing)-458.8(VA)-460.2(health)-464.6(care.)-460(Previous)]TJ
0 -1.1219 TD
[(studies)-269.6(have)-264.4(reported)-262.5(mental)-268.9(health)-263.4(conditions)-263.8(among)-265.7(VA)-265.1(users)]TJ
0 -1.128 TD
[(with)-427.2(MST,)-424.5(though)-426.1(few)-428.7(have)-429.1(reported)-427.1(on)-420.6(the)-430.5(experience)-425.1(of)-429.1(a)]TJ
0 -1.1219 TD
[(population-based)-305(sample)-299.1(of)-301.1(veterans.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.8899 0 TD
[(The)-377.9(objective)-376.8(of)-374.2(this)-376.1(study)-376.5(is)-382.7(to)-371.4(describe)-379.3(sex)]TJ
-6.8898 -1.1219 TD
[(differences)-485.8(in)-475(recent)-483.9(depression,)-477.8(anxiety,)-482.8(alcohol)-476.8(abuse,)-483(and)]TJ
0 -1.128 TD
[(PTSD)-301.7(among)-302.3(veterans)-300.1(reporting)-300.4(MST.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
.0164 Tc
[(Mater)-6.1(i)4.7(al/Methods)5.1(:)]TJ
/F4 1 Tf
8.8592 0 TD
.0171 Tc
[(VAs)-512.5()57.4()-3.5(Natio)4.9(nal)-512.8(H)3.4(ealth)-513.3(St)5.4(udy)-507.2(fo)4.9(r)-515.7(a)]TJ
-9.8592 -1.128 TD
0 Tc
[(Ne)18.7(w)-324.6(G)0(e)18.7(n)12.2(er)17.8(at)20.7(i)12.7(o)0(n)-317(o)12.2(f)-325.5(U)0(.)22.9(S)0(.)-319.9(V)0(e)24.8(t)0(e)20.7(r)0(a)17.8(n)12.2(s)71.7()-325.5(i)12.7(s)-328.4(a)-321.2(po)18.4(p)12.2(u)12.2(l)0(a)20.7(t)0(i)19.3(o)12.2(n)12.2(-)0(b)16(a)14.1(se)21.1(d)-329.2(h)12.2(ea)22.1(lt)19.3(h)]TJ
0 -1.1219 TD
-.0124 Tc
[(s)-12.4(u)6.8(r)-12.4(v)9.7(e)-12.4(y)-321.4(of)-325.7(2)-12.4(0)5.9(,563)-329.4(ve)-12.4(t)8.3(e)-12.4(r)5.4(a)-12.4(n)7.8(s)-328.6(de)-12.4(p)7.8(l).3(oy)-12.4(e)7.8(d)-329.4(in)-329.4(s)-12.4(u)6.8(ppo)-12.4(r)9.7(t)-328.9(of)-331.8(O)-12.4(p)10.5(e)-12.4(r)5.4(at)-12.4(i)6.9(o)-.2(n)-329.4(E)-12.4(n)10.2(-)]TJ
0 -1.128 TD
0 Tc
[(du)18.3(ri)22.6(n)12.2(g)-310.9(F)15.4(r)0(e)17.8(e)0(d)20.2(o)12.2(m)-304.3(a)0(n)20.2(d)-304.8(Op)16.8(e)14.1(r)0(a)17.8(t)12.7(io)18.8(n)-304.8(I)0(r)19.7(a)0(q)20.2(i)-304.3(Fr)19.2(e)14.1(e)0(d)20.2(o)0(m)-298.2(a)14.1(nd)-298.7(n)12.2(o)12.2(n)0(-)22.1(d)0(e)20.2(p)0(l)18.8(o)12.2(y)12.2(e)0(d)]TJ
0 -1.1219 TD
[(ve)20.2(te)20.7(ra)17.8(n)12.2(s)0(.)-474.7(V)0(A)-472.4(M)0(S)22.4(T)-483.5(sc)15(re)23.9(en)20.2(er)-476(q)12.2(u)12.2(e)0(s)21.1(t)0(i)19.3(o)12.2(n)12.2(s)-486.9(o)12.2(n)-487.7(t)12.7(h)12.2(e)-485.9(s)13.1(ur)22.1(ve)20.2(y)-487.8(a)14.1(ll)19.3(o)12.2(w)0(e)18.7(d)]TJ
0 -1.128 TD
[(me)20.7(as)15(u)12.2(r)0(e)23.9(m)0(e)20.8(n)0(t)-298.2(o)12.2(f)-307.2(M)0(S)22.4(T)-312.8(i)12.7(n)-304.8(a)-309.1(c)0(o)20.2(n)12.2(d)21.6(en)20.2(t)12.7(i)0(a)20.7(l)0(,)-298.2(n)12.2(o)12.2(n)0(-)16(c)14.1(li)19.3(n)12.2(i)0(c)20.7(a)0(l)-296.3(s)0(e)21.1(t)0(t)19.3(i)0(n)18.8(g)12.2(.)-304.8(T)0(h)16.5(e)]TJ
0 -1.1219 TD
-.013 Tc
[(P)-13(a)4.3(ti)-13(e)7.7(n)-13(t)-360(H)-13(e)11.8(a)-13(l)7.7(t)-13(h)-360(Q)-13(u)9.9(e)-13(s)8.1(t)-13(i)6.3(onn)-13(a)7.2(i)-13(re)-364.7(me)-13(asur)-13(e)4.8(d)-366.6(de)-13(p)7.2(r)-13(e)4.8(s).1(s)-13(i)6.7(on,)-366.6(a)-13(n)7.2(xi)-13(ety,)-366.6(a)-13(n)7.2(d)]TJ
0 -1.128 TD
0 Tc
[(al)14.6(c)14.1(o)12.2(ho)18.3(l)-340.9(a)14.1(b)12.2(u)0(s)19.2(e)0(.)-327.3(P)0(T)19.7(S)0(D)-327.5(i)0(s)-327.8(m)0(e)20.7(a)0(s)21.1(u)0(r)22.1(e)0(d)-333.4(u)12.2(s)13.1(i)0(n)18.8(g)-335.3(th)18.9(e)-339.5(P)0(C)22.9(L)0(-)20.2(1)12.2(7.)-329.2(We)-331.5(c)14.1(a)0(l)20.7(c)0(u)20.2(-)]TJ
0 -1.1219 TD
-.0202 Tc
[(l)-20.2(a)-5.6(t)-7.5(e)-20.2(d)-213.4(w)-20.2(ei)-7.5(g)-8(h)-8(t)-20.2(ed)-227.5(p)-8(r)-20.2(ev)-20.2(al)-20.2(en)-20.2(ce)-225.6(e)-20.2(s).9(t)-7.5(i)-20.2(ma)-20.2(te)-20.2(s)-212.5(o)-20.2(f)-211.5(m)-20.2(en)-20.2(ta)-20.2(l)-212.9(h)-8(e)-20.2(a)-4.2(l)-7.5(t)-7.5(h)-227.5(a)-6.1(m)-20.2(on)-8(g)-221.4(t)-20.2(ho)-8(s)-20.2(e)]TJ
0 -1.128 TD
0 Tc
[(re)17.8(p)12.2(o)12.2(r)0(t)16.5(i)12.7(n)12.2(g)-359.7(M)13.1(S)0(T)19.7(,)-353.6(an)20.2(d)-353.6(s)13.1(ex)20.2(ua)20.2(l)-359.2(h)12.2(ar)23.9(as)15(s)13.1(m)12.8(en)20.2(t)-359.2(a)14.1(n)12.2(d)-359.7(s)13.1(e)0(x)20.2(u)12.2(al)-345.1(as)21.1(sa)21.1(ul)18.9(t)-353.1(s)0(e)21.1(p)0(a)20.2(-)]TJ
0 -1.1219 TD
[(ra)17.8(t)12.7(e)0(l)20.7(y)0(.)-304.8(W)14.1(ei)14.6(g)12.2(h)12.2(t)12.7(ed)-302.9(ad)20.2(j)12.7(u)0(s)19.2(t)12.7(ed)-302.9(od)18.3(d)12.2(s)-310.1(ra)17.8(t)12.7(i)0(o)18.8(s)-310.1(an)20.2(d)-310.9(9)0(5)18.3(%)-313.3(c)14.1(o)12.2(n)21.6(de)20.2(nc)20.2(e)-315.2(i)12.7(n)12.2(t)0(e)20.7(r)0(-)]TJ
0 -1.128 TD
[(va)20.2(ls)-242.5(we)18.7(re)-244.3(c)14.1(a)0(l)20.7(c)0(u)20.2(l)0(a)20.7(t)0(e)20.7(d)-256.1(fo)22.1(r)-252.3(m)12.8(en)20.2(t)12.7(a)0(l)-247.6(h)12.2(e)14.1(a)0(l)20.7(t)0(h)-243.3(o)12.2(ut)18.8(co)20.2(m)12.8(e)0(s)21.1(,)-256.1(s)13.1(t)12.7(ra)17.9(t)12.7(i)0()22.1(e)0(d)-242(b)0(y)-243.8(s)13.1(ex)]TJ
0 -1.1219 TD
[(an)20.2(d)-292.6(c)14.1(on)18.3(t)12.7(r)0(o)22.1(l)0(l)19.3(i)12.7(ng)-280.4(fo)22.1(r)-288.9(m)0(i)19.4(l)12.7(it)19.3(ar)17.8(y)-286.5(a)0(n)20.2(d)-286.5(de)20.2(mo)18.9(g)12.2(r)0(a)17.8(p)12.2(h)12.2(i)12.7(c)-290.8(v)0(a)20.2(r)0(i)22.6(a)0(b)20.2(l)0(e)20.7(s)0(.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Results:)Tj
/F4 1 Tf
3.9083 0 TD
[(Am)17.4(o)12.2(n)12.2(g)-420.7(wo)16.8(m)12.8(e)0(n)20.2(,)-420.7(27)18.3(%)-416.9(o)0(f)-410.8(t)0(h)18.9(o)12.2(se)-411.8(re)17.8(p)12.2(o)0(r)16(t)12.7(in)18.8(g)-420.7(M)13.1(ST)-413.2(h)12.2(a)0(d)]TJ
-4.9082 -1.1219 TD
[(ma)14.6(j)12.7(o)0(r)-252.3(o)12.2(r)-264.5(o)12.2(th)18.8(er)-250.4(de)20.2(pr)16(es)21.1(si)19.7(v)12.2(e)-266.4(s)13.1(y)0(n)18.3(d)12.2(ro)16(m)12.8(e)0(.)-254.2(T)0(h)22.6(e)-260.3(pr)16(ev)20.2(al)20.7(en)20.2(ce)-252.3(of)-252.3(a)-266.4(d)12.2(ep)20.2(re)17.8(s)13.1(-)]TJ
0 -1.128 TD
[(si)19.7(ve)-260.3(s)13.1(y)12.2(nd)18.3(ro)22.1(me)-259.7(a)14.1(m)0(o)18.9(n)12.2(g)-268.2(m)12.8(en)-254.2(re)17.9(p)12.2(o)0(r)16(t)12.7(in)18.9(g)-262.1(M)0(S)16.3(T)-264(wa)18.7(s)-261.3(3)12.2(5%)16(.)-262.2(T)0(h)22.6(e)-266.4(p)12.2(a)0(t)14.6(t)12.7(er)17.8(n)]TJ
0 -1.1219 TD
[(wa)18.7(s)-267.4(s)13.1(im)19.4(il)19.3(ar)-256.5(fo)22.1(r)-264.5(a)0(n)20.2(x)12.2(ie)14.6(t)12.7(y)-262.1(\(m)16.5(e)14.1(n)]TJ
/F2 1 Tf
11.3835 0 TD
(=)Tj
/F4 1 Tf
.5426 0 TD
-.0132 Tc
[(20%)-13.2(,)-265.5(w)-13.2(ome)-13.2(n)]TJ
/F2 1 Tf
5.2131 0 TD
0 Tc
(=)Tj
/F4 1 Tf
.5366 0 TD
[(17)18.3(%\))19.7(,)-262.2(a)0(l)20.7(c)0(o)14.1(h)12.2(o)12.2(l)-267.7(a)14.1(b)0(u)18.3(s)0(e)]TJ
-17.6758 -1.128 TD
[(\(m)16.5(en)]TJ
/F2 1 Tf
2.0243 0 TD
(=)Tj
/F4 1 Tf
.5426 0 TD
[(3)12.2(7)0(%)16(,)-250(wo)22.9(me)14.6(n)]TJ
/F2 1 Tf
5.2009 0 TD
(=)Tj
/F4 1 Tf
.5426 0 TD
[(2)12.2(0)0(%)16(\))-246.2(an)14.1(d)-250(P)0(T)19.7(S)0(D)-242.1(\()0(m)22.6(e)0(n)]TJ
/F2 1 Tf
8.7495 0 TD
(=)Tj
/F4 1 Tf
.5366 0 TD
[(27)18.3(%,)-240.1(wo)16.8(m)12.7(e)0(n)]TJ
/F2 1 Tf
5.2009 0 TD
(=)Tj
/F4 1 Tf
.5426 0 TD
[(19)18.3(%\))19.7(.)]TJ
-23.34 -1.128 TD
[(Th)16.5(o)12.2(s)0(e)-399.6(r)0(e)17.8(p)12.2(o)12.2(r)0(t)16.5(i)12.7(ng)-396.3(MS)16.3(T)-404.2(w)0(e)18.7(r)0(e)-396.8(a)0(t)-393.9(i)0(n)18.8(c)0(r)17.8(e)0(a)16(s)13.1(ed)-400.5(ri)22.6(sk)-395.4(fo)16(r)-404.8(r)15.9(ec)22.1(e)14.1(n)12.2(t)-401.9(m)12.8(en)20.2(t)12.7(a)14.1(l)]TJ
0 -1.1219 TD
-.0128 Tc
[(he)-12.8(a)9.3(lth)-256.7(condition)5.5(s)-255.8(\()-12.8(e)11.1(.g.,)-256.7(PT)-12.8(S)13(D)-12.8(:)-245.4(w)-12.8(o)16.2(m)0(e)-12.8(n)-242.6()-256.7(a)-12.8(O)12(R)]TJ
/F2 1 Tf
17.7367 0 TD
0 Tc
(=)Tj
/F4 1 Tf
.5366 0 TD
-.0127 Tc
[(2.50)5.6(,)-256.6(95%C)-12.7(I)]TJ
/F2 1 Tf
4.957 0 TD
0 Tc
(=)Tj
/F4 1 Tf
.5426 0 TD
-.0122 Tc
[(1)6.1(.97,)]TJ
-23.7729 -1.128 TD
-.0129 Tc
[(3.18;)-262.4(men)-256.8()-262.9(aO)-12.9(R)]TJ
/F2 1 Tf
6.7191 0 TD
0 Tc
(=)Tj
/F4 1 Tf
.5426 0 TD
-.0122 Tc
[(2)6.1(.30,)-262.2(9)6.1(5)0(%)-12.2(C)11.3(I)]TJ
/F2 1 Tf
4.957 0 TD
0 Tc
(=)Tj
/F4 1 Tf
.5426 0 TD
-.0122 Tc
[(1.8)6.1(1,)-262.2(2.9)6.1(2\))-12.2(.)]TJ
/F3 1 Tf
-11.7615 -1.1219 TD
0 Tc
(Conclusions:)Tj
/F4 1 Tf
5.8594 0 TD
[(Mental)-372.3(health)-373.1(conditions)-373.6(are)-370.5(highly)-370.8(prevalent)]TJ
-6.8593 -1.128 TD
[(among)-326.7(both)-322.5(women)-322.1(and)-327.3(men)-320.7(MST)-326.9(victims.)-324.3(Veterans)-326(reporting)]TJ
0 -1.1219 TD
[(MST)-339.1(are)-333.9(at)-339(increased)-340.8(risk)-330.2(for)-340(potentially-related)-338.9(mental)-336(health)]TJ
0 -1.128 TD
[(conditions.)-251.6(One)-249.5(explanation)-248.7(may)-247.5(be)-248.1(that)-247(women)-249(are)-248.5(more)-243.8(likely)]TJ
0 -1.1219 TD
[(to)-304.3(seek)-300.2(treatment)-305.4(for)-297.3(MST.)]TJ
/F3 1 Tf
0 -3.573 TD
(14.)Tj
9.843 0 0 9.843 333.9779 132.4346 Tm
[(What)-281.8(Are)-283(the)-280.7(Barriers)-285.1(and)-285.2(Facilitators)]TJ
0 -1.1174 TD
[(to)-284.4(Improving)-282.5(Virginias)-283.8(HPV)-283.1(Vaccination)]TJ
0 -1.1116 TD
[(Rate)-282.9()-283.3(A)-278.4(Stakeholder)-285.8(Analysis)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 313.0582 93.9401 Tm
[(Miev)-338.1(Carhart,)-334.3(Jessica)-338.7(Malpass,)-334.4(Donna)-334.8(Schminkey,)]TJ
0 -1.128 TD
[(Emma)-334.2(Mitchell)]TJ
/F5 1 Tf
0 -1.7682 TD
[(University)-340(of)-334.8(Virginia)-334.6(School)-332.8(of)-328.7(Nursing,)-337.7(Charlottesville,)]TJ
0 -1.1219 TD
(Virginia)Tj
/F3 1 Tf
8.9663 0 0 8.9663 62.022 749.6502 Tm
(A-6)Tj
48.6864 0 TD
(ABSTRACTS)Tj
ET
endstream
endobj
209 0 obj
<>stream
/GS1 gs
BT
/F3 1 Tf
9.2982 0 0 9.2982 69.0519 725.5557 Tm
0 0 0 rg
0 Tc
0 Tw
(Background:)Tj
/F4 1 Tf
6.1094 0 TD
.0174 Tc
[(Despit)5.7(e)-505.1(a)1(vailab)5.2(ili)5.7(ty)-506.9(o)5.2(f)-503.2(the)-505.1(h)5.2(uman)-500.8(pap)5.2(illo)5.2(-)]TJ
-7.1093 -1.128 TD
.0162 Tc
[(mavirus)-354.9(\()-4.4(HPV\))-352(vaccine)-6.3(s)-354.9(a)-.2(nd)-355.7(rec)-6.3(o)4(mmendations)-354.8(from)-355.2(v)4(arious)]TJ
0 -1.1219 TD
.0168 Tc
[(professio)4.6(n)-1.5(al)-330.2(organ)4.6(i)-1(zatio)4.6(ns,)-330.7(H)-3(PV)]TJ
14.0052 0 TD
.0157 Tc
[(vacc)-6.8(ination)-331.8(c)-.7(ompletion)-331.8(r)-4.9(ate)]TJ
-14.0052 -1.128 TD
-.0127 Tc
[(r)-12.7(e)5.1(ma)-12.7(i)8(n)-12.7(s)-310.6(l)0(ow)-319(f)-12.7(o)3.3(r)-313.8(g)-12.7(i)6.1(r)-12.7(l)9.9(s)-322.8(at)-317(3)-12.7(9)5.6(.7%)-319.9(na)-12.7(t)8(i)-12.7(o)6.1(n)-.5(a)-12.7(l)8(l)-12.7(y)-310.9(an)-12.7(d)-311.4(35.9)-12.7(%)-307.7(i)-12.7(n)-310.9(V)-12.7(i)10.7(r)-12.7(g)9.4(i)-12.7(n)6.1(i)0(a)]TJ
0 -1.1219 TD
[(a)-12.8(n)7.4(d)-427.4(f)-12.8(o)9.3(r)-423.7(bo)-12.8(y)5.5(s)-426.5(21.6%)-429.7(na)-12.8(t)7.9(i)-.1(on)-12.8(a)7.4(l)-12.8(l)6.5(y)-427.4(an)-12.8(d)-415.2(22.)-12.8(5)5.5(%)-12.8(.)-411.4(T)-12.8(hes)-12.8(e)-418.5(r)-12.8(a)11.1(t)-12.8(e)7.9(s)-426.5(a)-12.8(r)5(e)-425.5(f)-12.8(a)11.1(r)]TJ
0 -1.128 TD
-.0124 Tc
[(b)-12.4(e)7.8(l)-12.4(o)6.5(w)-367.5(t)-12.4(h)6.4(e)-370.2(H)-12.4(e)12.4(a)-12.4(l)2.2(thy)-372.1(P)3(e)-12.4(o)7.8(pl)-12.4(e)-363.6(2020)-372.1(goa)-12.4(l)-363.6(o)-.2(f)-368.4(80%)-374.4(and)-372.1(m).4(a)-12.4(n)7.8(y)-372.1(a)1.7(d)-12.4(o)6(le)-12.4(s)8.7(-)]TJ
0 -1.1219 TD
0 Tc
[(ce)16(n)12.2(t)12.7(s)-291.8(a)0(r)17.8(e)-284.7(at)-284.1(ri)22.6(s)13.1(k)-292.6(fo)22.1(r)-288.9(d)12.2(ev)20.2(el)20.7(o)12.2(p)0(i)18.8(n)12.2(g)-292.6(p)12.2(re)23.9(ve)20.2(n)12.2(t)0(i)19.3(v)12.2(e)-290.8(H)0(P)20.1(V)0(-)20.6(r)0(e)17.8(l)12.7(at)20.7(ed)-278.5(ca)22.1(nc)20.2(er)17.8(s)13.1(.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.7801 0 TD
[(The)-262.1(purpose)-267.7(of)-270.6(this)-266.3(study)-266.8(is)-266.9(to)-267.7(identify)-267.1(barriers)]TJ
-6.7801 -1.1219 TD
[(and)-241.9(facilitators)-239.4(to)-237.2(improving)-232.3(the)-241.4(HPV)-237.5(vaccination)-234.6(rate)-241.9(in)-237.2(central)]TJ
0 -1.128 TD
[(and)-302.9(southern)-297.7(Virginia.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Material/Methods:)Tj
/F4 1 Tf
8.2983 0 TD
[(Se)17.3(m)12.8(i)12.7(-s)16.8(t)12.7(r)0(u)16(c)0(t)20.7(u)12.2(re)17.8(d,)-164.6(ke)20.2(y)-176.8(i)0(n)18.9(f)0(o)22.1(r)0(m)16.5(a)0(n)20.2(t)-176.3(i)12.7(n)0(t)18.8(e)0(r)17.8(v)12.2(ie)14.6(ws)]TJ
-9.2982 -1.128 TD
[(wi)17.3(th)-243.3(pu)18.3(rp)22.1(os)19.2(iv)18.9(e)-254.2(s)0(a)15(m)12.8(pl)18.8(i)12.7(n)0(g)-249.9(o)12.2(f)-252.3(s)0(t)13.6(a)14.1(ke)20.2(ho)18.3(ld)18.8(er)17.8(s)-255.2(w)0(e)18.7(r)0(e)-244.3(c)0(o)20.2(n)0(d)18.3(u)12.2(ct)20.7(ed)14.1(.)-250(T)0(h)16.5(i)12.7(rt)16.5(y)12.2(-)]TJ
0 -1.1219 TD
[(on)18.3(e)-248.1(s)0(t)13.6(a)14.1(ke)20.2(ho)18.3(ld)18.8(er)17.8(s)-249.1(w)0(e)18.7(r)0(e)-238.2(i)0(n)18.9(t)0(e)20.7(r)0(v)16(i)12.7(ew)18.7(ed)-242(an)20.2(d)-250(a)0(n)20.2(a)0(l)20.7(y)0(s)19.2(i)0(s)-242.5(i)12.7(s)-255.2(u)12.2(n)12.2(d)0(e)20.2(r)0(w)14.5(a)14.1(y.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Results:)Tj
/F4 1 Tf
3.7071 0 TD
[(The)-274.3(analysis)-273.8(of)-270.6(unique)-271.8(barriers)-276.2(and)-272.4(facilitators)-275.9(from)]TJ
-4.707 -1.128 TD
[(28)-304.8(interviews)-302.4(will)-298.7(be)-302.9(presented.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Conclusions:)Tj
/F4 1 Tf
5.8777 0 TD
[(The)-390.1(data)-392(from)-394.3(these)-391.1(interviews)-387.7(will)-396.2(be)-388.3(inter-)]TJ
-6.8776 -1.128 TD
[(preted)-248(through)-239.5(the)-241.4(lens)-246.7(of)-240.1(the)-241.4(socio-ecological)-245.8(model)-247(in)-237.2(order)-246.6(to)]TJ
0 -1.1219 TD
[(identify)-303.6(potential)-298.9(strategies)-304.3(to)-298.2(improve)-304.2(HPV)-298.5(vaccination)-301.7(rates.)]TJ
/F3 1 Tf
0 -4.0059 TD
(15.)Tj
9.843 0 0 9.843 80.674 510.4629 Tm
[(Occurrence)-290.8(of)-278.6(Pelvic)-281.1(Pain)-282(Post-Procedure)]TJ
0 -1.1116 TD
[(Among)-283.8(Women)-279.4(who)-280.5(have)-281.9(Undergone)-284.5(Female)]TJ
T*
[(Sterilization)-288.6(Procedures)-282.5(-)-283.3(A)-278.4(Retrospective)]TJ
T*
[(Claims)-285.1(Analysis)-280.1(of)-284.4(Commercially)-285.1(Insured)]TJ
0 -1.1174 TD
[(Women)-285.1(in)-278.6(the)-280.7(U.S.)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 59.7543 450.0849 Tm
[(Patricia)-339.4(Carney,)-332.4(Jianying)-337.5(Yao,)-334.9(Amy)-330.1(Law)]TJ
/F5 1 Tf
0 -1.7682 TD
[(Bayer)-338.6(HealthCare)-335.7(Pharmaceuticals)-335.6(Inc.,)-335.7(Whippany,)]TJ
0 -1.1219 TD
[(New)-336.7(Jersey)]TJ
/F3 1 Tf
.9999 -2.3047 TD
(Background:)Tj
/F4 1 Tf
6.2679 0 TD
[(Women)-666.3(with)-658.9(pre-existing)-669(pain)-662.1(\(headache,)]TJ
-7.2679 -1.128 TD
[(backache,)-252.6(pelvic)-245.1(pain,)-247.5(bromyalgia\))-252(may)-247.5(have)-246.1(an)-248.1(increased)-249.4(risk)]TJ
0 -1.1219 TD
[(of)-301.1(pelvic)-300(pain)-302.4(after)-305.2(sterilization.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.7679 0 TD
[(To)-257.9(evaluate)-259.6(occurrence)-257.3(of)-258.4(pelvic)-257.3(pain)-253.6(in)-255.5(the)-259.7(12)]TJ
-6.7679 -1.1219 TD
[(months)-516.2(following)-514.3(hysteroscopic)-512(\(HS\))-515.1(and)-510.2(laparoscopic)-517.1(\(LS\))]TJ
0 -1.128 TD
[(sterilization)-303.5(in)-304.3(the)-296.3(US.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Material/Methods:)Tj
/F4 1 Tf
8.4507 0 TD
.0112 Tc
[(Wom)11.2(e)-10.7(n)-372.9(a).9(ged)-379(1)-1(8)11.2()-7(49)-372.9(years)-378.1(w)-2.5(it)11.2(h)-384.6(c).9(laims)]TJ
-9.4506 -1.128 TD
0 Tc
[(f)-14.5(o)0(r)-343.8(H)-7.6(S)-332.1(o)-12.2(r)-331.6(L)-14(S)-332.1(\()-8.4(1)-12.2(/)-11.7(1/)-17.7(20)-18.2(1)-12.2(0)0()-18.2(1)-12.2(2/)-17.7(3)-12.2(1)0(/)-17.7(2)-12.2(01)-18.2(2\))-343.8(w)-7.6(e)-10.3(r)-14.5(e)-333.4(id)-17.7(e)-10.3(n)-12.2(ti)-17.2()-8.9(e)-10.3(d)-335.3(f)-8.4(r)-14.5(o)0(m)-340.9(t)-11.7(he)]TJ
0 -1.1219 TD
.0107 Tc
[(Mark)10.7(e)-5.7(t)-1(Scan)-483.1(Co)10.7(m)-7(m)-.9(ercial)-476.5(claims)-476.2(datab)10.7(a)-5.7(se.)-483.2(W).4(o)10.7(m)-7(en)-477(were)-481.3(re-)]TJ
0 -1.128 TD
.0178 Tc
[(qui)6.1(red)-445.6(t)0(o)-445.6(h)5.6(ave)-443.7(6)-445.6(mon)5.6(t)0(hs)-444.7(of)-441.8(cont)6.1(inu)5.6(ous)-444.7(in)5.6(surance)-443.7(c)1.4(ov)5.6(erag)5.6(e)]TJ
0 -1.1219 TD
.0174 Tc
[(prior)-332.5(t)5.7(o)-336.2(t)-.4(h)5.2(e)-334.3(date)-328.2(of)-332.5(th)5.2(e)-334.3(s)0(terili)5.7(zat)5.7(i)-.4(on)-330.1(proced)5.2(ure)-334.3(\()2.9(baseli)5.7(ne\))-332.5(a)1(nd)]TJ
0 -1.128 TD
.018 Tc
[(12)-372.2(mon)5.8(t).2(hs)-371.3(aft)6.3(e)-4.5(rward)-372.2(\()3.5(fo)5.8(llo)5.8(w-up)5.8(\).)-372.2(Di)6.3(agno)5.8(ses)-377.4(f)3.5(or)-374.6(p)5.8(a)1.6(in)-378.3(co)5.8(nd)5.8(i-)]TJ
0 -1.1219 TD
.0176 Tc
[(tio)5.4(ns)-255.9(du)5.4(ri)5.9(ng)-256.7(b)5.4(a)1.2(selin)5.4(e)-261(\()3.1(chro)5.4(nic)-254.9(h)-.7(ead)5.4(ach)5.4(e)1.2(,)-256.8()2.6(brom)6(yalg)5.4(ia,)-256.8(p)-.7(ai)5.9(n)-256.7(i)-.2(n)]TJ
0 -1.128 TD
.0173 Tc
[(lower)-497.2(b)5.1(ack)-488.7(o)-1(r)-497.2(p)5.1(elvi)5.6(s/lo)5.1(wer)-491.1(a).9(bdo)5.1(men\))-491.1(were)-493(iden)5.1(tied)-494.8(with)]TJ
0 -1.1219 TD
.0167 Tc
[(ICD-9-CM)-214.1(codes.)-208.9(Occurrence)-207(of)]TJ
13.6882 0 TD
.0176 Tc
[(acut)5.9(e)-212.2(pelv)5.4(ic)-212.2(p)5.4(a)1.2(in)-208(\(APP\))-204.2(post)5.9(-)]TJ
-13.6882 -1.128 TD
.0167 Tc
[(procedure)-213.1(w)-3.1(as)-214.1(dened)-215(as)]TJ
/F2 1 Tf
10.7006 0 TD
0 Tc
()Tj
/F4 1 Tf
.628 0 TD
.0163 Tc
[(1)-215.4(d)-2(iagnosis)-220.6(for)-217.7(p)4.1(elvic)-213.5(p)-2(ain)-215.4(2)-221.5(weeks)]TJ
-11.3286 -1.1219 TD
.0168 Tc
[(to)-324.6(3)-318.5(m)-.9(o)4.6(n)-1.5(th)4.6(s)-323.8(p)-1.5(o)4.6(s)-.6(t-pro)4.6(c)-5.7(ed)4.6(ure.)-324.6(Ch)4.6(roni)5.1(c)-322.7(p)-1.5(elv)4.6(i)-1(c)-322.7(p)-1.5(ai)5.1(n)-324.6(\()2.3(CPP\))-320.9(post)5.1(-)]TJ
0 -1.128 TD
.0164 Tc
[(procedure)-292.7(w)-3.4(as)-299.8(dened)-300.6(as)]TJ
/F2 1 Tf
11.0237 0 TD
0 Tc
()Tj
/F4 1 Tf
.6219 0 TD
.0173 Tc
[(2)-299.7(d)-1(i)5.6(a).9(gno)5.1(ses)-298.9(o)5.1(n)-299.7(d)5.1(ifferent)-293.1(dates)-292.8(f)-3.3(o)5.1(r)]TJ
-11.6456 -1.1219 TD
[(pelv)5.1(ic)-328.3(pai)5.6(n)-330.2(with)]TJ
/F2 1 Tf
7.341 0 TD
0 Tc
()Tj
/F4 1 Tf
.628 0 TD
.0154 Tc
[(1)-332.1(o)3.2(ccurring)-326(a)-1(fte)-7.1(r)-328.4(2)-326(w)1.7(ee)-7.1(ks)-331.3(and)-332.1(a)-1(nothe)-7.1(r)-328.4(oc-)]TJ
-7.969 -1.128 TD
.0166 Tc
(curring)Tj
/F2 1 Tf
3.4754 0 TD
0 Tc
(>)Tj
/F4 1 Tf
.628 0 TD
.0167 Tc
[(3)-300.3(m)-1(o)4.5(n)-1.6(th)4.5(s)-299.5(p)-1.6(o)4.5(s)-.7(t-proced)4.5(ure.)]TJ
/F3 1 Tf
-3.1035 -1.128 TD
0 Tc
(Results:)Tj
/F4 1 Tf
3.7376 0 TD
[(Among)-299.6(the)-302.4(study)-297.3(population,)-301.2(12,031)-298.6(underwent)-304.3(HS)]TJ
-4.7375 -1.1219 TD
[(\(mean)-235.8(age:)-233.4(37.0)-225.5(years\))-237.8(and)-229.7(7,286)-225.5(underwent)-237.2(LS)-230.3(\(mean)-229.7(age:)-233.4(35.8)]TJ
0 -1.128 TD
[(years\).)-207.3(During)-198.3(baseline,)-205.7(23.5%)-203.4(\(n)]TJ
/F2 1 Tf
13.298 0 TD
(=)Tj
/F4 1 Tf
.5487 0 TD
[(2,827\))-203.4(of)-197.4(women)-206.3(with)-201.6(HS)-205.5(and)]TJ
-13.8467 -1.1219 TD
[(27.1%)-355.9(\(n)]TJ
/F2 1 Tf
3.7681 0 TD
(=)Tj
/F4 1 Tf
.5548 0 TD
[(1,971\))-349.8(of)-356(women)-352.6(with)-354(LS)-352.2(received)-353.9(a)-351.7(diagnosis)-354.9(of)-349.9(a)]TJ
-4.3229 -1.128 TD
[(pain)-229.2(condition.)-222(In)-227.9(both)-218.9(the)-229.2(HS)-223.8(and)-223.6(LS)-224.2(groups,)-227(women)-224.6(who)-220.9(had)-223.6(a)]TJ
0 -1.1219 TD
[(pre-existing)-339.8(pain)-332.9(diagnosis)-336.6(vs.)-334.4(those)-332(without)-335.2(pre-existing)-333.7(pain,)]TJ
0 -1.128 TD
[(had)-272.4(higher)-268.1(rates)-271.5(of)-264.5(APP)-269.4(\(HS-cohort:)-270.5(9.1%)-264.4(vs.)-267.4(3.4%,)-270.5(p)]TJ
/F2 1 Tf
21.8036 0 TD
(<)Tj
/F4 1 Tf
.5487 0 TD
(0.0001\);)Tj
-22.3523 -1.1219 TD
[(LS-cohort:)-390.5(10.2%)-380.3(vs.)-383.2(3.70%,)-386.3(p)]TJ
/F2 1 Tf
12.9321 0 TD
(<)Tj
/F4 1 Tf
.5548 0 TD
[(0.0001\))-380.2(and)-388.3(CPP)-382.3(\(HS-cohort:)]TJ
-13.487 -1.128 TD
[(9.2%)-227.8(vs.)-224.7(3.6%)-227.8(p)]TJ
/F2 1 Tf
6.4813 0 TD
(<)Tj
/F4 1 Tf
.5487 0 TD
[(0.0001;)-224.9(LS-cohort:)-231.9(12.0%)-221.7(vs.)-224.7(4.5%,)-227.8(p)]TJ
/F2 1 Tf
15.054 0 TD
(<)Tj
/F4 1 Tf
.5487 0 TD
(0.0001\))Tj
-22.6328 -1.1219 TD
[(in)-304.3(the)-296.3(one)-302.9(year)-303.4(post-procedure.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Conclusions:)Tj
/F4 1 Tf
5.835 0 TD
[(Am)23.5(on)18.3(g)-335.3(w)0(o)22.9(m)0(e)14.7(n)-329.2(wi)17.3(t)12.7(h)-335.3(h)12.2(y)0(s)19.2(t)0(e)14.6(r)0(o)22.1(s)0(c)21.1(o)0(p)18.3(i)12.7(c)-339.5(a)14.1(nd)-329.2(l)12.7(a)0(p)20.2(a)0(r)17.8(o)12.2(-)]TJ
-6.8349 -1.1219 TD
[(sc)15(o)12.2(p)12.2(i)0(c)-339(s)13.1(te)20.7(ri)16.5(l)12.7(i)0(z)14.6(a)14.1(ti)19.4(on)-335.3(p)12.2(r)0(o)16(c)14.1(ed)20.2(ur)16(es)21.1(,)-341.4(t)0(h)18.9(o)0(s)19.2(e)-345.6(wi)23.4(th)-334.8(p)12.2(r)0(e)17.8(-)0(e)17.8(x)12.2(is)19.7(ti)19.4(ng)-335.3(p)12.2(a)0(i)14.6(n)-341.4(h)12.2(a)0(d)]TJ
0 -1.128 TD
[(hi)18.8(gh)18.3(er)-213.8(p)12.2(e)0(r)17.8(c)0(e)16(n)12.2(t)12.7(a)0(g)14.1(e)14.1(s)-224.7(of)-215.7(AP)20.1(P)-222.3(a)0(n)20.2(d)-225.6(CP)22.9(P)-228.4(a)14.1(ft)16.5(er)-213.8(s)13.1(t)0(e)14.6(r)0(i)22.6(l)0(i)19.3(z)0(a)16(t)12.7(io)18.8(n)-225.6(p)12.2(ro)22.1(ce)16(d)12.2(u)0(r)16(e)14.1(s,)]TJ
0 -1.1219 TD
[(al)14.6(t)12.7(h)12.2(ou)18.3(g)12.2(h)-359.7(c)14.1(a)0(u)14.1(s)13.1(al)20.7(it)19.3(y)-359.7(c)14.1(an)20.2(no)18.3(t)-353.1(b)0(e)-345.6(e)0(s)15(t)12.7(ab)20.2(li)19.3(sh)19.2(ed)20.2(.)-359.7(E)0(a)24.5(r)0(l)16.5(y)-353.6(id)18.8(en)20.2(t)12.7(i)0()16(c)0(a)22.1(t)0(i)19.3(o)0(n)-347.5(o)12.2(f)]TJ
27.0045 71.9468 TD
[(wo)22.9(me)14.6(n)-359.7(a)0(t)-357.3(h)12.2(ig)18.8(h)12.2(e)0(r)-360.2(r)0(i)22.6(s)0(k)-352.7(f)0(o)16(r)-362.1(AP)20.1(P)-362.6(o)0(r)-356(C)0(P)16.8(P)-362.6(af)17.8(t)12.7(e)0(r)-360.2(s)13.1(te)20.7(ri)16.5(l)12.7(i)0(z)14.6(a)14.1(ti)19.3(on)-353.6(pr)16(o)12.2(c)0(e)16(-)]TJ
0 -1.128 TD
-.0131 Tc
[(dur)-13.1(e)4.7(s)-304.9(ma)-13.1(y)-297.7(b)-.9(e)-303.9(h)-.9(e)-13.1(l)1.5(pf)-13.1(u)9(l)-305.2(du)-13.1(rin)-13.1(g)-293.5(pr)-13.1(e)4.7(-)-13.1(pr)-13.1(o)9(c)-13.1(e)9(d)-13.1(u)5.2(r)-13.1(a)4.7(l)-305.2(co)-13.1(u)5.2(n)-.9(s)-13.1(e)1.9(li)-13.1(n)5.8(g)-.9(.)]TJ
/F3 1 Tf
0 -3.9754 TD
0 Tc
(16.)Tj
9.843 0 0 9.843 331.7668 678.1038 Tm
[(Male)-278.7(Partner)-288.7(Role)-277.3(in)-284.4(Elective)-284.3(Abortion:)]TJ
0 -1.1116 TD
[(Implications)-280(for)-280.9(Family)-285.6(Planning)]TJ
0 -1.1174 TD
[(and)-279.4(Post-Abortion)-282(Care)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 310.8472 639.6093 Tm
[(Susan)-335.4(Cha,)-332(Saba)-334.4(Masho)]TJ
/F5 1 Tf
0 -1.7682 TD
[(Department)-332.5(of)-334.8(Family)-335.7(Medicine)-337(and)-329.2(Community)-333.9(Health,)]TJ
0 -1.1219 TD
[(Virginia)-334.6(Commonwealth)-332.4(University,)-340(Richmond,)-330(Virginia)]TJ
/F3 1 Tf
.9999 -2.3047 TD
(Background:)Tj
/F4 1 Tf
6.0667 0 TD
[(Approximately)-467.3(43%)-465.6(of)-465.7(all)-466.5(unintended)-470.6(preg-)]TJ
-7.0666 -1.128 TD
[(nancies)-303.8(end)-309(in)-304.3(elective)-307.8(abortions.)-309.4(Little)-308.8(is)-303.5(known)-306.2(about)-308.5(the)-302.4(ex-)]TJ
0 -1.1219 TD
[(tent)-375(to)-371.4(which)-377(paternal)-379.7(pregnancy)-374.5(desires)-374.3(inuence)-374.6(a)-376.1(womans)]TJ
0 -1.128 TD
[(decision)-299.1(to)-298.2(terminate)-305.4(pregnancy.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.9143 0 TD
[(This)-408.9(study)-407(examines)-406.9(the)-406.1(association)-411.6(between)]TJ
-6.9142 -1.128 TD
[(couple)-300.5(pregnancy)-301.4(intentions)-299.9(and)-302.9(elective)-301.7(abortion)-298.1(in)-304.3(women.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Material/Methods:)Tj
/F4 1 Tf
8.4019 0 TD
[(Data)-332.5(came)-335.2(from)-333.4(the)-332.9(National)-337.5(Survey)-332.5(of)]TJ
-9.4019 -1.128 TD
[(Family)-474.9(Growth)-474.2(\(20062010\).)-467.8(Primiparous)-472.6(women)-474.6(who)-477(lived)]TJ
0 -1.1219 TD
[(with)-457.7(one)-461.4(partner/husband)-466.4(at)-461(rst)-461.1(pregnancy)-459.9(conception)-462.6(were)]TJ
0 -1.128 TD
[(included)-306(in)-310.4(the)-308.5(analysis)-310.4(\(n)]TJ
/F2 1 Tf
10.7615 0 TD
(=)Tj
/F4 1 Tf
.5488 0 TD
[(4,263\).)-313.2(Couple)-307.1(pregnancy)-313.6(intention)]TJ
-11.3103 -1.1219 TD
[(dyads)-204.5(were)-207.3(categorized)-211.2(as:)-210.1(both)-206.7(intended,)-208.4(both)-200.6(unintended,)-208.4(mom)]TJ
0 -1.128 TD
[(intended)-299.9(only)-298.2(\(M)]TJ
/F2 1 Tf
7.2191 0 TD
(+)Tj
/F4 1 Tf
.7195 0 TD
[(D-\),)-298.8(dad)-296.8(intended)-299.9(only)-298.2(\(M-D)]TJ
/F2 1 Tf
11.9505 0 TD
(+)Tj
/F4 1 Tf
.7134 0 TD
[(\).)-301.1(Pregnancy)]TJ
-20.6024 -1.1219 TD
[(outcome)-269.4(for)-272.9(the)-265.8(rst)-272.1(pregnancy)-270.9(was)-273.1(dichotomized)-272.5(\(abortion;)-269.4(no)]TJ
0 -1.128 TD
[(abortion\).)-416.2(Descriptive)-416.3(statistics)-417.8(provided)-420.5(unweighted)-417.2(frequen-)]TJ
0 -1.1219 TD
[(cies)-415.5(and)-412.7(weighted)-411.2(percentages)-418.2(of)-410.8(characteristics.)-422.3(Multiple)-415.7(lo-)]TJ
0 -1.128 TD
[(gistic)-507.8(regressions)-509.8(were)-512.2(used)-509.3(to)-511.6(obtain)-509.1(odds)-505.1(ratios)-510.7(and)-510.2(95%)]TJ
0 -1.1219 TD
[(condence)-440.2(intervals.)-447.2(All)-439.4(analyses)-449.3(were)-439(conducted)-444.8(in)-444.5(SAS)-440.1(to)]TJ
0 -1.128 TD
[(account)-298.6(for)-303.4(the)-302.4(complex)-299.9(sampling)-300.4(design.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Results:)Tj
/F4 1 Tf
3.64 0 TD
-.0137 Tc
[(Co)4.6(u)4.6(p)-1.5(l)5.1(e).4(s)-201.8(w)3.1(it)5.1(h)-202.7(d)4.6(is)5.5(cord)4.6(an)4.6(t)-202.2(p)]TJ
9.9933 0 TD
-.0169 Tc
[(reg)-4.7(n)1.4(ancy)-205.9(in)-4.7(tent)-4.2(io)-4.7(ns)-205(\(M)]TJ
/F2 1 Tf
9.1092 0 TD
0 Tc
(+)Tj
/F4 1 Tf
.7012 0 TD
-.0164 Tc
(D-,)Tj
-24.4436 -1.128 TD
.0099 Tc
(M-D)Tj
/F2 1 Tf
2.134 0 TD
0 Tc
(+)Tj
/F4 1 Tf
.7317 0 TD
.0114 Tc
[(\))-259.2(a)1.1(n)11.4(d)-269(b)11.4(o)-6.8(th)-256.8(unin)11.4(t)-6.3(ended)-256.8(p)-.8(reg)11.4(n)-6.8(ancy)-256.8(had)-262.9(h)11.4(i)-6.3(gher)-259.2(p)11.4(r)-9.2(e)1.1(valence)]TJ
-2.8657 -1.1219 TD
[(of)-362.9(women)-360.5(w)-2.3(ho)-360.5(were)-364.7(raci)11.4(a)-10.6(l)-.3(/)11.4(e)-10.6(t)11.4(h)-6.3(nic)-364.7(m)11.4(i)-5.8(norities,)-360.5(of)-362.9(low)-362(i)-.3(n)11.4(c)-11.1(o)11.4(m)-6.3(e,)]TJ
0 -1.128 TD
.0116 Tc
[(and)-366.4(y)-.6(o)11.6(u)-6.6(ng)11.6(e)-10.9(r)-362.7(a)-4.8(g)11.6(e)-10.9(d)-366.4(at)-365.9(conceptio)11.6(n)-372.5(t)-.1(han)-366.4(c)-4.8(o)11.6(u)-6.6(ples)-365.5(wh)11.6(e)-10.9(r)3.2(e)-370.6(b)11.6(o)-6.6(t)-.1(h)-366.4(i)-.1(n-)]TJ
0 -1.1219 TD
0 Tc
[(t)12.7(e)0(n)20.2(d)12.2(ed)-199.3(pr)22.1(eg)20.2(na)20.2(n)12.2(c)0(y)-205.4(\()15.9(p)]TJ
/F2 1 Tf
7.9446 0 TD
(<)Tj
/F4 1 Tf
.5365 0 TD
-.0122 Tc
[(0)-12.2(.)6.1(000)-12.2(1)6.1(\))-12.2(.)-209.6(C)-12.2(o)7.5(upl)-12.2(e)8.5(s)-224.7(w)-12.2(i)11.2(t)-12.2(h)-212.9(di)-12.2(s)7.5(c)-12.2(o)8(r)-12.2(d)9.9(a)-12.2(n)8(t)-225.1(pr)-12.2(e)11.7(g)-12.2(n)6.1(a)1.9(n)-12.2(c)8(y)]TJ
-8.4812 -1.128 TD
0 Tc
[(i)12.7(n)12.2(te)20.7(nt)18.8(i)12.7(o)0(n)18.3(s)-407.6(an)20.2(d)-408.5(b)0(o)18.3(t)12.7(h)-408.5(u)0(n)18.3(i)12.7(n)12.2(t)0(e)14.6(n)12.2(d)12.2(e)0(d)-400.5(p)12.2(re)17.8(g)12.2(n)12.2(a)0(n)20.2(c)0(y)-400.5(h)12.2(ad)-400.5(si)19.7(g)12.2(n)12.2(i)0()22.1(c)0(a)16(n)12.2(t)12.7(l)0(y)-401.9(i)12.7(n-)]TJ
0 -1.1219 TD
[(c)14.1(r)0(e)17.8(a)0(s)21.1(e)0(d)-388.3(o)0(d)18.3(d)12.2(s)-401.5(o)12.2(f)-398.7(e)0(l)20.7(e)0(c)16(t)12.7(i)12.7(v)0(e)-394.4(a)14.1(bo)18.3(rt)22.6(i)12.7(o)0(n)-390.2(c)0(o)20.2(m)12.8(pa)20.2(re)17.8(d)-396.3(t)0(o)-389.7(t)0(h)18.8(o)12.2(se)-393.5(wh)22.9(o)-396.3(b)0(o)18.3(t)12.7(h)]TJ
0 -1.128 TD
[(i)12.7(n)12.2(te)20.7(nd)18.3(ed)-278.5(p)12.2(r)0(e)17.8(g)12.2(n)12.2(a)0(n)20.2(c)0(y)20.2(.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Conclusions:)Tj
/F4 1 Tf
5.8533 0 TD
[(Family)-365.1(planning)-362.7(or)-368.1(post-abortion)-366(service)-367.1(pro-)]TJ
-6.8532 -1.128 TD
[(viders)-541.6(may)-540.2(need)-544.9(to)-536(consider)-545.8(the)-540.2(interpersonal)-545.2(dynamics)-542.9(of)]TJ
T*
[(couple-based)-444.4(decision-making)-444.7(and)-437(behaviors)-448.2(to)-438.4(prevent)-443(elec-)]TJ
0 -1.1219 TD
[(tive)-320.2(abortions)-321.6(due)-327.3(to)-322.6(unintended)-318.1(pregnancy.)-325.8(Women)-324.8(should)-321.6(be)]TJ
0 -1.128 TD
[(encouraged)-342.2(to)-347(have)-343.7(ongoing)-340.8(discussions)-341(about)-345(pregnancy)-344.1(with)]TJ
0 -1.1219 TD
[(their)-298.1(partners.)]TJ
/F3 1 Tf
0 -3.2254 TD
(17.)Tj
9.843 0 0 9.843 331.7668 237.033 Tm
[(Abdominal)-282.4(Binders)-281.4(to)-278.6(Improve)-287.2(Ambulation)]TJ
0 -1.1174 TD
[(and)-279.4(Decrease)-286(Pain)-282(After)-279.3(Cesarean)-289.3(Delivery)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 310.8472 209.4803 Tm
[(Patricia)-333.3(Chambers)]TJ
/F5 1 Tf
0 -1.7682 TD
[(Northern)-335.8(Westchester)-332.5(Hospital,)-334.3(Mount)-337.1(Kisco,)-330.6(New)-336.7(York)]TJ
/F3 1 Tf
.9999 -2.3047 TD
(Background:)Tj
/F4 1 Tf
5.8167 0 TD
[(Wo)20.2(me)20.7(n)-207.3(a)0(f)17.8(t)0(e)20.7(r)-209.7(ce)16(s)13.1(a)0(r)17.8(e)0(a)22.1(n)-207.3(se)15(ct)20.7(i)12.7(o)0(n)-201.2(\()0(C)23.4(-)0(s)16.8(e)0(c)16(t)12.7(i)12.7(o)0(n)18.3(\))-209.7(re)17.9(p)12.2(o)12.2(r)0(t)]TJ
-6.8167 -1.1219 TD
[(m)12.8(o)0(r)16(e)-357.8(p)12.2(a)0(i)20.7(n)-359.7(wi)17.3(t)12.7(h)-359.7(ac)22.1(ti)19.4(vi)18.8(ty)-347(th)18.9(an)-351.7(t)12.7(h)0(o)18.3(s)13.1(e)-363.9(w)0(h)22.9(o)-359.7(h)12.2(a)0(d)-351.7(a)-357.8(v)12.2(a)0(g)20.2(i)0(n)18.9(a)0(l)-351.2(d)12.2(el)20.7(iv)18.9(er)17.8(y)12.2(.)]TJ
0 -1.128 TD
[(Th)22.6(ey)-193.2(al)20.7(so)-194.2(ex)20.2(pr)16(es)21.1(s)-200.3(c)0(o)14.1(n)12.2(ce)16(rn)22.1(s)-200.3(a)0(b)20.2(o)0(u)18.3(t)-200.7(ta)14.6(k)12.2(i)0(n)18.8(g)-201.2(an)20.2(al)20.7(ge)14.1(s)13.1(i)0(c)20.7(s)-206.4(wh)22.9(il)19.3(e)-205.4(n)12.2(ur)16(s)13.1(i)0(n)18.9(g)12.2(,)]TJ
0 -1.1219 TD
[(s)13.1(u)0(f)16(f)0(e)23.9(r)0(i)16.5(n)12.2(g)-390.2(p)12.2(ai)14.6(n)-384.1(t)0(o)-383.6(p)12.2(re)17.8(v)12.2(e)0(n)20.2(t)-389.7(m)12.8(e)0(d)14.1(i)12.7(ca)16(t)12.7(i)0(o)18.9(n)12.2(s)-389.3(e)0(n)20.2(t)0(e)14.6(r)0(i)22.6(n)12.2(g)-390.2(i)0(n)18.9(t)12.7(o)-390.2(t)0(h)18.8(e)0(i)20.7(r)-392.6(b)12.2(r)0(e)17.8(a)0(s)21.1(t)]TJ
0 -1.128 TD
[(m)12.8(i)0(l)19.3(k)12.2(.)-201.2(N)0(u)16.8(r)0(s)22.9(e)0(s)-192.3(n)12.2(ot)18.8(ed)-193.2(t)12.7(h)0(a)20.2(t)-200.7(wo)16.8(m)12.8(e)0(n)-193.2(w)0(h)22.9(o)-201.2(br)16(o)12.2(u)12.2(g)0(h)18.4(t)-200.7(ab)20.2(d)12.2(o)0(m)18.9(i)0(n)18.9(a)0(l)-192.7(b)12.2(i)12.7(n)0(d)18.3(e)0(r)17.8(s)-200.3(t)12.7(o)]TJ
0 -1.1219 TD
[(we)18.7(ar)-323.6(po)18.3(s)13.1(t)-340.9(C)13.6(-)0(s)16.8(e)0(c)22.1(t)0(i)19.3(o)0(n)-329.2(a)14.1(mb)18.9(ul)18.8(at)20.7(ed)-327.3(mo)18.9(re)-323.6(fr)19.7(eq)14.1(u)12.2(e)0(n)20.2(t)12.7(ly)-328.7(an)20.2(d)-335.3(l)0(o)18.9(n)12.2(ge)20.2(r.)-325.5(Of)14.5(-)]TJ
0 -1.128 TD
[(fe)17.8(ri)22.6(n)12.2(g)-463.4(ab)20.2(do)18.3(m)12.7(i)0(n)18.8(a)0(l)-454.9(b)12.2(in)18.8(d)12.2(e)0(r)17.8(s)-462.5(wa)18.7(s)-462.5(n)12.2(o)12.2(t)-462.9(st)19.7(an)20.2(da)14.1(rd)-447.4(of)-453.5(p)12.2(r)0(a)17.8(c)0(t)20.7(i)0(c)14.6(e)-461.5(a)14.1(n)0(d)18.3(,)-463.4(a)]TJ
0 -1.1219 TD
[(s)13.1(y)0(s)19.2(t)0(e)20.7(m)0(a)14.7(t)12.7(ic)-448.8(re)23.9(vi)18.8(ew)-444.7(of)-447.4(t)12.7(h)12.2(e)-455.4(l)0(i)19.3(t)0(e)14.6(r)0(a)23.9(t)0(u)18.8(r)0(e)-445.5(f)0(a)17.8(i)12.7(le)14.6(d)-451.2(t)0(o)-444.5(p)12.2(ro)16(d)12.2(u)12.2(c)0(e)-447.4(e)0(v)20.2(i)0(d)18.8(e)0(n)20.2(c)0(e)]TJ
0 -1.128 TD
[(ab)20.2(o)12.2(u)0(t)-279.9(t)0(h)18.8(e)-290.8(ef)17.8(fe)17.8(c)14.1(t)0(i)19.4(v)0(e)14.1(n)12.2(es)21.1(s)-291.8(o)12.2(f)-288.9(a)0(b)14.1(d)12.2(o)12.2(m)0(i)19.4(n)0(a)20.2(l)-292.1(b)12.2(i)0(n)18.8(d)12.2(er)17.8(s)-291.8(p)12.2(os)19.2(t)-292.1(C)0(-)17.3(s)13.1(ec)16(t)12.7(i)0(o)18.8(n)12.2(.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.7862 0 TD
[(The)-274.3(purpose)-279.9(of)-276.7(this)-278.5(project)-277.9(was)-279.2(to)-273.8(evaluate)-284(the)]TJ
-6.7862 -1.128 TD
[(use)-344.7(of)-343.8(abdominal)-342(binders)-346.5(to)-347(decrease)-345.6(pain)-345.1(and)-345.6(increase)-347(ambu-)]TJ
0 -1.1219 TD
[(lation)-301.3(in)-298.2(women)-297.7(post)-303.4(C-section.)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 59.7543 749.7069 Tm
(ABSTRACTS)Tj
53.1188 0 TD
(A-7)Tj
ET
endstream
endobj
213 0 obj
<>stream
/GS1 gs
BT
/F3 1 Tf
9.2982 0 0 9.2982 71.3197 725.5557 Tm
0 0 0 rg
0 Tc
0 Tw
(Material/Methods:)Tj
/F4 1 Tf
8.4385 0 TD
[(This)-372.3(EBP)-369.1(project)-369.4(received)-372.2(IRB)-371.5(exempt)]TJ
-9.4384 -1.128 TD
[(approval.)-247.9(All)-244.3(women)-242.9(post)-242.4(C-)-244.8(section)-244.2(were)-243.9(offered)-247.1(an)-248.1(abdominal)]TJ
0 -1.1219 TD
[(binder)-316.9(before)-311.8(the)-320.7(rst)-314.8(post-operative)-313.5(ambulation.)-317.1(Pain)-311.4(and)-315.1(am-)]TJ
0 -1.128 TD
[(bulation)-362.2(were)-359.8(assessed)-362.7(at)-357.3(12,)-359.7(24,)-359.7(36,)-359.7(48)-359.7(and)-357.8(60)-359.7(hours)-361.1(post-C-)]TJ
0 -1.1219 TD
[(section)-378.3(in)-371.4(94)-378(women)-370.9(with)-378.4(/without)-371.2(binders.)-377(The)-377.9(binders)-370.9(were)]TJ
0 -1.128 TD
[(removed)-546.7(for)-541.2(regular)-549.1(assessments)-543.7(per)-543.1(standards)-544.9(of)-545(care)-545.4(and)]TJ
0 -1.1219 TD
[(whenever)-302.9(the)-302.4(woman)-297.7(wanted)-302(it)-303.8(removed.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Results:)Tj
/F4 1 Tf
3.7559 0 TD
-.0193 Tc
[(9)5.1(4)-281.4(women)-275.4(p)-1(o)5.1(s)-.1(t)-281(C).4(-section)-275.4(w)3.6(ith)-275.4(an)-281.4(av)5.1(erage)-273.5(a)-5.2(g)5.1(e)-279.6(of)-271.6(33.4)]TJ
-4.7558 -1.1219 TD
.0117 Tc
[(years)-206.9(w)-2(ere)-212(i)0(n)11.7(c)-10.8(l)11.7(u)-6(ded)-213.9(i)0(n)-207.8(t)0(he)-212(project.)-213.9(A)4.1(cross)-206.9(a)-4.7(l)11.7(l)-218.9(asses)11.7(s)-4.8(ment)-213.4(times,)]TJ
0 -1.128 TD
.0113 Tc
[(wearing)-250.8(a)1(n)-256.9(a)1(bd)11.3(o)-6.9(m)-.3(inal)-250.4(bin)11.3(d)-6.9(er)-253.2(was)-250(s)0(ignicantly)-250.8(associated)-250.8(with)]TJ
0 -1.1219 TD
[(less)-567.1(p)11.3(a)-5.1(in)-567.9(\()]TJ
/F7 1 Tf
4.7863 0 TD
0 Tc
(v)Tj
/F4 1 Tf
6.9735 0 0 6.198 111.2882 625.0392 Tm
(2)Tj
/F2 1 Tf
9.2982 0 0 9.2982 114.8598 620.9573 Tm
(=)Tj
/F4 1 Tf
.5609 0 TD
.0126 Tc
[(27.4)12.6(2)-5.6(\()4.2(8\),)-560.5(p)]TJ
/F2 1 Tf
4.8412 0 TD
0 Tc
(=)Tj
/F4 1 Tf
.5609 0 TD
.011 Tc
[(.0)11(0)-7.2(1)-1.2(\),)-562.1(a)-5.4(n)11(d)-574.3(i)-.7(n)11(c)-5.4(reased)-568.2(amb)11(u)-7.2(lation)]TJ
-11.6456 -1.128 TD
0 Tc
(\()Tj
/F7 1 Tf
.3414 0 TD
(v)Tj
/F4 1 Tf
.5122 0 TD
(2)Tj
/F2 1 Tf
.5122 0 TD
(=)Tj
/F4 1 Tf
.5609 0 TD
.0106 Tc
[(19.)10.6(5)-7.6(5)-1.6(\(1\),)-282.1(p)]TJ
/F2 1 Tf
4.5485 0 TD
0 Tc
(<)Tj
/F4 1 Tf
.567 0 TD
[(.0)-18.2(0)-12.2(0)-12.2(\))-8.4(.)-286.6(N)-13.7(o)-286.5(s)-11.3(i)-11.7(g)0(n)-18.2(i)-11.7()-8.9(c)-16.4(a)-10.3(n)0(t)-298.2(d)-12.2(if)-20.1(f)-8.4(e)-10.3(r)-14.5(e)-10.3(n)-12.2(c)-10.3(e)-10.3(s)-285.7(i)-11.7(n)-292.6(th)-17.7(e)-290.8(l)12.7(en)20.2(g)12.2(t)0(h)]TJ
-7.0423 -1.1219 TD
[(o)12.2(f)-349.9(ti)19.3(m)12.8(e)-351.7(ou)18.3(t)-347(o)0(f)-343.8(b)12.2(ed)-339.5(\(p)]TJ
/F2 1 Tf
8.6519 0 TD
(=)Tj
/F4 1 Tf
.5426 0 TD
[(.)12.2(4)12.2(0)0(\))16(,)-347.5(o)12.2(r)-349.9(th)18.8(e)-351.7(l)12.7(ev)20.2(el)-339(of)-343.8(a)14.1(c)0(t)14.6(i)12.7(v)12.2(i)12.7(ty)-340.9(wh)16.8(e)14.1(n)-353.6(o)12.2(u)12.2(t)-353.1(o)12.2(f)]TJ
-9.1946 -1.128 TD
-.0122 Tc
[(be)-12.2(d)-443.2(\()-12.2(p)]TJ
/F2 1 Tf
2.6767 0 TD
0 Tc
(=)Tj
/F4 1 Tf
.5427 0 TD
-.0122 Tc
[(.13\))-453.5(w)-12.2(e)6.5(r)-12.2(e)-439.4(not)-12.2(e)8.5(d)-12.2(.)-445.1(A)-12.2(d)10.7(d)0(i)-12.2(t)7.1(ion)-12.2(a)8(l)-12.2(l)7.1(y,)-451.2(t)-12.2(h)6.6(e)-449.3(w)-12.2(o)10.7(m)-12.2(e)8.5(n)-451.2(c)-12.2(o)8(ns)-12.2(i)7.5(s)-12.2(t)7.5(e)-12.2(n)8(t).5(l)-12.2(y)]TJ
-3.2193 -1.128 TD
0 Tc
[(re)17.8(p)12.2(o)12.2(r)0(t)22.6(e)0(d)-455.4(t)12.7(ha)20.2(t)-462.9(t)0(h)18.9(e)-461.5(bi)18.8(n)12.2(d)12.2(e)0(r)17.8(s)-462.5(ma)20.7(d)12.2(e)-467.6(t)12.7(h)0(e)20.2(m)-462.8(fe)17.8(el)-454.9(m)12.8(o)12.2(re)-457.7(c)14.1(o)12.2(n)21.6(de)20.2(nt)-456.7(a)14.1(n)0(d)]TJ
0 -1.1219 TD
[(co)20.2(m)12.8(f)0(o)22.1(r)0(t)16.5(a)14.1(bl)18.8(e.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Conclusions:)Tj
/F4 1 Tf
5.7618 0 TD
[(Th)22.6(is)-212(p)12.2(r)0(o)16(j)12.7(ec)16(t)-219(a)0(d)20.2(d)0(s)-212.5(t)0(o)-212.8(t)0(h)18.9(e)-223.7(ev)20.2(i)12.7(d)0(e)14.1(n)12.2(ce)-215.7(t)12.7(h)12.2(at)-217.1(a)14.1(b)0(d)18.3(o)12.2(mi)19.4(na)20.2(l)]TJ
-6.7618 -1.1219 TD
[(b)12.2(i)0(n)18.8(d)0(e)20.2(r)0(s)-410(b)12.2(en)14.1(e)14.1()0(t)-410.8(w)0(o)22.9(m)0(e)14.7(n)-414.6(p)12.2(o)0(s)19.2(t)-420.2(C-)17.3(s)13.1(e)0(c)16(t)12.7(io)18.9(n)12.2(.)-420.7(Ac)18.7(ro)22.1(ss)-406.8(al)14.6(l)-414.1(a)0(s)15(s)13.1(es)21.1(sm)19.7(en)14.1(t)12.7(s)0(,)]TJ
0 -1.128 TD
[(wo)16.8(m)12.8(e)0(n)-437.1(w)0(e)18.7(a)14.1(ri)16.5(n)12.2(g)-445.1(b)12.2(i)0(n)18.8(d)12.2(er)17.8(s)-444.2(s)0(c)15(a)14.1(le)14.6(d)-439(t)0(h)18.9(e)0(i)20.7(r)-447.4(p)12.2(a)0(i)20.7(n)-445.1(le)20.7(ss)13.9(,)-439(a)0(n)20.2(d)-445.1(am)20.8(bu)18.3(la)20.7(te)14.6(d)]TJ
0 -1.1219 TD
[(ea)16(rl)22.6(ie)20.7(r)-325.5(t)12.7(h)12.2(a)0(n)-315.1(t)12.7(h)12.2(o)0(s)19.2(e)-321.2(wh)16.8(o)-317(d)0(i)18.8(d)-323.1(n)12.2(o)12.2(t)-322.6(we)18.7(ar)-311.4(a)-321.2(b)12.2(in)18.8(d)12.2(e)0(r)17.8(.)-323.1(B)13.6(a)0(s)15(e)14.1(d)-323.1(o)12.2(n)-323.1(t)12.7(he)-315.1(d)12.2(a)0(t)20.7(a)]TJ
0 -1.128 TD
[(fr)19.7(o)12.2(m)-170.2(t)12.7(h)12.2(is)-157.1(p)12.2(r)0(o)16(j)12.7(ec)16(t)12.7(,)-164.6(ab)20.2(do)18.3(mi)19.4(n)12.2(a)0(l)-156.1(b)0(i)18.8(n)12.2(de)14.1(rs)-153.9(p)12.2(o)12.2(s)0(t)19.7(s)-169.8(C)13.6(-)0(s)16.8(e)0(c)22.1(t)0(i)19.3(o)0(n)-158.5(a)0(r)17.8(e)-162.7(b)12.2(e)0(n)20.2(e)0()17.3(c)0(i)20.7(a)0(l)14.6(.)]TJ
/F3 1 Tf
0 -4.1583 TD
(18.)Tj
9.843 0 0 9.843 82.9417 477.6377 Tm
[(The)-281.8(Psychosocial)-287.2(Impact)-279.2(Among)-283.8(Women)]TJ
0 -1.1174 TD
[(with)-281.7(Abnormal)-282.4(Cervical)-284.1(Pap)-280.8(Smear)-285.2(Result)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 62.022 450.0849 Tm
[(Ya-Ping)-260.3(Chen)]TJ
6.9735 0 0 6.198 117.4677 454.2235 Tm
(1)Tj
9.2982 0 0 9.2982 120.9259 450.0849 Tm
[(,)-256.1(Lee-Ing)-258.7(Tsao)]TJ
6.9735 0 0 6.198 175.6913 454.2235 Tm
(1)Tj
9.2982 0 0 9.2982 179.1496 450.0849 Tm
[(,)-256.1(Whei-Mei)-262.9(Shih)]TJ
6.9735 0 0 6.198 241.6251 454.2235 Tm
(2)Tj
9.2982 0 0 9.2982 245.1401 450.0849 Tm
[(,)-256.1(Yen-Yen)-257.5(Yu)]TJ
6.9735 0 0 6.198 297.6377 454.2235 Tm
(3)Tj
/F5 1 Tf
-33.7872 -2.6526 TD
(1)Tj
9.2982 0 0 9.2982 65.537 433.644 Tm
[(School)-332.8(of)-334.8(Nursing)-331.6(National)-332.3(Taipei)-335.2(University)-333.9(of)-334.8(Nursing)-331.6(and)]TJ
-.378 -1.1219 TD
[(Health)-333.8(Sciences,)-338.5(Taipei,)-335.2(Taiwan)]TJ
6.9735 0 0 6.198 62.022 416.8629 Tm
(2)Tj
9.2982 0 0 9.2982 65.537 412.7243 Tm
[(Chang)-333.8(Gung)-330.6(University)-333.9(of)-334.8(Science)-339.4(and)-329.2(Technology,)-337.9(Taipei,)]TJ
-.378 -1.1219 TD
(Taiwan)Tj
6.9735 0 0 6.198 62.022 395.9432 Tm
(3)Tj
9.2982 0 0 9.2982 65.537 391.8046 Tm
[(Taoyuan)-330.1(Innovation)-334.6(Institute)-332.8(of)-334.8(Technology,)-331.8(Taipei,)-335.2(Taiwan)]TJ
/F3 1 Tf
.6219 -2.3047 TD
(Background:)Tj
/F4 1 Tf
5.8045 0 TD
[(In)-197.4(the)-204.9(Past)-200.8(20)-201.2(years,)-198.8(the)-204.8(incidence)-204.7(and)-199.2(mortality)]TJ
-6.8045 -1.1219 TD
[(of)-331.6(cervical)-335.1(invasion)-331.4(cancer)-336.2(has)-332.5(been)-331.5(decreasing)-334.7(because)-332.9(rigors)]TJ
0 -1.128 TD
[(National)-453.3(screening)-446.4(policy)-454.3(approximately)-445.6(60,000)-451.1(women)-450.2(who)]TJ
0 -1.1219 TD
[(had)-339.5(abnormal)-344.9(cervical)-341.2(pap)-345.6(every)-339.9(year)-340(in)-340.9(Taiwan.)-346.5(The)-341.3(Psycho-)]TJ
0 -1.128 TD
[(social)-408.9(impact)-415.3(of)-404.7(this)-412.7(group)-404.7(of)-410.8(woman)-413.6(induced)-410.2(feared)-407.5(cancer,)]TJ
0 -1.1219 TD
[(fertility)-384.3(and)-388.3(sexual)-385(activate,)-387.1(there)-382.1(were)-390.2(only)-377.4(a)-388.3(few)-386(studies)-385.5(on)]TJ
0 -1.128 TD
[(topic)-301.9(in)-298.2(the)-302.4(literature.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.7131 0 TD
[(To)-203(describe)-202.5(the)-204.8(psychosocial)-204.8(impact)-208(and)-199.2(related)]TJ
-6.713 -1.128 TD
[(factors)-511.6(among)-503.5(women)-511.1(with)-506.5(abnormal)-503.5(cervical)-511.9(smear)-509.3(during)]TJ
0 -1.1219 TD
[(follow-up)-303.8(period.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Material/Methods:)Tj
/F4 1 Tf
8.469 0 TD
[(Purposive)-398.1(sampling)-398(a)-400.5(total)-398.9(of)-398.6(109)-396.2(par-)]TJ
-9.4689 -1.1219 TD
[(ticipants)-560.2(were)-561(women.)-559.9(Research)-559.5(tools)-559(include)-562.1(demographic)]TJ
0 -1.128 TD
[(background)-345.9(questionnaire)-347.7(and)-345.6(Process)-347.2(Outcome)-344.1(Specic)-347(Mea-)]TJ
0 -1.1219 TD
[(sure)-304.4(\(POSM\))-297.5(questionnaire.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Results:)Tj
/F4 1 Tf
3.7925 0 TD
[(In)-362.1(t)12.7(h)12.2(e)-351.7(s)0(t)19.7(u)12.2(dy)-341.4(a)14.1(p)0(p)18.3(r)0(o)16(x)12.2(i)12.7(m)0(a)14.7(t)12.7(el)20.7(y)-347.5(s)0(i)19.7(x)0(t)18.8(y)-347.5(pe)20.2(rs)16.8(o)12.2(n)0(s)-340.5(o)12.2(f)-349.9(w)0(o)22.9(m)0(e)14.7(n)]TJ
-4.7924 -1.1219 TD
[(fe)17.8(ar)-287(ab)20.2(ou)18.3(t)-298.2(t)0(h)18.8(e)-296.9(di)18.8(ag)20.2(no)18.3(si)19.7(s)-297.9(c)0(a)16(n)12.2(ce)16(r,)-288.9(al)20.7(l)-298.2(w)0(o)16.8(m)12.8(en)-290.7(wh)22.9(o)-298.7(h)0(a)14.1(d)-298.7(p)12.2(l)12.7(an)20.2(ne)14.1(d)-298.7(f)0(o)22.1(r)]TJ
0 -1.128 TD
[(p)12.2(r)0(e)17.8(g)0(n)18.3(a)0(n)20.2(t)-487.2(m)12.8(i)0(g)18.8(h)0(t)-475(w)0(o)16.8(r)0(r)19.7(i)12.7(ed)-479.7(ab)20.2(o)12.2(u)0(t)-481.1(f)0(e)23.9(r)0(t)16.5(i)12.7(li)19.3(ty)18.8(.)-487.8(I)0(n)-477.9(t)12.7(he)-479.7(s)13.1(e)0(x)20.2(u)0(a)14.1(l)12.7(ly)-475(ac)16(t)12.7(i)0(v)18.8(e)]TJ
T*
[(g)12.2(r)0(o)16(u)12.2(p)12.2(,)-432.9(fo)22.1(rt)16.5(y)-426.8(p)0(e)20.2(r)0(s)16.8(o)12.2(ns)-419.8(wo)16.8(rr)19.7(i)12.7(e)0(d)-424.9(a)0(b)20.2(o)12.2(ut)-420.2(se)15(x)12.2(u)12.2(a)0(l)14.6(l)12.7(y)-432.9(l)12.7(if)16.5(e)14.1(.)-432.9(Th)22.6(e)-431(a)0(g)20.2(e)-437.1(a)14.1(n)0(d)]TJ
0 -1.1219 TD
[(h)12.2(e)0(l)14.6(p)12.2(fu)22.1(l)-377.5(k)12.2(n)12.2(o)0(w)16.8(l)12.7(ed)14.1(g)12.2(e)-370(so)19.2(ur)16(ce)22.1(s)-377.1(f)0(r)19.7(o)12.2(m)-371.4(m)0(e)14.7(d)12.2(i)12.7(c)0(a)16(l)-371.4(st)19.7(af)17.8(f)-374.3(a)0(r)17.8(e)-370(pr)16(ed)20.2(i)12.7(c)0(t)14.6(i)12.7(v)12.2(e)-376.1(to)]TJ
0 -1.128 TD
[(p)12.2(s)0(y)19.2(c)0(h)20.2(o)0(s)19.2(o)0(c)20.2(i)0(a)14.6(l)-469(i)12.7(m)0(p)18.9(a)0(c)22.1(t)-469(fo)16(r)-465.7(1)12.2(6.)18.3(6%)-459.6(o)12.2(f)-471.8(v)12.2(a)0(r)17.8(i)12.7(at)14.6(i)12.7(o)12.2(n)-469.5(\()0(F)]TJ
/F2 1 Tf
19.4317 0 TD
(=)Tj
/F4 1 Tf
.5427 0 TD
-.0122 Tc
[(8.)-12.2(1)6.1(9)0(,)-481.7(p)]TJ
/F2 1 Tf
2.9145 0 TD
0 Tc
(<)Tj
/F4 1 Tf
.5426 0 TD
[(.0)18.3(0)12.2(1)0(\))16(.)]TJ
-23.4315 -1.1219 TD
[(Du)16.8(ri)22.6(n)12.2(g)-335.3(fo)22.1(ll)19.3(o)12.2(w)0(-)14.5(u)12.2(p)-329.2(p)0(e)20.2(r)0(i)16.5(o)12.2(d)-335.3(w)0(o)22.9(m)0(e)20.7(n)-335.3(n)12.2(e)0(e)16(d)-329.2(cl)20.7(ea)16(r)-331.6(e)0(x)20.2(p)12.2(la)14.6(n)12.2(a)0(t)20.7(i)0(o)18.8(n)-329.2(of)-325.5(t)12.7(h)0(e)20.2(i)0(r)]TJ
0 -1.128 TD
[(co)20.2(nd)18.3(i)12.7(t)0(i)19.3(o)0(n)-341.4(a)14.1(nd)-341.4(t)12.7(r)0(e)17.8(a)0(t)20.7(m)0(e)14.6(n)12.2(t)-347(\()0(8)22.1(6)0(%)16(\))0(,)-337.7(e)14.1(xp)18.3(ed)20.2(it)19.4(io)18.8(u)12.2(s)-346.7(di)18.8(ag)20.2(no)18.3(si)19.7(s)-346.7(a)0(n)20.2(d)-347.5(tr)16.5(ea)22.1(t-)]TJ
0 -1.1219 TD
[(me)20.7(nt)-212.8(\(7)22.1(2.)18.3(5)12.2(%)0(\))19.7(,)-225.6(a)-217.6(w)0(a)18.7(r)0(m)-215.2(t)12.7(ru)22.1(st)19.7(y)-225.6(e)14.1(nv)18.3(ir)16.5(o)12.2(n)12.2(m)0(e)20.8(n)0(t)-212.8(f)0(o)16(r)-215.7(co)14.1(n)12.2(s)13.1(ul)18.8(ta)20.7(ti)19.3(on)-213.3(\(3)22.1(2%)16(\).)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Conclusions:)Tj
/F4 1 Tf
5.7679 0 TD
[(W)14.1(e)-272.5(n)12.2(e)0(e)22.1(d)-268.2(to)-261.6(p)12.2(a)14.1(y)-268.2(m)0(o)18.9(r)0(e)-256.5(a)0(t)20.7(t)0(e)20.7(n)0(t)18.8(i)12.7(o)12.2(n)-268.2(to)-261.6(c)14.1(a)0(r)17.8(e)-266.4(fo)22.1(r)-270.6(t)12.7(ho)18.3(s)13.1(e)]TJ
-6.7679 -1.1219 TD
[(wo)22.9(me)20.7(n)16(s)-200.3(n)12.2(ee)16(d)12.2(s)-200.3(wh)16.8(o)-201.2(w)0(i)23.4(t)0(h)-194.6(a)0(b)20.2(n)12.2(o)12.2(r)0(m)16.5(a)14.1(l)-206.8(P)0(a)23.4(p)-207.3(s)13.1(m)12.8(ea)16(r;)-190.8(i)12.7(t)-206.8(i)12.7(s)-206.4(re)23.9(co)20.2(mm)19.4(en)20.2(d)12.2(e)0(d)]TJ
0 -1.128 TD
[(t)12.7(o)-347.5(bu)18.3(i)12.7(l)12.7(d)-347.5(a)-351.7(s)13.1(p)12.2(e)0(c)16(i)12.7(al)20.7(i)12.7(s)0(t)-340(a)14.1(dv)18.3(i)12.7(c)0(e)-337.6(a)0(n)20.2(d)-347.5(a)-345.6(p)0(r)22.1(i)0(v)18.9(a)0(c)22.1(y)-347.5(me)20.7(di)18.8(ca)22.1(l)-347(e)0(n)20.2(v)12.2(ir)16.5(o)12.2(n)12.2(m)12.8(en)20.2(t.)]TJ
0 -1.1219 TD
[(Sh)21.6(o)12.2(u)0(l)18.8(d)-457.3(fo)22.1(cu)20.2(s)-456.4(o)12.2(n)-457.3(y)0(o)18.3(u)12.2(n)12.2(g)-457.3(wo)16.8(m)12.8(e)0(n)20.2()0(s)-446.6(f)0(e)17.8(r)0(t)22.6(i)12.7(li)19.3(t)12.7(y)-457.3(an)20.2(d)-457.3(f)0(a)17.9(m)12.8(il)19.3(y)-457.3(s)13.1(up)18.3(p)12.2(o)12.2(r)0(t)16.5(.)]TJ
0 -1.128 TD
[(Re)21.6(ga)20.2(rd)22.1(le)20.7(ss)-339.7(o)12.2(f)-349.9(th)18.8(e)-345.6(s)0(m)19.7(e)0(a)22.1(r)-349.9(re)17.8(s)13.1(u)0(l)18.8(t)-347(se)21.1(v)12.2(e)0(r)17.8(i)12.7(ty)18.8(,)-347.5(w)0(e)-341(m)12.8(u)12.2(s)0(t)-340(f)0(o)22.1(c)0(u)20.2(s)-346.7(on)-341.4(i)12.7(n)12.2(di)18.8(-)]TJ
0 -1.1219 TD
[(v)12.2(i)0(d)18.8(u)12.2(al)-259.7(wo)22.9(me)20.7(n)-268.2(o)12.2(f)-270.6(c)0(o)20.2(n)12.2(su)19.2(l)12.7(t)0(i)19.3(n)12.2(g)12.2(.)-268.3(Th)16.5(e)-266.4(s)13.1(tu)18.8(d)12.2(y)-268.2(al)20.7(so)-261.3(l)12.7(i)12.7(s)0(t)19.7(s)-267.4(th)18.8(o)12.2(s)13.1(e)-272.5(Q)0(u)22.9(e)0(s)21.1(t)0(i)19.3(o)12.2(n)12.2(s)]TJ
0 -1.128 TD
[(an)20.2(d)-304.8(a)14.1(ns)19.2(we)18.7(rs)-288(wh)16.8(i)12.7(c)0(h)-290.7(w)0(o)16.8(m)12.8(en)-290.7(of)16(t)12.7(e)0(n)-290.7(i)0(n)18.8(q)12.2(u)12.2(i)0(r)22.6(e)-309.1(t)12.7(o)-304.8(p)12.2(r)0(o)22.1(v)12.2(i)12.7(d)0(e)-296.8(c)14.1(li)19.3(n)12.2(i)0(c)20.7(a)0(l)-296.3(c)0(a)22.1(r)0(e)]TJ
0 -1.1219 TD
[(re)17.8(fe)23.9(re)17.8(n)12.2(c)0(e)22.1(.)]TJ
/F3 1 Tf
26.9984 71.9468 TD
(19.)Tj
9.843 0 0 9.843 333.9779 725.5557 Tm
[(Depression)-285.5(and)-285.2(Internet)-282.4(Use)-281.6(in)-278.6(Married)]TJ
0 -1.1174 TD
[(and)-285.2(Working)-280.5(Women)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 313.0582 698.0029 Tm
[(Insook)-336.7(Cho)]TJ
6.9735 0 0 6.198 356.9385 702.1416 Tm
(1)Tj
9.2982 0 0 9.2982 360.4534 698.0029 Tm
[(,)-329.2(Young)-336.7(Sook)-332(Park)]TJ
6.9735 0 0 6.198 433.4172 702.1416 Tm
(2)Tj
/F5 1 Tf
-17.2595 -2.6527 TD
(1)Tj
9.2982 0 0 9.2982 316.5731 681.562 Tm
[(Inha)-331.5(University,)-340(Nursing)-331.6(Department,)-338.6(Incheon,)-333.8(South)-328.6(Korea)]TJ
6.9735 0 0 6.198 313.0582 675.2691 Tm
(2)Tj
9.2982 0 0 9.2982 316.5731 671.1306 Tm
-.0182 Tc
[(Seoul)-194.5(National)-194.5(Uni)-5.5(ver)-5.1(sity,)-195(C)1.5(ollege)-193.1(of)-194.5(Nursing,)-195(Seoul,)-195(South)-195(K)1.5(or)-5.1(ea)]TJ
/F3 1 Tf
.6219 -2.3047 TD
0 Tc
(Background:)Tj
/F4 1 Tf
5.8838 0 TD
[(The)-274.3(Internet)-280.3(\(including)-279.2(social)-280.8(media\))-277.9(has)-277.7(been)]TJ
-6.8837 -1.128 TD
[(considered)-458.5(an)-455.4(effective)-459.4(medium)-453.7(for)-455.9(delivering)-454.2(mental)-458(health)]TJ
0 -1.1219 TD
[(interventions)-379.6(to)-377.5(childbearing)-379.1(women)-377(in)-371.4(the)-375.6(community.)-380(How-)]TJ
0 -1.128 TD
[(ever,)-303.4(little)-300.3(is)-303.5(known)-300.1(about)-296.3(their)-304.2(Internet-use)-304.2(behaviors.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.7679 0 TD
[(We)-252.3(explored)-254(their)-261.5(overall)-253.5(Internet)-255.9(use)-253.3(and)-260.2(type)]TJ
-6.7679 -1.128 TD
[(of)-246.2(Internet)-243.7(use)-241.1(according)-246(to)-243.3(their)-243.3(occupation)-243.1(and)-241.9(the)-241.4(presence)-243.8(of)]TJ
0 -1.1219 TD
(depression.)Tj
/F3 1 Tf
.9999 -1.128 TD
(Material/Methods:)Tj
/F4 1 Tf
8.4019 0 TD
[(This)-329.6(work)-326.9(was)-334(performed)-331.9(as)-326.5(a)-333.4(part)-329.1(of)-331.6(a)]TJ
-9.4019 -1.1219 TD
[(survey)-456.8(that)-454.3(investigated)-454.6(depression)-459.6(among)-454.8(married,)-451(working,)]TJ
0 -1.128 TD
[(and)-363.9(childbearing)-366.9(women)-364.8(in)-365.3(South)-362(Korea.)-359.7(\(1\))-364.4(In)-362(2010,)-365.7(a)-363.9(ques-)]TJ
0 -1.1219 TD
[(tionnaire)-277.4(was)-273.1(sent)-271(to)-273.8(a)-266.4(convenience)-276.4(sample)-274.7(of)-270.6(765)-268.2(women)-273.3(aged)]TJ
0 -1.128 TD
[(2445)-445(years)-442.7(nationwide,)-441.1(who)-440.4(were)-445.1(stratied)-444(by)-438.9(occupational)]TJ
0 -1.1219 TD
[(class.)-365.8(The)-365.7(subjects)-365.3(were)-365.8(asked)-361.1(about)-363.3(their)-365.2(overall)-363.3(and)-363.9(type)-363.3(of)]TJ
0 -1.128 TD
[(Internet)-219.3(use)-222.8(and)-217.5(their)-218.9(level)-214.6(of)-221.8(depression)-215.7(were)-219.5(assessed)-222.5(using)-218(the)]TJ
0 -1.1219 TD
[(Beck)-421.6(Depression)-424.5(InventoryII,)-415.3(along)-424.3(with)-415(other)-420.6(personal)-423.9(and)]TJ
0 -1.128 TD
[(social)-305.2(factors.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Results:)Tj
/F4 1 Tf
3.7742 0 TD
[(Th)16.5(e)-284.7(d)12.2(ep)14.1(re)23.9(ss)13.9(i)12.7(o)12.2(n)-286.5(s)0(c)15(o)12.2(re)-274.8(wa)18.7(s)-291.8(s)13.1(ig)18.9(n)12.2(i)0()16(c)14.1(an)14.1(t)12.7(l)0(y)-279.9(h)12.2(i)12.7(g)0(h)18.3(e)0(r)-280.9(i)12.7(n)-286.5(s)0(e)21.1(r)0(-)]TJ
-4.7741 -1.128 TD
[(vi)18.8(ce)-435.2(an)20.2(d)-439(m)0(a)14.6(n)12.2(u)12.2(a)0(l)-430.5(w)0(o)16.8(r)0(k)22.1(e)0(r)17.8(s)-444.2(t)12.7(h)0(a)20.2(n)-445.1(i)12.7(n)-439(pr)16(o)12.2(f)0(e)17.8(s)13.1(si)19.7(on)18.3(al)-430.5(em)14.7(p)12.2(l)12.7(oy)18.3(ee)16(s)-438.1(\()0(F)]TJ
/F2 1 Tf
25.1631 0 TD
(=)Tj
/F4 1 Tf
-25.1631 -1.1219 TD
[(9.)18.3(0)12.2(9)0(,)-384.1(P)]TJ
/F2 1 Tf
2.8901 0 TD
(=)Tj
/F4 1 Tf
.5426 0 TD
[(0.)18.3(0)12.2(0)0(0)18.3(1)12.2(\).)-380.4(Th)16.5(e)-388.3(I)0(n)22.1(t)0(e)20.7(r)0(n)16(e)14.1(t)-389.7(w)0(a)18.7(s)-389.3(us)19.2(ed)-382.2(b)12.2(y)-390.2(9)12.2(9)12.2(.)0(9)18.3(%)0(,)-380.3(9)12.2(4)12.2(.)0(5)18.3(%)0(,)-380.3(a)0(n)20.2(d)]TJ
-3.4327 -1.128 TD
[(84)18.3(.)12.2(9)0(%)-429.1(o)12.2(f)-435.2(p)12.2(ro)22.1(fe)17.8(ss)20(io)18.8(na)20.2(ls)19.7(,)-439(s)13.1(er)17.8(v)12.2(i)0(c)20.7(e)-437.1(wo)16.8(rk)22.1(er)17.8(s)13.1(,)-432.9(an)14.1(d)-432.9(m)12.8(an)20.2(ua)20.2(l)-438.5(w)0(o)22.9(r)0(k)16(e)14.1(rs)16.8(,)]TJ
0 -1.1219 TD
[(re)17.8(sp)19.2(ec)16(t)12.7(i)0(v)18.8(e)0(l)20.7(y)0(.)-213.4(I)0(n)22.1(f)0(o)16(r)0(m)22.6(a)0(t)20.7(i)0(o)18.9(n)-225.6(g)12.2(a)0(t)20.7(h)0(e)20.2(r)0(i)16.5(n)12.2(g)-225.6(w)0(a)18.7(s)-218.6(th)18.8(e)-223.7(m)12.8(ai)14.6(n)-219.5(r)0(e)17.8(a)0(s)21.1(o)0(n)-213.3(f)0(o)22.1(r)-221.8(us)19.2(in)18.8(g)]TJ
0 -1.128 TD
[(th)18.8(e)-492(I)0(n)22.1(t)0(e)14.6(r)0(n)22.1(e)0(t)-479.3(a)0(m)20.7(o)0(n)18.4(g)-487.7(9)12.2(4)0(%)-484(o)12.2(f)-490.1(p)12.2(ro)22.1(fe)17.8(ss)20(io)18.8(na)20.2(ls)19.7(,)-493.9(w)0(h)22.9(i)0(l)19.3(e)-492(i)12.7(n)12.2(te)14.6(rp)22.1(er)17.8(s)13.1(o)0(n)18.3(a)0(l)]TJ
0 -1.1219 TD
[(co)14.1(m)12.8(m)12.8(u)0(n)18.3(i)0(c)20.7(a)0(t)14.6(i)12.7(o)12.2(n)-402.4(an)20.2(d)-402.4(e)0(n)20.2(t)0(e)20.7(r)0(t)16.5(a)0(i)20.7(n)12.2(me)14.6(n)12.2(t)-401.9(we)18.7(re)-390.7(m)12.8(o)0(r)16(e)-400.5(co)20.2(mm)19.4(o)12.2(n)-402.4(re)17.8(as)21.1(o)12.2(n)0(s)]TJ
0 -1.128 TD
[(am)14.6(o)12.2(n)12.2(g)-250(se)15(rv)22.1(ic)20.7(e)-254.2(a)0(n)20.2(d)-250(m)12.8(a)0(n)20.2(u)0(a)14.1(l)-249.5(wo)22.9(rk)16(e)14.1(r)0(s)-245.4(\()0(X)20.6(2)]TJ
/F2 1 Tf
15.7369 0 TD
(=)Tj
/F4 1 Tf
.5426 0 TD
[(3)12.2(9)0(.)18.3(1)12.2(2,)-243.8(P)]TJ
/F2 1 Tf
3.2376 0 TD
(<)Tj
/F4 1 Tf
.5427 0 TD
[(0.)18.3(0)12.2(0)0(0)18.3(1)12.2(\).)]TJ
/F3 1 Tf
-19.0598 -1.1219 TD
(Conclusions:)Tj
/F4 1 Tf
5.7557 0 TD
[(These)-265.4(ndings)-269.6(suggest)-264(that)-265.3(service)-269.6(and)-266.3(manual)]TJ
-6.7557 -1.128 TD
[(workers)-436.3(should)-431.4(be)-437.1(the)-430.4(rst)-436.7(intervention)-435.3(targets)-429.5(of)-435.2(depression)]TJ
0 -1.1219 TD
[(intervention,)-349.9(and)-345.6(that)-350.7(the)-345.1(digital)-349.6(approaches)-353.5(for)-346.1(delivering)-344.4(on-)]TJ
0 -1.128 TD
[(line)-283.6(mental)-275(health)-281.7(services)-280.9(should)-279(vary)-280.9(with)-274.8(occupational)-283.4(class.)]TJ
0 -1.1219 TD
[(Services)-321.2(aimed)-318.2(at)-314.6(service)-318.4(and)-315.1(manual)-318.2(workers)-314.3(should)-315.5(focus)-316.6(on)]TJ
0 -1.128 TD
[(utilizing)-306.3(the)-302.4(communication)-308.5(and)-302.9(entertainment)-303(functions)-303.3(of)-301.1(the)]TJ
0 -1.1219 TD
[(Internet)-274.2(rather)-268.6(than)-271.9(providing)-269.4(only)-267.7(relevant)-269.9(factual)-269.9(information.)]TJ
/F3 1 Tf
0 -3.829 TD
(20.)Tj
9.843 0 0 9.843 333.9779 300.3023 Tm
[(What)-281.8(do)-278.5(Lebanese)-289.3(Women)-279.4(Know)-282.8(About)-282.5(Cervical)]TJ
0 -1.1174 TD
[(Cancer)-287.3(and)-279.4(Human)-284(Papillomavirus?)-279.2(A)-284.2(Report)]TJ
0 -1.1116 TD
[(on)-284.3(Awareness)-285.3(Levels)-280.6(in)-284.4(Urban)-277.9(Communities)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 313.0582 261.8078 Tm
[(Jacques)-340(Choucair,)-331.9(Sara)-336.7(Abboud)]TJ
/F5 1 Tf
0 -1.7682 TD
[(Saint)-334.2(Joseph)-336.7(University,)-333.9(School)-332.8(of)-334.8(Medicine,)-336.9(Beirut,)-333.3(Lebanon)]TJ
/F3 1 Tf
.9999 -2.3047 TD
(Background:)Tj
/F4 1 Tf
5.8411 0 TD
-.0179 Tc
[(Knowledg)-5.7(e)-192.8(a)-3.8(bout)-194.2(HPV)-196.2(a)2.3(nd)-200.8(cervical)-200.3(c)2.3(ancer)-197.1(l).9(acks.)]TJ
/F3 1 Tf
-5.8411 -1.1219 TD
0 Tc
(Objective\(s\):)Tj
/F4 1 Tf
6.0789 0 TD
[(To)-574.9(evaluate)-570.5(the)-570.7(knowledge)-576.3(of)-569.4(urban)-567.4(adult)]TJ
-7.0788 -1.128 TD
[(Lebanese)-596.9(women)-584.3(regarding)-591.7(the)-589(symptoms)-588(and)-589.5(risk)-592.3(factors)]TJ
T*
[(of)-398.6(cervical)-402.2(cancer)-403.2(and)-394.4(the)-400(diagnostic)-396.1(tests)-403.8(and)-394.4(vaccination)-399.2(of)]TJ
0 -1.1219 TD
[(human)-247.5(papillomavirus)-251(\(HPV\))-242.2(infection.)-246.9(To)-245.7(measure)-251.3(in)-243.3(the)-247.5(same)]TJ
0 -1.128 TD
[(population)-282.9(the)-284.1(uptake)-282.2(of)-276.7(the)-284.1(cervical)-280.2(cancer-screening)-291(test)-276.6(\(Pap)]TJ
0 -1.1219 TD
[(smear\))-365.3(and)-357.8(the)-363.4(uptake)-355.3(of)-362.1(HPV)-359.4(vaccination,)-362.6(and)-357.8(determine)-360.8(the)]TJ
0 -1.128 TD
[(factors)-304.3(that)-301.9(may)-302.4(inuence)-301.4(them.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Material/Methods:)Tj
/F4 1 Tf
8.3653 0 TD
[(444)-298.7(Lebanese)-298.2(women)-297.7(above)-294.9(18)-292.6(years)-296.4(of)]TJ
-9.3653 -1.128 TD
[(age,)-429.1(residing)-419.2(in)-426.2(Beirut)-424.8(and)-418.8(Mount-Lebanon,)-425.6(with)-421.1(no)-420.7(medical)]TJ
0 -1.1219 TD
[(background,)-236.1(were)-237.8(recruited)-235.7(online)-234.8(and)-229.7(in)-231.1(health)-239(care)-234.4(facilities)-237(to)]TJ
0 -1.128 TD
[(ll)-300.6(out)-292.1(a)-296.9(3)0(2)-292.6(item)-301.3(questionnaire)-292.8(about)-296.3(cervical)-298.5(cancer)-299.6(and)-296.8(HPV.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Results:)Tj
/F4 1 Tf
3.9205 0 TD
-.0128 Tc
[(45)-12.8(.)5.5(7)-.6(%)-441.9(o)-12.8(f)-435.8(t)-12.8(h)6(e)-443.8(w)-12.8(o)4(me)-12.8(n)-431.6(a)-12.8(ged)-445.7(18)-445.7(to)-445.7(25)-171.3(y,)-445.7(r)-12.8(e)5.1(si)-12.8(d)6(i)-12.8(n)6.1(g)-445.7(in)]TJ
-4.9204 -1.128 TD
0 Tc
[(Mo)19.2(un)18.3(t)12.7(-)0(L)14.1(e)14.1(b)0(a)14.1(n)12.2(o)12.2(n)-469.5(\(5)22.1(1)12.2(.)0(8)18.3(%)0(\))19.7(,)-469.5(s)13.1(i)0(n)18.9(g)12.2(le)-461(\(4)22.1(9)12.2(.)0(3)18.3(%)0(\))19.7(,)-463.4(wi)17.3(th)-456.7(h)12.2(i)0(g)18.9(h)-469.5(e)14.1(d)0(u)18.3(c)0(a)16(t)12.7(io)18.8(n)]TJ
0 -1.1219 TD
[(qu)18.3(al)20.7(i)16(ca)22.1(ti)19.3(on)18.3(s)-279.6(\()0(7)22.1(3)12.2(.9)18.3(%\))-266.8(an)14.1(d)-274.3(c)0(u)20.2(r)0(r)19.7(e)0(n)20.2(t)0(l)19.3(y)-280.4(em)20.8(pl)18.8(o)12.2(y)0(e)20.2(d)-280.4(\(4)22.1(9.)18.3(1)12.2(%)0(\))-272.9(i)12.7(n)-280.4(a)-278.6(e)17.3(l)12.7(d)]TJ
0 -1.128 TD
[(no)18.3(t)-164.1(r)0(e)17.8(l)0(a)20.7(t)0(e)14.6(d)-164.6(t)12.7(o)-164.6(he)14.1(a)14.1(l)0(t)19.3(h)-164.6(\(8)16(4)12.2(.)12.2(9)0(%)16(\))0(.)-154.8(T)0(h)22.6(e)0(y)-156.6(d)0(i)18.8(d)-164.6(n)12.2(o)0(t)-158(v)12.2(is)19.7(it)-157.5(a)-168.8(g)12.2(en)20.2(er)17.8(al)-156.1(p)12.2(h)0(y)18.4(s)13.1(ic)14.6(i)12.7(a)0(n)]TJ
0 -1.1219 TD
[(\(6)16(4)12.2(%)0(\))-254.7(o)12.2(r)-264.5(a)-260.3(gy)18.3(n)12.2(e)0(c)16(o)12.2(lo)18.8(g)12.2(i)0(s)19.7(t)-267.7(\(6)22.1(4)12.2(.)0(6)18.3(%)0(\))-254.7(r)0(e)23.9(g)0(u)18.3(l)0(a)20.7(r)0(l)16.5(y)12.2(.)-262.2(8)0(5)18.3(.)12.2(6%)-252.3(we)18.7(re)-256.5(a)14.1(w)0(a)18.7(r)0(e)-256.5(o)12.2(f)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 62.022 749.6502 Tm
(A-8)Tj
48.6864 0 TD
(ABSTRACTS)Tj
ET
endstream
endobj
218 0 obj
<>stream
/GS1 gs
BT
/F4 1 Tf
9.2982 0 0 9.2982 59.7543 725.5557 Tm
0 0 0 rg
0 Tc
0 Tw
[(ce)16(rv)22.1(ic)14.6(a)14.1(l)-188.5(ca)16(n)12.2(c)0(e)16(r)0(;)-178.6(H)0(P)20.1(V)-190.5(i)12.7(n)12.2(fe)17.8(ct)14.6(i)12.7(o)12.2(n)-189(i)0(n)18.8(v)12.2(ol)18.8(v)12.2(e)0(m)14.7(e)0(n)20.2(t)-188.5(i)12.7(n)-189(th)18.8(e)-187.1(p)0(a)20.2(t)0(h)18.8(o)0(g)18.3(e)0(n)20.2(e)0(s)21.1(i)0(s)-181.5(o)12.2(f)]TJ
0 -1.128 TD
[(ce)16(rv)22.1(ic)14.6(a)14.1(l)-206.8(ca)16(n)12.2(c)0(e)16(r)-203.6(wa)18.7(s)-206.4(i)0(d)18.8(e)0(n)20.2(t)0(i)19.3()0(e)17.3(d)-207.3(i)12.7(n)-207.3(5)12.2(3)12.2(.)0(9)18.3(%)-209.6(o)12.2(f)-203.6(ca)16(s)13.1(e)0(s)15(.)-207.3(3)12.2(5)12.2(.)0(6)18.3(%)-203.5(of)-197.4(wo)16.8(m)12.8(e)0(n)]TJ
0 -1.1219 TD
[(we)18.7(re)-354.1(a)14.1(w)0(a)18.7(r)0(e)-354.1(o)12.2(f)-356(H)0(P)20.1(V)-361.2(i)12.7(n)0(f)16(e)0(c)22.1(t)0(i)19.3(o)0(n)-347.5(b)0(u)18.3(t)-359.2(8)12.2(0)0(.)18.3(4)12.2(%)-362(b)12.2(el)20.7(ie)20.7(ve)14.1(d)-353.6(t)0(h)18.8(e)0(y)-351.7(l)12.7(ac)16(k)-353.6(i)0(n)18.8(-)]TJ
0 -1.128 TD
[(fo)16(rm)22.6(at)20.7(io)18.8(n.)-225.6(3)12.2(7)0(.)18.3(6)12.2(%)-234(o)12.2(f)-234(p)0(a)14.1(r)0(t)22.6(i)0(c)20.7(i)0(p)18.8(a)0(n)20.2(t)0(s)-224.2(h)0(a)20.2(d)-237.8(b)12.2(e)0(e)16(n)-231.7(s)13.1(c)0(r)17.8(e)0(e)16(n)12.2(ed)-223.7(b)12.2(y)-237.8(Pa)23.4(p)-237.8(s)13.1(me)20.7(ar)]TJ
0 -1.1219 TD
[(fo)16(r)-240.1(c)14.1(er)17.8(vi)18.8(ca)16(l)-237.3(c)0(a)16(n)12.2(ce)16(r)-240.1(a)14.1(t)-243.4(l)12.7(ea)16(s)13.1(t)-243.4(o)12.2(n)12.2(c)0(e)-234(w)0(h)22.9(e)0(r)17.8(e)0(a)16(s)-236.9(9%)-234(d)12.2(i)12.7(d)-243.9(n)12.2(o)12.2(t)-243.4(k)12.2(n)12.2(o)0(w)-233.1(w)0(h)22.9(a)0(t)-229.3(a)]TJ
0 -1.128 TD
[(Pa)17.3(p)-310.9(s)0(m)19.7(e)0(a)16(r)-307.2(wa)18.7(s.)-304(Sc)23.4(re)17.8(en)20.2(in)18.9(g)-310.9(w)0(a)18.7(s)-310.1(si)19.7(gn)18.3(i)12.7()0(c)17.3(a)0(n)20.2(t)0(l)19.3(y)-310.9(as)21.1(so)19.2(ci)14.6(a)14.1(t)0(e)14.6(d)-310.9(wi)23.4(th)-304.3(c)14.1(e)0(r)17.8(-)]TJ
0 -1.1219 TD
[(vi)18.8(ca)16(l)-261.7(c)0(a)16(n)12.2(ce)16(r)-264.5(a)0(w)18.7(a)0(r)17.8(e)0(n)20.2(e)0(s)21.1(s)-267.4(an)20.2(d)-268.2(r)0(e)17.8(g)12.2(u)12.2(l)0(a)14.6(r)-264.5(v)12.2(i)0(s)19.7(i)0(t)19.3(s)-267.4(t)12.7(o)-268.2(g)12.2(e)0(n)20.2(e)0(r)17.8(a)0(l)-259.7(h)12.2(ea)16(l)12.7(t)0(h)-255.5(p)0(h)18.3(y)12.2(si)19.7(-)]TJ
0 -1.128 TD
[(ci)14.6(a)14.1(n)0(s)-206.4(a)14.1(nd)-201.2(gy)18.3(n)12.2(e)0(c)16(o)12.2(lo)18.8(g)12.2(i)0(s)19.7(t)0(s)19.7(.)-213.4(On)16.8(l)12.7(y)-213.4(1)12.2(1)12.2(.)0(7)18.3(%)-209.6(of)-203.5(p)12.2(a)0(r)17.8(t)0(i)19.3(c)0(i)20.7(p)0(a)20.2(n)0(t)18.8(s)-212.5(ag)20.2(ed)-205.4(1)12.2(8)-213.4(t)12.7(o)-213.4(3)12.2(5)]TJ
0 -1.1219 TD
[(we)18.7(re)-409(v)12.2(a)0(c)16(c)0(i)20.7(n)0(a)20.2(t)0(e)14.6(d)-414.6(ag)20.2(ai)20.7(ns)19.2(t)-420.2(H)0(P)20.1(V)0(.)-403.9(V)0(a)18.7(c)0(c)16(i)12.7(n)12.2(a)0(t)14.6(i)12.7(on)-408.5(u)12.2(p)12.2(t)0(a)14.6(k)12.2(e)-418.8(w)0(a)18.7(s)-413.7(si)19.7(gn)18.3(i)12.7()0(-)]TJ
0 -1.128 TD
[(ca)16(n)12.2(t)0(l)19.3(y)-213.4(as)21.1(so)19.2(ci)20.7(at)14.6(e)14.1(d)-213.4(wi)17.3(t)12.7(h)-213.4(ce)16(rv)22.1(i)12.7(c)0(a)16(l)-212.9(ca)22.1(nc)14.1(e)14.1(r)-215.7(a)14.1(w)0(a)18.7(r)0(e)17.8(n)0(e)20.2(s)0(s)20(,)-213.4(re)17.8(l)12.7(i)0(g)18.8(i)0(o)18.8(n)12.2(,)-213.4()0(e)17.3(l)12.7(d)-213.4(o)12.2(f)]TJ
0 -1.1219 TD
[(wo)16.8(rk)-240.1(an)20.2(d)-250(s)0(t)19.7(u)12.2(di)18.8(es)21.1(,)-250(a)0(n)14.1(d)-250(re)23.9(gu)18.3(la)20.7(r)-252.3(v)12.2(is)19.7(it)19.3(s)-249.1(t)0(o)-243.3(g)12.2(yn)18.3(ec)22.1(ol)18.8(og)18.3(i)12.7(s)0(t)19.7(s)0(.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Conclusions:)Tj
/F4 1 Tf
5.896 0 TD
[(Ur)20.6(b)12.2(a)0(n)-345.6(L)0(e)18.4(b)0(a)20.2(n)0(e)20.2(s)0(e)-350.9(w)0(o)22.9(m)0(e)20.7(n)-359.7(i)12.7(n)-353.6(Be)15.5(i)12.7(r)0(u)16(t)-353.1(an)20.2(d)-353.6(M)0(o)19.2(u)12.2(nt)18.8(-)]TJ
-6.8959 -1.1219 TD
[(Le)18.4(ba)20.2(no)18.3(n)-329.2(a)0(r)17.8(e)-333.4(n)12.2(o)12.2(t)-334.8(we)18.7(l)12.7(l)-334.8(i)12.7(n)12.2(fo)16(rm)22.6(ed)-321.2(ab)20.2(ou)18.3(t)-328.7(c)0(e)16(r)0(v)22.1(i)0(c)14.6(a)14.1(l)-334.8(c)0(a)22.1(n)0(c)14.1(e)14.1(r)-331.6(an)20.2(d)-335.3(H)0(P)20.1(V)0(.)]TJ
0 -1.128 TD
[(Sc)17.3(re)17.8(en)20.2(i)12.7(n)0(g)-329.2(b)12.2(y)-335.3(P)0(a)17.3(p)-335.3(s)13.1(m)0(e)14.7(a)14.1(r)-337.7(a)0(n)20.2(d)-335.3(HP)20.1(V)-336.8(v)12.2(ac)16(ci)20.7(na)20.2(ti)19.3(on)-329.2(u)12.2(p)12.2(t)0(a)14.6(k)12.2(es)-326.5(ar)17.8(e)-333.4(n)0(o)18.3(n)12.2(-)]TJ
T*
[(sa)15(t)12.7(i)0(s)19.7(f)0(a)17.8(c)0(t)20.7(o)0(r)16(y)12.2(.)-341.4(F)0(u)21.6(r)0(t)16.5(h)12.2(er)-335.8(i)12.7(n)0(t)18.8(e)0(r)17.8(v)12.2(en)20.2(ti)19.3(on)18.3(s)-346.7(a)14.1(re)-335.8(re)17.8(q)12.2(u)12.2(i)0(r)16.5(e)0(d)-333.4(t)12.7(o)-347.5(i)12.7(mp)18.9(ro)22.1(ve)-333.4(th)18.9(es)21.1(e)]TJ
0 -1.1219 TD
[(nu)18.3(m)12.8(b)0(e)14.1(r)0(s)22.9(.)]TJ
/F3 1 Tf
0 -2.9328 TD
(21.)Tj
9.843 0 0 9.843 80.674 541.3605 Tm
[(Bless)-283.9(Her)-283.3(Heart)-279.7(Initiat)-7.5(ive:)-276.4(Use)-287.4(of)-278.6(Information)]TJ
0 -1.1116 TD
[(Technology)-284.9(to)-278.6(Target)-286.4(High-Risk)-282.4(Women)-279.4(Veterans)]TJ
T*
[(for)-280.9(Ischemic)-289.4(Vascular)-282.5(Disease)-281.4(Prevention)]TJ
0 -1.1174 TD
(Interventions)Tj
/F4 1 Tf
9.2982 0 0 9.2982 59.7543 491.9243 Tm
[(Sharon)-338.6(Jamie)]TJ
6.9735 0 0 6.198 111.0047 496.0629 Tm
(1)Tj
9.2982 0 0 9.2982 114.4629 491.9243 Tm
[(,)-335.3(Ralph)-337.6(W)-333.4(Clark)]TJ
6.9735 0 0 6.198 177.9023 496.0629 Tm
(1)Tj
9.2982 0 0 9.2982 181.4173 491.9243 Tm
[(,)-329.2(Linda)-334.7(Hyder)-337.2(Ferry)]TJ
6.9735 0 0 6.198 258.1794 496.0629 Tm
(1)Tj
9.2982 0 0 9.2982 261.6944 491.9243 Tm
(,)Tj
-21.7182 -1.1219 TD
[(Patricia)-339.4(Applegate)]TJ
6.9735 0 0 6.198 129.77 485.6314 Tm
(2)Tj
/F5 1 Tf
-10.0402 -2.6526 TD
(1)Tj
9.2982 0 0 9.2982 66.3874 465.0518 Tm
[(Loma)-333.5(Linda)-331.5(University,)-333.9(Loma)-333.5(Linda,)-331.5(California)]TJ
6.9735 0 0 6.198 59.7543 458.7022 Tm
(2)Tj
9.2982 0 0 9.2982 63.2693 454.5637 Tm
[(Loma)-333.5(Linda)-331.5(University,)-340(Redlands,)-333.8(California)]TJ
/F3 1 Tf
.6219 -2.3047 TD
(Background:)Tj
/F4 1 Tf
5.9204 0 TD
[(Th)16.5(e)-309.1(V)0(e)18.7(t)12.7(er)17.8(an)20.2(s)-310.1(H)0(e)18.7(a)14.1(lt)19.3(h)-310.9(A)0(f)20.6(f)0(a)17.8(i)12.7(rs)-300.2(\(V)20.6(HA)15.3(\))-307.2(E)0(l)23.1(e)0(c)16(t)12.7(ro)16(n)12.2(i)12.7(c)]TJ
-6.9203 -1.1219 TD
[(He)18.7(al)14.6(t)12.7(h)-231.7(Re)15.5(c)14.1(o)0(r)16(d)-231.7(\(E)20.2(HR)18.2(\))-234(i)12.7(s)-230.8(n)0(o)18.3(t)-231.2(d)12.2(e)0(s)15(i)12.7(gn)18.3(ed)-223.7(t)12.7(o)-231.7(ea)16(s)13.1(i)0(l)19.3(y)-231.7(se)15(l)12.7(e)0(c)16(t)-231.2(v)12.2(e)0(t)14.6(e)14.1(ra)17.8(ns)-224.7()64.7()0(a)17.9(t)]TJ
0 -1.128 TD
[(ri)16.5(s)13.1(k)0()70.8()-429.1(fo)16(r)-429.1(i)0(s)19.7(c)0(h)20.2(e)0(m)14.7(i)12.7(c)-431(h)0(e)14.1(a)14.1(r)0(t)16.5(,)-432.9(c)14.1(e)0(r)17.8(e)0(b)20.2(r)0(a)17.8(l)0(,)-420.2(o)0(r)-423(p)0(e)20.2(r)0(i)16.5(p)12.2(he)20.2(ra)17.8(l)-432.4(a)0(r)17.8(t)12.7(er)17.8(y)-432.9(d)12.2(is)19.7(ea)16(s)13.1(e)]TJ
0 -1.1219 TD
[(us)19.2(in)18.9(g)-262.2(t)12.7(h)12.2(e)-266.4(At)23.4(he)20.2(ro)16(s)13.1(c)0(l)20.7(e)0(r)17.8(o)0(t)18.8(i)0(c)-253.6(C)13.6(ar)17.8(d)12.2(i)0(o)18.8(v)0(a)20.2(s)0(c)15(u)12.2(l)12.7(a)0(r)-256.5(D)0(i)23.4(s)0(e)15(a)14.1(se)-253.3(\(A)20.6(SC)16.8(VD)21.4(\))-258.4(R)0(i)20.2(s)0(k)]TJ
0 -1.128 TD
[(Es)17.3(ti)19.3(m)12.8(a)0(t)14.6(o)12.2(r.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.7862 0 TD
[(The)-274.3()52.5(Bless)-277.2(Her)-276.3(Heart)53()-276.7(initiative)-279.6(identied)-271.8(the)]TJ
-6.7862 -1.128 TD
[(at-risk)-342.3(population)-331.7(of)-337.7(Women)-337(Veterans)-338.1(\(only)-337.1(8%)-337.6(of)-337.7(VHA)-333.7(pop-)]TJ
0 -1.1219 TD
[(ulation\))-224.4(for)-224.2(any)-217.5(ischemic)-229.6(vascular)-220.8(disease)-223.7(\(IVD\))-223.4(diagnosis)-220.8(at)-223.2(the)]TJ
0 -1.128 TD
[(VA)-484.6(Loma)-487.1(Linda)-481(Healthcare)-487.1(System)-486.7(using)-480.2(information)-482.2(tech-)]TJ
0 -1.1219 TD
[(nology)-200.6(to)-206.7(motivate)-201.3(those)-204(at)-198.8(highest)-203.4(risk)-202.1(to)-200.6(reduce)-203.9(at)-204.9(least)-207.7(one)-199.3(risk)]TJ
0 -1.128 TD
[(factor)-305.2(in)-298.2(a)-303(year.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Material/Methods:)Tj
/F4 1 Tf
8.3592 0 TD
[(The)-286.5(risk)-293.6(factors)-286(included)-293.8(in)-286(the)-290.2(ASCVD)]TJ
-9.3592 -1.128 TD
[(Risk)-399.6(Estimator)-395.6(were)-402.4(gathered)-398.5(from)-394.3(EHR)-398.2(diagnoses)-396.2(and)-400.5(labo-)]TJ
0 -1.1219 TD
[(ratory)-514.4(results)-503.7(\(age,)-510.7(diabetes,)-510.6(tobacco,)-511.9(hypertension,)-508.6(HDL)-510.8(&)]TJ
0 -1.128 TD
[(TChol\))-447.3(to)-444.5(identify)-443.9(Women)-446.8(Veterans)-441.8(at)-448.8(highest)-441.2(risk)-446(\(10)-441.3(year)]TJ
0 -1.1219 TD
[(ASCVD)-396.1(risk)]TJ
/F2 1 Tf
5.8228 0 TD
(>)Tj
/F4 1 Tf
.7195 0 TD
[(20%\),)-388.7(including)-386.6(those)-393(who)-385.5(already)-392.4(have)-392.5(a)-388.3(di-)]TJ
-6.5423 -1.128 TD
[(agnosis)-446.9(of)-447.4(IVD.)-444.3(For)-444.2(all)-448.2(Women)-446.8(Veterans)-447.9(with)-445.5(existing)-446.8(IVD)]TJ
0 -1.1219 TD
[(diagnoses,)-341.4(we)-334.9(veried)-336.2(their)-334.7(clinical)-339.7(diagnosis)-336.6(and)-333.4(conducted)-335.1(a)]TJ
0 -1.128 TD
[(quality)-380.6(improvement)-380.4(audit)-375(for)-376.6(IVD)-377.2(management)-380.9(adherence)-383(to)]TJ
0 -1.1219 TD
[(clinical)-303.1(practice)-304.6(guidelines.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Results:)Tj
/F4 1 Tf
3.8778 0 TD
[(Out)-439.9(of)-435.2(4072)-438.9(Women)-434.6(Veterans,)-441.8(we)-438.6(identied)-442.5(263)]TJ
-4.8778 -1.1219 TD
[(with)-305.3(an)-309(IVD)-304.1(diagnosis)-306.2(and)-309(114)-304.8(in)-304.3(the)-308.5(high-risk)-301.4(group)-307.1(from)-302.9(the)]TJ
0 -1.128 TD
[(EHR.)-331.1(We)-331.5(found)-325.4(no)-329.2(evidence)-327.1(for)-327.8(an)-333.4(IVD)-328.4(diagnosis)-330.5(for)-327.8(the)-326.8(263)]TJ
T*
[(\(misclassication\).)-366(All)-360.2(high-risk)-356.3(women)-358.7(\()]TJ
/F2 1 Tf
17.377 0 TD
(>)Tj
/F4 1 Tf
.7195 0 TD
[(20%\))-358.3(were)-359.8(invited)]TJ
-18.0965 -1.1219 TD
.0108 Tc
[(to)-501.3(women-on)10.8(l)-6.9(y)-501.3(worksho)10.8(p)-7.4(s)-500.5(f)2.4(or:)-500.8(o)10.8(n)-7.4(line)-493.4(V)-2.9(HA)-502.8(h)10.8(e)-11.7(alt)10.8(h)-6.9(-risk)-495.2(a).5(s-)]TJ
0 -1.128 TD
.0113 Tc
[(se)-5.1(s)11.3(s)-5.2(ment,)-317.9(h)11.3(e)-11.2(a)1(lt)11.3(h)-323.5(l)-.4(earn)11.3(i)-6.4(ng)-317.9(co)11.3(m)-6.4(p)-.9(etency,)-311.8(d)-.9(epressi)11.3(o)-6.4(n)-317.9(scree)-5.1(n)11.3(,)-324(a)1(nd)]TJ
0 -1.1219 TD
[(verication)-238.7(o)11.3(f)-247.1(a)1(ll)-238.2(IVD)-240.2(r)2.9(isk)-238.7(f)2.9(actors)-237.8(uniqu)11.3(e)-248.9(t)11.3(o)-244.2(w)-2.4(om)11.3(e)-10.6(n)11.3(,)-244.7(\()-3.2(e.g)11.3(.)-6.9(,)-238.7(p)-.9(re-)]TJ
0 -1.128 TD
[(eclamp)11.3(s)-6.1(i)-.4(a,)-287.4(PCOS,)-287.4(hormon)11.3(e)-297.7(th)11.3(e)-11.2(r)2.9(apy,)-281.3(etc.)11.3(\))-9.3(.)-287.4(In)-287.4(addit)11.3(i)-5.9(on,)-287.4(women)]TJ
0 -1.1219 TD
.0124 Tc
[(with)-322.9(Hgb)12.4(A)-7.3(1c)]TJ
/F2 1 Tf
6.0972 0 TD
0 Tc
(>)Tj
/F4 1 Tf
.6219 0 TD
.0103 Tc
[(9%)-327.4(\(n)]TJ
/F2 1 Tf
2.5364 0 TD
0 Tc
(=)Tj
/F4 1 Tf
.5609 0 TD
.0113 Tc
[(53\))-326.4(were)-328.2(scheduled)-324(fo)11.3(r)-338.6(a)-328.2(worksho)11.3(p)-336.2(to)]TJ
-9.8165 -1.128 TD
.0118 Tc
[(meet)-207.2(with)-213.8(p)11.8(h)-6.4(ysicians)11.8(,)-219(p)-.4(sycho)11.8(l)-5.9(ogi)11.8(s)-5.1(t).1(s,)-213.8(ph)11.8(a)-10.7(r)3.4(macists)-212.9(a)1.5(nd)-213.8(d)11.8(i)-5.9(etitians)]TJ
0 -1.1219 TD
.012 Tc
[(to)-244.1(remo)12(v)-6.2(e)-248.3(b)12(a)-10.5(rriers)-243.2(t).3(o)-244.1(a)1.7(ch)12(i)-5.7(e)1.7(ving)-244.1(bett)12(e)-10(r)-240.3(co)12(n)-6.2(t).3(rol,)-244.1(e.g.)12(,)-250.1(d)-.2(epressi)12(o)-5.7(n)-.2(,)]TJ
0 -1.128 TD
[(transp)12(o)-6.2(r)3.6(tation,)-298.9(n)12(o)-305(internet)-298.4(access,)-298.9(fear)-295.2(of)-301.3(n)12(eed)12(l)-5.7(e)1.7(s.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
0 Tc
(Conclusions:)Tj
/F4 1 Tf
5.9326 0 TD
[(EHRs)-446.1(can)-447.4(effectively)-452.8(identify)-443.9(target)-448.7(popula-)]TJ
-6.9325 -1.128 TD
[(tions)-351.7(to)-353.1(cost-effectively)-354.2(intervene)-349.2(with)-354(those)-350.3(at)-351.2(highest)-349.7(risk)-348.5(of)]TJ
0 -1.1219 TD
[(IVD)-401.6(and)-400.5(reduce)-399(morbidity)-396.4(and)-400.5(mortality.)-400.1(Women-only)-393.6(initia-)]TJ
0 -1.128 TD
[(tives)-398.6(help)-399.9(to)-395.8(overcome)-398.4(unique)-399.9(challenges)-398.9(inherent)-399.8(in)-401.9(a)-394.4(male-)]TJ
0 -1.1219 TD
[(dominated)-305.4(healthcare)-302.7(system.)]TJ
/F3 1 Tf
27.0045 71.9468 TD
(22.)Tj
9.843 0 0 9.843 331.7668 725.5557 Tm
[(Safety)-278.3(of)-284.4(Flibanserin)-280.3(in)-284.4(Women)-279.4(Treated)]TJ
0 -1.1174 TD
[(for)-280.9(Depression)-285.5(with)-281.7(an)-278.5(SSRI)-281.2(or)-279.8(SNRI:)-283.3(A)-284.2(12-Week,)]TJ
0 -1.1116 TD
[(Randomized,)-283.3(Placebo-Controlled)-285.6(Study)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 310.8472 687.0613 Tm
[(Anita)-333.8(Clayton)]TJ
6.9735 0 0 6.198 364.1952 691.1998 Tm
(1)Tj
9.2982 0 0 9.2982 367.6534 687.0613 Tm
[(,)-335.3(Harry)-333.5(Croft)]TJ
6.9735 0 0 6.198 417.5432 691.1998 Tm
(2)Tj
9.2982 0 0 9.2982 421.0582 687.0613 Tm
[(,)-329.2(James)-335.3(Yuan)]TJ
6.9735 0 0 6.198 472.4219 691.1998 Tm
(3)Tj
9.2982 0 0 9.2982 475.9369 687.0613 Tm
[(,)-335.3(Louise)-333.8(Brown)]TJ
6.9735 0 0 6.198 535.0676 691.1998 Tm
(3)Tj
9.2982 0 0 9.2982 538.5825 687.0613 Tm
(,)Tj
-24.4924 -1.128 TD
[(Sam)-329.6(Spigelman)]TJ
6.9735 0 0 6.198 370.3747 680.7117 Tm
(3)Tj
/F5 1 Tf
-8.5362 -2.6526 TD
(1)Tj
9.2982 0 0 9.2982 314.3054 660.1321 Tm
[(University)-340(of)-334.8(Virginia)-328.5(School)-338.9(of)-328.7(Medicine,)-336.9(Charlottesville,)]TJ
-.3719 -1.1219 TD
(Virginia)Tj
6.9735 0 0 6.198 310.8472 643.351 Tm
(2)Tj
9.2982 0 0 9.2982 314.3054 639.2124 Tm
[(San)-268.2(Antonio)-268.9(Psychiatric,)-273.2(Research)-268.7(Center,)-273.8(San)-268.2(Antonio,)-268.9(Texas)]TJ
6.9735 0 0 6.198 310.8472 632.9195 Tm
(3)Tj
9.2982 0 0 9.2982 314.3054 628.7809 Tm
[(Sprout)-333.8(Pharmaceuticals,)-335.6(A)-337.2(Division)-332.4(of)-334.8(Valeant)]TJ
-.3719 -1.128 TD
[(Pharmaceuticals)-262.4(North)-265.4(America)-266.3(LLC,)-260.4(Bridgewater,)-268.1(New)-263.6(Jersey)]TJ
/F3 1 Tf
.9999 -2.2986 TD
(Background:)Tj
/F4 1 Tf
5.8594 0 TD
[(Sexual)-254.6(dysfunction)-260.6(is)-254.7(common)-259.1(in)-255.5(patients)-255.9(with)]TJ
-6.8593 -1.128 TD
[(untreated)-361.4(depressive)-360.1(disorders,)-360.2(and)-363.9(antidepressant)-357.2(medications)]TJ
0 -1.1219 TD
[(may)-320.7(contribute)-326.1(to)-322.6(sexual)-324(dysfunction.)-327.6(Flibanserin)-322(is)-327.8(a)-321.2(5-HT1A)]TJ
0 -1.128 TD
[(agonist)-227.8(and)-235.8(5-HT2A)-232.7(antagonist)-231.4(FDA-approved)-232.2(for)-230.3(the)-235.3(treatment)]TJ
0 -1.1219 TD
[(of)-441.3(acquired,)-453.3(generalized)-449(hypoactive)-444.3(sexual)-445.9(desire)-448.3(disorder)-446.4(in)]TJ
0 -1.128 TD
[(premenopausal)-303.6(women.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.9143 0 TD
[(To)-404.2(assess)-407.3(the)-406.1(safety)-405.6(of)-410.8(ibanserin)-401.8(in)-408(women)]TJ
-6.9142 -1.128 TD
[(\(1850)-563.2(years)-570.8(old,)-572.5(not)-566.5(postmenopausal\))-572.4(who)-568.5(were)-567.1(taking)-570.1(a)]TJ
T*
[(selective)-648.4(serotonin)-650.8(reuptake)-648.4(inhibitor)-652.5(\(SSRI\))-645.5(or)-648.6(serotonin-)]TJ
0 -1.1219 TD
[(norepinephrine)-327(r)-14.5(e)-10.3(u)-12.2(p)0(t)-17.7(a)-10.3(k)-12.2(e)-339.5(i)-11.7(n)-12.2(hi)-17.7(b)-12.2(i)-11.7(t)-11.7(o)0(r)-349.9(\()-8.4(S)-8.9(N)-13.7(R)-10.8(I)-8.4(\))-343.8(f)-8.4(o)-12.2(r)-337.7(t)-11.7(r)-8.4(e)-10.3(a)-10.3(t)-11.7(m)-11.6(e)-10.3(n)-12.2(t)-340.9(o)-12.2(f)-337.7(de)-22.5(-)]TJ
0 -1.128 TD
.0111 Tc
[(pression)-458.4(and)-458.4(h)-1.1(ad)-458.4(sym)11.1(p)-6.6(toms)-457.5(of)-454.6(dec)-5.3(r)2.7(eased)-464.5(sex)11.1(u)-7.1(al)-463.9(d)11.1(e)-11.4(si)11.1(r)-9(e)-456.5(a)-5.3(n)11.1(d)]TJ
0 -1.1219 TD
.0107 Tc
[(related)-300.2(d)-1.5(istress.)]TJ
/F3 1 Tf
.9999 -1.128 TD
0 Tc
(Material/Methods:)Tj
/F4 1 Tf
8.6214 0 TD
[(In)-557.2(this)-552.9(12-week,)-560.9(multicenter,)-554.9(double-)]TJ
-9.6214 -1.1219 TD
[(blind,)-254.9(placebo-controlled)-255.1(study,)-254.6(eligible)-256.2(patients)-255.9(were)-256.1(randomly)]TJ
0 -1.128 TD
[(assigned)-414.6(to)-420.1(receive)-414.9(ibanserin)-420.1(100)-164.5(mg/d)-413.5(or)-416.9(placebo,)-420.5(adminis-)]TJ
0 -1.1219 TD
[(tered)-223.6(at)-223.2(bedtime)-226.2(\(qhs\).)-223.3(The)-219.4(primary)-227.3(endpoint)-222.5(was)-224.3(the)-223.1(occurrence)]TJ
0 -1.128 TD
[(of)-301.1(adverse)-300.6(events)-299.6(\(AEs\).)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Results:)Tj
/F4 1 Tf
3.9144 0 TD
[(Overall,)-486.7(111)-481.6(patients)-487.6(were)-481.7(randomly)-487(assigned)-481.6(to)]TJ
-4.9143 -1.128 TD
[(treatment)-476.2(\(ibanserin,)-471.2(n)]TJ
/F2 1 Tf
10.0543 0 TD
(=)Tj
/F4 1 Tf
.5548 0 TD
[(73;)-468.9(placebo,)-475.4(n)]TJ
/F2 1 Tf
6.0972 0 TD
(=)Tj
/F4 1 Tf
.5487 0 TD
[(38\).)-471.8(The)-475.5(number)-475.4(of)]TJ
-17.255 -1.1219 TD
[(randomized)-446.7(patients)-444.9(was)-443.8(lower)-446.5(than)-442.6(planned)-446.8(\(n)]TJ
/F2 1 Tf
20.0963 0 TD
(=)Tj
/F4 1 Tf
.5487 0 TD
[(200)-445(overall\))]TJ
-20.6451 -1.128 TD
[(because)-351.2(the)-351.2(study)-352.2(was)-352.3(terminated)-354.2(early)-351.6(by)-347.5(the)-351.2(sponsor)-348(for)-352.2(ad-)]TJ
0 -1.1219 TD
[(ministrative)-494.4(reasons.)-496.7(Among)-500.8(randomized)-495.4(patients,)-499.8(3.6%)-490(\(i-)]TJ
0 -1.128 TD
[(banserin,)-362.9(2.7%;)-355.4(placebo,)-365.6(5.3%\))-358.2(discontinued)-359.4(due)-363.9(to)-359.2(AEs.)-356(AEs)]TJ
0 -1.1219 TD
[(were)-262.2(reported)-262.5(by)-262.1(65.8%)-264.4(and)-260.2(71.1%)-264.4(of)-258.4(patients)-262(in)-261.6(the)-265.8(ibanserin)]TJ
0 -1.128 TD
[(and)-357.8(placebo)-365.6(groups,)-361.1(respectively.)-364.1(The)-359.6(most)-363.9(common)-362.7(AEs)-362.2(\(in-)]TJ
0 -1.1219 TD
(cidence)Tj
/F2 1 Tf
3.5851 0 TD
()Tj
/F4 1 Tf
.7195 0 TD
[(3%)-349.8(for)-346.1(ibanserin\))-349.3(in)-347(the)-351.2(ibanserin)-346.9(versus)-352.3(placebo)]TJ
-4.3046 -1.128 TD
[(groups,)-263.5(respectively,)-260.5(were)-268.3(dry)-258.4(mouth)-267.1(\(5.5%)-260.7(vs)-261.3(2.6%\),)-260.7(headache)]TJ
0 -1.1219 TD
[(\(5.5%)-266.8(vs)-267.4(18.4%\),)-266.8(insomnia)-269.9(\(5.5%)-266.8(vs)-267.4(2.6%\),)-272.9(back)-264.4(pain)-271.9(\(4.1%)-266.8(vs)]TJ
0 -1.128 TD
[(2.6%\),)-352.1(dizziness)-363.4(\(4.1%)-352.1(vs)-358.8(0.0%\),)-352.1(fatigue)-357.2(\(4.1%)-358.2(vs)-352.7(5.3%\),)-358.2(and)]TJ
0 -1.1219 TD
[(sedation)-238.1(\(4.1%)-230.2(vs)-236.9(5.3%\).)-236.3(No)-233.1(worsening)-238.2(of)-234(depression)-240.1(or)-234(anxiety)]TJ
0 -1.128 TD
[(was)-321.9(noted)-320.6(in)-316.5(ibanserin-treated)-326.6(compared)-325.3(with)-317.4(placebo-treated)]TJ
0 -1.1219 TD
[(patients.)-262(No)-263.6(serious)-266.4(AEs)-264.6(were)-262.2(reported;)-268(there)-266.3(were)-262.2(no)-262.1(instances)]TJ
0 -1.128 TD
[(of)-514.5(suicidal)-512(ideation)-518.9(or)-514.5(behavior.)-516.2(There)-512.5(was)-517(no)-512.1(evidence)-522.3(of)]TJ
0 -1.1219 TD
[(withdrawal)-298.6(AEs)-301.2(during)-300.5(the)-302.4(post-treatment)-300.3(period.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Conclusions:)Tj
/F4 1 Tf
5.774 0 TD
[(Flibanserin)-297.6(100)-164.5(mg)-292.1(qhs)-291.7(was)-291.4(generally)-294.3(safe)-290.3(and)]TJ
-6.774 -1.1219 TD
[(well)-352.2(tolerated)-354.7(in)-347(this)-351.7(study)-352.2(of)-349.9(premenopausal)-358.5(women)-352.6(with)-347.9(de-)]TJ
0 -1.128 TD
[(creased)-396.3(desire)-393.4(and)-394.4(related)-391.9(distress)-393.1(receiving)-397.9(treatment)-396.9(for)-388.8(de-)]TJ
0 -1.1219 TD
[(pression)-431(with)-433.3(an)-431(SSRI)-427.4(or)-435.2(SNRI.)-426(ClinicalTrials.gov)-438(identier:)]TJ
0 -1.128 TD
(NCT01040208.)Tj
/F3 1 Tf
0 -3.829 TD
(23.)Tj
9.843 0 0 9.843 331.7668 163.7858 Tm
[(MyHealtheVet)-285.9(to)-278.6(Enable)-285.1(Shared)-279.2(Decision)-288.4(Making)]TJ
0 -1.1116 TD
[(Regarding)-283.6(Menopause)-284.5(and)-279.4(Hormone)-282.9(Therapy)]TJ
0 -1.1174 TD
[(in)-278.6(Postmenopausal)-283(Women)-285.1(Veterans)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 310.8472 125.2913 Tm
[(Stuti)-330.5(Dang)]TJ
6.9735 0 0 6.198 351.666 129.4299 Tm
(1)Tj
9.2982 0 0 9.2982 355.181 125.2913 Tm
[(,)-335.3(Berry)-330.6(Thavalathil)]TJ
6.9735 0 0 6.198 427.5211 129.4299 Tm
(2)Tj
9.2982 0 0 9.2982 430.9794 125.2913 Tm
[(,)-335.3(Carlos)-333(Gomez-Orozco)]TJ
6.9735 0 0 6.198 521.2345 129.4299 Tm
(2)Tj
9.2982 0 0 9.2982 524.7495 125.2913 Tm
(,)Tj
-23.0047 -1.1219 TD
[(Victor)-336.2(Cevallos)]TJ
6.9735 0 0 6.198 373.4928 118.9984 Tm
(2)Tj
9.2982 0 0 9.2982 376.9511 114.8598 Tm
[(,)-335.3(Diana)-332.5(Ruiz)]TJ
6.9735 0 0 6.198 425.3668 118.9984 Tm
(1)Tj
9.2982 0 0 9.2982 428.8818 114.8598 Tm
[(,)-329.2(Alyce)-338.6(Kuo)]TJ
6.9735 0 0 6.198 475.6534 118.9984 Tm
(1)Tj
9.2982 0 0 9.2982 479.1117 114.8598 Tm
(,)Tj
-18.0965 -1.128 TD
[(Remberto)-331.4(Rodriguez)]TJ
6.9735 0 0 6.198 389.5369 108.5102 Tm
(1)Tj
9.2982 0 0 9.2982 393.0518 104.3716 Tm
[(,)-329.2(Panagiota)-337.5(Caralis)]TJ
6.9735 0 0 6.198 464.7684 108.5102 Tm
(1)Tj
9.2982 0 0 9.2982 468.2833 104.3716 Tm
[(,)-335.3(Silvina)-328.6(Levis)]TJ
6.9735 0 0 6.198 523.9557 108.5102 Tm
(1)Tj
/F5 1 Tf
-30.5597 -2.6526 TD
(1)Tj
9.2982 0 0 9.2982 314.3054 87.9307 Tm
[(Miami)-338.1(Veterans)-331(Affairs)-333.8(Healthcare)-341.3(System)-331.6(-)-337.7(GRECC,)-331.6(Miami,)]TJ
-.3719 -1.1219 TD
(Florida)Tj
6.9735 0 0 6.198 310.8472 71.1496 Tm
(2)Tj
9.2982 0 0 9.2982 314.3054 67.011 Tm
[(South)-334.7(Florida)-335.2(VA)-332.9(Research)-335.8(Foundations,)-335.1(Miami,)-332(Florida)]TJ
6.9735 0 0 6.198 310.8472 60.7181 Tm
(3)Tj
9.2982 0 0 9.2982 314.3054 56.5795 Tm
[(Miami)-338.1(Veterans)-331(Affairs)-333.8(Healthcare)-341.3(System,)-331.6(Miami,)-338.1(Florida)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 59.7543 749.7069 Tm
(ABSTRACTS)Tj
53.1188 0 TD
(A-9)Tj
ET
endstream
endobj
222 0 obj
<>stream
/GS1 gs
BT
/F3 1 Tf
9.2982 0 0 9.2982 71.3197 725.5557 Tm
0 0 0 rg
0 Tc
0 Tw
(Background:)Tj
/F4 1 Tf
6.1216 0 TD
[(Perimenopausal)-519.4(women)-517.2(would)-519.1(benet)-516.7(from)]TJ
-7.1215 -1.128 TD
[(discussions)-652(with)-658.9(provider)-648.5(regarding)-658.8(menopause,)-651.3(associated)]TJ
0 -1.1219 TD
[(conditions,)-355.2(and)-357.8(appropriate)-357.6(hormone)-359.5(therapy)-357.7(in)-353.1(order)-356.4(to)-359.2(make)]TJ
0 -1.128 TD
[(shared)-235.4(decisions)-237.2(regarding)-232(this)-229.7(sensitive)-236.7(and)-235.8(controversial)-234.2(topic.)]TJ
0 -1.1219 TD
[(The)-292.6(Health)-289.3(Information)-290(Technology)-290(for)-291.2(Economic)-289.5(and)-290.7(Clinical)]TJ
0 -1.128 TD
[(\(HITECH\))-439(Act)-438(aims)-441.2(for)-437.6(universal)-435.5(adoption)-435.9(and)-437()52.5(meaningful)]TJ
0 -1.1219 TD
[(use)49.2()-374.3(o)0(f)-374.2(electronic)-383.3(health)-379.2(records)-378(in)-377.5(the)-375.6(primary)-379.7(care)-380.8(settings.)]TJ
0 -1.128 TD
[(M)13.1(e)0(a)16(n)12.2(i)12.7(n)0(g)18.3(f)0(u)22.1(l)-347(us)19.2(e)-351.7(i)12.7(n)12.2(c)0(l)20.7(u)0(d)18.3(e)0(s)-338.7(p)12.2(ro)22.1(vi)18.8(d)12.2(e)0(r)17.8(s)-346.7(u)12.2(s)0(i)19.7(n)12.2(g)-353.6(s)13.1(ec)22.1(ur)16(e)-345.6(e)0(l)20.7(e)0(c)16(t)12.7(ro)22.1(n)12.2(i)0(c)-345.1(m)12.8(es)21.1(-)]TJ
0 -1.1219 TD
[(sa)21.1(g)12.2(i)0(n)18.9(g)-286.5(to)-279.9(co)20.2(m)12.8(m)0(u)18.9(n)12.2(ic)20.7(at)20.7(e)-290.8(w)0(i)17.3(t)12.7(h)-286.5(p)0(a)20.2(t)0(i)19.3(e)0(n)20.2(t)12.7(s)-291.8(v)12.2(i)12.7(a)-290.8(pa)20.2(ti)19.3(en)20.2(t)-286(p)0(o)18.3(r)0(t)22.6(a)0(l)20.7(s)0(.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.9143 0 TD
[(To)-404.2(evaluate)-412(the)-406.1(Veterans)-405.2(Health)-405.1(Administra-)]TJ
-6.9142 -1.1219 TD
[(tions)-299.1(patient)-299.4(portal)-298.1()52.5(MyHealtheVet)51.3()-295(use)-302.1(by)-298.7(women)-297.7(Veterans,)]TJ
0 -1.128 TD
[(determine)-336.4(their)-334.7(knowledge)-338.5(and)-333.4(discussions)-334.9(of)-331.6(menopause)-340.3(with)]TJ
0 -1.1219 TD
(providers.)Tj
/F3 1 Tf
.9999 -1.128 TD
(Material/Methods:)Tj
/F4 1 Tf
8.2739 0 TD
[(We)-209.6(surveyed)-204.9(women)-206.3(Veterans)-210.1(age)-209.6(4560)]TJ
-9.2738 -1.128 TD
[(in)-298.2(the)-302.4(Miami,)-300.4(West)-305.7(Palm)-298.6(Beach)-303.8(and)-296.8(Orlando)-300.1(VAHS.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Results:)Tj
/F4 1 Tf
3.762 0 TD
[(Six)-325.4(hundred)-329.6(fty-one)-328.2(women)-328.2(responded.)-326.8(The)-323(aver-)]TJ
-4.7619 -1.128 TD
[(age)-203.5(age)-203.5(was)-206(53,)-201.1(12%)-203.5(Hispanic,)-209.1(68%)-203.5(White,)-202.4(25%)-203.5(Black,)-201.5(and)-205.3(90%)]TJ
0 -1.1219 TD
[(had)-528.5(college)-529.7(education.)-529.7(There)-530.8(were)-530.5(no)-524.3(ethnic)-531.6(differences)-528.4(in)]TJ
0 -1.128 TD
[(socio-demographic)-476.1(characteristics.)-477.2(All)-476(participants)-475.3(performed)]TJ
0 -1.1219 TD
[(well)-352.2(on)-353.6(the)-351.2(menopause)-352.5(knowledge)-350.7(test;)-355.4(the)-351.2(average)-354.4(score)-351.3(was)]TJ
0 -1.128 TD
[(83.9%.)-221.7(However,)-220.9(their)-218.9(knowledge)-222.6(lacked)-219.3(in)-218.9(dening)-219.8(menopause)]TJ
0 -1.1219 TD
[(and)-455.3(its)-449.3(impact)-451.9(on)-451.1(urinary)-453.4(symptoms.)-453.8(Overall,)-456.2(61%)-447.4(had)-455.3(My-)]TJ
0 -1.128 TD
[(HealtheVet)-286.4(access,)-289.4(of)-282.8(those)-289.3(only)-279.9(2/3)-286(used)-283.7(it)-285.5(in)-286(the)-284.1(last)-282.7(30)-286.5(days;)]TJ
0 -1.1219 TD
[(27%)-337.6(communicated)-337.7(with)-341.8(providers)-336.6(via)-339(secure)-337.2(messaging,)-340.8(only)]TJ
0 -1.128 TD
[(12%)-727.8(regarding)-731.9(menopause.)-736.6(Sixty-seven)-731(percent)-727.7(expressed)]TJ
0 -1.1219 TD
[(wanting)-364.3(to)-359.2(use)-363(secure)-361.6(messaging)-365.2(for)-358.3(menopause)-364.7(management,)]TJ
0 -1.128 TD
[(but)-426.2(29%)-416.9(of)-423(these)-427.7(did)-420.1(not)-426.2(have)-422.9(MyHealtheVet)-425.7(access.)-429.6(Miami)]TJ
0 -1.1219 TD
[(participants)-444.8(were)-445.1(surveyed)-448.8(regarding)-445.4(shared)-442.7(decision)-445.4(making)]TJ
0 -1.128 TD
[(with)-506.5(their)-499.3(provider)-502.1(about)-503.6(menopause)-504.9(treatment.)-506.6(Twenty-ve)]TJ
0 -1.1219 TD
[(participants)-310.6(responded.)-302.4(Of)-308.7(these,)-305.7(32%)-307.1(stated)-305.2(their)-304.2(doctor)-310.8(asked)]TJ
0 -1.128 TD
[(about)-399.9(their)-401.8(preferences,)-405.1(28%)-398.6(selected)-405.1(an)-400.5(option)-401.3(together,)-399.8(and)]TJ
0 -1.1219 TD
[(36%)-301(reached)-299.6(an)-302.9(agreement)-304.6(on)-298.7(how)-300.2(to)-298.2(proceed.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Conclusions:)Tj
/F4 1 Tf
6.0118 0 TD
[(A)-519.7(need)-520.5(exists)-525.7(for)-522.9(increased)-523.8(communication)]TJ
-7.0118 -1.1219 TD
[(regarding)-439.3(menopause)-444(between)-440.3(patients)-438.8(and)-437(providers.)-440.3(Patient)]TJ
0 -1.128 TD
[(portals)-413.1(offer)-407.5(a)-412.7(feasible)-415.4(and)-406.6(economical)-417.5(tool)-407.4(to)-414.1(enhance)-406.9(com-)]TJ
0 -1.1219 TD
[(munication)-597.6(and)-601.7(shared)-595.1(decision)-597.8(making.)-600.6(The)-597.4(gap)-595.6(between)]TJ
0 -1.128 TD
[(women)-279.4(who)-275.8(use)-283.8(patient)-275(portals)-278.9(and)-278.5(those)-277.1(willing)-279.8(to)-279.9(needs)-281.8(to)-273.8(be)]TJ
0 -1.1219 TD
[(bridged)-298.6(by)-304.8(addressing)-301(access)-301.6(and)-302.9(usability)-299.9(issues.)]TJ
/F3 1 Tf
0 -4.1644 TD
(24.)Tj
9.843 0 0 9.843 82.9417 299.7921 Tm
[(Castor)-284.9(Oil)-281.3(as)-278.5(a)-277.6(Natural)-286.2(Alternative)-287.2(to)-278.6(Labor)]TJ
0 -1.1174 TD
[(Induction:)-282.1(A)-284.2(Retrospective)-285.7(Descriptive)-288.2(Study)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 62.022 272.2393 Tm
[(Andrea)-335.3(DeMaria)]TJ
6.9735 0 0 6.198 125.6315 276.3779 Tm
(1)Tj
9.2982 0 0 9.2982 129.1464 272.2393 Tm
[(,)-329.2(Beth)-337.6(Sundstrom)]TJ
6.9735 0 0 6.198 195.5338 276.3779 Tm
(1)Tj
9.2982 0 0 9.2982 199.0488 272.2393 Tm
[(,)-335.3(Grace)-333.5(Moxley)]TJ
6.9735 0 0 6.198 258.8031 276.3779 Tm
(1)Tj
9.2982 0 0 9.2982 262.2614 272.2393 Tm
(,)Tj
-21.5353 -1.1219 TD
[(Kendall)-338(Banks)]TJ
6.9735 0 0 6.198 117.8645 265.9464 Tm
(1)Tj
9.2982 0 0 9.2982 121.3795 261.8078 Tm
[(,)-335.3(Ashlan)-333.5(Bishop)]TJ
6.9735 0 0 6.198 182.5511 265.9464 Tm
(1)Tj
9.2982 0 0 9.2982 186.0661 261.8078 Tm
[(,)-335.3(Lesley)-331.9(Rathbun)]TJ
6.9735 0 0 6.198 251.0362 265.9464 Tm
(2)Tj
/F5 1 Tf
-27.1046 -2.6526 TD
(1)Tj
9.2982 0 0 9.2982 65.537 245.3669 Tm
[(College)-335.1(of)-328.7(Charleston,)-335.2(Charleston,)-335.2(South)-334.7(Carolina)]TJ
6.9735 0 0 6.198 62.022 239.0173 Tm
(2)Tj
9.2982 0 0 9.2982 65.537 234.8787 Tm
[(Charleston)-335.2(Birth)-329.1(Place,)-338.9(Charleston,)-335.2(South)-328.6(Carolina)]TJ
/F3 1 Tf
.6219 -2.2986 TD
(Background:)Tj
/F4 1 Tf
6.0667 0 TD
[(Fifty)-430.9(percent)-429(of)-423(US)-431.1(women)-425.8(report)-429(receiving)]TJ
-7.0666 -1.128 TD
[(Pitocin)-182.2(to)-176.3(induce)-178.5(or)-179.1(augment)-184.1(labor.)-176.7(Side)-177.2(effects)-186.6(include)-178(increased)]TJ
T*
[(risk)-318(of)-319.4(caesarean)-319.3(birth,)-318.3(infection,)-320(uterine)-320.6(hyperstimulation,)-317.5(and)]TJ
0 -1.1219 TD
[(decreased)-223.6(maternal)-226.7(satisfaction)-224.4(with)-219.9(the)-223.1(birth)-220.7(experience.)-223.9(Castor)]TJ
0 -1.128 TD
[(oil)-316(is)-309.6(a)-315.1(common)-314(alternative)-315.7(to)-316.5(pharmacological)-313.7(induction)-313.4(tech-)]TJ
0 -1.1219 TD
(niques.)Tj
/F3 1 Tf
.9999 -1.128 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.7192 0 TD
[(The)-213.3(purpose)-212.9(of)-209.6(this)-211.4(study)-211.9(is)-212(to)-212.8(better)-210.9(understand)]TJ
-6.7191 -1.1219 TD
[(castor)-302(oil)-297.7(as)-302.1(a)-303(nonmedical)-303.6(agent)-300.5(of)-301.1(labor)-298.6(stimulation.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Material/Methods:)Tj
/F4 1 Tf
8.3166 0 TD
[(A)-251.5(retrospective)-250.6(clinical)-248.2(chart)-248(review)-249.5(was)]TJ
-9.3165 -1.1219 TD
[(conducted)-329(of)-325.5(all)-326.3(women)-328.2(who)-324.6(gave)-331.5(birth)-324.4(at)-326.8(a)-327.3(freestanding)-332.3(birth)]TJ
0 -1.128 TD
[(center)-246.1(located)-237.1(in)-243.3(the)-241.4(southeastern)-243.7(US)-236(between)-245.2(January)-241.5(2008)-237.7(and)]TJ
0 -1.1219 TD
[(May)-369.1(2015.)-371.8(Overall,)-370.9(323)-365.8(women)-370.9(who)-367.3(used)-375.2(castor)-369.1(oil)-370.8(for)-364.4(labor)]TJ
0 -1.128 TD
[(stimulation)-579.3(gave)-581.5(birth)-580.5(afterwards.)-586.7(De-identied)-584.6(information)]TJ
0 -1.1219 TD
[(from)-290.7(birth)-287.8(logs)-285.1(and)-290.7(electronic)-285.8(medical)-291.4(records)-292.6(was)-285.3(entered)-288.7(into)]TJ
0 -1.128 TD
[(SPSS)-291.9(22.0)-292.6(for)-297.3(analysis.)-292.1(Descriptive)-300.5(statistics)-295.8(were)-292.7(analyzed)-296.7(for)]TJ
0 -1.1219 TD
[(trends)-303.9(in)-298.2(safety)-302(and)-296.8(effectiveness.)]TJ
/F3 1 Tf
27.9983 71.9468 TD
(Results:)Tj
/F4 1 Tf
3.701 0 TD
-.013 Tc
[(O)-13(f)-211.9(t)5.8(h)-.8(e)-224.5(3)5.3(23)-220.3(mo)5.3(th)5.3(er)-13(s)-209.6(w)3.8(ho)-220.3(ut)5.8(ili)5.8(zed)-226.4(cas)6.2(tor)-222.7(o)5.3(il)-219.8(to)-220.3(sti)5.8(m)-.3(u)5.3(l)-.3(ate)]TJ
-4.7009 -1.128 TD
-.0146 Tc
[(labor,)-191.4(only)-185.3(30)-185.3(\()-14.6(9)13.6(.3%\))-193.8(required)-185.3(a)]TJ
12.3651 0 TD
-.0153 Tc
[(caesarean)-192.1(birth,)-192.1(while)-190.2(2)-3.1(87)-192.1(\(88.9%\))]TJ
-12.3651 -1.1219 TD
-.0136 Tc
[(w)-13.6(e)11.2(re)-267.8(en)4.7(abl)5.2(e).5(d)-269.7(t)5.2(o)-269.7(b)4.7(irth)-263.6(vag)4.7(i)-.9(n)4.7(a).5(lly)-263.6(at)-263.1(th)4.7(e)-267.8(b)-1.4(i)5.2(r)-13.6(t)15.1(h)-269.7(cen)4.7(ter)-265.9(o)4.7(r)-265.9(h)-1.4(o)4.7(s)-.5(p)4.7(ital)5.2(.)-269.7(The)]TJ
0 -1.128 TD
-.0148 Tc
[(incidence)-317.8(o)3.5(f)-315.9(m)-2(aternal)-313(s)-1.7(ide)-317.8(e)-.7(ffect)]TJ
12.9382 0 TD
-.014 Tc
[(s)-311.9(w)2.8(as)-311.9(less)-311.9(than)-312.7(7%,)-312.8(a).1(nd)-312.7(adverse)]TJ
-12.9382 -1.1219 TD
-.0138 Tc
[(ef)-13.8(f)12(ect)5(s)-342.2(o)-1.6(f)-339.3(a).3(n)4.5(y)-343(k)4.5(i)-1.1(nd)-336.9(wer)-13.8(e)-331.3(rep)4.5(o)-1.6(rted)-336.9(in)-336.9(less)-336.1(th)4.5(an)-343(1)4.5(5)-1.6(%)-339.3(o)-1.6(f)-339.3(b)4.5(irth)4.5(s.)-343(In)4.5(-)]TJ
0 -1.128 TD
-.0149 Tc
[(dependent)-404.6(s)4.3(ample)-403.2(t)-2.2(-tests)-398.2(r)-14.9(e)9(vealed)-399(that)-404.6(gestational)-404.6(a)-.8(ge)-403.2(\(p)]TJ
/F2 1 Tf
22.9254 0 TD
0 Tc
(=)Tj
/F4 1 Tf
.5366 0 TD
-.0175 Tc
[(0.)-5.3(26)-5.3(\),)]TJ
-23.462 -1.1219 TD
0 Tc
[(wo)29(m)12.7(a)14.1(n)18.3()0(s)-312.4(a)14.1(g)12.2(e)-321.2(\(p)]TJ
/F2 1 Tf
6.396 0 TD
(=)Tj
/F4 1 Tf
.5366 0 TD
-.0139 Tc
[(0.)4.4(23)4.4(\),)-343.1(an)4.4(d)-337(B)-.3(MI)-339.4(\(p)]TJ
/F2 1 Tf
7.3044 0 TD
0 Tc
(=)Tj
/F4 1 Tf
.5426 0 TD
-.0172 Tc
[(0.)-5(28)-5(\))-336.6(w)-17.2(e)7.6(r)-1.3(e)-344.5(n)1.1(o)-5(t)-339.8(s)-4.1(i)-4.5(gn)-5(ican)-5(tl)-4.5(y)]TJ
-14.7796 -1.128 TD
-.0147 Tc
[(associated)-246.4(w)-14.7(i)14.8(th)-252.5(ability)-252.5(to)-252.5(successfu)]TJ
13.615 0 TD
-.017 Tc
[(l)-4.3(l)-4.3(y)-254.8(gi)-4.3(ve)-252.9(b)-4.8(i)-4.3(rth)-254.8(a)-2.9(t)-254.3(t)-4.3(he)-252.9(b)-4.8(i)-4.3(rth)-254.8(cen)-4.8(ter)]TJ
-13.615 -1.1219 TD
-.0145 Tc
[(af)-14.5(t)14.2(e)-.4(r)-242.4(cas)4.7(tor)-242.4(o)3.8(il)-239.6(cons)4.7(umption.)-240.1(However,)-234(a)-244.3(t)4.3(-test)-233.5(r)-14.5(e)9.4(v)3.8(ealed)-234(signicant)]TJ
0 -1.128 TD
-.0151 Tc
[(differences)-447.1(by)-448(parity)-454.1(\(p)]TJ
/F2 1 Tf
9.664 0 TD
0 Tc
(<)Tj
/F4 1 Tf
.5366 0 TD
-.0133 Tc
[(0.)5(01)5(\))-13.3(,)-436.3(s)5.9(u)-1.1(g)5(g)-1.1(est)5.5(i)-.6(n)5(g)-446.2(parou)5(s)-445.3(w)-13.3(o)15.7(men)-446.2(w)3.5(er)-13.3(e)]TJ
-10.2006 -1.1219 TD
[(more)-255.4(lik)4.9(ely)-257.3(t)-.7(o)-257.3(b)4.9(irth)-257.3(at)-256.8(th)4.9(e)-261.5(b)-1.2(i)5.4(r)2.5(th)-257.3(cent)5.4(e).7(r)-259.6(a).7(fter)-259.6(u)4.9(s)-.3(in)4.9(g)-257.3(casto)4.9(r)-259.6(o)4.9(il.)]TJ
/F3 1 Tf
.9999 -1.128 TD
0 Tc
(Conclusions:)Tj
/F4 1 Tf
5.9935 0 TD
[(Our)-503.8(study)-504.6(demonstrated)-506.2(castor)-509.3(oil)-505(use)-503.3(as)-509.4(a)]TJ
-6.9935 -1.1219 TD
[(natural)-314.5(alternative)-309.6(to)-310.4(stimulate)-309.7(labor.)-310.8(Nearly)-310.4(90%)-307.1(of)-307.2(women)-309.9(in)]TJ
0 -1.128 TD
[(the)-332.9(study)-333.9(who)-330.7(received)-335.6(castor)-332.5(oil)-334.3(were)-335.4(able)-331(to)-334.8(give)-332.9(birth)-330.5(vagi-)]TJ
T*
[(nally.)-375(Findings)-366.7(indicate)-370.7(further)-370.4(research)-374.2(is)-370.5(needed)-366.1(to)-371.4(compare)]TJ
0 -1.1219 TD
[(the)-247.5(safety)-241(and)-241.9(effectiveness)-248.4(of)-240.1(castor)-247.1(oil)-242.8(to)-243.3(other)-243.8(labor)-237.7(induction)]TJ
0 -1.128 TD
[(techniques)-303.2(in)-304.3(a)-296.9(clinical)-303.1(trial.)]TJ
/F3 1 Tf
0 -2.9815 TD
(25.)Tj
9.843 0 0 9.843 333.9779 530.4188 Tm
[(Community)-283.4(Based)-283.8(Outreach)-283.9(and)-279.4(Intervention)]TJ
0 -1.1116 TD
[(Models)-286.3(That)-281.7(Facilitate)-285.6(Enrollment)-280.3(of)-284.4(African)]TJ
0 -1.1174 TD
[(American)-284.9(Older)-285.5(Adults)-283.5(in)-278.6(Brain)-284.1(Related)-281.5(Research)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 313.0582 491.9243 Tm
[(Cornelya)-338(Dorbin,)-332.5(Monica)-336.2(Parker)]TJ
/F5 1 Tf
0 -1.7682 TD
[(Emory)-335.8(University,)-340(School)-332.8(of)-334.8(Medicine,)-330.9(Atlanta,)-335.5(Georgia)]TJ
/F3 1 Tf
.9999 -2.3047 TD
(Background:)Tj
/F4 1 Tf
6.1216 0 TD
[(While)-513.4(Alzheimers)-522.3(occurs)-515.9(in)-517.7(all)-515.3(racial)-520(and)]TJ
-7.1215 -1.1219 TD
[(ethnic)-281.7(groups,)-269.6(research)-282.8(shows)-274.1(that)-277.5(the)-271.9(burden)-274.7(is)-279.1(especially)-276.5(high)]TJ
0 -1.128 TD
[(among)-503.5(African)-507.9(Americans.)-502.2(Some)-506.4(studies)-501.3(indicate)-504.8(that)-503.1(older)]TJ
0 -1.1219 TD
[(African)-361.6(Americans)-362(are)-364.4(two)-360.7(to)-353.1(three)-363.8(times)-361.5(more)-359.6(likely)-356.2(to)-359.2(have)]TJ
0 -1.128 TD
[(Alzheimers)-534.5(disease)-534.6(and)-528.5(dementia)-535.3(than)-528(Caucasians.)-537.4(Despite)]TJ
0 -1.1219 TD
[(these)-342.3(facts)-338.6(and)-339.5(the)-339(implementation)-338(of)-337.7(a)-339.5(U.S.)-339.6(federal)-339.9(law)-340.5(\(NIH)]TJ
0 -1.128 TD
[(Revitalization)-548.7(Act)-547.8(of)-545(1993,)-542.5(PL)-541.2(103-43\))-547.2(African)-544.5(Americans)]TJ
0 -1.1219 TD
[(continue)-202.4(to)-200.6(be)-199.3(underrepresented)-209.4(in)-194.6(Alzheimers)-205.3(disease)-205.4(research.)]TJ
0 -1.128 TD
[(The)-329.1(Emory)-326.7(Alzheimers)-333.3(Disease)-328.8(Research)-327.8(Center)-331.9(\(ADRC\))-328(de-)]TJ
0 -1.1219 TD
[(veloped)-215.1(a)-205.4(community)-209.2(based)-214.8(approach)-209.9(to)-206.7(address)-210.2(these)-214.3(barriers)-209.1(to)]TJ
0 -1.128 TD
[(research)-471.8(participation.)-463.4(The)-469.4(Registry)-466.6(for)-462(Remembrance)-465.9(\(RfR\))]TJ
0 -1.1219 TD
[(was)-462.1(established)-454.3(in)-456.7(2008,)-457.2(with)-451.6(support)-458.1(from)-455.3(the)-454.8(National)-459.4(In-)]TJ
0 -1.128 TD
[(stitutes)-457.6(of)-459.6(Health,)-453.9(as)-460.6(the)-454.8(cornerstone)-454.8(of)-459.6(the)-454.8(Emory)-454.8(ADRCs)]TJ
0 -1.1219 TD
[(effort)-315.5(to)-310.4(reduce)-313.7(the)-308.5(stigma)-312.7(and)-315.1(threat)-308.4(of)-313.3(clinical)-315.3(trial)-309.8(participa-)]TJ
0 -1.128 TD
[(tion)-303.8(for)-297.3(women)-303.8(and)-296.8(minorities.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.7984 0 TD
[(Understand)-291.2(the)-284.1(use)-289.9(of)-288.9(translational)-291.8(approaches)]TJ
-6.7984 -1.128 TD
[(that)-545.8(foster)-537.9(biomedical)-546.9(research)-544.9(participation)-542.7(among)-540.1(African)]TJ
0 -1.1219 TD
[(American)-466.5(older)-463.3(adults.)-465.6(Recognize)-466(meaningful)-466.3(and)-461.4(reciprocal)]TJ
0 -1.128 TD
[(community)-483.6(engagement)-479(supports)-475.6(productive)-479(alliances)-483.8(with)-482.1(a)]TJ
0 -1.1219 TD
[(coalition)-305(of)-301.1(partners.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Material/Methods:)Tj
/F4 1 Tf
8.469 0 TD
[(Re)21.6(su)19.2(lt)19.3(s)-346.7(f)0(r)19.7(o)0(m)-340.9(f)0(o)22.1(c)0(u)20.2(s)-346.7(g)12.2(r)0(o)16(u)12.2(p)12.2(s)-346.7(pr)16(o)12.2(v)12.2(i)0(d)18.8(e)0(d)-339.5(k)12.2(ey)]TJ
-9.4689 -1.1219 TD
[(st)19.7(ra)17.8(te)14.6(g)12.2(i)12.7(es)-265.5(t)12.7(o)-274.3(o)12.2(v)0(e)20.2(r)0(c)17.8(o)12.2(me)-265.8(b)12.2(a)0(r)17.8(r)0(i)16.5(e)14.1(rs)-263.7(t)12.7(o)-274.3(re)17.8(s)13.1(e)0(a)16(r)0(c)17.8(h)-268.2(pa)20.2(rt)16.5(i)12.7(c)0(i)14.6(p)12.2(at)20.7(io)18.8(n)-274.3(f)0(o)22.1(r)-270.6(AA)21.4(s.)]TJ
0 -1.128 TD
[(Th)16.5(e)-174.9()0(r)19.2(s)0(t)-169.3(s)13.1(er)17.8(ie)14.6(s)-175.9(o)12.2(f)-179.2(f)0(o)22.1(c)0(u)20.2(s)-175.9(gr)16(o)12.2(u)12.2(p)0(s)-169.8(w)0(a)18.7(s)-175.9(he)20.2(ld)-170.2(i)12.7(n)-176.8(20)18.3(0)12.2(9)0(.)-170.7(S)15.5(ub)18.3(se)21.1(qu)18.3(en)20.2(t)-176.3(f)0(o)16(c)0(u)20.2(s)]TJ
0 -1.1219 TD
[(gr)16(o)12.2(u)12.2(p)0(s)-249.1(l)0(e)20.7(d)-262.1(b)12.2(y)-256.1(th)18.8(e)-260.3(E)0(m)23.1(o)12.2(ry)-252.3(AD)21.4(RC)-247.2(Ou)16.8(t)12.7(r)0(e)17.8(a)0(c)16(h)-256.1(Di)23.4(re)17.8(ct)20.7(or)16(s)-255.2(w)0(e)18.7(r)0(e)-250.4(h)12.2(el)20.7(d)-262.2(i)12.7(n)]TJ
0 -1.128 TD
[(20)18.3(1)12.2(4)0(.)-426.8(T)0(h)16.5(e)14.1(me)14.7(s)-432(f)0(r)19.7(o)12.2(m)-438.4(t)12.7(he)-424.9(qu)18.3(an)20.2(ti)19.3(t)12.7(a)0(t)14.6(i)12.7(ve)-424.9(an)20.2(d)-439(q)12.2(u)12.2(a)0(l)14.6(i)12.7(t)12.7(a)0(t)14.6(i)12.7(ve)-424.9(da)20.2(ta)-430.5(we)18.7(re)]TJ
T*
[(co)14.1(l)12.7(l)0(e)20.7(c)0(t)14.6(e)14.1(d)-250(f)0(r)19.7(o)0(m)-243.3(m)12.8(en)-242(an)20.2(d)-250(w)0(o)16.8(m)12.8(en)-242(ra)17.8(n)12.2(g)12.2(i)0(n)18.8(g)-250(in)-243.3(a)14.1(g)0(e)-242(f)0(r)19.7(o)12.2(m)-255.5(4)12.2(0)-249.9(t)12.7(o)-250(9)0(0)18.3(.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Results:)Tj
/F4 1 Tf
3.7681 0 TD
[(Focus)-329.3(group)-331.5(ndings)-330.6(identied)-326.6(strategies)-334.7(to)-328.7(reduce)]TJ
-4.768 -1.128 TD
[(barriers)-209.1(for)-205.9(research)-203.5(participation)-207.3(of)-203.5(AAs.)-203.3(A)-208.8(key)-199.2(strategy)-210(was)-206(the)]TJ
0 -1.1219 TD
[(development)-303.5(of)-301.1(Brain)-303.4(Health)-307.5(Forums.)]TJ
/F8 1 Tf
15.7308 0 TD
()Tj
/F4 1 Tf
.8048 0 TD
[(Host)-298.8(preventive)-306.4(health)]TJ
-16.5356 -1.128 TD
[(and)-467.5(aging)-467(well)-468(educational)-472.4(programs,)-464.7(that)-466.5(facilitate)-473.8(research)]TJ
0 -1.1219 TD
[(navigation)-214(and)-217.5(healthcare)-217.3(systems)]TJ
/F8 1 Tf
13.8406 0 TD
()Tj
/F4 1 Tf
.7134 0 TD
[(Provide)-210(personal)-216.6(and)-211.4(timely)]TJ
-14.554 -1.128 TD
[(response)-405.2(to)-408(all)-399.5(questions)]TJ
/F8 1 Tf
10.6884 0 TD
()Tj
/F4 1 Tf
.9024 0 TD
[(Produce)-403.7(easy)-403.8(to)-401.9(understand)-405.5(docu-)]TJ
-11.5908 -1.1219 TD
[(ments)-362(that)-356.8(explain)-360.9(studies)-355(and)-357.8(feature)-364.3(actual)-359.1(investigators)-360.4(and)]TJ
0 -1.128 TD
(participants)Tj
/F8 1 Tf
5.1765 0 TD
()Tj
/F4 1 Tf
.9816 0 TD
[(Provide)-484.4(dedicated)-491.2(nancial)-483.8(and)-485.8(administrative)]TJ
-6.1582 -1.1219 TD
[(support)-317.9(to)-316.5(expand)-313.2(outreach)-319.2(programs)-312.3(and)-315.1(operational)-318.1(activities)]TJ
/F8 1 Tf
0 -1.128 TD
()Tj
/F4 1 Tf
.8597 0 TD
[(Reciprocate)-362.3(by)-353.6(building)-358(on)-359.7(collective)-356.1(strengths)-357.3(of)-362(AA)-356.6(com-)]TJ
-.8597 -1.1219 TD
[(munity)-236.1(partners)-237.2(through)-233.4(the)-235.3(identication)-238.3(of)-234(mutual)-234.2(self-interest)]TJ
/F8 1 Tf
0 -1.128 TD
()Tj
/F4 1 Tf
.8475 0 TD
[(Establish)-350.2(and)-351.7(maintain)-347.6(partnerships)-351.6(with)-347.9(community)-343.4(organi-)]TJ
-.8475 -1.1219 TD
[(zations)-305.2(that)-301.9(provide)-298.6(services)-305.3(in)-298.2(the)-302.4(AA)-301.7(community.)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 62.022 749.6502 Tm
(A-10)Tj
48.6864 0 TD
(ABSTRACTS)Tj
ET
endstream
endobj
227 0 obj
<>stream
/GS1 gs
BT
/F3 1 Tf
9.2982 0 0 9.2982 69.0519 725.5557 Tm
0 0 0 rg
0 Tc
0 Tw
(Conclusions:)Tj
/F4 1 Tf
5.957 0 TD
[(Participation)-466.3(in)-462.8(translational)-468.6(approaches)-469.4(that)]TJ
-6.9569 -1.128 TD
[(foster)-312.3(biomedical)-315.2(research)-313.2(participation)-311(among)-308.4(African)-312.8(Ameri-)]TJ
0 -1.1219 TD
[(can)-447.4(older)-445(adults)-447.3(in)-444.5(partnership)-444(with)-445.5(churches,)-446.9(sororities,)-444.5(and)]TJ
0 -1.128 TD
[(civic)-562.2(organizations)-555(has)-558.1(successfully)-559.9(addressed)-555.8(many)-558.4(of)-551.1(the)]TJ
0 -1.1219 TD
[(barriers)-306.7(to)-298.2(AA)-301.7(recruitment)-301.7(that)-301.9(are)-303.4(identied)-296.2(in)-304.3(the)-296.3(literature.)]TJ
/F3 1 Tf
0 -4.1644 TD
(26.)Tj
9.843 0 0 9.843 80.674 644.9951 Tm
[(What)-281.8(will)-282.1(we)-280.7(learn)-284.3(from)-283.1(Screening)-284.9(10,000)-279.6(African)]TJ
0 -1.1174 TD
[(American)-284.9(Women)-285.1(for)-280.9(Heart)-279.7(Disease)-287.1(Risk)-281.5(Factors?)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 59.7543 617.4424 Tm
[(Molly)-333.3(Dunham-Friel)]TJ
6.9735 0 0 6.198 138.3874 621.5809 Tm
(1)Tj
9.2982 0 0 9.2982 141.9023 617.4424 Tm
[(,)-329.2(Senait)-339.4(Asier)]TJ
6.9735 0 0 6.198 193.8897 621.5809 Tm
(1)Tj
9.2982 0 0 9.2982 197.348 617.4424 Tm
[(,)-335.3(Gina)-334.4(Lundberg)]TJ
6.9735 0 0 6.198 260.2204 621.5809 Tm
(1)Tj
/F5 1 Tf
-28.7468 -2.6526 TD
(1)Tj
9.2982 0 0 9.2982 63.2693 601.0014 Tm
[(Emory)-335.8(University,)-333.9(School)-332.8(of)-334.8(Medicine,)-337(Atlanta,)-335.5(Georgia)]TJ
6.9735 0 0 6.198 59.7543 594.7085 Tm
(2)Tj
9.2982 0 0 9.2982 63.2693 590.5699 Tm
[(Emory)-335.8(University,)-333.9(Atlanta,)-335.5(Georgia)]TJ
/F3 1 Tf
.6219 -2.3047 TD
(Background:)Tj
/F4 1 Tf
6.0606 0 TD
[(Hypertension)-455.3(in)-456.7(the)-460.9(Southeast)-454.3(region)-457.1(of)-453.5(the)]TJ
-7.0605 -1.1219 TD
[(United)-400.9(States)-405.6(is)-394.9(at)-400(an)-400.5(all-time)-404.4(high,)-395.7(especially)-404.5(in)-401.9(the)-400(African)]TJ
0 -1.128 TD
[(American)-466.5(female)-459(population.)-459.7(It)-459.1(has)-460.6(been)-459.5(found)-459.5(that)-454.3(61%)-459.6(of)]TJ
T*
[(African)-312.8(American)-308(women)-309.9(have)-307.1(hypertension)-307.4(and)-302.9(63%)-307.1(of)-307.2(those)]TJ
0 -1.1219 TD
[(women)-267.2(will)-268.2(have)-270.5(a)-266.4(stroke.)-267.3(The)-262.1(cause)-267.8(for)-266.8(concern)-270.9(is)-266.9(that)-265.3(36%)-264.4(of)]TJ
0 -1.128 TD
[(the)-308.5(population)-307.3(with)-305.3(hypertension)-307.4(is)-309.6(undiagnosed)-305.6(and)-309(going)-304.2(un-)]TJ
0 -1.1219 TD
[(treated.)-239.4(Cardiovascular)-237.6(disease)-242(is)-236.4(the)-235.3(number)-237.6(one)-235.8(cause)-237.3(of)-234(death)]TJ
0 -1.128 TD
[(in)-218.9(women;)-217.9(this)-223.6(is)-218.1(10)-219.4(times)-215.1(the)-223.1(death)-215.1(rate)-223.6(from)-217.5(breast)-222.7(cancer.)-220.3(Due)]TJ
0 -1.1219 TD
[(to)-347(the)-345.1(high)-346.9(prevalence)-352(of)-343.8(hypertension)-344(and)-345.6(cardiovascular)-352.9(dis-)]TJ
0 -1.128 TD
[(ease)-401.9(in)-401.9(this)-400.5(region,)-402.2(there)-400.4(is)-401(a)-400.5(high)-401.8(need)-398.6(for)-401(community)-398.3(heart)]TJ
0 -1.1219 TD
[(health)-275.6(screenings.)-274.8(These)-271.5(screenings)-274.8(will)-274.3(enable)-274.2(further)-272.8(research)]TJ
0 -1.128 TD
[(while)-303.4(beneting)-302.8(the)-296.3(community.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.7496 0 TD
.011 Tc
[(Research)-239(ob)11(j)-6.7(e).7(c)-5.4(t)-.7(i)11(v)-6.7(es)-238.1(of)-241.3(th)11(i)-6.7(s)-238.1(project:)-238.5(-)-3.5(To)-239(screen)]TJ
-6.7496 -1.128 TD
.0113 Tc
[(10,0)11.3(0)-6.9(0)-391.1(African)-385(A)-2.4(merican)-385(W)-5.1(o)11.3(m)-6.4(en)-391.1(fo)11.3(r)-399.5(h)-.9(eart)-390.6(d)-.9(isease)-389.2(r)-3.2(isk)-385(f)-3.2(ac-)]TJ
0 -1.1219 TD
.0111 Tc
[(tors)-341.7(in)-336.4(the)-340.6(M)-.2(etro-Atlanta)-340.6(C).3(o)11.1(m)-6.6(mun)11.1(i)-6.6(ty.)-336.4(-)-3.4(To)-342.5(benet)-342(t)11.1(h)-6.6(e)-340.6(M)-.2(etro)11.1(-)]TJ
0 -1.128 TD
.0115 Tc
[(Atlant)11.5(a)-230(c)1.2(ommu)11.5(n)-6.7(ity)-220.2(and)-220.2(p)-.7(rovi)11.5(d)-6.2(e)-224.4(a)-218.3(c)-4.9(o)11.5(m)-6.2(prehensive,)-220.2(q)-.7(u)11.5(a)-11(l)11.5(i)-5.7(ty)-220.2(heart)]TJ
0 -1.1219 TD
.0113 Tc
[(health)-391.1(screenin)11.3(g)-6.9(.)-391.1(-To)-391.1(c)1(ollect)-390.6(data)-395.3(for)-387.4(s)0(tatistical)-390.6(analysis)-390.2(and)]TJ
0 -1.128 TD
.0121 Tc
[(parti)12.1(c)-9.9(i)12.1(p)-5.6(ant)-292.2(f)3.7(ollo)12.1(w)-294.2(up.)-286.6(-To)-292.7(h)12.1(e)-10.4(l)12.1(p)-298.3(u)-.1(s)-285.8(und)12.1(e)-10.4(r)3.7(stand)-286.6(t).4(he)-284.8(cu)12.1(r)-8.5(r)3.7(ent)-292.2(s).8(t)12.1(a)-9.9(t)12.1(e)]TJ
0 -1.1219 TD
.0112 Tc
[(of)-594.8(hypertensio)11.2(n)-604.6(and)-592.4(h)-1(eart)-598(d)11.2(i)-6.5(sease)-596.6(r)2.8(isk)-592.4(f)-3.3(actors)-597.6(i)-.5(n)-592.4(A)-2.5(frican)]TJ
0 -1.128 TD
.3473 Tc
[(A)333.6(m)335.7(e)337(r)338.9(i)335.6(c)337(a)330.9(n)-.2(w)339.7(o)335.1(m)335.7(e)337(ni)335.6(nM)336(e)337(t)335.6(r)338.9(o)335.1(-)338.9(A)333.6(t)335.6(l)347.3(a)325.3(n)347.3(t)329.6(a)337(.-)332.8(T)339.4(o)-.2(d)335.1(r)338.9(a)330.9(w)4.4(c)330.9(o)347.3(n)329.1(c)337(l)335.6(u)335.1(s)336(i)335.6(o)347.3(n)329.1(so)335.1(n)]TJ
0 -1.1219 TD
.0115 Tc
[(what)-286.7(socio)11.5(-)-9.1(econo)11.5(m)-6.2(i)-.2(c)-291.5(f)3.1(actors)-292.5(c)1.2(ou)11.5(l)-6.2(d)-287.2(pot)11.5(e)-10.5(n)11.5(t)-6.2(i)-.2(ally)-287.2(be)-285.4(contribu)11.5(t)-6.2(i)-.2(ng)]TJ
0 -1.128 TD
.0119 Tc
[(to)-299(poo)11.9(r)-307.5(h)-.3(eart)-304.6(h)11.9(ealt)11.9(h)-304.6(outcom)11.9(e)-10(s.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
0 Tc
(Material/Methods:)Tj
/F4 1 Tf
8.28 0 TD
[(We)-209.6(conduct)-215.1(a)-205.4(monthly)-211.7(community)-209.2(health)]TJ
-9.2799 -1.128 TD
[(screening)-269.5(which)-267.3(includes)-268.6(collecting)-266.5(patient)-268.9(data)-270(and)-266.3(testing)-270(for:)]TJ
0 -1.1219 TD
[(blood)-340.8(pressure,)-340.5(cholesterol,)-341.6(body)-335.2(mass)-343.3(index,)-338.9(waist)-339.1(circumfer-)]TJ
0 -1.128 TD
[(ence)-378.4(and)-382.2(cardiovascular)-377.3(risk)-378.9(score.)-375.7(Once)-381.8(the)-375.6(data)-379.8(is)-376.6(collected)]TJ
0 -1.1219 TD
[(an)20.2(d)-365.8(a)14.1(ll)-352.6(sc)21.1(re)17.8(e)14.1(n)0(i)18.8(n)12.2(g)-365.8(a)14.1(re)-354.1(co)20.2(m)12.8(p)12.2(le)20.7(te)-357.3(e)14.1(a)0(c)16(h)-359.7(p)12.2(a)0(r)17.8(t)12.7(i)12.7(c)0(i)20.7(p)0(a)20.2(n)0(t)-353.1(i)12.7(s)-365(g)12.2(iv)18.8(e)14.1(n)-365.8(e)14.1(d)0(u)18.3(c)0(a)22.1(-)]TJ
0 -1.128 TD
[(ti)19.4(o)12.2(n)0(a)20.2(l)-237.3(m)12.8(a)0(t)20.7(e)0(r)23.9(i)0(a)14.6(l)-231.2(an)20.2(d)-231.7(h)12.2(as)-222.8(th)18.8(e)-235.9(c)14.1(h)12.2(a)0(n)20.2(c)0(e)-227.9(t)12.7(o)-231.7(r)0(e)17.9(v)12.2(i)12.7(e)0(w)-225.2(r)0(e)17.9(s)13.1(u)12.2(l)0(t)19.3(s)13.1(,)-237.8(a)14.1(sk)-224.7(q)12.2(u)12.2(e)0(s)15(t)12.7(i)12.7(o)12.2(ns)]TJ
0 -1.1219 TD
[(an)20.2(d)-207.3(g)12.2(et)-198.8(ad)20.2(v)12.2(i)0(c)20.7(e)-211.5(fr)25.8(om)-200.6(C)13.6(a)0(r)17.8(d)12.2(i)12.7(o)0(l)18.8(o)12.2(g)12.2(y)-207.3(Ph)21.6(y)12.2(s)0(i)19.7(c)0(i)20.7(a)0(n)20.2(s)0(,)-200.3(N)0(u)22.9(r)0(s)22.9(e)-205.4(Pr)19.2(ac)16(t)12.7(i)12.7(t)0(i)19.3(o)12.2(n)12.2(e)0(r)17.9(s)-206.4(o)12.2(r)]TJ
0 -1.128 TD
[(Re)15.5(g)12.2(i)12.7(st)19.7(er)17.8(e)14.1(d)-292.6(Nu)22.9(rs)16.8(e)14.1(s)0(.)-279.6(T)0(h)16.5(e)-290.8(p)12.2(a)0(r)17.8(t)12.7(i)12.7(c)0(i)20.7(p)0(a)20.2(n)0(t)-279.9(i)0(s)-285.2(r)0(e)23.9(f)0(e)17.8(r)0(r)19.7(e)14.1(d)-292.6(i)0(f)-282.3(n)12.2(ee)16(d)12.2(e)14.1(d)-292.6(a)0(n)20.2(d)-292.6(p)12.2(r)0(o)22.1(-)]TJ
0 -1.1219 TD
[(vi)18.8(d)12.2(e)0(d)-357.8(w)0(i)23.4(t)12.7(h)-365.8(e)0(x)20.2(t)12.7(en)20.2(si)19.7(v)12.2(e)-363.9(in)18.8(fo)22.1(rm)22.6(at)20.7(io)18.8(n)-365.8(o)12.2(n)-365.8(h)12.2(ea)22.1(rt)-355.5(h)12.2(e)0(a)16(l)12.7(t)12.7(h)12.2(,)-365.8(h)12.2(yp)18.4(er)23.9(te)20.7(ns)19.2(i)12.7(o)0(n)18.3(,)]TJ
0 -1.128 TD
[(he)20.2(ar)17.8(t)-432.4(d)12.2(is)19.7(ea)16(s)13.1(e)0(,)-424.9(d)12.2(ie)20.7(t,)-426.3(e)14.1(x)0(e)20.2(r)0(c)17.8(i)12.7(se)21.1(,)-439(d)12.2(i)12.7(a)0(b)20.2(e)0(t)20.7(e)0(s)-424(a)0(n)20.2(d)-432.9(Em)17(o)12.2(r)0(y)-423(s)0(o)19.2(c)14.1(ia)20.7(l)-438.5(m)12.8(ed)20.2(i)12.7(a)]TJ
0 -1.1219 TD
[(op)18.3(t)12.7(i)0(o)18.8(n)12.2(s)13.1(.)-189(Th)16.5(i)12.7(s)-188.1(sc)21.1(re)17.8(en)20.2(i)12.7(n)12.2(g)-189(i)0(s)-181.5(r)0(u)22.1(n)-189(o)12.2(n)-189(a)-193.2(1)12.2(0)12.2(0)0(%)-179.1(v)0(o)18.3(l)12.7(u)12.2(n)0(t)18.8(e)0(e)22.1(r)-191.4(b)12.2(a)0(s)21.1(i)0(s)19.7(,)-189(re)17.8(q)12.2(u)12.2(i)12.7(ri)16.5(n)12.2(g)]TJ
0 -1.128 TD
[(at)-430.5(le)20.7(as)21.1(t)-438.5(2)0(0)-432.8(c)14.1(li)19.3(n)12.2(i)0(c)20.7(a)0(l)-430.5(v)12.2(ol)18.8(u)12.2(n)12.2(t)0(e)20.7(e)0(r)17.8(s)-438.1(p)12.2(e)0(r)-433.3(s)13.1(cr)17.8(e)14.1(e)0(n)20.2(i)0(n)18.8(g)12.2(.)-439(O)0(n)22.9(c)0(e)-435.2(t)12.7(h)12.2(e)-443.2(d)12.2(a)0(t)20.7(a)-437.1(is)]TJ
0 -1.1219 TD
[(co)20.2(ll)19.4(ec)22.1(te)20.7(d)-274.3(a)0(n)20.2(d)-274.3(t)12.7(h)0(e)-266.3(p)12.2(at)20.7(ie)20.7(n)12.2(t)-273.8(ha)20.2(s)-273.5(c)0(o)20.2(m)0(p)18.9(l)12.7(et)20.7(ed)-266.3(t)12.7(h)12.2(e)-278.6(s)13.1(cr)17.8(e)14.1(e)0(n)20.2(i)0(n)18.9(g)12.2(,)-274.4(t)12.7(h)12.2(e)-278.6(d)12.2(a)0(t)20.7(a)-272.5(is)]TJ
0 -1.128 TD
[(en)20.2(te)20.7(re)17.8(d)-317(i)0(n)18.8(t)12.7(o)-323.1(a)-321.2(HI)20.6(P)15.4(P)0(A)-309.2(a)0(p)20.2(p)12.2(ro)16(v)12.2(e)0(d)-309(R)13.6(ED)15(C)13.6(A)0(P)-309.2(d)12.2(at)20.7(ab)20.2(as)21.1(e)-321.2(f)0(o)22.1(r)-325.5(a)14.1(n)12.2(al)20.7(ys)19.2(i)12.7(s)0(.)]TJ
T*
[(Si)22.1(x)-341.4(m)0(o)18.9(n)12.2(th)18.8(s)-340.6(p)12.2(o)12.2(s)0(t)-333.9(s)13.1(cr)17.8(ee)22.1(ni)18.8(n)12.2(g)-341.4(we)-334.9(f)15.9(o)0(l)18.8(l)12.7(ow)-330.7(up)-335.3(wi)23.4(t)12.7(h)-341.4(th)18.8(e)-339.5(p)0(a)20.2(t)0(i)19.3(e)0(n)20.2(t)-340.9(t)12.7(o)-341.4(se)21.1(e)]TJ
0 -1.1219 TD
[(if)-373.7(t)12.7(h)0(e)20.2(y)-384.1(h)12.2(a)0(v)20.2(e)-382.2(ex)20.2(p)12.2(e)0(r)17.8(i)12.7(en)20.2(c)14.1(e)0(d)-376.1(a)14.1(ny)-371.9(b)12.2(e)0(h)20.2(a)0(v)20.2(i)0(o)18.8(r)-380.4(ch)20.2(an)20.2(g)12.2(e)0(s)-369.2(o)0(r)-374.2(n)12.2(ee)22.1(d)-384.1(f)0(u)22.1(r)0(t)22.6(h)0(e)20.2(r)]TJ
0 -1.128 TD
.0119 Tc
[(cl)11.9(i)-5.3(n)-.3(ical)-304.6(care.)-299(We)-297.2(partn)11.9(e)-4.5(r)-301.4(w)-1.8(ith)-299(th)11.9(e)-309.3(c)1.6(omm)11.9(u)-5.8(nity)-299(in)-299(o)11.9(r)-8.7(der)-301.4(t)11.9(o)-310.7(h)11.9(o)-6.3(l).2(d)]TJ
0 -1.1219 TD
.0113 Tc
[(these)-297.8(h)-.9(ea)-5.1(l)11.3(t)-5.9(h)-299.6(s)0(creening)-293.5(e)-5.1(v)11.3(e)-11.2(n)11.3(t)-6.4(s.)]TJ
/F3 1 Tf
.9999 -1.128 TD
0 Tc
(Results:)Tj
/F4 1 Tf
3.6583 0 TD
[(Our)-217.2(preliminary)-224.3(results)-223.2(have)-215.6(shown:)-219.5(Blood)-223.6(Pressure:)]TJ
-4.6583 -1.1219 TD
[(Out)-342.4(of)-343.8(the)-345.1(87)-341.4(patients)-341.2(we)-347.1(have)-343.7(complete)-340.2(screening)-348.8(data)-343.2(on)-341.4(28)]TJ
0 -1.128 TD
[(were)-317.1(found)-307.1(to)-310.4(have)-307.1(high/elevated)-313.3(blood)-310.3(pressure)-310.1(which)-310(is)-309.6(32%)]TJ
0 -1.1219 TD
[(of)-240.1(our)-240.1(screened)-237.7(population.)-240.2(\(systolic)-241(of)-234(140)-237.7(and)-241.9(above\))-236.3(BMI:)-237.3(Of)]TJ
0 -1.128 TD
[(the)-357.3(87)-347.5(patients)-353.4(screen)-355.5(54)-347.5(had)-351.7(a)-351.7(BMI)-353.7(of)-349.9(30)-353.6(or)-349.9(greater)-352.1(\(62%)-352.2(of)]TJ
0 -1.1219 TD
[(women)-255.1(screened\).)-258.3(That)-249.4(puts)-254.6(over)-256.5(half)-249.9(of)-252.3(the)-253.6(women)-255.1(screened)-256(in)]TJ
0 -1.128 TD
[(the)-357.3(obese)-361.1(category)-355.8(according)-355.8(to)-359.2(the)-357.3(NIH)-352.8(BMI)-359.8(guidelines.)-353.4(Un-)]TJ
0 -1.1219 TD
[(insured:)-217.9(We)-215.7(found)-209.5(12)-213.3(out)-212.8(of)-209.6(87)-213.3(patients)-219.3(were)-213.4(uninsured)-212.3(\(13.7%\).)]TJ
0 -1.128 TD
[(Low)-417.9(Income:)-412(We)-416.9(found)-416.9(26)-414.6(out)-414(of)-410.8(87)-414.6(patients)-414.4(had)-418.7(an)-412.7(annual)]TJ
0 -1.1219 TD
[(household)-520.9(income)-513.3(between)-519.6($12-$24,000)-514.3(\(29.8%\))-513(Cardiovas-)]TJ
27.0045 71.9468 TD
[(cular)-345.5(risk)-342.4(assessment:)-348.9(25)-341.4(out)-347(of)-343.8(87)-341.4(Women)-349.2(screened)-347.5(had)-339.5(a)-345.6(1)0(0)]TJ
0 -1.128 TD
[(year)-297.3(cardiovascular)-304.1(risk)-305.8(assessment)-300.7(score)-302.5(of)-301.1(7.5%.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Conclusions:)Tj
/F4 1 Tf
5.7009 0 TD
[(This)-219.9(project)-216.9(will)-219.4(continue)-220.6(over)-213.8(the)-217(course)-223.2(of)-215.7(the)]TJ
-6.7008 -1.128 TD
[(next)-247.5(ve)-250.9(years,)-253.7(and)-248(possibly)-247.1(extend)-251.7(further.)-248.4(We)-252.3(will)-249.9(continue)-251.1(to)]TJ
0 -1.1219 TD
[(analyze)-583.2(the)-582.9(data)-587.1(as)-582.6(we)-584.9(collect)-584.1(and)-583.4(conduct)-580.9(further)-583.8(health)]TJ
0 -1.128 TD
[(screenings)-299.2(in)-304.3(the)-302.4(community.)-300.7(Our)-296.5(goal)-302.4(is)-303.5(to)-298.2(reach)-301.5(10,000)-298.6(Afri-)]TJ
0 -1.1219 TD
[(can)-276.6(American)-271.4(women.)-279.4(Once)-272(we)-280(have)-270.5(this)-278.5(large)-272.4(data)-276.1(set)-277.2(we)-273.9(will)]TJ
0 -1.128 TD
[(have)-301(publishable)-298.5(results.)]TJ
/F3 1 Tf
0 -3.012 TD
(27.)Tj
9.843 0 0 9.843 331.7668 624.3022 Tm
[(Effect)-280.6(of)-284.4(Stabilizing)-278.2(Exercises)-286.1(Augmented)]TJ
0 -1.1116 TD
[(by)-278.5(Pelvic)-281.1(Floor)-284.5(Training)-281.7(on)-278.5(Postpa)-7.4(rtum)]TJ
0 -1.1174 TD
[(Low)-281.7(Back)-282.9(Pain)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 310.8472 585.8077 Tm
[(Abeer)-335.3(ElDeeb)]TJ
6.9735 0 0 6.198 364.6487 589.9463 Tm
(1)Tj
9.2982 0 0 9.2982 368.1637 585.8077 Tm
[(,)-335.3(Adly)-330.1(A.)-336.8(Sabbour)]TJ
6.9735 0 0 6.198 438.3495 589.9463 Tm
(1)Tj
9.2982 0 0 9.2982 441.8644 585.8077 Tm
[(,)-329.2(Khaled)-338.5(S.)-332.1(Abd-Ghafar)]TJ
6.9735 0 0 6.198 532.7432 589.9463 Tm
(1)Tj
9.2982 0 0 9.2982 536.2581 585.8077 Tm
(,)Tj
-24.2424 -1.1219 TD
[(Waled)-335.2(A.)-330.7(Ayad)]TJ
6.9735 0 0 6.198 370.5448 579.5148 Tm
(2)Tj
/F5 1 Tf
-8.5606 -2.6526 TD
(1)Tj
9.2982 0 0 9.2982 314.3054 558.9353 Tm
[(Department)-295.9(of)-298.2(Physical)-294.8(Therapy)-296.9(for)-291.2(Womens)-296(Health,)-297.2(Faculty)]TJ
-.3719 -1.128 TD
[(of)-334.8(Physical)-331.4(Therapy,)-333.4(Cairo)-332.5(University,)-340(Giza,)-335.4(Egypt)]TJ
6.9735 0 0 6.198 310.8472 542.1542 Tm
(2)Tj
9.2982 0 0 9.2982 314.3054 538.0156 Tm
[(Department)-338.6(of)-334.8(Obstetrics)-334.9(and)-329.2(Gynecology,)-340.8(Faculty)-332.3(of)]TJ
-.3719 -1.128 TD
[(Medicine,)-336.9(Al-Azhar)-332.9(University,)-333.9(Cairo,)-332.5(Egypt)]TJ
/F3 1 Tf
.9999 -2.3047 TD
(Background:)Tj
/F4 1 Tf
5.9996 0 TD
[(Low)-399.6(back)-398.6(pain)-399.9(\(LBP\))-398.2(is)-401(a)-400.5(common)-399.3(problem)]TJ
-6.9996 -1.1219 TD
[(during)-452.9(pregnancy,)-453.8(which)-456.3(may)-454.8(persist)-454.9(after)-457.7(delivery)-460.8(affecting)]TJ
0 -1.128 TD
[(25%)-234(of)-227.9(postpartum)-235.7(women.)-236.8(It)-233.5(is)-230.3(a)-235.9(dull)-230.6(aching)-233.4(pain)-235.3(in)-231.1(the)-235.3(lumbar)]TJ
0 -1.1219 TD
[(region)-237.6(experienced)-236.1(on)-237.7(trunk)-233.4(forward)-238.3(exion)-238.1(and)-235.8(associated)-239.5(with)]TJ
0 -1.128 TD
[(restricted)-496.5(lumbar)-499.3(spine)-496.6(movements.)-499.7(Postpartum)-494.6(LBP)-497.1(has)-497.2(an)]TJ
0 -1.1219 TD
[(adverse)-398.1(impact)-397(on)-396.3(the)-400(quality)-398.9(of)-398.6(life)-395.7(\(QOL\))-399.7(and)-394.4(may)-399.9(lead)-398.1(to)]TJ
0 -1.128 TD
[(socioeconomic)-300.8(detriment.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.9204 0 TD
[(This)-415(study)-413.1(aimed)-415.8(to)-420.2(investigate)-411.9(the)-418.3(effect)-419.2(of)]TJ
-6.9203 -1.128 TD
[(adding)-338.9(pelvic)-336.5(oor)-334.4(training)-340.2(to)-334.8(stabilizing)-340.2(exercises)-340(on)-341.4(pain)-339(in-)]TJ
0 -1.1219 TD
[(tensity,)-239.5(functional)-234.7(disability)-238.4(and)-241.9(strength)-236.2(of)-240.1(pelvic)-239(oor)-236.8(muscles)]TJ
0 -1.128 TD
[(in)-298.2(postnatal)-304.6(women)-297.7(with)-299.2(LBP.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Material/Methods:)Tj
/F4 1 Tf
8.3288 0 TD
[(Forty)-260.7(postnatal)-261.9(women,)-255(with)-262.6(a)-260.3(history)-262.5(of)]TJ
-9.3287 -1.128 TD
[(low)-385(back)-380.3(pain)-387.7(during)-379.7(pregnancy)-386.7(persisting)-387.3(for)-382.7(6)-384.1(months)-382.1(after)]TJ
0 -1.1219 TD
[(delivery,)-393.7(engaged)-396.6(in)-395.8(the)-393.9(study.)-394.8(They)-396.2(aged)-398.6(2535)-396.2(years;)-393.4(body)]TJ
0 -1.128 TD
[(mass)-337.2(index)-345(was)]TJ
/F2 1 Tf
6.963 0 TD
(>)Tj
/F4 1 Tf
.6158 0 TD
[(25)-335.3(and)]TJ
/F2 1 Tf
3.1279 0 TD
(<)Tj
/F4 1 Tf
.439 0 TD
[(30)-170.7(kg/m)]TJ
6.9735 0 0 6.198 444.529 363.7983 Tm
(2)Tj
9.2982 0 0 9.2982 447.9873 359.6598 Tm
[(.)-341.4(They)-341.3(were)-341.5(randomly)-340.7(dis-)]TJ
-14.7491 -1.1219 TD
[(tributed)-364.6(into)-364.7(two)-366.8(groups;)-366.7(the)-363.4(control)-365.2(group)-362(\(n)]TJ
/F2 1 Tf
18.9745 0 TD
(=)Tj
/F4 1 Tf
.5548 0 TD
[(20\))-362(engaged)-366.1(in)]TJ
-19.5293 -1.128 TD
[(stabilizing)-199.9(exercises,)-205.8(which)-206.3(focused)-198.8(on)-201.2(exercising)-208(multidus)-201(and)]TJ
0 -1.1219 TD
[(transverse)-289.3(abdominals)-292.4(while)-291.2(the)-290.2(study)-285.1(group)-288.8(\(n)]TJ
/F2 1 Tf
19.2062 0 TD
(=)Tj
/F4 1 Tf
.5487 0 TD
[(20\))-288.9(enga)22.1(g)12.2(e)14.1(d)-274.3(i)12.7(n)]TJ
-19.7549 -1.128 TD
-.0129 Tc
[(the)-340.2(s).2(a)-12.9(m)7.8(e)-340.2(s).2(ta)-12.9(b)13.4(iliz)-12.9(i)7.8(n)-.7(g)-342.1(e)1.2(xer)-12.9(c)11(ise)-12.9(s)-333.3(and)-342.1(p)-.7(elvic)-346.3()2.6(oor)-344.5(stre)-12.9(n)7.3(g)5.4(the)-12.9(n)13.4(ing)-342.1(e)-12.9(x)7.3(-)]TJ
0 -1.1219 TD
[(er)-12.9(c)11(i)-.2(ses.)-293.4(Both)-287.2(groups)-286.4(e)-12.9(x)13.4(e)-12.9(r)11(c)-12.9(i)7.8(sed)-287.2(3)-287.2(s).2(e)-12.9(s)8.2(sions)-286.4(per)-289.6(w)-12.9(e)11.9(e)-12.9(k)-279.2(f)3(or)-289.6(12)-287.2(w)-12.9(e)11.9(eks.)]TJ
0 -1.128 TD
0 Tc
[(V)16.8(i)12.7(su)25.3(al)-461(an)20.2(a)14.1(l)12.7(o)12.2(g)-469.5(s)13.1(c)0(a)22.1(l)12.7(e)-473.7(\()16(VA)21.4(S)15.4(\))-471.8(wa)24.8(s)-474.7(u)12.2(s)13.1(e)14.1(d)-475.6(t)12.7(o)-469.5(a)14.1(ss)20(e)14.1(s)13.1(s)-474.7(p)12.2(a)14.1(i)12.7(n)-469.5(i)12.7(n)12.2(t)12.7(e)14.1(n)12.2(s)13.1(i)12.7(t)12.7(y)12.2(,)]TJ
0 -1.1219 TD
-.0134 Tc
[(Os)-13.4(w)10.4(e)-13.4(s)7.7(t)-.7(ry)-428(disability)-428(index)-428(\()2.5(O)-13.4(D)8(I\))-430.4(to)-428(asse)-13.4(s)7.7(s)-427.1(functional)-427.5(d)-1.2(isa)-13.4(b)12.9(ility,)]TJ
0 -1.128 TD
-.0132 Tc
[(mod)5.1(i)-.5()-13.2(e)10.2(d)-244.9(S)2.2(chober)-247.2(t)-.5(est)-244.4(t)-.5(o)-238.8(m)-.4(ea)-13.2(s)7.9(u)-1(re)-243(f)-13.2(o)15(r)-13.2(w)7.4(ar)-13.2(d)-228.9()-13.2(e)10.2(x)-1(ion)-238.8(r)-13.2(a)10.7(nge)-243(o)5.1(f)-247.2(mo)5.1(tion)]TJ
0 -1.1219 TD
0 Tc
[(\()15.9(R)13.6(OM)23.8(\))-508.4(o)12.2(f)-514.5(t)12.7(h)18.3(e)-510.3(t)12.7(r)0(u)22.1(n)12.2(k)-506(a)14.1(n)12.2(d)-512.1(Ke)24.8(g)12.2(e)14.1(l)-511.6(p)12.2(e)14.1(r)15.9(i)12.7(n)12.2(eo)20.2(m)12.8(e)14.1(t)12.7(e)14.1(r)-508.4(t)12.7(o)-512.1(m)12.7(e)14.1(a)0(s)21.1(u)18.3(re)-500.4(t)12.7(h)12.2(e)]TJ
0 -1.128 TD
-.013 Tc
[(stre)-13(n)7.2(g)5.3(th)-305.6(o)5.3(f)-301.9(the)-303.8(p)5.3(e)-13(l)7.7(vic)-297.7()2.4(oor)-301.9(muscle)-13(.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
0 Tc
(Results:)Tj
/F4 1 Tf
3.9632 0 TD
-.0246 Tc
[(Compared)-488(with)-481.9(t)-5.8(h)5.9(e)-492.2(c)1.7(ontrol)-487.5(g)-.2(rou)5.9(p)-.2(,)-488(t).3(he)-486.1(study)-488(gro)5.9(u)-.2(p)]TJ
-4.9631 -1.128 TD
-.0247 Tc
[(showed)-268.6(a)-272.8(s).6(ignicant)-268.1(d)-.3(ecrease)-272.8(\(P)]TJ
/F2 1 Tf
12.42 0 TD
0 Tc
(<)Tj
/F4 1 Tf
.5305 0 TD
-.0249 Tc
[(0.00)5.6(1\))-271.1(in)-274.9(p)5.6(a)-4.7(in)-268.8(and)-274.9(f)3.2(unctional)-274.4(d)-.5(is-)]TJ
-12.9504 -1.1219 TD
[(ability,)-378.6(a)-4.8(s)-377.8(w)-2.1(el)-6.2(l)-378.1(a)1.3(s)-383.9(a)-382.8(signicant)-384.2(i)-.1(n)5.5(c)-4.8(rease)-382.8(\()-3(P)]TJ
/F2 1 Tf
16.7612 0 TD
0 Tc
(<)Tj
/F4 1 Tf
.5244 0 TD
-.0241 Tc
[(0.001\))-380.1(in)-377.7(pelvic)-375.8(oor)]TJ
-17.2855 -1.128 TD
-.0248 Tc
[(muscle)-163.1(strength)5.7(,)-165(but)-158.4(non-signicant)-158.4(d)]TJ
13.926 0 TD
[(ifferen)5.7(c)-4.6(e)-163.1(i).1(n)-158.9(t).1(runk)-165(exion)-158.9(ROM.)]TJ
/F3 1 Tf
-12.926 -1.128 TD
0 Tc
(Conclusions:)Tj
/F4 1 Tf
5.835 0 TD
[(Th)22.6(e)-345.6()15.4(nd)18.3(i)12.7(n)12.2(gs)-334.4(s)13.1(u)12.2(g)12.2(g)0(e)20.2(s)0(t)-333.9(t)12.7(h)12.2(a)0(t)-332.9(p)12.2(el)20.7(v)12.2(i)12.7(c)-345.6()15.5(oo)18.3(r)-337.7(s)0(t)19.7(r)0(e)17.8(n)12.2(g)12.2(t)12.7(h-)]TJ
-6.8349 -1.1219 TD
[(e)14.1(n)0(i)18.8(n)12.2(g)-268.2(e)0(x)20.2(e)0(r)17.9(c)14.1(is)19.7(e)-272.5(s)13.1(h)12.2(o)0(u)18.3(l)12.7(d)-268.2(b)12.2(e)-272.5(r)0(e)23.9(c)0(o)20.2(m)0(m)19.4(e)0(n)20.2(d)12.2(ed)20.2(,)-268.3(a)0(s)-259.4(a)14.1(n)-268.2(i)0(n)18.8(t)12.7(eg)20.2(ra)17.8(l)-267.8(p)12.2(ar)17.8(t)-267.8(i)12.7(n)-268.2(t)0(h)18.8(e)]TJ
0 -1.128 TD
[(m)12.8(a)0(n)20.2(a)0(g)20.2(e)0(m)20.8(e)0(n)20.2(t)-286(st)19.7(ra)17.8(t)12.7(e)0(g)20.2(i)12.7(es)-283.8(o)12.2(f)-288.9(p)12.2(o)12.2(s)0(t)19.7(p)12.2(ar)17.8(t)12.7(u)0(m)-279.9(L)0(B)17.9(P)15.4(.)]TJ
/F3 1 Tf
0 -3.012 TD
(28.)Tj
9.843 0 0 9.843 331.7668 153.8078 Tm
[(The)-281.8(Impact)-279.2(of)-284.4(Energy)-280.5(Efcient)-282.6(Projects)]TJ
0 -1.1116 TD
[(on)-278.5(Gender-Based)-284.4(Violence)-284(in)-284.4(Humanitarian)]TJ
T*
(Emergencies)Tj
/F4 1 Tf
9.2982 0 0 9.2982 310.8472 115.3701 Tm
[(Shaza)-332.5(Elmahdi)]TJ
/F5 1 Tf
0 -1.7682 TD
[(Afrotechana,)-331.3(Springeld,)-337.5(Virginia)]TJ
/F3 1 Tf
.9999 -2.3047 TD
(Background:)Tj
/F4 1 Tf
5.8411 0 TD
[(Th)16.5(e)-229.8(d)0(a)20.2(n)0(g)18.3(e)0(r)-226(o)12.2(f)-234(a)0(s)21.1(s)0(a)21.1(u)0(l)18.8(t)-231.2(wh)16.8(i)12.7(l)0(s)13.6(t)-231.2(co)20.2(l)12.7(l)0(e)14.6(c)14.1(ti)19.3(ng)-225.5(r)19.2(e)14.1(w)0(o)16.8(o)12.2(d)]TJ
-6.841 -1.128 TD
[(i)12.7(s)-261.3(m)12.8(u)12.2(ch)-248.1(cl)14.6(e)14.1(a)0(r)17.9(e)0(r)-250.4(i)12.7(n)-256.1(c)0(o)20.2(n)0()15.5(i)12.7(ct)-247.6(se)15(t)12.7(t)12.7(i)0(n)18.8(g)0(s)-249.1(t)12.7(ha)14.1(n)-256.1(i)12.7(n)-256.1(n)0(o)18.3(r)0(m)22.6(a)0(l)-247.6(s)0(e)15(t)12.7(ti)19.3(ng)18.3(s)13.1(,)-262.2(wh)22.9(er)17.8(e)]TJ
0 -1.1219 TD
[(wo)22.9(me)14.6(n)-237.8(a)14.1(nd)-231.6(g)12.2(i)0(r)16.5(l)12.7(s)-236.9(a)0(r)17.8(e)-242(o)12.2(f)0(t)22.6(e)0(n)-229.8(a)0(s)15(s)13.1(ig)18.9(n)12.2(e)0(d)-229.8(t)0(o)-231.1(c)14.1(ol)18.8(le)20.7(ct)-229.3(r)19.2(ew)18.7(oo)18.3(d)12.2(.)-237.8(Fi)16(re)23.9(wo)16.8(o)12.2(d)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 59.7543 749.7069 Tm
(ABSTRACTS)Tj
52.6193 0 TD
(A-11)Tj
ET
endstream
endobj
232 0 obj
<>stream
/GS1 gs
BT
/F4 1 Tf
9.2982 0 0 9.2982 62.022 725.5557 Tm
0 0 0 rg
0 Tc
0 Tw
[(co)20.2(ll)19.3(ec)16(t)12.7(o)0(r)16(s)-438.1(c)14.1(a)0(n)-431(w)0(a)18.7(l)0(k)-426.2(t)0(e)14.6(n)12.2(s)-438.1(o)12.2(f)-441.3(m)12.8(il)19.3(es)-430.1(aw)18.7(ay)-431(fr)19.7(o)12.2(m)-438.4(th)18.8(ei)20.7(r)-441.3(v)12.2(il)19.4(la)20.7(ge)14.1(s)-438.1(o)12.2(r)]TJ
0 -1.128 TD
[(ca)16(m)12.8(p)12.2(s)-541.8(t)0(o)-529.9()0(n)21.6(d)-542.6(t)12.7(h)0(e)-534.6(i)12.7(n)12.2(c)0(r)17.8(e)0(a)16(s)13.1(in)18.8(g)12.2(l)0(y)-529.9(s)0(c)15(a)0(r)17.8(c)14.1(e)-540.7(c)0(o)20.2(m)0(b)18.9(u)0(s)19.2(t)0(i)19.3(b)12.2(le)-534.1(m)12.8(a)0(t)14.6(e)14.1(ri)16.5(al)20.7(s.)]TJ
0 -1.1219 TD
[(Th)16.5(a)14.1(t)0()16.5(s)-310.1(wh)16.8(y)-310.9(t)0(h)18.9(e)0(y)-302.9(a)0(r)17.8(e)-315.1(p)12.2(o)12.2(t)0(e)14.6(n)12.2(ti)19.3(al)-302.4(ta)14.6(rg)22.1(et)20.7(s)-316.2(f)0(o)22.1(r)-313.3(p)12.2(e)0(r)17.8(p)0(e)20.2(t)0(r)16.5(a)0(t)20.7(o)12.2(rs)16.8(.)-310.9(I)0(n)-307.2(A)0(u)22.9(g)0(u)18.3(s)13.1(t)]TJ
0 -1.128 TD
[(2)12.2(0)0(0)18.3(6)-426.8(t)12.7(h)0(e)-418.8(I)0(n)22.1(t)0(e)20.7(r)0(n)16(a)0(t)20.7(i)12.7(on)18.3(al)-418.3(R)13.6(e)0(s)15(c)0(u)20.2(e)-424.9(Co)19.7(m)12.8(m)0(i)19.4(t)0(t)19.3(e)0(e)-416.9(\()0(I)19.7(R)0(C)15(\))-423(re)17.8(p)12.2(o)12.2(r)0(t)16.5(e)0(d)-412.7(o)0(v)18.3(e)0(r)]TJ
0 -1.1219 TD
[(tw)17.3(o)-213.4(h)12.2(un)18.3(d)12.2(r)0(e)17.8(d)12.2(s)-218.6(a)0(s)21.1(s)0(a)15(u)12.2(l)12.7(t)0(s)-205.9(i)0(n)-206.7(a)-217.6()15.4(v)0(e)14.1(-)0(w)20.6(e)0(e)22.1(k)-219.5(p)12.2(e)0(r)17.8(i)12.7(od)-207.2(fr)19.7(o)12.2(m)-212.8(a)-217.6(s)0(i)19.7(n)12.2(gl)18.8(e)-217.6(c)0(a)16(m)12.8(p)-213.4(i)0(n)]TJ
0 -1.128 TD
[(Da)18.7(rf)19.7(u)12.2(r)0(.)-288.9(W)0(h)20.2(i)0(l)19.4(e)-303(M)13.1(e)]TJ
6.8045 .0427 TD
()Tj
.378 -.0427 TD
[(d)12.2(e)0(c)16(i)12.7(ns)-291.8(s)13.1(a)0(n)20.2(s)-297.9(Fr)19.2(on)18.3(t)12.7(i)0(e)]TJ
7.2435 .0427 TD
(`)Tj
.378 -.0427 TD
[(re)23.9(s)-297.9(r)0(e)17.8(p)0(o)18.3(r)0(t)22.6(e)0(d)-290.7(o)12.2(ve)14.1(r)-295(2)12.2(00)-286.5(ca)16(se)21.1(s)]TJ
-14.804 -1.1219 TD
[(p)12.2(e)0(r)-335.8(m)0(o)18.9(n)12.2(th)-334.8(in)-334.8(2)12.2(0)0(0)18.3(5)12.2(.)-347.5(G)0(i)23.4(v)0(e)20.2(n)-347.5(t)12.7(h)0(e)-333.4(s)0(t)19.7(i)0(g)18.9(m)0(a)-332.9(a)0(s)15(s)13.1(oc)20.2(ia)14.6(t)12.7(e)0(d)-333.4(w)0(i)17.3(t)12.7(h)-347.5(r)0(a)17.8(p)12.2(e,)-333.4(i)12.7(t)-347(i)12.7(s)]TJ
0 -1.128 TD
[(ex)20.2(tr)16.5(e)14.1(m)0(e)14.7(l)12.7(y)-225.6(l)0(i)19.4(k)12.2(el)14.6(y)-225.6(t)12.7(ha)20.2(t)-225.1(t)0(h)18.9(e)-229.8(re)17.8(a)14.1(l)-225.1(nu)18.3(mb)18.9(er)-213.9(of)-215.7(ra)17.8(pe)-217.6(su)19.2(rv)22.1(iv)18.8(o)12.2(r)0(s)-221(a)14.1(nd)-219.4(s)13.1(e)0(x)20.2(u)0(a)14.1(l)]TJ
0 -1.1219 TD
[(as)21.1(sa)15(u)12.2(l)0(t)19.3(s)-224.7(is)-218.1(h)12.2(i)0(g)18.8(h)12.2(er)-219.9(\(M)22.9(SF)-219.1(2)12.2(0)12.2(0)0(5)18.3(\))-227.9(Th)22.6(e)-229.8(h)12.2(i)12.7(g)0(h)-219.4(r)0(i)22.6(s)0(k)-218.6(o)12.2(f)-227.9(G)0(B)18.2(V)-221(in)-218.9(re)17.8(l)12.7(a)0(t)20.7(i)0(o)18.8(n)-225.6(to)]TJ
0 -1.128 TD
[(r)19.2(ew)18.7(o)12.2(o)0(d)-249.9(c)0(o)20.2(l)12.7(le)14.6(ct)20.7(i)12.7(o)0(n)-249.9(c)0(a)16(n)-256.1(b)12.2(e)-260.3(ch)20.2(ar)17.8(ac)22.1(te)14.6(ri)22.6(ze)16(d)-256.1(o)12.2(n:)-249.4(\(1)22.1(\))-258.4(g)0(e)20.2(n)0(d)18.3(e)0(r)17.8(,)-256.1(\(2)16(\))-252.3(t)0(i)19.3(m)0(e)14.6(,)]TJ
0 -1.1219 TD
[(an)20.2(d)-317(\()0(3)22.1(\))-313.3(d)12.2(i)0(s)19.7(t)0(a)14.6(n)12.2(ce)-301.1(re)17.8(la)14.6(t)12.7(e)0(d)-302.9(t)0(o)-304.3()0(r)19.2(e)0(w)18.7(o)12.2(od)-304.8(co)20.2(l)12.7(l)0(e)14.6(c)0(t)20.7(i)12.7(on)-304.8(in)-304.3(ad)20.2(d)12.2(i)0(t)19.3(i)0(o)18.8(n)-317(t)12.7(o)-310.9(th)18.8(e)]TJ
0 -1.128 TD
[(st)19.7(at)20.7(us)-279.6(of)-282.8(t)12.7(h)0(e)-284.6(c)0(o)20.2(n)12.2(i)16(c)14.1(t)-292.1(it)19.3(se)21.1(lf)-282.3(\(w)20.6(he)20.2(th)18.8(er)-280.9(it)-279.4(is)-285.2(a)14.1(c)0(t)14.6(i)12.7(v)12.2(e)-290.8(or)-282.8(n)12.2(o)0(t)18.9(\))0(.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.8533 0 TD
[(To)-282.3(i)12.7(d)12.2(en)14.1(t)12.7(i)12.7(f)0(y)-282.8(a)0(n)20.2(d)-292.6(an)20.2(al)14.6(y)12.2(z)0(e)-282.8(l)0(i)19.3(t)0(e)20.7(r)0(a)17.8(t)0(u)18.8(r)0(e)-280.9(r)0(e)17.8(g)0(a)20.2(r)0(d)16(i)12.7(n)12.2(g)-292.6(th)18.8(e)]TJ
-6.8532 -1.128 TD
[(im)19.4(p)12.2(a)0(c)16(t)12.7(s)-267.4(o)12.2(f)-264.5(c)0(o)14.1(o)12.2(k)12.2(-)0(s)16.8(t)12.7(ov)18.3(es)-253.3(in)18.8(it)19.3(ia)20.7(ti)19.3(ve)20.2(s)-267.4(o)12.2(n)-268.2(G)0(B)18.2(V)-263.6(an)20.2(d)-262.1(w)0(o)16.8(m)12.8(en)-260.3(a)14.1(n)0(d)-256(g)12.2(ir)16.5(l)12.7(s)0()]TJ
T*
-.0188 Tc
[(p)-6.6(r)-18.8(ot)-6.1(e)-18.8(c)-2.8(t)-6.1(i)-18.8(on)-634.6(i)-6.1(n)-634.6(h)-6.6(u)-18.8(ma)-18.8(ni)-18.8(ta)-18.8(ri)-6.1(a)-18.8(n)-626.6(s)-5.7(i)-18.8(tu)-18.8(at)-18.8(io)-18.8(ns)-18.8(.)]TJ
/F8 1 Tf
16.3892 0 TD
0 Tc
()Tj
/F4 1 Tf
.5 0 TD
[(To)-605.4(i)12.7(d)0(e)14.1(n)12.2(t)12.7(i)0(f)16.5(y)-609.7(ef)17.8(fe)17.9(ct)20.7(iv)18.8(e)]TJ
-16.8892 -1.1219 TD
[(st)19.7(ra)17.8(t)12.7(e)0(g)14.1(i)12.7(es)-174(t)12.7(o)-182.9(d)12.2(e)0(c)16(r)0(e)17.8(a)0(s)21.1(e)-181(vi)18.8(ol)18.8(en)20.2(ce)-173(ag)20.2(ai)14.6(n)12.2(s)13.1(t)-182.4(w)0(o)16.8(m)12.8(en)-174.9(t)12.7(h)0(r)16(o)12.2(u)12.2(g)0(h)-176.8(c)14.1(le)14.6(a)14.1(n)-182.9(co)20.2(ok)18.3(-)]TJ
0 -1.128 TD
[(st)19.7(o)12.2(v)0(e)14.1(s)-322.3(as)-320.4(a)-327.3(p)0(u)18.3(b)12.2(li)19.3(c)-327.3(h)0(e)20.2(a)0(l)14.6(t)12.7(h)-329.2(i)12.7(nt)18.8(er)17.8(v)12.2(e)0(n)20.2(t)0(i)19.3(o)0(n)-317(m)0(e)20.8(t)0(h)18.8(o)0(d)18.3(.)]TJ
/F8 1 Tf
18.822 0 TD
()Tj
/F4 1 Tf
.5 0 TD
[(To)-312.8(id)18.9(en)20.2(ti)19.3(fy)-319.4(b)12.2(e)0(s)21.1(t)]TJ
-19.322 -1.1219 TD
[(p)12.2(r)0(a)17.8(c)0(t)20.7(i)0(c)14.6(e)0(s)-241.1(f)0(o)22.1(r)-252.3(i)12.7(n)0(c)20.2(r)0(e)17.8(a)0(s)21.1(i)0(n)18.8(g)-250(sa)15(fe)-238.2(ac)16(c)14.1(e)0(s)15(s)-249.1(t)12.7(o)-250(en)14.1(e)14.1(r)0(g)16(y)-250(e)14.1(f)0()19.2(c)0(i)14.6(e)14.1(nt)-243.3(p)12.2(r)0(o)16(j)12.7(ec)16(t)12.7(s)0(.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Material/Methods:)Tj
/F4 1 Tf
8.2861 0 TD
-.0124 Tc
[(A)-221.2(c)-12.4(o)7.8(m).4(pr)-12.4(e)5.4(h)-.2(e)-12.4(n)7.8(s)-12.4(i)7.3(ve)-223.9(se)-12.4(a)9.7(r)-12.4(c)5.4(h)-219.7(of)-222(pe)-12.4(e)9.7(r)-12.4(-)7.3(r)-12.4(e)5.4(v)-.2(ie)-12.4(w)6.3(e)-12.4(d)]TJ
-9.286 -1.1219 TD
[(a)-12.4(r)5.4(tic)-12.4(l)8.3(e)-12.4(s)-235.2(a)-12.4(n)7.8(d)-244.1(gr)-12.4(e)11.5(y)-244.1(l)-12.4(i)6.9(te)-12.4(r)5.4(a)-12.4(t)8.3(u)-.2(r)-12.4(e)-232.3(w)-12.4(a)6.3(s)-243.2(c)-12.4(o)7.8(nduc)-12.4(t)8.3(e)-12.4(d)-236.1(u)-.2(s)-12.4(i)7.3(ng)-244.1(P)-12.4(u)9.2(bMe)-12.4(d)7.8(,)-244.1(S)-12.4(c)4.9(opus)-12.4(,)]TJ
0 -1.128 TD
.0123 Tc
[(Lancet,)-371.8(G)-1.4(oog)12.3(l)-5.4(e)-376(Sch)12.3(o)-5.9(lar)-380.3(a)2(nd)-371.8(Goo)12.3(g)-5.9(le,)-377.9(a)2(s)-377(w)4.7(el)12.3(l)-383(a)2(s)-377(c)-4.1(o)12.3(n)-5.9(centrat)12.3(e)-9.7(d)]TJ
0 -1.1219 TD
.0116 Tc
[(searches)-298.5(of)-295.6(specic)-297.5(jou)11.6(r)-9(n)11.6(a)-10.9(l)11.6(s)-310.1(and)-293.2(w)-2.1(ebsites.)]TJ
/F3 1 Tf
.9999 -1.128 TD
0 Tc
(Results:)Tj
/F4 1 Tf
3.7559 0 TD
[(Twenty)-317.9(ve)-311.9(\(25\))-321.7(studies)-312.3(were)-323.2(included)-318.2(in)-316.5(the)-314.6(anal-)]TJ
-4.7558 -1.1219 TD
[(ysis.)-570.8(Intervention)-572.3(programs)-574.4(shown)-567.6(to)-572.6(decrease)-571.2(exposure)-576.8(to)]TJ
0 -1.128 TD
[(SGBV)-284.9(risks)-286.6(for)-285.1(women)-279.4(and)-284.6(girls)-287(after)-286.9(involvement)-286.6(in)-279.9(the)-284.1(clean)]TJ
0 -1.1219 TD
[(cookstoves)-420.6(projects,)-429.5(especially)-422.8(with)-421.1(the)-424.3(interventions)-422.2(that)-423.8(in-)]TJ
0 -1.128 TD
[(cluded)-257.8(awareness,)-256.6(community)-251.9(education,)-255.3(women)-255.1(empowerment)]TJ
0 -1.1219 TD
[(and)-302.9(income)-299.9(generating)-300.4(support.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Conclusions:)Tj
/F4 1 Tf
5.9509 0 TD
[(Wh)14.1(ile)-448.2(man)14.7(y)-451.2(stu)13.6(di)12.8(es)-454.5(lo)12.7(ok)12.3(ed)-455.4(at)-448.8(th)12.8(e)-455.4(imp)13.3(act)-446.9(of)]TJ
-6.9508 -1.1219 TD
[(ene)16(rgy)-404.7(ef)11.8(c)11.2(ien)14.7(t)-414.1(pro)16(jec)16.5(ts)-413.2(on)-402.4(SGB)15.4(V,)-410(fe)11.7(w)-416.1(o)0(f)-404.7(the)14.7(m)-414(has)-405.7(th)12.8(e)-412.7(bas)15(e)]TJ
0 -1.128 TD
[(lin)13.3(e)-607.8(sur)16.8(vey)-601.7(to)-609.2(co)14.1(mpa)14.7(re)-610.2(th)12.8(e)-613.9(r)0(e)11.7(s)0(u)13.1(lts)14.1(,)-609.7(and)-601.7(man)14.7(y)-609.7(oth)12.8(er)-604.1(in)12.7(ter)12.3(-)]TJ
0 -1.1219 TD
[(ven)14.1(ti)13.2(on)-396.3(pro)16(gra)11.8(ms)-394.9(hav)14.1(e)-406.6(n)0(o)12.2(t)-401.9(bee)16(n)-402.4(rig)16.5(oro)16(usl)13.6(y)-402.4(eva)16(lua)14.7(ted)-393.9(or)-398.6(we)12.6(ll-)]TJ
0 -1.128 TD
[(do)12.2(cum)14.7(ent)14.7(ed,)-217.6(th)12.7(rou)16(gh)-225.5(th)12.8(is)-218.1(sys)14(tem)15.2(ati)15.2(c)-229.8(l)0(i)13.3(ter)12.3(atu)14.7(re)-219.9(rev)11.8(ie)14.6(w,)-227.1(pr)16(omi)13.3(sin)13.6(g)]TJ
0 -1.1219 TD
[(pra)11.8(ct)14.6(ice)10.4(s)-462.5(hav)14.1(e)-461.5(been)-453.4(id)12.7(ent)14.6(ie)17.9(d)-463.4(and)-455.3(rec)13.7(om)12.8(men)14.7(dat)14.6(io)12.8(ns)-462.5(mad)14.7(e)-461.5(t)0(o)]TJ
0 -1.128 TD
[(str)17.3(eng)14.1(th)12.8(en)-199.3(th)12.8(e)-199.3(evi)14.6(den)14.1(ce-)13.7(ba)14.1(se)-198.4(of)-191.3(eff)15.5(ect)10.4(iv)12.8(e)-199.3(int)13.3(er)11.7(ven)14.1(ti)13.3(on,)-188.9(in)-194.6(ter)12.3(ms)-193.7(of)]TJ
0 -1.1219 TD
[(re)11.8(duc)14.1(in)12.7(g)-378(t)0(h)12.8(e)-376.1(ra)11.8(tes)-368.6(of)-368.2(ex)14.1(po)12.2(sure)-359.3(to)-371.4(SG)14(BV,)-365.9(esp)15(eci)16.5(all)15.2(y)-378(i)0(n)-365.3(con)14.1(ic)17.9(t)]TJ
0 -1.128 TD
[(and)-284.6(po)12.2(st)-291.3(con)14.1(ic)17.9(t)-298.2(s)0(i)13.6(t)0(u)12.7(ati)15.2(ons)-285.6(and)-284.6(hu)12.3(man)14.7(ita)15.2(ria)12.3(n)-292.6(eme)16.6(rge)11.8(nc)14.1(ies)15.5(.)]TJ
/F3 1 Tf
0 -4.1095 TD
(29.)Tj
9.843 0 0 9.843 82.9417 310.7338 Tm
[(Demographics)-283.2(of)-284.4(Study)-281.5(Participants)-281.4(in)-284.4(Clinical)]TJ
0 -1.1116 TD
[(Trials)-210.5(for)-211.8(Oncology)-207(Drugs)-208.8(Approved)-213.1(by)-209.4(FDA)-207.8(CDER)]TJ
0 -1.1174 TD
[(from)-283.1(January)-279.3(to)-284.4(November)-279(10,)-282.1(2015)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 62.022 272.2393 Tm
[(Emmanuel)-337.8(Fadiran,)-330.1(Hilary)-336.2(Wright,)-334.7(Merina)-332.4(Elahi,)]TJ
0 -1.1219 TD
[(Ayomide)-333.8(Igun,)-331.5(Greg)-337.2(Soon,)-332(Alice)-338.1(Chen,)-332(Anne)-334.9(Pariser)]TJ
/F5 1 Tf
0 -1.7682 TD
[(FDA,)-334.4(Silver)-335.7(Spring,)-333.8(Maryland)]TJ
/F3 1 Tf
.9999 -2.3047 TD
(Background:)Tj
/F4 1 Tf
6.1277 0 TD
[(In)-526.7(2015,)-530.3(an)-528.5(estimated)-527.8(810,170)-524.2(new)-530(cancer)]TJ
-7.1276 -1.1219 TD
[(cases)-358.4(will)-353.5(be)-351.7(diagnosed)-354.4(in)-353.1(females.)-360.5(In)-349.9(order)-356.4(to)-353.1(assess)-358.5(efcacy)]TJ
0 -1.128 TD
[(and)-248(safety)-241(of)-246.2(drugs)-245.3(in)-243.3(the)-247.5(diverse)-241(patient)-250.6(populations)-245.5(who)-239.2(might)]TJ
T*
[(use)-241.1(them)-240.9(post-approval,)-242.7(the)-241.4(US)-242.1(FDA)-237.5(has)-241.1(implemented)-241.5(guidance)]TJ
0 -1.1219 TD
[(and)-272.4(regulation)-277.3(to)-273.8(encourage)-275.1(greater)-278.9(participation)-274.4(of)-276.7(women)-273.3(and)]TJ
0 -1.128 TD
[(minorities)-301.7(in)-298.2(clinical)-303.1(trials)-302.9(\(CTs\).)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.8167 0 TD
[(To)-306.7(assess)-303.7(demographics)-311.6(in)-304.3(oncology)-302.3(CTs)-310.5(sub-)]TJ
-6.8167 -1.128 TD
[(mitted)-416.6(in)-414.1(support)-415.5(of)-416.9(new)-414.2(molecular)-415.7(entity)-417.2(\(NME\))-415.6(New)-415.7(Drug)]TJ
0 -1.1219 TD
[(Ap)22.9(pl)18.8(i)12.7(c)0(a)16(t)12.7(i)12.7(o)0(n)18.3(s)-218.6(\(N)20.6(DA)21.4(s)13.1(\))-221.8(an)20.2(d)-219.5(B)13.6(io)18.8(l)12.7(o)12.2(gi)18.8(cs)-210.6(Li)23.1(ce)22.1(ns)19.2(e)-217.6(A)0(p)16.8(p)12.2(l)12.7(i)12.7(c)0(a)16(t)12.7(io)18.8(n)12.2(s)-218.6(\(B)23.4(LA)15(s)13.1(\))]TJ
0 -1.128 TD
[(\()74.6(n)22.1(ew)-280(d)12.2(r)0(u)16(g)12.2(s)13.1()64.7(\))-279.1(re)17.8(ce)22.1(n)12.2(t)0(l)19.3(y)-292.6(a)14.1(p)12.2(pr)16(o)12.2(v)12.2(e)0(d)-278.5(b)12.2(y)-292.6(t)12.7(h)12.2(e)-290.8(FD)20.1(A)20.6(s)-291.8(C)13.6(en)20.2(t)12.7(e)0(r)-280.9(f)0(o)22.1(r)-288.9(Dr)20.6(ug)]TJ
0 -1.1219 TD
[(Ev)22.6(al)20.7(ua)20.2(ti)19.3(o)12.2(n)-292.6(a)14.1(n)0(d)-280.4(R)13.6(es)15(e)14.1(a)0(r)17.8(c)0(h)-278.5(\()0(C)23.4(D)0(E)21.1(R)0(\))17.3(.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Material/Methods:)Tj
/F4 1 Tf
8.3897 0 TD
[(Subjects)-328.7(sex,)-320.3(race,)-325.9(and)-321.2(age)-325.4(\()]TJ
/F2 1 Tf
12.0298 0 TD
(<)Tj
/F4 1 Tf
.4451 0 TD
[(65)-323.1(years,)]TJ
/F2 1 Tf
-21.8645 -1.1219 TD
()Tj
/F4 1 Tf
.7195 0 TD
[(65)-353.6(years\),)-359.7(and)-351.7(presence)-359.7(of)-356(sex-based)-354.6(analyses)-357.8(were)-359.8(assessed)]TJ
-.7195 -1.128 TD
[(from)-461.4(sponsors)-465.4(nal)-457.7(clinical)-467.7(study)-461.9(reports)-458.6(for)-462(new)-462.9(oncology)]TJ
0 -1.1219 TD
[(drugs)-300.2(approved)-303.3(between)-300.1(January)-302.5(1)-298.7(and)-302.9(November)-298.2(10,)-298.7(2015.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Results:)Tj
/F4 1 Tf
3.701 0 TD
[(Se)17.3(v)12.2(e)0(n)-205.4(N)0(D)21.4(A)0(s)-207.9(a)0(n)20.2(d)-213.4(1)-213.4(B)0(L)17.9(A)-214.9(we)18.7(re)-201.6(ap)20.2(pr)16(o)12.2(v)12.2(e)0(d)14.1(,)-213.4(b)12.2(u)12.2(t)-219(t)12.7(h)12.2(e)-217.6(B)0(L)17.9(A)]TJ
-4.7009 -1.1219 TD
[(wa)18.7(s)-249.1(e)14.1(xc)14.1(l)12.7(u)12.2(de)20.2(d)-250(b)12.2(ec)16(au)20.2(s)13.1(e)-248.1(it)-236.7(h)12.2(a)0(d)-242(a)-242(p)0(e)20.2(d)0(i)18.8(a)0(t)14.6(r)0(i)22.6(c)-248.1(i)12.7(n)0(d)18.3(i)12.7(ca)16(t)12.7(i)0(o)18.8(n)0(.)-237.7(A)-245.4(to)18.9(t)12.7(a)0(l)-241.5(o)12.2(f)-246.2(1)12.2(57)]TJ
26.9984 71.9468 TD
[(tr)16.5(i)12.7(a)0(l)14.6(s)-151.6(\(p)22.1(ha)20.2(se)15(s)-151.6(1)12.2(,)-152.4(2)0(,)-146.3(a)0(n)20.2(d)-152.4(3)12.2(\))-154.8(i)12.7(n)0(c)14.1(l)12.7(u)12.2(d)0(i)18.8(n)0(g)-146.3(1)12.2(2)12.2(,)0(6)18.3(5)12.2(4)-152.4(s)0(u)19.2(b)12.2(je)14.6(ct)20.7(s)-151.6(w)0(e)18.7(r)0(e)-146.8(e)0(x)20.2(a)0(m)20.7(i)0(n)18.8(e)0(d)20.2(.)]TJ
0 -1.128 TD
[(Ov)16.8(er)17.8(al)20.7(l,)-267.7(5)12.2(2)12.2(.)0(2)18.3(%)-276.7(o)12.2(f)-276.7(s)13.1(u)12.2(bj)18.8(ec)16(t)12.7(s)-273.5(we)18.7(re)-268.7(wo)22.9(me)14.6(n)12.2(,)-274.4(6)12.2(6)0(.)18.3(1)12.2(%)-276.7(w)0(e)18.7(r)0(e)-262.6(C)0(a)15.5(u)12.2(ca)16(s)13.1(i)0(a)14.6(n)12.2(,)]TJ
0 -1.1219 TD
[(an)14.1(d)-396.3(2)0(0)18.3(.)12.2(9%)-392.5(we)18.7(re)]TJ
/F2 1 Tf
7.2557 0 TD
()Tj
/F4 1 Tf
.7134 0 TD
-.0129 Tc
[(65)-415.3(ye)-12.9(ar)-12.9(s)10(.)-415.3(W)-12.9(o)7.3(me)-12.9(n)-407.3(w)-12.9(e)5.8(r)-12.9(e)-403.6(4)-.7(0)-12.9(.)5.4(8%)-12.9(,)-405.4(5)-.7(4)-12.9(.)5.4(2%)-12.9(,)-405.4(a)-12.9(n)7.3(d)]TJ
-7.969 -1.128 TD
-.0131 Tc
[(5)-13.1(7)5.2(.2)-13.1(%)-216.6(o)-13.1(f)-216.6(s)-13.1(u)6.1(b)-13.1(j)5.7(e)-13.1(cts)-225.6(i)-13.1(n)-219.8(pha)-13.1(se)-224.6(1)-13.1(,)-220.4(2,)-226.5(a)-13.1(n)7.1(d)-226.5(3)-226.5(C)-13.1(T)4.8(s)0(,)-226.5(r)-13.1(e)4.7(s)-13.1(p)6.1(e)-13.1(ctiv)-13.1(ely.)-226.5(T)-13.1(h)3.4(e)-224.6(r)-13.1(a)4.8(t)-13.1(i)6.2(o)]TJ
0 -1.1219 TD
0 Tc
[(of)-215.7(th)18.8(e)-229.8(p)12.2(ro)22.1(po)18.3(rt)22.6(io)18.8(n)-225.6(o)12.2(f)-227.9(w)0(o)16.8(m)12.8(en)-217.6(i)12.7(n)-225.6(la)20.7(te)14.6(-p)22.1(h)12.2(a)0(s)15(e)-223.7(CT)17.9(s)-224.7(t)12.7(o)-225.6(t)0(h)18.8(e)-223.7(pr)16(o)12.2(p)12.2(o)0(r)16(t)12.7(io)18.8(n)-225.6(o)12.2(f)]TJ
0 -1.128 TD
[(wo)16.8(m)12.8(e)0(n)-333.4(i)12.7(n)-341.4(d)12.2(is)19.7(ea)16(s)13.1(e)-339.5(po)18.3(p)12.2(u)0(l)18.8(a)0(t)20.7(i)0(o)18.8(n)-341.4(\(P)25.3(PR)16.8(\))-337.7(w)0(a)18.7(s)]TJ
/F2 1 Tf
16.8404 0 TD
()Tj
/F4 1 Tf
.7073 0 TD
.3414 Tc
[(0)341.4(.)359.7(8f)341.4(o)363.5(r)3.7(6N)341.4(D)362.8(A)341.4(s)11.5(a)341.4(n)361.6(d)]TJ
/F2 1 Tf
-17.5477 -1.1219 TD
0 Tc
(<)Tj
/F4 1 Tf
.5427 0 TD
[(0.)18.3(8)-182.9(f)0(o)22.1(r)-185.3(1)-176.8(N)0(D)15.3(A)0(.)-172.2(F)0(i)22.1(v)12.2(e)-187.1(N)0(D)21.4(A)0(s)-171.3(i)0(n)18.8(c)0(l)20.7(u)0(d)18.3(e)0(d)-174.9(b)12.2(o)12.2(t)0(h)-176.3(e)14.1(f)19.2(ca)16(cy)-168.8(an)14.1(d)-176.8(s)0(a)15(f)0(e)23.9(t)0(y)-176.3(s)13.1(ex)20.2(-)]TJ
-.5427 -1.128 TD
[(ba)14.1(s)13.1(e)0(d)-309(a)0(n)20.2(a)0(l)20.7(y)12.2(se)15(s)13.1(,)-317(1)-317(N)0(D)21.4(A)-318.5(in)18.8(cl)20.7(u)12.2(d)0(e)14.1(d)-310.9(on)18.3(ly)-304.3(sa)15(fe)23.9(ty)-310.4(s)13.1(e)0(x)20.2(-)0(b)16(a)0(s)21.1(e)0(d)-309(a)0(n)20.2(a)0(l)20.7(y)12.2(si)19.7(s,)]TJ
0 -1.1219 TD
[(an)14.1(d)-250(1)-250(N)0(D)21.4(A)-251.5(i)12.7(n)0(c)20.2(l)0(u)18.8(d)0(e)20.2(d)-250(on)18.3(l)12.7(y)-250(ef)17.8(c)17.3(ac)22.1(y)-250(s)0(e)15(x)12.2(-b)22.1(as)15(ed)-242(a)14.1(n)0(a)14.1(l)12.7(y)12.2(s)0(i)19.7(s)0(.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Conclusions:)Tj
/F4 1 Tf
6.0728 0 TD
[(Relative)-582.7(to)-578.7(their)-584.7(proportion)-576.6(of)-581.6(the)-582.9(disease)]TJ
-7.0727 -1.1219 TD
[(population,)-337.8(female)-337(representation)-342.1(was)-334(comparable)-341.1(to)-334.8(\(PPR)-335.9(be-)]TJ
0 -1.128 TD
[(tween)-241(0.8)-231.6(and)-235.8(1.2\))-234(or)-234(greater)-236.2(than)-235.3(mens)-236.8(in)-231.1(late)-239(phase)-233.1(trials)-235.8(for)-236.4(6)]TJ
0 -1.1219 TD
[(of)-221.8(the)-223.1(7)-213.4(oncology)-223(drugs)-220.9(we)-219.1(examined.)-218.7(Participation)-222.4(of)-221.8(women)-218.5(in)]TJ
0 -1.128 TD
[(early-phase)-428.5(CTs)-420.3(was)-425.5(lower)-422.1(than)-418.2(in)-420.1(late-phase)-425.7(CTs;)-425.8(however,)]TJ
T*
[(improvements)-214.9(have)-203.4(been)-209.5(made)-209(in)-206.7(female)-215.1(participation)-207.3(compared)]TJ
0 -1.1219 TD
[(to)-468.9(previous)-468.4(ndings.)-464.7(Late-phase)-470.7(CTs)-469(are)-468(where)-469.5(FDAs)-464.6(risk-)]TJ
0 -1.128 TD
[(benet)-303.3(assessments)-305.9(are)-297.3(typically)-305(made.)]TJ
/F3 1 Tf
0 -4.1583 TD
(30.)Tj
9.843 0 0 9.843 333.9779 519.4771 Tm
[(Do)-285.3(Forms)-279.5(of)-278.6(Addres)-9.3(s)-277.4(Reveal)-286.4(Gender)-281.7(Bias)]TJ
0 -1.1174 TD
[(in)-284.4(a)-277.6(Professional)-287.1(Setting?)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 313.0582 491.9243 Tm
[(Julia)-337.6(Files)]TJ
6.9735 0 0 6.198 351.8928 496.0629 Tm
(1)Tj
9.2982 0 0 9.2982 355.4078 491.9243 Tm
[(,)-335.3(Sharonne)-330.5(Hayes)]TJ
6.9735 0 0 6.198 422.3054 496.0629 Tm
(2)Tj
9.2982 0 0 9.2982 425.8204 491.9243 Tm
[(,)-329.2(Patricia)-339.4(Friedrich)]TJ
6.9735 0 0 6.198 497.0833 496.0629 Tm
(3)Tj
9.2982 0 0 9.2982 500.5416 491.9243 Tm
(,)Tj
-20.1634 -1.1219 TD
[(Marjorie)-340.4(Jenkins)]TJ
6.9735 0 0 6.198 376.7243 485.6314 Tm
(4)Tj
9.2982 0 0 9.2982 380.1826 481.4928 Tm
[(,)-335.3(Michael)-333.8(Bryan)]TJ
6.9735 0 0 6.198 442.0345 485.6314 Tm
(1)Tj
9.2982 0 0 9.2982 445.5495 481.4928 Tm
[(,)-335.3(Christopher)-334.7(Wittich)]TJ
6.9735 0 0 6.198 526.11 485.6314 Tm
(5)Tj
9.2982 0 0 9.2982 529.5684 481.4928 Tm
(,)Tj
-23.2852 -1.128 TD
[(Melissa)-340(Lyle)]TJ
6.9735 0 0 6.198 362.2676 475.1432 Tm
(5)Tj
9.2982 0 0 9.2982 365.7826 471.0046 Tm
[(,)-329.2(Suneela)-338(Vegunta)]TJ
6.9735 0 0 6.198 435.4015 475.1432 Tm
(6)Tj
9.2982 0 0 9.2982 438.8597 471.0046 Tm
[(,)-335.3(Ryan)-332(Melikian)]TJ
6.9735 0 0 6.198 500.7117 475.1432 Tm
(3)Tj
9.2982 0 0 9.2982 504.2267 471.0046 Tm
(,)Tj
-20.5597 -1.1219 TD
[(Trevor)-339.9(Duston)]TJ
6.9735 0 0 6.198 368.3904 464.655 Tm
(3)Tj
9.2982 0 0 9.2982 371.8487 460.5731 Tm
[(,)-335.3(Yu-Hui)-334(Chang)]TJ
6.9735 0 0 6.198 433.0771 464.655 Tm
(1)Tj
9.2982 0 0 9.2982 436.5353 460.5731 Tm
[(,)-335.3(Marcia)-336.7(Ko)]TJ
6.9735 0 0 6.198 482.8534 464.655 Tm
(1)Tj
9.2982 0 0 9.2982 486.3116 460.5731 Tm
[(,)-335.3(Anita)-333.8(Mayer)]TJ
6.9735 0 0 6.198 539.8865 464.655 Tm
(6)Tj
/F5 1 Tf
-32.5271 -2.6435 TD
(1)Tj
9.2982 0 0 9.2982 316.5731 444.1322 Tm
[(Mayo)-335.7(Clinic)-330.4(in)-334.8(Arizona,)-334.8(Scottsdale,)-335.1(Arizona)]TJ
6.9735 0 0 6.198 313.0582 437.7826 Tm
(2)Tj
9.2982 0 0 9.2982 316.5731 433.644 Tm
[(Mayo)-335.7(Clinic)-330.4(Division)-338.5(of)-334.8(Cardiovascular)-332.4(Diseases,)-335.9(Rochester,)]TJ
-.378 -1.1219 TD
(Minnesota)Tj
6.9735 0 0 6.198 313.0582 416.8629 Tm
(3)Tj
9.2982 0 0 9.2982 316.5731 412.7243 Tm
[(Arizona)-334.8(State)-332.3(University,)-340(Phoenix,)-332.7(Arizona)]TJ
6.9735 0 0 6.198 313.0582 406.3747 Tm
(4)Tj
9.2982 0 0 9.2982 316.5731 402.2928 Tm
[(Texas)-333.5(Tech)-334.4(University)-340(Health)-333.8(Sciences)-338.5(Center,)-334.8(Amarillo,)]TJ
-.378 -1.128 TD
(Texas)Tj
6.9735 0 0 6.198 313.0582 385.455 Tm
(5)Tj
9.2982 0 0 9.2982 316.5731 381.3731 Tm
[(Mayo)-335.7(Clinic)-330.4(Rochester,)-341.3(Rochester,)-335.2(Minnesota)]TJ
6.9735 0 0 6.198 313.0582 375.0235 Tm
(6)Tj
9.2982 0 0 9.2982 316.5731 370.8849 Tm
[(Mayo)-335.7(Clinic)-330.4(Womens)-338.7(Health)-333.8(Clinic,)-336.5(Scottsdale,)-329(Arizona)]TJ
/F3 1 Tf
.6219 -2.3047 TD
(Background:)Tj
/F4 1 Tf
5.957 0 TD
[(Gender)-359.7(bias)-356.4(has)-356.9(been)-349.8(identied)-357.1(as)-357(one)-357.8(of)-349.9(the)]TJ
-6.9569 -1.1219 TD
[(drivers)-434.2(of)-423(gender)-431.4(disparity)-430.8(in)-426.2(academic)-428.4(advancement)-434.4(and)-424.8(re-)]TJ
0 -1.128 TD
[(mains)-227.8(a)-223.7(signicant)-228.2(challenge)-223(for)-224.2(women)-224.6(in)-225(the)-223.1(workplace.)-229.2(Word)]TJ
0 -1.1219 TD
[(choice)-383.9(and)-376.1(selective)-380.1(use)-381.3(of)-374.3(forms)-381.3(of)-374.2(address)-380.9(may)-375.5(reect)-383.1(con-)]TJ
0 -1.128 TD
[(scious)-306.7(or)-295(unconscious)-304.7(assumptions)-298.6(about)-302.4(gender)-297.2(roles.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.8472 0 TD
[(To)-337.1(evaluate)-338.8(the)-339(prevalence)-345.9(of)-331.6(use)-338.6(of)-337.7(a)-339.5(formal)]TJ
-6.8471 -1.128 TD
[(professional)-327.2(title)-325.2(during)-324.9(speaker)-325(introductions)-326.6(at)-320.7(Internal)-329(Med-)]TJ
0 -1.1219 TD
[(icine)-306.1(Grand)-300.6(Rounds)-296.4(\(IMGR\).)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Material/Methods:)Tj
/F4 1 Tf
8.4812 0 TD
[(We)-410.8(conducted)-414.3(a)-406.6(retrospective)-415.3(observa-)]TJ
-9.4811 -1.1219 TD
[(tional)-398.9(study)-394.8(of)-392.5(speaker)-398.1(introductions)-399.7(occurring)-396.6(at)-393.9(consecutive)]TJ
0 -1.128 TD
[(IMGR.)-257.6(We)-252.3(restricted)-258.7(the)-253.6(analysis)-255.5(to)-255.5(the)-253.6(sessions)-256.2(where)-256.1(both)-249.4(the)]TJ
0 -1.1219 TD
[(speaker)-221.3(and)-217.5(the)-217(referents)-213.3(had)-217.5(a)-217.6(doctoral)-216.9(degree)-216.1(\(MD/PhD/Pharm)]TJ
0 -1.128 TD
[(D/DMD\).)-334.6(We)-331.5(recorded)-334.3(gender)-333.8(and)-333.4(credentials)-333.7(of)-331.6(speakers)-336.3(and)]TJ
0 -1.1219 TD
[(referents.)-298.7(We)-294.9(reported)-299.1(the)-290.2(frequency)-297.7(counts)-295.4(and)-290.7(percentages)-296.2(of)]TJ
0 -1.128 TD
[(referents)-365.7(that)-356.8(were)-365.9(called)-359.1(and)-357.8(were)-359.8(not)-359.2(called)-365.1(by)-353.6(their)-359.1(profes-)]TJ
T*
[(sional)-301(titles.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Results:)Tj
/F4 1 Tf
3.7803 0 TD
[(A)-342.9(total)-344(of)-343.8(321)-341.4(forms)-338.6(of)-343.8(address)-344.3(between)-342.7(a)-345.6(speaker)]TJ
-4.7802 -1.128 TD
[(and)-309(a)-303(referent)-311.8(were)-304.9(analyzed.)-308.8(Female)-307(speakers)-305.8(\(FS\))-303.1(were)-311(more)]TJ
0 -1.1219 TD
[(likely)-344(to)-334.8(use)-338.6(a)-339.5(professional)-339.4(title)-337.4(when)-334.9(introducing)-340.2(any)-339.5(referent)]TJ
0 -1.128 TD
[(male)-251.2(\(MR\))-252.4(or)-252.3(female)-251.6(\(FR\))-250(during)-245.6(the)-253.6(rst)-247.7(form)-248(of)-252.3(address)-252.8(when)]TJ
0 -1.1219 TD
[(compared)-331.4(to)-322.6(male)-330.5(speakers)-330.2(\(MS\).)-323.7(\(FS)-325.1(96.2%)-325.4(\(102/106\))-327.2(vs)-322.3(MS)]TJ
0 -1.128 TD
[(65.6%)-343.7(\(141/215\);)-332.7(p)]TJ
/F2 1 Tf
7.9873 0 TD
(<)Tj
/F4 1 Tf
.5548 0 TD
[(0.001\))-337.6(Female)-337.5(dyads)-344.7(\(FS)-337.3(introducing)-340.2(FR\))]TJ
-8.5422 -1.1219 TD
[(utilized)-274.5(formal)-270(titles)-269.5(during)-270(the)-271.9(rst)-266(form)-272.4(of)-270.6(address)-271.1(97.8%)-264.4(\(45/)]TJ
0 -1.128 TD
[(46\))-264.5(compared)-258.2(to)-261.6(male)-263.4(dyads)-259.3(\(MS)-260.4(introducing)-260.9(MR\))-256.1(who)-263.6(utilized)]TJ
0 -1.1219 TD
[(a)-309.1(formal)-312.7(title)-307(72.4%)-307.1(\(110/152\))-308.9(of)-307.2(the)-308.5(time)-307.4(\(p)]TJ
/F2 1 Tf
18.3769 0 TD
(=)Tj
/F4 1 Tf
.5488 0 TD
[(0.007\).)-307.1(In)-307.2(mixed)]TJ
-18.9257 -1.128 TD
[(gender)-346(dyads)-344.7(where)-347.5(the)-345.1(speaker)-349.4(was)-346.2(female)-343.1(and)-345.6(referent)-348.3(male)]TJ
0 -1.1219 TD
[(\(FS)-355.6(introduces)-356.3(MR\),)-359.8(formal)-355.3(titles)-354.9(were)-353.7(used)-356.9(95.0%)-355.9(\(57/60\))-351.6(of)]TJ
0 -1.128 TD
[(the)-229.2(time.)-228.2(Male)-232.6(speakers)-226.5(introducing)-230.4(female)-227.3(referents)-231.6(utilized)-225.7(the)]TJ
0 -1.1219 TD
[(professional)-302.9(title)-300.8(49.2%)-301(\(31/63\))-302.8(of)-295(the)-302.4(time.)-301.3(\(p)]TJ
/F2 1 Tf
19.0354 0 TD
(<)Tj
/F4 1 Tf
.5487 0 TD
(0.001\).)Tj
/F3 1 Tf
8.9663 0 0 8.9663 62.022 749.6502 Tm
(A-12)Tj
48.6864 0 TD
(ABSTRACTS)Tj
ET
endstream
endobj
236 0 obj
<>stream
/GS1 gs
BT
/F3 1 Tf
9.2982 0 0 9.2982 69.0519 725.5557 Tm
0 0 0 rg
0 Tc
0 Tw
(Conclusions:)Tj
/F4 1 Tf
5.8228 0 TD
[(We)-337.6(report)-337.6(the)-339(rst)-339.1(study)-333.9(to)-334.8(examine)-340.7(the)-332.9(asso-)]TJ
-6.8228 -1.128 TD
[(ciation)-311.6(between)-318.3(gender)-309.4(and)-309(address)-313.8(practices)-315.9(during)-306.6(formal)-312.6(in-)]TJ
0 -1.1219 TD
[(troductions)-558.8(of)-557.2(participants)-560.6(at)-558.5(IMGR.)-562.5(In)-557.2(this)-559(study,)-559.5(women)]TJ
0 -1.128 TD
[(introduced)-271.7(by)-268.2(men)-271.9(at)-265.8(IMGR)-269.8(were)-268.3(less)-270.2(likely)-270.8(to)-267.7(be)-272.4(addressed)-269.2(by)]TJ
0 -1.1219 TD
[(their)-218.9(professional)-211.4(title)-215.5(than)-217(were)-213.4(men)-217(introduced)-210.8(by)-213.3(men.)-217(Subtle,)]TJ
0 -1.128 TD
[(yet)-278(pervasive)-275.6(practices)-273.3(can)-276.6(negatively)-273.1(impact)-275(a)-272.5(womans)-274.8(career)]TJ
0 -1.1219 TD
[(trajectory)-302.2(and)-302.9(her)-299.2(satisfaction)-303.7(with)-305.3(her)-299.2(career.)-301.9(Unequal)-301.9(address)]TJ
0 -1.128 TD
[(practices)-407.4(may)-406(amplify)-407.3(the)-406.1(issues)-403.4(of)-404.7(isolation,)-403.5(marginalization)]TJ
0 -1.1219 TD
[(and)-418.8(professional)-412.6(discomture)-419.5(expressed)-415.5(by)-414.6(women)-413.6(faculty)-418.1(in)]TJ
0 -1.128 TD
[(academic)-306.4(medicine.)]TJ
/F3 1 Tf
0 -3.6034 TD
(31.)Tj
9.843 0 0 9.843 80.674 597.8833 Tm
[(Marital)-282.1(Satisfa)-7.4(ction,)-280.7(Sexual)-278.3(Dysfunction)-284.3(and)]TJ
0 -1.1116 TD
[(Obsessive-Compulsive)-292.7(Disorder)-283.7(\(OCD\):)]TJ
T*
[(The)-281.8(Neglected)-286.1(Links)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 59.7543 559.4456 Tm
[(Firoozeh)-336.1(Raisi)]TJ
6.9735 0 0 6.198 115.1433 563.5274 Tm
(1)Tj
9.2982 0 0 9.2982 118.6582 559.4456 Tm
[(,)-329.2(Habibollah)-337.4(Ghassemzadeh)]TJ
6.9735 0 0 6.198 224.4472 563.5274 Tm
(1)Tj
9.2982 0 0 9.2982 227.9621 559.4456 Tm
(,)Tj
-18.0904 -1.128 TD
[(Narges)-340.6(Karamghadiri)]TJ
6.9735 0 0 6.198 144.1133 553.0959 Tm
(1)Tj
9.2982 0 0 9.2982 147.5716 548.9573 Tm
[(,)-335.3(Alipasha)-337.1(Meysamie)]TJ
6.9735 0 0 6.198 228.0755 553.0959 Tm
(2)Tj
9.2982 0 0 9.2982 231.5338 548.9573 Tm
(,)Tj
-18.4745 -1.1219 TD
[(Reihaneh)-339.8(Firoozikhojastefar)]TJ
6.9735 0 0 6.198 166.4503 542.6077 Tm
(3)Tj
9.2982 0 0 9.2982 169.9653 538.5258 Tm
[(,)-335.3(Maryam)-332.4(Sorayani)]TJ
6.9735 0 0 6.198 243.1558 542.6077 Tm
(1)Tj
9.2982 0 0 9.2982 246.6708 538.5258 Tm
(,)Tj
-20.1024 -1.128 TD
[(Abbas)-334(Ali)-335.8(Nasehi)]TJ
6.9735 0 0 6.198 127.4456 532.1762 Tm
(4)Tj
9.2982 0 0 9.2982 130.9606 528.0377 Tm
[(,)-329.2(Jalil)-337.1(Fallah)]TJ
6.9735 0 0 6.198 178.4125 532.1762 Tm
(5)Tj
9.2982 0 0 9.2982 181.8708 528.0377 Tm
[(,)-335.3(Narges)-334.5(Ebrahimkhani)]TJ
6.9735 0 0 6.198 269.5747 532.1762 Tm
(6)Tj
/F5 1 Tf
-30.0882 -2.6526 TD
(1)Tj
9.2982 0 0 9.2982 63.2693 511.5967 Tm
[(Roozbeh)-334.3(Psychiatric)-334.2(Hospital,)-334.3(Tehran)-335.3(University)-333.9(of)-334.8(Medical)]TJ
-.378 -1.1219 TD
[(Sciences)-338.5(\(TUMS\),)-334.5(Tehran,)-335.3(Iran)]TJ
6.9735 0 0 6.198 59.7543 494.8156 Tm
(2)Tj
9.2982 0 0 9.2982 63.2693 490.677 Tm
[(Medical)-332.8(Faculty,)-338.4(Tehran)-329.2(University)-340(of)-334.8(Medical)-332.8(Sciences,)]TJ
-.378 -1.1219 TD
[(Tehran,)-335.3(Iran)]TJ
6.9735 0 0 6.198 59.7543 473.8959 Tm
(3)Tj
9.2982 0 0 9.2982 63.2693 469.7574 Tm
[(Psychosexual)-339.4(Department)-332.5(of)-334.8(Roozbeh)-334.3(Psychiatry)-334.7(Hospital,)]TJ
-.378 -1.128 TD
[(Tehran,)-335.3(Iran)]TJ
6.9735 0 0 6.198 59.7543 452.9763 Tm
(4)Tj
9.2982 0 0 9.2982 63.2693 448.8376 Tm
[(Iran)-330.7(Helal)-339.9(Institute)-332.8(of)-334.8(Applied)-334.1(Science)-333.3(&)-334.8(Technology,)]TJ
-.378 -1.128 TD
[(Tehran,)-335.3(Iran)]TJ
6.9735 0 0 6.198 59.7543 432.0566 Tm
(5)Tj
9.2982 0 0 9.2982 63.2693 427.918 Tm
[(Department)-338.6(of)-328.7(health,)-332.3(National)-338.4(Organization)-333.3(for)-333.9(Civil)]TJ
-.378 -1.128 TD
[(Registration,)-337.4(Tehran,)-335.3(Iran)]TJ
6.9735 0 0 6.198 59.7543 411.1369 Tm
(6)Tj
9.2982 0 0 9.2982 63.2693 406.9983 Tm
[(Bahonar)-330.1(Hospital,)-334.3(Alborz)-334.8(University)-340(of)-328.7(Medical)-338.9(Sciences,)]TJ
-.378 -1.128 TD
[(Alborz,)-334.8(Iran)]TJ
/F3 1 Tf
.9999 -2.2986 TD
(Background:)Tj
/F4 1 Tf
5.9509 0 TD
[(Although)-347.8(OCD)-349.1(has)-350.8(major)-346.9(impact)-348.2(on)-347.5(familial,)]TJ
-6.9508 -1.128 TD
[(occupational,)-234.6(social)-225.9(and)-229.7(interpersonal)-228.1(functions,)-224(there)-229.7(are)-230.2(sparse)]TJ
0 -1.1219 TD
[(clinical)-297(research)-301.1(on)-292.6(the)-296.3(correlation)-296.1(between)-294(marital)-295.2(satisfaction)]TJ
0 -1.128 TD
[(and)-302.9(OCD.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Objective\(s\):)Tj
/F4 1 Tf
6.024 0 TD
[(This)-506.5(study)-516.8(assesses)-514.3(the)-509.7(correlation)-515.6(between)]TJ
-7.024 -1.128 TD
[(sexual)-305.7(dysfunction)-297.1(and)-302.9(marital)-301.3(satisfaction)-303.7(in)-298.2(OCD)-300.3(patients)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Material/Methods:)Tj
/F4 1 Tf
8.408 0 TD
[(Samples)-344.6(consisted)-340.9(of)-337.7(56)-335.3(\(36)-337.6(female,)-343.1(20)]TJ
-9.408 -1.1219 TD
[(male\))-223.1(married)-213.2(OCD)-221(patients)-219.3(\(18)-215.7(and)-217.5(50)-213.3(years)-217.1(old\))-215.2(referred)-223.2(to)-212.8(the)]TJ
0 -1.128 TD
[(Outpatient)-257.7(Clinic)-257.3(of)-252.3(Roozbeh)-256.9(Psychiatric)-259.2(Hospital)-253.2(and)-260.2(3)-250(private)]TJ
0 -1.1219 TD
[(psychiatric)-250.2(clinics)-249.8(in)-243.3(Tehran)-244.2(since)-250.9(2011)-243.8(to)-243.3(2013.)-249.9(Questionnaires)]TJ
0 -1.128 TD
[(including:)-239.8(FSFI,)-230.4(IIEF,)-235(MOCI,)-239.3(OCI-R,)-235.1(Demographic)-234.7(and)-235.8(Marital)]TJ
0 -1.1219 TD
[(Satisfaction)-307.4(questionnaire.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Results:)Tj
/F4 1 Tf
3.6461 0 TD
[(A)-214.9(signicant)-209.9(correlation)-216.8(was)-212.1(found)-209.5(between)-208.6(washing)]TJ
-4.6461 -1.1219 TD
[(subscale)-376.1(of)-368.2(MOCI)-367.4(and)-370(marital)-374.4(satisfaction.)-370.8(Also,)-372(sexual)-366.7(func-)]TJ
0 -1.128 TD
[(tions)-280.8(scores)-283.3(in)-279.9(female)-282.1(\(arousal,)-279.9(lubrication,)-276.8(sexual)-281.3(satisfaction,)]TJ
0 -1.1219 TD
[(pain)-308.5(and)-309(total)-307.5(scores\))-310.1(and)-309(marital)-307.4(satisfactions)-311.3(score)-308.6(were)-311(sig-)]TJ
0 -1.128 TD
[(nicant)-436.9(and)-437(correlation)-436.3(between)-440.3(IIEF/FSFI)-434.4(and)-437(marital)-435.4(satis-)]TJ
0 -1.1219 TD
[(faction)-302.3(was)-303.6(satisfactory.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Conclusions:)Tj
/F4 1 Tf
5.6948 0 TD
[(OCD)-208.8(seems)-207.3(to)-206.7(have)-209.5(an)-205.4(effect)-211.9(on)-207.3(sexual)-208.1(function)]TJ
-6.6947 -1.1219 TD
[(and)-455.3(marital)-447.6(satisfaction)-456.1(through)-452.9(avoidance,)-449(compulsions,)-451.9(im-)]TJ
0 -1.128 TD
[(paired)-376(intimacy.)-372(Therefore,)-375(assessment)-373.8(of)-368.2(sexual)-372.8(function)-377.3(and)]TJ
0 -1.1219 TD
[(marital)-307.4(satisfaction)-297.6(should)-303.4(be)-296.8(considered)-306.1(in)-298.2(these)-299.6(patients.)]TJ
/F3 1 Tf
0 -3.6034 TD
(32.)Tj
9.843 0 0 9.843 80.674 121.9464 Tm
[(The)-281.8(Impact)-284.9(of)-278.6(Pain)-282(on)-278.5(BMI,)-286.3(Exercise,)]TJ
0 -1.1116 TD
[(and)-279.4(Weight)-285.3(History)-280.7(on)-284.3(African-American)]TJ
0 -1.1174 TD
[(Breast)-286.2(Cancer)-281.5(Survivors)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 59.7543 83.4519 Tm
[(Sherilyn)-337.5(Francis)]TJ
6.9735 0 0 6.198 121.833 87.5905 Tm
(1)Tj
9.2982 0 0 9.2982 125.348 83.4519 Tm
[(,)-329.2(Selina)-339.4(Smith)]TJ
6.9735 0 0 6.198 179.433 87.5905 Tm
(2)Tj
9.2982 0 0 9.2982 182.948 83.4519 Tm
[(,)-335.3(Lee)-333.4(Caplan)]TJ
6.9735 0 0 6.198 231.9306 87.5905 Tm
(3)Tj
9.2982 0 0 9.2982 235.4456 83.4519 Tm
(,)Tj
-18.8952 -1.1219 TD
[(Ernest)-336.2(Alema-Mensah)]TJ
6.9735 0 0 6.198 144.1133 77.159 Tm
(4)Tj
/F5 1 Tf
-12.0971 -2.6526 TD
(1)Tj
9.2982 0 0 9.2982 63.2693 56.5795 Tm
[(Morehouse)-332(School)-338.9(of)-328.7(Medicine,)-336.9(Atlanta,)-335.5(Georgia)]TJ
6.9735 0 0 6.198 310.8472 729.6943 Tm
(2)Tj
9.2982 0 0 9.2982 314.3054 725.5557 Tm
[(Institute)-338.9(of)-328.7(Public)-334.2(and)-335.3(Preventative)-337.4(Health,)-333.8(Department)-338.6(of)]TJ
-.3719 -1.128 TD
[(Family)-335.7(Medicine,)-330.9(Georgia)-339.5(Regents)-331.9(University,)-340(Augusta,)]TJ
0 -1.1219 TD
(Georgia)Tj
6.9735 0 0 6.198 310.8472 698.2864 Tm
(3)Tj
9.2982 0 0 9.2982 314.3054 694.1478 Tm
[(Community)-340(Health)-333.8(and)-329.2(Preventative)-337.4(Medicine,)-337(Morehouse)]TJ
-.3719 -1.1219 TD
[(School)-332.8(of)-334.8(Medicine,)-330.9(Atlanta,)-335.5(Georgia)]TJ
6.9735 0 0 6.198 310.8472 677.3667 Tm
(4)Tj
9.2982 0 0 9.2982 314.3054 673.2281 Tm
[(Clinical)-336(Research)-335.8(Center)-334.8(&)-334.8(R-Center)-339(Biomedical)-333.2(Informatics)]TJ
-.3719 -1.1219 TD
[(Unit,)-329.6(Morehouse)-338.1(School)-332.8(of)-334.8(Medicine,)-330.9(Atlanta,)-335.5(Georgia)]TJ
/F3 1 Tf
.9999 -2.3047 TD
(Background:)Tj
/F4 1 Tf
6.0606 0 TD
[(African-American)-470.7(\(AA\))-458.8(breast)-466.6(cancer)-464.2(survi-)]TJ
-7.0605 -1.128 TD
[(vors)-275.8(are)-272.9(dying)-273.7(at)-278(higher)-274.2(rates)-277.6(than)-271.9(Caucasians.)-281.3(This)-274.8(disparity)-272.3(in)]TJ
0 -1.1219 TD
[(mortality)-266(may)-271.9(be)-266.3(remedied)-269.9(by)-268.2(interventions)-269.8(focusing)-267.2(on)-268.2(health-)]TJ
0 -1.128 TD
[(related)-300.4(quality)-301.3(of)-301.1(life)-298.2(factors)-304.3(\(HRQoL\).)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.835 0 TD
[(In)-325.5(this)-327.3(study,)-321.7(we)-328.8(assessed)-332.2(the)-326.8(associations)-325.4(be-)]TJ
-6.8349 -1.128 TD
[(tween)-375.1(pain)-369.4(and)-376.1(BMI,)-372(exercise,)-371.3(and)-376.1(weight)-370.4(history)-372.3(among)-375.5(AA)]TJ
0 -1.1219 TD
[(breast)-302(cancer)-299.6(survivors.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Material/Methods:)Tj
/F4 1 Tf
9.1458 0 TD
[(Study)-1081.4(participants)-1078.9(\(n)]TJ
/F2 1 Tf
10.0116 0 TD
(=)Tj
/F4 1 Tf
.5487 0 TD
[(175,)-1079.1(mean)]TJ
-20.7061 -1.1219 TD
(age)Tj
/F2 1 Tf
1.3963 0 TD
(=)Tj
/F4 1 Tf
.5488 0 TD
[(56.8)-268.2(years\))-268.3(completed)-267(a)-272.5(survey)-267.8(assessing)-266.5(demographic)-269.8(and)]TJ
-1.945 -1.128 TD
[(HRQoL)-387.5(factors.)-389.7(The)-390.1(study)-382.6(population)-386.6(was)-388.9(compared)-392.3(to)-383.6(a)-388.3(na-)]TJ
0 -1.1219 TD
[(tional)-563.5(population)-569.5(using)-565.6(NHIS)-569.1(data)-562.7(\(n)]TJ
/F2 1 Tf
16.4075 0 TD
(=)Tj
/F4 1 Tf
.5487 0 TD
[(432,)-566.9(mean)-568.8(age)]TJ
/F2 1 Tf
6.4569 0 TD
(=)Tj
/F4 1 Tf
.5488 0 TD
(66.5)Tj
-23.962 -1.128 TD
[(years\).)-329.2(Bivariate)-329(and)-333.4(multivariate)-328.8(modeling)-331.7(was)-327.9(used)-332.5(to)-328.7(assess)]TJ
0 -1.1219 TD
[(the)-296.3(relationship)-306.4(between)-300.1(the)-302.4(pain)-302.4(and)-296.8(outcome)-299.9(variables.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Results:)Tj
/F4 1 Tf
4.0119 0 TD
[(Study)-575.4(participants)-572.8(reported)-579.5(lower)-574.5(pain)-576.8(intensity)]TJ
-5.0119 -1.1219 TD
[(scores)-411.4(than)-412.1(the)-412.2(NHIS)-410.6(population)-411(\(2.1)-416.9(vs.)-407.6(3.2,)-414.5(p)]TJ
/F2 1 Tf
20.0719 0 TD
(<)Tj
/F4 1 Tf
.5548 0 TD
[(0.01\).)-410.8(There)]TJ
-20.6268 -1.128 TD
[(were)-201.2(no)-201.1(population)-203.7(differences)-205.3(in)-200.6(pain)-198.7(interference)-209.8(\(p)]TJ
/F2 1 Tf
21.578 0 TD
(>)Tj
/F4 1 Tf
.8841 0 TD
[(0.05\).)-197.4(A)]TJ
-22.462 -1.1219 TD
[(large)-491.9(portion)-495.1(of)-496.2(both)-493.3(populations)-495.5(were)-493.9(overweight)-498.8(or)-490.1(obese)]TJ
0 -1.128 TD
[(\(72.3%)-461.9(vs.)-456.4(65.3%,)-465.6(p)]TJ
/F2 1 Tf
9.097 0 TD
(>)Tj
/F4 1 Tf
.8841 0 TD
[(0.05\).)-465.6(Although)-457.6(72.67%)-465.6(of)-459.6(the)-460.9(study)]TJ
-9.9811 -1.1219 TD
[(participants)-249.7(reported)-250.3(regular)-244.2(participation)-250(in)-249.4(exercise,)-249.4(compared)]TJ
0 -1.128 TD
[(to)-347(24.0%)-355.9(of)-349.9(the)-351.2(NHIS)-349.6(population)-356.1(\(p)]TJ
/F2 1 Tf
14.9747 0 TD
(<)Tj
/F4 1 Tf
.5548 0 TD
[(0.001\),)-349.8(the)-351.2(study)-352.2(partici-)]TJ
-15.5295 -1.128 TD
[(pants)-234.4(reported)-238.1(fewer)-234.1(days)-235(and)-235.8(minutes)-239.5(of)-234(exercise)-237.2(\(2.11)-234(days)-235(vs.)]TJ
0 -1.1219 TD
[(3.5)-396.2(days,)-399.6(p)]TJ
/F2 1 Tf
4.6278 0 TD
(<)Tj
/F4 1 Tf
.5487 0 TD
[(0.001;)-395.7(33.30)-402.3(minutes)-398(vs.)-395.4(46.1)-396.2(minutes,)-398(p)]TJ
/F2 1 Tf
17.1514 0 TD
(<)Tj
/F4 1 Tf
.5548 0 TD
(0.001\).)Tj
-22.8828 -1.128 TD
[(More)-225.1(of)-227.9(the)-229.2(study)-230.2(population)-222(attempted)-229.9(to)-231.1(lose)-228.4(weight)-230.2(following)]TJ
0 -1.1219 TD
[(diagnosis)-239.1(and)-235.8(treatment)-238.4(\(67.8%)-242.4(vs.)-236.9(30.4%,)-233.9(p)]TJ
/F2 1 Tf
17.8343 0 TD
(<)Tj
/F4 1 Tf
.5548 0 TD
[(0.001\).)-233.9(Within)-240.3(the)]TJ
-18.3891 -1.128 TD
[(study)-376.5(population,)-374.4(pain)-375.5(intensity)-379.2(\(odds)-373.3(ratio)]TJ
/F2 1 Tf
17.8282 0 TD
(=)Tj
/F4 1 Tf
.5548 0 TD
[(3.7,)-371.8(p)]TJ
/F2 1 Tf
2.3718 0 TD
(<)Tj
/F4 1 Tf
.5548 0 TD
[(0.001\))-374.2(and)]TJ
-21.3097 -1.1219 TD
[(pain)-204.8(interference)-209.8(\(odds)-202.6(ratio)]TJ
/F2 1 Tf
11.2066 0 TD
(=)Tj
/F4 1 Tf
.5487 0 TD
[(3.3,)-207.2(p)]TJ
/F2 1 Tf
2.2072 0 TD
(<)Tj
/F4 1 Tf
.5487 0 TD
[(0.01\))-203.5(were)-207.3(associated)-209(with)-207.7(a)]TJ
-14.5113 -1.128 TD
[(lack)-337.1(of)-337.7(exercise.)-334.8(Within)-337.9(the)-339(NHIS)-337.4(population)-331.7(there)-339.4(was)-340.1(an)-333.4(as-)]TJ
0 -1.1219 TD
[(sociation)-280.2(between)-275.7(pain)-284.1(intensity)-275.5(and)-278.5(BMI)-280.5(\(p)]TJ
/F2 1 Tf
17.9806 0 TD
(<)Tj
/F4 1 Tf
.5548 0 TD
[(0.05\).)-276.6(There)-280.8(were)]TJ
-18.5355 -1.128 TD
[(no)-317(associations)-319.3(between)-318.3(pain)-320.7(intensity)-312.1(or)-319.4(pain)-320.7(interference)-319.6(and)]TJ
0 -1.1219 TD
[(weight)-297.2(history)-305.2(\(p)]TJ
/F2 1 Tf
7.2739 0 TD
(>)Tj
/F4 1 Tf
.8841 0 TD
(0.05\).)Tj
/F3 1 Tf
-7.1581 -1.128 TD
(Conclusions:)Tj
/F4 1 Tf
5.7862 0 TD
[(AA)-307.8(breast)-302(cancer)-305.7(survivors)-301.1(may)-308.5(not)-298.2(engage)-305.2(in)]TJ
-6.7862 -1.1219 TD
[(the)-259.7(recommended)-261.8(physical)-262.5(activity)-268.4(frequencies)-263.9(because)-259.8(of)-264.5(pain.)]TJ
0 -1.128 TD
[(These)-204.4(results)-204.9(suggest)-203.1(that)-204.3(interventions)-202.8(which)-200.2(assess)-206.1(pain)-204.8(among)]TJ
0 -1.1219 TD
[(AA)-301.7(breast)-302(cancer)-299.6(survivors)-301.1(are)-303.4(urgently)-298.1(needed.)]TJ
/F3 1 Tf
0 -2.9876 TD
(33.)Tj
9.843 0 0 9.843 331.7668 268.3842 Tm
[(Colorectal)-280.6(Cancer)-287.3(Screening)-284.9(Among)-283.8(Privately)]TJ
0 -1.1116 TD
[(Insured)-279.9(Post-ACA)-288.8(by)-278.5(Sex)-280.8(and)-279.4(Race)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 310.8472 240.8881 Tm
[(Idalid)-334.7(Franco)]TJ
6.9735 0 0 6.198 361.5873 245.0267 Tm
(1)Tj
9.2982 0 0 9.2982 365.0456 240.8881 Tm
[(,)-335.3(Mark)-334.9(Ommerborn)]TJ
6.9735 0 0 6.198 439.1999 245.0267 Tm
(2)Tj
9.2982 0 0 9.2982 442.7148 240.8881 Tm
[(,)-335.3(Therese)-332.9(Fitzgerald)]TJ
6.9735 0 0 6.198 518.6266 245.0267 Tm
(1)Tj
9.2982 0 0 9.2982 522.1416 240.8881 Tm
(,)Tj
-22.7242 -1.128 TD
[(Amy)-330.1(Glynn)]TJ
6.9735 0 0 6.198 355.7479 234.5385 Tm
(1)Tj
/F5 1 Tf
-6.4388 -2.6526 TD
(1)Tj
9.2982 0 0 9.2982 314.3054 213.959 Tm
[(Harvard)-339.2(Medical)-332.8(School/Brigham)-334.1(&)-334.8(Womens)-332.6(Hospital,)]TJ
-.3719 -1.1219 TD
[(Connors)-332.1(Center)-334.8(for)-333.9(Womens)-332.6(Health,)-333.8(Boston,)-335.7(Massachusetts)]TJ
6.9735 0 0 6.198 310.8472 197.1779 Tm
(2)Tj
9.2982 0 0 9.2982 314.3054 193.0393 Tm
[(Brigham)-337.2(&)-334.8(Womens)-332.6(Hospital,)-334.3(Center)-334.8(for)-333.9(Community)-333.9(Health)]TJ
-.3719 -1.1219 TD
[(and)-329.2(Health)-333.8(Equity,)-334.2(Boston,)-335.7(Massachusetts)]TJ
/F3 1 Tf
.9999 -2.3047 TD
(Background:)Tj
/F4 1 Tf
6.0545 0 TD
[(Th)22.6(e)-443.2(A)0(C)18.2(A)0()20.6(s)-444.2(re)23.9(mo)18.9(v)12.2(a)0(l)-430.5(o)0(f)-435.2(c)0(o)20.2(s)13.1(t)-444.6(s)13.1(ha)20.2(ri)16.5(n)12.2(g)-439(fo)16(r)-441.3(p)12.2(re)17.8(-)]TJ
-7.0545 -1.128 TD
[(v)12.2(e)0(n)20.2(t)12.7(iv)18.8(e)-309.1(s)0(e)15(r)15.9(vi)18.8(ce)22.1(s)-316.2(a)14.1(mo)18.9(n)12.2(g)-310.9(pr)16(i)12.7(v)12.2(at)20.7(el)20.7(y)-310.9(i)0(n)18.8(s)13.1(ur)22.1(ed)-302.9(se)21.1(ek)20.2(s)-316.2(t)12.7(o)-310.9(a)0(d)20.2(d)12.2(re)17.9(s)13.1(s)-316.2(n)21.6(a)14.1(n)0(-)]TJ
0 -1.1219 TD
[(c)14.1(i)0(a)20.7(l)-682.4(b)12.2(a)14.1(rr)19.7(ie)20.7(rs)-666.1(in)-670.1(a)14.1(c)0(c)16(e)14.1(ss)20(in)18.9(g)-676.8(t)12.7(i)12.7(m)0(e)20.7(l)0(y)-670.1(c)14.1(ar)17.8(e.)-668.8(P)15.4(r)0(i)16.5(o)12.2(r)-673(s)0(t)19.7(u)12.2(di)18.8(es)-667.9(fo)22.1(u)12.2(n)12.2(d)]TJ
0 -1.128 TD
[(d)12.2(i)12.7(sp)19.2(ar)17.8(i)12.7(t)12.7(i)0(e)20.7(s)-285.7(i)12.7(n)-280.4(co)20.2(l)12.7(o)12.2(re)17.8(ct)20.7(al)-271.9(ca)22.1(nc)20.2(er)-274.8(\(C)23.4(RC)21.1(\))-282.8(t)12.7(es)21.1(ti)19.3(n)12.2(g)-280.4(bu)18.3(t)-279.9(n)12.2(o)12.2(n)0(e)-272.4(e)0(x)20.2(a)0(m)20.7(i)12.7(ne)20.2(d)]TJ
0 -1.1219 TD
[(t)12.7(h)12.2(e)-211.5(e)0(f)17.8(f)0(e)17.8(c)14.1(ti)19.3(v)12.2(e)0(n)20.2(e)0(s)21.1(s)-212.5(o)12.2(f)-209.6(th)18.8(e)-211.5(A)0(C)18.2(A)-208.8(o)12.2(n)-213.4(p)12.2(r)0(i)22.6(v)12.2(at)14.6(e)14.1(l)0(y)-200.6(i)12.7(ns)19.2(u)12.2(r)0(e)17.8(d)-207.3(by)-201.1(se)21.1(x)-213.4(a)0(n)20.2(d)-207.3(ra)17.8(ce)22.1(.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.9021 0 TD
[(To)-398.1(understand)-399.4(the)-393.9(barriers)-398.1(to)-395.8(CRC)-398.2(testing)-398(in)]TJ
-6.902 -1.1219 TD
[(privately)-301.8(insured)-297.7(individuals)-299.9(post)-303.4(ACA)-300.3(by)-298.7(sex)-302.1(and)-302.9(race.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Material/Methods:)Tj
/F4 1 Tf
8.5056 0 TD
[(We)-435.2(used)-436.2(2013)-438.9(Behavioral)-439.2(Risk)-436.2(Factor)]TJ
-9.5055 -1.1219 TD
[(Surveillance)-447.1(System)-444.1(survey)-444.6(to)-438.4(evaluate)-448.6(CRC)-447(testing)-440.7(rates)-448.3(of)]TJ
0 -1.128 TD
[(privately)-460.3(insured)-462.4(patients)-463.2(by)-457.2(race)-460(and)-461.4(sex.)-460.6(CRC)-459.2(testing)-465.1(was)]TJ
0 -1.1219 TD
[(dened)-486.7(by)-481.6(USPSTF)-484.2(recommendations.)-485.5(Multivariable)-486.9(logistic)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 59.7543 749.7069 Tm
(ABSTRACTS)Tj
52.6193 0 TD
(A-13)Tj
ET
endstream
endobj
240 0 obj
<>stream
/GS1 gs
BT
/F4 1 Tf
9.2982 0 0 9.2982 62.022 725.5557 Tm
0 0 0 rg
0 Tc
0 Tw
[(regression)-522.9(models)-520.5(estimated)-521.7(associations)-520.5(between)-525.6(covariates)]TJ
0 -1.128 TD
[(and)-302.9(CRC)-300.7(testing.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Results:)Tj
/F4 1 Tf
3.7742 0 TD
[(Thirty-nine)-338.3(states)-340.9(asked)-342.8(about)-338.9(insurance)-342.7(type,)-339(with)]TJ
-4.7741 -1.128 TD
[(142,641)-353.5(of)-349.9(respondents)-355.9(privately)-350.5(insured.)-352.6(Adjusted)-351.2(for)-352.2(covari-)]TJ
0 -1.1219 TD
[(ates)-287.5(Whites)-286.9(who)-281.9(had)-284.6(low)-287.5(income)-281.6(\(OR)-289(0.58,)-280.4(95%CI)-283.7(0.450.75\),)]TJ
0 -1.128 TD
[(less)-203.1(than)-198.7(high)-200.6(school)-203.9(education)-200.4(\(OR)-203.6(0.55)-201.1(95%CI)-198.3(0.360.85\),)-203.3(ve)]TJ
0 -1.1219 TD
[(or)-301.1(more)-298.6(years)-302.5(since)-299.6(last)-301(check-up)-301.4(\(OR)-301.2(0.21,)-298.7(95%CI)-295.9(0.150.30\))]TJ
0 -1.128 TD
[(and)-254.1(did)-249.4(not)-255.5(have)-252.2(a)-254.2(personal)-253.2(doctor)-255.9(\(OR)-252.4(0.59,)-249.9(95%CI)-253.2(0.470.74\))]TJ
0 -1.1219 TD
[(were)-311(less)-306.8(likely)-307.4(to)-304.3(have)-307.1(CRC)-306.8(testing.)-306.5(Blacks)-310.4(who)-306.3(were)-311(in)-304.3(poor)]TJ
0 -1.128 TD
[(health)-342.6(\(OR)-337.8(3.02,)-341.3(95%)-337.6(CI)-342.4(1.138.09\))-337.5(were)-347.6(more)-335.2(likely)-344(to)-340.9(have)]TJ
0 -1.1219 TD
[(CRC)-245.8(testing.)-239.5(Hispanics)-244.8(with)-244.3(ve)-244.8(or)-240.1(more)-243.8(years)-241.5(since)-244.8(last)-246.2(check-)]TJ
0 -1.128 TD
[(up)-304.8(\(OR)-313.4(0.01,)-304.8(95%CI)-308.1(0.010.09\))-307(and)-302.9(dissatised)-311.9(with)-305.3(care)-313.7(\(OR)]TJ
0 -1.1219 TD
[(0.07,)-323.1(95%)-319.3(CI)-324.1(0.010.44\))-319.2(were)-323.2(less)-319(likely)-325.7(to)-322.6(have)-319.3(CRC)-325(testing.)]TJ
0 -1.128 TD
[(Men)-228.9(\(OR)-228(0.46,)-231.6(95%CI)-228.8(0.340.63\))-227.7(and)-229.7(women)-224.6(\(OR)-234.1(0.66,)-225.5(95%CI)]TJ
T*
[(0.480.91\))-209.5(who)-208.7(did)-206.7(not)-206.7(have)-209.5(a)-205.4(personal)-210.5(doctor)-207.1(were)-213.4(less)-209.2(likely)-209.9(to)]TJ
0 -1.1219 TD
[(have)-301(CRC)-300.7(testing.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Conclusions:)Tj
/F4 1 Tf
5.9204 0 TD
[(Disparities)-429(by)-432.8(socioeconomic)-428.8(status)-434.3(and)-424.8(pat-)]TJ
-6.9203 -1.1219 TD
[(terns)-358.8(of)-362.1(care)-362.5(seeking)-354.5(are)-364.4(still)-356.8(apparent)-361.9(in)-359.2(privately)-362.7(insured)-358.7(in-)]TJ
0 -1.128 TD
[(dividuals.)-647.9(Further)-645.3(research)-648.6(is)-651(needed)-646.6(to)-645.7(better)-649.9(understand)]TJ
0 -1.1219 TD
[(disparities)-354.4(by)-347.5(subpopulations)-348.2(among)-351.1(privately)-350.5(insured)-346.5(and)-351.7(can)]TJ
0 -1.128 TD
[(be)-382.2(more)-384(fully)-385.4(understood)-383(by)-384.1(looking)-382.9(at)-387.8(factors)-383.6(beyond)-382.1(socio-)]TJ
0 -1.1219 TD
[(economic)-426(status)-422.1(including)-423.2(regular)-421(source)-424.4(of)-423(care,)-423.4(satisfaction)]TJ
0 -1.128 TD
[(with)-299.2(care,)-301.5(and)-302.9(health)-300(status.)]TJ
/F3 1 Tf
0 -3.0364 TD
(34.)Tj
9.843 0 0 9.843 82.9417 467.1495 Tm
[(Listening)-282.5(to)-278.6(Women:)-286.2(Expectations)]TJ
0 -1.1116 TD
[(and)-279.4(Experiences)-289.3(in)-278.6(Breast)-286.2(Imaging)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 62.022 439.6534 Tm
[(Aimee)-338(Gallagher)]TJ
6.9735 0 0 6.198 126.822 443.7353 Tm
(1)Tj
9.2982 0 0 9.2982 130.2803 439.6534 Tm
[(,)-335.3(Susan)-335.4(Harvey)]TJ
6.9735 0 0 6.198 188.3905 443.7353 Tm
(2)Tj
/F5 1 Tf
-18.1212 -2.6526 TD
(1)Tj
9.2982 0 0 9.2982 65.537 423.2125 Tm
[(Society)-334.6(for)-333.9(Womens)-332.6(Health)-333.8(Research)-335.8(\(SWHR\),)-333.4(Washington,)]TJ
-.378 -1.128 TD
[(District)-337.2(of)-334.8(Columbia)]TJ
6.9735 0 0 6.198 62.022 406.3747 Tm
(2)Tj
9.2982 0 0 9.2982 65.537 402.2928 Tm
[(Johns)-332.5(Hopkins)-333.4(Medical)-332.8(Institutions,)-333.2(Lutherville,)-341.6(Maryland)]TJ
/F3 1 Tf
.6219 -2.3047 TD
(Background:)Tj
/F4 1 Tf
6.3716 0 TD
[(Women)-769.9(may)-771.9(have)-770.5(misconceptions)-770.7(about)]TJ
-7.3715 -1.128 TD
[(mammography)-240.7(which)-249(impact)-238.5(breast)-247.1(cancer)-244.7(screening)-245.2(behaviors.)]TJ
0 -1.1219 TD
[(Screening)-383(mammography)-380.9(has)-381.3(been)-380.3(shown)-378.6(to)-383.6(reduce)-380.7(mortality)]TJ
0 -1.128 TD
[(20%)-380.3(in)-383.6(women)-383.1(\(aged)-382.6(4074\),)-380.2(demonstrating)-385.6(its)-382.2(effectiveness.)]TJ
0 -1.1219 TD
[(Understanding)-296.7(womens)-299.2(views)-296.9(on)-298.7(mammography)-295.5(may)-302.4(assist)-299.3(in)]TJ
0 -1.128 TD
[(understanding)-392.8(how)-385.5(to)-389.7(improve)-389.5(utilization,)-389.3(early)-394.3(detection)-389(and)]TJ
0 -1.1219 TD
[(therefore)-305.6(impact)-299.4(survival.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.9631 0 TD
[(To)-459.1(assess)-462.2(womens)-457.7(knowledge)-460.4(and)-455.3(attitudes)]TJ
-6.963 -1.1219 TD
[(t)12.7(o)0(w)16.8(a)14.1(rd)16(s)-310.1(m)12.8(am)20.8(m)12.8(o)12.2(gr)16(a)14.1(p)12.2(hy)18.3(,)-310.9(i)12.7(n)12.2(c)0(l)20.7(u)0(d)18.3(i)12.7(n)12.2(g)-310.9(mi)19.4(s)13.1(c)0(o)20.2(n)12.2(ce)16(p)12.2(t)12.7(io)18.9(n)12.2(s)0(,)-297.9(b)0(a)20.2(r)0(r)19.7(i)0(e)20.7(r)0(s)16.8(,)-304.8(mo)18.9(-)]TJ
0 -1.128 TD
[(t)12.7(i)0(v)18.8(a)0(t)20.7(o)12.2(rs)16.8(,)-286.6(a)0(n)20.2(d)-286.5(em)20.8(ot)18.8(i)12.7(o)0(n)18.3(a)14.1(l)-292.1(r)0(e)17.8(s)13.1(p)12.2(o)12.2(n)0(s)19.2(e)0(s)21.1(.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Material/Methods:)Tj
/F4 1 Tf
8.4812 0 TD
[(SWHR)-409.5(queried)-412.5(3501)-408.4(women)-413.6(of)-410.8(varied)]TJ
-9.4811 -1.128 TD
[(race/ethnicity)-215.7(in)-212.8(the)-210.9(US)-211.6(\(aged)-211.9(1893\))-215.6(in)-206.7(2014)-213.3(using)-211.9(a)-211.5(survey)-212.9(that)]TJ
0 -1.1219 TD
[(consisted)-560.4(of)-563.3(10)-560.9(eligibility)-561.4(questions)-562.2(and)-559(39)-560.9(attitudinal)-560(and)]TJ
0 -1.128 TD
[(knowledge)-216.5(questions)-214.7(about)-210.9(mammography.)-216.3(Women)-215.1(participated)]TJ
0 -1.1219 TD
[(through)-398(internet)-405.4(surveys,)-401(telephone)-401.7(interviews)-406(or)-398.6(personal)-405.6(in-)]TJ
0 -1.128 TD
[(tercepts)-305.7(in)-298.2(English)-298.6(or)-301.1(Spanish.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Results:)Tj
/F4 1 Tf
3.9083 0 TD
[(Al)23.4(th)18.8(ou)18.3(g)12.2(h)-463.4(7)12.2(8)12.2(%)-465.7(wo)22.9(me)20.7(n)-463.4(a)0(g)20.2(r)0(e)17.8(e)0(d)-449.3(t)0(h)18.9(a)0(t)-448.8(m)0(a)14.7(m)12.8(m)12.8(o)0(g)18.3(r)0(a)17.8(p)12.2(hy)]TJ
-4.9082 -1.128 TD
[(wa)18.7(s)-255.2(a)0(n)-248.1(i)12.7(mp)18.9(or)16(t)12.7(a)0(n)20.2(t)-255.6(pa)20.2(rt)-251.8(o)12.2(f)-258.4(b)12.2(r)0(e)17.8(a)14.1(st)-248.6(h)12.2(e)0(a)16(l)12.7(th)18.8(,)-256.1(o)0(n)18.3(l)12.7(y)-256.1(5)0(4)18.3(%)-258.4(re)23.9(po)18.3(rt)16.5(e)14.1(d)-256.1(ha)14.1(v)12.2(i)12.7(ng)]TJ
T*
-.0185 Tc
[(an)-524.5(annual)-524(m).4(ammogram.)-524.6(C)1.2(ost)-524(a)1.7(nd)-524.5(lack)-524.5(of)-520.8(ad)5.9(eq)5.9(uate)-522.7(in)5.9(s)-5.4(u)5.9(rance)]TJ
0 -1.1219 TD
-.0187 Tc
[(coverage)-297.3(were)-303.4(cited)-299.1(a)1.5(s)-298.3(b)-.4(arriers)-298.3(t).1(o)-293(s).5(ched)5.7(uling)-299.1(a)1.5(nd)-293(attend)5.7(ing)-299.1(m).2(am-)]TJ
0 -1.128 TD
[(mography)-305.3(appoi)6.1(ntments.)-305.4(Th)5.6(e)-309.6(m).1(ajority)-305.3(of)-301.6(wom)6.2(e)-4.7(n)-305.3(\()3.2(63%\))-307.7(w)4.1(ere)-303.5(un-)]TJ
0 -1.1219 TD
[(aware)-358.2(t).1(hat)-359.6(m).2(amm)6.2(ograph)5.7(y)-360.1(was)-365.4(a)-358.2(no-cost-to)5.7(-)-2.8(the-co)5.7(nsumer)-362.5(benet)]TJ
0 -1.128 TD
-.0191 Tc
[(under)-338.5(t)-.3(he)-340.3(Affordable)-340.3(Care)-340.3(Act)-341.7(\()-3.2(ACA\).)-336.1(M).1(otivating)-336.1(f)-3.2(actors)-341.4(f)-3.2(or)-338.5(at-)]TJ
0 -1.1219 TD
[(tending)-409.2(mammography)-409.2(appointm)5.9(e)-4.9(nts)-408.3(i)-.2(ncluded)-409.2(r)-3.1(ecommendation)5.4(s)]TJ
0 -1.128 TD
-.0188 Tc
[(from)-445(a)-449.8(h)-.5(ealthcare)-449.8(provider)-447.9(\()3.2(56%\))-447.9(o)-.5(r)-447.9(a)-449.8(remin)5.6(d)-.5(er)-447.9(at)-445.1(a)-449.8(c)1.4(heck-up)]TJ
0 -1.1219 TD
-.0184 Tc
[(\(5)6(3%\).)-347.6(Fo)6(rty-seven)-347.6(p)6(ercent)-347.1(rep)6(o)-.1(rted)-347.6(having)-347.6(received)-347.6(a)-4.3(t)-347.1(l).4(east)-353.2(o)6(ne)]TJ
0 -1.128 TD
-.0189 Tc
[(call-back)-329.8(after)-332.2(u)5.5(ndergo)5.5(i)-.1(ng)-329.8(mammography)-329.8(screening)-323.7(r)-3(oun)5.5(ds;)-329.3(w)-2.1(ith)]TJ
0 -1.1219 TD
.0113 Tc
[(furt)11.3(h)-6.4(e)1(r)-350.8(e)1(valuatio)11.3(n)-6.9(,)-348.4(89%)-344.7(of)-350.8(t)11.3(h)-6.4(e)-352.6(call-backs)-347.6(w)-2.4(ere)-352.6(d)-.9(etermined)-348.4(t)-.4(o)]TJ
0 -1.128 TD
.0119 Tc
[(be)-297.2(false)-297.2(positi)11.9(v)-5.8(e)1.6(s.)-299(Thi)11.9(s)-309.8(was)-298.2(i).2(den)11.9(t)-5.8(ied)-299(as)-298.2(a)-303.2(c)1.6(on)11.9(c)-10.6(e)1.6(rn)-299(by)-299(wom)11.9(e)-10(n)]TJ
0 -1.1219 TD
0 Tc
[(an)20.2(d)-384.1(8)12.2(2)12.2(%)-380.3(of)-374.2(re)17.8(s)13.1(p)12.2(o)12.2(n)0(d)18.3(e)0(n)20.2(t)12.7(s)-383.2(w)0(a)18.7(n)12.2(t)12.7(e)0(d)-376.1(i)12.7(m)12.8(a)0(g)20.2(i)0(n)18.8(g)-384.1(wi)23.4(t)12.7(h)-384.1(i)12.7(m)0(p)18.9(r)0(o)22.1(v)12.2(ed)-376.1(s)13.1(p)12.2(ec)16(i)12.7(-)]TJ
0 -1.128 TD
[(c)17.3(i)12.7(t)12.7(y)12.2(.)-304.8(I)0(n)16(c)14.1(re)17.8(a)14.1(s)0(e)15(d)-304.8(s)13.1(e)0(n)20.2(s)13.1(it)19.3(i)12.7(v)0(i)18.8(t)12.7(y)-304.8(i)0(n)-298.2(m)12.8(am)20.8(m)12.8(o)12.2(gr)16(a)14.1(p)12.2(hy)-298.7(wa)24.8(s)-310.1(a)14.1(ls)19.7(o)-304.8(i)12.7(de)20.2(n)12.2(t)0(i)19.3()0(e)17.3(d)]TJ
0 -1.1219 TD
[(as)-277.7(an)-284.6(i)12.7(m)12.8(p)12.2(o)0(r)16(t)12.7(an)20.2(t)-286(f)0(a)17.8(c)0(t)20.7(o)12.2(r)-288.9(f)0(o)22.1(r)-288.9(81)18.3(%)-288.9(o)12.2(f)-288.9(w)0(o)16.8(m)12.8(en)20.2(.)]TJ
/F3 1 Tf
27.9983 71.9468 TD
(Conclusions:)Tj
/F4 1 Tf
5.7923 0 TD
[(Barriers)-305.3(and)-302.9(motivators)-308.3(regarding)-305.1(mammogra-)]TJ
-6.7923 -1.128 TD
[(phy)-463.3(were)-469.5(identied.)-460.8(Misconceptions)-465.5(about)-460.9(costs)-465.3(and)-467.5(lack)-459(of)]TJ
0 -1.1219 TD
[(adequate)-229.6(coverage)-232.5(may)-223.1(be)-229.8(overcome)-227.7(by)-225.5(educating)-224.8(women)-230.7(about)]TJ
0 -1.128 TD
[(ACA)-397.9(coverage.)-397.1(Healthcare)-395.7(providers)-393.9(recommendations)-394(moti-)]TJ
0 -1.1219 TD
[(vated)-459(women)-450.2(to)-450.6(have)-453.4(a)-455.4(mammogram,)-453.6(identifying)-455.5(a)-449.3(provider)]TJ
0 -1.128 TD
[(education)-322.4(opportunity.)-317.6(Educating)-313.9(women)-322.1(about)-314.6(newer)-317.1(technol-)]TJ
0 -1.1219 TD
[(ogies)-399.1(may)-393.8(reduce)-392.9(the)-393.9(anxiety)-391.4(associated)-398.1(with)-390.6(this)-394.4(testing)-398(and)]TJ
0 -1.128 TD
[(improve)-304.2(outcomes.)]TJ
/F3 1 Tf
0 -3.6034 TD
(35.)Tj
9.843 0 0 9.843 333.9779 618.803 Tm
[(Use)-281.6(of)-284.4(Social)-278.6(Media)-285.4(and)-279.4(Text)-283(Messaging)]TJ
0 -1.1116 TD
[(Outreach)-283.9(in)-284.4(the)-280.7(Recruitment)-283.4(of)-284.4(Millennials)]TJ
T*
[(into)-280.8(a)-283.3(Phase)-284(3)-277.6(Contraceptive)-284.5(Patch)-284.1(Study)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 313.0582 580.3652 Tm
[(Elizabeth)-335.9(Garner)]TJ
/F5 1 Tf
0 -1.7682 TD
[(Agile)-340.3(Therapeutics,)-329.6(Inc.,)-335.7(Princeton,)-337.5(New)-330.6(Jersey)]TJ
/F3 1 Tf
.9999 -2.3047 TD
(Background:)Tj
/F4 1 Tf
5.8289 0 TD
[(Recruitment)-230.9(of)-227.9(healthy)-226.8(millennials)-229.9(into)-224.5(clinical)]TJ
-6.8289 -1.128 TD
[(trials)-522.4(in)-517.7(the)-515.8(digital)-514.2(age)-520.5(can)-520.5(be)-516.3(challenging.)-516.9(Millennials)-516.1(are)]TJ
0 -1.1219 TD
[(known)-318.4(to)-316.5(rely)-316.9(on)-317(social)-317.4(media)-318.2(and)-315.1(text)-314.1(messaging)-322.5(for)-315.6(commu-)]TJ
0 -1.128 TD
[(nication)-427.4(and)-424.9(information.)-421.3(In)-423(addressing)-429.1(slower)-421.2(than)-424.3(expected)]TJ
0 -1.1219 TD
[(enrollment)-313.4(in)-310.4(the)-314.6(SECURE)-310(trial,)-309.8(a)-309(Phase)-315.2(3)-310.9(study)-309.5(of)-307.2(an)-309(investi-)]TJ
0 -1.128 TD
[(gational)-427.4(hormonal)-426.1(contraceptive)-430.2(patch,)-422.4(a)-431(digital)-422.7(social)-427.1(media)]TJ
0 -1.1219 TD
[(and)-302.9(text)-301.9(messaging)-298.2(recruitment)-307.8(campaign)-298(was)-303.6(undertaken.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.8716 0 TD
[(To)-361.5(measure)-367.1(the)-363.4(impact)-360.4(of)-362.1(a)-363.9(social)-360.1(media)-367(and)]TJ
-6.8715 -1.1219 TD
[(text)-375(messaging)-371.3(outreach)-374.1(campaign)-371.2(used)-375.2(to)-371.4(enhance)-370.3(awareness)]TJ
0 -1.128 TD
[(and)-217.5(boost)-211.9(enrollment)-215.8(in)-218.9(a)-211.5(large)-217.5(Phase)-217.6(3)-213.4(trial)-218.4(of)-209.6(an)-217.6(investigational)]TJ
0 -1.1219 TD
[(contraceptive)-308.2(patch.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Material/Methods:)Tj
/F4 1 Tf
8.7678 0 TD
.0118 Tc
[(Teu)11.8(t)-5.9(eberg)-695.4(I)3.4(ncorpo)11.8(rat)11.8(e)-4.1(d,)-695.5(a)-693.6(c)1.5(omp)11.8(a)-4.6(ny)]TJ
-9.7677 -1.1219 TD
0 Tc
[(s)-11.3(p)-12.2(e)-10.3(c)-10.3(i)-11.7(a)-10.3(l)-11.7(iz)-15.9(i)-11.7(n)-12.2(g)-219.5(i)-11.7(n)-225.6(c)-10.3(l)-11.7(i)0(n)-17.7(i)-11.7(c)-10.3(a)-10.3(l)-225.1(tr)-20.1(ia)-15.9(l)-225.1(r)-8.4(e)-16.4(c)-10.3(r)-8.4(u)-12.2(it)-17.2(i)-11.7(n)0(g)-231.6(t)-11.7(hr)-20.6(ou)-18.2(gh)-231.6(s)-11.3(o)-12.2(c)-10.3(i)0(a)-15.9(l)-225.1(m)-11.6(e)-10.3(d)-12.2(i)0(a)-229.3(a)-10.3(n)-12.2(d)]TJ
0 -1.128 TD
.0124 Tc
[(onl)12.4(ine)-467.4(a)2.1(dv)12.4(erti)12.4(sin)12.4(g)-5.8(,)-469.3(a)2.1(nd)-463.2(mPro)12.4(v)-5.8(e)-467.4(Heal)12.4(th,)-469.3(a)-467.4(com)12.4(p)-5.3(any)-469.2(f)4(o)12.4(c)-4(used)]TJ
0 -1.1219 TD
.0112 Tc
[(on)-238.8(text)-238.3(messag)11.2(i)-6.5(ng)11.2(/)-6.5(S)2.3(MS)-241.6(sy)11.2(s)-6.2(t)-.5(ems)-237.9(f)2.8(or)-241.1(recru)11.2(i)-6.5(tmen)11.2(t)-6.5(,)-238.8(were)-243(eng)11.2(a)-5.2(ged)]TJ
0 -1.128 TD
[(to)-494.8(supp)11.2(o)-7(r)2.8(t)-494.3(p)-1(atien)11.2(t)-506.5(recruitm)11.2(ent)-494.3(f)-3.3(o)11.2(r)-503.3(the)-493(S)2.3(ECURE)-496.7(t)-.5(rial.)-494.9(G)-2.5(eo)11.2(-)]TJ
0 -1.1219 TD
0 Tc
[(t)-11.7(a)-10.3(r)-14.5(g)0(e)-16.4(t)-11.7(e)-10.3(d)-12.2(,)-219.5(IRB)12.6(-a)11.7(ppro)16(ved)-199.3(ad)14.1(ver)11.8(tis)14.1(eme)16.5(nts)-199.8(for)-199.8(th)12.7(e)-211.5(s)0(t)13.6(udy)-201.1(we)12.6(re)-207.7(pl)12.7(ace)11.8(d)]TJ
0 -1.128 TD
[(on)-499.9(key)-491.9(sea)16.9(rch)-494.3(eng)14.2(ine)14.6(s)-505.2(\(us)16.8(in)12.7(g)-506(tar)18.4(get)14.6(ed)-498(key)14.1(wor)14.5(ds\),)-489.2(Fa)11.2(cebo)16(ok)12.2(,)]TJ
0 -1.1219 TD
[(Pandora,)-312.3(and)-309(Spotify.)-308.9(Interested)-308(subjects)-310.4(living)-309.3(within)-310.8(a)-309.1(set)-307.7(ra-)]TJ
0 -1.128 TD
[(dius)-224.2(to)-218.9(study)-224.1(sites)-220.9(were)-225.6(directed)-221.1(to)-218.9(the)-223.1(study)-224.1(website)-221.3(via)-223.1(targeted)]TJ
0 -1.1219 TD
[(online)-692.1(advertisements,)-692(from)-687(which)-688(a)-693.2(prequalication)-690.4(web)]TJ
0 -1.128 TD
[(screener)-380.3(could)-381.6(be)-376.1(accessed)-378.9(online)-381.1(or)-374.3(via)-375.6(SMS)-376.7(text)-381.1(messaging)]TJ
T*
[(through)-349.2(mProve)-350.2(Healths)-345.6(mCAST)-351.7(system.)-348.9(The)-347.4(prescreener)-350.3(in-)]TJ
0 -1.1219 TD
[(cluded)-428.5(5)-426.8(questions)-428.1(to)-426.2(assess)-431.7(potential)-426.9(eligibility)-427.2(for)-425.4(the)-430.4(trial.)]TJ
0 -1.128 TD
[(Potential)-368.8(subjects)-371.4(meeting)-366.5(prescreening)-367.5(criteria)-369.3(were)-365.9(provided)]TJ
0 -1.1219 TD
[(the)-345.1(option)-340.3(to)-340.9(have)-337.6(their)-340.8(contact)-340.7(information)-342(given)-338.9(to)-340.9(a)-345.6(partici-)]TJ
0 -1.128 TD
[(pating)-247(site)-240.1(in)-243.3(their)-243.3(location)-244.5(via)-241.4(a)-242(secure)-245.7(encrypted)-246(patient)-244.6(portal.)]TJ
0 -1.1219 TD
[(Weekly)-322.9(metrics)-313.1(were)-317.1(gathered,)-319.2(including)-313.4(number)-316.9(of)-319.4(hits)-315.1(to)-310.4(the)]TJ
0 -1.128 TD
[(study)-358.3(website,)-361.5(number)-353.5(of)-356(referrals,)-362(and)-351.7(conversions)-362(to)-353.1(screen-)]TJ
0 -1.1219 TD
[(ings)-309.5(at)-308.5(each)-305.2(study)-309.5(site.)-307.1(Sites)-303.9(were)-311(asked)-306.2(to)-310.4(provide)-304.7(nal)-305.3(dispo-)]TJ
0 -1.128 TD
[(sitions)-301.5(of)-301.1(all)-301.9(referrals.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Results:)Tj
/F4 1 Tf
3.9876 0 TD
[(The)-542.5(outreach)-550.9(campaign)-548(increased)-548.1(screening)-550(and)]TJ
-4.9875 -1.128 TD
[(enrollment)-471.9(for)-474.2(the)-473.1(trial)-468.4(over)-469.9(a)-473.7(2-month)-470.6(period,)-469.3(allowing)-473.5(for)]TJ
0 -1.1219 TD
[(successful)-316.6(completion)-311(of)-313.3(enrollment.)-307.3(Final)-310.8(metrics)-313.1(are)-315.6(pending)]TJ
0 -1.128 TD
[(at)-302.4(the)-302.4(time)-301.3(of)-301.1(abstract)-299.6(preparation.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Conclusions:)Tj
/F4 1 Tf
5.8411 0 TD
[(Social)-351.6(media)-354.8(and)-351.7(mobile)-350.1(technology)-354.7(outreach)]TJ
-6.841 -1.128 TD
[(platforms)-427.1(are)-419.3(highly)-425.7(effective)-422.8(tools)-418.7(to)-420.1(support)-421.6(recruitment)-423.6(of)]TJ
0 -1.1219 TD
[(healthy)-306(millennials)-303.1(into)-297.7(clinical)-303.1(trials.)]TJ
/F3 1 Tf
0 -3.6034 TD
(36.)Tj
9.843 0 0 9.843 333.9779 121.9464 Tm
[(A)-284.2(Procedure)-287.3(Curriculum)-281.2(to)-284.4(Train)]TJ
0 -1.1116 TD
[(Community-Based)-286.1(Family)-285.6(Medicine)-285.2(Residents)]TJ
0 -1.1174 TD
[(on)-284.3(Long-Acting)-279.9(Reversible)-287.2(Contraception)-289(Insertion)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 313.0582 83.4519 Tm
[(Bhavika)-335.6(Patel,)-339.4(Rose)-331.1(Ann)-336.8(Ghabour,)-331.1(Neha)-333(Sachdev,)]TJ
0 -1.1219 TD
[(Annabelle)-336.1(Dimapilis)]TJ
/F5 1 Tf
0 -1.7682 TD
[(Virtua)-335.2(Family)-335.7(Medicine,)-337(Voorhees,)-331.5(New)-336.7(Jersey)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 62.022 749.6502 Tm
(A-14)Tj
48.6864 0 TD
(ABSTRACTS)Tj
ET
endstream
endobj
244 0 obj
<>stream
/GS1 gs
BT
/F3 1 Tf
9.2982 0 0 9.2982 69.0519 725.5557 Tm
0 0 0 rg
0 Tc
0 Tw
(Background:)Tj
/F4 1 Tf
6.0423 0 TD
[(The)-432.8(use)-442.3(of)-435.2(long-acting)-435.8(reversible)-442.1(contracep-)]TJ
-7.0423 -1.128 TD
[(tives)-429(\(LARCs\))-431.1(has)-430.1(increased)-432.3(signicantly,)-428.9(yet)-424.4(the)-430.4(number)-426.6(of)]TJ
0 -1.1219 TD
[(family)-358.6(physicians)-353(providing)-354.8(these)-360.6(services)-354.1(remains)-356.3(low)-354.6(\(1,)-355.9(3\).)]TJ
0 -1.128 TD
[(This)-421.1(leads)-421.6(to)-414.1(barriers)-422.5(in)-420.1(accessing)-423(LARCs)-420.3(for)-419.3(many)-418.2(women,)]TJ
0 -1.1219 TD
[(especially)-227.7(adolescents.)-227.3(Family)-224.9(physicians)-225(who)-227(train)-225(in)-225(residency)]TJ
0 -1.128 TD
[(programs)-653.7(where)-652.4(LARC)-652.9(insertions)-649.4(are)-650.9(routinely)-651.2(performed)]TJ
0 -1.1219 TD
[(are)-327.8(more)-323(comfortable)-326.6(and)-321.2(more)-329.1(likely)-319.6(to)-328.7(continue)-324.3(these)-324(proce-)]TJ
0 -1.128 TD
[(dures)-310.5(in)-304.3(their)-310.3(practice)-304.6(\(3,)-307.2(4\),)-307.2(yet)-308.5(many)-302.4(community-based)-310.5(fami-)]TJ
0 -1.1219 TD
[(ly)-578.7(medicine)-578(residencies)-577.2(do)-573.1(not)-572.6(include)-580.4(LARC)-573.6(insertion)-577.2(in)]TJ
0 -1.128 TD
(curriculum.)Tj
/F3 1 Tf
.9999 -1.1219 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.9813 0 TD
[(The)-469.4(objectives)-473.4(of)-471.8(this)-473.6(curriculum)-468.7(are)-474.1(to)-468.9(in-)]TJ
-6.9813 -1.128 TD
[(crease)-317(the)-320.7(number)-310.8(of)-313.3(LARC)-317.5(insertions)-314.1(performed)-319.7(at)-314.6(a)-315.1(commu-)]TJ
0 -1.1219 TD
[(nity-based)-325.8(family)-322(medicine)-321.9(residency)-324.4(and)-321.2(increase)-322.6(the)-320.7(comfort)]TJ
0 -1.128 TD
[(level)-293.9(of)-288.9(resident)-295.3(physicians)-286(in)-292.1(discussing)-293.1(and)-290.7(inserting)-290.6(LARCs.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Material/Methods:)Tj
/F4 1 Tf
8.7007 0 TD
[(Dedicated,)-639.1(mandatory)-631.5(training)-632.9(work-)]TJ
-9.7006 -1.1219 TD
.0161 Tc
[(shops)-233(w)-3.7(ere)-238.1(h)-2.2(eld)-240(o)3.9(n)-233.9(N)-3.7(explanon)-233.9(a)-6.4(n)3.9(d)-233.9(I)-4.5(UD)-235.4(ins)4.8(e)-.3(rtion)-233.9(f)1.6(or)-236.2(residents)]TJ
0 -1.128 TD
.0166 Tc
[(and)-404.1(f)2.1(aculty.)-398(A)-405.6(p)4.4(rocedure)-402.2(c).2(omm)]TJ
13.737 0 TD
[(ittee)-402.3(of)-400.5(res)5.2(i)-1.3(dent)-403.7(and)-398.1(f)-4.1(aculty)]TJ
-13.737 -1.1219 TD
.0174 Tc
[(champ)5.2(i)-.4(on)5.2(s,)-439.9(nu)5.2(rs)6.1(es)-445.1(an)5.2(d)-439.9(M)0(As)-439(devel)5.7(oped)-439.9(o)5.2(fce)-438(prot)5.7(ocol)5.7(s)-439(f)-3.2(o)5.2(r)]TJ
0 -1.128 TD
[(schedu)5.2(lin)5.2(g,)-336.2(p)5.2(e)1(rformi)5.7(ng)-336.2(an)5.2(d)-336.2(b)-.9(il)5.7(lin)5.2(g)-336.2(L)-2.7(ARC)-334.8(i)-.4(n)5.2(s)0(ert)5.7(i)-.4(on)5.2(.)-336.2(G)-2.4(radu)5.2(a-)]TJ
0 -1.1219 TD
.0164 Tc
[(tion)-282.3(r)1.9(equireme)-6.1(nts)-281.5(w)2.7(ere)-280.5(u)4.2(pdated)-282.3(to)-276.2(include)-280.5(LAR)5.6(C)-281(insertion)-282.3(a)0(s)]TJ
0 -1.128 TD
.0159 Tc
[(a)-305.3(r)1.4(equired)-301.1(p)-2.4(rocedure.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
0 Tc
(Results:)Tj
/F4 1 Tf
3.829 0 TD
[(Five)-390.6(insertions)-387.3(were)-396.3(performed)-386.7(since)-391.1(implementa-)]TJ
-4.829 -1.128 TD
[(tion)-303.8(of)-301.1(the)-302.4(curriculum)-304.1(in)-298.2(October)-304.3(2015.)-304.7(The)-298.7(electronic)-304.1(medical)]TJ
0 -1.1219 TD
[(record)-263(will)-256(be)-254.2(used)-259.3(to)-255.5(track)-254.1(insertion)-260.1(numbers)-255(for)-260.8(two)-250.9(years.)-259.8(An)]TJ
0 -1.128 TD
[(anonymous)-289.2(baseline)-291.1(survey)-292.2(was)-291.4(sent)-289.3(to)-286(18)-292.6(residents,)-288.4(12)-286.5(alumni)]TJ
0 -1.1219 TD
[(and)-248(5)-250(faculty)-247.4(members)-246.5(regarding)-250.3(overall)-247.4(comfort)-245.6(and)-248(likelihood)]TJ
0 -1.128 TD
[(of)-392.5(providing)-391.4(insertions)-387.3(in)-389.7(practice.)-396.1(Currently,)-390.5(40%)-386.4(of)-392.5(respon-)]TJ
0 -1.1219 TD
[(de)20.2(nt)18.8(s)-212.5(r)0(e)17.8(p)12.2(o)12.2(r)0(t)16.5(e)14.1(d)-219.5(b)12.2(ei)20.7(n)12.2(g)-219.5()64.7()0(v)22.1(e)14.1(ry)16()64.7()-215.7(o)12.2(r)-215.7()64.7()0(m)22.6(o)0(s)19.2(t)12.7(ly)18.8()64.7()-215.7(l)12.7(i)0(k)18.8(e)0(l)20.7(y)-213.4(to)-206.7(p)12.2(r)0(o)22.1(v)0(i)18.8(d)12.2(e)-217.6(L)0(A)21.1(R)0(C)]TJ
0 -1.128 TD
[(in)18.8(s)13.1(e)0(r)17.8(t)12.7(io)18.9(n)-359.7(i)12.7(n)-359.7(t)0(h)18.8(e)0(i)20.7(r)-362.1(p)12.2(r)0(a)23.9(c)0(t)20.7(i)0(c)20.7(e)-363.9(an)20.2(d)-359.7(5)12.2(0)12.2(%)-362(re)23.9(po)18.3(rt)22.6(ed)-351.7(b)12.2(e)0(i)20.7(n)12.2(g)-359.7()64.7(m)16.5(o)12.2(s)13.1(tl)19.3(y)12.2()64.7()-362.1(o)12.2(r)]TJ
0 -1.1219 TD
[()64.7()0(v)16(e)14.1(ry)22.1()58.6()-374.3(co)20.2(m)12.8(f)0(o)22.1(r)0(t)22.6(a)0(b)20.2(l)0(e)-369.5(d)12.2(i)12.7(s)0(c)15(u)12.2(s)13.1(s)0(i)19.7(n)12.2(g)-378(L)0(A)21.1(R)0(C)21.1(s)13.1(.)-378(T)0(h)22.6(e)-382.2(s)13.1(u)12.2(rv)22.1(ey)-370(wi)23.4(l)12.7(l)-377.5(be)-370(re)23.9(-)]TJ
0 -1.128 TD
[(pe)20.2(at)20.7(ed)-272.4(a)14.1(t)-279.9(th)18.8(e)-278.6(e)0(n)20.2(d)-280.4(o)12.2(f)-276.7(th)18.8(e)-278.6(n)12.2(ex)20.2(t)-279.9(t)12.7(wo)-269.7(ac)16(a)14.1(d)12.2(em)20.8(ic)-271.9(y)12.2(e)0(a)16(r)15.9(s)-279.6(f)0(o)22.1(r)-282.8(co)20.2(m)12.8(p)12.2(ar)17.8(i)12.7(s)0(o)19.2(n)]TJ
0 -1.1219 TD
[(an)20.2(d)-292.6(a)14.1(na)20.2(ly)18.8(s)13.1(i)0(s)19.7(.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Conclusions:)Tj
/F4 1 Tf
6.0972 0 TD
[(Current)-604.4(comfort)-611.4(level)-604.8(with)-610.1(discussing)-604(and)]TJ
-7.0971 -1.1219 TD
[(performing)-479.5(LARC)-476.1(insertions)-478.7(in)-475(family)-474.4(medicine)-480.4(residents)-477.4(is)]TJ
0 -1.128 TD
[(low.)-586.2(With)-582.3(procedure)-584.2(training)-584.1(and)-583.4(regular)-585.6(opportunities)-582.7(for)]TJ
0 -1.1219 TD
[(LARC)-329.7(insertions,)-320.2(resident)-325.8(comfort)-324.8(level)-324.4(and)-327.3(numbers)-322.1(of)-325.5(inser-)]TJ
0 -1.128 TD
[(tions)-302.9(are)-303.4(expected)-302.7(to)-298.2(increase.)]TJ
/F3 1 Tf
0 -4.0546 TD
(37.)Tj
9.843 0 0 9.843 80.674 311.244 Tm
[(Comparative)-287(Analysis)-280.1(of)-284.4(Inpatient)-281.2(Costs)]TJ
0 -1.1116 TD
[(for)-280.9(Obstetrics)-286(and)-279.4(Gynecology)-285.3(Surgery)-281.6(Patients)]TJ
0 -1.1174 TD
[(Treated)-288.5(with)-281.7(Intravenous)-284.3(\(IV\))-281.5(Acetaminophen)-284.2(Plus)]TJ
0 -1.1116 TD
[(Opioids)-273.6(or)-268.3(IV)-267.8(Opioids)-267.9(Alone)-272.5(for)-263.6(Postop)-7.4(erative)-270.5(Pain)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 59.7543 261.8078 Tm
[(Ryan)-338.1(Hansen)]TJ
6.9735 0 0 6.198 110.4378 265.9464 Tm
(1)Tj
9.2982 0 0 9.2982 113.896 261.8078 Tm
[(,)-335.3(A)0(n)-330.7(Pham)]TJ
6.9735 0 0 6.198 154.9417 265.9464 Tm
(2)Tj
9.2982 0 0 9.2982 158.4566 261.8078 Tm
[(,)-335.3(Stela)-333.3(Balaban)]TJ
6.9735 0 0 6.198 216.2267 265.9464 Tm
(2)Tj
9.2982 0 0 9.2982 219.7417 261.8078 Tm
[(,)-335.3(George)-335.3(Wan)]TJ
6.9735 0 0 6.198 273.2598 265.9464 Tm
(2)Tj
/F5 1 Tf
-30.6166 -2.6526 TD
(1)Tj
9.2982 0 0 9.2982 63.2693 245.3669 Tm
[(University)-333.9(of)-334.8(Washington,)-335.6(Seattle,)-336(Washington)]TJ
6.9735 0 0 6.198 59.7543 239.0173 Tm
(2)Tj
9.2982 0 0 9.2982 63.2693 234.8787 Tm
[(Mallinckrodt)-336.9(Pharmaceuticals,)-335.6(Hazelwood,)-332(Missouri)]TJ
/F3 1 Tf
.6219 -2.2986 TD
(Background:)Tj
/F4 1 Tf
5.8289 0 TD
[(Recovery)-233(from)-223.6(obstetrics)-226.9(and)-229.7(gynecology)-227.2(\(OB/)]TJ
-6.8289 -1.128 TD
[(GYN\))-293.3(surgery)-288.4(is)-285.2(oriented)-290.1(toward)-287.9(restoring)-293.5(functional)-289.5(outcomes)]TJ
T*
[(while)-218(reducing)-217.4(length)-216.5(of)-215.7(stay)-216.2(and)-217.5(medical)-218.3(expenditures.)-214.1(Optimal)]TJ
0 -1.1219 TD
[(pain)-302.4(management)-301.7(is)-303.5(a)-296.9(key)-302.9(to)-298.2(reaching)-300.9(these)-305.7(objectives.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Objective\(s\):)Tj
/F4 1 Tf
6.0057 0 TD
[(To)-495.7(compare)-496(OB/GYN)-497.8(surgery)-495.7(patients)-499.8(who)]TJ
-7.0057 -1.1219 TD
[(received)-518.5(combination)-512.2(IV)-509.9(acetaminophen)-513.1(\(IV-APAP\))-513.4(and)-510.2(IV)]TJ
0 -1.128 TD
[(opioid)-468.3(analgesia)-478.2(to)-468.9(those)-466.1(who)-470.9(received)-469.7(IV)-473.3(opioids)-467.5(alone)-471.2(on)]TJ
0 -1.1219 TD
[(length)-301.8(of)-301.1(stay)-301.5(\(LOS\))-297.4(and)-302.9(hospitalization)-301.1(costs.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Material/Methods:)Tj
/F4 1 Tf
8.6031 0 TD
[(Retrospective)-539.6(analysis)-529.9(of)-532.8(the)-534.1(Premier)]TJ
-9.6031 -1.1219 TD
[(database)-509.2(\(between)-503.6(January)-503.7(2009-June)-505.5(2015\))-502.2(comparing)-503.4(OB/)]TJ
0 -1.128 TD
[(GYN)-461.7(surgery)-465.2(patients)-463.2(who)-458.7(received)-463.6(perioperative)-464.9(pain)-460.9(man-)]TJ
0 -1.1219 TD
[(agement)-407.8(with)-408.9(combination)-408.6(IV-APAP)-405(and)-406.6(IV)-406.2(opioids)-406.5(to)-401.9(those)]TJ
0 -1.128 TD
[(who)-263.6(received)-262.4(only)-255.5(IV)-259.9(opioids)-260.2(starting)-260.1(on)-256(the)-259.7(day)-260.2(of)-258.4(surgery)-264(and)]TJ
0 -1.1219 TD
[(continuing)-356.1(up)-353.6(to)-353.1(the)-351.2(second)-355(post-operative)-356.2(day.)-357.8(OB/GYN)-351.5(sur-)]TJ
0 -1.128 TD
[(gery)-323.5(\(caesarean)-321.6(section/total)-319.4(hysterectomy\))-325.7(patients)-316.8(were)-323.2(iden-)]TJ
0 -1.1219 TD
[(tied)-377.9(using)-376.5(common)-374.9(procedural)-376.4(terminology)-376.2(and)-376.1(international)]TJ
27.0045 71.9468 TD
[(classication)-485.2(of)-484(diseases)-485(version)-480.6(9)-487.7(procedure)-480.6(codes.)-483(Among)]TJ
0 -1.128 TD
[(those)-490.5(subjects,)-487.2(the)-491.4(receipt)-489.4(of)-490.1(IV-APAP)-490.4(and)-491.9(IV)-485.5(opioids)-491.8(was)]TJ
0 -1.1219 TD
[(identied)-399.8(using)-407(service)-403.7(records)-402.4(and)-406.6(patients)-402.2(who)-403.8(received)-408.8(IV)]TJ
0 -1.128 TD
[(non-steroidal)-370.3(anti-inammatory)-370.5(drugs)-367.2(were)-372(excluded)-371.7(from)-370(the)]TJ
0 -1.1219 TD
[(IV)-296.5(opioids)-302.8(group.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Results:)Tj
/F4 1 Tf
3.9205 0 TD
[(We)-483.9(identied)-485.2(225,142)-481.5(OB/GYN)-485.6(surgery)-483.5(patients)]TJ
-4.9204 -1.1219 TD
[(with)-311.4(89,568)-310.8(\(40%\))-305.7(who)-312.4(had)-309(received)-317.3(IV-APAP.)-307.5(Subjects)-314.1(aver-)]TJ
0 -1.128 TD
[(aged)-264.4(36)-262.1(years)-259.8(of)-264.5(age)-264.5(and)-260.2(were)-262.2(predominantly)-264.5(Caucasian)-263.9(\(60%\).)]TJ
0 -1.1219 TD
[(Majority)-260.1(of)-264.5(subjects)-267.7(ranked)-266.7(in)-261.6(the)-259.7(minor)-263.4(or)-264.5(moderate)-269.9(categories)]TJ
0 -1.128 TD
[(for)-242.5(both)-243.3(severity)-240.5(of)-240.1(illness)-244.7(and)-241.9(risk)-244.8(of)-240.1(mortality)-247.7(\(APR-DRG)-240.9(SOI)]TJ
0 -1.1219 TD
[(and)-248(ROM,)-243.1(respectively\).)-250.6(Unadjusted)-251.7(LOS)-243.9(for)-248.6(IV-APAP)-246.5(was)-248.7(3.1)]TJ
0 -1.128 TD
.0187 Tc
[(days)-425.5(\(S.D.)-426.4(2.7\))-428.7(com)-5.1(p).4(ared)-426.4(to)-426.4(3.3)-426.4(days)-425.5(\(S.D.)-426.4(3.0\))-422.6(wi)-5.2(th)-426.4(only)]TJ
0 -1.1219 TD
[(IV)-342.5(opi)-5.2(oids,)-347.1(a)-345.2(st)-5.2(at)-5.2(isti)-5.2(call)-5.2(y)-341(s)1.3(i)-5.2(gnicant)-346.6(d).4(ifference)-345.2(o).4(f)-343.4(0.2)-5.7(0)-341(d).4(ays)]TJ
0 -1.128 TD
0 Tc
(\(p)Tj
/F2 1 Tf
.8292 0 TD
(<)Tj
/F4 1 Tf
.5548 0 TD
[(0.0001\).)-288.8(Unadjusted)-288.3(hospitalization)-288.9(costs)-288.5(were)-286.6($9,043)-286.4(\(S.D.)]TJ
-1.3841 -1.128 TD
[($7,564\))-301(for)-309.5(IV-APAP)-301.4(and)-309($9,546)-304.7(\(S.D.)-305.4($8,653\))-301(for)-303.4(IV)-308.7(opioids,)]TJ
0 -1.1219 TD
[(also)-527.1(signicantly)-526.4(lower)-531.8(by)-524.3($503)-530.4(\(p)]TJ
/F2 1 Tf
15.3161 0 TD
(<)Tj
/F4 1 Tf
.5548 0 TD
[(0.0001\).)-526.6(Differences)-530(in)]TJ
-15.871 -1.128 TD
[(hospitalization)-532.8(costs)-532.4(remained)-538.2(statistically)-531.5(signicant)-533.1(in)-536(our)]TJ
0 -1.1219 TD
[(instrumental)-440(variable)-434.5(models,)-441.2(with)-439.4(IV-APAP)-435.5(associated)-440.7(w)-25.9(i)-30(t)-23.9(h)]TJ
0 -1.128 TD
.0295 Tc
[($)5.1(4)-1(8)5.1(4)-244.8(lo)5.1(wer)-247.2(h)5.1(os)6(p)5.1(ita)7(li)5.6(zati)5.6(o)5.1(n)-250.9(c)7(os)6(ts)-244(\(95)5.1(%)-247.2(C)6.5(I)-3.3(:)]TJ
/F2 1 Tf
18.2611 0 TD
0 Tc
(-)Tj
/F4 1 Tf
.7439 0 TD
.0242 Tc
[($)-6.3(760)-256.2(to)]TJ
/F2 1 Tf
3.6095 0 TD
0 Tc
(-)Tj
/F4 1 Tf
.7439 0 TD
.0244 Tc
[($2)-6.1(08,)]TJ
-23.3583 -1.1219 TD
0 Tc
(p)Tj
/F2 1 Tf
.5244 0 TD
(=)Tj
/F4 1 Tf
.5792 0 TD
.0247 Tc
[(0.)-5.8(00)-5.8(06\).)]TJ
/F3 1 Tf
-.1037 -1.128 TD
0 Tc
(Conclusions:)Tj
/F4 1 Tf
5.7009 0 TD
[(Compared)-209.9(to)-212.8(opioids)-217.5(alone,)-209(managing)-214.5(post-OB/)]TJ
-6.7008 -1.1219 TD
[(GYN)-333.7(surgery)-331.1(pain)-332.9(with)-329.6(the)-332.9(addition)-331.8(of)-331.6(IV-APAP)-331.9(is)-333.9(associated)]TJ
0 -1.128 TD
[(with)-299.2(decreased)-302.9(hospitalization)-301.1(costs.)]TJ
/F3 1 Tf
0 -5.2863 TD
(38.)Tj
9.843 0 0 9.843 331.7668 446.2298 Tm
[(Assessing)-281.8(Medical)-283.1(Student)-284.6(Competency)-286.8(in)-278.6(IPV)]TJ
0 -1.1116 TD
[(Screening)-284.9(and)-279.4(Management)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 310.8472 418.7337 Tm
[(Memoona)-311.7(Hasnain)]TJ
6.9735 0 0 6.198 381.9967 422.8156 Tm
(1)Tj
9.2982 0 0 9.2982 385.5117 418.7337 Tm
[(,)-310.9(Sonia)-317.4(Oyola)]TJ
6.9735 0 0 6.198 437.6125 422.8156 Tm
(2)Tj
9.2982 0 0 9.2982 441.1274 418.7337 Tm
[(,)-310.9(Fasika)-320.8(Alem)]TJ
6.9735 0 0 6.198 494.3054 422.8156 Tm
(1)Tj
9.2982 0 0 9.2982 497.8204 418.7337 Tm
[(,)-310.9(Talia)-320.1(Shear)]TJ
6.9735 0 0 6.198 546.4628 422.8156 Tm
(2)Tj
/F5 1 Tf
-33.7872 -2.6526 TD
(1)Tj
9.2982 0 0 9.2982 314.3054 402.2928 Tm
[(University)-340(of)-334.8(Illinois)-328.6(College)-335.1(of)-334.8(Medicine,)-336.9(Chicago,)-331.4(Illinois)]TJ
6.9735 0 0 6.198 310.8472 395.9432 Tm
(2)Tj
9.2982 0 0 9.2982 314.3054 391.8046 Tm
[(University)-340(of)-334.8(Chicago)-331.4(Pritzker)-335.8(School)-332.8(of)-334.8(Medicine,)-336.9(Chicago,)]TJ
-.3719 -1.1219 TD
(Illinois)Tj
/F3 1 Tf
.9999 -2.3047 TD
(Background:)Tj
/F4 1 Tf
6.0606 0 TD
[(Despite)-465.2(the)-460.9(recognized)-469.7(need)-459.5(for)-462(health)-464.6(pro-)]TJ
-7.0605 -1.128 TD
[(fessionals)-446(to)-444.5(competently)-449.4(assess)-450(and)-443.1(address)-447.9(health)-452.4(needs)-446.5(of)]TJ
0 -1.1219 TD
[(persons)-334(experiencing)-335(IPV,)-329.8(preparing)-335.6(physicians)-334.7(to)-334.8(address)-332.1(this)]TJ
0 -1.128 TD
[(issue)-367.7(remains)-374.6(suboptimal.)-373(The)-371.8(lack)-367.6(of)-374.3(training)-370.7(in)-365.3(IPV)-372.5(in)-371.4(U.S.)]TJ
0 -1.1219 TD
[(medical)-346.3(schools)-349.4(represents)-350.3(a)-351.7(missed)-348.9(opportunity)-342(to)-347(adequately)]TJ
0 -1.128 TD
[(prepare)-303.8(future)-301(physicians.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.8289 0 TD
[(The)-323(purpose)-322.6(of)-325.5(this)-321.2(research)-325.4(was)-321.8(to)-322.6(conduct)-324.8(a)]TJ
-6.8289 -1.128 TD
[(cross)-236.5(sectional)-241.8(study)-236.3(to)-237.2(assess)-242.7(medical)-236.6(students)-241.5(preparedness)-239.1(to)]TJ
0 -1.1219 TD
[(screen)-367.7(for)-370.5(and)-370(address)-374.8(the)-369.5(needs)-367.2(of)-368.2(persons)-370.6(who)-373.3(have)-368.1(experi-)]TJ
0 -1.128 TD
[(enced)-299.1(IPV.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Material/Methods:)Tj
/F4 1 Tf
8.3471 0 TD
[(An)-245.3(online)-240.9(survey)-237.3(was)-242.6(administered)-243.6(to)-243.3(all)]TJ
-9.347 -1.128 TD
[(medical)-163.4(students)-165.9(at)-162.2(two)-165.5(LCME)-166(accredited)-168.6(medical)-163.4(schools)-166.5(during)]TJ
0 -1.1219 TD
[(Fall)-170.6(2014-Spring)-171.5(2015.)-176.7(The)-170.6(survey)-176.3(questions)-172(were)-176.8(drawn)-172.6(from)-174.8(an)]TJ
0 -1.128 TD
[(existing)-263.8(survey)-267.8(instrument,)-271.7(PREMIS)-263.7(\(Short)-269.1(et.)-265.8(al,)-265.8(2006\),)-270.5(a)-266.4(vali-)]TJ
0 -1.1219 TD
[(dated)-245.6(tool)-242.8(designed)-244.7(to)-249.4(assess)-242.7(healthcare)-253.9(professionals)-245.7(attitudes)]TJ
0 -1.128 TD
[(and)-248(preparedness)-257.4(related)-251.7(to)-255.5(screening)-251.3(for)-254.7(IPV.)-250.5(An)-251.4(online)-253.1(survey)]TJ
T*
[(tool,)-206.2(Qualtrics,)-217(was)-212.1(used)-210.6(to)-206.7(collect)-212.2(survey)-212.9(data.)-209(Quantitative)-212.6(data)]TJ
0 -1.1219 TD
[(were)-414.6(analyzed)-418.6(using)-413.1(descriptive)-414.8(statistics.)-417.7(Narrative)-420.1(data)-416.3(was)]TJ
0 -1.128 TD
[(summarized)-262.4(using)-260.7(content)-257.3(analysis)-261.6(methodology.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Results:)Tj
/F4 1 Tf
3.8412 0 TD
[(137)-402.3(medical)-407.3(students)-403.7(consented)-407.4(to)-401.9(participate)-407.2(and)]TJ
-4.8412 -1.128 TD
[(completed)-285.3(the)-290.2(online)-283.5(survey.)-292.2(The)-286.5(mean)-288.3(perceived)-286.8(preparedness)]TJ
0 -1.1219 TD
[(score)-424.4(was)-425.5(32.57)-420.6(\(SD)-421.3(12.7\),)-423(corresponding)-426.1(to)-420.1(the)-424.3()52.5(minimally)]TJ
0 -1.128 TD
[(prepared)53.6()-526.7(level.)-525.6(The)-530.3(mean)-526.1(perceived)-530.7(knowledge)-527.5(score)-528.1(was)]TJ
0 -1.1219 TD
[(46.24)-310.8(\(S.D.)-317.6(17.3\),)-319.3(corresponding)-316.4(to)-316.5(the)-314.6()52.5(very)-313.7(little)51()-319.4(perceived)]TJ
0 -1.128 TD
[(knowledge)-478.7(level.)-476.8(66%)-483.9(of)-477.9(students)-476.9(reported)-482(that)-478.7(they)-479.2(do)-475.5(not)]TJ
0 -1.1219 TD
[(currently)-243.7(screen)-245.7(patients)-243.7(for)-248.6(IPV,)-244.5(7%)-240.1(reported)-244.2(screening)-245.2(all)-247(new)]TJ
0 -1.128 TD
[(patients,)-463.2(and)-455.3(20%)-459.6(reported)-463.7(screening)-464.7(all)-460.4(patients)-463.2(with)-457.7(abuse)]TJ
0 -1.1219 TD
[(indicators)-300.9(on)-298.7(history)-305.2(or)-301.1(exam)-300.5()52.5(Time)-300(constraints)51.3()-301.1(and)-302.9()52.5(lack)-302.9(of)]TJ
0 -1.128 TD
[(role)-365.7(models)50.3()-368.2(were)-372(major)-371.3(themes)-366.2(identied)-375.4(as)-369.2(obstacles)-369.5(to)-371.4(in-)]TJ
0 -1.1219 TD
[(tegrating)-301.8(IPV)-299.3(training)-297.6(into)-303.8(medical)-303.6(school)-295.4(curriculum.)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 59.7543 749.7069 Tm
(ABSTRACTS)Tj
52.6193 0 TD
(A-15)Tj
ET
endstream
endobj
248 0 obj
<>stream
/GS1 gs
BT
/F3 1 Tf
9.2982 0 0 9.2982 71.3197 725.5557 Tm
0 0 0 rg
0 Tc
0 Tw
(Conclusions:)Tj
/F4 1 Tf
5.8228 0 TD
[(Medical)-339.9(students)-342.8(report)-337.6(low)-336.3(perceived)-341.7(knowl-)]TJ
-6.8228 -1.128 TD
[(edge)-325.4(and)-321.2(preparedness)-324.5(related)-318.7(to)-322.6(IPV)-323.7(screening.)-318.3(Moreover,)-323.1(we)]TJ
0 -1.1219 TD
[(found)-569.3(low)-574.1(reported)-573.4(rates)-570.3(of)-569.4(actual)-572.5(IPV)-573.7(screening)-574.4(amongst)]TJ
0 -1.128 TD
[(medical)-358.5(students.)-361(Medical)-358.2(student)-361.9(reported)-360(barriers)-355.5(to)-359.2(training)]TJ
0 -1.1219 TD
[(include)-409.7(time)-405(limitations)-408.1(and)-406.6(lack)-404.2(of)-404.7(faculty)-406(role)-408.4(models.)-404.6(The)]TJ
0 -1.128 TD
[(ndings)-367.2(of)-368.2(this)-363.9(study)-364.3(indicate)-370.7(a)-363.9(need)-368.1(for)-364.4(further)-370.4(medical)-370.7(edu-)]TJ
0 -1.1219 TD
[(cation)-300(innovation)-301.2(in)-298.2(this)-302.9(eld.)]TJ
/F3 1 Tf
0 -3.579 TD
(39.)Tj
9.843 0 0 9.843 82.9417 629.5179 Tm
[(Recruitment)-289.2(Feasibility)-279.6(Study)-281.5(for)-280.9(Reducing)]TJ
0 -1.1116 TD
[(Postpartum)-284.6(Smoking)-279.1(Among)-283.8(Low-Income)]TJ
T*
[(and)-279.4(Hispanic)-281.7(Women)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 62.022 591.0802 Tm
[(Helai)-338.1(Hesham,)-331.6(Sandra)-336.7(Curet)]TJ
/F5 1 Tf
0 -1.7682 TD
[(Lehigh)-335.7(Valley)-332.3(Health)-333.8(Network,)-339.5(Allentown,)-332.2(Pennsylvania)]TJ
/F3 1 Tf
.9999 -2.3047 TD
(Background:)Tj
/F4 1 Tf
6.0484 0 TD
[(Tobacco)-447.2(smoking)-443(is)-443.7(the)-448.7(leading)-446.3(preventable)]TJ
-7.0484 -1.128 TD
[(cause)-395.8(of)-386.4(premature)-394.2(morbidity)-390.3(and)-394.4(mortality.)-387.9(Pregnant)-391(women)]TJ
0 -1.1219 TD
[(represent)-339(a)-339.5(unique)-332.8(subgroup)-336.7(for)-333.9(who)-336.8(continued)-336.5(smoking)-339.4(is)-333.9(as-)]TJ
0 -1.128 TD
[(sociated)-516.7(with)-506.5(adverse)-514(outcomes,)-512.4(including)-514.7(increased)-511.6(risk)-513.1(of)]TJ
0 -1.1219 TD
[(ectopic)-285.9(pregnancy,)-277(spontaneous)-286.4(abortion,)-279.8(preterm)-280.3(delivery,)-284(low)]TJ
0 -1.128 TD
[(birth)-300(weight,)-303.3(and)-296.8(perinatal)-306(mortality.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.8533 0 TD
[(This)-347.9(study)-352.2(examines)-345.9(the)-351.2(feasibility)-348.6(of)-349.9(recruit-)]TJ
-6.8532 -1.128 TD
[(ment)-314(for,)-309.5(and)-309(implementation)-313.6(of,)-313.3(a)-309(smoking)-308.9(cessation)-314.6(program)]TJ
0 -1.1219 TD
[(among)-552.3(low-income)-559.3(pregnant)-558.9(women)-553.8(in)-554.3(a)-552.9(community-based)]TJ
0 -1.128 TD
[(healthcare)-302.7(setting.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Material/Methods:)Tj
/F4 1 Tf
8.5483 0 TD
[(We)-477.8(recruited)-473.5(60)-475.5(low-income)-480(pregnant)]TJ
-9.5482 -1.128 TD
[(smokers)-278.6(who)-281.9(received)-280.7(either)-277.9(the)-284.1(Forever)-278.1(Free)-281.9(for)-279(Baby)-277.1(and)-278.5(Me)]TJ
0 -1.1219 TD
[(or)-484(Libres)-488.6(Para)-483.1(Siempre)]TJ
/F9 1 Tf
9.9689 0 TD
(.)Tj
/F4 1 Tf
1.4816 0 TD
[(Por)-486.8(Mi)-480.3(Bebe)]TJ
5.2009 .0366 TD
()Tj
.8658 -.0366 TD
[(y)-481.6(Por)-486.8(M)]TJ
3.7193 .0366 TD
()Tj
.2988 -.0366 TD
[(,)-481.7(smoking)]TJ
-21.5353 -1.128 TD
[(cessation)-381.7(self-help)-383(booklets)-380.2(and)-376.1(completed)-382.8(baseline,)-376.4(1)-384.1(month,)]TJ
0 -1.1219 TD
[(8)-298.7(month)-303.7(and)-296.8(12)-298.7(month)-303.7(postpartum)-296.6(assessments.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Results:)Tj
/F4 1 Tf
3.6827 0 TD
[(To)22.6(ta)14.6(l)-194.6(n)12.2(um)18.9(b)12.2(e)0(r)-189.5(o)12.2(f)-197.5(e)0(l)20.7(i)0(g)18.8(i)0(b)18.8(l)0(e)-186.6(p)0(a)20.2(t)0(i)19.3(e)0(n)20.2(t)0(s)-187.6(w)0(a)18.7(s)-200.3(1)12.2(0)12.2(7)-195.1(an)14.1(d)-195.1(6)12.2(0)-195.1(w)0(e)18.7(r)0(e)]TJ
-4.6826 -1.128 TD
[(re)17.8(cr)17.8(u)12.2(i)0(t)19.3(e)0(d)-278.5(w)0(i)17.3(t)0(h)-279.9(a)-296.9(5)12.2(6)12.2(.)0(1)18.3(%)-288.9(en)20.2(ro)16(l)12.7(l)0(m)19.4(e)0(n)20.2(t)-292.1(ra)17.8(t)12.7(e)0(.)-284.7(P)0(e)17.3(r)0(m)22.6(a)0(n)20.2(e)0(n)20.2(t)-292.1(at)20.7(tr)16.5(i)12.7(t)0(i)19.3(o)0(n)-280.4(r)0(a)17.9(t)0(e)20.7(s)]TJ
0 -1.1219 TD
[(we)18.7(re)-256.5(fo)16(u)12.2(n)12.2(d)-268.2(t)12.7(o)-268.2(b)12.2(e)-266.4(16)18.3(.)12.2(7)0(%)-258.4(\()0(1)-258.4(m)12.8(o)12.2(n)0(t)18.8(h)12.2(\),)-258.4(4)12.2(3)0(.)18.3(3)12.2(%)-270.6(\()0(8)-252.3(m)0(o)18.9(n)12.2(th)18.8(\),)-258.4(an)20.2(d)-268.2(5)12.2(6)12.2(.)0(7)18.3(%)]TJ
0 -1.128 TD
[(\(1)22.1(2)-207.3(m)12.8(o)12.2(n)0(t)18.8(h)12.2(\).)-197.4(Ov)22.9(er)17.8(al)20.7(l)-200.7(q)0(u)18.3(i)0(t)-194.1(r)0(a)17.8(t)12.7(e)-205.4(a)14.1(t)-206.8(1)12.2(2)-201.2(m)12.8(on)18.3(th)18.9(s)-200.3(p)0(o)18.3(s)13.1(tp)18.9(ar)17.8(t)12.7(u)0(m)-194.5(w)0(a)18.7(s)-200.3(19)18.3(.)12.2(2)0(%)16(.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Conclusions:)Tj
/F4 1 Tf
5.9021 0 TD
[(Within)-411.1(our)-416.9(population)-411(demographic)-416.1(self-help)]TJ
-6.902 -1.128 TD
[(booklets)-471.7(for)-468.1(smoking)-467.4(cessation)-473.1(provided)-469.3(wanted)-472.7(and)-467.5(needed)]TJ
0 -1.1219 TD
[(education)-334.6(with)-335.7(positive)-330.9(results.)-333(The)-335.2(program)-331.4(had)-333.4(a)-333.4(19.2%)-331.5(quit)]TJ
0 -1.128 TD
[(rate)-424.8(overall)-418.2(at)-424.4(1)-420.7(year)-419.2(postpartum)-418.6(and)-424.8(nearly)-418.7(50%)-423(of)-416.9(patients)]TJ
0 -1.1219 TD
[(reported)-439.3(not)-444.5(smoking)-436.9(at)-442.7(all)-442.1(or)-435.2()52.5()0(a)-445.5(few)56.7()-441.3(cigarettes)-443.5(at)-442.7(1)-439(year.)]TJ
0 -1.128 TD
[(Nearly)-578.7(96%)-581.5(showed)-577.9(some)-582(reduction)-576.6(from)-583.3(what)-578.3(they)-576.8(were)]TJ
0 -1.1219 TD
[(smoking)-388.2(prior)-382.1(to)-389.7(the)-387.8(program.)-386.3(Self-help)-386.8(booklets)-386.3(were)-384.1(efca-)]TJ
0 -1.128 TD
[(cious)-453.9(and)-449.2(offered)-454.4(a)-455.4(low-cost)-451.1(modality)-453.2(for)-449.8(relapse-prevention)]TJ
0 -1.1219 TD
[(assistance)-305.8(to)-298.2(low-income)-303.2(pregnant)-302.8(and)-296.8(postpartum)-302.7(women.)]TJ
/F3 1 Tf
0 -3.5791 TD
(40.)Tj
9.843 0 0 9.843 82.9417 237.4866 Tm
[(Regional)-281.7(Variations)-283.6(in)-284.4(Vaginal)-279.4(HPV)-283.1(Prevalence)]TJ
0 -1.1116 TD
[(and)-279.4(Vaccination)-285.9(Among)-283.8(Females)-282.9(Across)-280.1(Time)]TJ
T*
[(in)-278.6(NHANES)-287.8(\(20032012\))]TJ
/F4 1 Tf
9.2982 0 0 9.2982 62.022 199.0488 Tm
[(Jacqueline)-337.9(Hirth,)-332(Tabassum)-337.1(Haque)-333(Laz,)-333.4(Yong-Fang)-333.9(Kuo,)]TJ
0 -1.128 TD
[(Christine)-338(McGrath,)-333.9(Jonathan)-336.1(Starkey,)-330.1(Richard)-338(Rupp,)]TJ
0 -1.1219 TD
[(Abbey)-334.8(Berenson)]TJ
/F5 1 Tf
0 -1.7682 TD
[(University)-340(of)-328.7(Texas)-339.6(Medical)-332.8(Branch,)-334.3(Galveston,)-331(Texas)]TJ
/F3 1 Tf
.9999 -2.3047 TD
(Background:)Tj
/F4 1 Tf
5.9326 0 TD
[(The)-329.1(South)-331.5(has)-326.4(a)-333.4(lower)-330.6(rate)-327.3(of)-331.6(human)-326.7(papillo-)]TJ
-6.9325 -1.128 TD
[(mavirus)-236.2(\(HPV\))-236.1(vaccination)-240.7(compared)-233.8(to)-237.2(other)-237.7(regions)-236.8(of)-234(the)-235.3(US)]TJ
0 -1.1219 TD
[(despite)-384.4(having)-387.7(higher)-384(rates)-381.3(of)-386.4(cervical)-383.9(cancer.)-391(Lower)-381.7(rates)-387.4(of)]TJ
0 -1.128 TD
[(vaccination)-393.1(may)-393.8(contribute)-393.2(to)-395.8(inequalities)-393.1(in)-389.7(HPV)-396(prevalence)]TJ
0 -1.1219 TD
[(and)-302.9(prolong)-300.5(regional)-296.2(cervical)-304.6(cancer)-305.7(disparities.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.8655 0 TD
[(To)-361.5(evaluate)-357.1(vaginal)-360.9(HPV)-359.4(regional)-363.3(prevalence)]TJ
-6.8654 -1.1219 TD
[(of)-319.4(vaccine-type)-327(HPV)-316.8(\(types)-322.1(6,)-323.1(11,)-317(16,)-323.1(and)-321.2(18\))-319.3(and)-321.2(vaccination)]TJ
0 -1.128 TD
[(between)-367.1(regions)-364.8(using)-364.4(data)-367.6(from)-363.8(the)-363.4(National)-361.9(Health)-368.5(and)-363.9(Nu-)]TJ
0 -1.1219 TD
[(trition)-299(Examination)-300.6(Survey)-302(\(NHANES\).)]TJ
/F3 1 Tf
27.9983 71.9468 TD
(Material/Methods:)Tj
/F4 1 Tf
8.4324 0 TD
[(Five)-354(NHANES)-358.1(cycles)-364.8(\(20032012\),)-352(in-)]TJ
-9.4324 -1.128 TD
[(cluding)-411.6(10,247)-408.4(women)-413.6(between)-409.8(14)-408.5(and)-412.7(59)-408.5(years)-412.3(of)-410.8(age)-410.8(with)]TJ
0 -1.1219 TD
[(adequate)-314.9(vaginal)-312.1(samples)-310.4(to)-310.4(detect)-310.3(HPV)-310.7(DNA,)-309.3(were)-311(combined)]TJ
0 -1.128 TD
[(to)-426.2(evaluate)-424.2(regional)-418.1(variations)-422.8(in)-426.2(HPV)-420.4(prevalence)-425.1(between)-422(4)]TJ
0 -1.1219 TD
[(Census)-433.9(regions)-431.9(of)-429.1(the)-424.3(US.)-431.1(Bivariate)-432.6(comparisons)-428.5(were)-432.9(made)]TJ
0 -1.128 TD
[(using)-431.4(Rao-Scott)-437.9(chi-square)-430.4(tests.)-434.3(Stratied)-435.5(logistic)-428(regression)]TJ
0 -1.1219 TD
[(analyses)-315.1(were)-311(used)-308.1(in)-310.4(order)-307.6(to)-310.4(assess)-309.8(differences)-315(in)-304.3(HPV)-310.7(prev-)]TJ
0 -1.128 TD
[(alence)-357.7(between)-348.8(regions)-346.5(by)-353.6(pre-vaccine)-348.2(years)-351.3(\(20032006\))-352(and)]TJ
0 -1.1219 TD
[(post-licensure)-318.7(years)-314.7(\(20072012\).)-309.3(Estimators)-309.3(were)-317.1(weighted)-313.6(to)]TJ
0 -1.128 TD
[(adjust)-301(for)-303.4(complex)-299.9(sampling)-300.4(design.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Results:)Tj
/F4 1 Tf
4.0424 0 TD
[(Vaccine)-603(initiation)-604.6(among)-601.1(the)-601.2(total)-606.2(sample)-603.9(was)]TJ
-5.0424 -1.128 TD
[(lowest)-357.4(in)-347(the)-351.2(South)-349.8(\(5.7%\))-348.4(compared)-355.8(to)-347(the)-351.2(Northeast)-351.7(\(6.3%\),)]TJ
0 -1.1219 TD
[(the)-381.7(Midwest)-374.8(\(6.2%\),)-372.8(and)-376.1(the)-381.7(West)-372.8(\(6.5%\).)-378.9(Regional)-377.8(compari-)]TJ
0 -1.128 TD
[(sons)-382.3(revealed)-384.4(differences)-382.1(for)-382.7(any)-382.2(type)-375.5(of)-380.3(HPV)-383.8(\(p)]TJ
/F2 1 Tf
20.6756 0 TD
(<)Tj
/F4 1 Tf
.5488 0 TD
[(0.01\),)-380.3(high)]TJ
-21.2243 -1.128 TD
[(risk)-366.7(types)-368.6(\(p)]TJ
/F2 1 Tf
5.1765 0 TD
(<)Tj
/F4 1 Tf
.5548 0 TD
[(0.05\),)-362(high)-365.2(risk)-366.8(non-vaccine)-366(types)-368.6(\(p)]TJ
/F2 1 Tf
15.2917 0 TD
(<)Tj
/F4 1 Tf
.5488 0 TD
[(0.05\),)-368.1(and)]TJ
-21.5719 -1.1219 TD
[(any)-217.5(non-vaccine)-219.7(types)-222.2(\(p)]TJ
/F2 1 Tf
9.9506 0 TD
(<)Tj
/F4 1 Tf
.5548 0 TD
[(0.01\).)-215.6(In)-215.7(analyses)-223.7(stratied)-218.4(by)-213.3(the)-217(pre-)]TJ
-10.5055 -1.128 TD
[(vaccine)-217.4(and)-211.4(post-licensure)-215.1(years,)-217.1(women)-212.4(in)-212.8(the)-210.9(South)-215.6(had)-211.4(higher)]TJ
0 -1.1219 TD
[(odds)-303.9(of)-301.1(any)-302.9(HPV)-304.6(types)-301.5(and)-302.9(non-vaccine)-299(types)-307.6(compared)-300.9(to)-298.2(the)]TJ
0 -1.128 TD
[(Northeast.)-498(During)-497.1(post-licensure)-495.5(years,)-497.6(women)-498.9(in)-493.3(the)-491.4(South)]TJ
0 -1.1219 TD
[(were)-237.8(more)-231.6(likely)-234.3(to)-231.1(test)-227.9(positive)-233.4(for)-236.4(vaccine)-229.6(type)-235.3(HPV)-231.4(and)-229.7(high-)]TJ
0 -1.128 TD
[(risk)-305.8(vaccine)-302.8(type)-296.3(HPV.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Conclusions:)Tj
/F4 1 Tf
5.6948 0 TD
[(Wo)20.2(m)12.7(e)0(n)-144.4(i)0(n)-145.8(t)12.7(he)-144.4(So)21.6(ut)18.8(h)-152.4(e)0(x)14.1(p)12.2(er)17.8(i)12.7(e)0(n)20.2(c)0(e)16(d)-152.4(a)-156.6(h)12.2(i)12.7(g)0(h)18.3(e)0(r)-146.8(o)12.2(d)12.2(d)0(s)-145.4(o)12.2(f)]TJ
-6.6947 -1.128 TD
[(te)14.6(s)13.1(t)0(i)19.3(n)0(g)-195.1(p)12.2(os)19.2(it)19.3(iv)18.8(e)-205.4(f)0(o)22.1(r)-203.6(HP)14(V,)-190.5(wi)17.3(t)12.7(h)-207.3(t)12.7(h)0(e)-199.3(m)12.8(o)12.2(s)0(t)-199.8(n)12.2(o)12.2(t)0(a)20.7(b)0(l)18.8(e)-205.4(be)20.2(in)18.8(g)-207.3(t)12.7(h)12.2(e)-205.4(hi)18.8(gh)-195.1(ri)22.6(sk)]TJ
0 -1.1219 TD
[(va)14.1(c)14.1(c)0(i)14.6(n)12.2(e-)17.8(t)12.7(y)0(p)18.3(e)-223.7(HP)20.1(V)-221(d)12.2(ur)16(i)12.7(n)0(g)-213.3(t)0(h)18.8(e)-223.7(p)12.2(o)12.2(s)0(t)19.7(-)0(l)16.5(i)12.7(ce)16(n)12.2(s)0(u)19.2(r)0(e)-213.8(y)12.2(ea)16(rs)-214.9(fo)22.1(r)-221.8(t)0(h)18.8(e)-223.7(v)12.2(a)0(c)16(c)14.1(in)18.8(e.)]TJ
0 -1.128 TD
[(Th)16.5(es)21.1(e)-376.1()0(n)21.6(d)0(i)18.8(n)12.2(gs)-364.9(su)19.2(gg)18.3(es)21.1(t)-377.5(t)12.7(ha)20.2(t)-377.5(d)12.2(is)19.7(pa)14.1(ri)22.6(t)12.7(i)0(e)14.6(s)-371.1(in)-365.3(va)20.2(cc)16(i)12.7(n)0(a)14.1(t)12.7(i)12.7(o)0(n)-365.8(m)0(a)20.7(y)-378(co)20.2(n)12.2(-)]TJ
0 -1.1219 TD
[(tr)16.5(i)12.7(b)0(u)18.3(t)0(e)-241.5(t)12.7(o)-250(u)0(n)18.3(e)0(q)20.2(u)0(a)20.2(l)-249.5(re)17.8(gi)18.8(o)12.2(n)0(a)14.1(l)-249.5(p)12.2(r)0(e)17.8(v)12.2(al)20.7(en)14.1(c)14.1(e)-254.2(o)12.2(f)-252.3(HP)20.1(V)-251.5(v)12.2(ac)16(c)14.1(i)0(n)18.8(e)-254.2(t)12.7(y)12.2(pe)14.1(s)13.1(.)]TJ
/F3 1 Tf
0 -4.1095 TD
(41.)Tj
9.843 0 0 9.843 333.9779 425.8204 Tm
[(Is)-284(Resilience)-287.3(a)-277.6(Protective)-287.6(Factor)-280.8(for)-280.9(African)]TJ
0 -1.1174 TD
[(American)-284.9(Women)-285.1(with)-281.7(Depressive)-286.8(Symptoms)-281.1(in)-278.6(a)]TJ
0 -1.1116 TD
[(Community)-283.4(Based)-283.8(Primary)-283.1(Healthcare)-287.5(Center?)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 313.0582 387.3259 Tm
[(Kisha)-339.6(Holden)]TJ
/F5 1 Tf
0 -1.7682 TD
[(Morehouse)-338.1(School)-332.8(of)-334.8(Medicine,)-330.8(Atlanta,)-335.5(Georgia)]TJ
/F3 1 Tf
.9999 -2.3047 TD
(Background:)Tj
/F4 1 Tf
5.8594 0 TD
[(Depression)-253.8(is)-248.6(one)-254.1(of)-252.3(the)-253.6(most)-248(prevalent)-257.7(mental)]TJ
-6.8593 -1.1219 TD
[(health)-342.6(problems)-346(in)-340.9(the)-339(United)-339.9(States.)-344.6(Depression)-345.2(is)-340(a)-339.5(treatable)]TJ
0 -1.128 TD
[(medical)-218.3(illness)-220.3(that)-216.5(can)-215.7(occur)-211.9(in)-218.9(any)-211.4(woman,)-218.5(at)-217.1(any)-211.4(time,)-216(and)-217.5(for)]TJ
0 -1.1219 TD
[(various)-480.7(reasons)-484.5(regardless)-484.5(of)-477.9(age,)-483.9(race)-478.3(or)-477.9(income.)-482.8(Research)]TJ
0 -1.128 TD
[(centered)-372.2(on)-359.7(improving)-366.5(mental)-366.5(health)-360.9(outcomes)-366.1(in)-365.3(the)-363.4(primary)]TJ
0 -1.1219 TD
[(care)-271(setting)-270(is)-273(considered)-269.5(a)-266.4(public)-271.3(health)-269.5(priority.)-271.3(Not)-269.2(only)-267.7(do)-268.2(a)]TJ
0 -1.128 TD
[(large)-235.8(percentage)-242.2(of)-234(individuals)-232.8(receive)-238.1(all)-234.8(or)-234(part)-231.6(of)-234(their)-237.2(mental)]TJ
0 -1.1219 TD
[(health)-245.1(treatment)-238.4(in)-237.2(primary)-239.5(care)-240.5(settings,)-238.6(but)-237.2(racial)-239.5(minorities)-240.8(in)]TJ
0 -1.128 TD
[(particular)-503.4(are)-498.5(more)-499.8(likely)-496.4(to)-499.4(report)-502.2(depressive)-500.4(symptoms)-496.5(to)]TJ
0 -1.1219 TD
[(primary)-526(care)-527.1(physicians)-523.8(than)-521.9(to)-523.8(mental)-525(health)-525.6(practitioners.)]TJ
0 -1.128 TD
[(Nevertheless,)-365.3(more)-353.5(women)-358.7(than)-357.3(men)-357.3(reported)-353.9(that)-356.8(they)-357.3(prefer)]TJ
0 -1.1219 TD
[(advice)-249.8(about)-247.5(depression)-246.2(from)-241.9(their)-249.4(primary)-245.6(care)-246.6(physician)-244.2(and)-248(a)]TJ
0 -1.128 TD
[(critical)-305.5(link)-303.8(to)-298.2(aid)-302.4(in)-298.2(identifying)-303.1(and)-296.8(addressing)-301(depression)-307.1(and)]TJ
0 -1.1219 TD
[(associated)-306.6(issues)-299.8(for)-303.4(African)-300.6(American)-301.9(women)-303.8(\(AAW\).)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.8838 0 TD
[(Th)16.5(e)-321.2(o)12.2(bj)18.8(ec)16(t)12.7(i)0(v)18.8(e)0(s)-314.3(o)12.2(f)-325.5(t)0(h)18.8(e)-321.2(st)19.7(ud)18.3(y)-323.1(a)0(r)17.8(e)-321.2(to)18.8(:)-322.6(1)0(\))-313.3(a)0(s)15(c)14.1(er)17.8(ta)14.6(i)12.7(n)]TJ
-6.8837 -1.128 TD
[(se)15(l)12.7(e)0(c)16(t)12.7(ed)-473.7(ri)22.6(sk)19.2(s)-480.8(a)14.1(nd)-469.4(pr)16(o)12.2(t)12.7(ec)16(t)12.7(i)0(v)18.8(e)-479.8(fa)17.8(ct)20.7(or)16(s)-474.7(f)0(o)16(r)-477.9(d)12.2(e)0(p)20.2(r)0(e)17.8(s)0(s)20(i)0(v)18.8(e)-479.8(s)13.1(y)0(m)18.9(p)0(t)18.8(o)12.2(ms)]TJ
0 -1.1219 TD
[(am)14.6(o)12.2(n)12.2(g)-304.8(AA)15.3(W)-302.9(s)0(e)15(e)14.1(ki)18.8(ng)-298.7(p)12.2(r)0(i)22.6(m)0(a)14.6(r)0(y)-295(c)0(a)22.1(r)0(e)17.8(,)-304.8(an)20.2(d)-304.8(2)0(\))-301.1(d)12.2(et)20.7(er)17.8(m)12.7(i)0(n)18.9(e)-309.1(t)12.7(h)0(e)-296.8(p)12.2(re)17.8(va)20.2(-)]TJ
0 -1.128 TD
[(le)14.6(n)12.2(c)0(e)-197.4(a)0(n)14.1(d)-207.3(c)14.1(o)0(r)16(r)0(e)17.8(l)12.7(at)20.7(es)-198.4(of)-197.4(de)14.1(p)12.2(r)0(e)17.9(s)13.1(si)19.7(ve)-199.3(sy)19.2(mp)18.9(t)12.7(o)0(m)18.9(s)0(,)-200.3(i)12.7(nc)20.2(lu)18.9(d)12.2(i)0(n)18.9(g)-207.3(th)18.9(e)-211.5(r)0(o)22.1(l)0(e)-198.8(o)12.2(f)]TJ
0 -1.1219 TD
[(re)17.8(si)19.7(li)19.3(en)20.2(ce)-215.7(am)14.7(o)12.2(n)12.2(g)-225.6(AA)21.4(W)-223.7(i)0(n)-218.9(a)-223.7(c)14.1(o)0(m)18.9(m)0(u)18.9(n)12.2(it)19.3(y)-225.6(b)12.2(as)15(e)14.1(d)-225.6(p)12.2(r)0(i)16.5(m)12.8(ar)17.8(y)-225.6(h)12.2(ea)16(l)12.7(t)0(h)18.8(c)0(a)16(r)0(e)]TJ
0 -1.128 TD
[(ce)16(n)12.2(t)0(e)14.6(r)0(.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Material/Methods:)Tj
/F4 1 Tf
8.6763 0 TD
[(Th)22.6(i)12.7(s)-554(cr)17.8(o)12.2(s)0(s)20(-)0(s)16.8(e)0(c)22.1(t)0(i)19.4(o)0(n)18.3(a)0(l)-540.2(p)0(i)18.8(l)0(o)18.8(t)-548.2(st)19.7(ud)18.3(y)-548.7(a)0(s)15(c)0(e)22.1(r)0(-)]TJ
-9.6762 -1.128 TD
[(ta)14.6(i)12.7(n)0(e)20.2(d)-298.7(s)13.1(e)0(l)14.6(f)0(-)19.7(r)0(e)23.9(p)0(o)18.3(r)0(t)-288.4(d)12.2(at)20.7(a)-296.9(f)0(r)19.7(o)12.2(m)-298.2(2)12.2(90)-286.5(AA)21.4(W)-296.8(w)0(o)16.8(m)12.8(en)-284.6(co)14.1(n)12.2(c)0(e)22.1(r)0(n)16(i)12.7(ng)-286.5(b)12.2(a)0(c)16(k)12.2(-)]TJ
0 -1.1219 TD
[(gr)16(o)12.2(u)12.2(n)0(d)-524.3(f)0(a)17.8(c)0(t)20.7(o)0(r)16(s)13.1(,)-536.5(d)12.2(ia)20.7(gn)18.3(o)12.2(s)0(e)15(d)-530.4(ch)20.2(ro)16(n)12.2(i)0(c)-528(d)12.2(i)12.7(s)0(e)15(a)14.1(se)15(s)13.1(,)-536.5(an)20.2(d)-536.5(m)12.7(ea)16(s)13.1(u)12.2(re)17.8(s)-535.7(o)12.2(f)]TJ
0 -1.128 TD
[(de)14.1(p)12.2(r)0(e)17.8(s)13.1(si)19.7(ve)-302.9(s)13.1(y)12.2(mp)18.9(to)18.8(ms)-297.3(an)20.2(d)-310.9(r)0(e)17.8(s)13.1(il)19.3(ie)20.7(nc)14.1(y)12.2(.)-304.8(De)18.7(sc)15(ri)22.6(pt)18.8(i)12.7(v)0(e)-302.9(s)13.1(ta)14.6(t)12.7(i)0(s)19.7(t)0(i)19.3(c)0(s)21.1(,)-310.9(Pe)17.4(a)14.1(r)0(-)]TJ
0 -1.1219 TD
[(so)19.2(n)-317(p)12.2(ro)22.1(du)18.3(ct)20.7(-m)16.5(o)12.2(m)0(e)20.7(n)0(t)-304.3(c)0(o)20.2(r)0(r)19.7(e)0(l)14.6(a)14.1(ti)19.3(on)-304.8(an)20.2(d)-317(l)12.7(o)12.2(g)0(i)18.8(s)0(t)19.7(i)0(c)-308.5(r)0(e)23.9(g)0(r)16(e)14.1(ss)13.9(i)12.7(o)12.2(n)-317(a)0(n)20.2(a)0(l)20.7(y)12.2(se)15(s)]TJ
0 -1.128 TD
[(we)18.7(re)-244.3(co)20.2(n)12.2(d)0(u)18.3(c)0(t)20.7(e)0(d)20.2(.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Results:)Tj
/F4 1 Tf
3.7559 0 TD
[(Findings)-324(indicate)-315.8(that)-320.2(depressive)-323.6(symptoms)-319.7(are)-321.7(ex-)]TJ
-4.7558 -1.128 TD
[(perienced)-231.9(by)-231.6(49%)-221.8(of)-227.9(AAW)-232.7(and)-229.7(10%)-227.9(of)-227.9(these)-226.5(women)-230.7(indicated)-230.4(a)]TJ
0 -1.1219 TD
[(history)-415(of)-410.8(suicidal)-414.4(ideation.)-415.2(AAW)-415.6(had)-406.6(moderately)-415.7(high)-414(resil-)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 62.022 749.6502 Tm
(A-16)Tj
48.6864 0 TD
(ABSTRACTS)Tj
ET
endstream
endobj
253 0 obj
<>stream
/GS1 gs
BT
/F4 1 Tf
9.2982 0 0 9.2982 59.7543 725.5557 Tm
0 0 0 rg
0 Tc
0 Tw
[(iency)-324.9(scores)-326(that)-320.2(had)-327.3(a)-321.2(statistically)-324.2(signicant)-325.8(inverse)-320.2(relation-)]TJ
0 -1.128 TD
[(ship)-224.1(with)-219.9(depressive)-226(symptoms.)-216(This)-219.9(suggests)-226.6(that)-216.5(resiliency)-225.8(is)-218.1(a)]TJ
0 -1.1219 TD
[(protective)-446.2(factor)-445.4(for)-443.7(depressive)-439.4(symptoms.)-441.6(Depressive)-447(symp-)]TJ
0 -1.128 TD
[(toms)-284.6(were)-286.6(positive)-288.2(correlated)-288.7(with)-280.9(AAWs)-289.1(diagnosis)-281.8(of)-288.9(at)-284.1(least)]TJ
0 -1.1219 TD
[(one)-321.2(chronic)-321.1(disease)-321.2(\(e.g.,)-323.5(diabetes,)-321.6(heart)-321.1(condition,)-319.5(and)-321.2(mental)]TJ
0 -1.128 TD
[(health)-385.3(disorder\).)-375.6(The)-377.9(strongest)-381.7(predictors)-383(of)-380.3(depressive)-378.4(symp-)]TJ
0 -1.1219 TD
[(toms)-302.9(were)-304.9(previous)-303.8(diagnoses)-298.7(of)-301.1(a)-303(mental)-305.5(health)-300(condition)-307.4(and)]TJ
0 -1.128 TD
(unemployment.)Tj
/F3 1 Tf
.9999 -1.1219 TD
(Conclusions:)Tj
/F4 1 Tf
5.8594 0 TD
[(Th)16.5(i)12.7(s)-365(s)13.1(t)0(u)18.8(d)12.2(y)-365.8(a)14.1(dd)18.3(s)-365(t)12.7(o)-359.7(t)0(h)18.9(e)-363.9(d)12.2(e)0(a)16(r)0(t)22.6(h)-359.7(of)-356(re)17.8(s)13.1(e)0(a)16(r)0(c)17.8(h)-359.7(co)20.2(n)12.2(-)]TJ
-6.8593 -1.128 TD
[(ce)16(rn)22.1(in)18.8(g)-274.3(c)0(o)20.2(r)0(r)19.7(e)0(l)20.7(a)0(t)14.6(e)14.1(s)-273.5(a)0(n)14.1(d)-268.2(pr)16(e)14.1(d)0(i)18.8(c)0(t)14.6(o)12.2(rs)-263.6(o)12.2(f)-276.7(d)12.2(e)0(p)20.2(r)0(e)17.8(s)0(s)20(i)0(v)18.8(e)-272.5(sy)19.2(m)12.8(p)0(t)18.8(o)0(m)18.9(s)-273.5(am)20.8(on)18.3(g)]TJ
0 -1.1219 TD
[(a)-205.4(c)0(l)20.7(i)0(n)18.8(i)0(c)-192.7(s)0(a)15(m)12.8(p)12.2(l)0(e)-192.7(o)0(f)-197.4(A)0(A)21.4(W)0(.)-193.2(I)0(t)-190.8(s)0(u)19.2(p)12.2(po)18.3(rt)16.5(s)-200.3(t)12.7(he)-193.2(ne)14.1(e)14.1(d)-207.3(fo)22.1(r)-203.6(b)12.2(et)20.7(te)14.6(r)-197.5(i)0(n)18.9(t)0(e)14.6(g)12.2(ra)17.9(t)12.7(i)0(o)18.8(n)]TJ
0 -1.128 TD
[(of)-282.8(m)12.8(e)0(n)20.2(t)0(a)14.6(l)-286(an)14.1(d)-286.5(b)12.2(eh)14.1(a)14.1(v)0(i)18.8(o)12.2(ra)17.8(l)-292.1(h)12.2(ea)16(l)12.7(t)0(h)-279.9(i)0(n)-279.9(p)0(r)16(i)12.7(ma)20.8(ry)-282.8(h)12.2(e)0(a)16(l)12.7(th)18.8(ca)16(re)-280.9(s)13.1(e)0(t)14.6(t)12.7(in)18.8(g)12.2(s)0(.)]TJ
/F3 1 Tf
0 -3.0669 TD
(42.)Tj
9.843 0 0 9.843 80.674 581.9526 Tm
[(The)-281.8(Support)-284.7(Group)-278.3(as)-284.2(a)-277.6(Tool)-282(to)-278.6(Address)]TJ
0 -1.1116 TD
[(Sexual)-284.1(Abuse)-283.5(Issue)-282.4(Among)-278(Young)-282.5(Girls)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 59.7543 554.4565 Tm
[(Elyse)-339.9(Igihozo)]TJ
/F5 1 Tf
0 -1.7682 TD
[(Capacitar,)-336.1(Kigali)-332.3(Rwanda)]TJ
/F3 1 Tf
.9999 -2.3047 TD
(Background:)Tj
/F4 1 Tf
5.8472 0 TD
[(In)-227.9(R)13.6(w)0(a)18.7(n)12.2(da)-229.8(d)12.2(u)12.2(r)0(i)16.5(n)12.2(g)-231.7(t)0(h)18.8(e)-235.9(g)12.2(e)0(n)14.1(o)12.2(ci)20.7(d)12.2(e)0(,)-229.8(s)13.1(ex)20.2(ua)20.2(l)-237.3(v)12.2(io)18.8(le)20.7(nc)20.2(e)]TJ
-6.8471 -1.128 TD
[(ha)14.1(s)-304(b)0(e)14.1(e)14.1(n)-310.9(us)19.2(ed)-302.9(a)14.1(s)-310.1(a)-315.1(w)0(e)18.7(a)14.1(po)18.3(n)-310.9(o)12.2(f)-313.3(w)0(a)18.7(r)-307.2(wh)16.8(e)14.1(r)0(e)-305.3(a)14.1(bo)18.3(u)12.2(t)-310.4(25)18.3(0)12.2(,)0(0)18.3(0)12.2(0)-310.9(w)0(o)16.8(m)12.8(en)]TJ
0 -1.1219 TD
[(we)18.7(re)-305.3(ra)17.8(p)12.2(e)0(d)-309(a)14.1(nd)-304.8(ma)20.7(ny)-304.8(we)18.7(re)-305.3(in)18.8(fe)17.8(c)14.1(t)0(e)14.6(d)-310.9(wi)17.3(t)12.7(h)-317(HI)20.6(V/)17.3(AI)20.6(DS)-303.1(\(U)20.6(NI)20.6(FE)19.7(M,)]TJ
0 -1.128 TD
[(20)18.3(0)12.2(6)0(\))16(.)-201.2(Th)22.6(e)-205.4(G)0(o)22.9(v)12.2(er)17.8(nm)18.9(en)20.2(t)-200.7(o)12.2(f)-203.6(R)0(w)18.2(a)0(n)20.2(d)12.2(a)-205.4(c)0(o)20.2(n)12.2(si)19.7(de)20.2(rs)-196.6(g)12.2(e)0(n)20.2(d)12.2(er)-195.6(as)-192.3(o)12.2(n)12.2(e)-205.4(o)12.2(f)-203.6(t)12.7(h)0(e)]TJ
0 -1.1219 TD
[(mo)18.9(st)-193.7(im)19.4(p)12.2(o)0(r)16(t)12.7(an)20.2(t)-206.8(i)12.7(ni)18.8(ti)19.3(at)20.7(iv)18.8(es)-192.3(in)-194.6(th)18.8(e)-205.4(c)0(o)20.2(n)12.2(st)19.7(ru)16(c)14.1(t)0(i)19.3(o)0(n)-195.1(o)12.2(f)-203.6(d)0(u)18.3(r)0(a)17.8(b)12.2(le)-192.7(pe)20.2(ac)16(e)-205.4(a)0(n)20.2(d)]TJ
0 -1.128 TD
[(su)19.2(st)19.7(ai)14.6(n)12.2(a)0(b)20.2(l)12.7(e)-431(s)13.1(oc)20.2(io)18.8(ec)16(o)12.2(n)12.2(o)0(m)18.9(i)0(c)-418.3(d)12.2(ev)20.2(el)14.6(o)12.2(p)12.2(m)0(e)20.7(n)0(t)18.8(.)-426.8()64.7()0(I)19.7(t)-426.3(is)-413.2(es)15(s)13.1(e)0(n)20.2(t)0(i)19.3(a)0(l)-418.3(t)12.7(o)-426.8(a)0(c)16(t)]TJ
0 -1.1219 TD
[(no)18.3(w,)16.8()64.7()-258.4(Cl)20.2(ai)14.6(re)-250.4(in)18.8(s)13.1(i)0(s)19.7(t)0(e)14.6(d)-262.1(B)13.6(i)0(s)19.7(a)0(m)14.7(a)14.1(za)-252.3(Pe)17.3(rm)16.5(a)14.1(n)0(e)20.2(n)0(t)-255.5(S)0(e)23.4(c)0(r)17.8(e)0(t)14.6(a)14.1(ry)-252.3(Mi)19.7(ni)18.8(st)19.7(ry)-252.3(o)12.2(f)]TJ
0 -1.128 TD
[(Yo)16.8(u)12.2(t)0(h)18.8(,)-256.1(ci)20.7(ti)19.3(ng)-249.9(a)-254.2(s)0(t)19.7(u)0(d)18.3(y)-256.1(of)-246.2(be)14.1(h)12.2(a)0(v)20.2(i)12.7(or)16(al)-247.6(s)13.1(u)0(r)16(v)12.2(ei)20.7(ll)19.3(an)20.2(ce)-252.3(i)12.7(n)-256.1(20)18.4(0)12.2(6)-262.1(i)12.7(n)-256.1(wh)16.8(i)12.7(c)0(h)]TJ
0 -1.1219 TD
[(12)18.3(.)12.2(1)0(%)-215.7(o)12.2(f)-221.8(R)13.6(wa)18.7(nd)18.3(an)-211.5(g)12.2(i)0(r)16.5(l)12.7(s)-224.7(r)0(e)23.9(p)0(o)18.3(r)0(t)16.5(e)14.1(d)-225.6(h)12.2(av)20.2(i)12.7(n)0(g)-213.3(h)12.2(ad)-211.5(r)19.2(st)-212(re)17.8(p)12.2(o)12.2(r)0(t)16.5(s)-218.6(se)15(x)-219.5(w)0(i)23.4(t)0(h)]TJ
0 -1.128 TD
-.0133 Tc
[(a)-328.4(m)-.5(a)-13.3(n)-316.2(a)-13.3(t)-315.7(le)-13.3(ast)-323.7(t)-13.3(en)-324.2(ye)-13.3(ar)-13.3(s)-313.5(o)-1.1(l)-13.3(d)5.5(e)-13.3(r)4.5(.)-324.2(I)-13.3(n)-314.4(a)-322.3(20)-13.3(0)5(5)-324.2(su)-13.3(rve)-13.3(y)-316.2(on)-324.2(de)-13.3(mogr)-13.3(a)4.5(p)-13.3(h)5(y)]TJ
0 -1.1219 TD
0 Tc
[(an)14.1(d)-408.5(h)0(e)14.1(a)14.1(l)0(t)19.3(h)0(,)-408.5(y)12.2(ea)22.1(rs)-410(HI)20.6(V)-416.1(p)12.2(re)17.8(v)12.2(a)0(l)20.7(e)0(n)20.2(c)0(e)-410.8(w)0(a)18.7(s)-413.7(es)21.1(ti)19.3(m)12.8(a)0(t)14.6(e)14.1(d)-414.6(a)0(t)-406.1(1)0(.)18.3(4)12.2(%)-416.9(H)0(I)20.6(V)]TJ
0 -1.128 TD
[(pr)16(ev)20.2(al)20.7(en)20.2(ce)-301.1(a)14.1(m)0(o)18.9(n)12.2(g)-310.9(w)0(o)22.9(m)0(e)20.8(n)-304.8(ag)20.2(ed)-296.8(15)18.3()12.2(2)0(4)18.3(,)-304.8(a)-309.1(r)0(a)23.9(t)0(e)-296.3(t)0(h)18.8(r)0(e)17.8(e)-309(t)12.7(i)12.7(m)0(e)14.7(s)-304(h)12.2(i)0(g)18.9(h)12.2(er)]TJ
0 -1.1219 TD
[(th)18.8(an)-284.6(a)14.1(m)0(o)18.9(n)12.2(g)-292.6(y)12.2(ou)18.3(n)12.2(g)-292.6(m)12.8(e)0(n)-284.6(t)12.7(h)12.2(e)-290.8(sa)15(m)12.8(e)-290.8(ag)20.2(e.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.9752 0 TD
[(Inform)-469.8(the)-467(community)-465.3(about)-467(the)-467(extent)-464.6(and)]TJ
-6.9752 -1.1219 TD
[(consequences)-372.7(of)-362.1(sexual)-366.7(abuse)-367.2(based)-367.2(on)-365.8(gender.)-364.3(Create)-366.6(aware-)]TJ
0 -1.128 TD
[(ness)-270.7(for)-266.8(health)-269.5(professionals)-271.5(on)-268.2(psycho)-271.5(social)-268.6(care)-271(of)-270.6(the)-265.8(young)]TJ
0 -1.1219 TD
[(girls)-305.3(sexually)-299.1(abused.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Material/Methods:)Tj
/F4 1 Tf
8.5422 0 TD
-.024 Tc
[(Si)-5.2(nce)-455(2)-5.7(010,)-456.9(Capaci)-5.2(tar)-453.1(R)-4.3(wand)-5.7(a)-455(t).9(ook)-456.9(the)]TJ
-9.5421 -1.1219 TD
-.0237 Tc
[(i)-4.9(n).7(it)-4.9(iative)-381.5(t)-4.9(o)-377.3(c)-3.5(oach)-5.4(ing)-383.4(g).7(irls)-382.6(teenage)-381.5(g).7(irls)-382.6(\(14)-5.4(18)-377.3(years\))-379.7(who)-383.4(w)-.8(ere)]TJ
0 -1.128 TD
-.0211 Tc
[(se)5.2(xually)-332(abus)4.2(ed)-332(and)-332(i)3.8(nf)7(ected)-332(with)]TJ
13.6028 0 TD
-.0241 Tc
[(HIV.)-335(C)-4.4(a)-3.9(pacit)-5.3(a)2.2(r)-337.4(i)-5.3(ts)-340.3(holi)-5.3(s)1.2(ti)-5.3(c)-333.2(b)-5.8(io-)]TJ
-13.6028 -1.1219 TD
-.0237 Tc
[(p)-5.4(s)1.6(ychos)-4.5(ocial)-510.9(a)2.6(pp)-5.4(ro)-5.4(ach)-511.4(h).7(as)-510.6(grea)]TJ
12.8224 0 TD
-.0232 Tc
[(tl)-4.4(y)-510.9(c)3.1(o)-4.9(n)1.2(cerned)-510.9(the)-509.1(p)-4.9(sychol)-4.4(ogical)]TJ
-12.8224 -1.128 TD
0 Tc
[(aspect)-279.4(by)-274.3(individual)-276.3(therapy,)-278.4(family)-273.2(therapy,)-278.4(and)-278.5(group)-270.5(therapy)]TJ
0 -1.1219 TD
[(and)-376.1(relaxation)-373(area)-374.7(while)-376.5(working)-375.1(effectively)-373.5(with)-372.3(others)-377(ser-)]TJ
0 -1.128 TD
[(vices,)-287.4(among)-277.9(others,)-285.6(medical,)-285.3(nutritional)-284.3(and)-278.5(social.)-286.9(During)-277.6(the)]TJ
0 -1.1219 TD
[(school)-332(holiday,)-326.2(Capacitar)-327.6(put)-328.7(into)-328.1(place)-329.1(the)-326.8(holiday)-326.2(camp)-331(pro-)]TJ
0 -1.128 TD
[(gram)-280.3(for)-285.1(the)-278(young)-280.3(girls)-280.9(to)-279.9(educate)-284.5(them)-277.5(their)-279.8(rights.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Results:)Tj
/F4 1 Tf
3.8412 0 TD
[(CAPACITAR)-409.7(RWANDA)-405(created)-408.8(a)-400.5(meeting)-409.1(place)]TJ
-4.8412 -1.128 TD
[(for)-474.2(the)-467(support)-470.3(group)-471.7(at)-473.2(the)-473.1(Muslim)-466.1(school)-472.2(in)-468.9(Nyamirambo)]TJ
0 -1.1219 TD
[(Kada)-323.6(every)-315.5(Sunday)-317.9(afternoon.)-317.3(This)-317.4(group)-319.3(includes)-317.3(17)-317(female)]TJ
0 -1.128 TD
[(rape)-266.8(victims)-263.3(\(1418)-264.4(years\))-268.3(including)-264.7(12)-262.1(abused)-263.5(by)-268.2(older)-262.1(men,)-265.8(2)]TJ
T*
[(abused)-446.4(by)-438.9(family)-443.9(members)-441.6(1)-445.1(abused)-440.3(by)-438.9(his)-443.7(adoptive)-440.1(parent.)]TJ
0 -1.1219 TD
[(These)-350.8(girls)-347.9(have)-343.7(group)-343.7(therapy)-345.5(where)-347.5(they)-351.2(are)-346.1(sharing)-346.5(experi-)]TJ
0 -1.128 TD
[(ence.)-354(From)-346.1(the)-351.2(years)-351.3(above,)-349.7(over)-347.9(90%)-349.8(of)-349.9(the)-351.2(members)-350.2(of)-343.8(this)]TJ
0 -1.1219 TD
[(group)-301(became)-302.8(more)-298.6(cohesive)-303.8(and)-302.9(integrated.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Conclusions:)Tj
/F4 1 Tf
5.9326 0 TD
[(Support)-449.7(groups)-440.4(for)-449.8(young)-445(women)-444.1(who)-446.5(have)]TJ
-6.9325 -1.1219 TD
[(been)-252.2(sexually)-244.2(abused)-251.3(are)-248.5(a)-248.1(successful)-249.5(strategy)-246.6(to)-249.4(address)-246.7(gender)]TJ
0 -1.128 TD
[(based)-306.2(violence.)]TJ
/F3 1 Tf
0 -3.0608 TD
(43.)Tj
9.843 0 0 9.843 80.674 111.5149 Tm
[(Sexual)-284.1(and)-279.4(Reproductive)-289.1(Rights)-277.9(and)-279.4(Experience)]TJ
0 -1.1174 TD
[(of)-284.4(Intimate)-281.5(Partner)-282.9(Violence)-284(Among)-283.8(Female)]TJ
0 -1.1116 TD
[(Teachers)-284.9(in)-284.4(South-West)-283.2(Nigeria)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 59.7543 73.0205 Tm
[(Winifred)-335.1(Imoyera,)-335.6(Ayodeji)-333.8(Adebayo)]TJ
/F5 1 Tf
0 -1.7682 TD
[(University)-340(of)-334.8(Ibadan,)-331.5(Ibadan,)-331.5(Nigeria)]TJ
/F3 1 Tf
28.0044 71.9468 TD
(Background:)Tj
/F4 1 Tf
6.085 0 TD
[(Intimate)-490.3(partner)-488.1(violence)-487(\(IPV\))-486.9(is)-486.4(the)-485.3(most)]TJ
-7.0849 -1.128 TD
[(common)-228.6(form)-229.7(of)-234(domestic)-231.5(violence)-231(in)-231.1(Nigeria)-236.7(and)-229.7(a)-229.8(violation)-233.7(of)]TJ
0 -1.1219 TD
[(human)-454.8(rights.)-451.5(Many)-454.4(women)-456.3(in)-456.7(Nigeria)-456.2(are)-455.8(unaware)-455.4(of)-453.5(their)]TJ
0 -1.128 TD
[(sexual)-220.3(and)-223.6(reproductive)-223.4(rights)-219.9(\(SRRs\))-223.4(and)-223.6(are)-224.1(unable)-221.2(to)-225(exercise)]TJ
0 -1.1219 TD
[(them)-326.2(especially)-331.3(in)-322.6(the)-326.8(face)-332(of)-325.5(violations)-324.3(to)-328.7(their)-328.6(persons)-321.8(by)-329.2(an)]TJ
0 -1.128 TD
[(intimate)-389.8(partner.)-390.5(There)-390.6(is)-394.9(paucity)-391.4(of)-386.4(information)-390.8(on)-390.2(womens)]TJ
0 -1.1219 TD
[(understanding)-380.6(of)-386.4(their)-383.5(SRRs)-383.3(and)-388.3(how)-385.5(it)-383.1(relates)-384.9(with)-384.5(their)-383.5(ex-)]TJ
0 -1.128 TD
[(perience)-299(of)-301.1(IPV)-299.3(in)-304.3(Nigeria.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.8777 0 TD
[(Th)22.6(is)-309.6(st)19.7(ud)18.3(y)-317(w)0(a)18.7(s)-322.3(co)20.2(n)12.2(d)0(u)18.3(c)0(t)20.7(e)0(d)-315.1(t)12.7(o)-317(a)0(s)15(s)13.1(es)15(s)-316.2(t)0(h)18.9(e)-321.2(k)12.2(n)0(o)18.4(w)0(l)17.3(-)]TJ
-6.8776 -1.128 TD
[(ed)20.2(g)12.2(e)0(,)-418.8(p)0(r)16(e)14.1(va)14.1(l)12.7(e)0(n)20.2(c)0(e)-423(a)14.1(nd)-420.7(p)12.2(a)0(t)20.7(t)0(e)14.6(r)0(n)-416.9(o)12.2(f)-429.1(I)0(P)19.2(V)-428.3(am)20.7(on)18.3(g)-426.8(f)0(e)17.8(m)12.8(al)14.6(e)-424.9(s)0(e)15(c)14.1(on)18.3(d)12.2(a)0(r)17.8(y)]TJ
0 -1.1219 TD
[(s)13.1(c)0(h)20.2(o)0(o)18.3(l)-273.8(t)12.7(e)0(a)16(c)14.1(he)14.1(rs)-257.6(an)20.2(d)-274.3(t)12.7(o)-268.2(d)0(e)20.2(t)0(e)14.6(r)0(m)22.6(i)0(n)18.8(e)-272.5(t)12.7(h)0(e)-260.3(a)0(s)15(s)13.1(oc)20.2(ia)14.6(t)12.7(i)0(o)18.8(n)-268.2(be)20.2(tw)17.4(ee)16(n)-268.2(k)12.2(no)18.4(wl)17.3(-)]TJ
0 -1.128 TD
[(ed)20.2(g)12.2(e)-254.2(o)12.2(f)-252.3(SR)22.9(Rs)-241.6(an)20.2(d)-250(e)0(x)20.2(p)0(e)20.2(r)0(i)16.5(e)0(n)20.2(c)0(e)-240.1(o)0(f)-240.1(I)0(P)19.2(V)-251.5(i)12.7(n)-250(So)15.5(u)12.2(t)12.7(h-)16(W)14.1(e)0(s)15(t)-249.5(Ni)17.3(g)12.2(e)0(r)17.8(i)12.7(a.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Material/Methods:)Tj
/F4 1 Tf
8.4324 0 TD
[(A)-361.2(descriptive)-366(cross)-370.6(sectional)-363.7(study)-364.3(was)]TJ
-9.4324 -1.128 TD
[(conducted)-469.2(among)-467(364)-463.3(teachers)-468.9(using)-468(a)-467.6(multi-stage)-464.5(sampling)]TJ
T*
[(technique.)-560.2(A)-556.3(semi-structured)-564.4(self-administered)-562(questionnaire)]TJ
0 -1.1219 TD
[(was)-370.6(used)-369.1(to)-371.4(obtain)-368.9(information)-372.5(on)-371.9(respondents)-370.4(knowledge)-375(of)]TJ
0 -1.128 TD
[(SRRs)-322.3(and)-327.3(experience)-333.7(of)-325.5(IPV.)-323.7(Data)-326.4(was)-328(analyzed)-327.1(with)-329.6(descrip-)]TJ
0 -1.1219 TD
[(tive)-326.3(statistics)-326.3(and)-327.3(association)-326.2(between)-324.4(SRRs)-328.4(and)-327.3(experience)-327.6(of)]TJ
0 -1.128 TD
[(IPV)-299.3(tested)-299.1(with)-305.3(Chi-square)-302.9(at)-296.3(p)]TJ
/F2 1 Tf
12.9078 0 TD
(=)Tj
/F4 1 Tf
.6097 0 TD
(0.05.)Tj
/F3 1 Tf
-12.5175 -1.1219 TD
(Results:)Tj
/F4 1 Tf
3.8107 0 TD
[(The)-377.9(mean)-379.7(age)-374.2(of)-380.3(respondents)-380.3(was)-376.7(36.1)]TJ
/F2 1 Tf
16.4746 0 TD
()Tj
/F4 1 Tf
.7195 0 TD
[(7.8.)-377.9(Less)]TJ
-22.0048 -1.128 TD
[(than)-204.8(one-half)-213.7(\(41.2%\))-208.1(had)-205.4(good)-207.2(knowledge)-210.4(of)-203.5(SRRs.)-212.6(About)-208.2(60%)]TJ
0 -1.1219 TD
[(had)-321.2(ever)-327.8(experienced)-327.6(at)-326.8(least)-323.5(one)-327.3(form)-327.3(of)-319.4(IPV)-329.8(\(sexual:)-325.8(19.8%;)]TJ
0 -1.128 TD
[(verbal:)-204.7(42.9%;)-209(physical:)-207.1(8.0%;)-202.9(emotional:)-206.9(38.2%\).)-205.8(Signicantly,)]TJ
0 -1.1219 TD
[(higher)-255.9(proportion)-253.5(of)-252.3(respondents)-258.3(with)-256.5(good)-249.9(knowledge)-259.2(of)-252.3(SRRs)]TJ
0 -1.128 TD
[(experienced)-406.8(verbal)-400.4(IPV)-403(compared)-404.5(to)-401.9(34%)-398.6(of)-404.7(those)-405.2(with)-402.8(poor)]TJ
0 -1.1219 TD
[(knowledge)-301.9(\(p)]TJ
/F2 1 Tf
5.5241 0 TD
(=)Tj
/F4 1 Tf
.5548 0 TD
(0.006\).)Tj
/F3 1 Tf
-5.079 -1.128 TD
(Conclusions:)Tj
/F4 1 Tf
5.8838 0 TD
[(The)-390.1(study)-394.8(revealed)-402.7(poor)-392.5(knowledge)-399.4(of)-392.5(SRRs)]TJ
-6.8837 -1.1219 TD
[(and)-199.2(high)-206.7(prevalence)-205.6(of)-203.5(IPV)-201.8(among)-198.7(the)-204.8(study)-205.8(population.)-203.7(There)-201.5(is)]TJ
0 -1.128 TD
[(a)-278.6(need)-276.6(for)-279(in-service)-283.6(training)-279.3(regarding)-274.6(SRRs)-279.6(among)-277.9(secondary)]TJ
0 -1.1219 TD
[(school)-277.1(female)-282.1(teachers)-279.9(who)-275.8(may)-278(serve)-278.1(as)-283.8(custodians)-273.8(of)-282.8(same)-275.2(to)]TJ
0 -1.128 TD
[(their)-298.1(students)-300.1(and)-302.9(communities.)]TJ
/F3 1 Tf
0 -3.0364 TD
(44.)Tj
9.843 0 0 9.843 331.7668 383.4708 Tm
[(Implementation)-284.4(and)-279.4(Assessment)-285(of)-278.6(the)-286.5()50.8(Its)-281.5(Only)]TJ
0 -1.1116 TD
[(Natural:)-223.9(Mothers)-231.9(Love,)-223.1(Mothers)-231.9(Milk)49.8()-225.7(Campaign)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 310.8472 355.918 Tm
[(Ashani)-333.5(Johnson-Turbes)]TJ
6.9735 0 0 6.198 399.6282 360.0566 Tm
(1)Tj
9.2982 0 0 9.2982 403.0865 355.918 Tm
[(,)-335.3(Ursuline)-335.3(Singleton)]TJ
6.9735 0 0 6.198 479.3951 360.0566 Tm
(2)Tj
9.2982 0 0 9.2982 482.9101 355.918 Tm
[(,)-329.2(Brieon)-339.9(Arthur)]TJ
6.9735 0 0 6.198 541.5873 360.0566 Tm
(1)Tj
9.2982 0 0 9.2982 545.0455 355.918 Tm
(,)Tj
-25.1875 -1.1219 TD
[(Danielle)-335.6(Nielsen)]TJ
6.9735 0 0 6.198 374.0598 349.6251 Tm
(1)Tj
/F5 1 Tf
-9.0647 -2.6526 TD
(1)Tj
9.2982 0 0 9.2982 314.3054 329.0456 Tm
[(ICF)-338.1(International,)-332.7(Atlanta,)-335.5(Georgia)]TJ
6.9735 0 0 6.198 310.8472 322.696 Tm
(2)Tj
9.2982 0 0 9.2982 314.3054 318.5574 Tm
[(Ofce)-338.6(on)-329.2(Womens)-338.7(Health,)-333.8(Washington,)-329.5(District)-337.2(of)-334.8(Columbia)]TJ
/F3 1 Tf
.628 -2.2986 TD
(Background:)Tj
/F4 1 Tf
5.8777 0 TD
[(A)-275.8(recent)-276.6(report)-276.6(demonstrated)-274.5(that)-277.5(racial/ethnic)]TJ
-6.8776 -1.128 TD
[(disparities)-458(in)-456.7(breastfeeding)-458.5(rates)-460.5(are)-455.8(a)-455.4(present)-460.5(and)-455.3(persistent)]TJ
0 -1.1219 TD
[(challenge)-235.2(in)-237.2(the)-235.3(United)-236.3(States)-241(with)-238.2(a)-235.9(high)-237.2(rate)-235.8(of)-234(discontinuance)]TJ
0 -1.128 TD
[(and)-315.1(racial/ethnic)-313.3(disparities,)-317.8(particularly)-313.9(among)-314.5(African)-318.9(Amer-)]TJ
0 -1.1219 TD
[(icans.)-354.5(Given)-358.7(this,)-351.7(the)-357.3(Ofce)-356.5(on)-353.6(Womens)-356.8(Health)-356.3(\(OWH\))-353.3(sup-)]TJ
0 -1.128 TD
[(ports)-433.8(ICF)-436.7(International)-441.9(to)-438.4(implement)-438.6(and)-437(test)-435.2(the)-442.6()58.6(Its)-438.6(Only)]TJ
0 -1.1219 TD
[(Natural:)-303.3(Mothers)-299.2(Love,)-298.6(Mothers)-305.3(Milk)54.5()-301.1(campaign)-298(\(ION\).)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.7131 0 TD
-.0149 Tc
[(This)-203(project)-209.5(is)-209.1(aimed)-210(a)-.8(t)-209.5(u)3.4(sing)-203.9(\()-14.9(a)9(nd)-210(examining)-210(u)3.4(se)]TJ
-6.713 -1.1219 TD
-.0133 Tc
[(o)5(f)2.6(\))-326.6(a)-322.4(cu)5(ltu)5(rally)5(-app)5(r)-13.3(o)14.9(pria)6.9(te,)-324.2(2)5(-)-13.3(p)14.9(ron)5(g)-1.1(ed)-318.1(campa)6.9(ign)-318.1(i)-.6(mp)5(lem)5.5(e).8(nta)6.9(tio)5(n)]TJ
0 -1.128 TD
-.0148 Tc
[(s)4.4(t)-2.1(rategy)-270.9(to)-270.8(enhance)-269(a)-.7(doption)-270.9(o)3.5(f)-273.2(b)3.5(reastfeeding)-270.9(a)-.7(s)-270(a)-269(best)-270.4(practice)-275.1(i)4(n)]TJ
T*
-.0146 Tc
[(Afr)-14.6(i)14.1(can)-240.2(A)-14.6(m)15(erican)-240.2(communities.)-240.2(Th)]TJ
13.8589 0 TD
[(e)-238.4(p)-2.5(roject)-239.8(seeks)-239.4(t)-2(o)-240.3(c)-.6(ontribute)-244.5(t)4.1(o)]TJ
-13.8589 -1.1219 TD
-.0132 Tc
[(a)-334.4(p)-1(o)5.1(s)-.1(i)5.6(tiv)5.1(e)-340.5(s)6(hi)5.6(f)-13.2(t)-326(i)5.6(n)-336.3(breas)6(tfeedi)5.6(n)-1(g)-336.3(i)5.6(ni)5.6(tiat)5.6(i)-.5(on)5.1(,)-336.3(d)5.1(urati)5.6(o)-1(n)5.1(,)-336.3(and)-336.3(a)7(tti)5.6(tud)5.1(e).9(s)]TJ
0 -1.128 TD
-.015 Tc
[(and)-447.9(t)-2.3(o)-447.9(m)-2.2(ake)-452.1(b)-2.8(reastfeeding)-447.9(a)-452.1(societal)-453.5(and)-447.9(c)-.9(ultural)-447.4(n)-2.8(orm)-453.4(i)3.8(n)-454(t)3.8(he)]TJ
0 -1.1219 TD
-.0145 Tc
[(Afr)-14.5(i)14.2(can)-301(American)-294.9(community.)]TJ
/F3 1 Tf
.9999 -1.128 TD
0 Tc
(Material/Methods:)Tj
/F4 1 Tf
8.4019 0 TD
[(A)-336.8(2-pronged)-331.9(ION)-334.5(implementation)-338(strat-)]TJ
-9.4019 -1.1219 TD
[(egy,)-278.5(along)-278(with)-280.9(use)-277.7(of)-276.7(the)-284.1(#itsonlynatural)-277.7(hashtag,)-281.3(was)-279.2(used)-277.6(to)]TJ
0 -1.128 TD
[(implement)-450.8(the)-448.7(ION)-450.4(in)-450.6(3)-451.2(states)-450.7(with)-451.6(low)-446(breastfeeding)-452.4(rates:)]TJ
0 -1.1219 TD
[(Alabama,)-299.5(Louisiana,)-300.9(and)-302.9(Mississippi.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Results:)Tj
/F4 1 Tf
3.6644 0 TD
[(Strategy)-225.9(1)-231.7(involved)-228.6(conduct)-227.3(of)-227.9(4)-231.7(trainings)-229.6(to)-231.1(train)-225(28)]TJ
-4.6643 -1.1219 TD
[(local)-251.2(women)-255.1(to)-255.5(disseminate)-258.6(the)-253.6(ION)-255.3(at)-253.7(the)-253.6(grass)-254.8(roots)-257(level)-257.3(in)-249.4(3)]TJ
0 -1.128 TD
[(states.)-377.5(Women)-373.6(also)-380.8(facilitated)-376.2(27)-378(in-person,)-373.2(mother-to-mother)]TJ
0 -1.1219 TD
[(support)-214.3(meetings)-213.2(across)-216.3(8)-213.4(breastfeeding)-214.6(clubs)-210(in)-212.8(AL)-216.7(and)-211.4(MS)-215.4(and)]TJ
0 -1.128 TD
[(distributed)-521.7(campaign)-523.6(materials)-524.1(during)-520(a)-522.5(national)-525(conference)]TJ
0 -1.1219 TD
[(targeting)-234.7(African)-233.5(American)-234.8(women)-236.8(\(the)-231.6(2015)-231.6(Essence)-238.2(Festival\).)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 59.7543 749.7069 Tm
(ABSTRACTS)Tj
52.6193 0 TD
(A-17)Tj
ET
endstream
endobj
257 0 obj
<>stream
/GS1 gs
BT
/F4 1 Tf
9.2982 0 0 9.2982 62.022 725.5557 Tm
0 0 0 rg
0 Tc
0 Tw
[(Strategy)-463.7(2)-457.3(involved)-460.3(211)-457.2(healthcare)-461.2(professionals)-460.5(attending)-464(3)]TJ
0 -1.128 TD
[(breastfeeding)-312.1(summits)-313.1(where)-311(399)-310.9(ION)-310.2(materials)-316.8(were)-311(dissemi-)]TJ
0 -1.1219 TD
[(nated.)-331(During)-326.4(20142015)-329(there)-333.3(were)-329.3(1.8)-329.2(thousand)-325.8(tweets)-331.1(from)]TJ
0 -1.128 TD
[(1.4)-237.7(thousand)-240.5(contributors)-244.1(reaching)-239.9(2.5)-243.8(million)-241.2(Twitter)-240(accounts.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Conclusions:)Tj
/F4 1 Tf
5.7192 0 TD
[(There)-238.1(is)-236.4(value)-233.4(in)-237.2(using)-230.2(a)-235.9(culturally-appropriate,)]TJ
-6.7191 -1.128 TD
[(2-pronged)-441.6(strategy)-441.7(to)-438.4(implement)-444.7(the)-442.6(ION.)-438.2(This)-445.5(approach)-441.6(in-)]TJ
0 -1.1219 TD
[(volved)-302.3(a)-309(partner)-305.2(with)-305.3(proven)-305.2(success)-302.6(reaching)-307(target)-308.4(audiences)]TJ
0 -1.128 TD
[(suggesting)-409.8(that)-405.5(this)-406.6(is)-401(an)-406.6(effective)-410.6(approach)-405.1(to)-408(reach)-405.1(African)]TJ
0 -1.1219 TD
[(American)-411.6(audiences)-417.7(and)-406.6(ultimately)-413.7(help)-412.1(reduce)-411.2(breastfeeding)]TJ
0 -1.128 TD
(disparities.)Tj
/F3 1 Tf
0 -2.7437 TD
(45.)Tj
9.843 0 0 9.843 82.9417 605.877 Tm
[(Quality)-279.7(Of)-279.9(Life)-283.2(and)-285.2(Psychosocial)-281.4(Status)]TJ
0 -1.1116 TD
[(of)-278.6(Women)-285.1(Cancer)-281.5(Patients)-281.6(\(Wcp\))-284(from)-283.1(Malwa)]TJ
0 -1.1174 TD
[(Region)-285.1(of)-278.6(Punjab,)-281.4(India)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 62.022 567.3826 Tm
[(Rajinder)-337.5(Kaur)]TJ
6.9735 0 0 6.198 115.8803 571.5211 Tm
(1)Tj
9.2982 0 0 9.2982 119.3385 567.3826 Tm
[(,)-335.3(Parneet)-334.3(Kaur)]TJ
6.9735 0 0 6.198 174.444 571.5211 Tm
(2)Tj
/F5 1 Tf
-16.1213 -2.6526 TD
(1)Tj
9.2982 0 0 9.2982 65.537 550.9416 Tm
[(Punjabi)-329.9(University,)-340(Patiala,)-329.4(India)]TJ
6.9735 0 0 6.198 62.022 544.6487 Tm
(2)Tj
9.2982 0 0 9.2982 65.537 540.5101 Tm
[(Guru)-329.8(Nanak)-338.1(Dev)-333(University)-333.9(Amritsar,)-334.9(Patiala,)-335.5(India)]TJ
/F3 1 Tf
.6219 -2.3047 TD
(Background:)Tj
/F4 1 Tf
5.9631 0 TD
[(Quality)-363.8(of)-362.1(life)-359.1(\(QOL\))-363.1(and)-363.9(psychosocial)-357.2(well-)]TJ
-6.963 -1.128 TD
[(being)-576.7(of)-575.5(breast)-582.5(and)-577.3(gynaecological)-574.1(women)-578.2(cancer)-580(patients)]TJ
0 -1.1219 TD
[(\(WCP\))-321.3(is)-327.8(inuenced)-319.7(by)-323.1(the)-326.8(diagnosis)-318.3(and)-327.3(treatment)-323.7(of)-319.4(the)-326.8(dis-)]TJ
0 -1.128 TD
[(ease.)-304.4(Moderate)-300(to)-298.2(severe)-306.7(depression)-301(is)-297.4(the)-302.4(main)-301.9(paradigm.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.8655 0 TD
[(To)-361.5(analyze)-357.7(the)-363.4(impact)-360.4(of)-356(diagnosis)-361(and)-357.8(treat-)]TJ
-6.8654 -1.128 TD
[(ment)-356.7(on)-353.6(QOL)-358.4(and)-351.7(psychosocial)-357.2(status)-355(of)-356(WCP)-353.2(suffering)-357.3(from)]TJ
0 -1.1219 TD
[(breast)-247.1(cancer)-244.7(\(BC\),)-239.7(cervix)-248(cancer)-244.7(\(CC\))-245.8(and)-241.9(ovarian)-241.8(cancer)-244.7(\(OC\))]TJ
0 -1.128 TD
[(in)-298.2(Malwa)-307.2(region)-298.6(of)-301.1(Punjab.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Material/Methods:)Tj
/F4 1 Tf
8.6519 0 TD
[(300)-579.2(WCP)-578.8(visiting)-582.3(OPDs)-580.4(of)-581.6(various)]TJ
-9.6519 -1.128 TD
[(Government)-254.9(Hospitals)-252.3(from)-248(February-April)-252.7(2014)-249.9(completed)-254.8(the)]TJ
0 -1.1219 TD
[(predesigned)-598.7(EORTC)-599.8(questionnaires)-596.8(viz.)-601.2(QLQ-C30)-597.1(\(general)]TJ
0 -1.128 TD
[(cancer)-549.6(module\),)-548(QLQ-BR23)-553(\(Breast)-546.8(cancer)-555.7(module\),)-548(QLQ-)]TJ
0 -1.1219 TD
[(CX24)-262.2(\(Cervix)-269.1(cancer)-269.1(module\))-261.5(and)-266.3(QLQ-OV28)-266.1(\(Ovarian)-264(cancer)]TJ
0 -1.128 TD
[(module\).)-401.7(Goldbergs)-399.1(depression)-404.7(scale)-401.4(and)-400.5(Kuppuswamys)-403.4(so-)]TJ
0 -1.1219 TD
[(cioeconomic)-387(scale)-389.2(\(2012\))-388.7(were)-384.1(administered)-389.9(for)-388.8(the)-387.8(measure-)]TJ
0 -1.128 TD
[(ment)-301.9(of)-301.1(depression)-301(and)-296.8(socioeconomic)-306.8(status,)-300.1(respectively.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Results:)Tj
/F4 1 Tf
3.8534 0 TD
-.0166 Tc
[(Pres)-3.5(ent)-418.5(s)-3.5(tu)-4.4(dy)-419(con)-4.4(c)-2.5(lu)-4.4(ded)-419(t)-3.9(hat)-418.5(m)2.3(o)-4.4(r)-.7(e)-417.1(t)-3.9(han)-419(h)1.7(al)-3.9(f)-415.3(o)-4.4(f)-415.3(t)-3.9(he)]TJ
-4.8534 -1.128 TD
-.0142 Tc
[(WCP)-267(w)-14.2(e)10.6(r)1.7(e)-268.4(i)-1.5(lliterate)-268.4(\()1.7(62.)]TJ
9.5543 0 TD
[(33)4.1(%\),)-270.3(d)-2(ep)4.1(ressed)-270.3(\()1.7(MDV)]TJ
/F2 1 Tf
9.286 0 TD
0 Tc
(=)Tj
/F4 1 Tf
.5366 0 TD
-.013 Tc
[(47)5.3(.5)5.3(4\))-265.3(and)-269.1(from)]TJ
-19.3769 -1.1219 TD
-.0165 Tc
[(ru)-4.3(ral)-363.5(b)-4.3(ackg)-4.3(r)-.6(o)-4.3(u)1.8(n)-4.3(d)-364(\(7)-4.3(3.)-4.3(33)-4.3(%\).)-370.1(S)-1.1(tu)-4.3(di)-3.8(ed)-364(ag)-4.3(e)-368.2(g)1.8(ro)-4.3(up)-370.1(39)-4.3(5)-4.3(8)-364(y)-4.3(ears)-369.3(s)2.7(u)-4.3(f)-.6(-)]TJ
0 -1.128 TD
-.0144 Tc
[(fered)-563.1(e)-.3(xtens)4.8(i)-1.7(vely)-563.1(from)-556.5(w)-14.4(o)14.6(m)-1.6(en)-557(related)-557(cancers)-556.2(\()-14.4(B)15.1(C)-.8(,)-563.1(5)3.9(4.84%)-14.4(,)]TJ
0 -1.1219 TD
-.015 Tc
(MDV)Tj
/F2 1 Tf
2.2803 0 TD
0 Tc
(=)Tj
/F4 1 Tf
.5366 0 TD
-.0167 Tc
[(41)-4.5(.5)-4.5(3;)-1125.9(CC,)-1120.3(5)-4.5(4)1.6(.)-4.5(5)1.6(5)-4.5(%)-.7(,)-1120.3(M)-3.6(DV)]TJ
/F2 1 Tf
12.8468 0 TD
0 Tc
(=)Tj
/F4 1 Tf
.5366 0 TD
-.0175 Tc
[(43)-5.3(.0)-5.3(7;)-1126.7(OC,)-1127.2(6).8(9)-5.3(.).8(2)-5.3(3).8(%)-17.5(,)]TJ
-16.2002 -1.128 TD
-.015 Tc
(MDV)Tj
/F2 1 Tf
2.2803 0 TD
0 Tc
(=)Tj
/F4 1 Tf
.5366 0 TD
-.015 Tc
[(46.78\).)-435.7(D)-15(e)9.8(p)3.3(ression)-435.7(levels)-440.9(elevated)-435.7(and)-429.6(Q)-15(O)12.5(L)-437.5(diminished)]TJ
-2.8169 -1.1219 TD
[(with)-423.5(each)-423.5(chemotherapy)-423.5(or)-425.9(r)-15(a)8.9(diother)-15(a)8.9(py)-423.5(dose.)-423.5(P).4(atients)-422.6(w)-15(i)14.5(t)-2.3(hout)]TJ
0 -1.128 TD
[(sur)-14.9(g)13.3(ery)-344.1(h)-2.7(a)5.3(v)-2.7(e)-342.2(p)-2.7(oor)-340.4(Q)-14.9(O)12.6(L)-346(and)-344.1(h)3.4(igh)-338(d)]TJ
14.176 0 TD
[(epr)-15(e)8.9(s)4.2(s)-1.9(ion)-344.2(l)-2.3(evels)-343.4(\().9(BC,)-338.1(7.09%)-15(,)]TJ
-14.176 -1.1219 TD
(MDV)Tj
/F2 1 Tf
2.2803 0 TD
0 Tc
(=)Tj
/F4 1 Tf
.5366 0 TD
-.0167 Tc
[(44)-4.5(.2)-4.5(7;)-1125.9(CC,)-1120.3(8)-4.5(1)1.6(.)-4.5(8)1.6(1)-4.5(%)-.7(,)-1120.3(M)-3.6(DV)]TJ
/F2 1 Tf
12.8468 0 TD
0 Tc
(=)Tj
/F4 1 Tf
.5366 0 TD
-.0175 Tc
[(43)-5.3(.0)-5.3(7;)-1126.7(OC,)-1127.2(7).8(6)-5.3(.).8(9)-5.3(2).8(%)-17.5(,)]TJ
-16.2002 -1.128 TD
-.015 Tc
(MDV)Tj
/F2 1 Tf
2.2803 0 TD
0 Tc
(=)Tj
/F4 1 Tf
.5366 0 TD
-.0142 Tc
[(46.2\))-364.1(a)-.1(long)-361.7(w)-14.2(i)15.3(th)-367.8(fatigue,)-367.8(pain)-361.7(and)-361.7(dys)5(pnoea.)-361.7(Statistically)]TJ
-2.8169 -1.128 TD
-.0159 Tc
[(s)-2.8(i)2.9(g)-3.7(n)2.4(i)-3.2()-.5(can)-3.7(t)-259.3(r)0(es)-2.8(ul)-3.2(ts)-265(ob)-3.7(ser)-15.9(v)12.3(ed)-259.8(i)-3.2(n)-259.8(QOL)-261.6(o)-3.7(f)-256(BC/)-3.2(CC)-258.4(pat)-3.2(i)-3.2(e)-1.8(nt)-3.2(s)-258.9(\()0(p)]TJ
/F2 1 Tf
22.5047 0 TD
0 Tc
(>)Tj
/F4 1 Tf
.7012 0 TD
-.0122 Tc
[(0.)6.1(00)6.1(1\))]TJ
-23.2059 -1.1219 TD
-.0148 Tc
[(as)-300.5(well)-300.8(as)-300.5(in)-301.3(social)-300.8(functionin)]TJ
11.7493 0 TD
-.0145 Tc
[(g)-301(o)-2.3(f)-297.3(BC/)4.3(O)-14.5(C)-288.9(and)-301(CC/)4.3(O)-14.5(C)-288.9(patients)4.7(.)]TJ
/F3 1 Tf
-10.7493 -1.128 TD
0 Tc
(Conclusions:)Tj
/F4 1 Tf
5.835 0 TD
[(We)-349.8(concluded)-353.4(that)-350.7(chemicals)-349.6(used)-350.8(in)-347(agricul-)]TJ
-6.835 -1.1219 TD
[(tural)-255.5(elds)-249.5(and)-254.1(lack)-251.7(of)-252.3(awareness)-256.6(regarding)-250.3(personal)-253.2(health)-257.3(care)]TJ
0 -1.128 TD
[(tremendously)-252(affects)-247.6(the)-247.5(health)-251.2(status)-251.4(and)-248(well-being)-248.4(of)-252.3(Punjabi)]TJ
0 -1.1219 TD
[(women.)-267.2(There)-274.7(is)-266.9(utmost)-265.7(need)-270.5(of)-264.5(personal)-271.4(health)-269.5(care)-271(awareness)]TJ
0 -1.128 TD
[(campaign)-346.8(for)-346.1(Indian)-347.4(women)-346.5(as)-344.8(most)-345.6(of)-343.8(the)-345.1(women)-346.5(reach)-350.3(hos-)]TJ
0 -1.1219 TD
[(pital)-301.4(at)-302.4(last)-301(stage)-299.6(of)-301.1(cancer.)]TJ
/F3 1 Tf
0 -3.2803 TD
(46.)Tj
9.843 0 0 9.843 82.9417 143.3763 Tm
(17)Tj
/F10 1 Tf
1.0022 0 TD
(b)Tj
/F3 1 Tf
.5472 0 TD
[(-Estra)-8.5(diol)-281(Induced)-279.9(Effects)-287.2(on)-278.5(ACL)-282.5(Laxness)]TJ
-1.5494 -1.1116 TD
[(and)-279.4(Neuromuscular)-285.3(Activation)-283.8(Patterns)]TJ
0 -1.1174 TD
[(in)-278.6(Female)-287.8(Runners)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 62.022 104.8819 Tm
[(Iman)-335.2(Khowailed)]TJ
/F5 1 Tf
0 -1.7682 TD
[(Touro)-331.1(University,)-340(Henderson,)-331.2(Nevada)]TJ
/F3 1 Tf
.9999 -2.3047 TD
(Background:)Tj
/F4 1 Tf
5.8594 0 TD
[(Female)-264.3(athletes)-262.4(increased)-261.6(risk)-263.1(for)-260.8(non-contact)]TJ
-6.8593 -1.1219 TD
[(anterior)-451(cruciate)-451(ligament)-451.3(\(ACL\))-451.7(injury)-446.3(has)-448.4(been)-453.4(well)-449.7(docu-)]TJ
26.9984 71.9468 TD
[(mented)-220.7(\(Dedrick)-221.3(et)-217.1(al.,)-223.1(2008,)-213.3(Ireland)-225.9(and)-217.5(Ott,)-219.9(2004\).)-215.6(Women)-221.2(are)]TJ
0 -1.128 TD
[(two)-342.4(to)-334.8(eight)-338.4(times)-337.1(more)-335.2(likely)-337.9(to)-334.8(injure)-340.8(their)-334.7(ACL)-337.2(when)-341(com-)]TJ
0 -1.1219 TD
[(pared)-382.6(to)-377.5(men)-381.6(in)-377.5(comparable)-383.8(sporting)-378.3(activities)-381(\(Wojtys)-382.6(et)-375.6(al.,)]TJ
0 -1.128 TD
[(1998\).)-368.1(The)-359.6(discrepancy)-365.2(in)-365.3(ACL)-361.6(injury)-367(risk)-360.7(between)-367.1(sexes)-360.3(has)]TJ
0 -1.1219 TD
[(been)-355.9(attributed)-350(to)-347(multiple)-349(factors)-353.1(including)-350(differences)-357.7(in)-347(an-)]TJ
0 -1.128 TD
[(atomical,)-473.8(hormonal,)-462.6(biomechanical,)-469.9(and)-467.5(neuromuscular)-466.4(char-)]TJ
0 -1.1219 TD
[(acteristics)-307.9(\(Ireland)-301.4(and)-302.9(Ott,)-299.2(2004\).)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Objective\(s\):)Tj
/F4 1 Tf
6.0911 0 TD
[(To)-587.1(investigate)-582.7(the)-582.9(effects)-582.9(of)-587.7(17)]TJ
/F7 1 Tf
14.1211 0 TD
(b)Tj
/F4 1 Tf
.5487 0 TD
(-Estradiol)Tj
-21.7609 -1.1219 TD
[(across)-368.7(phases)-360.2(of)-362.1(menstrual)-361.9(cycle)-365.7(on)-359.7(the)-363.4(anterior)-365.6(cruciate)-365.6(liga-)]TJ
0 -1.128 TD
[(ment)-271.4(\(ACL\))-274.9(laxness)-268.2(and)-272.4(neuromuscular)-271.3(control)-273.7(patterns)-270.9(around)]TJ
0 -1.1219 TD
[(the)-302.4(knee)-301(joint)-303.2(in)-298.2(female)-300.4(runners.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Material/Methods:)Tj
/F4 1 Tf
8.3836 0 TD
[(Twelve)-309.9(healthy)-312.1(female)-312.6(runners,)-312.8(who)-306.3(re-)]TJ
-9.3836 -1.1219 TD
[(ported)-292.5(normal)-292(menstrual)-288.7(cycles)-297.7(for)-285.1(the)-290.2(previous)-291.6(6)-292.6(months)-290.6(were)]TJ
0 -1.128 TD
[(tested)-488.1(twice)-484.4(across)-484.6(one)-485.8(complete)-486.5(menstrual)-483.8(cycle)-487.6(for)-486.3(serum)]TJ
T*
[(levels)-366.2(of)-356(17)]TJ
/F7 1 Tf
4.896 0 TD
(b)Tj
/F4 1 Tf
.9146 0 TD
[(Estradiol)-359.5(\(E\),)-360.1(and)-363.9(knee)-355.9(joint)-364.2(laxity)-362.3(\(KJL\).)-360.7(Elec-)]TJ
-5.8106 -1.1219 TD
[(tromyographic)-243(\(EMG\))-238.8(activity)-237.9(of)-234(the)-241.4(quadriceps)-239(and)-235.8(hamstrings)]TJ
0 -1.128 TD
[(muscles)-359.2(was)-358.4(also)-356.4(recorded)-352.6(during)-355.4(running)-355.3(on)-353.6(a)-357.8(treadmill.)-355.6(The)]TJ
0 -1.1219 TD
[(changes)-237.2(in)-237.2(the)-235.3(EMG)-234.1(activity,)-237.9(KJL,)-240.2(and)-235.8(hormonal)-231(concentrations)]TJ
0 -1.128 TD
[(were)-469.5(recorded)-474.5(for)-462(each)-469.9(subject)-469.8(during)-465.1(the)-467(follicular)-468.2(and)-467.5(the)]TJ
0 -1.1219 TD
[(ovulatory)-304.1(phases)-299.3(across)-301.6(the)-302.4(menstrual)-300.9(cycle.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Results:)Tj
/F4 1 Tf
3.6949 0 TD
[(An)-263.6(observed)-259.8(increased)-261.6(in)-255.5(KJL)-264.6(in)-255.5(response)-258.9(to)-261.6(peak)-258.3(E)]TJ
-4.6948 -1.1219 TD
[(during)-331(the)-332.9(ovulatory)-328.5(phase,)-330.6(was)-334(associated)-331(with)-335.7(increased)-328.6(pre-)]TJ
0 -1.128 TD
[(activity)-219.6(of)-215.7(the)-217(hamstring)-211.3(muscle)-219.8(before)-214.2(foot)-215.2(impact)-214.1(\(p)]TJ
/F2 1 Tf
21.4011 0 TD
(<)Tj
/F4 1 Tf
.5487 0 TD
[(0.001\).)-215.6(A)]TJ
-21.9499 -1.1219 TD
[(consistent)-303.8(pattern)-302.3(was)-303.6(also)-301.5(observed)-302.4(in)-298.2(the)-302.4(ring)-297.3(of)-301.1(the)-302.4(quadri-)]TJ
0 -1.128 TD
[(ceps)-294.1(muscle)-293(recruitment)-295.6(pattern)-290.1(throughout)-293.8(the)-290.2(follicular)-291.4(p)-12.2(h)-12.2(a)-10.3(s)-11.3(e)]TJ
0 -1.1219 TD
.0108 Tc
[(a)-5.6(s)10.8(s)-5.7(o)-1.4(ciat)10.8(e)-11.2(d)-208.7(with)-208.7(d)10.8(e)-5.6(creased)-208.7(h)10.8(a)-5.6(mstrin)10.8(g)-214.7(r)-3.7(ecrui)10.8(t)-6.4(m)-.8(en)10.8(t)-220.3(p)10.8(a)-5.6(ttern)-208.7(du)10.8(r)-9.8(i)10.8(n)-6.9(g)]TJ
0 -1.128 TD
.0118 Tc
[(weig)11.8(h)-6.4(t)-213.3(accept)11.8(a)-4.1(nce)-211.9(p)-.4(h)11.8(a)-10.7(s)11.8(e)-217.1(of)-210(ru)11.8(n)-6.4(n)11.8(i)-5.9(n)-.4(g)-207.7(\()-2.7(p)]TJ
/F2 1 Tf
15.5905 0 TD
0 Tc
(=)Tj
/F4 1 Tf
.5609 0 TD
[(0)-12.2(.)-12.2(0)0(2)-18.2(\))-8.4(.)-225.6(Add)16.9(iti)13.8(on)12.3(all)15.1(y,)-207.3(lo)12.7(w)]TJ
-16.1515 -1.1219 TD
[(rat)12.3(io)-316.5(of)-319.4(med)14.7(ial)-314.1(to)-316.5(late)17.1(ral)-317(qu)12.2(adr)11.8(ice)16.5(ps)-322.3(re)11.7(cr)11.7(uit)13.3(men)14.7(t)-322.6(was)-315.8(ass)15.8(oci)14.6(ate)10.4(d)]TJ
0 -1.128 TD
[(wit)11.8(h)-359.7(a)-363.9(sig)13.6(ni)16(cant)-349.3(red)11.8(uct)14.7(io)12.7(n)-365.8(o)0(f)-356(t)0(h)12.7(e)-363.9(qua)14.1(dric)18.4(eps)-356.9(to)-353.1(ham)14.7(str)11.2(in)12.8(g)-365.8(c)0(o)14.1(-)]TJ
0 -1.1219 TD
[(con)14.1(tra)12.3(cti)15.1(on)-292.6(ra)11.7(tio)-285.5(dur)16(ing)-286(the)-284.1(foll)17(icu)14.7(lar)-286.5(ph)12.2(ase)10.8(.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Conclusions:)Tj
/F4 1 Tf
5.8106 0 TD
[(Changes)-323.1(in)-322.6(KJL)-325.6(during)-318.8(the)-326.8(menstrual)-325.3(cycle)-323(in)]TJ
-6.8106 -1.1219 TD
[(response)-423.5(to)-420.1(17)]TJ
/F7 1 Tf
6.1216 0 TD
(b)Tj
/F4 1 Tf
.5487 0 TD
[(-Estradiol)-422.8(uctuations)-423.3(changes)-420.2(the)-418.3(neuromus-)]TJ
-6.6703 -1.128 TD
[(cular)-382.1(control)-377.3(around)-378.4(the)-381.7(knee)-380.3(during)-373.6(running.)-379.7(Female)-380.2(runners)]TJ
0 -1.1219 TD
[(utilize)-335.5(different)-331.4(neuromuscular)-326.2(control)-334.7(strategies)-328.6(during)-331(differ-)]TJ
0 -1.128 TD
[(ent)-357.3(phases)-354.1(of)-356(the)-351.2(menstrual)-355.8(cycle)-359.6(which)-352.6(may)-351.2(contribute)-356.6(to)-353.1(in-)]TJ
0 -1.1219 TD
[(crease)-304.8(ACL)-300.7(injury)-300(risk.)]TJ
/F3 1 Tf
0 -4.1644 TD
(47.)Tj
9.843 0 0 9.843 333.9779 320.7117 Tm
[(Routine)-286(Pelvic)-281.1(Exams:)-285(Womens)-281.4(Attitudes)]TJ
0 -1.1116 TD
[(and)-285.2(Beliefs)-281.8(in)-278.6(Light)-282.9(of)-278.6(New)-282.7(Guidelines)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 313.0582 293.159 Tm
[(Juliana)-335.7(Kling)]TJ
6.9735 0 0 6.198 363.7983 297.2975 Tm
(1)Tj
9.2982 0 0 9.2982 367.3133 293.159 Tm
[(,)-335.3(Suneela)-331.9(Vegunta)]TJ
6.9735 0 0 6.198 436.9322 297.2975 Tm
(1)Tj
9.2982 0 0 9.2982 440.3904 293.159 Tm
[(,)-335.3(Stephanie)-337.5(Faubion)]TJ
6.9735 0 0 6.198 516.2455 297.2975 Tm
(2)Tj
9.2982 0 0 9.2982 519.7038 293.159 Tm
(,)Tj
-22.2243 -1.1219 TD
[(Mina)-338.1(Al-Badri)]TJ
6.9735 0 0 6.198 368.9574 286.866 Tm
(1)Tj
9.2982 0 0 9.2982 372.4156 282.7275 Tm
[(,)-335.3(Amit)-335.2(Shah)]TJ
6.9735 0 0 6.198 418.7337 286.866 Tm
(1)Tj
9.2982 0 0 9.2982 422.192 282.7275 Tm
[(,)-335.3(Heather)-339(Fields)]TJ
6.9735 0 0 6.198 483.0235 286.866 Tm
(1)Tj
9.2982 0 0 9.2982 486.5385 282.7275 Tm
[(,)-329.2(Mark)-334.9(Wallace)]TJ
6.9735 0 0 6.198 545.8392 286.866 Tm
(1)Tj
9.2982 0 0 9.2982 549.3542 282.7275 Tm
(,)Tj
-25.4131 -1.128 TD
[(Barbara)-339(Ruddy)]TJ
6.9735 0 0 6.198 373.6062 276.3779 Tm
(1)Tj
9.2982 0 0 9.2982 377.0645 272.2393 Tm
[(,)-335.3(Michael)-333.8(Bryan)]TJ
6.9735 0 0 6.198 438.9731 276.3779 Tm
(1)Tj
9.2982 0 0 9.2982 442.4314 272.2393 Tm
[(,)-335.3(Kathy)-334.3(MacLaughlin)]TJ
6.9735 0 0 6.198 523.9557 276.3779 Tm
(2)Tj
/F5 1 Tf
-30.2427 -2.6526 TD
(1)Tj
9.2982 0 0 9.2982 316.5731 255.7984 Tm
[(Mayo)-335.7(Clinic)-330.4(in)-334.8(Arizona,)-334.8(Scottsdale,)-335.1(Arizona)]TJ
6.9735 0 0 6.198 313.0582 249.5054 Tm
(2)Tj
9.2982 0 0 9.2982 316.5731 245.3669 Tm
[(Mayo)-335.7(Clinic)-330.4(Rochester,)-341.3(Rochester,)-335.2(Minnesota)]TJ
/F3 1 Tf
.6219 -2.3047 TD
(Background:)Tj
/F4 1 Tf
5.8655 0 TD
[(Rou)13.6(tin)13.3(e)-260.3(pel)14.6(vi)12.7(c)-260.3(exam)16.6(s)-261.3(h)0(a)14.1(v)0(e)-254.2(been)-246.1(a)-260.3(fun)16(dam)14.7(ent)14.7(al)]TJ
-6.8654 -1.1219 TD
[(par)11.8(t)-310.4(o)0(f)-307.2(the)-302.4(ann)14.1(ual)-302.4(ph)12.2(ysi)13.6(cal)-306.6(ex)14.1(am)-308.5(for)-303.4(wom)17.4(en)-309(for)-303.4(dec)16(ades)16.9(.)-310.9(How)15.4(-)]TJ
0 -1.128 TD
[(ever)13.7(,)-250(r)0(e)11.7(cent)-239.5(gui)12.8(del)14.6(in)12.7(es)-253.3(fr)13.6(om)-249.4(th)12.8(e)-254.2(A)0(m)11.3(eri)12.3(can)-246.2(Co)13.6(lle)15.1(ge)-248.1(of)-246.2(Phy)15.5(sici)16(ans)]TJ
T*
[(\(ACP)19.1(\))-374.3(r)0(e)11.7(com)14.7(men)14.7(d)-371.9(aga)16(ins)13.6(t)-371.4(rou)16(tin)13.3(e)-370(pel)14.6(vi)12.7(c)-376.1(e)0(x)14.1(ams)-362.5(in)-365.3(asy)15(mpt)13.3(om)12.8(-)]TJ
0 -1.1219 TD
[(atic)17(,)-298.7(n)0(o)12.2(n-p)16(reg)11.8(na)14.1(nt,)-286(aver)13.7(ag)14.1(e)-296.9(ris)11.2(k)-292.6(wom)17.4(en.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.8594 0 TD
[(To)-349.3(evaluate)-344.9(womens)-354.1(attitudes)-346.8(and)-345.6(beliefs)-350.2(re-)]TJ
-6.8593 -1.1219 TD
[(garding)-213.2(pelvic)-214.6(exams)-208.1(and)-211.4(how)-208.7(knowledge)-210.4(of)-209.6(new)-212.9(guidelines)-213.1(will)]TJ
0 -1.128 TD
[(affect)-303.3(their)-304.2(attitude)-298.9(and)-302.9(beliefs.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Material/Methods:)Tj
/F4 1 Tf
8.5056 0 TD
[(A)-440.5(d)12.2(es)21.1(cr)17.8(ip)18.8(ti)19.3(v)12.2(e)-431(c)14.1(r)0(o)16(s)13.1(s-)16.8(s)13.1(e)0(c)16(t)12.7(io)18.9(na)20.2(l)-426.3(s)0(t)19.7(u)0(d)18.3(y)-426.8(wa)18.7(s)]TJ
-9.5055 -1.128 TD
[(pe)14.1(rf)19.7(o)12.2(r)0(m)22.6(e)0(d)-187.1(u)12.2(si)19.7(n)12.2(g)-195.1(a)-193.2(s)13.1(el)14.6(f-)19.7(a)14.1(d)0(m)18.9(i)0(n)18.8(i)12.7(st)19.7(er)17.8(ed)-181(wr)14.5(i)12.7(t)0(t)19.4(e)0(n)-181(s)0(u)19.2(r)0(v)16(e)14.1(y.)-182.9(No)16.8(n)12.2(-)0(p)22.1(r)0(e)17.8(g)12.2(na)14.1(n)12.2(t)]TJ
0 -1.1219 TD
[(wo)16.8(m)12.8(e)0(n)-290.7(a)0(g)20.2(e)0(d)-284.6(2)12.2(1)-298.7(y)12.2(ea)16(rs)-281.9(or)-288.9(m)12.8(o)0(r)16(e)-296.9(p)12.2(r)0(e)17.8(s)13.1(en)20.2(ti)19.3(ng)-286.5(to)-286(o)12.2(u)0(t)18.8(p)0(a)20.2(t)0(i)19.3(e)0(n)20.2(t)-298.2(cl)20.7(in)18.9(ic)20.7(s)-297.9(a)0(t)]TJ
0 -1.128 TD
[(Ma)15(y)12.2(o)-335.3(Cl)14.1(i)12.7(n)12.2(ic)-326.8(Ar)14.5(i)12.7(z)0(o)20.2(n)0(a)-327.3(o)0(r)-331.6(M)13.1(ay)20.2(o)-335.3(C)0(l)14.1(i)12.7(n)12.2(i)0(c)-332.9(R)13.6(oc)20.2(he)20.2(st)13.6(e)14.1(r)-337.7(we)18.7(re)-329.7(p)12.2(r)0(e)17.8(s)0(e)21.1(n)0(t)18.8(e)0(d)]TJ
0 -1.1219 TD
[(wi)17.3(th)-316.5(th)18.8(e)-327.3(s)0(u)19.2(r)0(v)16(e)14.1(y.)-323.1(Th)22.6(e)-327.3(s)0(u)19.2(r)0(v)22.1(e)0(y)-321.2(w)0(a)18.7(s)-328.4(d)12.2(e)0(v)20.2(e)0(l)14.6(o)12.2(p)12.2(e)0(d)-321.2(a)0(f)17.8(t)12.7(er)-317.5(a)-333.4(t)12.7(h)12.2(o)0(r)16(o)12.2(u)12.2(g)0(h)-323.1(r)0(e)23.9(-)]TJ
0 -1.128 TD
[(vi)18.8(ew)-353.2(o)12.2(f)-362.1(t)12.7(h)0(e)-351.7(l)12.7(it)19.3(er)17.8(at)20.7(ur)16(e)-357.8(a)0(n)20.2(d)-359.7(wa)18.7(s)-358.9(r)0(e)17.8(v)12.2(is)19.7(ed)-351.7(to)-347(a)-363.9()0(n)21.6(a)0(l)-351.2(f)0(o)22.1(r)0(m)-349.3(b)0(a)20.2(s)0(e)15(d)-359.7(o)12.2(n)]TJ
0 -1.1219 TD
[(pr)16(o)12.2(v)12.2(i)0(d)18.8(e)0(r)-512.6(s)13.1(ug)18.3(g)12.2(e)0(s)15(t)12.7(io)18.9(n)12.2(s)0(.)-511.3(T)0(h)16.5(e)-516.4(su)19.2(rv)22.1(ey)-510.2(wa)18.7(s)-523.5(p)12.2(re)17.8(-t)22.6(es)15(t)12.7(e)0(d)-510.2(b)12.2(y)-518.2(s)0(t)19.7(a)0(f)17.8(f)-520.6(fo)22.1(r)]TJ
0 -1.128 TD
[(cl)14.6(ar)17.8(i)12.7(t)12.7(y)-451.2(a)14.1(n)0(d)-438.9(c)0(o)20.2(m)12.8(pr)16(eh)20.2(en)20.2(si)19.7(o)12.2(n)0(.)-439(A)0(f)20.6(t)12.7(er)-439.4(in)18.8(q)12.2(u)0(i)18.8(r)0(i)16.5(n)12.2(g)-445.1(a)0(b)20.2(o)12.2(ut)-438.4(p)12.2(e)0(l)14.6(v)12.2(i)12.7(c)-449.3(ex)20.2(am)]TJ
0 -1.1219 TD
[(pr)16(ac)22.1(ti)19.3(ce)16(s)-243(a)0(n)20.2(d)-243.9(be)20.2(li)19.3(ef)17.8(s,)-236.9(p)12.2(a)0(r)17.8(t)12.7(ic)14.6(i)12.7(p)12.2(an)20.2(ts)-236.4(we)18.7(re)-238.2(t)12.7(h)12.2(en)-235.9(in)18.8(fo)22.1(rm)16.5(e)14.1(d)-243.9(of)-234(th)18.8(e)-248.1(A)0(C)18.2(P)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 62.022 749.6502 Tm
(A-18)Tj
48.6864 0 TD
(ABSTRACTS)Tj
ET
endstream
endobj
261 0 obj
<>stream
DFPDED+AdvPSMP12 yMO
AdvPSMP12 C np[F2\L^yLƳiw3aIq{WqϬ-{+SOT/
OT8i
endstream
endobj
264 0 obj
<>stream
/GS1 gs
BT
/F4 1 Tf
9.2982 0 0 9.2982 59.7543 725.5557 Tm
0 0 0 rg
0 Tc
0 Tw
[(gu)18.3(id)18.8(el)20.7(in)18.8(es)-204.5(t)12.7(o)-213.4(i)12.7(d)12.2(en)14.1(t)12.7(i)12.7(f)0(y)-203.5(h)12.2(ow)-202.7(it)-200.2(wo)16.8(u)12.2(l)0(d)-200.7(a)0(f)17.8(f)0(e)17.8(c)0(t)-198.8(t)0(h)18.8(e)0(i)20.7(r)-215.7(at)20.7(t)12.7(i)0(t)19.3(u)0(d)18.3(e)-211.5(an)20.2(d)-213.4(b)12.2(el)20.7(ie)14.6(fs)]TJ
0 -1.128 TD
[(re)17.8(ga)20.2(rd)16(i)12.7(n)12.2(g)-432.9(p)12.2(el)14.6(v)12.2(i)12.7(c)-431(e)0(x)20.2(a)0(m)-424.3(f)0(r)19.7(e)0(q)20.2(u)12.2(en)20.2(cy)14.1(.)-426.8(D)0(e)18.7(m)0(o)18.9(g)12.2(ra)17.8(p)12.2(h)0(i)18.8(c)0(s)-424(a)14.1(nd)-420.6(pe)20.2(rt)16.5(i)12.7(n)0(e)20.2(n)0(t)]TJ
0 -1.1219 TD
[(me)14.7(d)12.2(i)12.7(ca)16(l)-292.1(h)12.2(i)12.7(s)0(t)13.6(o)12.2(ry)-276.7(qu)18.3(es)21.1(ti)19.3(on)18.3(s)-291.8(w)0(e)18.7(r)0(e)-280.9(a)0(l)20.7(s)0(o)-279.6(c)0(o)20.2(l)0(l)19.3(e)0(c)16(t)12.7(ed)-284.6(fr)19.7(o)12.2(m)-292.1(p)12.2(a)0(r)17.8(t)12.7(ic)20.7(ip)18.8(an)20.2(ts)19.7(.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Results:)Tj
/F4 1 Tf
3.9388 0 TD
[(671)-499.9(mostly)-497.4(Caucasian,)-501.7(married,)-499.8(educated)-504(female)]TJ
-4.9387 -1.1219 TD
[(participants)-268(completed)-267(surveys.)-266.9(Pelvic)-266.2(exams)-263(were)-268.3(described)-263.4(as)]TJ
0 -1.128 TD
[(reassuring)-449.7(and)-449.2(respectful,)-448.2(and)-443.1(a)-449.3(majority)-443.4(believed)-450.5(they)-448.7(were)]TJ
0 -1.1219 TD
[(useful)-383.1(in)-383.6(detecting)-382.9(ovarian)-382.1(cancer)-384.9(\(74.6%\),)-378.8(were)-384.1(necessary)-383.2(to)]TJ
0 -1.128 TD
[(screen)-294.5(for)-297.3(sexually)-293(transmitted)-293.7(infections)-294.8(\(STIs\))-291.3(\(71%\))-293.5(or)-295(prior)]TJ
0 -1.1219 TD
[(to)-493.3(initiating)-494.8(contraception)-499.1(\(67%\).)-488.6(54%)-496.1(believed)-493.1(they)-497.5(should)]TJ
0 -1.128 TD
[(have)-526.6(yearly)-522.3(pelvic)-525.5(exams,)-525.2(and)-522.4(49%)-520.5(reported)-524.7(having)-521.8(yearly)]TJ
0 -1.1219 TD
[(pelvic)-403.6(exams.)-403.2(Once)-400.1(presented)-403.7(with)-402.8(the)-406.1(ACP)-399.2(guideline,)-403(a)-400.5(sig-)]TJ
0 -1.128 TD
[(nicantly)-418.1(lower)-416(percentage)-419(planned)-422.4(to)-414.1(continue)-415.7(yearly)-418.7(pelvic)]TJ
0 -1.1219 TD
[(exams)-305.7(\(34.9%,)-297.2(p)]TJ
/F2 1 Tf
6.8289 0 TD
(<)Tj
/F4 1 Tf
.5548 0 TD
(0.0001\).)Tj
/F3 1 Tf
-6.3838 -1.128 TD
(Conclusions:)Tj
/F4 1 Tf
5.9996 0 TD
[(Women)-507.7(report)-508.3(pelvic)-507.3(exams)-513(are)-504.6(reassuring,)]TJ
-6.9996 -1.128 TD
[(important)-431.1(and)-430.9(despite)-427.1(evidence)-436.9(to)-426.2(the)-430.4(contrary,)-427.1(believe)-432.2(them)]TJ
0 -1.1219 TD
[(necessary)-566.1(for)-565.6(STI)-561.9(screening)-562.2(or)-563.3(contraception)-560.1(initiation)-568(and)]TJ
0 -1.128 TD
[(useful)-383.1(for)-382.7(ovarian)-388.2(cancer)-384.9(detection.)-382.9(After)-381.8(education)-383.4(on)-384.1(pelvic)]TJ
0 -1.1219 TD
[(exam)-385.8(screening)-385.4(guidelines,)-383.9(fewer)-386.5(women)-383.1(planned)-385.8(to)-383.6(continue)]TJ
0 -1.128 TD
[(yearly)-302.8(pelvic)-299.9(exams.)]TJ
/F3 1 Tf
0 -2.9815 TD
(48.)Tj
9.843 0 0 9.843 80.674 509.4991 Tm
[(Research)-284.7(Professionals)-289.1(Experience)-288.4(and)]TJ
0 -1.1116 TD
[(Perspectives)-290.5(on)-278.5(Womens)-281.4(Participation)]TJ
0 -1.1174 TD
[(in)-284.4(Clinical)-281.9(Research)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 59.7543 471.0046 Tm
[(Anita)-339.9(Kurt,)-332.5(Lauren)-335.7(Semler,)-329.6(Matthew)-337.1(Meyers,)]TJ
0 -1.1219 TD
[(Bernadette)-339.8(Glenn-Porter,)-335.7(Samantha)-331.4(Myles,)-337.2(Stephen)-333.8(Dusza,)]TJ
0 -1.128 TD
[(Jeanne)-334.8(Jacoby,)-336.7(John)-334.4(Smulian)]TJ
/F5 1 Tf
0 -1.7682 TD
[(Lehigh)-335.7(Valley)-338.4(Health)-333.8(Network,)-333.4(Bethlehem,)-337.9(Pennsylvania)]TJ
/F3 1 Tf
.9999 -2.3047 TD
(Background:)Tj
/F4 1 Tf
6.0362 0 TD
[(Despite)-428.6(continued)-434(focus)-426.3(and)-430.9(federal)-431.3(funding)]TJ
-7.0362 -1.1219 TD
[(requisites,)-507.3(signicant)-502.6(gender)-504.5(and)-504.1(racial)-501.7(disparities)-506.8(persist)-503.7(in)]TJ
0 -1.128 TD
[(clinical)-351.9(research)-343.7(participation.)-347.5(Although)-347.8(understanding)-344(regard-)]TJ
0 -1.1219 TD
[(ing)-438.4(research)-441.3(professionals)-438.5(perspectives)-443.1(about)-436.5(barriers)-434.7(to)-438.4(mi-)]TJ
0 -1.128 TD
[(nority)-428(participation)-426.8(has)-430.1(improved,)-426.1(their)-426.2(perspective)-431.7(regarding)]TJ
0 -1.1219 TD
[(womens)-305.3(enrollment)-301.2(remains)-301.4(understudied.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.9935 0 TD
[(To)-483.5(research)-490.1(professionals)-487.2(attitudes,)-487(barriers)]TJ
-6.9935 -1.1219 TD
[(and)-223.6(potential)-219.6(facilitators)-221.1(to)-218.9(enrolling)-224.4(women)-218.5(in)-218.9(clinical)-223.9(research.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Material/Methods:)Tj
/F4 1 Tf
8.4873 0 TD
[(We)-423(conducted)-414.4(an)-418.8(anonymous)-417.2(and)-418.8(vol-)]TJ
-9.4872 -1.1219 TD
[(untary)-420.6(nationwide)-416.7(survey)-414.1(of)-416.9(research)-416.9(professionals)-423.9(whose)-413.3(in-)]TJ
0 -1.128 TD
[(stitution)-228.1(received)-225.9(NIH)-224.8(and/or)-225.4(AHRQ)-222.5(funding)-227.3(in)-225(2013)-219.4(to)-225(conduct)]TJ
0 -1.1219 TD
[(clinical)-589.7(research.)-593.7(Research)-590(professionals)-588.6(were)-591.4(surveyed)-589(re-)]TJ
0 -1.128 TD
[(garding)-518.1(factors)-517.7(perceived)-518.5(as)-515.5(barriers)-520.1(deterring)-518(women)-517.2(from)]TJ
0 -1.1219 TD
[(participation)-628(versus)-620.6(factors)-627.5(deterring)-621.7(research)-624.2(professionals)]TJ
0 -1.128 TD
[(from)-278.5(enrolling)-279.2(them)-271.4(\(7)-276.7(questions)-281.8(each\))-277.1(on)-274.3(a)-278.6(5-point)-275.6(Likert-type)]TJ
0 -1.1219 TD
[(scale)-340.4(ranging)-335.2(from)-333.4()52.5(strongly)-331.9(disagree)45.1()-331.6(\(score)]TJ
/F2 1 Tf
18.9866 0 TD
(=)Tj
/F4 1 Tf
.5548 0 TD
[(1\))-331.6(to)-334.8()52.5(strongly)]TJ
-19.5415 -1.128 TD
[(agree)49.8()-301.1(\(score)]TJ
/F2 1 Tf
5.5362 0 TD
(=)Tj
/F4 1 Tf
.5548 0 TD
(5\).)Tj
/F3 1 Tf
-5.0912 -1.1219 TD
(Results:)Tj
/F4 1 Tf
3.9571 0 TD
[(Out)-519.2(of)-520.6(13,541)-518.1(recipients,)-518.5(only)-517.7(1,007)-518.1(\(7.4%\))-519.1(re-)]TJ
-4.957 -1.128 TD
[(sponded.)-356.8(After)-363.5(excluding)-354.8(those)-356.4(374)-359.7(who)-355.1(were)-359.8(not)-359.2(involved)-356.7(in)]TJ
0 -1.1219 TD
[(enrolling)-443.9(patients,)-444.9(633)-438.9(surveys)-443.7(were)-445.1(analyzed.)-443(Of)-442.8(these,)-446(409)]TJ
0 -1.128 TD
[(\(64.6%\))-263(were)-268.3(from)-260.2(investigators,)-262.9(473)-262.1(\(74.7%\))-263(were)-262.2(enrolling)-267(in)]TJ
T*
[(federally)-290.6(funded)-286.9(studies,)-294(and)-284.6(335)-286.5(\(52.9%\))-287.4(were)-292.7(female.)-288.2(Fear)-288(of)]TJ
0 -1.1219 TD
[(unknown)-531.8(side-effects)-533.2(and)-528.5(unavailability)-527.6(for)-529(follow-up)-529.4(visits)]TJ
0 -1.128 TD
[(were)-286.6(the)-284.1(most)-284.6(signicant)-283.1(perceived)-286.8(patient)-287.2(barriers)-282.3(to)-286(womens)]TJ
0 -1.1219 TD
[(participation,)-408.5(both)-395.7(with)-402.8(a)-406.6(median)-397.5(score)-406.2(of)-398.6()52.5(4)50.2()-398.7(\(IQR)]TJ
/F2 1 Tf
22.2365 0 TD
(=)Tj
/F4 1 Tf
.5487 0 TD
[(1\).)-398.6(Re-)]TJ
-22.7852 -1.128 TD
[(spondents)-324.9(were)-323.2(neither)-320.6(hesitant)-322.9(nor)-325.4(listed)-318.8(any)-321.2(factor)-323.5(as)-320.4(signi-)]TJ
0 -1.1219 TD
[(cant)-459(barrier)-453.9(to)-450.6(enrolling)-456.1(women)-456.3(\(all)-456.7(with)-451.6(a)-455.4(median)-452.4(score)-454.9(of)]TJ
0 -1.128 TD
[()52.5(1,)50.2(IQR)]TJ
/F2 1 Tf
3.6949 0 TD
(=)Tj
/F4 1 Tf
.5548 0 TD
[(1\).)-398.6(Women)-398(over)-396.7(child-bearing)-405.8(age)-398.6(were)-402.4(considered)]TJ
-4.2497 -1.1219 TD
[(more)-323(likely)-319.6(to)-316.5(participate)-321.8(in)-322.6(research)-319.3(\(median)-320.6()52.5(3,)50.2()-319.4(IQR)]TJ
/F2 1 Tf
23.0474 0 TD
(=)Tj
/F4 1 Tf
.5487 0 TD
[(0\).)-319.4(A)]TJ
-23.5961 -1.128 TD
[(majority)-382.4(indicated)-382.9(that)-381.1(DVDs)-381.6(demonstrating)-379.5(how)-385.5(to)-377.5(approach)]TJ
0 -1.1219 TD
[(female)-361.4(candidates)-356.2(might)-358.1(be)-357.8(useful)-358.7(in)-353.1(enrollment)-356.1(training)-358.5(\(me-)]TJ
0 -1.128 TD
[(dian)-302.4()52.5(3,)56.3()-301.1(IQR)]TJ
/F2 1 Tf
6.024 0 TD
(=)Tj
/F4 1 Tf
.5548 0 TD
(1\).)Tj
/F3 1 Tf
-5.5789 -1.1219 TD
(Conclusions:)Tj
/F4 1 Tf
5.9691 0 TD
[(Research)-486.3(professionals)-484.9(perceive)-488(that)-484.8(women)]TJ
-6.9691 -1.128 TD
[(over)-317.4(child)-320.1(bearing)-315(age)-319.3(are)-315.6(more)-316.9(likely)-319.6(to)-316.5(participate)-315.7(in)-316.5(clinical)]TJ
0 -1.1219 TD
[(research)-538.8(than)-528(younger)-530.8(women.)-529.4(Although)-530.8(they)-534.1(expressed)-531.4(no)]TJ
27.0045 71.9468 TD
[(hesitance)-423.3(in)-420.1(approaching)-422.8(women)-419.7(for)-419.3(participation,)-420.7(a)-424.9(majority)]TJ
0 -1.128 TD
[(responded)-381.7(that)-387.2(DVDs)-387.7(demonstrating)-385.6(how)-385.5(to)-383.6(approach)-386.8(women)]TJ
0 -1.1219 TD
[(for)-236.4(research)-240.1(might)-236.1(improve)-243.2(their)-237.2(comfort)-239.5(with)-238.2(enrolling)-236.6(women.)]TJ
/F3 1 Tf
0 -4.1156 TD
(49.)Tj
9.843 0 0 9.843 331.7668 666.3683 Tm
[(The)-281.8(Clinical)-281.9(Utility)-279.6(of)-284.4(a)-277.6(Precision)-285.2(Medicine)]TJ
0 -1.1116 TD
[(Blood)-277.2(Test)-282.8(Incorporating)-287.9(Age,)-279.5(Sex,)-284.2(and)-279.4(Gene)]TJ
T*
[(Expression)-284.5(in)-278.6(the)-280.7(Evaluation)-282.7(of)-278.6(288)-279.8(Women)]TJ
T*
[(Presenting)-286(with)-281.7(Stable)-278.3(Symptoms)-281.1(Suggestive)]TJ
0 -1.1174 TD
[(of)-278.6(Obstructive)-287.1(Coronary)-282.6(Artery)-281.6(Disease:)]TJ
0 -1.1116 TD
[(Subgroup)-279.9(Analysis)-280.1(from)-283.1(the)-280.7(PRESET)-288.1(Registry)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 310.8472 595.0486 Tm
[(Joseph)-331.6(A.)-336.8(Ladapo,)-333.3(MD,)-329.8(PhD)]TJ
6.9735 0 0 6.198 421.5117 599.1873 Tm
(1)Tj
9.2982 0 0 9.2982 424.97 595.0486 Tm
[(,)-335.3(Matt)-337.6(Budoff,)-332.5(MD)]TJ
6.9735 0 0 6.198 497.8204 599.1873 Tm
(2)Tj
9.2982 0 0 9.2982 501.2786 595.0486 Tm
(,)Tj
-20.4805 -1.128 TD
[(David)-334.3(Sharp,)-332.5(DO)]TJ
6.9735 0 0 6.198 377.1779 588.6991 Tm
(3)Tj
9.2982 0 0 9.2982 380.6361 584.5605 Tm
[(,)-335.3(Michael)-333.8(Zapien,)-338.9(MS)]TJ
6.9735 0 0 6.198 464.4849 588.6991 Tm
(4)Tj
9.2982 0 0 9.2982 467.9999 584.5605 Tm
[(,)-329.2(Lin)-336.6(Huang,)-334.8(PhD)]TJ
6.9735 0 0 6.198 536.1447 588.6991 Tm
(4)Tj
9.2982 0 0 9.2982 539.6597 584.5605 Tm
(,)Tj
-24.6083 -1.1219 TD
[(Bruce)-332.5(Maniet,)-335.7(DO)]TJ
6.9735 0 0 6.198 381.4298 578.2676 Tm
(5)Tj
9.2982 0 0 9.2982 388.0062 574.129 Tm
[(Lee)-333.4(Herman,)-334.8(MD)]TJ
6.9735 0 0 6.198 455.4707 578.2676 Tm
(6)Tj
9.2982 0 0 9.2982 458.9857 574.129 Tm
[(,)-335.3(Mark)-328.8(Monane,)-336.7(MD)]TJ
6.9735 0 0 6.198 538.4691 578.2676 Tm
(4)Tj
9.2982 0 0 9.2982 541.9841 574.129 Tm
(,)Tj
-24.8582 -1.128 TD
[(Richard)-331.9(F.)-332.1(Wright,)-334.7(MD)]TJ
6.9735 0 0 6.198 400.7621 567.7794 Tm
(7)Tj
/F5 1 Tf
-12.8938 -2.6526 TD
(1)Tj
9.2982 0 0 9.2982 314.3054 547.1998 Tm
[(NYU)-338.3(School)-332.8(of)-334.8(Medicine,)-330.9(New)-336.7(York,)-335.4(New)-330.6(York)]TJ
6.9735 0 0 6.198 310.8472 540.9069 Tm
(2)Tj
9.2982 0 0 9.2982 314.3054 536.7684 Tm
[(UCLA,)-334(Torrance,)-338.7(California)]TJ
6.9735 0 0 6.198 310.8472 530.4188 Tm
(3)Tj
9.2982 0 0 9.2982 314.3054 526.2802 Tm
[(Doctors)-338.7(for)-333.9(Health,)-333.8(Omaha,)-332.1(Nebraska)]TJ
6.9735 0 0 6.198 310.8472 519.9872 Tm
(4)Tj
9.2982 0 0 9.2982 314.3054 515.8487 Tm
[(CardioDx,)-338.1(Redwood)-333.8(City,)-331(California)]TJ
6.9735 0 0 6.198 310.8472 509.4991 Tm
(5)Tj
9.2982 0 0 9.2982 314.3054 505.3605 Tm
[(Bells)-339.4(Medical)-332.8(Clinic,)-336.5(Bells,)-333.3(Texas)]TJ
6.9735 0 0 6.198 310.8472 499.0676 Tm
(6)Tj
9.2982 0 0 9.2982 314.3054 494.929 Tm
[(Johns)-338.6(Creek)-333.5(Primary)-334.4(Care,)-337.2(Suwanee,)-330(Georgia)]TJ
6.9735 0 0 6.198 310.8472 488.5794 Tm
(7)Tj
9.2982 0 0 9.2982 314.3054 484.4408 Tm
[(Pacic)-338.9(Heart)-333.5(Institute,)-332.8(Santa)-334.7(Monica,)-335.2(California)]TJ
/F3 1 Tf
.628 -2.3047 TD
(Background:)Tj
/F4 1 Tf
6.2496 0 TD
[(Advancements)-650.3(in)-645.7(precision)-648.9(medicine)-645(hold)]TJ
-7.2496 -1.1219 TD
[(signicant)-228.2(promise)-230.1(for)-224.2(improving)-226.2(care)-234.4(among)-223.1(patients)-231.5(at)-229.3(risk)-226.5(for)]TJ
0 -1.128 TD
[(or)-392.5(diagnosed)-397.1(with)-390.6(cardiovascular)-395.6(disease.)-400.5(A)-391.7(blood-based)-393.3(age/)]TJ
0 -1.1219 TD
[(sex/gene)-328.2(expression)-331.5(score)-326.9(\(ASGES\))-326.1(incorporating)-328.4(key)-327.3(features)]TJ
0 -1.128 TD
[(of)-386.4(precision)-386.8(medicine)-389(has)-387.4(shown)-390.7(clinical)-388.5(validity)-386.1(with)-390.6(a)-388.3(96%)]TJ
0 -1.1219 TD
[(negative)-535.8(predictive)-531.6(value)-538.3(in)-529.9(determining)-539(a)-534.6(patients)-532.6(current)]TJ
0 -1.128 TD
[(likelihood)-300.7(of)-301.1(obstructive)-300.9(coronary)-299.6(artery)-299.1(disease)-303(\(CAD\).)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.7923 0 TD
[(To)-282.3(better)-290.1(characterize)-289.1(the)-284.1(clinical)-284.8(utility)-283.9(of)-288.9(the)]TJ
-6.7923 -1.128 TD
[(ASGES,)-211.7(a)-211.5(community-based)-213(registry)-208.1(was)-212.1(established)-216.5(to)-206.7(evaluate)]TJ
0 -1.1219 TD
[(its)-296.8(effect)-303.3(on)-298.7(clinical)-303.1(decision-making.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Material/Methods:)Tj
/F4 1 Tf
8.4995 0 TD
[(The)-438.9(prospective)-433.6(PRESET)-436.6(Registry)-436.1(en-)]TJ
-9.4994 -1.1219 TD
[(rolled)-231(stable,)-232(non-acute)-233.8(adult)-234.8(patients)-231.5(presenting)-234.3(with)-232.1(symptoms)]TJ
0 -1.128 TD
[(suggestive)-328.6(of)-331.6(obstructive)-331.3(CAD)-330.8(from)-327.3(20)-329.2(US)-327.5(primary)-330.9(care)-332(prac-)]TJ
0 -1.1219 TD
[(tices)-213.8(f)22(r)15.9(o)24.4(m)-194.6(S)21.5(e)20.2(p)24.4(t)18.8(e)20.2(m)18.8(b)24.4(e)20.2(r)-197.5(2)24.4(0)18.3(1)24.4(2)-195.1(t)24.9(o)-195.1(A)22.9(u)18.3(g)24.4(u)18.3(s)19.2(t)-188.5(2)18.3(0)18.3(1)24.4(4)18.3(.)-189(D)16.8(e)20.2(m)24.9(o)18.3(g)24.4(r)15.9(a)20.2(p)24.4(h)18.3(i)24.9(c)20.2(s)19.2(,)-195.1(c)20.2(l)24.9(i)18.8(n)18.3(i)24.9(c)20.2(a)20.2(l)]TJ
0 -1.128 TD
[(characteristics,)-282.1(and)-278.5(ASGES)-284.8(results)-278.1(\(predened)-282.2(as)-277.7(low)-281.4([ASGES)]TJ
/F2 1 Tf
0 -1.1219 TD
()Tj
/F4 1 Tf
.7195 0 TD
[(15])-215.7(or)-215.7(el)20.7(ev)20.2(at)14.6(ed)-193.2([A)14.5(SG)20.1(ES)]TJ
/F2 1 Tf
9.9018 0 TD
(>)Tj
/F4 1 Tf
.7073 0 TD
[(1)12.2(5)0(])16(\))-203.6(we)18.7(re)-201.7(c)14.1(o)0(l)18.8(l)0(e)20.7(c)0(t)14.6(e)0(d)20.2(,)-207.3(as)-198.4(we)18.7(re)-195.6(re)17.8(fe)17.8(rr)19.7(al)20.7(s)]TJ
-11.3286 -1.128 TD
[(t)12.7(o)-219.5(ca)16(rd)22.1(io)18.8(lo)18.8(g)12.2(y)-225.6(o)12.2(r)-221.8(fu)22.1(rt)16.5(h)12.2(e)0(r)-213.8(f)0(u)22.1(n)12.2(ct)14.6(i)12.7(o)12.2(na)14.1(l)12.7(/)12.7(a)0(n)14.1(a)14.1(t)0(o)18.8(m)0(i)19.4(c)-223.7(ca)22.1(rd)16(i)12.7(a)0(c)-215.7(t)12.7(es)21.1(ti)19.4(ng)-213.3(\(E)20.2(TT)20.8(,)]TJ
0 -1.1219 TD
[(EC)17.9(HO)21.4(,)-390.2(M)13.1(PI)19.2(,)-390.2(C)13.6(CT)17.9(A,)-379.5(IC)23.4(A\))-381.8(af)17.8(t)12.7(e)0(r)-378.5(A)0(S)20.1(G)0(E)15(S)-387(t)12.7(e)0(s)15(t)12.7(in)18.9(g)12.2(.)-390.2(Pa)23.4(ti)19.3(en)14.1(t)12.7(s)-389.3(we)18.7(re)]TJ
0 -1.128 TD
[(fo)22.1(ll)19.3(o)12.2(w)0(e)18.7(d)-292.6(fo)22.1(r)-288.9(1)0(-)16(y)12.2(ea)16(r)-288.9(p)12.2(os)19.2(t-)16.5(AS)20.1(GE)21.1(S)-289.4(t)0(e)20.7(s)0(t)19.7(i)0(n)18.8(g)0(.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Results:)Tj
/F4 1 Tf
3.64 0 TD
[(Am)11.3(ong)-195(th)12.8(e)-205.4(2)0(8)12.2(8)-201.2(wom)11.3(en)-193.2(coh)14.2(ort)-196.9(\(me)18.4(dia)14.6(n)-201.2(age)-197.4(57)-195.1(yea)16(rs\))14.5(,)]TJ
-4.64 -1.128 TD
[(cli)15.1(ni)12.7(cia)10.4(ns)-328.3(refe)17.4(rre)15.5(d)-335.3(20/)12.8(21)12.3(8)-335.3(\(9%)13.7(\))-337.7(pat)14.6(ien)14.7(ts)-327.8(wit)11.8(h)-335.3(l)0(o)12.7(w)-336.8(sco)15(res)-328.8(ver)11.8(su)13.1(s)]TJ
0 -1.1219 TD
[(31)12.3(/70)-347(\(44)16(%\))-352.2(pat)14.6(ien)14.7(ts)-352.2(wi)11.2(th)-353.1(ele)10.4(va)14.1(ted)-351.2(sco)15(re)11.7(s)-358.9(t)0(o)-353.1(car)13.6(di)12.7(olo)12.8(gy)-353.6(or)-349.9(ad-)]TJ
0 -1.128 TD
[(van)14.2(ced)-282.7(car)13.6(di)12.7(ac)-288.9(tes)15.5(tin)13.3(g)-292.6(\(un)16(adj)14.6(ust)13.6(ed)-284.6(OR)-292.7(0.)12.2(13)12.2(,)-292.6(p)]TJ
/F2 1 Tf
18.5659 0 TD
(<)Tj
/F4 1 Tf
.5488 0 TD
[(0.)12.2(000)12.3(1;)-286(adj)14.6(us)13.1(ted)]TJ
-19.1147 -1.1219 TD
[(OR)-487.8(0.)12.2(14,)-481.6(p)]TJ
/F2 1 Tf
4.8351 0 TD
(<)Tj
/F4 1 Tf
.5487 0 TD
[(0.)12.2(000)12.3(1\).)-484(Six)-477.9(pati)15.2(ent)14.6(s)-493(exp)14.2(er)11.7(ien)14.7(ced)-483.9(maj)15.2(or)-490.1(adv)14.1(er)11.7(se)]TJ
-5.3838 -1.128 TD
[(car)13.7(di)12.7(ova)14.2(scu)15(lar)-347.5(ou)12.2(tco)14.7(mes)-344.2(dur)16(ing)-347(fol)16.5(lo)12.8(w-u)14.5(p:)-353.1(all)-344.6(we)12.6(re)-354.1(co)14.1(nsi)13.6(der)11.8(ed)]TJ
0 -1.1219 TD
[(un)12.3(rel)12.3(ate)16.5(d)-298.7(t)0(o)-286(obs)13.1(tru)16.5(cti)15.2(ve)-290.7(CAD)10.6(.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Conclusions:)Tj
/F4 1 Tf
5.7253 0 TD
[(In)-179.1(t)12.7(h)12.2(is)-181.5(co)20.2(m)12.8(m)0(u)18.9(n)0(i)18.8(t)12.7(y-)16(b)12.2(a)0(s)21.1(e)0(d)-181(c)0(a)16(r)0(d)22.1(i)12.7(ov)18.3(as)21.1(cu)14.1(l)12.7(a)0(r)-177.3(r)0(e)17.8(g)12.2(is)19.7(tr)16.5(y)12.2(,)]TJ
-6.7252 -1.128 TD
[(t)12.7(h)0(e)-162.7(a)0(g)20.2(e)0(/)14.6(s)13.1(ex)20.2(/g)18.9(en)20.2(e)-174.9(e)0(x)20.2(p)12.2(re)17.8(ss)20(io)18.8(n)-170.7(s)0(c)21.1(o)0(r)16(e)-168.8(de)14.1(m)12.8(o)12.2(ns)19.2(tr)16.5(at)20.7(ed)-162.7(cl)20.7(in)18.8(i)12.7(c)0(a)16(l)-170.2(ut)18.9(il)19.3(it)19.3(y)-170.7(a)0(n)20.2(d)]TJ
0 -1.1219 TD
[(l)12.7(o)0(n)18.3(g)12.2(-t)16.5(er)17.8(m)-310.4(s)13.1(af)17.8(et)20.7(y)-317(i)12.7(n)-310.9(t)0(h)18.8(e)-315.2(ev)20.2(al)20.7(u)12.2(a)0(t)14.6(i)12.7(on)-304.8(o)12.2(f)-313.3(wo)22.9(me)14.7(n)-310.9(w)0(i)23.4(t)0(h)-304.3(s)0(u)19.2(s)0(p)19.2(e)0(c)22.1(t)0(e)14.6(d)-310.9(o)12.2(b)0(-)]TJ
0 -1.128 TD
[(s)13.1(t)0(r)16.5(u)12.2(ct)20.7(iv)18.8(e)-254.2(C)0(A)18.2(D)0(,)-245.3(t)12.7(he)14.1(re)23.9(by)-243.8(mi)19.4(ni)18.8(m)12.8(i)0(z)14.6(i)12.7(ng)-243.8(u)12.2(n)0(n)18.3(e)0(c)16(e)0(s)21.1(s)0(a)21.1(r)0(y)-246.2(r)0(e)17.9(f)0(e)17.8(r)0(r)19.7(a)14.1(ls)-248.6(an)20.2(d)-256.1(a)14.1(d-)]TJ
0 -1.1219 TD
[(d)12.2(i)0(t)19.3(i)0(o)18.8(n)12.2(al)-180.5(t)12.7(e)0(s)15(t)12.7(in)18.8(g)-189(o)12.2(f)-191.4(l)12.7(ow)16.8(-r)19.7(i)12.7(s)0(k)-182(p)12.2(at)20.7(ie)20.7(nt)18.8(s.)-182(Ou)22.9(r)-191.4(w)0(o)22.9(r)0(k)-179.1(a)0(d)20.2(d)0(s)-182(t)12.7(o)-189(t)12.7(he)-181(ev)20.2(id)18.8(en)20.2(ce)]TJ
0 -1.128 TD
[(b)12.2(a)0(s)21.1(e)-254.2(fo)22.1(r)-252.3(p)12.2(re)17.8(ci)20.7(si)19.7(on)-243.8(m)12.7(e)0(d)20.2(i)0(c)20.7(i)0(n)18.9(e)-254.2(i)12.7(n)-250(ca)16(rd)22.1(io)18.8(v)12.2(a)0(s)15(c)14.1(ul)18.8(ar)-244.3(c)14.1(a)0(r)17.8(e)0(.)]TJ
/F3 1 Tf
0 -4.1095 TD
(50.)Tj
9.843 0 0 9.843 331.7668 100.5165 Tm
[(Prenatal)-283(Discussion)-283.1(of)-278.6(Contraceptive)]TJ
0 -1.1116 TD
[(Options)-279.2(in)-278.6(Teenage)-288.5(Pregnancies)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 310.8472 73.0205 Tm
[(Roxanne)-330(Lamarre)]TJ
/F5 1 Tf
0 -1.7682 TD
[(University)-333.9(of)-334.8(Texas)-333.5(Medical)-338.9(Branch,)-328.2(Galveston,)-337.1(Texas)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 59.7543 749.7069 Tm
(ABSTRACTS)Tj
52.6193 0 TD
(A-19)Tj
ET
endstream
endobj
268 0 obj
<>stream
/GS1 gs
BT
/F3 1 Tf
9.2982 0 0 9.2982 71.3197 725.5557 Tm
0 0 0 rg
0 Tc
0 Tw
(Background:)Tj
/F4 1 Tf
5.9996 0 TD
[(Teenage)-408.8(pregnancy)-398.9(has)-399.6(been)-404.7(associated)-404.2(with)]TJ
-6.9996 -1.128 TD
[(lost)-278.5(social)-274.7(and)-278.5(economic)-279.7(opportunities)-277.8(as)-277.7(a)-278.6(result)-272.9(of)-276.7(less)-282.4(formal)]TJ
0 -1.1219 TD
[(education.)-322.4(As)-323.8(well)-327.8(as)-320.4(greater)-327.7(emotional)-323.2(burden)-323.5(resulting)-321.1(in)-322.6(in-)]TJ
0 -1.128 TD
[(creased)-426.7(risk)-427.7(of)-423(depression)-429.1(and)-424.8(anxiety)-428(and)-424.9(lower)-428.2(overall)-424.2(life)]TJ
0 -1.1219 TD
[(satisfaction)-346.4(during)-343.2(and)-339.5(after)-341.8(the)-345.1(pregnancy.)-344(Up)-342.9(to)-340.9(one-third)-343.1(of)]TJ
0 -1.128 TD
[(teenage)-388.1(mothers)-388.7(will)-384(become)-390(pregnant)-388.1(again)-385.8(within)-384(a)-388.3(year)-388.7(of)]TJ
0 -1.1219 TD
[(delivery,)-448.6(highlighting)-442.3(the)-448.7(need)-447.3(for)-443.7(adequate)-449.1(postpartum)-449.1(con-)]TJ
0 -1.128 TD
[(traceptive)-487(use.)-478.9(There)-482(have)-483.9(been)-483.9(no)-481.6(published)-477.7(guidelines)-481.4(for)]TJ
0 -1.1219 TD
[(postpartum)-455.2(contraception)-462.5(counseling)-457.5(nor)-453.5(on)-457.2(the)-454.8(best)-460.1(time)-453.8(to)]TJ
0 -1.128 TD
[(initiate)-304.5(such)-295.9(a)-303(discussion.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.8472 0 TD
[(To)-337.1(determine)-342.5(if)-337.2(contraceptive)-344.8(options)-339.4(are)-340(dis-)]TJ
-6.8471 -1.128 TD
[(cussed)-299.3(during)-300.5(prenatal)-306.5(care)-301.5(among)-296.2(pregnant)-302.8(teenagers.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Material/Methods:)Tj
/F4 1 Tf
8.4446 0 TD
[(Hospital)-375.1(and)-376.1(outpatient)-372(clinical)-376.3(records)]TJ
-9.4445 -1.128 TD
[(were)-231.7(reviewed)-235.3(for)-230.3(teenagers)-231.1(between)-239.1(the)-229.2(ages)-233.1(of)-227.9(12)-231.6(and)-229.7(19,)-231.6(who)]TJ
T*
[(delivered)-355.3(between)-354.9(January)-351.2(1st)-352.2(and)-351.7(December)-355.4(31st)-346.1(2013)-353.5(at)-351.2(the)]TJ
0 -1.1219 TD
[(University)-249.4(of)-246.2(Texas)-247.1(Medical)-248.4(branch)-242.4(in)-249.4(Galveston)-245.7(\(UTMB\))-249.6(John)]TJ
0 -1.128 TD
[(Sealy)-291.2(Hospital)-283.6(and)-290.7(received)-286.8(prenatal)-294.3(care)-289.3(at)-284.1(one)-290.7(of)-282.8(the)-290.2(UTMB-)]TJ
0 -1.1219 TD
[(afliated)-266.2(ambulatory)-265.1(clinics.)-268.1(The)-262.1(data)-263.9(used)-265.4(a)-266.4(logistic)-263.3(regression)]TJ
0 -1.128 TD
[(model)-551.8(on)-548.7(receipt)-556.5(of)-551.1(prenatal)-556.5(contraceptive)-552.1(counseling)-555.1(in)-548.2(a)]TJ
0 -1.1219 TD
[(multivariate)-304.4(model.)-301.8(p)]TJ
/F2 1 Tf
8.7251 0 TD
(<)Tj
/F4 1 Tf
.5487 0 TD
[(0.05)-298.7(was)-303.6(considered)-300(signicant.)]TJ
/F3 1 Tf
-8.2739 -1.128 TD
(Results:)Tj
/F4 1 Tf
3.6461 0 TD
[(A)-166.1(t)12.7(ot)18.8(al)-156.1(o)12.2(f)-160.9(24)18.3(4)-164.6(p)12.2(o)12.2(s)0(t)19.7(p)0(a)20.2(r)0(t)16.5(u)12.2(m)-164.1(t)12.7(ee)16(n)12.2(a)0(g)20.2(e)0(r)17.8(s)-163.7(wi)17.3(t)12.7(h)-164.6(a)-162.7(m)12.8(ea)16(n)-158.5(a)0(g)14.1(e)-162.7(o)12.2(f)]TJ
-4.6461 -1.1219 TD
-.0122 Tc
[(17)-12.2(.)6.1(6)]TJ
/F2 1 Tf
1.8779 0 TD
0 Tc
()Tj
/F4 1 Tf
.7073 0 TD
[(1)12.2(.)0(2)-341.4(y)0(e)14.1(a)14.1(r)0(s)-342.9(w)0(e)18.7(r)0(e)-348(i)12.7(nc)20.2(lu)18.8(d)12.2(e)0(d)-345.6(i)0(n)-340.9(t)0(h)18.8(i)0(s)-346.1(s)13.1(tu)18.8(d)12.2(y)0(.)-347.5(T)0(h)22.6(e)-351.7(ma)14.7(j)12.7(o)12.2(ri)16.5(t)12.7(y)-353.6(we)18.7(re)]TJ
-2.5852 -1.128 TD
[(Hi)17.3(s)13.1(p)0(a)20.2(n)0(i)18.8(c)-242(\(5)22.1(7)12.2(%)0(\))19.7(,)-237.8(fo)16(l)12.7(l)12.7(o)0(w)16.8(e)0(d)-229.8(b)12.2(y)-237.8(w)0(h)22.9(i)0(t)19.3(e)-242(\(3)22.1(4)12.2(%)0(\))-230.3(a)0(n)20.2(d)-237.8(b)12.2(l)0(a)14.6(c)14.1(k)-237.8(\()0(9)16(%)0(\))19.7(.)-237.8(Of)-223.3(th)18.8(e)]TJ
0 -1.1219 TD
[(p)12.2(a)0(t)14.6(i)12.7(en)20.2(ts)19.7(,)-341.4(4)12.2(1%)-331.5(h)12.2(a)0(d)-333.4(l)12.7(es)15(s)-340.6(t)12.7(h)12.2(a)0(n)-333.4(1)12.2(0)-341.4(p)12.2(re)17.9(n)12.2(a)0(t)14.6(a)0(l)-326.8(v)0(i)18.8(s)0(i)19.7(t)0(s)19.7(.)-341.4(On)22.9(ly)-334.8(1)12.2(4)12.2(%)-343.8(o)12.2(f)-337.7(th)18.8(e)]TJ
0 -1.128 TD
-.0127 Tc
[(pa)-12.7(tie)-12.7(n)7.5(t)-12.7(s)-182(ha)-12.7(d)-181.5(a)-193.7(di)-12.7(s)7(c)-12.7(u)7.5(s)-12.7(sion)-189.5(a)-12.7(b)1.4(out)-195.1(co)-12.7(n)5.6(t)0(r)-12.7(a)5.2(c)-12.7(e)3.3(pt)-12.7(i)6.6(o)-.5(n)-195.6(dur)-12.7(ing)-189.5(t)-12.7(h)6.1(e)-12.7(s)8.4(e)-193.7(pr)-12.7(e)5.2(n)-.5(a)-12.7(t)1.9(a)-12.7(l)]TJ
0 -1.1219 TD
0 Tc
[(v)12.2(i)0(s)19.7(i)0(t)19.3(s)0(,)-243(m)12.8(os)19.2(t)-249.5(o)0(f)-240.1(w)0(h)16.8(i)12.7(ch)-242(o)12.2(c)0(c)16(u)12.2(rr)19.7(ed)-242(af)17.8(t)12.7(e)0(r)-244.3(2)12.2(9)-250(w)0(e)18.7(e)0(k)20.2(s)-249.1(of)-240.1(ge)14.1(s)13.1(t)0(a)20.7(t)0(i)19.4(o)0(n)-243.8(\()0(6)22.1(6)12.2(%\))19.7(.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Conclusions:)Tj
/F4 1 Tf
5.6948 0 TD
[(Pregnant)-208.1(teenagers)-206.7(are)-205.8(not)-206.7(frequently)-207(counseled)]TJ
-6.6947 -1.1219 TD
[(about)-223.1(postpartum)-229.6(contraceptives.)-222(When)-227.8(counseling)-225.8(does)-222.8(occur)-224.1(it)]TJ
0 -1.128 TD
[(happens)-275.7(in)-273.8(the)-271.9(third)-275.6(trimester,)-278.4(which)-273.4(may)-271.9(not)-273.8(provide)-274.2(sufcient)]TJ
0 -1.1219 TD
[(time)-551.3(for)-547.3(a)-552.9(thorough)-550.4(consideration)-548.9(of)-551.1(contraceptive)-552.1(options.)]TJ
0 -1.128 TD
[(Guidelines)-507.3(on)-499.9(when)-505.6(the)-503.6(provider)-508.2(should)-498.5(discuss)-507.1(postpartum)]TJ
0 -1.1219 TD
[(contraception)-236.9(during)-239.5(the)-235.3(pregnancy)-234.3(may)-241.4(improve)-237.1(these)-232.6(numbers)]TJ
0 -1.128 TD
[(and)-290.7(should)-285.1(be)-290.7(discussed)-285.6(among)-290.1(national)-287.2(medical)-291.4(organizations.)]TJ
/F3 1 Tf
0 -4.1644 TD
(51.)Tj
9.843 0 0 9.843 82.9417 352.0629 Tm
[(Why)-280.7(are)-282.1(Maternal)-284.1(Mortality)-284.2(Rates)]TJ
0 -1.1116 TD
[(Decreasing)-287(in)-278.6(California?)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 62.022 324.5668 Tm
[(Elizabeth)-335.9(Lawton)]TJ
6.9735 0 0 6.198 128.9196 328.7054 Tm
(1)Tj
9.2982 0 0 9.2982 132.4346 324.5668 Tm
[(,)-329.2(Dan)-334.9(\(Susan\))-334(Sun)]TJ
6.9735 0 0 6.198 202.3369 328.7054 Tm
(1)Tj
9.2982 0 0 9.2982 205.7952 324.5668 Tm
[(,)-335.3(Mark)-334.9(Damesyn)]TJ
6.9735 0 0 6.198 269.6314 328.7054 Tm
(1)Tj
9.2982 0 0 9.2982 273.0897 324.5668 Tm
(,)Tj
-22.6998 -1.128 TD
[(Connie)-337.5(Mitchell)]TJ
6.9735 0 0 6.198 123.7039 318.2173 Tm
(2)Tj
/F5 1 Tf
-8.8452 -2.6526 TD
(1)Tj
9.2982 0 0 9.2982 65.537 297.6377 Tm
[(California)-324.8(Department)-332.5(of)-328.7(Public)-328.1(Health,)-327.7(Maternal,)-327.7(Child)-332.8(and)]TJ
-.378 -1.1219 TD
[(Adolescent)-335.6(Health)-333.8(Division,)-338.5(Sacramento,)-331.5(California)]TJ
6.9735 0 0 6.198 62.022 280.8566 Tm
(2)Tj
9.2982 0 0 9.2982 65.537 276.718 Tm
[(California)-330.9(Department)-338.6(of)-328.7(Public)-334.2(Health,)-339.9(Center)-334.8(for)-333.9(Family)]TJ
-.378 -1.1219 TD
[(Health,)-333.8(Sacramento,)-337.6(California)]TJ
/F3 1 Tf
.9999 -2.3047 TD
(Background:)Tj
/F4 1 Tf
6.0423 0 TD
-.015 Tc
[(Af)-15(t)13.7(e)-.9(r)-401.5(a)-403.3(steady)-399.1(r).9(ise)-397.2(i)-2.3(n)-399.1(m)-2.2(ater)-15(n)13.2(a)-.9(l)-398.6(m)-2.2(ortality)-405.2(r).9(ates)]TJ
-7.0423 -1.1219 TD
-.0146 Tc
[(\(MMR\))-401.1(from)-404.3(1)3.7(999)-167()-167(2)-2.4(006,)-404.8(California)-402.9(exper)-14.6(i)14.1(enced)-398.7(a)-409(s)4.6(tatistically)]TJ
0 -1.128 TD
-.0129 Tc
[(si)5.9(gn)5.4(icant)-335.5(d)-.7(ecl)5.9(ine)-334.1(f)-12.9(r)12.9(o)5.4(m)-341.6(2)5.4(00)5.4(62)5.4(01)]TJ
13.615 0 TD
-.0144 Tc
[(3.)-337.5(This)-336.7(decline)-341.7(o)-2.2(ccur)-14.4(s)-326.8(concur-)]TJ
-13.615 -1.1219 TD
-.0132 Tc
[(rent)5.6(ly)-202.2(a)7(s)-201.3(U)-13.2(.)15.8(S)-199(M)-.1(M)6(R)-200.8(has)-195.2(i)-.5(nc)7(r)-13.2(e)10.7(as)6(ed.)-196.1(C).4(ali)5.6(f)-13.2(o)15(r)2.7(ni)5.6(a)-200.3(i)-.5(nv)5.1(est)5.6(i)-.5(gat)5.6(e).9(d)-202.2(m)5.7(aternal)]TJ
0 -1.128 TD
-.0192 Tc
[(d)-7(eath)-7(s)-274.4(from)-268.6(2)-.9(0)5.2(0)-.9(2)-165.5()-159.4(200)5.2(7)-269.2(t)-.4(o)-269.2(u)5.2(nders)6.1(tand)-269.2(t)5.7(h)-.9(e)-273.4(r)2.8(i)5.7(s)0(e,)-269.2(and)-269.2(b)5.2(ased)-269.2(on)-269.2(n)5.2(d-)]TJ
T*
-.0206 Tc
[(ings,)-227.9(i)4.3(mplemented)-227.9(targeted)-234(obstet)]TJ
12.859 0 TD
-.0204 Tc
[(rical)-227.2(quality)-227.7(i)-1.6(mprovement)-227.2(efforts.)]TJ
/F3 1 Tf
-11.859 -1.1219 TD
0 Tc
(Objective\(s\):)Tj
/F4 1 Tf
5.835 0 TD
[(To)-324.9(describe)-324.4(trends)-328.2(and)-321.2(select)-327.7(factors)-328.7(that)-326.3(may)]TJ
-6.835 -1.128 TD
[(have)-301(contributed)-301.7(to)-298.2(the)-302.4(decline)-304.1(in)-298.2(MMR.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Material/Methods:)Tj
/F4 1 Tf
8.5726 0 TD
[(Using)-506.1(death)-501.7(certicate)-506.3(data,)-501.7(we)-505.6(mea-)]TJ
-9.5726 -1.128 TD
[(sured)-432.4(trends,)-431.9(timing)-430.7(of)-429.1(mortality,)-430.6(population)-435.4(differences,)-430.9(and)]TJ
0 -1.1219 TD
[(causes)-303.5(of)-301.1(death)-300.5(among)-302.3(women)-297.7(before)-299.6(and)-302.9(after)-299.1(2006.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Results:)Tj
/F4 1 Tf
3.7742 0 TD
[(Th)22.6(e)-327.3(C)13.6(al)14.6(i)12.7(f)0(o)22.1(r)0(n)16(i)12.7(a)-327.3(M)13.1(MR)-320.8(d)12.2(e)0(c)22.1(l)0(i)19.3(n)0(e)14.1(d)-323.1(5)12.2(7)12.2(%)-325.5(be)20.2(tw)17.4(ee)16(n)-323.1(2)12.2(00)18.3(6)-158.5()]TJ
-4.7741 -1.1219 TD
-.0124 Tc
[(20)-12.4(1)5.9(3)-329.4(dr)-12.4(o)9.7(p)-12.4(p)5.9(i)-12.4(n)6.4(g)-329.4(f)-12.4(r)7.3(om)-328.9(16)-12.4(.)5.9(9)-329.4(de)-12.4(a)9.7(t)-12.4(h)6.4(s)-328.6(p)-12.4(e)7.8(r)-331.8(100)-12.4(,)5.9(0)-.2(0)-12.4(0)-317.2(l)-12.4(i)6.9(v)-12.4(e)-321.4(bi)-12.4(rth)-12.4(s)-316.4(i)-12.4(n)-322.8(200)-12.4(6)]TJ
0 -1.128 TD
0 Tc
[(to)-603.1(7)12.2(.)0(3)-603.6(d)12.2(ea)16(t)12.7(h)0(s)-602.7(i)0(n)-603.1(2)12.2(01)18.3(3)12.2(,)-615.8(re)17.8(e)23.4(ct)14.6(i)12.7(n)12.2(g)-615.8(a)-613.9(1)12.2(2)12.2(.)0(4)18.3(%)-612(an)20.2(n)12.2(u)0(a)14.1(l)-609.2(d)12.2(e)0(c)16(r)0(e)17.8(a)0(s)21.1(e)]TJ
0 -1.1219 TD
(\(p)Tj
/F2 1 Tf
.8109 0 TD
(<)Tj
/F4 1 Tf
.5427 0 TD
[(0.)18.3(0)12.2(0)0(0)18.3(1)12.2(\).)-343.8(Th)22.6(e)-351.7(M)0(M)20.1(R)-352.2(in)18.8(cl)20.7(ud)18.3(es)-338.7(e)17.8(ar)17.8(l)12.7(y)0()-343.8(m)12.8(at)14.6(e)14.1(r)0(n)16(a)0(l)-339(d)0(e)20.2(a)0(t)14.6(h)12.2(s)-352.8(\()0(d)22.1(e)0(a)16(t)12.7(h)12.2(s)]TJ
-1.3536 -1.128 TD
[(wh)16.8(i)12.7(l)0(e)-302.4(p)12.2(re)17.8(g)12.2(n)0(a)14.1(n)12.2(t)-310.4(o)12.2(r)-313.3(w)0(i)17.3(t)12.7(hi)18.8(n)-310.9(4)12.2(2)-310.9(d)0(a)20.2(y)0(s)-304(p)12.2(os)19.2(tp)18.9(ar)17.8(t)12.7(u)0(m)18.9(\))0(.)-301.1(I)0(f)-303.5()0(l)22.6(a)0(t)20.7(e)0()-305.3(m)12.8(at)14.6(e)14.1(r)0(n)16(a)14.1(l)]TJ
0 -1.1219 TD
[(d)12.2(e)0(a)16(t)12.7(h)-256.1(\()0(4)22.1(3)0()18.3(3)12.2(65)-243.8(da)14.1(y)12.2(s)-255.2(p)12.2(o)12.2(s)0(t)19.7(p)0(a)20.2(r)0(t)16.5(u)12.2(m\))-245.7(ra)17.8(t)12.7(e)0(s)-247.2(w)0(e)18.7(r)0(e)-244.3(c)0(a)16(l)12.7(cu)20.2(la)20.7(te)14.6(d)12.2(,)-256.1(C)13.6(a)0(l)14.6(i)12.7(fo)22.1(rn)16(i)12.7(a)]TJ
0 -1.128 TD
[(ex)20.2(pe)20.2(ri)16.5(en)20.2(ce)16(d)-262.1(a)-266.4(2)12.2(7)12.2(6)0(%)-258.4(i)12.7(nc)20.2(re)17.8(as)21.1(e)-266.4(\()0(p)]TJ
/F2 1 Tf
12.5968 0 TD
(<)Tj
/F4 1 Tf
.5366 0 TD
-.0127 Tc
[(0)-12.7(.)5.6(00)-12.7(0)5.6(1)-12.7(\))-271.1(dur)-12.7(ing)-274.8(2)-12.7(0)5.6(0)-.5(6)-12.7()5.6(20)-12.7(1)5.6(3)-.5(.)-281(T)-12.7(h)9.9(e)]TJ
-13.1333 -1.1219 TD
0 Tc
[(co)20.2(mb)18.9(i)12.7(n)0(e)14.1(d)-201.2(m)12.8(o)12.2(rt)16.5(al)20.7(it)19.3(y)-201.2(r)0(a)17.8(t)12.7(e)-205.4(\()0(0)22.1()0(3)18.3(6)12.2(5)-201.2(d)0(a)20.2(y)0(s)-194.2(p)12.2(os)19.2(tp)18.8(ar)17.8(t)12.7(u)12.2(m\))-196.9(d)12.2(u)12.2(r)0(i)16.5(n)12.2(g)-201.2(t)0(h)18.8(e)-199.3(sa)15(m)12.8(e)]TJ
26.9984 71.9468 TD
[(pe)14.1(ri)22.6(o)12.2(d)-378(wa)18.7(s)-371.1(o)0(v)18.3(e)0(r)17.8(a)0(l)20.7(l)-377.5(d)12.2(e)0(c)16(r)0(e)17.8(a)14.1(se)15(d)-371.9(b)12.2(y)-378(2)12.2(0)12.2(%)-380.3(\(p)]TJ
/F2 1 Tf
16.5173 0 TD
(=)Tj
/F4 1 Tf
.5426 0 TD
-.0136 Tc
[(0.4)-13.6(1)4.7(2)-1.4(1)-13.6(\))2.4(.)-385.5(E)-13.6(a)4.8(r)-13.6(ly)-385.5(de)-13.6(ath)-13.6(s)]TJ
-17.0599 -1.128 TD
0 Tc
[(de)14.1(c)14.1(r)0(e)17.8(a)0(s)15(e)14.1(d)-280.4(a)0(c)16(r)0(o)22.1(s)0(s)-272.6(a)0(l)20.7(l)-279.9(ag)20.2(e)-278.6(g)0(r)16(o)12.2(u)12.2(p)0(s)19.2(,)-280.5(bu)18.3(t)-279.9(l)12.7(at)14.6(e)-278.6(d)12.2(ea)16(t)12.7(h)0(s)-273.5(i)12.7(nc)20.2(re)17.8(as)21.1(ed)-272.4(am)20.7(on)18.3(g)]TJ
0 -1.1219 TD
[(wo)16.8(m)12.8(e)0(n)-406.6(a)0(g)20.2(e)0(d)-406.6(3)12.2(0)-414.6(y)12.2(ea)16(rs)-403.9(o)12.2(r)-417(m)12.8(o)12.2(re)17.8(.)-414.6(N)0(o)-403.9(d)12.2(if)16.5(fe)17.8(re)23.9(nc)14.1(e)14.1(s)-413.7(in)-408(t)12.7(r)0(e)17.8(n)12.2(ds)-407.6(we)18.7(re)]TJ
0 -1.128 TD
[(no)18.3(te)20.7(d)-317(f)0(o)22.1(r)-319.4(ra)23.9(ce)16(/)12.7(e)0(t)14.6(h)12.2(n)12.2(i)0(c)14.6(i)12.7(ty)18.8(,)-310.9(c)0(o)14.1(u)12.2(n)12.2(t)0(r)16.5(y)-310.9(of)-307.2(o)12.2(r)0(i)16.5(g)12.2(i)12.7(n)0(,)-304.8(o)0(r)-307.2(e)0(d)20.2(u)12.2(ca)16(t)12.7(i)0(o)18.8(n)0(a)20.2(l)-316.5(at)20.7(ta)14.6(i)12.7(n)12.2(-)]TJ
0 -1.1219 TD
-.0129 Tc
[(m)-12.9(e)1.7(nt)-12.9(.)-341.6(T)-12.9(r)7.3(e)-12.9(nds)-353.5(i)-.2(n)-354.3(c)-12.9(aus)-12.9(e)2.1(s)-353.5(o)-.7(f)-350.6(d)-12.9(eat)-12.9(h)-347.7(f)-12.9(o)9.2(r)-356.7(200)-12.9(6)5.4()-.7(2)-12.9(0)5.4(13)-354.3(s)-12.9(h)6.3(ow)-12.9(e)5.8(d)-354.3(a)-352.4(3)-12.9(.)5.4(4)-.7(%)]TJ
0 -1.128 TD
0 Tc
[(an)14.1(n)12.2(u)12.2(a)0(l)-442.7(d)12.2(ec)22.1(li)19.3(ne)-443.2(a)14.1(m)0(o)18.9(n)12.2(g)-451.2(g)12.2(ro)22.1(up)18.3(ed)-437.1(pr)16(e)14.1(e)0(c)16(l)12.7(am)14.7(p)12.2(s)0(i)19.7(a)0(,)-437.1(o)0(b)18.3(s)13.1(te)14.6(t)12.7(r)0(i)16.5(c)-443.2(he)14.1(m)12.8(o)12.2(r-)]TJ
0 -1.1219 TD
[(rh)16(ag)20.2(e,)-278.6(an)20.2(d)-292.6(o)12.2(bs)19.2(te)20.7(tr)16.5(i)12.7(c)-290.8(em)14.6(b)12.2(o)12.2(l)0(i)19.4(s)0(m)-279(d)0(e)14.1(a)14.1(t)0(h)18.8(s)-291.8(\(p)]TJ
/F2 1 Tf
15.8954 0 TD
(=)Tj
/F4 1 Tf
.5426 0 TD
[(0)12.2(.)0(4)18.3(0)12.2(9\))16(.)]TJ
/F3 1 Tf
-15.4381 -1.128 TD
(Conclusions:)Tj
/F4 1 Tf
5.9265 0 TD
[(The)-414.5(decl)16.5(ine)-418.2(in)-426.3(Cal)16(ifor)20.2(nia)18.4(s)-432(ear)13.6(ly)-426.3(MM)14(R)-431.5(i)0(s)-425.4(i)0(n)]TJ
-6.9264 -1.1219 TD
[(star)13.1(k)-365.8(con)14.1(tra)12.3(st)-364.4(to)-359.2(nat)14.6(ion)12.8(al)-363.4(rat)12.3(es.)-356.9(Howe)17.3(ver)11.8(,)-365.8(whe)12.6(n)-371.9(l)0(a)14.6(t)0(e)-369.5(d)0(e)14.1(ath)14.6(s)-371.1(are)]TJ
0 -1.128 TD
[(add)14.1(ed,)-333.4(th)12.7(e)-345.6(M)0(M)14(R)-340(rem)12.3(ain)14.6(s)-340.6(r)0(e)11.7(lati)15.7(vel)14.6(y)-341.4(s)0(t)13.6(abl)14.6(e.)-339.5(The)12.3(se)-332.6(nd)15.5(ing)12.8(s)-340.6(s)0(u)13.1(g)0(-)]TJ
0 -1.1219 TD
[(gest)-197.9(th)12.7(at)-204.9(ho)12.2(spi)13.6(tal)15.1(-ba)11.8(sed)-198.4(qu)12.2(ali)15.1(ty)-200.7(imp)13.3(rov)16(eme)10.4(nt)-200.7(ef)11.8(for)13.6(ts)-199.8(in)-206.8(Cal)16(ifo)16.5(rnia)]TJ
0 -1.128 TD
[(beg)14.1(un)-292.6(in)-286(201)12.3(0)-292.6(may)-284.1(be)-290.7(con)14.2(trib)17(ut)12.7(ing)-286(to)-292.1(im)13.3(pro)16(ved)-284.6(surv)16.9(iv)12.7(al)-290.2(duri)16.5(ng)]TJ
0 -1.1219 TD
[(acut)16.5(e)-309.1(o)0(b)12.2(ste)15.5(tric)18.9(al)-302.4(eme)16.5(rge)11.8(nci)14.6(es.)-296(Inc)11.8(re)11.7(ase)10.8(d)-304.8(l)0(a)14.6(ter)-298.7(dea)16(ths)-297.3(may)-296.3(be)-296.8(at-)]TJ
0 -1.128 TD
[(trib)17(ut)12.7(able)-398.1(to)-408(chr)11.8(on)12.2(ic)-406.1(di)12.7(sea)10.8(ses)-404.9(su)13.1(ch)-406.6(as)-405.7(car)13.6(dio)12.8(vas)15(cul)14.6(ar)-409(il)13.2(lne)14.6(sses)16.7(,)]TJ
T*
[(con)14.1(sis)14.5(ten)14.6(t)-225.1(w)0(i)11.2(t)0(h)-218.9(h)0(i)12.7(g)0(h)12.2(e)0(r)-219.9(r)0(a)11.7(tes)-216.2(of)-215.7(lat)15.2(e)-223.7(dea)16(ths)-212(amo)14.7(ng)-219.4(ol)12.7(der)-213.8(Cal)16(ifo)16.5(rnia)]TJ
0 -1.1219 TD
[(wom)11.3(en.)-296.8(Fur)13.1(th)12.7(er)-305.3(stu)13.6(dy)-304.8(is)-303.5(un)12.2(der)11.8(wa)12.6(y)-310.9(t)0(o)-304.3(ass)15.8(ess)-301.2(th)12.7(e)-309(decr)13.7(eas)16.9(e)-309.1(i)0(n)-304.3(the)]TJ
0 -1.128 TD
[(MMR)-289.5(in)-286(Cali)16.5(for)13.6(ni)12.7(a.)]TJ
/F3 1 Tf
0 -4.1583 TD
(52.)Tj
9.843 0 0 9.843 333.9779 519.4771 Tm
[(Health-Related)-285.8(Quali)-6.8(ty)-278.6(of)-278.6(Life)-283.2(and)-279.4(Related)-287.3(Factors)]TJ
0 -1.1174 TD
[(Among)-283.8(Women)-279.4(with)-281.7(Coronary)-288.3(Artery)-281.6(Disease)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 313.0582 491.9243 Tm
[(Chih-Ping)-338(Lee)]TJ
6.9735 0 0 6.198 368.4471 496.0629 Tm
(1)Tj
9.2982 0 0 9.2982 371.9621 491.9243 Tm
[(,)-335.3(Lee-Ing)-331.9(Tsao)]TJ
6.9735 0 0 6.198 428.0881 496.0629 Tm
(2)Tj
9.2982 0 0 9.2982 431.603 491.9243 Tm
[(,)-335.3(Chao-Chung)-332.8(Ho)]TJ
6.9735 0 0 6.198 499.0109 496.0629 Tm
(1)Tj
9.2982 0 0 9.2982 502.4691 491.9243 Tm
(,)Tj
-20.3707 -1.1219 TD
[(Mei-Hsiang)-338.6(Lin)]TJ
6.9735 0 0 6.198 373.6062 485.6314 Tm
(2)Tj
/F5 1 Tf
-8.6826 -2.6526 TD
(1)Tj
9.2982 0 0 9.2982 316.5731 465.0518 Tm
[(Hsinchu)-333.4(City,)-337.1(Taiwan)]TJ
6.9735 0 0 6.198 313.0582 458.7022 Tm
(2)Tj
9.2982 0 0 9.2982 316.5731 454.5637 Tm
[(Taipei,)-335.2(Taiwan)]TJ
/F3 1 Tf
.6219 -2.3047 TD
(Background:)Tj
/F4 1 Tf
5.9631 0 TD
[(Women)-355.3(have)-355.9(the)-357.3(same)-360.6(rate)-357.8(of)-356(suffering)-357.3(from)]TJ
-6.963 -1.1219 TD
[(coronary)-519.1(artery)-518.6(disease)-522.5(as)-515.5(men)-515.8(ten)-515.8(years)-515.9(after)-518.6(menopausal.)]TJ
0 -1.128 TD
[(Coronary)-257.4(artery)-250.3(disease)-254.2(is)-254.7(a)-254.2(chronic)-247.9(condition)-252.5(that)-253.1(requires)-255.5(long)]TJ
0 -1.1219 TD
[(term)-359.1(treatment)-354.2(and)-351.7(follow-up.)-358.6(The)-353.5(role)-353.5(of)-356(these)-354.5(women)-352.6(trans-)]TJ
0 -1.128 TD
[(forms)-283.7(from)-284.6(caregiver)-289.2(to)-279.9(caretaker)-287.3(after)-286.9(suffering)-284.1(from)-284.6(coronary)]TJ
0 -1.1219 TD
[(artery)-451.5(disease.)-443.2(This)-445.5(change)-445.4(affects)-448.8(their)-444.5(physical)-451.5(and)-443.1(mental)]TJ
0 -1.128 TD
[(status)-403.8(as)-399.6(well)-400.9(as)-399.6(their)-401.8(functional)-399.3(health)-403.6(status.)-397.7(However,)-403.9(it)-401.4(is)]TJ
0 -1.1219 TD
[(often)-225.5(underemphasized)-222.4(that)-216.5(which)-224.6(factors)-219(affect)-224.1(womens)-219.9(health)]TJ
0 -1.128 TD
[(related)-306.5(quality)-301.3(of)-301.1(life.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.896 0 TD
[(This)-390.6(research)-392.5(is)-382.7(to)-389.7(inspect)-390.5(ve)-385(health)-391.4(related)]TJ
-6.8959 -1.128 TD
[(quality)-240.3(of)-240.1(life)-237.2(\(physical)-240.4(limitation,)-238.2(stability)-238.4(of)-240.1(angina,)-233.4(frequency)]TJ
0 -1.1219 TD
[(of)-380.4(angina,)-379.7(satisfaction)-383(of)-380.3(treatment)-378.6(and)-382.2(quality)-380.6(of)-380.3(life\),)-379.8(social)]TJ
0 -1.128 TD
[(support)-372.8(\(family,)-367(friend,)-368(and)-370(health)-367(professionals\))-371.4(and)-370(their)-365.2(re-)]TJ
0 -1.1219 TD
[(lated)-452.4(factors)-444.6(and)-449.2(to)-444.5(analyze)-449.1(important)-443.3(predictive)-452.3(factors)-444.6(that)]TJ
0 -1.128 TD
[(affect)-303.3(womens)-305.3(health)-300(related)-300.4(quality)-301.3(of)-301.1(life.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Material/Methods:)Tj
/F4 1 Tf
8.4141 0 TD
[(This)-341.8(research)-349.8(is)-340(a)-345.6(cross-sectional)-346.5(corre-)]TJ
-9.4141 -1.128 TD
[(lational)-268.4(research)-264.5(with)-262.6(convenient)-261.4(sampling.)-263.8(Sixty-seven)-261.6(women)]TJ
0 -1.1219 TD
[(with)-274.8(coronary)-275.2(artery)-268.6(diseases)-277.7(were)-274.4(enrolled)-271.8(in)-267.7(this)-272.4(research)-276.7(in)-273.8(a)]TJ
0 -1.128 TD
[(cardiology)-393.7(outpatient)-396.4(clinic)-390.9(of)-392.5(a)-388.3(teaching)-395.6(hospital)-391.9(in)-389.7(northern)]TJ
0 -1.1219 TD
[(Taiwan)-596.5(from)-595.5(January)-595.1(2015)-591.3(to)-590.9(September)-595.9(2015.)-591.3(Structured)]TJ
0 -1.128 TD
[(questionnaire)-244.1(was)-242.6(implemented)-241.5(as)-241.1(data)-245.6(collection)-242.1(tool)-236.7(including)]TJ
0 -1.1219 TD
[(information)-287.1(of)-282.8(geographic)-288.7(characteristics,)-288.2(health)-287.8(related)-282.1(quality)]TJ
0 -1.128 TD
[(of)-416.9(life)-414(\(Seattle)-418.6(Angina)-413.6(Questionnaire,)-422.4(SAO,)-414.3(Chinese)-414.1(version\))]TJ
T*
[(and)-302.9(questionnaire)-305(of)-295(social)-305.2(support.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Results:)Tj
/F4 1 Tf
3.7193 0 TD
-.0127 Tc
[(F)-12.7(i)9.4(ve)-285.2(dimensi)-12.7(o)6.2(ns)-280.1(of)-283.3(hea)-12.7(l)8(th)-280.9(r)-12.7(e)5.1(late)-12.7(d)-273(qual)-12.7(i)6.6(ty)-281(of)-283.3(lif)-12.7(e)-275.3(w)4.1(e)-12.7(r)5.1(e)]TJ
-4.7192 -1.128 TD
[(a)-12.7(n)7.5(al)-12.7(y)6.1(z)1.4(e)-12.7(d)-321.7(using)-335.8(c)1.4(or)-12.7(r)7(e)1.4(la)-12.7(t)8(i)0(ona)-12.7(l)-321.2(r)-12.7(e)11.2(g)-.5(r)-12.7(e)11.2(s)-12.7(s)7.3(ion)-335.8(a)1.4(nal)-12.7(y)6.2(sis,)-335.8(includi)-12.7(n)6.2(g)-329.7(phys-)]TJ
0 -1.1219 TD
[(i)-12.6(c)8.1(a)-12.6(l)-296.7(limit)-12.6(a)8.1(tion)-311.3(a)1.5(nd)-305.2(a)-12.6(g)7.6(e,)-305.2(c)-12.6(o)7.6(mor)-12.6(b)9.5(idity,)-305.3(s).5(oc)-12.6(i)8.1(a)-12.6(l)-296.7(n)-.4(etw)-12.6(o)10.3(r)-12.6(k)9.5(ing,)-305.2(a)-12.6(n)7.6(d)-305.2(s).5(up-)]TJ
0 -1.128 TD
-.0129 Tc
[(po)-12.9(r)9.2(t)-292.8(f)-12.9(r)12.9(om)-292.8(f)-12.9(r)12.9(i)-12.9(e)7.8(nds.)-293.4(A)-12.9(g)10(e)-291.5(and)-293.3(s).2(uppor)-12.9(t)-283(f)3(r)-12.9(o)9.2(m)-292.8(f)3(r)-12.9(i)9.7(e)-12.9(n)7.3(ds)-292.5(ar)-12.9(e)-281.6(p)-.7(re)-12.9(d)7.3(i)-.2(c)-12.9(t)7.8(ive)-291.5(t)-.2(o)]TJ
0 -1.1219 TD
-.0126 Tc
[(ph)-12.6(y)5.7(s).5(ica)-12.6(l)-272.4(limita)-12.6(t)8.1(i).1(on,)-280.9(ac)-12.6(c)9.5(ounti)-12.6(n)6.2(g)-274.7(f)-12.6(o)9.5(r)-277.1(21.4%)-283.2(of)-277.1(var)-12.6(i)10(a)-12.6(t)8.1(ion.)-280.9(T)-12.6(r)13.7(e)-12.6(a)9.5(tme)-12.6(n)7.6(t)]TJ
0 -1.128 TD
[(i)-12.7(s)-297.9(pre)-12.7(d)7.5(ic)-12.7(t)8(i)0(ve)-303.5(to)-305.3(st)-12.7(a)8(b)-.5(ilit)-12.7(y)-292.6(o)-.5(f)-307.7(a)1.4(ng)-12.7(i)6.1(n)-.5(a,)-305.3(ac)-12.7(c)9.4(ount)-12.7(i)6.6(n)-.5(g)-305.3(f)3.2(or)-307.7(20.6%)-301.6(of)-307.7(var)-12.7(i)9.9(-)]TJ
0 -1.1219 TD
-.013 Tc
[(a)-13(t)7.7(ion.)-336.1(U)-13(n)9.9(der)-338.5(t)-.3(he)-334.2(c)-13(a)9.1(te)-13(g)7.2(o)-.8(ry)-336.1(of)-338.5(fr)-13(e)10.9(que)-13(n)7.2(c)1.1(y)-336.1(o)-.8(f)-338.5(a)1.1(ngina)-13(,)-322(a)-13(g)7.2(e)-334.2(a)-13(n)7.2(d)-330(t)-13(r)9.6(e)-13(a)9.1(t)-.3(-)]TJ
0 -1.128 TD
-.0126 Tc
[(m)-12.6(e)8.1(nt)-268.2(ar)-12.6(e)-256.9(p)-.4(r)-12.6(e)5.2(dictive)-272.9(t).1(o)-268.7(f)3.3(r)-12.6(e)5.2(quency)-268.7(o)-.4(f)-271(a)1.5(ngina)-12.6(,)-260.7(a)1.5(c)-12.6(c)9.5(ounting)-268.7(f)-12.6(o)9.5(r)-264.9(13.4%)]TJ
0 -1.1219 TD
[(of)-325.8(va)-12.5(r)11.4(i)-12.5(a)8.2(tion.)-323.4(U)-12.5(n)10.4(de)-12.5(r)-317.8(t).2(he)-321.6(c)-12.5(a)9.6(te)-12.5(g)7.7(o)-.3(r)-12.5(y)-313.6(of)-319.7(qua)-12.5(l)8.2(ity)-323.4(of)-325.8(li)-12.5(f)10.1(e)-12.5(,)-315.4(t).2(r)-12.5(e)11.4(a)-12.5(t)8.2(ment)-329(and)]TJ
0 -1.128 TD
[(s)-12.7(u)6.5(pport)-231.7(f)3.2(r)-12.7(o)9.4(m)-225.5(f)-12.7(r)13.1(i)0(e)-12.7(n)7.5(d)-226.1(a)1.4(r)-12.7(e)-214.4(pr)-12.7(e)5.1(d)-.5(icti)-12.7(v)6.1(e)-224.2(to)-226.1(qua)-12.7(l)8(ity)-226.1(of)-228.4(lif)-12.7(e)11.2(,)-226.1(ac)-12.7(c)9.4(ount)-12.7(i)6.6(n)-.5(g)-226.1(f)3.3(or)]TJ
0 -1.1219 TD
-.0123 Tc
[(21)-12.3(.)6(7)-.1(%)-295.1(o)-.1(f)-301.2(v)-.1(a)-12.3(r)11.6(i)-12.3(a)8.4(tion.)]TJ
/F3 1 Tf
.9999 -1.128 TD
0 Tc
(Conclusions:)Tj
/F4 1 Tf
5.707 0 TD
[(Ag)16.8(ed)-156.6(wo)16.8(m)12.8(e)0(n)-162.7(w)0(i)23.4(t)0(h)-164.1(l)12.7(i)12.7(m)0(i)19.4(t)0(e)14.6(d)-164.6(ph)18.3(y)12.2(s)0(i)19.7(c)0(a)16(l)-170.2(fu)22.1(n)12.2(c)0(t)14.6(i)12.7(o)12.2(n)-170.7(n)12.2(e)0(e)16(d)]TJ
-6.7069 -1.1219 TD
[(to)-371.4(b)12.2(e)-382.2(ca)16(re)23.9(fu)16(l)-377.5(o)12.2(f)-380.4(t)0(h)18.8(e)0(i)20.7(r)-380.4(ac)16(t)12.7(i)0(v)18.8(i)0(t)19.3(y)-378(st)19.7(at)20.7(us)19.2(.)-384.1(N)0(u)22.9(r)0(s)16.8(i)12.7(n)12.2(g)-384.1(d)12.2(i)12.7(se)15(as)21.1(e)-382.2(e)14.1(du)18.3(ca)16(t)12.7(i)0(o)18.8(n)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 62.022 749.6502 Tm
(A-20)Tj
48.6864 0 TD
(ABSTRACTS)Tj
ET
endstream
endobj
272 0 obj
<>stream
/GS1 gs
BT
/F4 1 Tf
9.2982 0 0 9.2982 59.7543 725.5557 Tm
0 0 0 rg
0 Tc
0 Tw
[(sh)19.2(al)14.6(l)-298.2(3)12.2(2b)18.3(e)-303(t)0(a)20.7(i)0(l)19.3(o)0(r)16(-)0(m)22.6(a)0(d)20.2(e)-303(b)12.2(a)0(s)15(e)-303(o)12.2(n)-304.8(t)12.7(h)12.2(ei)14.6(r)-301.1(a)0(g)20.2(e)-303(g)12.2(r)0(o)16(u)12.2(p)-298.7(a)0(n)20.2(d)-304.8(s)13.1(h)0(a)14.1(l)12.7(l)-304.3(i)12.7(nc)20.2(lu)18.8(d)12.2(e)]TJ
0 -1.128 TD
[(en)14.1(e)14.1(r)0(g)16(y)12.2(-s)16.8(a)14.1(v)0(i)18.8(n)12.2(g)-225.6(a)0(c)16(t)12.7(iv)18.8(it)19.3(y)-225.6(m)12.8(et)14.6(h)12.2(o)12.2(d)0(.)-219.5(I)0(t)-215.2(i)12.7(s)-224.7(r)0(e)17.8(c)0(o)20.2(m)12.8(me)14.6(n)12.2(d)12.2(e)0(d)-217.6(t)12.7(o)-225.6(f)0(o)16(r)0(m)-215.2(p)12.2(at)20.7(ie)20.7(nt)]TJ
0 -1.1219 TD
[(su)19.2(pp)18.3(o)12.2(r)0(t)-398.1(g)12.2(ro)22.1(up)-396.3(fo)22.1(r)-404.8(a)0(g)14.1(e)14.1(d)-408.5(wo)22.9(me)20.7(n)-408.5(w)0(i)23.4(t)0(h)-395.8(l)0(i)19.3(m)0(i)19.4(t)0(e)20.7(d)-408.5(p)12.2(h)12.2(y)0(s)19.2(i)0(c)14.6(a)14.1(l)-408(f)0(u)22.1(n)12.2(ct)14.6(i)12.7(o)0(n)18.3(,)]TJ
0 -1.128 TD
[(pr)16(o)12.2(v)12.2(i)0(d)18.8(i)0(n)18.8(g)-469.5(p)12.2(o)12.2(s)0(i)19.7(t)0(i)19.3(v)0(e)-461.5(s)13.1(up)18.3(p)12.2(o)0(r)16(t)12.7(.)-469.5(T)0(h)16.5(i)12.7(s)-468.6(r)0(e)17.8(s)13.1(ea)16(rc)17.9(h)-463.4(a)0(l)14.6(s)13.1(o)-469.5(d)12.2(is)19.7(co)20.2(ve)14.1(re)23.9(d)-469.5(t)0(h)18.8(a)0(t)]TJ
0 -1.1219 TD
[(sp)19.2(ou)18.3(s)13.1(e)0(s)-271.6(a)14.1(re)-268.7(n)12.2(o)0(t)-267.7(p)12.2(ar)17.8(ti)19.3(ci)20.7(pa)14.1(t)12.7(i)0(v)18.8(e)-272.5(in)-267.7(co)20.2(ro)16(n)12.2(a)0(r)17.8(y)-274.3(ar)17.8(t)12.7(e)0(r)17.8(y)-274.3(di)18.8(se)21.1(as)15(e)-272.5(c)0(a)16(r)0(e)17.8(.)-274.4(It)-264(is)]TJ
0 -1.128 TD
[(re)17.8(co)20.2(mm)19.4(en)20.2(de)20.2(d)-298.7(t)12.7(ha)20.2(t)-298.2(s)0(p)19.2(o)12.2(us)19.2(e)-296.9(a)0(n)20.2(d)-292.6(fa)17.8(mi)19.4(ly)-286(p)12.2(a)0(r)17.8(t)0(i)19.3(c)0(i)20.7(p)0(a)20.2(t)0(e)-290.2(i)12.7(n)-298.7(t)12.7(h)12.2(e)-296.9(co)20.2(ro)16(n)12.2(a)0(r)17.8(y)]TJ
0 -1.1219 TD
[(ar)17.8(te)20.7(ry)-307.2(d)12.2(i)12.7(se)15(as)21.1(e)-315.1(t)12.7(re)17.8(at)20.7(me)14.6(n)12.2(t)-310.4(an)20.2(d)-310.9(p)0(r)16(o)12.2(v)12.2(i)0(d)18.8(e)-315.1(n)12.2(e)0(c)16(e)0(s)21.1(s)0(a)21.1(r)0(y)-307.2(s)13.1(up)18.3(p)12.2(o)0(r)16(t)12.7(.)-310.9(I)0(t)-300.6(i)0(s)-303.5(i)0(m)19.4(-)]TJ
0 -1.128 TD
[(po)18.3(rt)16.5(a)14.1(n)0(t)-322.6(t)0(o)-322.6(i)0(n)18.8(s)0(p)19.2(e)0(c)16(t)-328.7(if)-325(p)12.2(a)0(t)14.6(i)12.7(en)20.2(ts)-327.8(d)12.2(e)0(v)20.2(e)0(l)20.7(o)0(p)-323.1(s)0(o)19.2(c)0(i)20.7(a)0(l)-326.8(i)12.7(so)19.2(la)20.7(ti)19.3(on)-323.1(be)20.2(ca)16(u)12.2(s)0(e)-326.5(o)12.2(f)]TJ
0 -1.1219 TD
[(th)18.8(ei)20.7(r)-307.2(p)12.2(h)12.2(y)0(s)19.2(i)0(c)20.7(a)0(l)-296.3(l)12.7(im)19.4(it)19.3(at)20.7(io)18.8(n)12.2(.)-304.8(En)22.6(co)20.2(ur)16(ag)20.2(e)-303(p)12.2(at)20.7(ie)14.6(n)12.2(t)12.7(s)-304(t)0(o)-292.1(p)12.2(ar)17.8(ti)19.3(ci)20.7(pa)20.2(te)-296.3(i)12.7(n)-304.8(a)14.1(c)0(-)]TJ
0 -1.128 TD
[(ti)19.4(vi)18.8(ti)19.3(es)-338.7(t)12.7(h)0(e)20.2(y)-347.5(ar)17.8(e)-345.6(i)12.7(nt)18.8(er)17.8(es)21.1(te)14.6(d)-341.4(i)0(n)-334.8(a)0(n)20.2(d)-347.5(to)-334.8(us)19.2(e)-345.6(c)0(o)20.2(m)0(m)19.4(u)0(n)18.3(i)12.7(ty)-340.9(re)23.9(so)19.2(ur)16(c)14.1(e)-345.6(to)]TJ
0 -1.1219 TD
[(ex)14.1(p)12.2(a)0(n)20.2(d)-201.2(an)14.1(d)-201.2(s)0(t)19.7(a)0(b)20.2(i)0(l)19.3(i)0(z)20.7(e)-205.4(th)18.8(ei)14.6(r)-203.6(s)13.1(oc)20.2(ia)14.6(l)-200.7(n)0(e)20.2(t)0(w)17.3(o)12.2(rk)-197.4(s)13.1(u)0(c)14.1(h)-201.2(as)-198.4(v)12.2(o)12.2(l)0(u)18.8(n)12.2(te)14.6(er)17.8(i)12.7(n)12.2(g)-207.3(a)0(n)20.2(d)]TJ
0 -1.128 TD
[(re)17.8(li)19.3(g)12.2(i)0(o)18.8(u)0(s)-249.1(a)0(c)22.1(t)0(i)19.3(v)0(i)18.8(t)0(i)19.3(e)0(s)21.1(.)-262.2(C)13.6(o)0(m)18.9(m)12.8(un)18.3(it)19.3(y)-256.1(h)12.2(ea)16(lt)19.3(h)-256.1(n)12.2(ur)16(s)13.1(e)0(s)-247.2(s)0(h)19.2(a)0(l)20.7(l)-261.7(ro)22.1(u)12.2(t)0(i)19.3(n)0(e)20.2(l)0(y)-249.4(v)12.2(is)19.7(it)]TJ
0 -1.1219 TD
[(pa)14.1(t)12.7(i)12.7(e)0(n)14.1(t)12.7(s)-194.2(w)0(i)17.3(t)12.7(h)-195.1(h)12.2(ig)18.8(h)12.2(e)0(r)-189.5(r)0(i)22.6(s)0(k)-188.1(o)12.2(r)-191.4(p)0(r)16(o)12.2(v)12.2(i)0(d)18.9(e)-193.2(ph)18.3(o)12.2(n)0(e)-187.1(s)0(u)19.2(p)12.2(po)18.3(rt)22.6(.)-195.1(A)0(c)18.7(t)0(i)19.3(v)12.2(el)14.6(y)-195.1(a)14.1(ss)20(es)15(s)]TJ
0 -1.128 TD
[(an)14.1(d)-280.4(u)0(n)18.3(d)12.2(er)17.8(st)19.7(an)20.2(d)-286.5(t)0(h)18.9(e)-284.7(ne)20.2(ed)-278.5(o)12.2(f)-288.9(wo)22.9(me)14.7(n)-280.4(w)0(i)17.3(t)12.7(h)-286.5(c)0(o)20.2(r)0(o)16(n)12.2(ar)17.8(y)-286.5(a)14.1(rt)16.5(er)17.8(y)-286.5(d)12.2(i)12.7(s)0(e)15(a)0(s)21.1(e)0(,)]TJ
T*
[(an)14.1(d)-323.1(p)12.2(ro)22.1(vi)18.8(d)12.2(e)-327.3(re)17.8(l)12.7(a)0(t)20.7(e)0(d)-315.1(i)0(n)18.8(f)0(o)22.1(r)0(m)16.5(a)0(t)20.7(i)0(o)18.9(n)-323.1(o)12.2(r)-325.5(re)17.8(s)13.1(o)0(u)18.3(r)0(c)17.8(e)0(.)-315.1(D)0(i)23.4(f)0(f)13.6(e)14.1(re)17.8(n)12.2(t)-328.7(t)12.7(r)0(e)17.8(a)0(t)20.7(m)0(e)20.7(n)0(t)]TJ
0 -1.1219 TD
[(wi)17.3(ll)-212.3(a)14.1(f)0(f)19.7(e)0(c)16(t)-219(th)18.8(e)-217.6(f)0(r)19.7(e)0(q)20.2(u)0(e)14.1(n)12.2(cy)-211.5(a)14.1(n)0(d)-213.3(s)13.1(ta)14.6(b)12.2(i)12.7(li)19.3(ty)-212.8(o)12.2(f)-221.8(an)20.2(g)12.2(i)0(n)18.8(a)0(.)-211.5(P)0(a)23.4(t)0(i)19.3(e)0(n)20.2(t)0(s)-212(a)0(n)20.2(d)-219.5(th)18.8(ei)20.7(r)]TJ
0 -1.128 TD
[(fa)17.8(mi)19.4(ly)-164.1(sh)19.2(al)14.6(l)-170.2(b)0(e)-168.8(e)0(d)20.2(u)0(c)20.2(a)0(t)14.6(e)14.1(d)-176.8(a)0(b)20.2(o)0(u)18.3(t)-176.3(em)20.8(er)17.8(g)12.2(e)0(n)20.2(t)-176.3(si)19.7(gn)18.3(s)-175.9(o)12.2(f)-179.2(d)12.2(is)19.7(ea)16(s)13.1(e)-181(a)14.1(n)0(d)-170.7(w)0(h)22.9(e)0(n)]TJ
0 -1.1219 TD
[(to)-194.6(s)13.1(e)0(e)16(k)-201.2(m)12.8(e)0(d)14.1(i)12.7(ca)16(l)-200.7(a)0(t)20.7(t)0(e)20.7(n)0(t)18.8(i)0(o)18.8(n)-201.2(n)12.2(o)-201.2(ma)14.7(t)12.7(t)0(e)20.7(r)-203.6(i)12.7(f)-203.6(th)18.8(ey)-193.2(h)12.2(a)0(v)20.2(e)-205.4(s)13.1(t)0(e)14.6(n)12.2(t)-200.7(p)12.2(la)14.6(c)14.1(e)0(m)14.7(e)14.1(nt)-194.6(o)12.2(r)]TJ
0 -1.128 TD
[(no)18.3(t)-170.2(i)12.7(n)-170.7(o)12.2(rd)22.1(er)-159(to)-158(p)12.2(r)0(e)17.8(v)12.2(en)14.1(t)-164.1(c)0(o)20.2(m)0(p)18.9(l)0(i)19.3(c)0(a)16(t)12.7(io)18.8(n)12.2(s)0(.)-157.6(I)0(t)-160.3(i)12.7(s)-169.8(a)0(l)20.7(s)0(o)-157.6(r)0(e)17.8(c)0(o)20.2(m)12.8(me)14.7(n)12.2(d)12.2(e)0(d)-162.7(t)12.7(o)-164.6(s)0(e)15(t)]TJ
0 -1.1219 TD
[(up)-487.7(co)20.2(ro)22.1(na)14.1(ry)-484(ar)17.8(t)12.7(e)0(r)17.8(y)-493.8(di)18.8(se)21.1(as)15(e)-492(c)0(a)16(s)0(e)-485(m)0(a)14.7(n)12.2(ag)20.2(er)-488.2(t)12.7(o)-499.9(fo)22.1(l)12.7(l)0(o)18.8(w)0(-)20.6(u)0(p)-487.7(h)12.2(ea)16(l)12.7(t)0(h)]TJ
0 -1.128 TD
[(fu)16(n)12.2(c)0(t)20.7(i)0(o)18.9(n)-250(st)19.7(at)20.7(us)-243(o)12.2(f)-252.3(p)12.2(a)0(t)20.7(i)0(e)14.6(n)12.2(ts)19.7(.)]TJ
/F3 1 Tf
0 -2.4755 TD
(53.)Tj
9.843 0 0 9.843 80.674 493.2849 Tm
[(Excluded)-282.5(Data:)-282.8(Women)-285.1(in)-278.6(the)-280.7(Fire)-284.5(Service:)]TJ
0 -1.1116 TD
[(A)-284.2(Review)-281.5(of)-278.6(Current)-288.2(Literature)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 59.7543 465.7889 Tm
[(Kayla)-338.6(Lindsay)]TJ
/F5 1 Tf
0 -1.7682 TD
[(The)-336.3(University)-333.9(of)-334.8(Alabama,)-331.9(Reston,)-339.9(Virginia)]TJ
/F3 1 Tf
.9999 -2.3047 TD
(Background:)Tj
/F4 1 Tf
6.0667 0 TD
[(There)-457.6(are)-461.9(112,950)-463.2(reghters)-462.4(in)-456.7(the)-460.9(United)]TJ
-7.0666 -1.128 TD
[(States,)-265.4(only)-255.5(3.7%)-258.3(are)-260.7(women.)-261.1(Over)-258(half)-262.1(of)-258.4(departments)-262.4(have)-258.3(no)]TJ
0 -1.1219 TD
[(female)-312.6(reghters)-310(at)-302.4(all.)-308(Female)-313.1(reghters)-303.9(are)-309.5(often)-310.8(excluded)]TJ
0 -1.128 TD
[(from)-327.3(research)-325.4(studies)-324.5(because)-326.8(of)-325.5(the)-320.7(low)-324.1(population,)-325.6(they)-320.7(may)]TJ
0 -1.1219 TD
[(be)-302.9(easily)-299.1(identied,)-302.2(or)-301.1(could)-296.3(have)-301(unknown)-300.1(effects)-302.5(on)-298.7(research)]TJ
0 -1.128 TD
[(results)-302.5(that)-301.9(are)-303.4(so)-297.9(heavily)-299.9(male)-306.1(dominated.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.8045 0 TD
[(The)-286.5(purpose)-292.1(of)-295(this)-290.7(project)-290.1(was)-291.4(to)-292.1(nd)-295.5(gaps)-289.8(in)]TJ
-6.8045 -1.128 TD
[(literature)-307.8(regarding)-299(female)-300.4(reghter)-304.8(health.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Material/Methods:)Tj
/F4 1 Tf
8.5361 0 TD
[(Inclusion)-461.8(criteria)-466.9(for)-462(this)-461.4(review)-469(were)]TJ
-9.536 -1.128 TD
[(articles)-488.1(in)-481.1(the)-479.2(English)-481.5(language,)-487.5(primary)-477.2(prevention)-485.1(studies,)]TJ
0 -1.1219 TD
[(interventions,)-208.8(wellness)-202.2(campaigns,)-205.7(and)-205.3(health)-202.4(related)-209(research)-203.5(of)]TJ
0 -1.128 TD
[(all)-375.1(research)-380.3(designs,)-373.8(searched)-377.9(in)-377.5(EBSCOHOST.)-376.8(The)-371.8(audience)]TJ
0 -1.1219 TD
[(targeted)-208.9(included)-202.3(female)-202.9(reghters)-206.4(of)-203.5(any)-199.3(age.)-203.5(Studies)-206.3(included)]TJ
0 -1.128 TD
[(focused)-497.6(on)-487.7(mental)-494.5(health,)-495.1(physical)-494.2(activity,)-487.9(nutrition,)-494(injury)]TJ
0 -1.1219 TD
[(prevention,)-265.6(and)-266.3(overall)-265.7(wellness)-263.1(at)-265.8(the)-265.8(primary)-263.8(prevention)-265.6(level)]TJ
0 -1.128 TD
[(from)-302.9(the)-302.4(years)-302.5(2005)-298.7(to)-298.2(2015.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Results:)Tj
/F4 1 Tf
3.8473 0 TD
[(There)-408.9(are)-407.1(very)-408.9(few)-410.4(academic)-416.2(research)-410.8(articles)-408.8(re-)]TJ
-4.8473 -1.128 TD
[(garding)-225.4(reghter)-225.5(health,)-220.7(tness,)-224.2(nutrition,)-225.7(and)-217.5(overall)-229.1(wellness.)]TJ
0 -1.1219 TD
[(There)-305.2(are)-303.4(even)-301(fewer)-301.1(that)-301.9(include)-299.9(female)-300.4(populations.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Conclusions:)Tj
/F4 1 Tf
5.8106 0 TD
[(The)-323(gender)-327.7(roles)-322.2(of)-319.4(the)-326.8(re)-320.3(department)-324.2(play)-320.7(a)]TJ
-6.8106 -1.1219 TD
[(pivotal)-313.5(part)-316.9(in)-310.4(tness)-309.6(and)-315.1(health)-312.1(among)-314.5(females)-311.8(in)-310.4(the)-314.6(re)-314.3(ser-)]TJ
0 -1.128 TD
[(vice.)-446.8(More)-444.6(research)-447.4(both)-444.5(qualitative)-448.9(and)-443.1(quantitative)-448.9(is)-443.7(war-)]TJ
0 -1.1219 TD
[(ranted)-345.5(in)-347(this)-345.6(area.)-344.2(Further)-346.5(understanding)-344(about)-345(mental)-348.2(health,)]TJ
0 -1.128 TD
[(physical)-311.3(activity,)-311.1(nutrition,)-311.1(injury)-306.1(prevention,)-308.3(and)-309(overall)-314.5(well-)]TJ
0 -1.1219 TD
[(ness)-368.3(of)-362.1(the)-363.4(female)-367.5(reghter)-365.8(population)-362.2(will)-365.7(help)-363.3(inform)-369.4(suc-)]TJ
0 -1.128 TD
[(cessful)-307.2(strategies)-298.2(for)-303.4(future)-301(wellness)-299.7(programs.)]TJ
/F3 1 Tf
0 -2.4755 TD
(54.)Tj
9.843 0 0 9.843 80.674 143.3763 Tm
[(Outcomes)-283.8(Associated)-284.5(with)-281.7(Abdominal)]TJ
0 -1.1116 TD
[(and)-279.4(Vaginal)-285.2(Hysterectomies:)-289.2(Complication)-281.3(Rates)]TJ
0 -1.1174 TD
[(and)-279.4(Post-Surgical)-288.2(Expenditures)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 59.7543 104.8819 Tm
[(Melissa)-340(Lo,)-331(Wade)-335.7(Bannister)]TJ
/F5 1 Tf
0 -1.7682 TD
[(Optum,)-337.7(Eden)-335.2(Prairie,)-332.4(Minnesota)]TJ
/F3 1 Tf
.9999 -2.3047 TD
(Background:)Tj
/F4 1 Tf
5.9752 0 TD
[(Hysterectomies)-370.3(are)-376.6(performed)-368.4(on)-371.9(approxima-)]TJ
-6.9752 -1.1219 TD
[(tely)-350.7(600,000)-347.4(women)-346.5(annually)-348.7(in)-347(the)-351.2(US;)-345.2(it)-346.5(is)-346.1(the)-351.2(second-most)]TJ
27.0045 71.9468 TD
[(common)-301.8(surgery)-300.6(for)-297.3(women.)-303.8(The)-298.7(two)-299.7(primary)-300.4(methods)-300.9(are)-303.4(ab-)]TJ
0 -1.128 TD
[(dominal)-472(hysterectomies)-478.6(which)-474.6(remove)-473.5(the)-479.2(uterus)-474.6(and)-473.6(cervix)]TJ
0 -1.1219 TD
[(through)-294.4(an)-296.8(incision)-294.3(in)-298.2(the)-296.3(abdomen)-300.4(and)-296.8(vaginal)-293.8(hysterectomies)]TJ
0 -1.128 TD
[(where)-298.8(the)-302.4(removal)-302.3(occurs)-302.5(through)-300.5(the)-296.3(vaginal)-306(canal.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.957 0 TD
[(To)-453(compare)-453.3(rates)-454.4(of)-453.5(post-surgical)-454.8(complica-)]TJ
-6.9569 -1.128 TD
[(tions)-278.5(and)-284.6(associated)-282.2(total)-283.1(healthcare)-284.4(costs)-282.4(nine)-278(months)-278.4(after)-286.9(the)]TJ
0 -1.1219 TD
[(procedure)-297.7(between)-306.2(abdominal)-299.4(and)-302.9(vaginal)-299.9(hysterectomies.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Material/Methods:)Tj
/F4 1 Tf
8.4995 0 TD
-.0145 Tc
[(U)-14.5(s)15.4(ing)-410.8(c)-.4(laims)-409.9(d)-2.3(ata)-408.9(f)-14.5(r)11.3(o)3.8(m)-416.4(a)-408.9(commercially)]TJ
-9.4994 -1.1219 TD
-.0167 Tc
[(in)-4.5(s)-3.6(u)1.6(red)-443.5(p)-4.5(op)-4.5(ul)-4(at)-4(io)-4.5(n)-443.5(b)1.6(et)-4(ween)-443.5(20)-4.5(13)]TJ
13.9199 0 TD
-.0133 Tc
[(and)-440.1(2)5(01)5(4,)-434(w)-13.3(e)-427.5(retros)5.9(pecti)5.5(v)-1.1(el)5.5(y)]TJ
-13.9199 -1.128 TD
-.0146 Tc
[(compar)-14.6(e)9.3(d)-325.5(wome)5.6(n)-331.6(r)1.3(eceiving)-331.6(abdominal)-331.1(h)3.7(ys)4.6(terectomies)-324.7(\()1.3(n)]TJ
/F2 1 Tf
22.6693 0 TD
0 Tc
(=)Tj
/F4 1 Tf
.5366 0 TD
-.0122 Tc
[(6,)6.1(93)6.1(7\))]TJ
-23.2059 -1.1219 TD
-.0134 Tc
[(t)5.4(o)-306(wom)5.5(e).7(n)-299.9(r)-13.4(e)10.5(cei)5.4(vi)5.4(ng)-299.9(vag)4.9(i)-.7(n)4.9(a).7(l)-305.5(h)4.9(ys)5.8(terecto)4.9(m)-.6(ies)-299.1(\()2.5(n)]TJ
/F2 1 Tf
18.2062 0 TD
0 Tc
(=)Tj
/F4 1 Tf
.5365 0 TD
-.0165 Tc
[(23)-4.3(,7)-4.3(35)-4.3(\).)-303.1(We)-307.3(u)-4.3(s)2.7(ed)]TJ
-18.7428 -1.128 TD
-.0147 Tc
[(chi-square)-317.7(tests)-318.7(t)-2(o)-319.5(c)-.6(ompare)-317.7(rate)]TJ
12.5602 0 TD
[(s)-318.8(o)3.5(f)-322(p)3.5(ost-)-14.8(s)14.2(u)-2.6(rgical)-319.1(events)-318.8(between)]TJ
-12.5602 -1.1219 TD
-.0144 Tc
[(s)4.8(u)-2.2(rgery)-325.3(t)-1.7(ypes)-330.6(and)-331.4(d)3.9(eveloped)-325.3(a)-329.5(s)-1.3(tatis)4.8(tical)-324.8(model)-330.9(t)4.4(o)-331.4(e)-.3(stimate)-329.5(p)-2.2(ost-)]TJ
0 -1.128 TD
-.0147 Tc
[(s)4.5(u)-2.5(rgical)-282.4(costs)4.5(.)]TJ
/F3 1 Tf
.9999 -1.128 TD
0 Tc
(Results:)Tj
/F4 1 Tf
3.7498 0 TD
[(Among)-311.8(women)-309.9(under)-317.4(age)-313.2(46,)-310.9(post-surgical)-314.5(rates)-320.3(of)]TJ
-4.7497 -1.1219 TD
[(endometriosis,)-628.7(infections,)-624(ovarian)-625.9(cysts,)-629.9(and)-626.1(benign)-625.5(uterus)]TJ
0 -1.128 TD
[(neoplasms)-292.1(were)-298.8(statistically)-299.8(signicantly)-294.7(higher)-292.5(among)-296.2(women)]TJ
0 -1.1219 TD
[(receiving)-263.8(abdominal)-268.9(hysterectomies)-265.2(while)-266.8(post-surgical)-265.8(rates)-271.5(of)]TJ
0 -1.128 TD
[(genital)-311.6(organ)-305.2(prolapse)-314.1(were)-311(signicantly)-306.9(higher)-310.8(among)-308.4(women)]TJ
0 -1.1219 TD
[(receiving)-251.6(vaginal)-245.1(hysterectomies.)-253(Similar)-251.2(results)-247.6(were)-250(found)-246.1(for)]TJ
0 -1.128 TD
[(the)-314.6(women)-316(age)-313.2(46)-310.9(and)-315.1(over,)-317.4(with)-311.4(post-surgical)-320.6(rates)-314.2(of)-313.3(genito-)]TJ
0 -1.1219 TD
[(urinary)-203.4(cancer)-208.1(also)-204(signicantly)-203.3(greater)-205.7(among)-204.8(women)-200.2(receiving)]TJ
0 -1.128 TD
[(vaginal)-446.3(hysterectomies.)-454.2(After)-448.8(controlling)-449.4(for)-449.8(patient)-451.9(age,)-447.4(co-)]TJ
0 -1.1219 TD
[(morbidities,)-289.5(and)-284.6(medical)-291.4(risk,)-287.5(the)-284.1(estimated)-290(expenditures)-293.4(in)-286(the)]TJ
0 -1.128 TD
[(nine)-503.6(months)-497.9(following)-502.1(surgery)-507.9(were)-500(signicantly)-508.1(higher)-499.8(for)]TJ
0 -1.1219 TD
[(women)-535.5(receiving)-532.1(abdominal)-537.1(hysterectomies)-539.5(as)-533.8(compared)-532.6(to)]TJ
0 -1.128 TD
[(vaginal)-287.7(hysterectomies,)-289.5(with)-287(an)-284.6(estimated)-290(difference)-291.5(of)-282.8($7,284.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Conclusions:)Tj
/F4 1 Tf
5.7436 0 TD
[(This)-262.6(study)-260.7(indicates)-260.1(higher)-262(rates)-259.3(of)-264.5(many)-259.7(types)]TJ
-6.7435 -1.128 TD
[(of)-337.7(complications)-344.3(for)-333.9(women)-340.4(who)-342.9(have)-337.6(total)-344(abdominal)-335.9(hyster-)]TJ
0 -1.1219 TD
[(ectomy)-287.7(compared)-294.8(to)-292.1(vaginal)-293.8(hysterectomies.)-289.6(Post-surgery)-292.2(costs)]TJ
0 -1.128 TD
[(nine)-296.3(months)-302.8(after)-299.1(were)-304.9(also)-301.5(signicantly)-300.8(higher.)]TJ
/F3 1 Tf
0 -3.9998 TD
(55.)Tj
9.843 0 0 9.843 331.7668 374.5133 Tm
[(Internal)-281.4(Medicine)-285.2(\(IM\))-282.9(Versus)-285.7(Obstetrics)]TJ
0 -1.1174 TD
[(and)-279.4(Gynecology)-279.5(\(OB/GYN\))-284.8(Resident)-288.1(Comfort)]TJ
0 -1.1116 TD
[(in)-278.6(Caring)-285.1(for)-280.9(Women)-279.4(at)-278.6(High)-282.1(Risk)-281.5(of)-284.4(Future)]TJ
T*
[(Cardiovascular)-284.5(Disease)-281.4(Due)-281.6(to)-284.4(Medical)]TJ
T*
[(Morbidity)-284(of)-278.6(Pregnancy)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 310.8472 314.0786 Tm
[(Amy)-330.1(Loden)]TJ
/F5 1 Tf
0 -1.7682 TD
[(Washington)-329.5(University)-340(in)-334.8(St.)-328.7(Louis,)-336.7(Saint)-328.1(Louis,)-336.7(Missouri)]TJ
/F3 1 Tf
.9999 -2.2986 TD
(Background:)Tj
/F4 1 Tf
5.9143 0 TD
-.0161 Tc
[(Wo)-3.9(men)-314.8(w)-16.1(i)13.4(t)-3.4(h)-314.8(p)-3.9(ri)-3.4(or)-317.2(ges)-3(t)-3.4(ati)-3.4(o)-3.9(nal)-314.3(d)-3.9(i)-3.4(a)-2(bet)-3.4(e)-2(s)-314(o)-3.9(r)-311.1(p)-3.9(reg)-3.9(-)]TJ
-6.9142 -1.128 TD
-.0132 Tc
[(n)5.1(a).9(ncy)-433.9(i)-.5(n)5.1(d)-1(u)5.1(ced)-433.9(hy)5.1(perten)5.1(si)5.6(on)5.1(,)-440(i)5.6(nc)]TJ
13.1151 0 TD
-.0146 Tc
[(luding)-435.3(pr)-14.6(e)9.3(e)5.6(clampsia,)-435.3(eclampsia)]TJ
-13.1151 -1.1219 TD
-.0151 Tc
[(and)-350.4(H)-15.1(E)12.1(L)1.4(L)-15.1(P)-336.8(Syndrome)-348.5(ar)-15.1(e)-338.7(a)-1(t)-349.9(i)-2.4(ncr)-15.1(e)]TJ
14.0052 0 TD
-.0149 Tc
[(as)4.3(ed)-350.2(risk)-350.2(of)-352.6(future)-354.4(cardiovas-)]TJ
-14.0052 -1.128 TD
-.0146 Tc
[(cular)-297.4(d)-2.4(isease.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
0 Tc
(Objective\(s\):)Tj
/F4 1 Tf
5.9021 0 TD
[(Investigate)-402.6(the)-400(difference)-401.3(between)-403.7(IM)-397.8(versus)]TJ
-6.902 -1.128 TD
[(OB/GYN)-571(residents)-565.1(comfort)-568.7(in)-572.6(advising)-563.1(women)-572.1(with)-567.4(prior)]TJ
0 -1.1219 TD
[(glycemic)-346.3(or)-343.8(hypertensive)-348.2(pregnancy)-350.2(complications)-350.4(of)-343.8(their)-346.9(fu-)]TJ
0 -1.128 TD
[(ture)-262.1(cardiovascular)-267.5(disease)-260.3(risk)-263.1(in)-261.6(order)-264.9(to)-261.6(evaluate)-265.7(the)-265.8(learning)]TJ
T*
[(needs)-300.1(of)-301.1(womens)-299.2(health)-299.9(care)-307.6(providers.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Material/Methods:)Tj
/F4 1 Tf
8.4568 0 TD
-.0191 Tc
[(An)-391(electronic,)-391(anon)5.3(ymous)-390.2(and)-384.9(volun)5.3(tary)]TJ
-9.4567 -1.128 TD
-.0188 Tc
[(survey)-372.4(wa)-4.7(s)-371.6(s).4(ent)-371.9(t)0(o)-372.4(149)-372.4(IM)-371.5(and)-372.4(3)-.5(4)-372.4(O)-2(b/GYN)-373.9(r)-2.9(esidents)-371.6(a)-4.7(t)-371.9(Barnes)]TJ
0 -1.1219 TD
-.0186 Tc
[(Jewish)-213.7(Hosp)5.8(ital.)-213.7(Residen)5.8(t).2(s)-218.9(i).2(d)5.8(e)-4.5(ntied)-213.7(their)-216.1(b)-.3(est)-219.3(p)5.8(ersonal)-219.3(d)5.8(escrip)5.8(tion)]TJ
0 -1.128 TD
-.0188 Tc
[(\()52(n)5.6(ot)52()-2.9(,)-299.3()52(somewhat)52(,)-299.3()52()3.2(very)52()-301.6(or)-301.6()58.1()-2.9(extremely)52(\))-301.6(regarding)-299.2(c)1.4(omfort)]TJ
0 -1.1219 TD
-.0181 Tc
[(in)-383.9(kn)6.3(owledge)-388.1(o)6.3(f)-386.3(preventive)-382(c)2.1(are)-388.1(g).2(u)6.3(i).7(delin)6.3(es)-383.1(for)-386.3(w)-1.3(om)6.8(en)-383.9(with)-383.9(ab-)]TJ
0 -1.128 TD
-.0187 Tc
[(no)5.7(rmal)-231.6(glycemic)-230.2(or)-234.4(h)5.7(ypertensive)-230.2(pregnancy)-232.1(d)-.4(isorders)-231.2(and)-226(a)-4.6(dv)5.7(ising)]TJ
0 -1.1219 TD
-.0194 Tc
[(these)-419.9(w)3.5(omen)-421.8(of)-418.1(their)-418.1(a)-5.3(ssociate)-5.3(d)-415.7(future)-413.8(increas)-6.3(ed)-415.7(ca)-5.3(rdiovascula)-5.3(r)]TJ
0 -1.128 TD
-.0187 Tc
[(risk.)-305.2(T)-2.2(hey)-305.2(a)1.5(lso)-305.2(i).1(dentied)-305.2(their)-307.6(c)1.5(omfort)-304.7(in)-305.2(caring)-299.1(f)-2.8(or)-301.5(non-p)5.7(r)-2.8(egnant)]TJ
0 -1.1219 TD
-.0185 Tc
[(adult)-213.1(w)-1.7(omen)-213.6(with)-213.6(1\))-216(g)5.9(l).3(ycemic)-217.8(d)5.9(i).3(sorders)-212.7(o)-.2(r)-216(2)5.9(\))-216(hypertension)-213.6(with)5.9(out)]TJ
0 -1.128 TD
-.0187 Tc
[(prior)-271(p)5.7(regnancy)-268.7(c)-4.6(omp)5.7(lications.)-268.7(R)1(esidents)-267.8(iden)5.7(tied)-268.7(their)-271(l).1(evel)-268.2(and)]TJ
0 -1.1219 TD
-.0183 Tc
[(program)-298.2(of)-301.1(t)6.6(r)-2.4(aining)-298.7(follo)6.1(wing)-298.7(the)-296.9(s).9(urvey.)]TJ
/F3 1 Tf
.9999 -1.128 TD
0 Tc
(Results:)Tj
/F4 1 Tf
3.9937 0 TD
-.0148 Tc
[(Survey)-557.4(response)-561.6(r)-14.8(a)9.1(tes)-562.7(w)2(er)-14.8(e)-551.8(5)3.5(9%)-559.8(\(N)]TJ
/F2 1 Tf
15.4503 0 TD
0 Tc
(=)Tj
/F4 1 Tf
.5366 0 TD
-.0171 Tc
[(87)-4.9(\))-562.1(f)-1.2(o)-4.9(r)-562.1(IM)]TJ
-20.9804 -1.1219 TD
-.0168 Tc
[(and)-376.5(7)-4.6(6%)-378.8(\(N)]TJ
/F2 1 Tf
4.957 0 TD
0 Tc
(=)Tj
/F4 1 Tf
.5366 0 TD
-.0156 Tc
[(26\))-377.7(f).3(or)-377.7(OB/GYN)-15.6(.)-364.6(I).3(M)-374.4(a)-1.5(nd)-375.3(OB/GY)-15.6(N)-360(trainees)-374.5(w)-15.6(e)9.2(re)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 59.7543 749.7069 Tm
0 Tc
(ABSTRACTS)Tj
52.6193 0 TD
(A-21)Tj
ET
endstream
endobj
277 0 obj
<>stream
/GS1 gs
BT
/F4 1 Tf
9.2982 0 0 9.2982 62.022 725.5557 Tm
0 0 0 rg
-.015 Tc
0 Tw
[(respectively)-368.6()55.8(very)-368.6(o)-2.8(r)-364.9(e)-.9(xtr)-15(e)8.9(mely)-368.6(comfortable)55.8()-371(\().9(6%)-371(vs)-373.9(55%\))-364.9(ad-)]TJ
0 -1.128 TD
-.0131 Tc
[(vi)5.7(sin)5.2(g)-244.8(w)-13.1(o)15.9(men)-244.8(w)3.7(it)5.7(h)-244.8(a)1(bn)5.2(ormal)-244.3(g)5.2(ly)5.2(cemic)-242.9(or)-241(hy)5.2(perten)5.2(si)5.7(ve)-242.9(pregn)5.2(a)1(ncy)]TJ
0 -1.1219 TD
-.015 Tc
[(disor)-15(d)13.2(ers)-422.6(o)3.3(f)-419.8(t)-2.3(heir)-419.8(future)-421.6(increas)]TJ
12.8224 0 TD
[(ed)-417.4(cardiovascular)-419.8(r).9(isk.)-417.4(Resident)]TJ
-12.8224 -1.128 TD
-.0167 Tc
[(co)-4.5(mfo)-4.5(r)-.8(t)-382(w)-16.7(a)14.2(s)-387.8(st)-4(at)-4(ic)-386.7(des)-3.6(p)1.6(i)-4(t)-4(e)-380.6(y)-4.5(e)-2.6(ar)-384.9(o)-4.5(f)-378.8(p)-4.5(o)1.6(s)-3.6(t)-4(grad)-4.5(uat)-4(e)-380.6(t)-4(r)-.8(ai)-4(ni)-4(ng)-382.5(fo)-4.5(r)-384.9(t)2.1(h)-4.5(i)2.1(s)]TJ
0 -1.1219 TD
-.0148 Tc
[(category)-405(o)-2.6(f)-407.4(w)2(omen.)-405(C)-1.2(onversely,)-411.1(IM)-404.1(and)-405(O)2(BG)-14.8(Y)12.7(N)-406.5(residents)-410.2(r)1.1(e-)]TJ
0 -1.128 TD
[(spectively)-301.3(r)-14.8(e)9.1(p)3.5(orted)-307.4(b)-2.6(eing)-301.3()49.9()1.1(ver)-14.8(y)]TJ
12.8224 0 TD
-.0143 Tc
[(or)-303.2(extremely)-300.8(c)-.2(omf)-14.3(o)13.9(rtable)50.4()-303.2(man-)]TJ
-12.8224 -1.1219 TD
-.0169 Tc
[(ag)-4.7(in)-4.7(g)-236.4(1)1.4(\))-238.7(h)-4.7(yp)-4.7(ert)-4.2(e)-2.8(ns)-3.8(i)-4.2(o)1.4(n)-236.4(\()-1(8)-4.7(2)1.4(%)-238.7(v)-4.7(s)-235.5(4)-4.7(%\))-238.7(or)-238.7(2)-4.7(\))-238.7(gl)-4.2(ycem)-4.1(ic)-240.6(d)-4.7(i)1.9(s)-3.8(o)-4.7(rders)-241.6(\()-1(64)-4.7(%)]TJ
0 -1.128 TD
-.0146 Tc
[(vs)-434.4(8%\).)-441.4(Resident)-440.9(comfort)-440.9(m)4.3(anaging)-435.3(t)-1.9(hese)-439.5(r)-14.6(i)14.1(sks)-440.5(i)-1.9(ncr)-14.6(e)9.3(as)4.6(ed)-441.4(with)]TJ
0 -1.1219 TD
-.015 Tc
[(each)-301.5(year)-303.9(of)-297.8(training.)]TJ
/F3 1 Tf
.9999 -1.128 TD
0 Tc
(Conclusions:)Tj
/F4 1 Tf
5.9631 0 TD
[(OB/GYNs)-478.7(should)-474.1(collaborate)-480.9(with)-476(Internists)]TJ
-6.963 -1.1219 TD
[(regarding)-372.2(women)-364.8(at)-369.5(high)-365.2(risk)-372.9(of)-368.2(future)-368(cardiovascular)-371.2(disease)]TJ
0 -1.128 TD
[(due)-296.8(to)-298.2(prior)-302.9(glycemic)-297.5(or)-301.1(hypertensive)-299.5(pregnancy)-301.4(complications)]TJ
0 -1.1219 TD
[(in)-298.2(order)-301.5(to)-304.3(optimize)-298.9(preventative)-304(cardiovascular)-304.1(care.)]TJ
/F3 1 Tf
0 -2.7742 TD
(56.)Tj
9.843 0 0 9.843 82.9417 574.2424 Tm
[(Internal)-281.4(Medicine)-285.2(\(IM\))-282.9(Versus)-285.7(Obstetrics)-286(and)]TJ
0 -1.1116 TD
[(Gynecology)-285.3(\(OB/GYN\))-284.8(Resident)-282.3(Comfort)]TJ
0 -1.1174 TD
[(in)-278.6(Providing)-282.9(Evidence)-283.8(Based)-283.8(Preventative)-289.7(Care)]TJ
0 -1.1116 TD
[(to)-278.6(Women)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 62.022 524.8062 Tm
[(Amy)-336.2(Loden)]TJ
/F5 1 Tf
0 -1.7682 TD
[(Washington)-335.6(University)-333.9(in)-334.8(St.)-334.8(Louis,)-330.6(Saint)-334.2(Louis,)-330.6(Missouri)]TJ
/F3 1 Tf
.9999 -2.3047 TD
(Background:)Tj
/F4 1 Tf
6.0484 0 TD
[(Adult)-445.5(women)-450.2(present)-448.3(for)-449.8(preventive)-446.7(care)-453.9(to)]TJ
-7.0484 -1.1219 TD
[(both)-523.8(OB/GYN)-528.3(and)-528.5(Internal)-524.2(Medicine)-528.8(physicians.)-523.7(Certifying)]TJ
0 -1.128 TD
[(Boards)-431(in)-426.2(both)-432.3(specialties)-433.6(expect)-426.6(Diplomats)-435.5(to)-426.2(provide)-426.6(com-)]TJ
0 -1.1219 TD
[(prehensive)-568.3(preventative)-572.3(care)-569.8(to)-566.5(non-pregnant)-567.2(adult)-564(women.)]TJ
0 -1.128 TD
[(Graduating)-273.2(residents)-276.2(from)-272.4(each)-274.7(specialty)-278.4(may)-271.9(feel)-278.5(inadequately)]TJ
0 -1.1219 TD
[(prepared)-340.4(to)-340.9(address)-344.3(concerns)-337.1(commonly)-343.9(seen)-336.7(in)-340.9(the)-339(other)-341.3(spe-)]TJ
0 -1.128 TD
[(cialty)-415.3(and)-418.7(may)-412.1(be)-412.7(unfamiliar)-419.4(with)-415(preventative)-413.8(recommenda-)]TJ
0 -1.1219 TD
[(tions)-302.9(of)-295(both)-304.3(specialties)-299.5(regarding)-305.1(the)-302.4(same)-299.6(topics.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.7679 0 TD
[(Investigate)-268.5(the)-259.7(difference)-261(between)-269.6(IM)-257.5(and)-260.2(OB/)]TJ
-6.7679 -1.128 TD
[(GYN)-327.6(residents)-327.3(comfort)-324.8(in)-328.7(providing)-324.3(preventative)-328.4(care)-325.9(regard-)]TJ
0 -1.1219 TD
[(ing)-249.4(ve)-250.9(measures)-256.5(addressed)-250.9(in)-249.4(both)-249.4(specialties)-256.8(for)-254.7(non-pregnant)]TJ
0 -1.128 TD
[(adult)-247(women)-242.9(in)-243.3(order)-240.5(to)-243.3(evaluate)-247.4(the)-247.5(learning)-241.3(needs)-245.3(of)-240.1(womens)]TJ
0 -1.1219 TD
[(health)-300(care)-301.5(providers.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Material/Methods:)Tj
/F4 1 Tf
8.4446 0 TD
-.0146 Tc
[(A)-14.6(n)-345.3(electronic,)-356(anonym)]TJ
9.0909 0 TD
-.0127 Tc
[(ou)5.6(s)-359.4(a)1.4(n)5.6(d)-354.1(vo)5.6(lu)5.6(nt)6.1(ar)-12.7(y)]TJ
-18.5355 -1.1219 TD
-.015 Tc
[(sur)-15(v)13.2(ey)-356.4(was)-355.6(s)-1.9(ent)-355.9(t)3.8(o)-356.4(1)-2.8(49)-356.4(IM)-361.6(and)-356.4(3)-2.8(4)-350.3(O)-15(b)14(/)-2.3(GY)-15(N)-347.2(r).9(es)4.2(idents)-355.6(at)-355.9(Barnes)]TJ
0 -1.128 TD
-.0136 Tc
[(Jewish)-178.2(Ho)4.7(spi)5.2(t)-.9(al.)-178.2(R)0(e)6.6(s)-.5(id)4.7(ents)-177.3(i)5.2(d)-1.4(en)4.7(ti)]TJ
13.176 0 TD
-.0142 Tc
[(ed)-178.8(their)-175.1(b)-2(est)-178.3(p)4.1(ersonal)-178.3(d)-2(es)5(cr)-14.2(i)14.5(p)-2(tion)]TJ
-13.176 -1.1219 TD
-.0156 Tc
[(\()49.1(not)55.2().3(,)-265.6()55.2(somewhat)49.1(,)-259.5()49.1().3(very)49.1()-261.8(or)]TJ
13.0297 0 TD
-.0148 Tc
[()49.9()1.1(extremely)56()-14.8(\))-251.2(regarding)-264.8(c)5.4(omfor)-14.8(t)]TJ
-13.0297 -1.128 TD
-.0134 Tc
[(in)-342.6(kn)4.9(owled)4.9(g)-1.2(e)-340.7(o)-1.2(f)-345(p)4.9(r)-13.4(e)10.5(v)4.9(e).7(nt)5.4(iv)4.9(e)-346.8(care)-346.8(g)-1.2(u)4.9(i)-.7(d)4.9(e).7(lin)4.9(es)-347.9(fo)4.9(r)-345(1)-1.2(\))-345(d)4.9(epress)5.8(ion)4.9(,)-342.6(2\))]TJ
0 -1.1219 TD
-.0132 Tc
[(ob)5.1(esi)5.6(t)-.5(y,)-397.3(3\))-399.7(hy)5.1(perl)5.6(ipi)5.6(d)-1(em)5.7(ia,)-403.4(4)5.1(\))-405.8(p)5.1(re-diab)5.1(e).9(tes)-402.5(a)7(nd)-403.4(d)5.1(i)-.5(ab)5.1(etes,)-397.3(a).9(nd)-397.3(5\))]TJ
0 -1.128 TD
-.0145 Tc
[(os)4.7(teoporosis)-403.8(screening)-404.7(i)-1.8(n)-410.8(t)4.3(he)-408.9(non-)-14.5(p)13.7(r)1.4(egnant)-404.2(adult)-410.3(f)1.4(emale)-408.9(p)-2.3(atient)]TJ
0 -1.1219 TD
[(bas)4.7(e)-.4(d)-538.8(o)-2.3(n)-532.7(c)-.4(urrent)-538.3(evidence)-537(based)-538.8(r)1.4(ecommendations.)-538.8(R)5.2(e)-.4(sidents)]TJ
0 -1.128 TD
-.0134 Tc
[(id)4.9(ent)5.4(i)-.7(ed)-287.7(t)-.7(h)4.9(e).7(ir)-290.1(p)4.9(r)-13.4(o)14.8(g)-1.2(ram)-287.2(a).7(nd)-287.7(p)4.9(o)-1.2(s)5.8(t)-.7(grad)4.9(uat)5.4(e)-292(year)-284(of)-290.1(t)5.4(r)-13.4(a)10.5(i)5.4(ni)5.4(ng)-287.7(fol)5.4(l)-.7(ow-)]TJ
0 -1.1219 TD
[(in)5(g)-281.5(t)5.5(he)-279.7(s)5.9(u)-1.1(rvey)5(.)]TJ
/F3 1 Tf
.9999 -1.128 TD
0 Tc
(Results:)Tj
/F4 1 Tf
3.7132 0 TD
[(Survey)-277.6(response)-283.3(rates)-277.6(were)-280.5(59%)-282.7(\(N)]TJ
/F2 1 Tf
14.4503 0 TD
(=)Tj
/F4 1 Tf
.5548 0 TD
[(87\))-276.7(for)-279(IM)-275.8(and)]TJ
-19.7183 -1.1219 TD
[(76%)-319.3(\(N)]TJ
/F2 1 Tf
3.201 0 TD
(=)Tj
/F4 1 Tf
.5548 0 TD
[(26\))-313.3(for)-321.7(OB/GYN)-314.9(residents.)-318.8(IM)-318.5(and)-321.2(OB/GYN)-314.9(trainees)]TJ
-3.7559 -1.128 TD
[(were)-207.3(respectively)-205.6()58.6(very)-203.9(or)-203.5(extremely)-202.3(comfortable)49.1()-203.6(managing)-202.3(1\))]TJ
0 -1.1219 TD
[(dep)14.1(re)11.7(ssi)14.5(on)-347.5(\(29)16(%)-356(v)0(s)-346.6(1)0(2)12.2(%\),)-340(2\))-349.9(ob)12.2(esi)15.5(ty)-347(\(39%)-340(vs)-346.6(15)12.3(%\),)-346.1(3\))-343.8(hy)12.2(per)11.8(-)]TJ
0 -1.128 TD
[(lip)13.3(id)12.7(emi)15.2(a)-199.3(\(82)16(%)-197.4(v)0(s)-194.2(4%\))19.7(,)-201.2(4)0(\))-191.3(pre)17.9(-dia)18.4(bet)14.6(es)-192.3(and)-187.1(dia)14.6(bet)14.7(es)-192.3(\(64%)-181.4(vs)-194.2(8%\))]TJ
0 -1.1219 TD
[(and)-199.3(5\))-203.5(ost)13.6(eop)14.1(oro)16(sis)-198.9(scr)12.6(een)16(ing)-200.6(\(33)16(%)-209.6(v)0(s)-206.4(2)0(7)12.2(%\).)-199.8(Res)16.4(iden)14.7(t)-206.8(com)14.7(for)13.6(t)-206.8(i)0(n)]TJ
0 -1.128 TD
[(man)14.7(agi)14.6(ng)-292.6(all)-295.8(co)14.1(ndi)12.8(tio)13.3(ns)-291.8(inc)14.7(rea)13.7(sed)-296(wi)11.2(th)-292.1(eac)11.8(h)-298.7(pos)13.1(tg)12.7(rad)11.8(uat)14.6(e)-303(tra)18.4(in-)]TJ
0 -1.1219 TD
[(ing)-286(yea)16(r)-295(for)-285.1(bot)12.8(h)-292.6(pro)16(gra)11.8(ms.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Conclusions:)Tj
/F4 1 Tf
5.707 0 TD
[(Both)-217.5(Internist)-225.9(and)-217.5(OB/GYNs)-222.6(are)-218(expected)-223.5(to)-218.9(be)]TJ
-6.7069 -1.1219 TD
[(experts)-216.6(in)-218.9(womens)-219.9(preventative)-218.7(care.)-216.1(Residency)-223.1(curricula)-217.4(in)-218.9(IM)]TJ
0 -1.128 TD
[(and)-235.8(OB/GYN)-235.7(should)-236.3(be)-235.9(optimized)-231.8(to)-237.2(better)-235.3(prepare)-236.7(graduates)-239.1(to)]TJ
0 -1.1219 TD
[(meet)-300(this)-302.9(expectation.)]TJ
/F3 1 Tf
0 -2.7742 TD
(57.)Tj
9.843 0 0 9.843 82.9417 105.5055 Tm
[(Safety)-284(and)-279.4(Efcacy)-281.6(of)-278.6(Eluxadoline)-284.9(in)-284.4(Female)]TJ
0 -1.1116 TD
[(Patients)-281.6(with)-281.7(Irritable)-284(Bowel)-285.2(Syndrome)]TJ
0 -1.1174 TD
[(with)-281.7(Diarrhea)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 62.022 67.011 Tm
[(Susan)-335.4(Lucak)]TJ
6.9735 0 0 6.198 110.6078 71.1496 Tm
(1)Tj
9.2982 0 0 9.2982 114.1228 67.011 Tm
[(,)-335.3(Albena)-332.4(Halpert)]TJ
6.9735 0 0 6.198 177.5621 71.1496 Tm
(2)Tj
9.2982 0 0 9.2982 181.0204 67.011 Tm
[(,)-335.3(Charlene)-336.1(Morris)]TJ
6.9735 0 0 6.198 248.5417 71.1496 Tm
(3)Tj
9.2982 0 0 9.2982 251.9999 67.011 Tm
(,)Tj
-20.4317 -1.1219 TD
[(Laryl)-337.1(Riley)]TJ
6.9735 0 0 6.198 105.6189 60.7181 Tm
(4)Tj
9.2982 0 0 9.2982 109.0771 56.5795 Tm
[(,)-335.3(Leonard)-335.6(S.)-332.1(Dove)]TJ
6.9735 0 0 6.198 179.3763 60.7181 Tm
(5)Tj
/F5 1 Tf
19.17 107.9351 TD
(1)Tj
9.2982 0 0 9.2982 316.5731 725.5557 Tm
[(Weill)-334.2(Cornell)-336.2(Medical)-332.8(Center,)-334.8(New)-336.7(York,)-335.4(New)-330.6(York)]TJ
6.9735 0 0 6.198 313.0582 719.2061 Tm
(2)Tj
9.2982 0 0 9.2982 316.5731 715.0675 Tm
[(Boston)-335.7(Medical)-332.8(Center,)-334.8(Boston,)-335.7(Massachusetts)]TJ
6.9735 0 0 6.198 313.0582 708.7747 Tm
(3)Tj
9.2982 0 0 9.2982 316.5731 704.636 Tm
[(Pamlico)-335.6(Medical)-332.8(Center,)-334.8(Bayboro,)-334.3(North)-332.5(Carolina)]TJ
6.9735 0 0 6.198 313.0582 698.2864 Tm
(4)Tj
9.2982 0 0 9.2982 316.5731 694.1478 Tm
[(Gastroenterology)-339(Specialists,)-333.7(Inc.,)-335.7(Westerly,)-335.3(Rhode)-329.1(Island)]TJ
6.9735 0 0 6.198 313.0582 687.855 Tm
(5)Tj
9.2982 0 0 9.2982 316.5731 683.7164 Tm
[(Allergan)-333.3(plc,)-332.9(Driftwood,)-339(Texas)]TJ
/F3 1 Tf
.6219 -2.3047 TD
(Background:)Tj
/F4 1 Tf
5.9752 0 TD
[(Eluxadoline,)-368.2(a)-370(locally)-372.6(active,)-371.2(mixed)]TJ
/F7 1 Tf
15.2979 0 TD
(l)Tj
/F4 1 Tf
.5487 0 TD
(-opioid)Tj
-22.8218 -1.128 TD
[(receptor)-431.3(and)]TJ
/F7 1 Tf
5.585 0 TD
(j)Tj
/F4 1 Tf
.5548 0 TD
[(-opioid)-421.9(receptor)-425.2(agonist,)-422.9(and)]TJ
/F7 1 Tf
12.4688 0 TD
(d)Tj
/F4 1 Tf
.5 0 TD
[(-opioid)-421.9(receptor)]TJ
-19.1086 -1.1219 TD
[(antagonist,)-542.4(is)-535.2(approved)-535(for)-535.1(the)-540.2(treatment)-537.1(of)-532.8(irritable)-541.4(bowel)]TJ
0 -1.128 TD
[(syndrome)-303.8(with)-299.2(diarrhea)-303.3(\(IBS-D\).)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.9631 0 TD
[(To)-446.9(evaluate)-454.7(the)-448.7(efcacy)-454.9(and)-449.2(safety)-448.3(of)-453.5(elux-)]TJ
-6.963 -1.128 TD
[(adoline)-513.3(in)-511.6(female)-507.7(patients)-512(with)-512.6(IBS-D)-513.7(in)-505.5(two)-513.1(double-blind,)]TJ
0 -1.1219 TD
[(placebo-controlled)-303.9(Phase)-303(3)-298.7(trials)-302.9(\(IBS-3001,)-301(IBS-3002\).)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Material/Methods:)Tj
/F4 1 Tf
8.5422 0 TD
[(Patients)-472.1(meeting)-470.1(Rome)-471.7(III)-470.4(criteria)-473(for)]TJ
-9.5421 -1.1219 TD
[(IBS-D)-617.3(were)-609.7(randomized)-611.3(to)-615.3(twice-daily)-611.8(eluxadoline)-614.5(\(75)-605.9(or)]TJ
0 -1.128 TD
[(100)-170.6(mg\))-355.4(or)-362.1(placebo.)-359.5(Efcacy)-361(was)-358.4(evaluated)-363.2(through)-355.3(26)-359.7(weeks)]TJ
0 -1.1219 TD
[(and)-394.4(assessed)-399.3(via)-393.9(a)-394.4(composite)-396.1(response)-393(endpoint,)-399.3(requiring)-391.9(si-)]TJ
0 -1.128 TD
[(multaneous)-402.1(improvement)-392.6(in)-395.8(abdominal)-396.9(pain)-393.8(and)-394.4(stool)-394.3(consis-)]TJ
0 -1.1219 TD
[(tency.)-550.5(Patients)-545.3(who)-550.2(met)-545.8(both)-548.1(daily)-545.7(pain)-546.3(responder)-548.7(\()]TJ
/F2 1 Tf
23.1693 0 TD
()Tj
/F4 1 Tf
.7134 0 TD
(30%)Tj
-23.8827 -1.128 TD
[(improvement)-459.7(in)-456.7(abdominal)-464(pain\))-457.2(and)-455.3(daily)-460.4(stool)-455.3(consistency)]TJ
0 -1.1219 TD
[(responder)-256(\(Bristol)-250.8(Stool)-251.7(Scale)-252.7(score)-253.7(of)]TJ
/F2 1 Tf
15.7551 0 TD
(<)Tj
/F4 1 Tf
.5548 0 TD
[(5\))-252.3(criteria)-253.5(for)]TJ
/F2 1 Tf
5.774 0 TD
()Tj
/F4 1 Tf
.7195 0 TD
[(50%)-246.2(of)]TJ
-22.8035 -1.128 TD
[(days)-302(were)-304.9(considered)-300(responders.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Results:)Tj
/F4 1 Tf
3.8046 0 TD
[(A)-355.1(t)0(o)18.8(t)12.7(al)-345.1(o)12.2(f)-356(2)12.2(4)0(2)18.3(3)-353.6(IB)23.4(S-)19.2(D)-355.1(p)12.2(at)20.7(i)12.7(e)0(n)20.2(t)0(s)-346.1(\()0(1)22.1(6)12.2(0)12.2(2)-359.7(fe)23.9(m)12.7(a)0(l)20.7(e)0(\))-348(w)0(e)18.7(r)0(e)]TJ
-4.8046 -1.128 TD
[(en)20.2(ro)22.1(ll)19.3(ed)-424.9(ac)16(r)15.9(o)0(s)19.2(s)-438.1(b)12.2(o)12.2(t)0(h)-426.2(t)0(r)16.5(i)12.7(a)14.1(l)0(s)19.7(.)-439(Si)22.1(g)12.2(n)12.2(i)0()22.1(c)0(a)16(n)12.2(t)12.7(l)12.7(y)-439(g)12.2(r)0(e)17.8(a)14.1(te)20.7(r)-441.3(p)12.2(ro)22.1(p)12.2(o)12.2(r)0(t)16.5(i)12.7(o)12.2(n)12.2(s)-438.1(o)12.2(f)]TJ
0 -1.1219 TD
[(pa)20.2(ti)19.3(en)20.2(t)12.7(s)-413.7(re)23.9(ce)22.1(iv)18.8(i)12.7(n)12.2(g)-414.6(e)0(l)20.7(u)12.2(x)12.2(a)0(d)20.2(o)12.2(l)12.7(i)0(n)18.8(e)-412.7(7)12.2(5)-158.5(m)12.7(g)-408.5(\(f)19.7(em)20.7(al)20.7(e:)-400(2)12.2(5)12.2(.)0(7)18.3(%)0(,)-398.6(p)]TJ
/F2 1 Tf
22.6998 0 TD
(=)Tj
/F4 1 Tf
.5426 0 TD
-.0122 Tc
[(0.0)-12.2(0)6.1(1)0(;)]TJ
-23.2425 -1.128 TD
0 Tc
[(male:)-500.7(27.3%,)-490(p)]TJ
/F2 1 Tf
6.5606 0 TD
(<)Tj
/F4 1 Tf
.5548 0 TD
[(0.001\))-496.1(or)-490.1(100)-170.6(mg)-493.3(\(female:)-497.4(27.5%,)-496.1(p)]TJ
/F2 1 Tf
15.5173 0 TD
(<)Tj
/F4 1 Tf
.5549 0 TD
(0.001;)Tj
-23.1876 -1.1219 TD
[(male:)-616.5(26.1%,)-611.9(p)]TJ
/F2 1 Tf
6.7984 0 TD
(=)Tj
/F4 1 Tf
.5548 0 TD
[(0.002\))-612(vs.)-614.9(placebo)-615.6(\(female:)-619.3(17.5%;)-611.4(male:)]TJ
-7.3532 -1.128 TD
[(15.2%\))-388.7(were)-384.1(composite)-383.9(responders)-383.2(over)-384.5(Weeks)-383.6(112.)-384(Similar)]TJ
T*
[(results)-381.7(were)-378(seen)-373.3(over)-378.4(Weeks)-377.5(126.)-371.8(For)-377.1(the)-375.6(stool)-376.1(consistency)]TJ
0 -1.1219 TD
[(component)-464.5(over)-463.8(Weeks)-469(112,)-463.3(signicantly)-465.5(more)-463.3(patients)-463.2(re-)]TJ
0 -1.128 TD
[(ceiving)-604.8(eluxadoline)-608.4(75)-164.6(mg)-603(\(female:)-607.1(33.3%,)-599.8(p)]TJ
/F2 1 Tf
19.7915 0 TD
(<)Tj
/F4 1 Tf
.5548 0 TD
[(0.001;)-603(male:)]TJ
-20.3463 -1.1219 TD
[(33.2%,)-496.1(p)]TJ
/F2 1 Tf
3.829 0 TD
(=)Tj
/F4 1 Tf
.5548 0 TD
[(0.002\))-490(or)-496.2(100)-164.5(mg)-499.4(\(female:)-497.4(34.6%,)-490(p)]TJ
/F2 1 Tf
15.5173 0 TD
(<)Tj
/F4 1 Tf
.5548 0 TD
[(0.001;)-493.2(male:)]TJ
-20.4561 -1.128 TD
[(35.1%,)-325.4(p)]TJ
/F2 1 Tf
3.6583 0 TD
(<)Tj
/F4 1 Tf
.5548 0 TD
[(0.001\))-319.3(were)-329.3(responders)-322.2(than)-326.8(those)-319.8(receiving)-330.9(placebo)]TJ
-4.2132 -1.1219 TD
.0151 Tc
[(\(female)4.8(:)-496.5(21.6%;)-490.4(m)-2.6(ale:)-490.4(21.3%\).)]TJ
13.9748 0 TD
[(The)-489(p)-3.1(roportion)-490.8(o)3(f)-493.2(p)3(ain)-490.8(r).7(e-)]TJ
-13.9748 -1.128 TD
.0157 Tc
[(sponders)-361.5(o)-2.6(ver)-364.7(Weeks)-367.6(1)3.5(12)-362.3(w)-4.1(as)-361.5(si)]TJ
14.493 0 TD
[(gnica)5.5(ntly)-362.2(higher)-364.6(only)-362.2(for)]TJ
-14.493 -1.1219 TD
0 Tc
[(m)-17.7(a)-16.4(l)-11.7(e)-400.5(p)-12.2(a)-16.4(t)-17.8(i)-11.7(e)-16.4(n)-18.3(t)-11.7(s)-395.4(receiving)-385.7(eluxadoline)-382.8(100)-164.5(mg)-377.4(\(46.3%,)-382.6(p)]TJ
/F2 1 Tf
22.584 0 TD
(=)Tj
/F4 1 Tf
.5488 0 TD
(0.048\))Tj
-23.1327 -1.128 TD
[(vs.)-224.7(pl)12.7(ace)11.8(bo)-225.5(\(37)16(.9)12.2(%\).)-224.2(Rep)15.5(ort)16.5(ing)-218.9(of)-227.9(gas)15(tro)16.5(int)13.3(est)15.5(ina)14.6(l)-231.2(adv)14.2(er)11.7(se)-228.9(eve)16(nts)]TJ
0 -1.1219 TD
[(was)-236.5(gen)14.1(er)11.7(all)15.2(y)-243.9(gre)11.8(at)14.6(er)-238.2(in)-237.2(fe)11.7(male)17.1(s)-243(\(75)-148.6(mg:)-236.7(33)12.2(.7)12.2(%;)-239.6(10)12.3(0)-158.5(mg:)-230.6(29.)12.2(9%;)]TJ
0 -1.128 TD
[(plac)16.5(ebo)14.1(:)-340.9(2)0(1)12.2(.7%\))-327.8(th)12.7(an)-339.5(in)-334.8(mal)15.2(es)-338.7(\(75)-148.6(mg:)-334.2(22)12.2(.6)12.2(%;)-337.1(100)-152.4(mg)12.8(:)-340.9(23.)12.2(4%;)]TJ
0 -1.1219 TD
[(plac)16.5(ebo)14.1(:)-298.2(1)0(5)12.3(.)0(2)12.2(%\).)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Conclusions:)Tj
/F4 1 Tf
5.8777 0 TD
[(Eluxadoline)-386.5(is)-388.8(effective)-392.3(and)-388.3(well)-388.7(tolerated)-391.3(in)]TJ
-6.8776 -1.1219 TD
[(women)-377(with)-372.3(IBS-D)-373.4(based)-373.3(on)-365.8(the)-375.6(results)-375.6(of)-368.1(two)-372.8(large)-376(Phase)-370.1(3)]TJ
0 -1.128 TD
[(clinical)-303.1(trials.)]TJ
/F3 1 Tf
0 -2.9267 TD
(58.)Tj
9.843 0 0 9.843 333.9779 258.4629 Tm
[(Can)-280.5(Mindf)-7.5(ul)-278.6(Body)-281.7(Awareness)-285.3(Buffer)]TJ
0 -1.1174 TD
[(the)-275(Effects)-270(of)-272.9(Poor)-271.7(Body)-270.2(Image)-266.7(on)-272.7(Stress)-273.3(Reactivity)]TJ
0 -1.1116 TD
[(in)-284.4(Women?)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 313.0582 219.9684 Tm
[(M.)-334.4(Kathleen)-336.1(B.)-333.9(Lustyk)]TJ
/F5 1 Tf
0 -1.7682 TD
[(Seattle)-336(Pacic)-338.9(University)-333.9(and)-335.3(University)-333.9(of)-334.8(Washington,)]TJ
0 -1.128 TD
[(Seattle,)-336(Washington)]TJ
/F3 1 Tf
.9999 -2.3047 TD
(Background:)Tj
/F4 1 Tf
5.8838 0 TD
[(Poor)-279.5(body)-280.4(image)-281.7(is)-285.2(prevalent)-282.1(in)-279.9(women)-279.4(and)-284.6(is)]TJ
-6.8837 -1.1219 TD
[(associated)-489.5(with)-482.1(stress.)-485.1(Mindful)-482(Body)-486.3(Awareness)-485.6(\(MBA\),)-485.5(an)]TJ
0 -1.128 TD
[(awareness)-207.9(of)-203.5(normal,)-206.6(non-emotive)-204.1(bodily)-200.1(processes)-207.4(and)-205.3(physical)]TJ
0 -1.1219 TD
[(sensations,)-327.8(buffers)-327.4(reactivity)-323.7(to)-322.6(a)-327.3(laboratory)-322.9(stressor)-328.9(in)-322.6(women)]TJ
0 -1.128 TD
[(\(Lustyk)-307.6(et)-302.4(al.,)-302.4(2012\).)-301(Given)-303.9(that)-301.9(poor)-307.1(body)-298.7(image)-306.1(is)-303.5(associated)]TJ
0 -1.1219 TD
[(with)-311.3(stress)-308.3(and)-309(MBA)-310.1(is)-303.5(stress)-308.3(reducing,)-308.9(investigating)-309.6(the)-308.5(inter-)]TJ
0 -1.128 TD
[(action)-306(among)-296.2(these)-305.7(variables)-299.5(is)-303.5(warranted.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.7984 0 TD
[(We)-294.9(investigated)-290(the)-290.2(effects)-296.4(of)-288.9(body)-286.5(image)-293.9(and)]TJ
-6.7984 -1.128 TD
[(MBA)-377.2(on)-365.8(hemodynamic)-376.7(and)-370(state)-372.3(anxiety)-373.1(responses)-373.9(to)-371.4(a)-370(labo-)]TJ
0 -1.1219 TD
[(ratory)-349.8(stressor)-347.2(in)-347(women.)-346.5(Our)-345.2(primary)-343.1(objective)-352.4(was)-346.2(to)-340.9(assess)]TJ
0 -1.128 TD
[(the)-265.8(moderating)-265.1(effect)-272.8(of)-264.5(MBA)-261.3(on)-268.2(the)-259.7(relationship)-269.8(between)-263.5(poor)]TJ
0 -1.1219 TD
[(body)-304.8(image)-300(and)-296.8(stress.)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 62.022 749.6502 Tm
(A-22)Tj
48.6864 0 TD
(ABSTRACTS)Tj
ET
endstream
endobj
281 0 obj
<>stream
/GS1 gs
BT
/F3 1 Tf
9.2982 0 0 9.2982 69.0519 725.5557 Tm
0 0 0 rg
0 Tc
0 Tw
(Material/Methods:)Tj
/F4 1 Tf
8.3958 0 TD
[(Reproductive)-323.3(age)-325.4(\(1845)-325.4(years\))-329.2(women)]TJ
-9.3958 -1.128 TD
(\(N)Tj
/F2 1 Tf
1.0548 0 TD
(=)Tj
/F4 1 Tf
.5487 0 TD
[(40\))-264.5(completed)-267(assessments)-263.2(of)-264.5(body)-256(image)-263.4(and)-266.3(MBA)-261.4(as)-265.5(part)]TJ
-1.6036 -1.1219 TD
[(of)-496.2(a)-498.1(laboratory)-499.7(stress)-497.3(test.)-502.2(Testing)-497.9(occurred)-498.9(mid-day)-493.2(during)]TJ
0 -1.128 TD
[(participants)-282.5(follicular)-279.2(phase.)-281.8(Electrocardiography)-278.1(continuously)]TJ
0 -1.1219 TD
[(monitored)-425.5(heart)-424.8(rate)-430.9(\(HR\),)-425.5(blood)-420.1(pressure)-425.9(\(BP\))-426.9(was)-425.5(taken)-422.4(at)]TJ
0 -1.128 TD
[(timed)-344(intervals,)-343.6(and)-339.5(state)-341.8(anxiety)-342.6(was)-346.2(assessed)-338.3(at)-345.1(baseline)-339.9(and)]TJ
0 -1.1219 TD
[(immediately)-350.8(following)-343.6(the)-345.1(stressor)-347.2(\(i.e.,)-347.4(Paced-Serial)-347.4(Addition)]TJ
0 -1.128 TD
[(Task)-303.9(\(Gronwall,)-303.4(1977\))-294.9(and)-302.9(recovery.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Results:)Tj
/F4 1 Tf
4.012 0 TD
[(Analyses)-574.6(with)-573.5(BP)-574.6(and)-577.3(state)-573.5(anxiety)-574.3(were)-573.2(non-)]TJ
-5.0119 -1.128 TD
[(signicant.)-557.5(MBA)-554(was)-553.5(inversely)-551.4(related)-556.5(to)-554.3(and)-552.9(signicantly)]TJ
0 -1.1219 TD
[(predicted)-501.6(HR)-500(reactivity)-506.7(and)-498(MBA)-499.1(signicantly)-502(buffered)-497(the)]TJ
0 -1.128 TD
[(effect)-303.3(of)-301.1(poor)-301(body)-298.7(image)-300(on)-298.7(HR)-304.9(reactivity.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Conclusions:)Tj
/F4 1 Tf
5.8655 0 TD
[(Our)-369.6(HR)-372(reactivity)-378.6(results)-375.6(for)-370.5(those)-374.7(with)-372.3(poor)]TJ
-6.8654 -1.128 TD
[(body)-286.5(image)-287.8(extends)-287.4(survey)-286.1(ndings)-281.8(\(Reaves)-287(et)-290.2(al.,)-284.1(2014\))-282.7(while)]TJ
T*
[(the)-460.9(effects)-461(of)-453.5(MBA)-456.5(on)-457.2(HR)-457.4(reactivity)-457.9(replicates)-461.8(prior)-455.3(results)]TJ
0 -1.1219 TD
[(\(Lustyk)-399(et)-400(al.,)-400(2012\).)-398.6(That)-401.8(MBA)-395.5(buffered)-399.5(the)-400(effects)-400(of)-398.6(poor)]TJ
0 -1.128 TD
[(body)-304.8(image)-306.1(on)-310.9(stress)-302.2(is)-309.6(a)-303(novel)-308.5(nding)-301(thus)-309.5(expanding)-306.5(our)-301.1(un-)]TJ
0 -1.1219 TD
[(derstanding)-435.5(of)-435.2(interrelationships)-433(among)-436.5(these)-433.8(variables)-433.7(while)]TJ
0 -1.128 TD
[(arguing)-249.8(for)-248.6(mindfulness-based)-250.7(stress-reduction)-247(interventions)-251.5(for)]TJ
0 -1.1219 TD
[(those)-301.5(with)-299.2(poor)-301(body)-298.7(image.)]TJ
/F3 1 Tf
0 -3.0364 TD
(59.)Tj
9.843 0 0 9.843 80.674 498.5574 Tm
[(Evaluation)-282.7(After)-285.1(Different)-284.9(Types)-283.8(of)-278.6(Surgery)]TJ
0 -1.1174 TD
[(Using)-282.6(Mesh)-283.9(for)-280.9(Pelvic)-281.1(Organ)-284.2(Prolapse)-282.8(Repair)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 59.7543 471.0046 Tm
[(Ana)-334.9(Carolina)-337.5(Marchesini)]TJ
6.9735 0 0 6.198 155.5086 475.1432 Tm
(1)Tj
9.2982 0 0 9.2982 159.0236 471.0046 Tm
[(,)-335.3(Thomaz)-332.8(Rafael)-336.2(Gollop)]TJ
6.9735 0 0 6.198 251.4897 475.1432 Tm
(2)Tj
9.2982 0 0 9.2982 255.0047 471.0046 Tm
(,)Tj
-20.9987 -1.1219 TD
(La)Tj
1.0426 .0366 TD
()Tj
.3049 -.0366 TD
[(s)-334.5(Rodrigues)-332.9(Bertoche)]TJ
6.9735 0 0 6.198 153.9779 464.655 Tm
(3)Tj
9.2982 0 0 9.2982 157.4929 460.5731 Tm
[(,)-329.2(La)]TJ
1.6219 .0366 TD
()Tj
.3049 -.0366 TD
[(s)-328.4(Paulon)-335.7(Sautchuk)]TJ
6.9735 0 0 6.198 245.707 464.655 Tm
(3)Tj
/F5 1 Tf
-26.6656 -2.6435 TD
(1)Tj
9.2982 0 0 9.2982 63.2693 444.1322 Tm
(Jundia)Tj
2.7011 .0305 TD
()Tj
.0244 -.0305 TD
[()-334.8(School)-332.8(of)-334.8(Medicine,)-337(Jundia)]TJ
11.8164 .0305 TD
()Tj
.0244 -.0305 TD
[(,)-334.8(Brazil)]TJ
6.9735 0 0 6.198 59.7543 437.7826 Tm
(2)Tj
9.2982 0 0 9.2982 63.2693 433.644 Tm
(Jundia)Tj
2.7011 .0305 TD
()Tj
.0244 -.0305 TD
[()-334.8(School)-332.8(of)-334.8(Medicine,)-337(Sa)]TJ
9.8043 .0122 TD
()Tj
.311 -.0122 TD
[(o)-329.2(Paulo,)-336.6(Brazil)]TJ
6.9735 0 0 6.198 59.7543 427.2944 Tm
(3)Tj
9.2982 0 0 9.2982 63.2693 423.2125 Tm
(Jundia)Tj
2.7011 .0305 TD
()Tj
.0244 -.0305 TD
[()-334.8(School)-332.8(of)-334.8(Medicine,)-337(Jundia)]TJ
11.8164 .0305 TD
()Tj
.0244 -.0305 TD
[(,)-334.8(Brazil)]TJ
/F3 1 Tf
-13.9443 -2.3047 TD
(Background:)Tj
/F4 1 Tf
5.9935 0 TD
[(Studies)-395.3(comparing)-387.6(the)-393.9(repair)-390.6(of)-392.5(pelvic)-391.4(organ)]TJ
-6.9935 -1.128 TD
[(prolapse)-503.1(\(POP\))-493.5(through)-501.7(conventional)-498.6(surgery)-495.7(versus)-498.6(surgery)]TJ
0 -1.1219 TD
[(using)-364.4(synthetic)-359.5(mesh)-362.5(do)-365.8(not)-359.2(present)-362.9(uniform)-363.3(performance)-364.6(and)]TJ
0 -1.128 TD
[(benet)-248.5(results)-241.5(from)-248(the)-241.4(use)-247.2(of)-246.2(mesh,)-240.5(which)-249(is)-242.5(partially)-246.4(related)-245.6(to)]TJ
0 -1.1219 TD
[(the)-302.4(great)-302.9(diversity)-302.8(of)-295(mesh)-301.5(kits)-302.9(available)-301.7(in)-298.2(the)-302.4(market.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.8289 0 TD
[(Analysis)-319.9(of)-319.4(Pelvic)-321.1(Organ)-318.9(Prolapse)-317(Quantica-)]TJ
-6.8289 -1.1219 TD
[(tion)-206.2(system)-208.6(\(POP-Q\))-204.7(parameters)-208.5(after)-207.7(POP)-208.4(repair)-201.5(surgeries)-212(using)]TJ
0 -1.128 TD
[(different)-307(types)-295.4(of)-301.1(synthetic)-304.6(mesh.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Material/Methods:)Tj
/F4 1 Tf
8.28 0 TD
[(Fifty-one)-205.7(women)-206.3(who)-202.6(undergone)-205.7(surgery)]TJ
-9.2799 -1.128 TD
[(in)-353.1(the)-345.1(Pelvic)-351.6(Floor)-352.2(wing)-348.4(of)-349.9(the)-345.1(School)-354(of)-343.8(Medicine)-352(of)-349.9(Jundia)]TJ
25.4131 .0427 TD
()Tj
-25.4131 -1.1646 TD
[(\(Brazil\))-263(were)-256.1(included)-257.2(retrospectively.)-262.3(The)-256(Study)-258.3(was)-260.9(approved)]TJ
0 -1.128 TD
[(by)-347.5(the)-351.2(Research)-346.1(Ethical)-350.1(Committee.)-351.8(Different)-351.2(types)-344.2(of)-349.9(macro-)]TJ
0 -1.1219 TD
[(porous)-306.2(and)-296.8(monolament)-301.7(polypropylene)-302.2(mesh)-301.5(have)-307.1(been)-301(made)]TJ
0 -1.128 TD
[(available)-509(free)-507(of)-508.4(charge)-508.8(through)-501.7(the)-509.7(Unied)-507.9(Health)-508.8(System)]TJ
0 -1.1219 TD
[(\(SUS\))-268(which)-267.3(is)-260.8(a)-266.4(state)-268.6(owned)-261.7(agency,)-268.6(however)-268.2(without)-262(patterns)]TJ
0 -1.128 TD
[(for)-236.4(the)-229.2(materials.)-237.5(We)-234(used)-235(the)-229.2(following)-233.8(kits:)-235.3(GynecareProlift)]TJ
/F2 1 Tf
24.6753 0 TD
()Tj
/F4 1 Tf
.7926 0 TD
(,)Tj
-25.468 -1.1219 TD
(Dynamesh-PR4)Tj
/F2 1 Tf
6.335 0 TD
()Tj
/F4 1 Tf
.7865 0 TD
[(,)-463.4(Dynamesh-SIS)]TJ
/F2 1 Tf
6.7618 0 TD
()Tj
/F4 1 Tf
.7926 0 TD
[(,)-457.3(Dynamesh-PR2)]TJ
/F2 1 Tf
7.0423 0 TD
()Tj
/F4 1 Tf
.7926 0 TD
[(,)-457.3(Dyna-)]TJ
-22.5108 -1.128 TD
(mesh-PRS)Tj
/F2 1 Tf
4.2193 0 TD
()Tj
/F4 1 Tf
1.0914 0 TD
[(and)-302.9(Uphold)]TJ
/F2 1 Tf
4.7436 0 TD
()Tj
/F4 1 Tf
.7926 0 TD
(.)Tj
/F3 1 Tf
-9.847 -1.1219 TD
(Results:)Tj
/F4 1 Tf
3.7559 0 TD
.0118 Tc
[(We)-321.6(us)11.8(ed)-317.4(mesh)-317.4(in)-317.4(84)11.8(%)-325.8(o)-.4(f)-313.7(s).5(ub)11.8(j)-5.9(ects;)-316.9(on)11.8(l)-5.9(y)-317.4(8)-317.4(p)-.4(ati)11.8(e)-4.1(nts)]TJ
-4.7558 -1.128 TD
.0125 Tc
[(have)-467.3(und)12.5(erg)12.5(o)-5.7(n)12.5(e)-479.4(con)12.5(v)-5.7(ent)12.5(i)-4.7(on)12.5(al)-474.7(su)12.5(rgery.)-469.2(Am)12.5(o)-5.2(n).3(g)-469.1(p)12.5(a)-10(t)12.5(ient)12.5(s)-480(w)4.9(ho)]TJ
T*
.0113 Tc
[(had)-305.7(m)-.3(es)11.3(h)-310.9(s)0(urgery,)-299.6(88%)-302(had)-299.6(i)-.4(nit)11.3(i)-5.9(al)-305.2(stag)11.3(e)-316(3)-299.6(or)-302(4)-305.7(a)1(nd)-305.7(i)11.3(n)-311.3(po)11.3(s)-6.1(t)-.4(op)11.3(-)]TJ
0 -1.1219 TD
[(erati)11.3(v)-6.4(e)-285.6(care)-285.6(o)-.9(n)11.3(l)-6.4(y)-281.3(9.5)11.3(%)-289.8(h)-.9(ad)-281.3(sho)11.3(w)-8.4(n)-281.3(s)0(tage)-279.5(3)-287.4(\()2.9(p)]TJ
/F2 1 Tf
18.3586 0 TD
0 Tc
(<)Tj
/F4 1 Tf
.5609 0 TD
.0122 Tc
[(0)12.2(.)-6.1(00)12.2(1)-6(\))3.8(.)-286.5(D)4.6(yn)36.6(a)32.4(m)31.1(i)37.1(c)]TJ
-18.9196 -1.128 TD
-.0208 Tc
[(POP-Q)-363.7(p)-2.5(arameters)-367.5(c)-.6(hanged)-362.2(expres)4.5(sively)-362.2(after)-364.6(s)-1.6(urgery)-362.2(\(p)]TJ
/F2 1 Tf
22.4803 0 TD
0 Tc
(<)Tj
/F4 1 Tf
.5305 0 TD
-.0189 Tc
[(0.)5.5(00)5.5(1\).)]TJ
-23.0108 -1.1219 TD
-.0203 Tc
[(Point)-239.3(C)-238.4(varied)-233.7(the)-244(m)4.6(ost,)-239.8(with)-233.7(average)-237.9(o)4.1(f)-242.1(l)4.6(ess)-238.9(1)-2(0)-166.6(c)-.1(m)-233.1(o)-2(n)-239.8(p)4.1(atients)-238.9(t)4.6(hat)]TJ
0 -1.128 TD
[(had)-380.1(m)4.6(esh)-380.1(s)4.9(urgery)-380.1(\(p)]TJ
/F2 1 Tf
8.1946 0 TD
0 Tc
(<)Tj
/F4 1 Tf
.5366 0 TD
-.0212 Tc
[(0.001\).)-380.9(A)-4.4(s)-374(r)-5.3(egards)-380.1(complications,)-380.9(w)1.7(e)-379(h)-2.9(ave)]TJ
-8.7312 -1.1219 TD
0 Tc
[(found:)-251.7(1)-243.9(patient)-250.7(developed)-243.6(stress)-253.4(urinary)-246.1(incontinence;)-246.3(1)-250(patient)]TJ
0 -1.128 TD
[(had)-241.9(increased)-243.3(bleeding)-245(without)-237.6(the)-241.4(need)-240(for)-242.5(blood)-237.2(transfusion;)-243.3(1)]TJ
0 -1.1219 TD
[(patient)-329.9(died)-320.7(after)-323.5(mesenteric)-327.6(thrombosis)-328.1(in)-322.6(the)-320.7(17th)-322.5(postopera-)]TJ
0 -1.128 TD
[(tive)-558(day.)-559(One)-554.4(patient)-555.5(showed)-559.6(symptomatic)-553.5(mesh)-557.6(exposure.)]TJ
0 -1.1219 TD
[(Another)-342.8(patient)-342.1(presented)-336.6(posterior)-342.2(vaginal)-336.5(wall)-340(prolapse)-344.6(after)]TJ
0 -1.128 TD
[(the)-302.4(repair)-305.2(exclusively)-296.6(of)-301.1(the)-302.4(anterior)-304.7(wall.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Conclusions:)Tj
/F4 1 Tf
6.1216 0 TD
[(Surgeries)-630.3(using)-632.6(mesh)-630.8(presented)-629.3(signicant)]TJ
-7.1215 -1.128 TD
[(improvement)-447.5(of)-447.4(POP-Q)-450(parameters)-446.3(regardless)-447.9(of)-447.4(the)-448.7(type)-442.6(of)]TJ
0 -1.1219 TD
[(mesh)-301.5(used.)]TJ
/F3 1 Tf
27.0045 71.9468 TD
(60.)Tj
9.843 0 0 9.843 331.7668 725.5557 Tm
[(Footprint)-282.7(to)-278.6(Evaluate)-281.7(the)-280.7(Feet)-284.4(of)-278.6(Diabetic)]TJ
0 -1.1174 TD
(Women)Tj
/F4 1 Tf
9.2982 0 0 9.2982 310.8472 698.0029 Tm
[(Beatriz)-335.6(Mart)]TJ
5.1643 .0427 TD
()Tj
.2988 -.0427 TD
[(nez,)-337.6(S)]TJ
2.512 .0427 TD
()Tj
.2988 -.0427 TD
[(lvia)-338.5(Tasso,)-333.5(Adriana)-334.8(Silva,)-335.2(Ana)]TJ
-8.2739 -1.1219 TD
[(Raphaela)-338(Simo)]TJ
5.7679 .0061 TD
()Tj
.4146 -.0061 TD
[(es,)-332.6(Nadja)-338.6(Barbosa,)-337.7(Marcos)-332.1(Mesquita)-334.8(Filho)]TJ
/F5 1 Tf
-6.1826 -1.7682 TD
[(Vale)-334.7(do)-329.2(Sapuca)]TJ
6.4264 .0305 TD
()Tj
.0305 -.0305 TD
[()-328.7(University,)-340(Pouso)-330.1(Alegre,)-338(MG,)-333(Brazil)]TJ
/F3 1 Tf
-5.457 -2.3047 TD
(Background:)Tj
/F4 1 Tf
5.9813 0 TD
[(Women)-385.8(with)-384.5(diabetes)-382.5(mellitus)-384.8(\(DM\))-389.4(can)-380.3(de-)]TJ
-6.9813 -1.128 TD
[(velop)-204.8(many)-204.8(different)-203.4(foot)-203(problems.)-205.7(Even)-201.1(ordinary)-209.5(problems)-199.6(can)]TJ
0 -1.1219 TD
[(get)-217(worse)-220.5(and)-223.6(lead)-221.2(to)-218.9(serious)-217.6(complications.)-222.4(Foot)-221.8(problems)-217.9(most)]TJ
0 -1.128 TD
[(often)-329.1(happen)-331.4(when)-334.9(there)-333.3(is)-333.9(nerve)-333.8(damage)-329(also)-332(called)-334.7(neuropa-)]TJ
0 -1.1219 TD
[(thy.)-523.8(This)-530.9(can)-532.7(cause)-530(tingling,)-528.2(pain)-528(\(burning)-528.4(or)-526.7(stinging\),)-530.2(or)]TJ
0 -1.128 TD
[(weakness)-237.9(in)-243.3(the)-241.4(foot.)-233.5(It)-239.6(can)-240.1(also)-240.6(cause)-243.4(loss)-241.6(of)-240.1(feeling)-241.3(in)-237.2(the)-241.4(foot,)]TJ
0 -1.1219 TD
[(so)-249.1(you)-256(can)-252.3(injure)-249.3(it)-255(and)-254.1(not)-249.4(know)-251.4(it.)-255(Poor)-249(blood)-249.4(ow)-254.3(or)-252.3(changes)]TJ
0 -1.128 TD
[(in)-267.7(the)-271.9(shape)-275.7(of)-270.6(your)-270.5(feet)-272.4(or)-270.6(toes)-271(may)-271.9(also)-277.1(cause)-273.9(problems.)-266.7(High)]TJ
0 -1.1219 TD
[(plantar)-436.4(pressure)-444.2(is)-437.6(a)-437.1(proven)-439.3(risk)-439.9(factor)-439.3(for)-437.6(ulceration)-440.1(among)]TJ
0 -1.128 TD
[(individuals)-342.5(with)-347.9(DM.)-342(The)-347.4(photopodoscopia)-341.6(is)-346.1(one)-345.6(of)-343.8(the)-345.1(tools)]TJ
0 -1.1219 TD
[(used)-210.6(in)-212.8(screening)-220.8(for)-212(high)-212.8(plantar)-216.9(pressure)-212.5(among)-217(these)-214.3(subjects.)]TJ
0 -1.128 TD
[(However,)-531.9(an)-534.6(examination)-534.7(photopodoscopy)-526.9(is)-535.1(not)-529.9(accurately)]TJ
0 -1.1219 TD
[(demonstrates)-468.8(the)-473.1(high)-468.9(pressure)-468.6(area)-472.2(and)-467.5(there)-473.6(is)-468.1(no)-469.4(specic)]TJ
0 -1.128 TD
[(computer)-302.2(program)-300.9(to)-298.2(analyze)-302.8(the)-302.4(image)-300(plant.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.9326 0 TD
[(Use)-431.6(footprint)-429.8(method)-429.8(to)-432.3(evaluate)-430.3(the)-430.4(feet)-430.9(of)]TJ
-6.9325 -1.128 TD
[(diabetic)-303.6(women.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Material/Methods:)Tj
/F4 1 Tf
8.3836 0 TD
[(Our)-320.9(footprint)-314(method)-320.1(was)-315.8(developed)-316.8(by)]TJ
-9.3836 -1.128 TD
[(medical)-285.3(professionals)-289.8(and)-290.7(systems)-287(analysts)-286(from)-284.6(the)-290.2(University)]TJ
0 -1.1219 TD
[(of)-215.7(Vale)-222.7(do)-219.4(Sapucai,)-222.1(Minas)-221.4(Gerais,)-218.1(and)-223.6(Brazil.)-221.7(It)-215.2(is)-224.2(in)-218.9(registration)]TJ
0 -1.128 TD
[(process)-594.3(with)-591.8(the)-595.1(National)-593.6(Institute)-594.9(of)-593.7(Intellectual)-595.7(Property)]TJ
0 -1.1219 TD
[(\(INPI\).)-239.3(Footprints)-240.4(were)-237.8(taken)-239.5(from)-241.9(64)-237.7(diabetic)-242.7(women)-236.8(using)-242.4(the)]TJ
0 -1.128 TD
[(photopodoscopia)-237.9(and)-241.9(our)-240.1(footprint)-240.8(method.)-240.8(It)-239.6(was)-242.6(compare)-239.9(high)]TJ
0 -1.1219 TD
[(pressure)-285.7(points)-284.6(plant)-289.7(between)-287.9(the)-284.1(two)-287.5(tests.)-287.9(It)-288.4(was)-285.3(analyzed)-290.6(the)]TJ
0 -1.128 TD
[(agreement)-304.6(and)-296.8(intra-rater)-300.8(reliability.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Results:)Tj
/F4 1 Tf
3.701 0 TD
[(The)-268.2(average)-269.1(age)-264.5(was)-267(63)]TJ
/F2 1 Tf
9.8653 0 TD
()Tj
/F4 1 Tf
.7195 0 TD
[(10.8.)-262.1(The)-268.2(weighted)-270.9(kappa)]TJ
-15.2857 -1.128 TD
[(coefcient)-313.5(was)-309.7(high)-310.3(concordance)-315.9(\(Kw)]TJ
/F2 1 Tf
16.1271 0 TD
(>)Tj
/F4 1 Tf
.7195 0 TD
[(0.79\))-313.2(for)-309.5(the)-308.5(intra-ex-)]TJ
-16.8465 -1.1219 TD
[(aminer)-302.3(analyses)-302.9(for)-297.3(most)-302.9(of)-295(the)-302.4(points)-302.9(studied)-301(on)-298.7(both)-298.2(feet.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Conclusions:)Tj
/F4 1 Tf
5.7801 0 TD
[(Our)-302.6(footprint)-295.7(method)-295.7(with)-299.2(a)-296.9(specic)-300.6(computer)]TJ
-6.7801 -1.1219 TD
[(program)-337.5(to)-334.8(analyze)-339.4(the)-339(footprints)-337.5(feature)-339.9(ease)-341(of)-337.7(handling)-338.4(and)]TJ
0 -1.128 TD
[(low)-336.3(cost,)-344.2(which)-340.4(can)-343.7(represent)-339(an)-339.5(important)-345.8(impact)-342.1(on)-335.3(the)-345.1(pre-)]TJ
0 -1.1219 TD
[(vention)-301.8(of)-295(foot)-300.5(ulcers)-302(in)-304.3(diabetic)-297.5(women.)]TJ
/F3 1 Tf
0 -3.8839 TD
(61.)Tj
9.843 0 0 9.843 331.7668 299.7921 Tm
[(Functional)-283.8(Capacity)-281.5(and)-279.4(Sleep)-284.1(Quality)]TJ
0 -1.1174 TD
[(in)-278.6(Diabetic)-282.8(Women)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 310.8472 272.2393 Tm
[(Beatriz)-335.6(Mart)]TJ
5.1643 .0427 TD
()Tj
.2988 -.0427 TD
(nez)Tj
6.9735 0 0 6.198 374.6267 276.3779 Tm
(1)Tj
9.2982 0 0 9.2982 378.1416 272.2393 Tm
[(,)-329.2(Vanessa)-341.5(Gomes)]TJ
6.9735 0 0 6.198 443.9621 276.3779 Tm
(1)Tj
9.2982 0 0 9.2982 447.4771 272.2393 Tm
[(,)-329.2(Thamires)-339.8(Santana)]TJ
6.9735 0 0 6.198 520.7809 276.3779 Tm
(1)Tj
9.2982 0 0 9.2982 524.2393 272.2393 Tm
(,)Tj
-22.9498 -1.1219 TD
[(Ronan)-332(Costa)]TJ
6.9735 0 0 6.198 359.433 265.9464 Tm
(2)Tj
9.2982 0 0 9.2982 362.9479 261.8078 Tm
[(,)-329.2(Raphael)-339.9(Dutra)]TJ
6.9735 0 0 6.198 423.2692 265.9464 Tm
(1)Tj
/F5 1 Tf
-16.1213 -2.6526 TD
(1)Tj
9.2982 0 0 9.2982 314.3054 245.3669 Tm
[(Vale)-334.7(do)-335.3(Sapuca)]TJ
6.5423 .0305 TD
()Tj
.5305 -.0305 TD
[(University,)-333.9(Pouso)-336.2(Alegre,)-338(MG,)-333(Brazil,)]TJ
6.9735 0 0 6.198 310.8472 239.0173 Tm
(2)Tj
9.2982 0 0 9.2982 314.3054 234.8787 Tm
[(Universidade)-340.4(do)-329.2(vale)-337.1(do)-329.2(Sapucai\(UNIVAS\),)-337.4(Pouso)-336.2(Alegre,)]TJ
-.3719 -1.1219 TD
[(MG,)-333(Brazil)]TJ
/F3 1 Tf
.9999 -2.3047 TD
(Background:)Tj
/F4 1 Tf
6.0789 0 TD
[(Some)-476(population-based)-475.7(surveys)-474.2(have)-477.8(shown)]TJ
-7.0788 -1.128 TD
[(that)-222.6(the)-229.2(prevalence)-230(of)-221.8(self-reported)-227.3(poor)-227.9(sleep)-226.5(increases)-230.2(after)-226(the)]TJ
0 -1.1219 TD
[(age)-410.8(of)-410.8(60.)-414.5(Poor)-413.7(sleepers)-415.1(subjectively)-411.9(experience)-413(longer)-414.5(sleep)]TJ
0 -1.128 TD
[(latencies,)-349.6(frequent)-353.9(nocturnal)-351(awakenings,)-347.9(less)-349.5(total)-350.1(sleep)-354.5(time,)]TJ
0 -1.1219 TD
[(more)-353.5(difculty)-361.4(initiating)-354.6(and)-357.8(maintaining)-359.3(sleep,)-354.5(and)-357.8(excessive)]TJ
0 -1.128 TD
[(daytime)-500.6(sleepiness.)-508.8(Many)-503.2(investigators)-500.7(report)-502.2(a)-504.2(female)-507.7(pre-)]TJ
0 -1.1219 TD
[(dominance)-548(in)-548.2(poor)-544.9(sleep,)-549.6(especially)-550.8(after)-555.2(45)-542.6(years)-552.5(of)-545(age.)]TJ
0 -1.128 TD
[(Concomitantly)-333.5(with)-335.7(these)-336.2(reports,)-336.7(females)-336.1(are)-333.9(more)-335.2(frequently)]TJ
0 -1.1219 TD
[(users)-352.3(of)-349.9(sedative-hypnotic)-357.4(medication.)-351.8(Physical)-356.8(exercise)-353.1(is)-352.2(as-)]TJ
0 -1.128 TD
[(sociated)-754.5(with)-750.4(improvement)-758.4(of)-752.3(cardiovascular,)-755.3(respiratory,)]TJ
0 -1.1219 TD
[(muscular,)-490.4(endocrine)-496(and)-491.9(nervous)-493.3(system,)-495.2(and)-491.9(a)-498.1(better)-491.3(sleep)]TJ
0 -1.128 TD
[(quality.)-380.6(However,)-385.6(the)-381.7(association)-387.2(of)-380.3(these)-385(two)-378.9(conditions)-385.7(and)]TJ
0 -1.1219 TD
[(diabetes)-303.3(mellitus)-299.4(\(DM\))-297.9(is)-303.5(unclear.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Objective\(s\):)Tj
/F4 1 Tf
6.024 0 TD
[(Evaluate)-519.4(the)-521.9(association)-515.3(between)-525.7(functional)]TJ
-7.024 -1.1219 TD
[(capacities)-305.1(and)-296.8(sleep)-305.7(quality)-295.2(in)-304.3(diabetic)-303.6(women.)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 59.7543 749.7069 Tm
(ABSTRACTS)Tj
52.6193 0 TD
(A-23)Tj
ET
endstream
endobj
285 0 obj
<>stream
/GS1 gs
BT
/F3 1 Tf
9.2982 0 0 9.2982 71.3197 725.5557 Tm
0 0 0 rg
0 Tc
0 Tw
(Material/Methods:)Tj
/F4 1 Tf
8.4446 0 TD
[(It)-379.8(was)-376.7(a)-376.1(cross-sectional)-376.9(study)-376.5(with)-378.4(200)]TJ
-9.4445 -1.128 TD
[(women)-334.3(with)-341.8(DM)-335.9(type)-332.9(2)-335.3(\(47)-337.6(no)-335.3(sedentary,)-336.6(and)-339.5(153)-335.3(sedentary\),)]TJ
0 -1.1219 TD
[(from)-302.9(a)-296.9(single)-301(public)-301.8(health)-300(service)-300.1(in)-298.2(Brazil.)-307(The)-298.7(patients)-298.6(were)]TJ
0 -1.128 TD
[(interviewed)-380.6(with)-372.3(a)-382.2(questionnaire)-378.2(which)-370.9(contained)-383.4(information)]TJ
0 -1.1219 TD
[(on)-512.1(sociodemographic)-516.5(prole)-514.9(and)-510.2(physical)-518.6(health)-513.4(conditions.)]TJ
0 -1.128 TD
[(Sleep)-370.4(quality)-368.4(was)-370.6(measured)-367.1(with)-372.3(the)-363.4(Pittsburgh)-368.5(Sleep)-370.4(Quality)]TJ
0 -1.1219 TD
[(Index)-347.9(\(PSQI\).)-343.5(Physical)-344.6(exercise)-347(was)-346.2(measured)-348.8(by)-341.4(time)-344(of)-343.8(aer-)]TJ
0 -1.128 TD
[(obic)-241.4(exercise)-243.3(at)-241.5(least)-244.3(150)-237.7(minutes)-239.5(per)-244.3(week.)-241.5(Functional)-241.3(capacity)]TJ
0 -1.1219 TD
[(was)-553.5(measured)-556.1(with)-555.2(Lawton)-555.7(Index.)-555.2(The)-554.7(analysis)-554.3(was)-559.6(made)]TJ
0 -1.128 TD
[(through)-489.5(chi-square)-491.4(test,)-490(Fisher)-489.6(test,)-490(Mann-Whitney)-488.4(test,)-490(and)]TJ
0 -1.1219 TD
[(Pearson)-585.8(Correlation.)-589.3(The)-591.3(signicance)-584.7(level)-592.6(was)-584(set)-588.1(at)-589(5%)]TJ
0 -1.128 TD
(\(p)Tj
/F2 1 Tf
.8353 0 TD
(<)Tj
/F4 1 Tf
.5487 0 TD
(0.05\).)Tj
/F3 1 Tf
-.3841 -1.1219 TD
(Results:)Tj
/F4 1 Tf
3.6522 0 TD
[(Mea)10.8(n)-213.4(age)-203.5(wer)10.3(e)-211.5(6)0(1)12.2(.04)]TJ
/F2 1 Tf
8.6153 0 TD
()Tj
/F4 1 Tf
.7134 0 TD
[(9.6)12.3(7)-213.4(i)0(n)-206.7(n)0(o)-207.2(sed)15(ent)14.6(ary)-207.7(\(NS)17.7(\))-215.7(and)]TJ
-13.9809 -1.128 TD
[(63)12.2(.9)]TJ
/F2 1 Tf
1.8962 0 TD
()Tj
/F4 1 Tf
.7134 0 TD
[(11)12.3(.3)-237.7(in)-237.2(sede)16.9(nta)14.7(ry)-240.1(\(S)13.1(\),)-240.1(p)]TJ
/F2 1 Tf
9.2311 0 TD
(=)Tj
/F4 1 Tf
.5487 0 TD
[(0.)12.2(6.)-237.8(Eth)17(nic)14.7(ity)13.3(,)-243.9(whi)17.4(te)-241.5(wer)16.4(e)-248.1(8)0(3)12.3(%)-240.1(in)]TJ
-12.3895 -1.128 TD
[(NS)-272.6(and)-266.3(79)12.2(.7)12.2(%)-276.7(i)0(n)-273.8(S)0(,)-265(p)]TJ
/F2 1 Tf
8.7129 0 TD
(=)Tj
/F4 1 Tf
.5427 0 TD
[(0.6)12.3(.)-274.4(Ove)12.6(r)-276.7(1)0(0)-268.2(yea)16(rs)-269.7(of)-270.6(DM)-274.9(we)12.6(re)-274.8(57)12.2(.4%)-264.5(in)]TJ
-9.2555 -1.1219 TD
[(NS)-242.1(and)-235.8(65)12.2(.3%)-234(in)-243.3(S,)-240.6(p)]TJ
/F2 1 Tf
8.5605 0 TD
(=)Tj
/F4 1 Tf
.5487 0 TD
[(0.)12.2(3.)-237.8(Psyc)18.2(hot)12.8(rop)16(ic)-241.5(dru)16(gs)-243(us)13.1(ers)-237.4(wer)10.3(e)-242(53.)12.3(2%)]TJ
-9.1092 -1.128 TD
[(in)-200.7(NS)-199.4(and)-199.3(63)12.2(.4)12.2(%)-209.6(i)0(n)-200.7(S)0(,)-197.9(p)]TJ
/F2 1 Tf
9.3409 0 TD
(=)Tj
/F4 1 Tf
.5487 0 TD
[(0.)12.2(2.)-201.2(Al)11.2(coh)14.1(ol)-200.7(drin)16.5(ki)12.7(ng)-201.2(wer)16.4(e)-211.5(8)0(5)12.2(.)0(1)12.2(%)-209.6(in)-200.7(N)-7.6(S)]TJ
-9.8896 -1.1219 TD
.0111 Tc
[(and)-226.7(88.)11.1(8)-7.1(%)-229(in)-226.7(S,)-232.8(p)]TJ
/F2 1 Tf
7.1642 0 TD
0 Tc
(=)Tj
/F4 1 Tf
.567 0 TD
[(0.)-18.3(5)-12.2(.)-237.8(C)-10.8(u)-12.2(r)-8.4(r)-8.4(e)-16.4(nt)-249.4(s)-11.3(m)-11.6(ok)-18.2(i)-11.7(n)-12.2(g)-237.8(w)-7.6(e)-16.4(r)-8.4(e)-242(1)0(2)-18.2(.)-12.2(5)-12.2(%)-234(i)-11.7(n)-237.8(N)-13.7(S)-240.6(a)-10.3(n)-12.2(d)]TJ
-7.7312 -1.128 TD
.0129 Tc
[(11%)-251.6(in)-255.3(S,)-255.4(p)]TJ
/F2 1 Tf
4.7741 0 TD
0 Tc
(=)Tj
/F4 1 Tf
.567 0 TD
[(0.)-18.3(5)-12.2(.)-268.3(C)-10.8(o)-12.2(f)-8.4(f)-14.5(e)-10.3(e)-266.4(d)-12.2(r)-14.5(in)-17.7(k)-12.2(i)-11.7(ng)-280.4(w)-7.6(e)-10.3(r)-14.5(e)-266.4(9)-24.4(8)-18.3(%)-282.8(i)-23.9(n)-274.3(N)-25.9(S)-277.2(a)-22.5(n)-24.4(d)-280.4(9)-18.3(5)-24.4(%)-276.7(i)-23.9(n)]TJ
-5.3411 -1.1219 TD
.0211 Tc
[(S,)-277.6(p)]TJ
/F2 1 Tf
1.6462 0 TD
0 Tc
(=)Tj
/F4 1 Tf
.5731 0 TD
.0196 Tc
[(0.)-4.8(4.)-279.1(A)-6.3(1)1.3(C)-283.9(l)1.8(es)-3.9(s)-278.3(t)-4.3(han)-279.1(7)-4.8(%)-275.4(w)-6.3(ere)-277.3(3)-4.8(1.)-4.8(9%)-281.5(i)-4.3(n)-279.1(NS)-282(and)-279.1(2)-4.8(6.)-4.8(8)-279.1(i)-4.3(n)-279.1(S)-1.5(,)]TJ
-2.2194 -1.128 TD
0 Tc
(p)Tj
/F2 1 Tf
.5244 0 TD
(=)Tj
/F4 1 Tf
.5731 0 TD
.0201 Tc
[(0.)-4.3(5.)-437.2(O)-5.8(b)1.8(es)-3.4(i)-3.8(t)2.3(y)-443.3(w).3(ere)-441.4(4)1.8(6)-4.3(.)1.8(8)-4.3(%)-439.5(i)-3.8(n)-437.2(NS)-440(an)-4.3(d)-437.2(4)-4.3(4.)-4.3(4%)-439.5(i)-3.8(n)-437.2(S,)-443.3(p)]TJ
/F2 1 Tf
22.4803 0 TD
0 Tc
(=)Tj
/F4 1 Tf
.5731 0 TD
.0244 Tc
[(0.)6.1(8.)]TJ
-24.151 -1.1219 TD
.0234 Tc
[(Goo)5.1(d)-409.5(sle)7(e).9(pers)-408.6(were)-407.6(4)5.1(0)-1(.)5.1(4)-1(%)-405.7(i)-.5(n)-409.5(N)3.6(S)-406.2(a).9(nd)-403.4(26)5.1(.1)5.1(%)-411.8(i)-.5(n)-403.4(S)2.3(,)-409.5(p)]TJ
/F2 1 Tf
23.0596 0 TD
0 Tc
(=)Tj
/F4 1 Tf
.5731 0 TD
.0183 Tc
[(0.)-6.1(05)-6.1(.)]TJ
-23.6327 -1.128 TD
.0216 Tc
[(There)-427.7(w)-4.3(as)-428.7(correlation)-429.6(with)-429.6(qual)]TJ
14.054 0 TD
.0221 Tc
[(ity)-429.1(o)3.8(f)-431.4(s)4.7(leep)-429.1(and)-429.1(f)1.5(unctiona)5.7(l)]TJ
-14.054 -1.1219 TD
[(capacity)-295(in)-301.1(NS)-297.9(\(r)]TJ
/F2 1 Tf
7.2739 0 TD
0 Tc
(=)Tj
/F4 1 Tf
.5731 0 TD
.0183 Tc
[(0.)-6.1(3;)-304.3(p)]TJ
/F2 1 Tf
2.4328 0 TD
0 Tc
(=)Tj
/F4 1 Tf
.5731 0 TD
.0244 Tc
[(0.)6.1(03)6.1(\))-301.1(a)1.9(n)6.1(d)-298.7(S)-295.5(\()3.8(r)]TJ
/F2 1 Tf
5.8838 0 TD
0 Tc
(=)Tj
/F4 1 Tf
.5731 0 TD
.0244 Tc
[(0.)6.1(4;)-298.2(p)]TJ
/F2 1 Tf
2.4389 0 TD
0 Tc
(<)Tj
/F4 1 Tf
.5731 0 TD
.0238 Tc
[(0,)5.5(00)5.5(1\).)]TJ
/F3 1 Tf
-19.322 -1.128 TD
0 Tc
(Conclusions:)Tj
/F4 1 Tf
5.7253 0 TD
[(There)-244.2(was)-242.6(no)-237.7(association)-247(between)-239.1(sleep)-244.8(quality)]TJ
-6.7252 -1.1219 TD
[(and)-333.4(physical)-341.7(exercise)-334.8(in)-334.8(diabetic)-340.2(women,)-334.3(however)-335.3(there)-339.4(was)-334(a)]TJ
0 -1.128 TD
[(positive)-465.1(correlation)-466.8(between)-464.7(sleep)-464.3(quality)-465.9(and)-461.4(functional)-466.4(ca-)]TJ
0 -1.1219 TD
[(pacity)-300(in)-304.3(no)-298.7(sedentary)-300(and)-302.9(sedentary)-300(women.)]TJ
/F3 1 Tf
0 -4.1644 TD
(62.)Tj
9.843 0 0 9.843 82.9417 404.3904 Tm
[(Risk)-281.5(Factors)-281.7(for)-280.9(Foot)-282(Complications)-288(in)-278.6(Diabetic)]TJ
0 -1.1116 TD
[(Patients:)-282.7(Sex)-280.8(Differences)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 62.022 376.8377 Tm
[(Beatriz)-335.6(Mart)]TJ
5.1643 .0427 TD
()Tj
.3049 -.0427 TD
[(nez,)-331.5(Camila)-334.6(Silveira,)-335.1(Gustavo)-333.4(Co)]TJ
13.3407 .0427 TD
()Tj
.4146 -.0427 TD
(rtes)Tj
/F5 1 Tf
-19.2244 -1.7621 TD
[(Universidade)-267.2(do)-256(vale)-263.9(do)-262.1(Sapucai\(UNIVAS\),)-264.3(Pouso)-257(Alegre,)-264.9(MG,)]TJ
0 -1.128 TD
(Brazil)Tj
/F3 1 Tf
.9999 -2.3047 TD
(Background:)Tj
/F4 1 Tf
5.9326 0 TD
[(The)-329.1(diabetes)-327.7(mellitus)-329.9(\(DM\))-328.4(is)-327.8(considered)-330.5(one)]TJ
-6.9325 -1.1219 TD
[(of)-471.8(the)-473.1(diseases)-472.8(which)-474.6(the)-473.1(most)-473.6(affects)-473.2(the)-473.1(contemporaneous)]TJ
0 -1.128 TD
[(women)-316(and)-315.1(men)-314.6(and)-315.1(strikes)-314.7(populations)-312.5(all)-314.1(over)-317.4(the)-314.6(world,)-314.2(re-)]TJ
0 -1.1219 TD
[(gardless)-356(of)-349.9(their)-353(economic)-359(and)-351.7(social)-354(levels.)-354(The)-353.5(foot)-349.3(compli-)]TJ
0 -1.128 TD
[(cations)-305.2(represent)-302.4(the)-308.5(major)-304.2(cause)-304.4(of)-301.1(lower)-306.2(limbs)-302.4(non-traumatic)]TJ
0 -1.1219 TD
[(amputation)-384.2(in)-389.7(the)-381.7(world,)-387.4(the)-387.8(85%)-380.3(of)-386.4(them)-387.2(being)-381.6(preceded)-391(by)]TJ
0 -1.128 TD
[(ulceration.)-324.2(The)-323(risk)-318(factors)-322.6(to)-322.6(the)-320.7(development)-327.9(of)-319.4(foot)-318.8(compli-)]TJ
0 -1.1219 TD
[(cations)-378.3(are)-382.7(decreased)-376(sensitivity,)-383.9(chronic)-376(foot)-373.7(pain,)-381.6(peripheral)]TJ
0 -1.128 TD
[(vascular)-373.2(disease,)-370(deformities,)-369.8(and)-363.9(others.)-370.9(No)-367.3(study)-370.4(has)-369.1(shown)]TJ
0 -1.1219 TD
[(differences)-302.9(in)-304.3(these)-299.6(risk)-299.7(factors)-304.3(between)-300.1(women)-303.8(and)-296.8(men.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.7436 0 TD
[(Compare)-240.4(the)-241.4(risk)-232.6(factors)-243.4(for)-236.4(foot)-239.6(complications)]TJ
-6.7435 -1.1219 TD
[(between)-300.1(women)-303.8(and)-302.9(men)-296.3(with)-299.2(DM.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Material/Methods:)Tj
/F4 1 Tf
8.597 0 TD
[(It)-526.2(was)-529.2(a)-522.5(cross-sectional)-529.4(study)-529(with)-524.8(a)]TJ
-9.597 -1.128 TD
[(sample)-262.5(of)-264.5(204)-262.1(diabetic)-267(patients)-262(\(113)-264.4(women)-267.2(and)-260.2(91)-262.1(men\).)-262(They)]TJ
0 -1.1219 TD
[(had)-315.1(eighteen)-316.3(years)-314.7(old)-310.4(or)-319.4(more)-310.8(and)-315.1(type)-314.6(2)-310.9(DM.)-317.6(The)-310.8(study)-315.6(was)]TJ
0 -1.128 TD
[(approved)-461.8(by)-463.3(the)-460.9(Research)-461.9(Ethics)-467.5(Committee)-461.6(of)-459.6(the)-460.9(Vale)-466.6(do)]TJ
0 -1.1219 TD
(Sapuca)Tj
2.8779 .0427 TD
()Tj
.6036 -.0427 TD
[(University)-304.3(\(UNIVA)]TJ
7.5483 .25 TD
()Tj
.5183 -.25 TD
[(S\),)-303.9(Brazil.)-307(The)-304.8(patients)-304.7(were)-304.9(inter-)]TJ
-11.5481 -1.128 TD
[(viewed)-442.2(with)-445.5(a)-443.2(questionnaire)-445.3(which)-444.1(contained)-444.3(information)-445.7(on)]TJ
0 -1.1219 TD
[(sociodemographic)-412.8(prole)-411.2(and)-412.7(physical)-408.8(health)-415.8(conditions.)-410.1(Sta-)]TJ
0 -1.128 TD
[(tistical)-261(analysis)-255.5(was)-260.9(carried)-254.5(out)-261.6(using)-254.6(the)-253.6(Statistical)-261.4(Package)-257.4(for)]TJ
0 -1.1219 TD
[(the)-241.4(Social)-241.9(Sciences)-243.8(\(SPSS\))-241.7(18.0)-237.7(\(SPSS)-239.3(Inc.,)-238.2(Chicago,)-244.2(IL,)-241.9(USA\).)]TJ
0 -1.128 TD
[(Results)-414.6(were)-408.5(expressed)-415.5(as)-411.8(mean)]TJ
/F2 1 Tf
13.6577 0 TD
()Tj
/F4 1 Tf
.7195 0 TD
[(standard)-411.7(deviation,)-409.1(and)-412.7(ab-)]TJ
-14.3772 -1.1219 TD
[(solute)-209.5(and)-205.3(relative)-214.5(frequencies.)-209(The)-207.2(statistical)-215(analysis)-206.8(was)-212.1(made)]TJ
0 -1.128 TD
[(through)-227.3(chi-square)-229.2(test,)-227.9(Wilcoxon)-226.7(rank)-226(sum)-224.1(test)-227.9(and)-223.6(Spearmans)]TJ
0 -1.1219 TD
[(correlation)-302.2(test.)-301(The)-304.8(signicance)-298.1(level)-306.1(was)-297.5(set)-301.6(at)-302.4(5%)-301.1(\(p)]TJ
/F2 1 Tf
22.5657 0 TD
(<)Tj
/F4 1 Tf
.5548 0 TD
(0.05\).)Tj
/F3 1 Tf
-22.1206 -1.128 TD
(Results:)Tj
/F4 1 Tf
3.7315 0 TD
[(Women)-300.4(and)-296.8(men)-296.3(showed)-297.4(mean)-294.4(age)-301(was)-297.5(62.9)]TJ
/F2 1 Tf
18.5172 0 TD
()Tj
/F4 1 Tf
.7195 0 TD
(12,7)Tj
-23.9681 -1.1219 TD
[(and)-388.3(64,2)]TJ
/F2 1 Tf
3.7498 0 TD
()Tj
/F4 1 Tf
.7195 0 TD
[(10,5)-384(years)-387.9(\(p)]TJ
/F2 1 Tf
5.4692 0 TD
(=)Tj
/F4 1 Tf
.5487 0 TD
[(0,1\),)-386.4(respectively.)-388.5(The)-390.1(prevalence)-388.6(of)]TJ
16.5112 71.9468 TD
[(single)-459.5(marital)-453.7(status)-452.6(was)-456(38%)-453.5(in)-456.7(women)-450.2(and)-455.3(17,6%)-453.4(in)-450.6(men)]TJ
0 -1.128 TD
(\(p)Tj
/F2 1 Tf
.8353 0 TD
(=)Tj
/F4 1 Tf
.5548 0 TD
[(0,01\).)-392.5(The)-396.2(proportion)-387.6(of)-398.6(physically)-396.1(inactive)-395.1(was)-395(75.2%)-392.4(in)]TJ
-1.3902 -1.1219 TD
[(women)-438(and)-430.9(70,3%)-435.1(in)-432.3(men)-430.4(\(p)]TJ
/F2 1 Tf
12.487 0 TD
(=)Tj
/F4 1 Tf
.5487 0 TD
[(0,4\).)-435.2(The)-432.8(women)-431.9(had)-437(a)-431(lower)]TJ
-13.0358 -1.128 TD
[(proportion)-448.6(of)-441.3(obesity)-447.3(\(37.2%)-443.6(vs)-444.2(64,8%)-447.3(in)-444.5(men;)-448.2(p)]TJ
/F2 1 Tf
21.1938 0 TD
(=)Tj
/F4 1 Tf
.5487 0 TD
[(0.01\))-447.4(and)]TJ
-21.7426 -1.1219 TD
[(alcohol)-269.4(drinking)-269.4(\(1,8%)-266.8(vs)-267.4(12,1%)-270.5(in)-267.7(men;)-265.3(p)]TJ
/F2 1 Tf
17.4014 0 TD
(=)Tj
/F4 1 Tf
.5548 0 TD
[(0,0001\).)-264.4(There)-274.7(was)]TJ
-17.9562 -1.128 TD
[(no)-506(association)-509.2(between)-507.4(physically)-505.8(inactive)-510.9(and)-504.1(chronic)-504(foot)]TJ
0 -1.1219 TD
[(pain,)-229.2(in)-225(both)-225(sex)-228.9(\(p)]TJ
/F2 1 Tf
7.6154 0 TD
(=)Tj
/F4 1 Tf
.5487 0 TD
[(0.2\).)-227.9(There)-225.9(was)-230.4(association)-228.7(between)-226.9(obesity)]TJ
-8.1641 -1.128 TD
[(and)-345.6(decrease)-351.7(of)-343.8(sensitivity)-347.3(of)-349.9(the)-345.1(foot)-343.2(in)-347(women)-346.5(\(p)]TJ
/F2 1 Tf
21.206 0 TD
(=)Tj
/F4 1 Tf
.5548 0 TD
[(0.05\),)-343.7(but)]TJ
-21.7609 -1.1219 TD
[(not)-304.3(in)-298.2(men)-302.4(\(p)]TJ
/F2 1 Tf
5.5241 0 TD
(=)Tj
/F4 1 Tf
.5548 0 TD
(0.5\).)Tj
/F3 1 Tf
-5.079 -1.128 TD
(Conclusions:)Tj
/F4 1 Tf
5.8777 0 TD
[(Although)-384.4(women)-383.1(have)-386.4(a)-382.2(lower)-385.5(prevalence)-388.6(of)]TJ
-6.8776 -1.1219 TD
[(obesity)-435.1(compared)-428.9(with)-427.2(men,)-430.4(there)-430.9(was)-431.6(an)-424.9(association)-436(of)-429.1(this)]TJ
0 -1.128 TD
[(disease)-303(with)-305.3(the)-296.3(decreased)-309(sensitivity)-298.5(of)-301.1(the)-302.4(foot.)]TJ
/F3 1 Tf
0 -6.3045 TD
(63.)Tj
9.843 0 0 9.843 333.9779 551.8487 Tm
[(Molecular)-286.5(Breast)-286.2(Imaging)-279.3(as)-278.5(an)-284.3(Adjunct)]TJ
0 -1.1174 TD
[(to)-284.4(Mammography)-282.3(and)-279.4(Breast)-286.2(Ultrasound:)]TJ
0 -1.1116 TD
[(Our)-282(Initial)-284.2(Experience)-288.4(in)-278.6(the)-280.7(Community)-283.4(Based)]TJ
T*
[(Tertiary)-284.1(Care)-284.1(Setting)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 313.0582 502.4125 Tm
[(Anne)-334.9(Moch)]TJ
6.9735 0 0 6.198 358.0156 506.551 Tm
(1)Tj
9.2982 0 0 9.2982 361.5306 502.4125 Tm
[(,)-329.2(Eileen)-338.4(Ming)]TJ
6.9735 0 0 6.198 414.0849 506.551 Tm
(2)Tj
9.2982 0 0 9.2982 417.5432 502.4125 Tm
[(,)-335.3(Laura)-335.7(Horne)]TJ
6.9735 0 0 6.198 471.118 506.551 Tm
(2)Tj
9.2982 0 0 9.2982 474.5762 502.4125 Tm
[(,)-335.3(Ann)-336.8(Curley)]TJ
6.9735 0 0 6.198 524.466 506.551 Tm
(1)Tj
9.2982 0 0 9.2982 527.981 502.4125 Tm
(,)Tj
-23.1144 -1.128 TD
[(Kymberly)-336.1(Macaron)]TJ
6.9735 0 0 6.198 387.0424 496.0629 Tm
(1)Tj
9.2982 0 0 9.2982 390.5574 491.9243 Tm
[(,)-329.2(Lillian)-339.2(Stern)]TJ
6.9735 0 0 6.198 443.6786 496.0629 Tm
(3)Tj
/F5 1 Tf
-18.7309 -2.6526 TD
(1)Tj
9.2982 0 0 9.2982 316.5731 475.4833 Tm
[(Capital)-332.3(Health)-333.8(Medical)-338.9(Center,)-334.8(Pennington,)-334.1(New)-330.6(Jersey)]TJ
6.9735 0 0 6.198 313.0582 469.1904 Tm
(2)Tj
9.2982 0 0 9.2982 316.5731 465.0518 Tm
[(Epi)-336.6(Excellence,)-336.9(Garnet)-333.5(Valley,)-332.3(Pennsylvania)]TJ
6.9735 0 0 6.198 313.0582 458.7022 Tm
(3)Tj
9.2982 0 0 9.2982 316.5731 454.5637 Tm
[(Methodist)-333.2(Hospital)-334.3(Division)-338.5(of)-328.7(Thomas)-332.6(Jefferson)-339(University)]TJ
-.378 -1.1219 TD
[(Hospital,)-334.3(Philadelphia,)-339.1(Pennsylvania)]TJ
/F3 1 Tf
.9999 -2.3047 TD
(Background:)Tj
/F4 1 Tf
5.8533 0 TD
[(Molecular)-256.8(breast)-253.2(imaging)-246.4(is)-254.7(a)-248.1(useful)-255.1(adjunct)-251.2(to)]TJ
-6.8532 -1.128 TD
[(mammography)-508.9(and)-504.1(ultrasound)-510.6(with)-506.5(high)-505.5(sensitivity)-505.8(\(100%\),)]TJ
0 -1.1219 TD
[(specicity)-262.9(\(88%\),)-250.8(and)-260.2(detection)-254.8(rate)-254.1(for)-260.8(cancers)-256(\(32%\))-256.9(and)-254.1(high)]TJ
0 -1.128 TD
[(risk)-305.8(lesions)-300.1(\(21%\).)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.8228 0 TD
[(This)-305.3(study)-309.5(describes)-311.4(our)-313.3(rst)-308.7(21)-304.8(months)-315(expe-)]TJ
-6.8228 -1.128 TD
[(rience)-435.1(with)-427.2(molecular)-427.9(breast)-430(imaging)-429.3(\(MBI\))-425.5(in)-432.3(a)-424.9(community)]TJ
0 -1.1219 TD
[(based)-306.2(tertiary)-298.1(care)-307.6(breast)-302(center.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Material/Methods:)Tj
/F4 1 Tf
8.3349 0 TD
-.0136 Tc
[(All)-257(M)-.5(B)6.1(I)-13.6(s)-246.8(p)4.7(er)-13.6(f)12.2(o)4.7(rmed)-257.5(fr)-13.6(o)14.6(m)-256.9(2/)5.2(201)4.7(2)-257.5(t)-.9(h)4.7(r)2.3(oug)4.7(h)]TJ
-9.3348 -1.1219 TD
[(11/)5.3(20)4.8(13)-336.6(were)-340.8(retro)4.8(s)-.4(pect)5.3(iv)4.8(ely)-336.6(r)2.4(evi)5.3(e).6(w)-13.5(e)11.3(d)-336.6(a).6(n)4.8(d)-336.6(pati)5.3(ent)5.3(s)-341.9(fo)4.8(llo)4.8(w)-13.5(e)11.3(d)-336.6(f)2.4(o)4.8(r)]TJ
0 -1.128 TD
-.0146 Tc
[(at)-306.7(least)-300.6(1)-2.4(2)-301.1(m)-1.8(onths.)-301.2(Data)-305.4(collected)]TJ
13.6821 0 TD
[(included)-301.1(patient)-306.7(d)3.7(emographics)]TJ
-13.6821 -1.1219 TD
.0136 Tc
[(an)-4.7(d)-419.3(b)-4.7(reast)-424.9(d)1.4(en)-4.7(si)-4.2(ty)-4.7(,)-419.3(i)-4.2(nd)-4.7(icat)-4.2(io)-4.7(n,)-425.4(bi)-4.2(op)-4.7(sy)-425.4(ou)-4.7(tcom)-4.1(e,)-419.3(BIRAD)-6.2(S)-422.1(3,)]TJ
0 -1.128 TD
.0174 Tc
[(and)-415.5(f)2.9(ol)5.7(lo)5.2(w-u)5.2(p)-421.6(n)5.2(d)5.2(i)-.4(n)5.2(g)-.9(s)6.1(.)-421.6(Sen)5.2(s)0(i)5.7(tiv)5.2(it)5.7(y,)-415.5(sp)5.2(eci)5.7(cit)5.7(y,)-415.5(and)-415.5(p)5.2(os)6.1(iti)5.7(ve)]TJ
0 -1.1219 TD
.0154 Tc
[(and)-411.4(n)-2.9(egative)-415.6(p)-2.9(redict)]TJ
8.7434 0 TD
.0167 Tc
[(ive)-414.3(v)-1.6(alue)6.4(s)-415.3(w)3(ere)-414.3(calcula)6.4(ted)-410.1(o)-1.6(n)-410.1(a)-414.3(pa)6.4(tie)6.4(nt)]TJ
-8.7434 -1.128 TD
.0116 Tc
[(\()-9(not)-304.9(l)-6.2(e)-4.8(si)-6.2(on)-6.7(\))-301.7(b)-6.7(as)-5.8(i)-6.2(s).3(.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
0 Tc
(Results:)Tj
/F4 1 Tf
3.7925 0 TD
[(Of)-357.5(151)-353.6(female)-355.3(patients)-359.5(who)-355.1(underwent)-353(MBI,)-359.8(most)]TJ
-4.7924 -1.128 TD
[(were)-335.4(white,)-333.8(post-menopausal,)-328.5(with)-335.7(dense)-330.6(broglandular)-331.8(tissue.)]TJ
0 -1.1219 TD
[(Median)-470.3(age)-471.8(was)-468.2(53.)-469.4(The)-469.4(most)-467.5(frequent)-469.8(indications)-468.7(included)]TJ
0 -1.128 TD
[(problem)-304.1(solving)-296.7(\(32%\),)-305.7(high)-298.2(risk)-299.7(screening)-300(\(30%\),)-299.6(and)-302.9(evalua-)]TJ
0 -1.1219 TD
[(tion)-212.3(for)-212(extent)-214.6(of)-209.6(disease)-217.6(\(16%\).)-208.2(52)-213.3(MBIs)-212.6(\(34%\))-214.3(were)-213.4(positive)-209(of)]TJ
0 -1.128 TD
[(which)-431.9(81%)-423(had)-424.8(dense)-428.2(breasts.)-429.1(All)-421.1(went)-431.9(on)-420.7(to)-426.2(biopsy)-425.3(\(63%\),)]TJ
0 -1.1219 TD
[(further)-528.9(imaging)-520.8(\(67%\))-525.2(and/or)-524.2(recommendation)-522.9(for)-522.9(6)-524.3(month)]TJ
0 -1.128 TD
[(follow)-514.9(up)-506(MBI)-506.1(\(BIRADS)-513.8(3;)-505.5(7%;\),)-510.2(unless)-507.9(lost)-510.2(to)-511.6(follow-up)]TJ
T*
[(\(11.9%\).)-342.3(Among)-342.3(the)-339(38)-341.4(biopsies)-336.7(in)-340.9(33)-341.4(patients)-341.2(with)-341.8(a)-339.5(positive)]TJ
0 -1.1219 TD
[(MBI,)-384.2(32%)-380.3(were)-384.1(malignant)-384.2(and)-382.2(21%)-380.3(high)-383.5(risk)-378.9(lesions;)-384.9(the)-381.7(re-)]TJ
0 -1.128 TD
[(mainders)-258.7(were)-262.2(negative/benign)-258.4(\(including)-254.8(broadenoma)-254.9(and)-260.2(fat)]TJ
0 -1.1219 TD
[(necrosis\).)-303.4(All)-305.3(available)-301.7(follow-up)-297.7(of)-301.1(BIRADS)-304.1(3)-298.7(were)-304.9(negative.)]TJ
0 -1.128 TD
[(Among)-415.5(99)-408.5(patients)-408.3(with)-408.9(negative)-413.9(MBIs,)-413.8(none)-406.5(of)-410.8(the)-412.2(88)-408.5(with)]TJ
0 -1.1219 TD
[(available)-338.3(information)-335.9(had)-333.4(cancer)-336.2(on)-335.3(follow-up.)-334.3(Sensitivity)-338.8(and)]TJ
0 -1.128 TD
[(NPV)-536.3(were)-530.5(100%,)-532.7(specicity)-537.3(was)-529.2(88%,)-532.7(and)-534.6(PPV)-531.5(was)-529.2(33%)]TJ
0 -1.1219 TD
[(overall)-302.3(and)-302.9(39%)-301(in)-298.2(the)-302.4(subset)-300.6(of)-301.1(patients)-298.6(with)-299.2(dense)-306.2(breasts.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Conclusions:)Tj
/F4 1 Tf
5.8289 0 TD
[(Our)-345.2(initial)-343(experience)-345.9(with)-341.8(MBI)-341.5(in)-340.9(a)-345.6(commu-)]TJ
-6.8289 -1.1219 TD
[(nity)-425.7(based)-422.1(tertiary)-420(care)-423.4(breast)-423.9(center)-422.9(supports)-426.8(the)-418.3(use)-424(of)-423(this)]TJ
0 -1.128 TD
[(modality)-264.2(as)-259.4(an)-266.3(adjunct)-263.3(to)-255.5(mammography)-265(and)-260.2(ultrasound.)-260.6(In)-264.5(this)]TJ
0 -1.1219 TD
[(tertiary)-377.3(care)-374.7(setting,)-367.5(we)-371.5(found)-374.2(a)-370(similarly)-374.9(high)-365.2(sensitivity)-377.8(and)]TJ
0 -1.128 TD
[(specicity)-384.9(for)-382.7(MBI)-378.1(comparable)-383.8(to)-377.5(that)-381.1(found)-380.3(in)-383.6(the)-381.7(academic)]TJ
0 -1.1219 TD
[(and)-302.9(community)-300.7(settings.)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 62.022 749.6502 Tm
(A-24)Tj
48.6864 0 TD
(ABSTRACTS)Tj
ET
endstream
endobj
289 0 obj
<>stream
/GS1 gs
BT
/F3 1 Tf
9.2982 0 0 9.2982 59.7543 725.5557 Tm
0 0 0 rg
0 Tc
0 Tw
(64.)Tj
9.843 0 0 9.843 80.674 725.5557 Tm
[(Promoting)-284(Womens)-281.4(Rights)-283.7(to)-278.6(Reduce)-287.1(Risk)]TJ
0 -1.1174 TD
[(of)-226.8(Gender)-224.1(Based)-226.2(Violence)-232.1(Among)-220.4(Rwandan)-227.8(Women)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 59.7543 698.0029 Tm
[(Christian)-338(Dominique)-333.2(Murinda)]TJ
/F5 1 Tf
0 -1.7682 TD
[(Akwos,)-339.1(Kigali,)-332.3(Rwanda)]TJ
/F3 1 Tf
.9999 -2.3047 TD
(Background:)Tj
/F4 1 Tf
6.0972 0 TD
[(The)-493.8(government)-497.3(of)-490.1(Rwanda)-496.2(in)-499.4(consultation)]TJ
-7.0971 -1.1219 TD
[(with)-238.2(its)-229.8(development)-236.5(partners,)-231.1(civil)-234.3(society)-238.1(organization,)-232.7(private)]TJ
0 -1.128 TD
[(sectors)-276.7(and)-278.5(non-government)-274(organizations)-280.6(has)-277.7(implemented)-272(the)]TJ
0 -1.1219 TD
[(necessary)-383.2(political)-377.6(legal)-373.1(and)-376.1(institutional)-377.6(framework)-376(to)-377.5(do)-378(so.)]TJ
0 -1.128 TD
[(According)-389.6(to)-389.7(reports,)-385.5(the)-387.8(women)-389.2(and)-388.3(children)-387.6(who)-385.5(suffer)-388.4(the)]TJ
0 -1.1219 TD
[(most)-504.1(from)-498(acts)-500.9(of)-496.2(domestic)-505.8(violence)-499.2(and)-498(its)-500.4(the)-503.6(men)-497.5(who)]TJ
0 -1.128 TD
[(consistently)-431.2(abuse)-422.1(the)-424.3(authority,)-425.6(power)-428.7(and)-424.8(responsibility)-428.8(as-)]TJ
0 -1.1219 TD
[(cribed)-272.3(to)-267.7(them)-271.4(by)-268.2(Traditional)-272.6(Rwandan)-270.6(Culture.)-266.2(A)-269.7(MIGEPROF)]TJ
0 -1.128 TD
[(study)-358.3(showed)-358.4(that)-356.8(from)-351.7(20022007)-359.5(over)-354(25%)-355.9(of)-356(women)-358.7(were)]TJ
0 -1.1219 TD
[(victims)-336.5(of)-337.7(sexual)-336.2(violence,)-334.6(over)-335.7(12%)-337.6(were)-335.4(victims)-336.5(of)-337.7(physical)]TJ
0 -1.128 TD
[(violence,)-279.7(and)-278.5(over)-274.8(13%)-270.5(were)-280.5(victims)-275.5(of)-276.7(physiological)-273.5(violence.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Objective\(s\):)Tj
/F4 1 Tf
6.1094 0 TD
[(Pr)19.2(o)12.2(v)12.2(i)0(d)18.9(e)-546.8(ps)19.2(yc)20.2(ho)18.3(-s)16.8(o)12.2(c)0(i)20.7(a)0(l)-540.2(a)0(n)20.2(d)-548.7(l)12.7(e)0(g)20.2(a)0(l)-540.2(s)0(u)19.2(p)12.2(po)18.3(rt)-538.4(fo)22.1(r)]TJ
-7.1093 -1.128 TD
[(wo)16.8(m)12.8(e)0(n)-363.9(w)0(h)22.9(o)-371.9(ar)17.8(e)-370(v)0(i)18.8(c)0(t)20.7(i)0(m)19.4(s)-371.1(of)-362.1(do)18.3(m)12.8(e)0(s)15(t)12.7(ic)-363.4(v)12.2(i)0(o)18.8(l)12.7(en)14.1(c)14.1(e)0(.)-363.9(E)0(d)22.6(u)0(c)14.1(a)14.1(t)0(e)-363.4(w)0(o)16.8(m)12.8(en)]TJ
0 -1.1219 TD
[(ab)14.1(o)12.2(u)12.2(t)-194.6(t)12.7(h)12.2(ei)14.6(r)-191.4(r)0(i)22.6(g)0(h)18.3(t)12.7(s)-194.2(a)0(n)20.2(d)-189(th)18.8(os)19.2(e)-193.2(o)12.2(f)-191.4(t)0(h)18.8(e)0(i)20.7(r)-191.4(ch)14.1(i)12.7(l)0(d)18.8(r)0(e)17.8(n)12.2(.)-189(T)0(o)-184.7(i)12.7(mp)18.9(ro)22.1(ve)-187.1(wo)22.9(me)20.7(n)16(s)]TJ
0 -1.128 TD
[(li)19.4(fe)17.8(.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Material/Methods:)Tj
/F4 1 Tf
8.53 0 TD
[(With)-460.4(partnership)-462.3(between)-458.6(AKWOS)-462.6(as)]TJ
-9.5299 -1.128 TD
[(Association)-494.2(of)-484(Kigali)-491.8(Women)-489.4(in)-487.2(Sport)-486.3(and)-485.8(WE-ACTx)-491.9(con-)]TJ
0 -1.1219 TD
[(ducted)-221.2(a)-223.7(survey)-219(of)-215.7(382)-219.4(HIV)]TJ
/F2 1 Tf
11.1579 0 TD
(+)Tj
/F4 1 Tf
.939 0 TD
[(women)-218.5(who)-220.9(attend)-220.7(the)-217(WE-ACTx)]TJ
-12.0968 -1.128 TD
[(Clinic.)-257.3(The)-262.1(results)-253.7(showed)-254.7(that)-259.2(32.7%)-258.3(had)-254.1(experienced)-260.5(physical)]TJ
0 -1.1219 TD
[(violence,)-560.2(25.9%)-557.1(had)-552.9(experienced)-565.4(sexual)-555.7(domestic)-554.6(violence,)]TJ
0 -1.128 TD
[(20.7%)-368.1(had)-363.9(experienced)-364.1(sexual)-366.7(violence,)-365.1(and)-363.9(46.6%)-362(had)-363.9(expe-)]TJ
0 -1.1219 TD
[(rienced)-453.4(psychological)-455.1(violence.)-450.4(AKWOS)-450.4(designed)-452(a)-455.4(psycho-)]TJ
0 -1.128 TD
[(social)-280.8(intervention)-282.9(using)-272.9(group)-282.7(therapy)-278.4(to)-273.8(support)-281.3(these)-281.3(women)]TJ
0 -1.1219 TD
[(and)-388.3(football)-382.9(as)-387.4(a)-388.3(relaxation)-385.2(to)-383.6(them.)-387.2(AKWOS)-383.4(established)-387.2(the)]TJ
0 -1.128 TD
[(anti-gender)-455.1(based)-452.6(violence)-456.6(campaign)-456.5(trough)-446.8(womens)-457.7(soccer)]TJ
0 -1.1219 TD
(game.)Tj
/F3 1 Tf
.9999 -1.128 TD
(Results:)Tj
/F4 1 Tf
3.6644 0 TD
[(Since)-230.2(2012)-225.5(the)-229.2(reports)-226.9(of)-227.9(the)-229.2(AKWOS)-224.8(psycho-social)]TJ
-4.6644 -1.1219 TD
[(and)-601.7(judicial)-603.8(services)-604.1(teams)-604(give)-601.1(testimony)-598.6(to)-603.1(the)-601.2(positive)]TJ
0 -1.128 TD
[(changes)-383.6(of)-374.3(their)-377.4(patients.)-377.8(78%)-374.2(of)-380.3(women)-377(legalized)-381(their)-377.4(legal)]TJ
0 -1.1219 TD
[(marriage,)-406.4(and)-400.5(they)-406(have)-398.6(learned)-404.6(about)-406(reclaiming)-403(their)-401.8(rights)]TJ
0 -1.128 TD
[(with)-384.5(the)-381.7(help)-375.5(of)-380.3(legal)-385.3(services,)-384.6(and)-376.1(psycho-social)-383.9(support)-378.9(has)]TJ
0 -1.1219 TD
[(given)-418.2(these)-415.5(women)-413.6(strength)-419.1(to)-414.1(combat)-415.8(depression)-416.9(and)-412.7(stress.)]TJ
0 -1.128 TD
[(Now)-411.4(they)-406(have)-410.8(the)-406.1(condence,)-409.7(strength,)-413(security)-411.2(to)-408(build)-407.4(for)]TJ
T*
[(their)-304.2(futures.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Conclusions:)Tj
/F4 1 Tf
5.707 0 TD
[(To)-215.2(eradicate)-217.4(the)-217(Gender)-219.5(based)-214.8(violence)-218.8(must)-217.5(be)]TJ
-6.7069 -1.128 TD
[(implemented)-357.4(in)-353.1(all)-350.7(domains)-349.7(and)-357.8(multi-disciplinary)-349.3(efforts:)-356.8(ad-)]TJ
0 -1.1219 TD
[(vocacy,)-262.5(sensitization,)-264.2(community)-264.1(mobilization)-261.2(and)-266.3(education)-261.4(in)]TJ
0 -1.128 TD
[(order)-301.5(to)-304.3(create)-299.1(a)-303(culture)-302.3(of)-301.1(non-violence.)]TJ
/F3 1 Tf
0 -3.829 TD
(65.)Tj
9.843 0 0 9.843 80.674 237.4866 Tm
[(Effect)-286.3(of)-278.6(Flibanserin)-286.1(on)-278.5(the)-280.7(Pharmacokinetic)-11.7(s)]TJ
0 -1.1116 TD
[(of)-186.5(a)-191.2(Combined)-190.1(Ethinylestradiol/Levonorgestrel)-199.5(Oral)]TJ
T*
[(Contraceptive)-290.3(in)-278.6(Healthy)-280.7(Premenopausal)-284.5(Women)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 59.7543 199.0488 Tm
[(Jamie)-335.7(Noll,)-335.7(Louise)-333.8(Brown,)-331.6(James)-335.3(Yuan,)-334.9(Sam)-335.7(Spigelman)]TJ
/F5 1 Tf
0 -1.7682 TD
[(Sprout)-333.8(Pharmaceuticals,)-335.6(Division)-338.5(of)-328.7(Valeant)-334.1(Pharmaceuticals)]TJ
0 -1.128 TD
[(North)-338.6(America)-333.4(LLC,)-333.5(Bridgewater,)-335.2(New)-336.7(Jersey)]TJ
/F3 1 Tf
.9999 -2.3047 TD
(Background:)Tj
/F4 1 Tf
6.0728 0 TD
.0113 Tc
[(Flibans)11.3(e)-10.3(rin,)-464.3(approved)-464.3(b)-.9(y)-470.3(t)11.3(h)-6.4(e)-468.5(US)-467.1(Foo)11.3(d)-476.4(and)]TJ
-7.0727 -1.1219 TD
[(Drug)-232.6(Admi)11.3(n)-6.4(i)-.4(stration)-232.6(f)-3.2(o)11.3(r)-241(the)-236.8(t)-.4(reatment)-232.1(of)-234.9(acquired,)-232.6(generalized)]TJ
0 -1.128 TD
.0116 Tc
[(hypo)11.6(acti)11.6(v)-6.1(e)-260.9(s).3(ex)11.6(u)-6.6(a)1.3(l)-256.1(d)-.6(esire)-254.8(d)-.6(iso)11.6(r)-9(d)11.6(e)-10.9(r)-252.9(i)-.1(n)-256.6(p)-.6(remenopausal)-256.1(women,)-256.7(is)]TJ
0 -1.1219 TD
.0118 Tc
[(pri)11.8(m)-5.4(arily)-408.9(metabol)11.8(ized)-408.9(by)-415(cy)11.8(t)-5.9(o)-.4(chrome)-413.1(P450)-408.9(3A4)-408.9(\()-2.7(CYP3A4)11.8(\))-8.8(.)]TJ
0 -1.128 TD
.019 Tc
[(C)-4(Y)-6.9(P3A4)-590.7(is)-589.8(als)-4.5(o)-590.7(in)-5.4(vo)-5.4(lv)-5.4(ed)-584.6(i)-4.9(n)-584.6(t)-4.9(h).7(e)-588.8(m)-4.8(et)-4.9(ab)-5.4(ol)-4.9(is)-4.5(m)-584.1(o)-5.4(f)-587(e)-3.5(th)-5.4(i)-4.9(n).7(y)-5.4(l)1.2(-)]TJ
0 -1.1219 TD
.0234 Tc
[(estrad)5.1(io)5.1(l)-384.6(\()2.8(EE\),)-385.1(a)-383.2(w)3.6(id)5.1(ely)-379(u)-1(sed)-379(e).9(st)5.6(ro)5.1(ge)7(nic)-383.2(c).9(o)5.1(m)-.4(p)5.1(o)-1(n)5.1(e).9(nt)-378.5(of)-381.4(oral)]TJ
0 -1.128 TD
.022 Tc
(contraceptives.)Tj
/F3 1 Tf
.9999 -1.1219 TD
0 Tc
(Objective\(s\):)Tj
/F4 1 Tf
5.8167 0 TD
[(To)-312.7(evaluate)-314.4(the)-308.5(effect)-309.4(of)-313.3(steady-state)-308.4(levels)-311.3(of)]TJ
-6.8167 -1.128 TD
[(ibanserin)-468.9(on)-469.4(single-dose)-471.2(pharmacokinetics)-471.4(of)-465.7(EE)-473.1(and)-467.5(levo-)]TJ
0 -1.1219 TD
[(norgestrel)-303.8(\(LNG\))-302.1(in)-298.2(a)-303(combination)-298.8(oral)-304.8(contraceptive.)]TJ
/F3 1 Tf
28.0044 71.9468 TD
(Material/Methods:)Tj
/F4 1 Tf
8.3471 0 TD
[(In)-276.7(this)-278.5(open-label,)-282.1(randomized,)-275.9(two-way)]TJ
-9.347 -1.128 TD
[(crossover,)-358.8(phase)-361.1(1)-359.7(study,)-358.2(healthy)-360.9(premenopausal)-364.6(women)-358.7(were)]TJ
0 -1.1219 TD
[(randomized)-306.4(to)-310.4(receive)-311.2(a)-309.1(single)-313.2(morning)-306(dose)-308.1(\(fasting\))-308(of)-307.2(30)]TJ
/F7 1 Tf
24.6631 0 TD
(l)Tj
/F4 1 Tf
.5487 0 TD
(g)Tj
-25.2119 -1.128 TD
(EE/150)Tj
/F7 1 Tf
3.1766 0 TD
(l)Tj
/F4 1 Tf
.5487 0 TD
[(g)-414.6(LNG)-419.4(alone)-416.3(or)-416.9(after)-421.1(14)-414.6(days)-417.9(of)-410.8(ibanserin)-420.1(100)-164.5(mg)]TJ
-3.7254 -1.1219 TD
-.0128 Tc
[(once)-12.8(-)11.1(da)-12.8(i)7.9(l)-.1(y)-323.7(\()-12.8(e)5(v)-.6(ening)-329.8(dose\))-326.1(tr)-12.8(e)5(a)1.3(tme)-12.8(n)7.4(t,)-323.7(w)-12.8(i)10.6(th)-329.8(a)-321.8(4)-.6(-)-12.8(w)7.8(ee)-12.8(k)-315.7(w)-12.8(a)12(s)-12.8(h)6.4(out)-323.2(pe)-12.8(-)]TJ
0 -1.128 TD
0 Tc
[(r)15.9(i)0(o)18.8(d)-292.6(b)12.2(e)14.1(t)12.7(w)0(e)18.7(e)14.1(n)-292.6(t)0(r)22.6(e)0(a)22.1(t)12.7(m)12.8(e)0(n)20.2(t)12.7(s)13.1(.)-292.6(Pl)22.1(as)21.1(m)12.7(a)-296.9(s)13.1(a)14.1(m)12.8(p)12.2(le)20.7(s)-291.8(w)0(e)18.7(r)15.9(e)-296.9(a)0(s)21.1(s)13.1(ay)20.2(e)14.1(d)-292.6(b)12.2(y)-292.6(a)-296.9(v)12.2(a)14.1(l)0(-)]TJ
0 -1.1219 TD
[(i)12.7(d)12.2(a)14.1(t)0(e)20.7(d)-475.5(high-performance)-488.3(liquid)-486.1(chromatography-tandem)-482.9(mass)]TJ
0 -1.128 TD
[(spectrometry)-301.3(method.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Results:)Tj
/F4 1 Tf
3.6522 0 TD
[(Of)-217.2(the)-217(24)-213.3(women)-218.5(enrolled)-216.9(\(mean)-217.5(age,)-215.7(38.0)-219.4(years\),)-213.4(23)]TJ
-4.6522 -1.128 TD
[(completed)-309.7(the)-308.5(study.)-309.5(After)-308.6(single-dose)-306.6(EE/LNG)-312.7(administration)]TJ
0 -1.1219 TD
[(alone,)-550.5(the)-546.3(EE)-546.3(maximum)-550.7(plasma)-549.1(concentration)-554(\(Cmax\))-549.6(was)]TJ
0 -1.128 TD
[(64.6)-164.5(pg/mL)-262.9(and)-260.2(area)-264.9(under)-262.5(the)-259.7(plasma)-262.5(concentration-time)-266.3(curve)]TJ
0 -1.1219 TD
[(from)-613.8(time)-612.3(zero)-614.3(to)-615.3(innity)-610.9(\(AUC0-)]TJ
/F11 1 Tf
15.3161 0 TD
(N)Tj
/F4 1 Tf
.9999 0 TD
[(\))-612.1(was)-614.5(654.3)-164.5(pg)]TJ
/F12 1 Tf
6.524 0 TD
($)Tj
/F4 1 Tf
.4451 0 TD
(h/mL.)Tj
-23.2852 -1.128 TD
[(Steady-state)-470.7(levels)-475.9(of)-471.8(ibanserin)-468.9(increased)-475(the)-473.1(EE)-467(Cmax)-471.7(by)]TJ
T*
[(1.06-fold)-339.4(and)-339.5(the)-339(EE)-339(AUC0-)]TJ
/F11 1 Tf
11.7371 0 TD
(N)Tj
/F4 1 Tf
1.3353 0 TD
[(by)-341.4(1.09-fold.)-339.4(After)-339.1(single-dose)]TJ
-13.0724 -1.1219 TD
[(EE/LNG)-434.7(administration)-433.4(alone,)-434.6(the)-436.5(LNG)-431.6(Cmax)-435.1(and)-430.9(AUC0-)]TJ
/F11 1 Tf
24.7119 0 TD
(N)Tj
/F4 1 Tf
-24.7119 -1.128 TD
[(was)-565.7(4.7)-164.6(pg/mL)-567.7(and)-565.1(48.6)-164.5(pg)]TJ
/F12 1 Tf
11.7005 0 TD
($)Tj
/F4 1 Tf
.4512 0 TD
[(h/mL,)-561.6(respectively.)-571.4(Steady-state)]TJ
-12.1517 -1.1219 TD
[(levels)-299.1(of)-301.1(ibanserin)-304.3(decreased)-302.9(the)-302.4(LNG)-297.4(Cmax)-301(by)-304.8(1.02-fold)-296.7(but)]TJ
0 -1.128 TD
[(did)-231.1(not)-231.1(change)-232(the)-229.2(LNG)-236.5(AUC0-)]TJ
/F11 1 Tf
12.6151 0 TD
(N)Tj
/F4 1 Tf
.9999 0 TD
[(.)-231.7(All)-232.1(adverse)-233.5(events)-232.5(were)-231.7(mild)]TJ
-13.615 -1.1219 TD
[(to)-383.6(moderate)-385.7(in)-383.6(intensity)-385.3(\(incidence:)-383.3(12.5%)-386.4(and)-382.2(100%)-380.3(for)-388.8(EE/)]TJ
0 -1.128 TD
[(LNG)-340.1(treatment)-348.1(alone)-343.2(and)-345.6(with)-341.8(coadministration)-346.1(of)-343.8(ibanserin,)]TJ
0 -1.1219 TD
(respectively\).)Tj
/F3 1 Tf
.9999 -1.128 TD
(Conclusions:)Tj
/F4 1 Tf
5.8472 0 TD
[(Pretreatment)-369.7(of)-362.1(ibanserin)-365.2(100)-164.5(mg)-365.3(once)-368.1(daily)]TJ
-6.8471 -1.1219 TD
[(for)-333.9(2)-329.2(weeks)-338.2(did)-328.7(not)-334.8(relevantly)-336.4(change)-329.6(the)-332.9(single-dose)-337.1(pharma-)]TJ
0 -1.128 TD
[(cokinetics)-388.1(of)-380.3(EE)-387.8(or)-386.4(LNG,)-382.8(suggesting)-385.4(that)-387.2(coadministration)-388.8(of)]TJ
0 -1.1219 TD
[(ibanserin)-517.7(may)-515.8(not)-517.7(affect)-522.8(the)-521.9(exposure)-515.8(and)-516.3(efcacy)-521.9(of)-520.6(the)]TJ
0 -1.128 TD
[(contraceptive.)-436.2(However,)-440.4(the)-436.5(incidence)-436.4(of)-435.2(adverse)-434.7(events)-439.8(was)]TJ
0 -1.1219 TD
[(increased)-304.2(with)-299.2(the)-302.4(coadministration)-297.3(of)-301.1(ibanserin.)]TJ
/F3 1 Tf
0 -4.1095 TD
(66.)Tj
9.843 0 0 9.843 331.7668 404.9007 Tm
[(Musculo-Skeletal)-287.8(and)-279.4(Other)-279.6(Work)-283(Related)]TJ
0 -1.1174 TD
[(Disorders)-284.6(Among)-278(Female)-287.8(Garment)-282.9(Workers)]TJ
0 -1.1116 TD
[(in)-278.6(Ibadan,)-280.1(Southwest)-281.9(Nigeria)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 310.8472 366.4062 Tm
[(Folashade)-331(Omokhodion,)-335.6(Mary)-334.9(Balogun)]TJ
/F5 1 Tf
0 -1.7682 TD
[(University)-333.9(of)-334.8(Ibadan)-331.5(and)-335.3(University)-333.9(College)-335.1(Hospital,)]TJ
0 -1.128 TD
[(Ibadan,)-331.5(Nigeria)]TJ
/F3 1 Tf
.9999 -2.2986 TD
(Background:)Tj
/F4 1 Tf
5.957 0 TD
[(Garment)-358.7(workers)-363.1(in)-353.1(Nigeria)-358.7(are)-364.4(mostly)-357.2(self)-358.8(-)]TJ
-6.9569 -1.128 TD
[(employed.)-373(Many)-375.2(are)-382.7(women)-370.9(who)-379.4(work)-375.7(within)-377.9(their)-371.3(homes)-380.7(or)]TJ
0 -1.1219 TD
[(designated)-309.3(shops.)-303(Their)-306.6(work)-308.6(involves)-307(hand)-309(raising,)-309.4(lifting)-305.1(and)]TJ
0 -1.128 TD
[(pedaling)-415.7(and)-424.9(consequently)-419(they)-418.2(may)-418.2(suffer)-418.9(musculo-)-419.1(skeletal)]TJ
0 -1.1219 TD
[(and)-296.8(other)-304.7(work)-296.4(related)-306.5(disorders.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.8106 0 TD
[(To)-306.7(assess)-303.7(the)-308.5(work)-302.5(conditions,)-306.5(musculo-skele-)]TJ
-6.8106 -1.1219 TD
[(tal)-295.8(and)-296.8(other)-292.5(work)-296.4(related)-300.4(disorders)-299.2(of)-295(female)-294.3(garment)-302.3(workers)]TJ
0 -1.128 TD
[(in)-298.2(Ibadan,)-303.3(southwest)-301.6(Nigeria.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Material/Methods:)Tj
/F4 1 Tf
8.4385 0 TD
[(A)-367.3(cross)-370.6(sectional)-369.8(study)-370.4(design)-368.6(was)-364.5(uti-)]TJ
-9.4385 -1.128 TD
[(lized.)-354.8(Data)-356.9(on)-347.5(work)-357.4(conditions)-355.3(and)-351.7(musculo-skeletal)-356.1(disorders)]TJ
0 -1.1219 TD
[(were)-317.1(collected)-320(from)-315.1(consenting)-317.3(female)-318.7(garment)-320.6(workers)-314.3(work-)]TJ
0 -1.128 TD
[(ing)-249.4(within)-249.8(the)-253.6(catchment)-252.9(area)-258.8(of)-252.3(the)-247.5(Primary)-254.5(Health)-252.7(Care)-253.2(center)]TJ
T*
[(run)-368.1(by)-365.8(the)-369.5(University)-371.3(College)-371.7(Hospital,)-369(Ibadan.)-370.4(Permission)-371.8(to)]TJ
0 -1.1219 TD
[(conduct)-324.8(the)-332.9(study)-327.8(was)-327.9(obtained)-330.4(from)-327.3(the)-326.8(garment)-332.8(workers)-328.8(as-)]TJ
0 -1.128 TD
[(sociation.)-353.4(The)-359.6(Oyo)-355.1(State)-351.6(Ministry)-358.7(of)-356(Health)-356.3(Ethics)-357.7(committee)]TJ
0 -1.1219 TD
[(gave)-301(ethical)-303.7(approval.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Results:)Tj
/F4 1 Tf
3.8961 0 TD
[(A)-458.8(total)-459.9(of)-453.5(125)-463.3(female)-459(garment)-460.8(workers)-460.6(were)-463.4(re-)]TJ
-4.896 -1.1219 TD
[(cruited.)-210.8(Their)-209(mean)-215.1(age)-209.6(was)-212.1(26.5)]TJ
/F2 1 Tf
13.4687 0 TD
()Tj
/F4 1 Tf
.8902 0 TD
[(9.3)-207.2(years,)-211(52%)-209.6(were)-213.4(married)]TJ
-14.3589 -1.128 TD
[(and)-473.6(77%)-471.7(had)-473.6(secondary)-477.4(education)-474.8(or)-471.8(higher.)-475.4(Majority,)-473.5(95%)]TJ
0 -1.1219 TD
[(worked)-337.2(more)-341.3(than)-345.1(8)-341.4(hours)-336.7(a)-345.6(day,)-339.5(87%)-337.6(worked)-343.3(6)-341.4(days)-338.6(a)-345.6(week,)]TJ
0 -1.128 TD
[(21%)-209.6(spent)-210.1(more)-207.2(than)-210.9(3)-213.4(hours)-208.7(a)-205.4(day)-211.4(standing)-209.5(and)-211.4(58%)-209.6(spent)-210.1(more)]TJ
0 -1.1219 TD
[(than)-314.6(3)-323.1(hours)-318.5(a)-315.1(day)-321.2(sitting.)-314(Work)-323.5(activities)-320(involved)-320.1(bending)-314.5(in)]TJ
0 -1.128 TD
[(92%,)-246.1(lifting)-256.3(in)-249.4(32%,)-246.1(hand)-254.1(raising)-248.5(in)-249.4(14%)-252.2(and)-254.1(pedaling)-251.1(in)-249.4(100%.)]TJ
0 -1.1219 TD
[(Workplace)-366(hazards)-367.7(reported)-366.1(were)-365.9(noise,)-368.6(63%,)-362(vibration,)-370.7(40%,)]TJ
0 -1.128 TD
[(dust)-291.2(exposure,)-290.2(19%)-294.9(and)-290.7(exposure)-296.3(to)-292.1(moving)-291.5(parts)-291.7(of)-295(machines,)]TJ
0 -1.1219 TD
[(58%.)-441.3(Needle)-446.4(prick)-445(accidents)-447.7(were)-451.2(reported)-445.4(by)-445(81%.)-441.3(Current)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 59.7543 749.7069 Tm
(ABSTRACTS)Tj
52.6193 0 TD
(A-25)Tj
ET
endstream
endobj
294 0 obj
<>stream
hlJ@$2GZR^ʹYLvO7(=
k7=ypnÜ݊;mUM QƧ+N?O_}?8XЩXd{M5Hbf}߇Vq*3(nTuH @#4RAa1B$!џ 1um"eJNR#LXM(
[
mqq".MVs7aNaR[tx9`Bf\V+ {
endstream
endobj
296 0 obj
<>stream
hbd`ab`ddvqputvL)6176t2 Kf!#;EM67-1,83?O@@O9(3=D!F9FS@58,3H!8935/9U)LG1$(%1WG!$#U/$#('1/X$PWRXPZ UH,.)L*-ӊRSsҕ`|ԲԢTC2SRK
Rr3K@3K2KKSJӰ9bvĢļJļJlpF}fFF&t}|j~~HIku4Cg<3Eih6|{3=Vm+~'9E]ボ\W,;|'v>9E4$?EI-Kw_8.9t<@ 쐞
endstream
endobj
299 0 obj
<>stream
/GS1 gs
BT
/F4 1 Tf
9.2982 0 0 9.2982 62.022 725.5557 Tm
0 0 0 rg
0 Tc
0 Tw
[(health)-543.8(problems)-541.1(were)-548.8(low)-537.5(back)-544.9(pain,)-546.3(14%,)-538.8(other)-542.5(musculo-)]TJ
0 -1.128 TD
[(skeletal)-217.4(pain,)-217(14%,)-215.7(eye)-215.7(problems)-217.9(11%)-215.7(and)-217.5(respiratory)-214.6(symptoms)]TJ
0 -1.1219 TD
[(13%.)-325.4(The)-323(top)-328.7(three)-321.1(health)-330.4(problems)-321.6(of)-325.5(concern)-325.8(were)-329.3(low)-324.1(back)]TJ
0 -1.128 TD
[(pain)-442.6(64%,)-441.3(musculo-skeletal)-447.5(/joint)-442.9(problems,)-443.5(54%)-441.3(and)-443.1(needle)]TJ
0 -1.1219 TD
[(prick)-298.6(injuries,)-302.8(21%.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Conclusions:)Tj
/F4 1 Tf
6.3411 0 TD
[(Simple)-859(workplace)-857.2(remedies)-854.4(can)-855.9(be)-857.8(re-)]TJ
-7.341 -1.1219 TD
[(commended)-334.5(to)-334.8(reduce)-331.9(musculo-skeletal)-337.8(disorders)-329.7(in)-334.8(this)-333.4(group)]TJ
0 -1.128 TD
[(of)-349.9(workers)-357(and)-351.7(health)-348.7(services)-354.1(can)-355.9(be)-351.7(channeled)-351.5(through)-349.2(their)]TJ
0 -1.1219 TD
[(unions)-297.3(by)-298.7(building)-297.1(on)-292.6(existing)-300.4(structures)-296.8(of)-295(the)-302.4(Primary)-297.2(Health)]TJ
0 -1.128 TD
[(Care)-302(system.)]TJ
/F3 1 Tf
0 -4.1095 TD
(67.)Tj
9.843 0 0 9.843 82.9417 593.1778 Tm
[(Why)-280.7(do)-278.5(Married)-284.1(Women)-285.1(Resort)-280.3(to)-284.4(Induced)]TJ
0 -1.1116 TD
[(Abortion)-281.3(Despite)-287.1(Availability)]TJ
0 -1.1174 TD
[(of)-278.6(Free)-285.6(Contraceptive)-284.5(Services?)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 62.022 554.6833 Tm
[(Ernest)-336.2(Orji)]TJ
/F5 1 Tf
0 -1.7682 TD
[(Obafemi)-335.3(Awolowo)-333.8(University,)-340(Ile-Ife,)-331.4(Nigeria)]TJ
/F3 1 Tf
.9999 -2.3047 TD
(Background:)Tj
/F4 1 Tf
6.0484 0 TD
[(Unintended)-447.7(pregnancy)-447.7(reects)-449.3(the)-448.7(failure)-451(of)]TJ
-7.0484 -1.1219 TD
[(family)-261(planning)-259.1(programmes)-261(to)-261.6(meet)-263.4(the)-259.7(contraceptive)-259.4(needs)-263.6(of)]TJ
0 -1.128 TD
[(all)-277.5(women)-279.4(at)-284.1(risk)-275.3(especially)-282.6(married)-280.3(women.)-279.4(While)-281.7(studies)-275.7(had)]TJ
0 -1.1219 TD
[(been)-331.5(done)-327.3(in)-334.8(Nigeria)-328.2(on)-329.2(induced)-330.9(abortion,)-328.5(all)-332.4(these)-330.1(studies)-330.6(fo-)]TJ
0 -1.128 TD
[(cused)-233.1(on)-231.6(women)-230.7(generally)-233.3(or)-227.9(on)-231.6(adolescents)-233.4(or)-234(teenagers.)-231.1(There)]TJ
0 -1.1219 TD
[(is)-547.3(scarcity)-549.5(of)-551.1(studies)-544(focusing)-553.8(primarily)-543.3(on)-548.7(sexually)-549(active)]TJ
0 -1.128 TD
[(married)-438.8(women)-431.9(in)-432.3(reproductive)-436.8(age)-435.2(group.)-435.1(According)-438.4(to)-432.3(Ni-)]TJ
0 -1.1219 TD
[(gerian)-406.5(NDHS)-403.6(report)-404.6(in)-408(2013)-402.3(contraceptive)-405.8(prevalence)-406.9(among)]TJ
0 -1.128 TD
[(currently)-207.1(married)-213.2(women)-206.3(was)-212.1(15%.)-203.5(This)-213.8(is)-205.9(worrisome)-209.6(bearing)-211.3(in)]TJ
0 -1.1219 TD
[(mind)-224.5(that)-228.7(contraceptives)-228.1(are)-224.1(now)-227(provided)-225.4(free)-226.5(in)-225(Nigeria)-230.6(health)]TJ
0 -1.128 TD
(facilities.)Tj
/F3 1 Tf
.9999 -1.1219 TD
(Objective\(s\):)Tj
/F4 1 Tf
6.1582 0 TD
[(To)-654.2(understand)-655.5(why)-647.7(these)-653.3(women)-657.5(procure)]TJ
-7.1581 -1.128 TD
[(abortions)-388.6(when)-389.7(the)-387.8(means)-391.1(to)-389.7(avoid)-387.7(unwanted)-393.4(pregnancies)-389.6(are)]TJ
0 -1.1219 TD
[(available)-301.7(free)-305.8(of)-301.1(charge.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Material/Methods:)Tj
/F4 1 Tf
8.2739 0 TD
[(This)-207.7(study)-205.8(assessed)-210.3(the)-204.8(factors)-206.8(associated)]TJ
-9.2738 -1.1219 TD
[(with)-469.9(induced)-471.1(abortion)-474.9(among)-467(married)-475.4(women)-468.5(in)-475(Ife)-472.3(Central)]TJ
0 -1.128 TD
[(Local)-314.5(Government)-315.9(in)-310.4(Osun)-311.5(state,)-311.3(Nigeria.)-316(The)-310.9(study)-315.6(employed)]TJ
0 -1.1219 TD
[(both)-377.4(quantitative)-387.9(and)-376.1(qualitative)-381.8(research)-386.4(methods.)-380.2(The)-384(quan-)]TJ
0 -1.128 TD
[(titative)-286.2(study)-285.1(was)-279.2(cross-sectional)-291.6(in)-279.9(design)-283.2(and)-284.6(carried)-285(out)-286(with)]TJ
0 -1.1219 TD
[(the)-223.1(aid)-217(of)-221.8(a)-217.6(semi-structured)-223(questionnaire)-219.7(applied)-220.7(to)-218.9(402)-219.4(married)]TJ
0 -1.128 TD
[(women)-334.3(attending)-329.9(the)-332.9(primary)-330.9(health)-330.4(centres)-330.6(in)-334.8(the)-326.8(Local)-332.8(Gov-)]TJ
0 -1.1219 TD
[(ernment.)-381.5(The)-377.9(qualitative)-381.8(design)-374.6(consisted)-383.5(of)-380.3(four)-376.6(focus)-377.5(group)]TJ
0 -1.128 TD
[(discussions)-603.2(with)-604(married)-603.4(women.)-602.6(Univariate,)-600.1(bivariate)-604.7(and)]TJ
0 -1.1219 TD
[(multivariate)-286.1(analyses)-284.6(were)-280.5(done)-284.6(and)-284.6(statistical)-282.1(signicance)-285.9(was)]TJ
0 -1.128 TD
[(accepted)-313.1(at)-314.6(p)]TJ
/F2 1 Tf
5.3716 0 TD
(<)Tj
/F4 1 Tf
.5548 0 TD
[(0.05.)-310.9(The)-310.8(qualitative)-314.7(data)-312.7(was)-315.8(analysed)-309.9(and)-315.1(pre-)]TJ
-5.9265 -1.1219 TD
[(sented)-299.6(with)-305.3(Z-Y)-298.3(index)-302.4(table.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Results:)Tj
/F4 1 Tf
3.829 0 TD
[(The)-390.1(results)-387.8(showed)-394.9(that)-387.2(34.3%)-392.4(of)-386.4(the)-393.9(respondents)]TJ
-4.829 -1.1219 TD
[(have)-398.6(had)-400.5(unintended)-397.4(pregnancies)-401.8(within)-396.2(their)-401.8(marriage)-400.3(years.)]TJ
0 -1.128 TD
[(Majority)-241.8(of)-246.2(them)-240.9(\(84.1%\))-244.7(reported)-244.2(that)-240.9(they)-241.4(had)-248(one)-241.9(unintended)]TJ
0 -1.1219 TD
[(pregnancy.)-234.3(A)-233.2(major)-231(reason)-235.4(for)-236.4(having)-229.2(the)-235.3(unintended)-232.8(pregnancy)]TJ
0 -1.128 TD
[(was)-236.5(not)-237.2(using)-236.3(contraceptives)-240.3(despite)-238.1(the)-235.3(fact)-235.8(that)-240.9(majority)-236.1(of)-234(the)]TJ
T*
[(respondents)-294.9(were)-292.7(aware)-296.9(of)-295(family)-291.5(planning)-289.6(methods)-294.8(and)-290.7(where)]TJ
0 -1.1219 TD
[(they)-290.2(could)-290.2(get)-290.2(the)-290.2(methods.)-288.7(14.2%)-288.8(of)-288.9(the)-290.2(respondents)-288.8(have)-288.8(had)]TJ
0 -1.128 TD
[(one)-394.4(or)-398.6(multiple)-397.8(induced)-398(abortion)-395.6(during)-398(their)-395.7(marriage)-400.3(years.)]TJ
0 -1.1219 TD
[(Dilatation)-354.7(and)-351.7(Curettage)-347.8(was)-352.3(the)-351.2(most)-351.7(common)-350.6(method)-350.6(of)-349.9(in-)]TJ
0 -1.128 TD
[(duced)-307.1(abortion.)-304.1(The)-304.8(respondents)-307.1(with)-305.3(1)-304.8(living)-303.2(child)-308(were)-304.9(more)]TJ
0 -1.1219 TD
[(likely)-392.8(to)-395.8(have)-392.5(had)-394.4(unintended)-397.4(pregnancies)-395.7(when)-395.8(compared)-398.4(to)]TJ
0 -1.128 TD
[(the)-308.5(respondents)-307.1(who)-312.4(have)-307.1(3)-304.8(living)-309.3(children)-308.4([OR)-313.4(8.37,)-304.8(\(95%)-309.5(CI)]TJ
0 -1.1219 TD
[(2.8924.06\))-215.5(p)]TJ
/F2 1 Tf
5.5484 0 TD
(<)Tj
/F4 1 Tf
.5548 0 TD
[(0.001].)-215.6(Those)-218.5(who)-220.9(had)-217.5(never)-218(used)-216.7(contraceptives)]TJ
-6.1033 -1.128 TD
[(were)-256.1(also)-252.8(more)-249.9(likely)-252.5(to)-255.5(have)-252.2(had)-248(unintended)-257.2(pregnancies)-249.3(when)]TJ
0 -1.1219 TD
[(compared)-294.8(to)-292.1(those)-289.3(who)-294.1(had)-290.7(ever)-291.2(used)-289.8(contraceptives)-295.2([OR)-295.1(4.08,)]TJ
0 -1.128 TD
[(\(95%)-327.8(CI)-324.1(2.257.42\))-325.3(p)]TJ
/F2 1 Tf
8.9751 0 TD
(<)Tj
/F4 1 Tf
.5487 0 TD
[(0.001].)-325.4(The)-323(respondents)-325.4(who)-324.6(had)-327.3(never)]TJ
-9.5238 -1.1219 TD
[(used)-564.2(contraceptives)-563.4(were)-561(more)-560.8(likely)-563.5(to)-560.4(have)-557.1(had)-565.1(induced)]TJ
0 -1.128 TD
[(abortion)-420(when)-420.2(compared)-422.8(to)-426.2(those)-417.4(who)-422.1(had)-418.8(ever)-425.3(used)-417.9(contra-)]TJ
0 -1.1219 TD
[(ceptives)-400.8([OR)-392.6(2.91,)-396.2(\(95%)-394.8(CI)-397.3(1.346.32\))-392.4(p)]TJ
/F2 1 Tf
17.377 0 TD
(=)Tj
/F4 1 Tf
.5487 0 TD
[(0.007].)-398.5(Those)-395.3(who)]TJ
9.0726 71.9468 TD
[(have)-331.5(had)-327.3(2)-329.2(o)0(r)-325.5(more)-329.1(pregnancies)-328.6(were)-329.3(also)-325.9(more)-329.1(likely)-325.7(to)-328.7(have)]TJ
0 -1.128 TD
[(terminated)-207.9(unintended)-208.4(pregnancies)-206.7(when)-206.8(compared)-203.3(to)-206.7(those)-203.9(who)]TJ
0 -1.1219 TD
[(had)-357.8(had)-351.7(1)-353.6(pregnancy.)-350.1(The)-353.5(association)-356.7(between)-354.9(the)-351.2(fertility)-353.8(in-)]TJ
0 -1.128 TD
[(tention)-368.4(of)-362.1(the)-363.4(respondents)-368.1(and)-363.9(their)-365.2(use)-363(of)-368.2(contraceptives)-368.3(was)]TJ
0 -1.1219 TD
[(statistically)-446.1(signicant)-441.6(\(p)]TJ
/F2 1 Tf
10.475 0 TD
(<)Tj
/F4 1 Tf
.5548 0 TD
[(0.001\))-435.1(showing)-445.1(an)-443.2(unmet)-442.1(need)-441.2(for)]TJ
-11.0298 -1.128 TD
[(contraception)-352.8(among)-351.1(those)-344.2(who)-349(wish)-347.6(to)-347(delay)-349.3(their)-353(next)-345.1(birth.)]TJ
0 -1.1219 TD
[(Results)-231.7(from)-229.7(the)-229.2(qualitative)-229.4(study)-224.1(showed)-230.3(that)-228.7(the)-229.2(major)-224.9(reasons)]TJ
0 -1.128 TD
[(married)-280.3(women)-273.3(were)-280.5(not)-273.8(using)-279(contraceptives)-276.9(included)-275.5(the)-278(fear)]TJ
0 -1.1219 TD
[(of)-398.6(side)-393(effects)-400(and)-394.4(their)-395.7(husbands)-401(being)-393.8(against)-396.6(it.)-395.2(16.4%)-392.4(of)]TJ
0 -1.128 TD
[(them)-521.4(had)-522.4(abortions)-516.7(complications)-521.1(such)-521.5(as)-515.5(abdominal)-518.9(pains,)]TJ
0 -1.1219 TD
[(excessive)-252.3(vaginal)-251.2(bleeding,)-251.1(and)-248(fever)-250.9(among)-247.5(others.)-249(While)-245.1(70%)]TJ
0 -1.128 TD
[(of)-368.2(these)-366.7(women)-370.9(sought)-364.3(treatment)-366.4(in)-371.4(private)-363.3(clinics,)-371.7(30%)-362(used)]TJ
0 -1.1219 TD
(self-medications.)Tj
/F3 1 Tf
.9999 -1.128 TD
(Conclusions:)Tj
/F4 1 Tf
5.8045 0 TD
[(The)-317(study)-315.6(showed)-315.7(that)-314.1(despite)-317.4(high)-310.3(awareness)]TJ
-6.8045 -1.128 TD
[(of)-575.5(family)-571.9(planning)-570.1(methods,)-569.2(a)-571.2(high)-572.5(percentage)-571.5(of)-575.5(married)]TJ
0 -1.1219 TD
[(women)-364.8(still)-356.8(have)-362(unintended)-360.8(pregnancies)-365.2(and)-357.8(resort)-361.1(to)-365.3(having)]TJ
0 -1.128 TD
[(induced)-306.5(abortion)-298.1(though)-298.1(they)-302.4(were)-298.8(aware)-303(that)-301.9(it)-303.8(is)-297.4(illegal.)]TJ
/F3 1 Tf
0 -2.9815 TD
(68.)Tj
9.843 0 0 9.843 333.9779 530.4188 Tm
[(Return)-285.9(of)-278.6(Menstruation)-287.9(and)-279.4(Perceived)-287.6(Risk)]TJ
0 -1.1116 TD
[(of)-284.4(Pregnancy)-285(Among)-278(Women)-285.1(on)-278.5(Exclusive)-283.9(Breast)]TJ
0 -1.1174 TD
[(Feeding)-287.5(in)-278.6(Nigeria)-281.9(Community)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 313.0582 491.9243 Tm
[(Ernest)-336.2(Orji)]TJ
/F5 1 Tf
0 -1.7682 TD
[(Obafemi)-335.3(Awolowo,)-333.8(University,)-340(Ile-Ife,)-337.5(Nigeria)]TJ
/F3 1 Tf
.9999 -2.3047 TD
(Background:)Tj
/F4 1 Tf
6.1947 0 TD
[(Misconceptions)-587.5(about)-588.9(timing)-589.2(for)-583.9(return)-587.5(of)]TJ
-7.1947 -1.1219 TD
[(menstruation,)-318.6(pregnancy)-313.6(risk,)-311.9(and)-315.1(inadequate)-314.4(knowledge)-320.2(about)]TJ
0 -1.128 TD
[(effective)-575.3(use)-570.3(of)-569.4(modern)-566.9(contraceptive)-576.5(methods)-569.2(pose)-570.3(major)]TJ
0 -1.1219 TD
[(public)-423.8(health)-428(challenge)-424.2(in)-426.2(women)-419.7(of)-423(reproductive)-424.6(age)-423(in)-426.2(de-)]TJ
0 -1.128 TD
[(veloping)-301.8(countries.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.8228 0 TD
[(This)-311.4(study)-309.5(aimed)-312.1(at)-308.5(determining)-313.4(pattern)-314.5(of)-307.2(re-)]TJ
-6.8228 -1.128 TD
[(sumption)-643.7(of)-642.5(menstruation)-647.8(among)-643.8(exclusively)-644.1(breastfeeding)]TJ
0 -1.1219 TD
[(women,)-261.1(determinants)-261.9(of)-258.4(variations)-258.2(in)-261.6(the)-259.7(return)-258.3(of)-258.4(menstruation)]TJ
0 -1.128 TD
[(after)-439.4(delivery)-436.4(and)-437(perceived)-439.2(risk)-433.8(of)-435.2(pregnancy)-441.6(among)-430.4(exclu-)]TJ
0 -1.1219 TD
[(sively)-392.4(breastfeeding)-391.4(women)-389.2(within)-384(Ife)-393(Central)-386.3(Local)-387.7(Govern-)]TJ
0 -1.128 TD
[(ment)-301.9(Area,)-304.9(Osun)-299.3(State.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Material/Methods:)Tj
/F4 1 Tf
8.4934 0 TD
[(The)-420.6(study)-419.2(was)-419.4(a)-418.8(descriptive)-420.9(cross-sec-)]TJ
-9.4933 -1.128 TD
[(tional)-209.9(survey,)-212.9(employed)-208.4(both)-212.8(qualitative)-211.1(and)-205.3(quantitative)-211.1(design.)]TJ
0 -1.1219 TD
[(A)-342.9(semi-)-346(structured)-340.3(interviewer)-346.4(administered)-341.1(questionnaire)-347.7(was)]TJ
0 -1.128 TD
[(used)-228.9(to)-225(collect)-230.5(data)-227.3(for)-230.3(the)-223.1(quantitative)-229.4(study)-230.2(while)-224.1(Focus)-231.7(Group)]TJ
0 -1.1219 TD
[(Discussion)-306.8(Guide)-297.8(was)-303.6(used)-302(for)-297.3(the)-302.4(qualitative)-302.5(study.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Results:)Tj
/F4 1 Tf
4.1095 0 TD
[(Findings)-665.4(revealed)-671(that)-673.8(a)-668.8(signicant)-673.3(proportion)]TJ
-5.1094 -1.1219 TD
[(\(89.4%\))-354.5(of)-349.9(breastfeeding)-354.8(women)-352.6(in)-347(Ife)-356.4(Central)-349.7(Local)-351.1(Govern-)]TJ
0 -1.128 TD
[(ment)-533.6(effectively)-532(breastfeed)-538.3(their)-529.8(babies)-531.3(in)-529.9(line)-533.6(with)-530.9(World)]TJ
0 -1.1219 TD
[(Health)-374.6(Organization)-380.6(recommendations.)-369.6(Sixty)-373.7(seven)-373.3(percent)-374.1(of)]TJ
0 -1.128 TD
[(the)-235.3(breastfeeding)-239(women)-236.8(remained)-239.4(amenorrhoeic)-233.7(at)-235.4(sixth)-235.8(month)]TJ
0 -1.1219 TD
[(pos)13.1(t-d)16.5(eliv)15.2(er)11.8(y,)-225.6(12.)12.3(8%)-227.9(of)-221.8(the)-223.1(wom)11.3(en)-223.7(res)12.6(um)12.8(ed)-229.8(men)14.7(str)11.2(ua)14.1(tio)13.3(n)-231.7(w)0(i)11.2(thi)13.3(n)]TJ
0 -1.128 TD
[(the)-363.4(rs)14(t)-371.4(t)0(w)11.2(o)-371.9(mo)12.8(nth)12.8(s,)-364.9(14)12.3(.8)12.2(%)-374.2(r)0(e)11.7(sum)13.6(ed)-363.9(bet)14.6(wee)14.5(n)-371.9(thi)13.3(rd)-362.1(and)-363.9(fou)16(rth)]TJ
0 -1.1219 TD
[(months,)-363.8(5.4%)-355.9(resumed)-362.9(between)-361(fth)-358.3(to)-359.2(sixth)-357.8(months)-363.8(after)-360.1(de-)]TJ
0 -1.128 TD
[(livery.)-353(Seventy)-352.1(ve)-354.6(percent)-355.8(of)-349.9(the)-351.2(women)-352.6(relied)-351.1(only)-353(on)-353.6(Lac-)]TJ
T*
[(tational)-426.9(ammenorhea)-420.4(as)-417.9(a)-424.9(means)-421.6(of)-416.9(contraception)-425.9(while)-419.2(only)]TJ
0 -1.1219 TD
[(24.4%)-203.4(use)-204.5(modern)-201(contraceptive)-204.6(method)-198.1(after)-207.7(delivery.)-198.6(Forty)-199.7(six)]TJ
0 -1.128 TD
[(per)11.8(cen)16(t)-304.3(o)0(f)-301.1(t)0(h)12.8(e)-309.1(bre)17.9(ast)15.5(feed)13.7(in)12.7(g)-304.8(wom)17.4(en)-302.9(so)13.1(lel)15.1(y)-304.8(cho)14.1(se)-302.1(th)12.8(e)-303(con)14.1(tra)12.3(cep)16(-)]TJ
0 -1.1219 TD
[(tiv)13.3(e)-345.6(meth)15.2(od)-341.4(us)13.1(ed)-339.5(whi)11.3(le)-339(a)-351.7(q)0(u)12.3(a)0(r)11.7(ter)-341.4(of)-337.7(the)14.7(m)-347(mad)14.7(e)-345.6(suc)15(h)-347.5(deci)16.5(si)13.6(ons)]TJ
0 -1.128 TD
[(wit)11.8(h)-268.2(t)0(h)12.7(eir)-256(hus)13.1(ban)14.2(d)-262.1(whi)11.3(ch)-260.3(sug)13.1(ges)15(ts)-260.8(a)-266.4(h)0(i)12.7(g)0(h)-262.1(lev)14.7(el)-265.9(of)-258.4(aut)14.7(on)12.2(omy)-255.5(and)]TJ
0 -1.1219 TD
[(info)16.5(rme)12.3(d)-250(d)0(e)14.1(cisi)16(on)-243.8(mak)14.7(ing)-243.3(amo)14.7(ng)-243.8(thi)13.3(s)-249.1(cat)10.4(ego)14.1(ry)-246.2(of)-246.2(wom)17.4(en)-248(in)-243.3(thi)13.3(s)]TJ
0 -1.128 TD
[(sub)-243(re)11.8(gi)12.7(on.)-237.7(Age)-237.3(\(OR)]TJ
/F2 1 Tf
8.2617 0 TD
(=)Tj
/F4 1 Tf
.5427 0 TD
[(0.5)12.3(74)12.3(,)-250(9)0(5)12.3(%)-246.2(CI\))-241.1(and)-235.8(par)11.8(it)13.2(y)-250(\(OR)]TJ
/F2 1 Tf
12.3163 0 TD
(=)Tj
/F4 1 Tf
.5487 0 TD
[(0.)12.2(94,)-237.7(95)12.2(%)]TJ
-21.6694 -1.1219 TD
[(CI\))-204.5(of)-197.4(bre)11.8(ast)15.5(fee)13.6(din)12.8(g)-207.3(wom)17.4(en)-205.4(are)-199.8(the)-198.7(mo)12.8(st)-205.9(sig)13.6(ni)12.8(ca)13.1(nt)-206.8(de)14.1(ter)12.3(min)13.3(ant)14.6(s)]TJ
0 -1.128 TD
[(of)-209.6(res)12.6(um)12.8(pti)13.3(on)-207.2(of)-209.6(men)14.7(str)17.3(uati)15.2(on)-207.3(af)11.7(ter)-207.2(del)14.6(iv)12.7(ery)11.8(.)-213.4(Maj)15.5(ori)16.5(ties)-203.5(\(70)16(%\))-205.9(of)]TJ
0 -1.1219 TD
[(the)-278(bre)17.9(ast)15.5(fee)13.6(din)12.8(g)-280.4(wom)11.3(en)-272.4(per)11.8(cei)16.5(ved)-272.4(the)14.6(msel)16(ves)-271.6(to)-273.8(be)-278.5(at)-278(low)-275.3(ris)17.3(k)]TJ
0 -1.128 TD
[(of)-362.1(pre)11.8(gn)12.2(ancy)-355.9(an)14.1(d)-365.8(wer)10.3(e)-363.9(sim)14.1(ilar)18.9(ly)-365.3(ob)12.2(ser)12.6(ved)-357.8(to)-359.2(be)-363.9(at)-357.3(low)-360.7(ris)17.3(k)-365.8(o)0(f)]TJ
0 -1.1219 TD
[(pre)11.8(gn)12.3(ancy)-282.7(whe)12.6(n)-292.6(asse)17.7(ssed)15.9(.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Conclusions:)Tj
/F4 1 Tf
5.9692 0 TD
[(Age)-481.2(and)-479.7(parity)-481(of)-477.9(the)-485.3(breastfeeding)-482.8(women)]TJ
-6.9691 -1.1219 TD
[(were)-256.1(the)-253.6(signicant)-252.6(determinants)-255.8(of)-252.3(resumption)-254(of)-252.3(menstruation)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 62.022 749.6502 Tm
(A-26)Tj
48.6864 0 TD
(ABSTRACTS)Tj
ET
endstream
endobj
303 0 obj
<>stream
/GS1 gs
BT
/F4 1 Tf
9.2982 0 0 9.2982 59.7543 725.5557 Tm
0 0 0 rg
0 Tc
0 Tw
[(after)-360.1(delivery.)-363.2(Majority)-357.7(of)-356(the)-357.3(breastfeeding)-360.9(women)-358.7(perceived)]TJ
0 -1.128 TD
[(themselves)-387.2(to)-383.6(be)-382.2(at)-381.7(low)-385(risk)-385(of)-380.3(pregnancy)-386.7(and)-382.2(were)-384.1(similarly)]TJ
0 -1.1219 TD
[(observed)-302.4(to)-298.2(be)-302.9(at)-302.4(low)-299.7(risk)-299.7(of)-301.1(pregnancy)-301.4(when)-298.3(assessed.)]TJ
/F3 1 Tf
0 -3.579 TD
(69.)Tj
9.843 0 0 9.843 80.674 671.3573 Tm
[(OB-GYN)-282.5(Resident)-288.1(Physicians)-283.6(Recommendations)]TJ
0 -1.1116 TD
[(for)-280.9(Long)-281.7(Acting)-285(Reversible)-287.1(Contraception)]TJ
T*
[(and)-279.4(Possible)-287.3(Coercion)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 59.7543 632.9195 Tm
[(Latoya)-338.9(Patterson,)-334.8(Beverly)-331.9(Gray)]TJ
/F5 1 Tf
0 -1.7682 TD
[(Duke)-339.1(University)-333.9(Medical)-338.9(Center,)-334.8(Durham,)-331.2(North)-332.5(Carolina)]TJ
/F3 1 Tf
.9999 -2.3047 TD
(Background:)Tj
/F4 1 Tf
6.024 0 TD
[(Contraceptive)-424.6(coercion)-428.9(has)-417.9(been)-422.9(used)-424(in)-420.1(the)]TJ
-7.024 -1.128 TD
[(past)-557.6(to)-554.3(prevent)-552.8(reproduction)-554.5(in)-554.3(minorities)-557.8(and)-552.9(low)-555.8(income)]TJ
0 -1.1219 TD
[(women.)-291.6(Recommending)-289.9(long)-286(acting)-287.8(reversible)-289.7(contraception)-291.8(to)]TJ
0 -1.128 TD
[(low)-263.1(income)-257.2(and)-260.2(minority)-256.2(postpartum)-260(patients)-262(who)-257.5(do)-262.1(not)-255.5(prefer)]TJ
0 -1.1219 TD
[(these)-305.7(methods)-300.9(may)-296.3(be)-302.9(coercive.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.7679 0 TD
[(The)-262.1(purpose)-255.6(of)-258.4(this)-260.2(study)-254.6(is)-260.8(to)-255.5(test)-258.4(the)-259.7(effect)-260.6(of)]TJ
-6.7679 -1.1219 TD
[(patients)-581.4(sociodemographic)-571.3(characteristics)-580.8(and)-577.3(contraceptive)]TJ
0 -1.128 TD
[(preferences)-490.5(on)-487.7(resident)-490.4(physicians)-489.5(postpartum)-485.6(contraceptive)]TJ
0 -1.1219 TD
[(counseling)-305.1(patterns.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Material/Methods:)Tj
/F4 1 Tf
8.469 0 TD
[(We)-398.6(surveyed)-393.9(a)-400.5(national)-397(sample)-396.6(of)-398.6(258)]TJ
-9.4689 -1.1219 TD
[(obstetrics)-391.5(and)-382.2(gynecology)-385.7(resident)-386.8(physicians,)-383.5(with)-390.6(a)-382.2(3)0(0)-384.1(item)]TJ
0 -1.128 TD
[(instrument,)-338.8(each)-341.8(composed)-336.1(of)-337.7(8)-341.4(o)0(f)-331.6(3)0(2)-341.4(scenarios)-335.8(of)-337.7(postpartum)]TJ
0 -1.1219 TD
[(patients)-298.6(that)-301.9(varied)-296.7(by)-292.6(race,)-301.5(parity,)-298.1(socioeconomic)-294.7(status)-300.1(\(SES\))]TJ
0 -1.128 TD
[(and)-376.1(patients)-380.2(preferred)-375.6(form)-376(of)-380.3(contraception.)-377.2(Resident)-376.9(physi-)]TJ
0 -1.1219 TD
[(cians)-269.1(indicated)-267(which)-267.3(form)-266.3(of)-264.5(contraception)-267.4(they)-265.8(recommended)]TJ
0 -1.128 TD
[(for)-303.4(each)-299.1(patient.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Results:)Tj
/F4 1 Tf
3.9144 0 TD
[(Contraceptive)-473.3(recommendations)-479.4(that)-472.6(matched)-474.8(the)]TJ
-4.9143 -1.128 TD
[(patients)-209.4(preference)-204.8(did)-200.6(not)-200.6(differ)-205.8(by)-201.2(race,)-210(parity)-200.6(or)-203.5(SES)-202.6(\(p)]TJ
/F2 1 Tf
23.1693 0 TD
(=)Tj
/F4 1 Tf
.5487 0 TD
(0.77,)Tj
-23.7181 -1.1219 TD
(p)Tj
/F2 1 Tf
.5 0 TD
(=)Tj
/F4 1 Tf
.5548 0 TD
[(0.99,)-493.8(p)]TJ
/F2 1 Tf
2.9937 0 TD
(=)Tj
/F4 1 Tf
.5548 0 TD
[(0.48\).)-496.1(However)-501.4(when)-499.5(patients)-499.8(were)-500(unsure)-493.4(about)]TJ
-4.6034 -1.128 TD
[(contraceptive)-357(preference,)-357.2(resident)-350.2(physicians)-353(were)-353.7(more)-353.5(likely)]TJ
T*
[(to)-377.5(recommend)-379.6(long)-371.3(acting)-379.2(reversible)-381.1(contraception)-377.2(to)-377.5(patients)]TJ
0 -1.1219 TD
[(with)-262.6(higher)-255.9(parity)-255.4(\(p)]TJ
/F2 1 Tf
8.2922 0 TD
(=)Tj
/F4 1 Tf
.5548 0 TD
[(0.01\);)-257.8(though)-255.4(this)-254.1(was)-260.9(not)-255.5(associated)-263.9(with)]TJ
-8.847 -1.128 TD
[(race)-447.8(or)-441.3(SES)-440.4(\(p)]TJ
/F2 1 Tf
6.3838 0 TD
(=)Tj
/F4 1 Tf
.5548 0 TD
[(0.84,)-438.9(p)]TJ
/F2 1 Tf
2.9388 0 TD
(=)Tj
/F4 1 Tf
.5487 0 TD
[(0.12\).)-441.2(When)-441.2(patients)-444.9(preferred)-442.6(Nex-)]TJ
-10.4262 -1.1219 TD
[(planon,)-552.3(those)-557.6(residents)-556.6(who)-550.2(recommended)-554.5(Nexplanon)-558(were)]TJ
0 -1.128 TD
[(more)-298.6(like)-301.9(to)-292.1(recommend)-300.3(inpatient)-298.9(placement)-301.7(of)-295(the)-296.3(implant)-300.8(for)]TJ
0 -1.1219 TD
[(patients)-341.2(with)-341.8(increased)-340.8(parity)-340.8(and)-339.5(lower)-342.8(SES)-336.8(\(p)]TJ
/F2 1 Tf
19.6939 0 TD
(=)Tj
/F4 1 Tf
.5487 0 TD
[(0.03,)-341.3(p)]TJ
/F2 1 Tf
2.8413 0 TD
(=)Tj
/F4 1 Tf
.5487 0 TD
(0.01\))Tj
-23.6327 -1.128 TD
[(but)-304.3(not)-298.2(based)-300.1(on)-298.7(race)-301.5(\(p)]TJ
/F2 1 Tf
9.8531 0 TD
(=)Tj
/F4 1 Tf
.5548 0 TD
(0.89\).)Tj
/F3 1 Tf
-9.408 -1.1219 TD
(Conclusions:)Tj
/F4 1 Tf
5.9204 0 TD
[(Resident)-437.9(physicians)-438.4(contraceptive)-436.3(counseling)]TJ
-6.9203 -1.128 TD
[(practices)-492.8(for)-486.3(long)-487.2(active)-493.2(reversible)-484.8(contraception)-493(may)-485.3(differ)]TJ
0 -1.1219 TD
[(based)-318.4(on)-310.9(parity)-316.4(and)-309(SES.)-312.4(Unconscious)-318.4(bias)-313.7(may)-314.6(underlie)-314.5(these)]TJ
0 -1.128 TD
[(differences.)-467.5(In)-453.5(order)-460(to)-462.8(address)-460.1(the)-460.9(potential)-457.4(for)-462(coercion)-459.4(in)]TJ
0 -1.1219 TD
[(specic)-398.1(patient)-403.1(groups,)-391.6(it)-401.4(is)-394.9(important)-394.6(to)-395.8(educate)-400.3(residents)-398.1(of)]TJ
0 -1.128 TD
[(these)-305.7(differences.)]TJ
/F3 1 Tf
0 -3.573 TD
(70.)Tj
9.843 0 0 9.843 80.674 227.0551 Tm
[(Effectiveness)-290.2(of)-278.6(Intraperitoneal)-285.6(Chemotherapy)]TJ
0 -1.1116 TD
[(in)-284.4(Recurrent)-287(Ovarian)-280.8(Carcinoma:)-280.2(Toxic)-7.8(ity,)]TJ
0 -1.1174 TD
[(Survival)-286.4(Benets)-281.2(and)-279.4(Related)-287.3(Quality)-279.7(of)-278.6(Life)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 59.7543 188.5605 Tm
[(Giorgia)-336.2(Perniola,)-335.6(Cristina)-338(Don)-330.7(Francesco,)-338.1(Elisa)-333.3(Morrocchi,)]TJ
0 -1.1219 TD
[(Claudia)-335.1(Marchetti,)-335.6(Violante)-337.5(Di)-336.3(Donato,)-334.3(Innocenza)-336.1(Palaia,)]TJ
0 -1.128 TD
[(Angela)-338.5(Musella,)-334.8(Ludovico)-334.6(Muzii,)-331.5(Pierluigi)-336.5(Benedetti)-332.7(Panici)]TJ
/F5 1 Tf
0 -1.7682 TD
[(Sapienza)-338(University)-333.9(of)-334.8(Rome,)-336.7(Rome,)-330.6(Italy)]TJ
/F3 1 Tf
.9999 -2.3047 TD
(Background:)Tj
/F4 1 Tf
5.8472 0 TD
[(Up)-245.3(to)-243.3(now,)-239.2(the)-241.4(favorable)-248.4(results)-241.5(of)-246.2(randomized)]TJ
-6.8471 -1.1219 TD
[(clinical)-333.6(trials)-327.2(and)-321.2(meta-analyses)-330.9([15])-327.8(supported)-328.2(the)-326.8(use)-326.4(of)-325.5(In-)]TJ
0 -1.128 TD
[(traperitoneal)-385.1(\(IP\))-375.7(chemotherapy)-383.8(as)-375.2(rst)-381.8(line)-381.1(treatment)-378.6(in)-377.5(opti-)]TJ
0 -1.1219 TD
[(mally)-301.3(cytoreducted)-304.5(advanced)-303.3(ovarian)-302.8(cancer.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.9631 0 TD
-.018 Tc
[(The)-412.4(p).3(u)-5.8(r)4(pose)-418.5(o).3(f)-416.7(t).8(his)-413.4(s)1.2(tudy)-414.3(was)-413.4(t).8(o)-414.3(e)-3.9(valuate)-412.4(t).8(he)]TJ
-6.963 -1.1219 TD
[(effecti)-5.3(v).3(eness)-267.1(o).3(f)-264.2(i).8(nt)-5.3(raperitoneal)]TJ
12.1944 0 TD
-.0177 Tc
[(\(IP\))-270(c)2.5(hemotherapy)-261.6(i)1.1(n)-267.7(t)1.1(erms)-266.8(of)-263.9(tox-)]TJ
-12.1944 -1.128 TD
-.0181 Tc
[(i)-5.4(c)2.1(ity,)-176.6(s)-5(urvi)-5.4(val)-176.1(b).2(enets)-175.7(and)-176.6(r)3.9(elat)-5.4(ed)-176.6(quality)-176.6(of)-179(life)-174.7(\()-2.2(QoL\))-172.9(in)-176.6(a)-180.8(c)2.1(ohort)-176.1(o).2(f)]TJ
0 -1.1219 TD
[(pl)-5.5(atinum)-5.4(-sensit)-5.5(i).6(ve)-260.2(recurrent)-261.6(ovarian)-262.1(cancer)-258.3(\(ROC\))-264.4(p).1(ati)-5.5(e)2(nts.)]TJ
/F3 1 Tf
28.0044 71.9468 TD
0 Tc
(Material/Methods:)Tj
/F4 1 Tf
8.3349 0 TD
[(ROC)-273(patients)-268.1(were)-268.3(evaluated)-271.7(to)-267.7(undergo)]TJ
-9.3348 -1.128 TD
[(secondary)-404.2(cytoreduction)-403.4(and/or)-408.4(to)-401.9(receive)-408.8(chemotherapy)-402.1(with)]TJ
0 -1.1219 TD
[(endovenous)-367.1(gemcitabine)-368.2(and)-363.9(ip)-365.3(cisplatin,)-365.1(administrated)-371.1(by)-365.8(di-)]TJ
0 -1.128 TD
[(rect)-302.9(puncture)-296.7(needle,)-304.7(under)-299.1(ultrasonographic)-301.2(guidance.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Results:)Tj
/F4 1 Tf
3.9815 0 TD
[(Between)-554.8(January)-546.3(2008)-548.6(and)-546.8(December)-556.6(2014,)-542.5(57)]TJ
-4.9814 -1.128 TD
[(consecutive)-252.6(patients)-249.8(were)-250(enrolled.)-253.5(A)-251.5(total)-246.5(of)-252.3(621)-249.9(IP)-249.1(procedures)]TJ
0 -1.1219 TD
[(were)-408.5(performed,)-411.1(with)-415(a)-412.7(mean)-410.2(of)-410.8(10.9)-408.4(procedures)-412.6(per)-408.9(patient.)]TJ
0 -1.128 TD
[(Nine)-358.8(procedures)-363.9(\(1.4%\))-360.6(were)-359.8(not)-359.2(performed)-362.4(as)-363.1(a)-357.8(result)-364.3(of)-356(pa-)]TJ
0 -1.1219 TD
[(tients)-321.1(non-compliance.)-316.1(A)-318.5(specic)-325(analysis)-316.5(for)-321.7(2)-317(sub-groups)-319.9(of)]TJ
0 -1.128 TD
[(patients)-469.3(was)-474.3(conducted:)-474.8(Group)-467.1(1,)-469.4(including)-472(optimally)-470.9(cytor-)]TJ
0 -1.1219 TD
[(educed)-354(patients)-359.5(\(42)-355.9(patients;)-359(74%\))-352.2(and)-357.8(Group)-357.4(2,)-353.6(consisting)-360.5(of)]TJ
0 -1.128 TD
[(not-cytoreduced)-373.9(patients,)-365.6(undergoing)-371.7(laparoscopy)-373.1(or)-368.2(paracent-)]TJ
0 -1.1219 TD
[(esis)-221.4(\(15)-215.7(patients,)-219.3(26%\).)-224.1(There)-219.8(was)-218.2(32%)-221.8(grade)-218(2)-219.5(and)-217.5(14%)-221.8(grade)-218(3)]TJ
0 -1.128 TD
[(neutropenia;)-263.2(14%)-264.4(grade)-266.8(2)-268.2(and)-260.2(4%)-264.5(grade)-266.8(3)-268.2(anemia,)-261.5(25%)-264.4(grade)-266.8(2)]TJ
T*
[(and)-345.6(11%)-343.7(grade)-346(3)-341.4(thrombocytopenia.)-347.9(Non-hematologic)-343.4(toxicity)]TJ
0 -1.1219 TD
[(was)-376.7(mild,)-382.5(and)-376.1(procedural)-382.5(complications)-380.9(rate)-376(was)-382.8(2.9%.)-374.2(Com-)]TJ
0 -1.128 TD
[(pliance)-249.3(for)-248.6(HRQL)-253.4(assessments)-251(was)-254.8(high)-249.4(whilst)-249(patients)-249.8(were)-250(on)]TJ
0 -1.1219 TD
[(treatment)-268.9(\(range,)-263(95%)-264.4(to)-267.7(98%\).)-266.8(Patients)-264.8(optimally)-269.7(cytoreducted)]TJ
0 -1.128 TD
[(achieved)-327.1(a)-327.3(median)-330.4(OS)-327.5(of)-325.5(54)-329.2(months)-327.2(\(95%)-327.8(CI,)-324.1(875)-164.5(mo\))-331(and)-327.3(a)]TJ
0 -1.1219 TD
[(median)-263.3(DFS)-257.2(of)-264.5(19)-256(months)-260.1(\(95%)-266.8(CI,)-257(675)-164.5(mo\).)-263.9(Group)-259.8(2)-262.2(showed)]TJ
0 -1.128 TD
[(a)-296.9(median)-306(OS)-297(of)-301.1(21)-298.7(months)-302.8(\(95%)-297.3(CI,)-299.7(637)-164.5(mo\),)-300.5(p)]TJ
/F2 1 Tf
20.0963 0 TD
(<)Tj
/F4 1 Tf
.5548 0 TD
(0.001.)Tj
/F3 1 Tf
-19.6512 -1.1219 TD
(Conclusions:)Tj
/F4 1 Tf
5.8167 0 TD
[(IP)-328.3(chemotherapy)-328.9(conrmed)-330(to)-328.7(be)-327.3(feasible)-330(and)]TJ
-6.8167 -1.128 TD
[(safe)-302.5(with)-299.2(scarce)-304.8(side)-301.5(effects)-302.5(and)-296.8(good)-298.7(survival)-303.3(outcomes.)]TJ
/F3 1 Tf
0 -2.9815 TD
(71.)Tj
9.843 0 0 9.843 331.7668 467.6597 Tm
[(Contraceptive)-284.5(Initiation)-281.5(Following)-282.9(Abortion)]TJ
0 -1.1116 TD
[(and)-279.4(Risk)-281.5(of)-278.6(Subsequent)-282.9(Unintended)-284.2(Pregnancy)]TJ
0 -1.1174 TD
[(Among)-278(Insured)-285.6(Women)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 310.8472 429.1653 Tm
[(Debbie)-332.4(Postlethwaite)]TJ
6.9735 0 0 6.198 391.1243 433.3038 Tm
(1)Tj
9.2982 0 0 9.2982 394.5826 429.1653 Tm
[(,)-335.3(Justine)-330.6(Lee)]TJ
6.9735 0 0 6.198 442.9983 433.3038 Tm
(2)Tj
9.2982 0 0 9.2982 446.5132 429.1653 Tm
[(,)-329.2(Maqdooda)-336.6(Merchant)]TJ
6.9735 0 0 6.198 530.5321 433.3038 Tm
(1)Tj
9.2982 0 0 9.2982 534.0471 429.1653 Tm
(,)Tj
-24.0046 -1.1219 TD
[(Katie)-332(Alton)]TJ
6.9735 0 0 6.198 355.3511 422.8156 Tm
(3)Tj
9.2982 0 0 9.2982 358.866 418.7337 Tm
[(,)-335.3(Amy)-330.1(Alabaster)]TJ
6.9735 0 0 6.198 421.6818 422.8156 Tm
(1)Tj
9.2982 0 0 9.2982 425.1967 418.7337 Tm
[(,)-335.3(Pratima)-335.1(Gupta)]TJ
6.9735 0 0 6.198 485.518 422.8156 Tm
(4)Tj
9.2982 0 0 9.2982 488.9763 418.7337 Tm
(,)Tj
-19.1574 -1.128 TD
[(Tina)-334.7(Raine-Bennett)]TJ
6.9735 0 0 6.198 385.0015 412.3842 Tm
(1)Tj
/F5 1 Tf
-10.6337 -2.6526 TD
(1)Tj
9.2982 0 0 9.2982 314.3054 391.8046 Tm
[(Division)-265.3(of)-255.5(Research,)-262.6(Kaiser)-262.7(Permanente,)-264.4(Oakland,)-255(California)]TJ
6.9735 0 0 6.198 310.8472 385.455 Tm
(2)Tj
9.2982 0 0 9.2982 314.3054 381.3731 Tm
[(Kaiser)-335.8(Permanente,)-337.6(Vallejo,)-333.6(California)]TJ
6.9735 0 0 6.198 310.8472 375.0235 Tm
(3)Tj
9.2982 0 0 9.2982 314.3054 370.8849 Tm
[(Kaiser)-335.8(Permanente,)-337.6(Oakland,)-334.3(California)]TJ
6.9735 0 0 6.198 310.8472 364.5353 Tm
(4)Tj
9.2982 0 0 9.2982 314.3054 360.4534 Tm
[(Kaiser)-335.8(Permanente,)-337.6(San)-335.3(Francisco,)-331(California)]TJ
/F3 1 Tf
.628 -2.3047 TD
(Background:)Tj
/F4 1 Tf
5.9509 0 TD
[(Barriers)-354.1(persist)-357.4(for)-352.2(insured)-352.6(women)-352.6(as)-350.9(well)-358.3(as)]TJ
-6.9508 -1.128 TD
[(uninsured)-456.2(women)-456.3(regarding)-463.7(immediate)-455(initiation)-458.2(of)-459.6(effective)]TJ
0 -1.1219 TD
[(contraception)-218.6(post-abortion,)-219.7(thus)-211.9(putting)-217.8(them)-216.5(at)-217.1(risk)-220.4(for)-218.1(another)]TJ
0 -1.128 TD
[(unintended)-299.9(pregnancy.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.7923 0 TD
[(The)-292.6(primary)-288.2(aim)-289.7(was)-291.4(to)-286(compare)-288.7(the)-290.2(initiation)]TJ
-6.7923 -1.128 TD
[(of)-295(contraception)-297.9(within)-292.5(90)-292.6(days)-295.9(of)-295(abortion)-292(by)-292.6(type)-296.3(of)-295(abortion)]TJ
0 -1.1219 TD
[(services)-329.7(provided)-329(within)-335.2(an)-327.3(insured)-328.2(population.)-331.7(The)-329.1(secondary)]TJ
0 -1.128 TD
[(aim)-338.5(was)-346.2(to)-340.9(assess)-340.2(the)-345.1(risks)-341.5(of)-337.7(having)-345(a)-339.5(subsequent)-341.3(unintended)]TJ
0 -1.1219 TD
[(pregnancy)-386.7(\(abortion)-385.8(or)-386.4(self-reported)-391.9(at)-381.7(entry)-390.1(to)-383.6(prenatal)-391.9(care\))]TJ
0 -1.128 TD
[(within)-298.6(12)-298.7(months.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Material/Methods:)Tj
/F4 1 Tf
8.5178 0 TD
[(A)-446.6(retrospective)-451.9(cohort)-444.9(study)-443.6(was)-449.9(con-)]TJ
-9.5177 -1.128 TD
[(ducted)-251.7(on)-256(12,671)-255.9(insured)-255.1(women)-255.1(age)-252.3(1544)-256(receiving)-257.7(abortions)]TJ
0 -1.1219 TD
[(through)-574.8(Kaiser)-577.9(Permanente)-581.8(Northern)-576.8(California)-583.2(\(KPNC\))-576.1(in)]TJ
0 -1.128 TD
[(20112012.)-414.4(Randomized)-418.5(proportional)-421.8(sampling)-416.3(\(abortion)-416.2(ser-)]TJ
T*
[(vices)-409.4(provided)-402.2(within)-408.4(KPNC)-412.9(versus)-407.2(from)-406.5(contracted)-408.2(abortion)]TJ
0 -1.1219 TD
[(providers\))-308.5(was)-309.7(used)-308.1(to)-304.3(select)-315.5(the)-308.5(analytic)-309.7(cohort.)-304.7(Demographic)]TJ
0 -1.128 TD
[(and)-229.7(clinical)-230(characteristics)-239.4(\(age,)-230.2(race/ethnicity,)-234(gravidity,)-230.5(parity,)]TJ
0 -1.1219 TD
[(type)-345.1(of)-349.9(contraception)-346.7(initiated)-347.1(within)-347.4(90)-347.5(days)-344.7(of)-349.9(abortion,)-346.8(and)]TJ
0 -1.128 TD
[(evidence)-369.8(of)-368.2(an)-370(unintended)-366.9(pregnancy)-368.5(within)-365.7(12)-371.9(months\))-366.2(were)]TJ
0 -1.1219 TD
[(collected)-320(through)-312.6(electronic)-322.4(database)-320.2(extraction)-318.1(and)-315.1(physician-)]TJ
0 -1.128 TD
[(led)-418.2(medical)-425.6(record)-427.6(review.)-420.2(Analysis)-423.5(included)-421.8(descriptive)-427(sta-)]TJ
0 -1.1219 TD
[(tistics,)-396.6(chi-square)-399.9(tests)-397.7(and)-394.4(t-tests.)-399.5(Logistic)-399.8(regression)-401(models)]TJ
0 -1.128 TD
[(were)-280.5(used)-271.5(to)-279.9(assess)-279.3(predictors)-279.4(of)-276.7(contraception)-279.6(initiation)-275.3(within)]TJ
0 -1.1219 TD
[(90)-573.1(days)-570.3(post-abortion)-579.4(and)-571.2(having)-576.7(a)-571.2(subsequent)-573(unintended)]TJ
0 -1.128 TD
[(pregnancy)-301.4(within)-298.6(12)-298.7(months.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Results:)Tj
/F4 1 Tf
3.8229 0 TD
[(No)-391.7(contraception)-395.5(was)-395(initiated)-389.8(by)-390.2(38%)-392.5(of)-392.5(women)]TJ
-4.8229 -1.128 TD
[(with)-847.9(abortions)-845.9(performed)-844(within)-847.4(KPNC)-851.9(compared)-843.5(with)]TJ
0 -1.1219 TD
[(49%)-490(from)-491.9(contracted)-493.6(providers)-489.1(\(p)]TJ
/F2 1 Tf
14.5418 0 TD
(=)Tj
/F4 1 Tf
.5487 0 TD
[(0.005\).)-490(Women)-489.4(initiating)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 59.7543 749.7069 Tm
(ABSTRACTS)Tj
52.6193 0 TD
(A-27)Tj
ET
endstream
endobj
307 0 obj
<>stream
/GS1 gs
BT
/F4 1 Tf
9.2982 0 0 9.2982 62.022 725.5557 Tm
0 0 0 rg
0 Tc
0 Tw
[(short-acting)-242.2(reversible)-247(contraception)-243(\(SARC\))-244(or)-240.1(no)-243.8(method)-240.8(\(ref.)]TJ
0 -1.128 TD
[(long-acting)-679.7(reversible)-679.9(contraception)-682([LARC]\))-684.3(post-abortion)]TJ
0 -1.1219 TD
[(were)-304.9(almost)-306.6(4)-304.8(times)-300.5(as)-308.2(likely)-301.3(to)-304.3(have)-307.1(another)-302.8(unintended)-306(preg-)]TJ
0 -1.128 TD
[(nancy)-227.8(within)-225.4(12)-225.5(months)-229.7(\(OR:)-227.5(3.66,)-225.5(CI:)-226(1.489.03,)-225.4(p)]TJ
/F2 1 Tf
20.7426 0 TD
(=)Tj
/F4 1 Tf
.5487 0 TD
[(0.005;)-225(OR:)]TJ
-21.2914 -1.1219 TD
[(3.75,)-353.5(CI:)-348(1.509.36,)-347.3(p)]TJ
/F2 1 Tf
9.0787 0 TD
(=)Tj
/F4 1 Tf
.5548 0 TD
[(0.005,)-347.4(respectively\).)-354.3(There)-354(was)-352.3(no)-353.6(sig-)]TJ
-9.6336 -1.128 TD
[(nicant)-241.8(difference)-248.9(in)-237.2(unintended)-245(pregnancy)-240.4(within)-243.7(12)-243.8(months)-241.9(in)]TJ
0 -1.1219 TD
[(women)-273.3(initiating)-269.2(SARC)-275.9(versus)-273(no)-268.2(method)-271.3(\(OR:)-276.3(1.03,)-268.2(CI:)-274.8(0.63)]TJ
0 -1.128 TD
[(1.66,)-298.7(p)]TJ
/F2 1 Tf
2.7986 0 TD
(=)Tj
/F4 1 Tf
.5548 0 TD
(0.92\).)Tj
/F3 1 Tf
-2.3535 -1.1219 TD
(Conclusions:)Tj
/F4 1 Tf
5.8411 0 TD
[(Immediate)-360.3(and)-357.8(effective)-355.8(post-abortion)-353.8(contra-)]TJ
-6.841 -1.128 TD
[(ception,)-348.7(as)-344.8(an)-345.6(essential)-344.6(component)-342.5(of)-343.8(abortion)-346.8(care,)-350.3(should)-339.9(be)]TJ
0 -1.1219 TD
[(integrated)-482.8(into)-474.5(all)-484.8(abortion)-474.9(care)-484.4(settings,)-476.4(thereby)-479.6(reducing)-479.6(a)]TJ
0 -1.128 TD
[(womans)-299.2(risk)-305.8(for)-297.3(a)-303(subsequent)-298.7(unintended)-299.9(pregnancy.)]TJ
/F3 1 Tf
0 -2.9328 TD
(72.)Tj
9.843 0 0 9.843 82.9417 583.1998 Tm
[(Integrating)-284.7(Behavioral)-285.2(Health)-279.6(with)-281.7(Centralized)]TJ
0 -1.1116 TD
[(Intake)-283.7(for)-280.9(Maternal,)-281.7(Infant)-282.5(and)-279.4(Early)-284.3(Childhood)]TJ
T*
[(Home)-284.3(Visiting)-280.4(\(MIECHV\):)-286.6(Lessons)-279.9(from)-283.1(a)]TJ
0 -1.1174 TD
[(Multi-Community)-286.6(System)-279.2(Enhancement)-287.7(Pilot)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 62.022 533.7637 Tm
[(Sarah)-336.7(Price)]TJ
6.9735 0 0 6.198 105.5055 537.9022 Tm
(1)Tj
9.2982 0 0 9.2982 108.9637 533.7637 Tm
[(,)-335.3(D)0(.)-336.8(Crystal)-332.4(Coles)]TJ
6.9735 0 0 6.198 177.7322 537.9022 Tm
(2)Tj
9.2982 0 0 9.2982 181.2472 533.7637 Tm
[(,)-329.2(Nancy)-339.1(Jallo)]TJ
6.9735 0 0 6.198 231.6472 537.9022 Tm
(3)Tj
9.2982 0 0 9.2982 235.1621 533.7637 Tm
(,)Tj
-18.6208 -1.1219 TD
[(Patricia)-339.4(Kinser)]TJ
6.9735 0 0 6.198 118.4882 527.4707 Tm
(4)Tj
9.2982 0 0 9.2982 121.9464 523.3322 Tm
[(,)-335.3(Susan)-335.4(Kornstein)]TJ
6.9735 0 0 6.198 189.3543 527.4707 Tm
(5)Tj
/F5 1 Tf
-18.2594 -2.6526 TD
(1)Tj
9.2982 0 0 9.2982 65.537 506.8912 Tm
[(Virginia)-334.6(Commonwealth)-332.4(University,)-333.9(School)-338.9(of)-328.7(Social)-338.4(Work)]TJ
-.378 -1.128 TD
[(and)-335.3(Institute)-332.8(for)-333.9(Womens)-332.6(Health,)-333.8(Richmond,)-336.1(Virginia,)-334.6(USA,)]TJ
6.9735 0 0 6.198 62.022 490.1101 Tm
(2)Tj
9.2982 0 0 9.2982 65.537 485.9715 Tm
[(VCU,)-331.1(Richmond,)-336.1(Virginia,)-334.6(USA,)]TJ
6.9735 0 0 6.198 62.022 479.6219 Tm
(3)Tj
9.2982 0 0 9.2982 65.537 475.4833 Tm
[(School)-332.8(of)-334.8(Nursing,)-331.6(Institute)-332.8(for)-333.9(Womens)-332.6(Health,)-339.9(Virginia)]TJ
-.378 -1.1219 TD
[(Commonwealth)-338.5(University,)-333.9(Richmond,)-336.1(Virginia,)-334.6(USA,)]TJ
6.9735 0 0 6.198 62.022 458.7022 Tm
(4)Tj
9.2982 0 0 9.2982 65.537 454.5637 Tm
[(School)-332.8(of)-334.8(Nursing,)-331.6(Virginia)-334.6(Commonwealth)-332.4(University,)]TJ
-.378 -1.1219 TD
[(Institute)-332.8(of)-334.8(Womens)-332.6(Health,)-339.9(Virginia)-328.5(Commonwealth)]TJ
0 -1.128 TD
[(University,)-340(Richmond,)-330(Virginia,)-334.6(USA,)]TJ
6.9735 0 0 6.198 62.022 427.2944 Tm
(5)Tj
9.2982 0 0 9.2982 65.537 423.2125 Tm
[(Institute)-332.8(for)-333.9(Womens)-332.6(Health,)-333.8(Virginia)-334.6(Commonwealth)]TJ
-.378 -1.128 TD
[(University,)-340(Richmond,)-330(Virginia,)-334.6(USA)]TJ
/F3 1 Tf
.9999 -2.3047 TD
(Background:)Tj
/F4 1 Tf
5.9204 0 TD
[(Enhancing)-314.4(womens)-317.5(mental)-323.8(health)-318.2(during)-312.7(and)]TJ
-6.9203 -1.1219 TD
[(around)-360.1(the)-357.3(time)-356.2(of)-356(pregnancy)-356.3(is)-358.3(a)-357.8(public)-356.7(health)-360.9(concern.)-356.3(Uni-)]TJ
0 -1.128 TD
[(versal)-430(screening)-422(has)-430.1(been)-422.9(criticized)-431.6(for)-425.4(identication)-427.3(without)]TJ
0 -1.1219 TD
[(service)-495.2(engagement,)-497.3(particularly)-496.8(for)-492.4(low)-494.8(income)-495(women)-492.8(re-)]TJ
0 -1.128 TD
[(ceiving)-306(public)-301.8(assistance)-305.8(\(Kozhimannil)-302.7(et)-308.5(al,)-302.4(2011\).)-301(The)-304.8(Beha-)]TJ
0 -1.1219 TD
[(vioral)-389.6(Health)-392.9(Integrated)-394.2(Centralized)-394.1(Intake)-388.2(project)-393.8(is)-388.8(a)-394.4(multi-)]TJ
0 -1.128 TD
[(year)-303.4(effort)-303.4(to)-298.2(enhance)-303.3(behavioral)-300.4(health)-300(risk)-305.8(screening)-300(and)-302.9(ser-)]TJ
0 -1.1219 TD
[(vice)-404.2(utilization)-407.6(among)-406(low-income)-400.8(and)-406.6(under-resourced)-403.2(com-)]TJ
0 -1.128 TD
[(munities)-299.9(in)-304.3(Virginia.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.8411 0 TD
[(This)-335.7(study)-327.8(considers)-337.6(the)-332.9(initial)-330.8(efcacy)-339(of)-331.6(the)]TJ
-6.841 -1.128 TD
[(BH-CI)-350.9(approach)-344.1(by)-347.5(examining)-348.1(prevalence)-352(and)-345.6(patterns)-350.2(of)-349.9(risk)]TJ
0 -1.1219 TD
[(for)-394.9(perinatal)-403.5(depression,)-398.6(substance)-394.4(use,)-399.6(interpersonal)-398.9(violence)]TJ
0 -1.128 TD
[(and)-437(smoking)-430.8(in)-432.3(community)-434.8(settings)-433.7(which)-431.9(are)-437.5(points)-430.9(of)-435.2(rst)]TJ
0 -1.1219 TD
[(contact)-285.9(for)-279(home)-278(visiting)-283.5(enrollment)-282.9(\(N)]TJ
/F2 1 Tf
16.2856 0 TD
(=)Tj
/F4 1 Tf
.7134 0 TD
[(1,515\);)-282.2(and)-278.5(exploring)]TJ
-16.999 -1.128 TD
[(referral)-271.4(patterns)-264.8(for)-266.8(women)-267.2(with)-268.7(one)-266.3(or)-264.5(more)-268.1(identied)-265.7(areas)-270.1(of)]TJ
0 -1.1219 TD
[(behavioral)-300.4(health)-306(risk.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Material/Methods:)Tj
/F4 1 Tf
8.3532 0 TD
[(Initial)-278.8(identication)-281(utilized)-280.6(the)-284.1(Institute)]TJ
-9.3531 -1.1219 TD
[(for)-699.7(Health)-703.9(and)-699.2(Recovery)-702.4(\(IHR\))-702.2(Behavioral)-701.4(Health)-703.9(Risks)]TJ
0 -1.128 TD
[(Screening)-407.4(Tool)-403.7(which)-401.4(includes)-408.8(concurrent)-406.9(screening)-403.7(for)-407.1(peri-)]TJ
T*
[(natal)-409.7(depression,)-416.9(substance)-412.7(abuse,)-409.9(interpersonal)-411.1(violence,)-413.9(and)]TJ
0 -1.1219 TD
[(smoking.)-540.6(This)-537(tiered)-540.1(community)-538.5(screening)-543.9(and)-540.7(engagement)]TJ
0 -1.128 TD
[(protocol)-292(moves)-289.3(from)-290.7(initial)-294.2(risk)-293.6(identication,)-293.2(to)-292.1(application)-290.9(of)]TJ
0 -1.1219 TD
[(standardized)-462.2(screening)-464.7(instruments)-459.9(and)-455.3(nally)-463.2(to)-456.7(service)-464.7(en-)]TJ
0 -1.128 TD
[(gagement)-304.1(using)-297.3(SBIRT)-303(for)-297.3(service)-306.2(engagement.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Results:)Tj
/F4 1 Tf
3.6583 0 TD
[(During)-216.6(the)-223.1(rst)-217.2(full)-220.8(year)-218(of)-221.8(program)-221.7(implementation,)]TJ
-4.6583 -1.128 TD
[(1,515)-451.1(perinatal)-452.3(women)-450.2(participated)-456(in)-444.5(centralized)-454.6(intake)-452.4(and)]TJ
0 -1.1219 TD
[(1,409)-384(engaged)-384.4(the)-387.8(behavioral)-385.7(health)-385.3(risk)-385(screening)-391.5(\(93%)-382.6(par-)]TJ
0 -1.128 TD
[(ticipation\).)-270.2(Of)-272.1(these)-275.2(women,)-267.2(22%)-270.5(met)-271.4(risk)-269.2(triggers)-275.2(for)-266.8(perinatal)]TJ
0 -1.1219 TD
[(depression;)-343.2(11.6%)-337.6(for)-340(current)-341.8(alcohol)-336.5(or)-343.8(substance)-339.5(use,)-338.6(10.2%)]TJ
0 -1.128 TD
[(for)-218.1(current)-219.8(or)-215.7(past)-216.2(intimate)-219.1(partner)-219.8(violence,)-218.8(and)-217.5(18%)-215.7(for)-218.1(current)]TJ
0 -1.1219 TD
[(tobacco)-304.7(use.)-302(Over)-306.8(80%)-301(of)-301.1(risk-identied)-305.5(participants)-304.5(were)-304.9(suc-)]TJ
0 -1.128 TD
[(cessfully)-324.9(referred)-320.7(to)-322.6(one)-321.2(or)-319.4(more)-323(home)-320.6(visiting,)-326.2(mental)-317.7(health/)]TJ
0 -1.1219 TD
[(substance)-577.3(abuse)-580.6(treatment)-579.8(or)-575.5(community)-581.2(service)-580.6(programs.)]TJ
26.9984 71.9468 TD
[(Clusters)-404.7(of)-404.7(elevated)-399.8(risk)-403.3(were)-402.4(associated)-404.2(with)-402.8(higher)-402.3(rates)-399.6(of)]TJ
0 -1.128 TD
(referral.)Tj
/F3 1 Tf
.9999 -1.1219 TD
(Conclusions:)Tj
/F4 1 Tf
5.9448 0 TD
[(Behavioral)-457.5(health)-458.5(risk)-458.2(screening)-458.6(and)-455.3(service)]TJ
-6.9447 -1.128 TD
[(enhancement)-568.6(were)-561(able)-562.7(to)-560.4(be)-559(successfully)-559.9(implemented)-564.7(by)]TJ
0 -1.1219 TD
[(centralized)-393.6(intake)-391.4(staff)-385.5(members)-392.9(in)-383.6(standard)-393.4(community)-386.1(care.)]TJ
0 -1.128 TD
[(Rates)-273.9(of)-270.6(risk)-275.3(identication)-268.8(at)-271.9(point)-267.1(of)-270.6(rst)-272.1(contact)-273.7(are)-272.9(similar)-271.8(to)]TJ
0 -1.1219 TD
[(national)-317.7(prevalence)-315.4(estimates.)-319.7(Embedding)-309.7(screening)-318.3(into)-316(exist-)]TJ
0 -1.128 TD
[(ing)-371.3(community)-373.9(context)-367(partnering)-371.7(with)-372.3(multiple)-367.3(providers)-373.2(ap-)]TJ
0 -1.1219 TD
[(pears)-369.6(to)-365.3(be)-363.9(an)-363.9(effective)-367.9(way)-365.4(to)-365.3(immediately)-363(link)-364.7(women)-364.8(with)]TJ
0 -1.128 TD
[(supportive)-303.3(community)-300.7(interventions.)]TJ
/F3 1 Tf
0 -3.0364 TD
(73.)Tj
9.843 0 0 9.843 333.9779 603.1558 Tm
[(Factors)-287.5(Associated)-284.5(with)-281.7(Maternal)-284.1(Knowledge)]TJ
0 -1.1174 TD
[(of)-284.4(Pertussis)-283.5(and)-279.4(the)-280.7(Tdap)-281.6(Vaccine)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 313.0582 575.603 Tm
[(Denise)-337.7(Ragland,)-335.6(Kristie)-334.8(Hadden,)-332.9(Nalin)-333.8(Payakachat)]TJ
/F5 1 Tf
0 -1.7682 TD
[(University)-340(of)-334.8(Arkansas)-332.6(for)-333.9(Medical)-332.8(Sciences,)-338.5(Little)-334.2(Rock,)]TJ
0 -1.1219 TD
(Arkansas)Tj
/F3 1 Tf
.9999 -2.3047 TD
(Background:)Tj
/F4 1 Tf
6.1277 0 TD
[(In)-526.7(2013,)-530.3(the)-521.9(Centers)-532.3(for)-522.9(Disease)-530.1(Controls)]TJ
-7.1276 -1.128 TD
[(Advisory)-392.5(Committee)-388.4(on)-384.1(Immunization)-386(Practices)-392(released)-389.6(new)]TJ
0 -1.1219 TD
[(guidelines)-457(recommending)-452.2(Tdap)-451.1(\(tetanus,)-447.8(diphtheria,)-454.1(and)-449.2(per-)]TJ
0 -1.128 TD
[(tussis\))-571.8(vaccination)-570(during)-562.7(pregnancy)-569.7(regardless)-569.8(of)-569.4(previous)]TJ
0 -1.1219 TD
[(pertussis)-301.6(vaccination.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.7192 0 TD
[(This)-207.7(study)-205.8(explored)-205.2(factors)-206.8(that)-210.4(were)-207.3(associated)]TJ
-6.7191 -1.1219 TD
[(with)-347.9(knowledge)-350.7(of)-343.8(pertussis)-344.3(and)-345.6(the)-345.1(Tdap)-347.4(vaccine)-351.6(in)-340.9(pregnant)]TJ
0 -1.128 TD
(women.)Tj
/F3 1 Tf
.9999 -1.1219 TD
(Material/Methods:)Tj
/F4 1 Tf
8.4751 0 TD
-.0183 Tc
[(A)-397.8(c)-4.2(ross-sectional)-401.9(s)-5.2(urvey)-396.3(s)-5.2(tudy)-402.4(was)-401.5(c)1.9(on-)]TJ
-9.475 -1.128 TD
[(ducted)-377.9(a)-4.1(t)-377.4(a)-376(university-based)-377.9(womens)-377.1(c)2(l)-5.5(i).6(nic)-376(during)-377.9(M)1(ay-August)]TJ
0 -1.1219 TD
[(2014.)-219.4(Consented)-219.4(p).1(articipants)-218.5(took)-213.3(a)-217.5(m).6(ul)-5.5(ti-part)-212.8(electronic)-217.5(s)-5.1(urvey)-213.3(o).1(n)]TJ
0 -1.128 TD
-.0185 Tc
[(a)-205.6(t).3(abl)-5.8(e)1.7(t)-200.9(d)-.2(evi)-5.8(c)1.7(e)-199.5(w)-1.7(hile)-205.6(at)-200.9(the)-205.6(c)1.7(lini)-5.8(c)1.7(.)-201.4(T)-2(he)-199.5(survey)-201.4(consisted)-201.4(o)-.2(f)-197.7(a)-205.6(10-item)]TJ
0 -1.1219 TD
-.0191 Tc
[(a)-5(sse)-5(ssme)-5(n)-.8(t)-213.7(o)-.8(f)-216.6(h)-.8(ea)-5(lth)-214.2(l)-6.4(iterac)-5(y)-.8(,)-214.2(a)-218.4(9-i)-6.4(t)-.3(em)-219.8(pre)-5(-)2.9(te)-5(st)-213.7(a)-5(sse)-5(ssing)-220.3(participa)-5(n)-.8(t)]TJ
0 -1.128 TD
-.0182 Tc
[(knowledge)-333.4(of)-337.6(pertuss)-5.1(i).6(s)-334.4(\()-2.3(score)-333.3(r)-2.3(anges)-334.4(from)-334.7(0)-335.2(to)-335.2(9\),)-335.2(a)-4.1(nd)-335.2(ques)-5.1(tions)]TJ
0 -1.1219 TD
[(regarding)-371.7(p).2(erceptions)-370.9(of)-368(the)-369.8(v).2(accine)-369.8(and)-371.7(d).2(emographics.)-371.7(A)-373.2(Tdap)]TJ
0 -1.128 TD
-.0177 Tc
[(vaccine)-290.2(i)1.1(nformation)-285.9(s)1.5(tatem)-4.9(e)2.5(nt)-285.4(\(V)]TJ
13.0541 0 TD
-.0186 Tc
[(IS\))-289.2(w)-1.8(as)-292.1(provi)-5.9(ded)-286.9(a)-4.5(fterward.)-286.9(T)-2.1(he)]TJ
-13.0541 -1.1219 TD
-.0179 Tc
[(s)-4.8(a)2.3(me)-339.1(9-item)-334.4(knowledge)-339.1(of)-337.3(pertuss)-4.8(i)]TJ
13.8589 0 TD
-.0183 Tc
[(s)-340.6(questi)-5.6(o)6.1(ns)-340.6(were)-339.5(administered)]TJ
-13.8589 -1.128 TD
-.0179 Tc
[(after)-300.7(p).4(art)-5.2(i).9(cipants)-297.5(r)-2(eviewed)-304.4(t)]TJ
10.9201 0 TD
[(he)-302.5(VIS.)-298.3(The)-302.5(p).5(re-)-300.6(a)-3.7(nd)-298.2(post-knowledge)]TJ
-10.9201 -1.1219 TD
-.0186 Tc
[(s)-5.5(c)1.6(ores)-407.9(were)-406.9(compa)-4.5(r)3.4(e)-4.5(d)-402.7(using)-408.8(a)-406.9(paired)-408.8(t-t)-5.9(e)1.6(st.)-408.8(R)1.1(egre)-4.5(ssion)-402.7(a)-4.5(n)-.3(alys)-5.5(is)]TJ
0 -1.128 TD
-.0178 Tc
[(was)-303.5(e)2.4(mployed)-304.3(t)1(o)-304.3(e)2.4(xplore)-302.5(a)-3.7(ssoci)-5.1(ations)-303.5(between)-298.2(d).5(emographics)-303.5(and)]TJ
0 -1.1219 TD
-.0186 Tc
[(healt)-5.9(h)-299(literacy)-299(l)-5.9(e)1.6(vel)-304.6(o)-.3(n)-299(p)-.3(er)]TJ
10.4811 0 TD
-.0184 Tc
[(tuss)-5.3(is/Tdap)-298.8(knowledge.)]TJ
/F3 1 Tf
-9.4811 -1.128 TD
0 Tc
(Results:)Tj
/F4 1 Tf
3.7986 0 TD
[(A)-355.1(total)-362.3(of)-356(279)-359.7(pregnant)-357.7(women)-358.7(participated)-364.5(in)-353.1(the)]TJ
-4.7985 -1.1219 TD
[(study.)-291.2(The)-286.5(participants)-288.6(average)-293.5(age)-288.8(was)-285.3(26.4)-286.5(years)-290.3(\(SD)]TJ
/F2 1 Tf
22.834 0 TD
(=)Tj
/F4 1 Tf
.5487 0 TD
(5.69\).)Tj
-23.3827 -1.128 TD
[(27%)-343.7(of)-337.7(the)-339(study)-340(population)-343.9(had)-339.5(adequate)-339.3(health)-342.6(literacy.)-342.6(The)]TJ
T*
[(average)-476.4(post-test)-478.7(knowledge)-472.6(scores)-472.4(were)-475.6(signicantly)-477.6(higher)]TJ
0 -1.1219 TD
[(than)-241.4(pre-test)-236.7(scores)-234.6(\(6.4)-234(vs.)-236.9(4.2,)-237.7(p)]TJ
/F2 1 Tf
13.3711 0 TD
(<)Tj
/F4 1 Tf
.5487 0 TD
[(0.001\).)-233.9(Higher)-239.1(health)-239(literacy)]TJ
-13.9199 -1.128 TD
[(scores)-222.4(\(p)]TJ
/F2 1 Tf
3.5486 0 TD
(<)Tj
/F4 1 Tf
.5548 0 TD
[(0.001\),)-215.6(advanced)-211.8(education)-218.7(levels)-219.8(\(p)]TJ
/F2 1 Tf
14.5601 0 TD
(=)Tj
/F4 1 Tf
.5548 0 TD
[(0.001\),)-215.6(and)-211.4(later)]TJ
-19.2183 -1.1219 TD
[(gestational)-241.2(age)-234(\(p)]TJ
/F2 1 Tf
7.0484 0 TD
(=)Tj
/F4 1 Tf
.5548 0 TD
[(0.004\))-227.8(were)-237.8(positively)-232.8(associated)-239.5(with)-232.1(higher)]TJ
-7.6032 -1.128 TD
[(pertussis/Tdap)-252.2(pre-test)-242.8(knowledge)-247(scores.)-246.7(Higher)-245.2(health)-245.1(literacy)]TJ
0 -1.1219 TD
[(scores)-319.9(\(p)]TJ
/F2 1 Tf
3.6522 0 TD
(=)Tj
/F4 1 Tf
.5487 0 TD
[(0.029\))-319.3(and)-315.1(older)-316.9(age)-313.2(\(p)]TJ
/F2 1 Tf
9.5848 0 TD
(=)Tj
/F4 1 Tf
.5487 0 TD
[(0.041\))-319.3(were)-317.1(associated)-318.8(with)]TJ
-14.3345 -1.128 TD
[(improved)-304.1(knowledge)-301.9(scores.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Conclusions:)Tj
/F4 1 Tf
5.707 0 TD
[(Providing)-211.3(information)-220.1(about)-210.9(Tdap)-219.4(vaccine)-217.4(via)-217(a)]TJ
-6.7069 -1.128 TD
[(VIS)-476.2(signicantly)-477.6(increased)-475(maternal)-476.7(knowledge)-472.6(of)-471.8(pertussis/)]TJ
0 -1.1219 TD
[(Tdap)-432.8(vaccination.)-429.7(Health)-435.6(literacy)-427.9(played)-428.5(a)-431(signicant)-429.4(role)-432.8(in)]TJ
0 -1.128 TD
[(pa)14.1(rt)22.6(ic)20.7(ip)18.8(an)20.2(ts)19.7()-203.6(l)0(e)14.6(a)14.1(rn)16(i)12.7(n)0(g)-195(i)12.7(n)-207.3(o)12.2(u)12.2(r)-203.6(sa)15(m)12.7(p)12.2(le)14.6(.)-201.2(C)0(o)19.7(u)12.2(ns)19.2(el)20.7(in)18.9(g)-207.3(p)12.2(re)17.8(g)12.2(n)12.2(a)0(n)20.2(t)-206.8(wo)22.9(me)14.7(n)12.2(,)]TJ
0 -1.1219 TD
[(es)15(p)12.2(e)0(c)16(i)12.7(al)20.7(ly)-231.1(th)18.8(o)12.2(s)0(e)-228.9(w)0(i)17.3(t)0(h)-231.1(l)12.7(im)19.4(it)19.3(ed)-229.8(h)12.2(e)0(a)16(l)12.7(th)-231.1(l)12.7(i)0(t)19.3(e)0(r)17.8(a)0(c)16(y)12.2(,)-237.8(a)0(b)20.2(o)0(u)18.3(t)-237.3(pe)20.2(rt)16.5(u)12.2(s)0(s)20(i)0(s)19.7(/)0(T)17(d)12.2(ap)]TJ
0 -1.128 TD
[(ha)14.1(s)-285.7(t)0(h)18.8(e)-290.8(p)12.2(o)0(t)18.8(e)0(n)20.2(t)0(i)19.3(a)0(l)-284.1(t)12.7(o)-292.6(i)12.7(mp)18.9(ro)22.1(ve)-284.6(v)12.2(a)0(c)16(c)14.1(in)18.8(at)14.6(i)12.7(o)12.2(n)-292.6(r)0(a)17.8(t)12.7(es)-283.8(i)12.7(n)-292.6(t)12.7(h)0(i)18.8(s)-291.8(p)12.2(o)12.2(p)0(u)18.3(l)0(a)20.7(t)0(i)19.3(o)0(n)18.3(.)]TJ
/F3 1 Tf
0 -3.0364 TD
(74.)Tj
9.843 0 0 9.843 333.9779 122.4567 Tm
[(BRCA1)-285.6(Mutations)-282.4(in)-278.6(Women)-285.1(with)-281.7(HGSOC)]TJ
0 -1.1116 TD
[(and)-285.2(TNBC:)-280(Molecular)-286.5(Players)-281.9(that)-280.6(Drive)]TJ
0 -1.1174 TD
[(Transformation)-290.1(as)-278.5(Potential)-283(Therapeutic)]TJ
0 -1.1116 TD
(Targets)Tj
/F4 1 Tf
9.2982 0 0 9.2982 313.0582 73.0205 Tm
[(Alexus)-339.6(Footman,)-329(Veena)-337.2(Rao)]TJ
/F5 1 Tf
0 -1.7682 TD
[(Morehouse)-338.1(School)-332.8(of)-334.8(Medicine,)-330.8(Atlanta,)-335.5(Georgia)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 62.022 749.6502 Tm
(A-28)Tj
48.6864 0 TD
(ABSTRACTS)Tj
ET
endstream
endobj
311 0 obj
<>stream
/GS1 gs
BT
/F3 1 Tf
9.2982 0 0 9.2982 69.0519 725.5557 Tm
0 0 0 rg
0 Tc
0 Tw
(Background:)Tj
/F4 1 Tf
5.9326 0 TD
[(African)-331.1(American)-332.4(women)-328.2(have)-325.4(a)-333.4(higher)-329.1(mor-)]TJ
-6.9325 -1.128 TD
[(tality)-404.5(rate)-406.5(of)-404.7(triple)-401.3(negative)-407.8(breast)-405.6(cancer)-403.2(\(TNBC\))-407.6(than)-406(other)]TJ
0 -1.1219 TD
[(ethnic)-232.9(groups.)-233.1(High)-226.5(grade)-230.2(serous)-230.3(ovarian)-235.7(cancers)-231.6(\(HGSOC\))-230.1(also)]TJ
0 -1.128 TD
[(have)-233.9(higher)-231.5(mortality)-235.5(rates)-234.9(in)-231.1(AA)-234.6(women)-230.7(than)-229.2(that)-234.8(of)-234(Caucasian)]TJ
0 -1.1219 TD
[(Americans)-471.7(\(CA\).)-468.1(Women)-471.1(who)-470.9(carry)-470.4(a)-467.6(germline)-466.4(mutation)-471.5(in)]TJ
0 -1.128 TD
[(BRCA1)-289.9(gene)-288.8(typically)-286.7(develop)-288.2(TNBC)-287.1(and)-284.6(HGSOC.)-286.3(Our)-284.3(group)]TJ
0 -1.1219 TD
[(has)-308.2(previously)-303.3(cloned)-306.6(several)-306.2(BRCA1)-308.2(isoforms)-300.6(which)-310(function)]TJ
0 -1.128 TD
[(as)-375.2(tumor)-367.1(suppressors)-371.1(of)-368.2(TNBC)-372.4(and)-370(ovarian)-369.9(cancers.)-378(We)-368.1(have)]TJ
0 -1.1219 TD
[(found)-343.7(WT)-347.4(BRCA1)-344.8(isoforms)-343.3(unlike)-338.4(the)-345.1(disease-associated)-349.7(mu-)]TJ
0 -1.128 TD
[(tant)-210.4(to)-206.7(bind)-206.7(a)-211.5(novel)-204.8(protein)-212.7(Ubc9.)-206.8(These)-210.5(mutant)-209.8(BRCA1)-204.6(proteins)]TJ
0 -1.1219 TD
[(have)-301(lost)-302.9(their)-298.1(capacity)-308.3(to)-298.2(function)-298.1(as)-302.1(tumor)-300(suppressors.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.7984 0 TD
[(This)-293.1(study)-291.2(is)-291.3(based)-294(on)-292.6(the)-290.2(hypothesis)-293.9(that)-289.7(lack)]TJ
-6.7984 -1.1219 TD
[(of)-264.5(association)-265.3(of)-264.5(Ubc9)-261.7(with)-268.7(BRCA1)-259.4(in)-267.7(patients)-262(with)-262.6(TNBC)-268.8(and)]TJ
0 -1.128 TD
[(HGSOC)-536.3(results)-528.1(in)-529.9(deregulated)-536.2(levels)-530.8(of)-532.8(Ubc9)-530(which)-529.5(could)]TJ
T*
[(triggers)-305.7(migration)-297(and)-302.9(distant)-300.5(metastasis)-300.5(of)-301.1(tumor)-300(cells.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Material/Methods:)Tj
/F4 1 Tf
8.5726 0 TD
[(The)-506(methods)-502.1(used)-503.2(in)-499.4(this)-504.1(study)-504.6(were)]TJ
-9.5726 -1.128 TD
[(tissue)-318.4(culture,)-314.5(immunouorescence)-316.2(analysis,)-316.5(western)-315.7(blot)-309.9(anal-)]TJ
0 -1.1219 TD
[(ysis,)-394(RT)-390.6(PCR)-390.3(analysis,)-389.7(siRNA)-390.4(analysis,)-395.8(migration)-388.5(assays)-389.9(and)]TJ
0 -1.128 TD
[(ECIS)-304.4(assays.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Results:)Tj
/F4 1 Tf
3.8534 0 TD
.0139 Tc
[(In)-412.9(t)-3.9(h)1.7(i)-3.9(s)-412(s)-3.5(t)-3.9(udy)-419(we)-417.1(hav)-4.4(e)-411(u)-4.4(s)2.6(ed)-419(phy)-4.4(s)-3.5(i)2.2(o)-4.4(l)2.2(o)-4.4(g)1.7(i)-3.9(c)3.6(al)-3.9(ly)-419(rele-)]TJ
-4.8534 -1.128 TD
.0154 Tc
[(vant)-234.1(patient)-234.1(d)-2.9(erived)-234.6(cell)-234.1(lines)]TJ
12.4139 0 TD
.0141 Tc
[(w)-5.7(h)1.9(i)-3.7(c)3.8(h)-242(h)1.9(arbo)-4.2(r)-238.2(B)3.3(RCA1)-235.9(m)-3.6(ut)-3.7(ati)-3.7(o)1.9(n)-4.2(s)]TJ
-12.4139 -1.1219 TD
.299 Tc
[(a)282.6(n)280.7(dr)284.5(e)282.6(p)280.7(o)286.8(r)284.5(t)-5.3(i)287.3(n)-5.8(v)286.8(i)281.2(v)286.8(oa)282.6(s)281.6(s)281.6(o)286.8(c)282.6(i)287.3(a)282.6(t)281.2(i)287.3(o)280.7(no)280.7(fB)282.1(R)288.2(C)282.1(A)285.3(1)-5.8(a)282.6(n)286.8(dU)279.2(b)286.8(c)282.6(9i)281.2(nn)280.7(o)286.8(r)284.5(m)281.3(a)282.6(l)]TJ
0 -1.128 TD
.0128 Tc
[(m)-4.9(a)-3.6(mm)-4.9(ary)-212.8(e)-3.6(pi)-5(th)-5.5(el)-5(i)-5(a)2.5(l)-212.3(cel)-5(ls)-211.9(b)-5.5(u).6(t)-212.3(n).6(o)-5.5(t)-212.3(in)-212.8(B)-4.1(R)-4.1(C)2(A)-7(1)-206.7(m)-4.9(u).6(t)-5(a)-3.6(nt)-212.3(TN)-7(B)-4.1(C)-211.4(an)-5.5(d)]TJ
0 -1.1219 TD
.0137 Tc
[(H)-6.1(G)0(SOC)-362.9(cell)-4.1(s)-363.4(by)-364.3(im)-4(m)-4(uno)-4.6(uo)-4.6(r)-.8(es)]TJ
13.7187 0 TD
.017 Tc
[(cenc)6.7(e)-359.1(analys)5.7(is.)-354.9(BRC)6.2(A1)-354.9(mu-)]TJ
-13.7187 -1.128 TD
[(tan)4.9(t)-311.6(TNBC,)-306(HGSOC)-310.7(a)6.8(nd)-306(ov)4.9(arian)-306(t)5.4(um)5.5(or)-308.4(t)5.4(i)-.7(ss)5.8(ue)-304.1(sho)4.9(w)3.4(ed)-306(hi)5.4(gh)4.9(er)]TJ
0 -1.1219 TD
.0151 Tc
[(levels)-441.3(of)-438.4(Ubc9)-442.2(compared)-442.2(to)-442.2(norma)4.8(l)-441.7(cells)-441.3(and)-442.2(t)-2.7(issues)-441.3(using)]TJ
0 -1.128 TD
.0141 Tc
[(w)-5.7(e)-2.3(st)-3.7(ern)-315.1(b)-4.2(lo)-4.2(t)-320.7(/)2.4(RT)-317(PCR)-319.8(a)-2.3(nal)-3.7(y)1.9(s)-3.3(i)2.4(s)-3.3(.)-321.2(Furt)-3.7(herm)-3.6(ore)-319.3(w)-5.7(e)-319.3(h)1.9(av)-4.2(e)-319.3(kno)-4.2(ck-)]TJ
0 -1.1219 TD
.0175 Tc
[(do)5.3(wn)-256.8(Ubc)7.2(9)-262.9(ex)5.3(pres)6.2(si)5.8(on)-256.8(us)6.2(in)5.3(g)-262.9(s)6.2(iR)]TJ
13.6028 0 TD
.0153 Tc
[(NA)-260.5(in)-259(thes)4(e)-263.3(cells)-264.3(and)-259(s)-2.1(tudied)]TJ
-13.6028 -1.128 TD
.0167 Tc
[(th)4.5(e)-457(p)4.5(ro)4.5(liferat)5(io)4.5(n)-452.8(a).3(n)4.5(d)-452.8(m)5.1(i)-1.1(g)4.5(r)-3.9(a)6.4(tio)]TJ
12.8651 0 TD
.0153 Tc
[(n)-454.2(u)3.1(sing)-448.1(electric)-452.3(cell)-453.7(s)-2.1(ubs)4(t)-2.5(rate)]TJ
-12.8651 -1.1219 TD
.0168 Tc
[(im)5.2(ped)4.6(a).4(nc)6.5(e)-304.4(s)5.5(ens)5.5(i)-1(n)4.6(g)-300.2(\(ECIS\))-296.5(ass)5.5(a).4(y.)]TJ
/F3 1 Tf
.9999 -1.128 TD
0 Tc
(Conclusions:)Tj
/F4 1 Tf
5.9874 0 TD
[(Our)-497.7(results)-497.6(demonstrate)-500.2(for)-492.4(the)-497.5(rst)-497.7(time)-496.5(a)]TJ
-6.9874 -1.1219 TD
[(physiological)-450.4(link)-450.1(between)-452.5(BRCA1)-448.4(mutation,)-447.1(high)-450.6(Ubc9)-450.7(ex-)]TJ
0 -1.128 TD
[(pression,)-235.9(increased)-231.1(growth)-228.8(and)-229.7(migration)-229.9(of)-234(TNBC)-232.2(and)-229.7(HGSOC)]TJ
0 -1.1219 TD
[(cells.)-238.1(These)-234.9(studies)-239.1(suggest)-233.5(Ubc9)-237.3(to)-231.1(be)-235.9(a)-235.9(major)-237.1(player)-235.8(in)-231.1(driving)]TJ
0 -1.128 TD
[(cancer)-537.4(cell)-537.8(migration)-534.8(and)-534.6(tumor)-531.7(metastasis)-538.3(implicating)-529.5(this)]TJ
0 -1.1219 TD
[(pathway)-612.9(as)-606.9(a)-607.8(potential)-609.8(therapeutic)-608.9(target)-613.3(in)-609.2(BRCA1linked)]TJ
0 -1.128 TD
[(TNBC)-305.4(and)-296.8(HGSOC.)]TJ
/F3 1 Tf
0 -4.0546 TD
(75.)Tj
9.843 0 0 9.843 80.674 311.244 Tm
[(Recent)-287.2(Violence)-284(Against)-279(Homeless)-289.6(and)-279.4(Unstably)]TJ
0 -1.1116 TD
[(Housed)-285(Women:)-280.5(Addressing)-284.2(Unique)-284.8(Findings)]TJ
0 -1.1174 TD
[(to)-284.4(Improve)-281.5(Health)-279.6(Care)-284.1(Delivery)-284.1(in)-284.4(Areas)]TJ
0 -1.1116 TD
[(of)-284.4(High)-276.3(Poverty)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 59.7543 261.8078 Tm
[(Elise)-339.4(Riley,)-331(Jennifer)-334.8(Cohen,)-338.1(Kelly)-333.8(Knight,)-329.6(Kara)-335.4(Marson,)]TJ
0 -1.128 TD
[(Alyson)-335.3(Decker,)-339.5(Martha)-332.4(Shumway)]TJ
/F5 1 Tf
0 -1.7682 TD
[(University)-340(of)-334.8(California,)-330.9(San)-335.3(Francisco,)-331(California)]TJ
/F3 1 Tf
.9999 -2.2986 TD
(Background:)Tj
/F4 1 Tf
5.8838 0 TD
[(Poverty)-283.2(and)-278.5(psychiatric)-286.8(disorders)-280.9(are)-279(linked)-283.5(to)]TJ
-6.8837 -1.128 TD
[(gender-based)-502.2(violence)-493.1(and)-498(violence)-499.2(predicts)-496.5(missed)-495.2(medical)]TJ
T*
[(appointments)-456.5(among)-454.8(women,)-456.3(yet)-454.8(contextual)-456(information)-451.8(that)]TJ
0 -1.1219 TD
[(could)-302.4(aid)-302.4(in)-298.2(prevention)-302.2(and)-296.8(treatment)-305.5(planning)-301.8(is)-297.4(sparse.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.8228 0 TD
[(We)-313.2(determined)-318.1(correlates)-318.3(of)-313.3(violence)-310.2(that)-314.1(dif-)]TJ
-6.8228 -1.1219 TD
[(ferentiated)-349.1(perpetrators)-340.8(\(primary)-345.5(partner)-341.8([PP])-339.6(and)-339.5(non-primary)]TJ
0 -1.128 TD
[(partner)-335.7([non-PP]\),)-332.1(and)-333.4(violence)-334.6(types)-332(\(emotional,)-337.8(physical)-335.6(and)]TJ
0 -1.1219 TD
[(sexual\))-302(among)-302.3(homeless)-304.3(and)-296.8(unstably)-300.9(housed)-302(women.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Material/Methods:)Tj
/F4 1 Tf
8.6031 0 TD
[(A)-477(p)12.2(ro)16(b)12.2(a)0(b)20.2(i)0(l)19.3(i)12.7(ty)-468.9(sa)15(m)12.8(p)12.2(le)-473.2(o)12.2(f)-477.9(ho)18.3(m)12.8(e)0(l)14.6(e)0(s)21.1(s)-480.8(an)20.2(d)]TJ
-9.6031 -1.1219 TD
[(un)18.3(st)19.7(ab)20.2(ly)-298.2(h)12.2(o)12.2(u)0(s)19.2(e)0(d)-296.8(w)0(o)22.9(m)0(e)14.6(n)-304.8(wa)24.8(s)-310.1(r)0(e)23.9(c)0(r)17.8(u)0(i)18.8(t)0(e)20.7(d)-304.8(fr)19.7(om)-298.2(S)15.5(a)0(n)-296.8(F)0(r)19.2(a)0(n)20.2(c)0(i)20.7(s)0(c)15(o)-304.8(c)14.1(o)0(m)18.9(-)]TJ
0 -1.128 TD
[(mu)18.9(n)12.2(i)0(t)19.3(y)-189(ve)20.2(nu)18.3(es)21.1(.)-189(S)0(t)16(u)12.2(d)12.2(y)-189(pa)20.2(rt)16.5(i)12.7(c)0(i)14.6(p)12.2(an)20.2(t)12.7(s)-194.2(c)14.1(o)0(m)18.9(p)12.2(le)14.6(t)12.7(e)0(d)-181(i)12.7(nt)18.8(er)17.8(v)12.2(i)0(e)14.6(w)0(s)-177.4(r)0(e)17.8(g)12.2(ar)17.8(d)12.2(i)0(n)18.8(g)]TJ
0 -1.1219 TD
[(so)19.2(ci)14.6(o)12.2(d)12.2(e)0(m)20.8(o)0(g)18.3(r)0(a)17.8(p)12.2(hi)18.8(c)-168.8(f)0(a)17.8(c)0(t)20.7(o)12.2(rs)-160(an)20.2(d)-170.7(v)12.2(i)12.7(o)0(l)18.8(e)0(n)20.2(c)0(e)16(;)-170.2(p)12.2(s)13.1(yc)14.1(h)12.2(i)12.7(at)14.6(ri)22.6(c)-168.8(d)12.2(is)19.7(or)16(d)12.2(e)0(r)17.8(s)-163.7(we)18.7(re)]TJ
0 -1.128 TD
[(as)15(s)13.1(e)0(s)15(s)13.1(ed)-242(u)12.2(s)0(i)19.7(n)0(g)-243.8(t)12.7(h)12.2(e)-254.2(Di)23.4(ag)14.1(n)12.2(o)12.2(s)0(t)19.7(i)0(c)-241.5(I)0(n)16(t)12.7(er)17.8(v)12.2(i)0(e)20.7(w)-251.5(Sc)17.3(h)12.2(e)0(d)20.2(u)0(l)18.8(e)0(-)17.8(I)0(V)20.6(.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Results:)Tj
/F4 1 Tf
3.7315 0 TD
[(Among)-299.6(291)-292.6(women,)-297.7(the)-296.3(mean)-294.4(age)-294.9(was)-297.5(40)-298.7(and)-290.7(90%)]TJ
-4.7314 -1.128 TD
[(screened)-329.2(positive)-324.8(for)]TJ
/F2 1 Tf
8.6702 0 TD
.0577 Tc
(=>)Tj
/F4 1 Tf
1.2194 0 TD
0 Tc
[(1)-329.2(mental)-323.8(illness.)-324(Violence)-330(experienced)]TJ
-9.8896 -1.1219 TD
[(included)-440.1(emotional)-439.1(violence)-438.3(perpetrated)-441.1(by)-432.8(PPs)-437.7(and)-437(non-PPs)]TJ
27.0045 71.9468 TD
[(\(24%)-321.7(PP)-316.7(vs.)-322.2(50%)-319.3(non-PP,)-325(p)]TJ
/F2 1 Tf
11.5298 0 TD
(<)Tj
/F4 1 Tf
.5487 0 TD
[(0.01\),)-319.3(physical)-323.4(violence)-322.4(\(11%)-321.7(PP)]TJ
-12.0785 -1.128 TD
[(vs.)-328.3(19%)-325.4(non-PP,)-325(p)]TJ
/F2 1 Tf
7.6337 0 TD
(=)Tj
/F4 1 Tf
.5548 0 TD
[(0.01\))-325.4(and)-327.3(sexual)-330.1(violence)-328.5(\(7%)-327.8(PP)-328.8(vs.)-328.3(22%)]TJ
-8.1885 -1.1219 TD
[(non-PP,)-239.7(p)]TJ
/F2 1 Tf
3.9266 0 TD
(<)Tj
/F4 1 Tf
.5548 0 TD
[(0.01\).)-240(The)-243.8(odds)-242.9(of)-240.1(PP)-243.5(and)-241.9(non-PP)-239.7(violence)-249.3(increased)]TJ
-4.4814 -1.128 TD
-.0148 Tc
[(with)-380.6(each)-374.5(additional)-380.1(ps)4.4(ychiatric)-378.7(d)]TJ
13.6089 0 TD
-.0144 Tc
[(iagnosis)-373.3(and)-374.1(d)-2.2(ecreasing)-374.1(l)-1.7(evels)]TJ
-13.6089 -1.1219 TD
-.0148 Tc
[(of)-376.9(social)-374(is)4.4(olation)-374.5(acr)-14.8(o)13.4(s)-1.7(s)-373.7(v)-2.6(iolence)-372.6(t)-2.1(ypes)-373.7(\()-14.8(p)]TJ
/F2 1 Tf
17.1636 0 TD
0 Tc
(<)Tj
/F4 1 Tf
.5366 0 TD
-.0125 Tc
[(0.)5.8(05)5.8(*\).)-372.2(T)4(he)-370.3(od)5.8(ds)-371.4(of)]TJ
-17.7001 -1.128 TD
.0122 Tc
[(ph)12.2(y)-6(s).9(ical)-353.1(vio)12.2(l)-5.5(en)12.2(ce)-357.8(fro)12.2(m)-359.1(a)-357.8(n)12.2(o)-6(n)0(-PP)-356.5(w)4.6(ere)-351.7(h)0(igh)12.2(e)-10.3(r)-349.9(a)1.9(mong)-347.5(perso)12.2(n)-6(s)]TJ
0 -1.1219 TD
.0113 Tc
[(reporting)-574(u)11.3(n)-6.9(m)-.3(et)-573.5(subsis)11.3(t)-5.6(e)-5.1(n)11.3(c)-5.1(e)-578.2(n)-.9(eeds)-573.2(\()2.9(Adju)11.3(s)-6.1(t)-.4(ed)-574(Odd)11.3(s)-585.3(Ratio)11.3(n)]TJ
0 -1.128 TD
.0088 Tc
[([A)-4.9(OR])]TJ
/F2 1 Tf
2.823 0 TD
0 Tc
(=)Tj
/F4 1 Tf
.5609 0 TD
.0114 Tc
[(2.3)11.4(0)-6.8(*)-.8(\),)-378.8(wh)11.4(i)-6.3(l)-.3(e)-383(t)-.3(h)11.4(e)-389.1(od)11.4(d)-6.8(s)-377.9(of)-381.2(sex)11.4(u)-6.8(al)-384.4(v)11.4(i)-6.3(olence)-376.9(from)-378.3(a)-376.9(P)-3.6(P)]TJ
-3.3839 -1.1219 TD
.0118 Tc
[(in)11.8(c)-10.7(r)3.4(eased)-299.1(with)-299.1(age)-297.3(\()3.4(AOR)]TJ
/F2 1 Tf
10.5177 0 TD
0 Tc
(=)Tj
/F4 1 Tf
.5609 0 TD
.0121 Tc
[(1.)12.1(1)-6.1(1)-298.8(per)-301.2(y)12.1(ear*\).)]TJ
/F3 1 Tf
-10.0787 -1.128 TD
0 Tc
(Conclusions:)Tj
/F4 1 Tf
5.957 0 TD
[(All)-469.9(types)-472.2(of)-471.8(violence)-474.8(were)-469.5(more)-475.4(commonly)]TJ
-6.9569 -1.1219 TD
[(perpetrated)-477.6(by)-481.6(persons)-480.3(who)-477(were)-481.7(not)-475(primary)-483.3(partners,)-475(sug-)]TJ
0 -1.128 TD
[(gesting)-490(that)-497(a)-492(sole)-490.5(focus)-493.4(on)-493.8(domestic)-493.6(violence)-493.1(screening)-495.1(in)]TJ
0 -1.1219 TD
[(health)-251.2(care)-252.7(settings)-250.8(may)-247.5(inadvertently)-250.5(miss)-253.3(most)-248(of)-246.2(the)-253.6(violence)]TJ
0 -1.128 TD
[(in)-255.5(this)-260.2(population.)-264.6(In)-258.4(addition,)-258.6(the)-259.7(odds)-261.2(of)-258.4(violence)-261.5(increased)-267.7(as)]TJ
T*
[(social)-244.2(isolation)-251.1(decreased,)-248(which)-242.9(is)-248.6(inconsistent)-248.3(with)-244.3(some)-246.6(prior)]TJ
0 -1.1219 TD
[(studies.)-409.8(Contrary)-409.3(to)-408(ndings)-409.9(in)-408(the)-412.2(general)-410.7(population,)-411(social)]TJ
0 -1.128 TD
[(isolation)-391.4(may)-393.8(be)-394.4(protective)-397.4(for)-394.9(women)-395.3(in)-395.8(impoverished)-392.3(com-)]TJ
0 -1.1219 TD
[(munities)-464.5(with)-457.7(high)-462.8(levels)-463.7(of)-465.7(psychiatric)-463.6(co-morbidity.)-457.8(These)]TJ
0 -1.128 TD
[(ndings)-214.8(may)-210.9(have)-215.7(applicability)-216.6(to)-212.8(settings)-214.2(in)-212.8(which)-212.4(violence)-218.8(and)]TJ
0 -1.1219 TD
[(mental)-299.4(health)-300(are)-303.4(not)-298.2(routinely)-303.6(assessed.)]TJ
/F3 1 Tf
0 -3.0364 TD
(76.)Tj
9.843 0 0 9.843 331.7668 498.5574 Tm
[(Female)-282(Condom)-278.9(Provides)-288.6(a)-277.6(Non-Hormonal)-282.3(Dual)]TJ
0 -1.1174 TD
[(Protection)-280.6(Option)-284.1(for)-280.9(Female)-282(Contraception)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 310.8472 471.0046 Tm
[(Brooke)-334.3(Faught,)-329.6(Irwin)-334.9(Goldstein,)-338.5(Mark)-328.8(Martens,)]TJ
0 -1.1219 TD
[(Kelli)-333.3(Rodriguez,)-338(Lisa)-333.9(Levin)]TJ
/F5 1 Tf
0 -1.7682 TD
[(The)-330.2(Female)-340.4(Health)-333.8(Company,)-333.4(Chicago,)-331.4(Illinois,)-334.7(USA)]TJ
/F3 1 Tf
.9999 -2.3047 TD
(Background:)Tj
/F4 1 Tf
6.0423 0 TD
[(Use)-437.7(of)-441.3(male)-440.2(condoms)-441.7(for)-437.6(contraception)-444.2(and)]TJ
-7.0423 -1.128 TD
[(STI)-494.8(protection)-490.7(can)-496.1(be)-491.9(associated)-495.6(with)-494.3(a)-498.1(lack)-489.5(of)-496.2(control)-493.2(for)]TJ
0 -1.1219 TD
[(women,)-413.6(as)-417.9(well)-419.2(as,)-417.9(decreased)-418.7(pleasure)-415.9(for)-419.3(them,)-417.7(their)-414(sexual)]TJ
0 -1.128 TD
[(partners,)-298.2(and)-296.8(negative)-304.1(reactions)-299.5(to)-298.2(latex.)-300(With)-295.8(the)-302.4(recent)-301(report)]TJ
0 -1.1219 TD
[(from)-302.9(the)-308.5(CDC)-309.6(warning)-306.2(that)-308(STIs)-307.3(are)-309.5(at)-308.5(epidemic)-309.7(levels.)-305.2(What)]TJ
0 -1.128 TD
[(options)-296.7(are)-303.4(out)-298.2(there)-302.9(for)-303.4(women?)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.8472 0 TD
[(The)-341.3(objective)-346.3(of)-337.7(this)-339.5(study)-340(was)-346.2(to)-340.9(survey)-340.9(and)]TJ
-6.8471 -1.128 TD
[(interview)-260.6(women)-261.2(with)-262.6(regard)-256.9(to)-261.6(use)-259.4(of)-264.5(the)-259.7(only)-255.5(FDA)-261.9(and)-260.2(WHO)]TJ
0 -1.1219 TD
[(approved)-199.6(class)-207.3(III)-202.2(medical)-206.1(device,)-201(the)-204.8(FC2)-202.6(Female)-203.4(Condom.)-199.1(The)]TJ
0 -1.128 TD
[(FC2)-281.9(has)-283.8(the)-284.1(dual)-290.2(indication)-280.6(for)-285.1(preventing)-283.9(pregnancy)-289.2(and)-284.6(HIV/)]TJ
0 -1.1219 TD
[(AIDS)-300.8(and)-296.8(other)-304.7(STIs.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Material/Methods:)Tj
/F4 1 Tf
8.2983 0 TD
[(This)-232.1(study)-230.2(involved)-234.7(an)-229.8(online)-234.8(survey)-231.2(and)]TJ
-9.2982 -1.1219 TD
[(was)-297.5(conducted)-304.6(on)-298.7(two)-299.7(all)-295.8(women)-303.8(audiences.)-301.9(The)-298.7(rst)-302.6(audience)]TJ
0 -1.128 TD
[(were)-500(condoms/short)-503(term)-499.3(hormonal)-505.3(contraceptive)-503.3(users)-498.6(who)]TJ
0 -1.1219 TD
[(volunteered)-263.7(to)-261.6(switch)-265.9(to)-261.6(FC2)-263.6(during)-263.9(a)-260.3(6-month)-263.3(trial)-267.1(period.)-262(The)]TJ
0 -1.128 TD
[(second)-263.5(audience)-260.1(was)-260.9(independent)-267.5(online)-259.1(purchasers)-265.4(of)-258.4(the)-265.8(FC2.)]TJ
0 -1.1219 TD
[(Nineteen)-452(came)-451(from)-449.2(the)-448.7(focus)-450.7(group)-447.3(participants)-457(and)-449.2(15)-451.1(re-)]TJ
0 -1.128 TD
[(sponses)-300.3(came)-298.6(from)-302.9(the)-302.4(independent)-298(purchasers.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Results:)Tj
/F4 1 Tf
3.8534 0 TD
-.0176 Tc
[(Res)-4.5(p).7(o)-5.4(ndent)-4.9(s)-419.1(i)-4.9(dent)-4.9(ied)-420(as)-425.2(67%)-422.3(Cau)-5.4(c)-3.5(as)-4.5(ian,)-420(9)-5.4(%)-416.2(H)-17.6(i)11.9(s)-4.5(-)]TJ
-4.8534 -1.128 TD
-.017 Tc
[(pani)-4.3(c)-320(o)-4.8(r)-324.2(L)-.5(ati)-4.3(no,)-327.9(9%)-324.2(Black,)-321.8(6)-4.8(%)-324.2(A)-.2(meri)-4.3(can)-327.9(I)-1.1(ndi)-4.3(an)-327.9(or)-324.2(Al)-4.3(askan)-327.9(N)-.2(a-)]TJ
0 -1.1219 TD
-.0173 Tc
[(ti)-4.6(ve,)-468.5(6)1(%)-464.7(A)-17.3(s)12.6(i)-4.6(an)-468.5(and)-468.5(3)-5.1(%)-464.7(d)1(i)-4.6(d)-468.5(not)-468(want)-468(t)-4.6(o)-468.5(iden)-5.1(ti)-4.6(fy.)-468.5(I)-1.4(ndep)-5.1(e)2.9(n)-5.1(d)1(ent)]TJ
0 -1.128 TD
-.0171 Tc
[(purch)-4.9(as)-4(ers)-235.7(w)-.3(ere)-240.8(a)3.1(g)-4.9(e)-234.7(2)-4.9(56)-4.9(4,)-236.6(and)-242.7(f)-1.2(ocus)-235.7(g)-4.9(r)-1.2(oup)-236.6(r)-17.1(e)12.9(s)-4(p)1.2(o)-4.9(ndent)-4.4(s)-235.7(w)-.3(ere)-240.8(a)-3(ge)]TJ
T*
-.0168 Tc
[(22)-4.6(45.)-327.7(Th)-4.6(irt)-4.1(y)1.5(-t)-4.1(wo)-327.7(percen)-4.6(t)-327.2(w)0(ere)-325.9(s)-3.7(ing)-4.6(l)2(e,)-327.7(59%)-330.1(were)-325.9(i)-4.1(n)-327.7(a)-325.9(l)2(o)-4.6(n)1.5(g)-327.7(t)2(erm)]TJ
0 -1.1219 TD
-.0178 Tc
[(relati)-5.1(ons)-4.7(hi)-5.1(p,)-219(and)-219(9)-5.6(%)-215.2(w)-17.8(e)13.1(r)-1.9(e)-223.2(m)1(arri)-5.1(ed)-5.6(.)-219(O)-1(f)-221.3(t)1(he)-223.2(qu)-5.6(es)-4.7(ti)-5.1(on)-5.6(s)-218.1(a)-3.7(sked)-5.6(,)-219(w)-1(om)-5(en)]TJ
0 -1.128 TD
[(respo)-5.5(nded)-316.4(p)-5.5(os)-4.6(it)-5(ivel)-5(y)-316.4(t)1.1(o)-5.5(,)-316.4()53.1()-1.8(Ov)-5.5(er)-17.7(a)12.3(l)-5(l)-315.9(h).6(o)-5.5(w)-317.9(well)-322(did)-322.5(you)-316.4(l)-5(i)1.1(k)-5.5(e)-314.6(t)-5(h).6(e)-320.7(F)-2.3(C2)]TJ
0 -1.1219 TD
-.0173 Tc
[(female)-381.2(co)-5.1(ndo)-5.1(m?)53.5()-379.4(\(7)-5.1(1%\);)-382.6(pos)-4.2(it)-4.6(iv)-5.1(el)-4.6(y)-383.1(o)1(r)-379.4(n)-5.1(eu)-5.1(trall)-4.6(y)-377(t)-4.6(o)1(,)-383.1()53.5(Ho)-5.1(w)-378.5(easy)]TJ
0 -1.128 TD
[(was)-284.8(i)1.4(t)-291.2(t)1.4(o)-285.6(u)-5.2(se)-289.9(the)-289.9(F)-2(C2)-285.6(fem)-4.6(a)2.8(l)-4.7(e)-283.8(co)-5.2(ndo)-5.2(m?)53.4()-288(\(82)-5.2(%)4.7(\))-17.4(.)-275.8(Amo)-5.2(n).9(g)-285.6(a)-3.3(tt)-4.7(ribu)-5.2(tes)]TJ
0 -1.1219 TD
-.0166 Tc
[(respo)-4.4(nden)-4.4(t)2.2(s)-412(a)-2.5(greed)-412.9(w).2(i)-3.9(t)2.2(h)-406.8(w)-16.6(e)14.3(r)-.7(e:)-412.4()54.2(Is)-412(an)-406.8(effect)-3.9(iv)-4.4(e)-411(f)-.7(orm)-406.3(o)-4.4(f)-409.2(c)-2.5(ont)-3.9(ra-)]TJ
0 -1.128 TD
-.017 Tc
[(cep)-4.8(t)1.8(i)-4.3(on)47.7()-403.5(\()-1.1(8)-4.8(5)1.3(%\);)-406.7()53.8(A)-17(l)12.5(l)-4.3(owed)-407.2(me)-411.4(to)-407.2(t)-4.3(a)-2.9(ke)-405.3(co)-4.8(ntro)-4.8(l)-406.7(o)1.3(f)-409.6(m)1.8(y)-407.2(o)-4.8(wn)-407.2(pro)-4.8(-)]TJ
0 -1.1219 TD
-.016 Tc
[(tection)48.7()-225.7(\()-16(7)12.2(9)2.3(%\);)-228.9()48.7(M)3.2(ade)-233.6(m)2.8(e)-233.6(f)-.1(eel)-228.9(protected)54.8()-231.7(\(71%\);)-228.9()54.8()-.1(Made)-233.6(me)-233.6(fe)4.2(el)]TJ
0 -1.128 TD
-.0157 Tc
[(good)-637.6(a)-1.6(bout)-637.1(my)-637.6(contraceptive)-641.8(ch)]TJ
14.0113 0 TD
-.0153 Tc
[(oice)55.5(\(65%\);)-636.7()55.5(Improved)-637.2(the)]TJ
-14.0113 -1.1219 TD
-.0173 Tc
[(feel)-4.6(in)-5.1(g/p)-5.1(l)1.5(easu)-5.1(r)-1.4(e)-491(o)-5.1(f)-489.1(s)-4.2(ex)53.5()-495.2(\(21)-5.1(%)-489.1(w)-17.3(i)12.2(t)-4.6(h)-492.9(32%)-495.2(neut)-4.6(ral\);)-492.4()47.4(Fel)-4.6(t)-492.4(m)1.6(o)-5.1(r)-1.4(e)]TJ
0 -1.128 TD
[(natu)-5(ral)-291(f)-1.3(o)-5(r)-293.9(m)-4.5(y)-291.5(p)-5(a)-3.1(rtner)-300(t)1.6(han)-297.6(m)1.7(al)-4.5(e)-295.8(c)-3.1(ond)-5(om)47.5()-293.9(\(41)-5(%)-1.2(\);)-297.1(an)-5(d)-297.6()53.6(All)-4.5(ow)-17.2(e)13.7(d)]TJ
0 -1.1219 TD
-.0169 Tc
[(sp)-4.7(ont)-4.2(aneit)-4.2(y)1.4()53.9()-433.9(\(4)-4.7(7%\).)-431.5(Fo)-4.7(rty-s)-3.8(e)-2.8(ven)-431.5(p)-4.7(ercent)-437.1(o)1.4(f)-433.9(s)-3.8(urv)-4.7(e)3.3(y)-437.6(r)-1(espo)-4.7(nden)-4.7(t)1.9(s)]TJ
0 -1.128 TD
-.0178 Tc
[(report)-5.1(e)-3.7(d)-304.3(p).5(u)-5.6(r)-1.9(ch)-5.6(asi)-5.1(n).5(g)-304.3(F)-2.4(C)-4.2(2)-304.3(m)-5(u).5(l)-5.1(tip)-5.6(le)-308.6(t)-5.1(i)1(m)-5(e)2.4(s)-4.7(,)-304.4(4)-5.6(7).5(%)-306.7(w)-1(o)-5.6(u).5(ld)-310.4(buy)-310.4(it)-309.9(again)]TJ
0 -1.1219 TD
-.0137 Tc
[(wi)5.1(th)4.6(in)-294.1(6)-300.2(m)5.1(on)4.6(t)5.1(h)-1.5(s)5.5(,)-300.3(an)4.6(d)-300.2(8)4.6(2)4.6(%)-296.5(w)-13.7(o)]TJ
11.9017 0 TD
-.0153 Tc
[(uld)-295.7(r).6(ecommend)-301.8(i)3.5(t)-301.3(t)3.5(o)-301.8(o)3(thers.)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 59.7543 749.7069 Tm
0 Tc
(ABSTRACTS)Tj
52.6193 0 TD
(A-29)Tj
ET
endstream
endobj
315 0 obj
<>stream
/GS1 gs
BT
/F3 1 Tf
9.2982 0 0 9.2982 71.3197 725.5557 Tm
0 0 0 rg
0 Tc
0 Tw
(Conclusions:)Tj
/F4 1 Tf
5.9996 0 TD
[(While)-507.3(barrier)-514.9(contraceptives)-508.6(are)-516.8(most)-504.1(often)]TJ
-6.9996 -1.128 TD
[(used)-350.8(by)-347.5(males,)-347.9(the)-345.1(FC2)-349(Female)-349.7(Condom)-345.5(offers)-351.8(an)-345.6(internal)-350.6(fe-)]TJ
0 -1.1219 TD
[(male)-220.7(condom)-216.9(that)-216.5(provides)-218.4(a)-217.6(non-hormonal,)-214.9(latex)-220.7(free)-220.4(option)-212.2(for)]TJ
0 -1.128 TD
[(dual)-460.9(protection)-460.2(against)-457.6(HIV/STIs)-464.5(and)-461.4(unplanned)-458.9(pregnancy.)]TJ
0 -1.1219 TD
[(This)-488.2(study)-480.2(indicated)-486.5(a)-485.9(positive)-483.3(acceptance)-492.2(by)-481.6(a)-485.9(majority)-486(of)]TJ
0 -1.128 TD
[(women,)-224.6(and)-223.6(counseling)-219.7(regarding)-225.9(its)-223.7(indications)-224.8(and)-223.6(availability)]TJ
0 -1.1219 TD
[(should)-297.3(be)-302.9(provided)-298.6(in)-304.3(discussions)-298.3(with)-299.2(female)-306.5(patients.)]TJ
/F3 1 Tf
0 -3.1035 TD
(77.)Tj
9.843 0 0 9.843 82.9417 633.94 Tm
[(Negotiating)-284.9(the)-280.7(Divide:)-280.5(Gender)-287.5(and)-279.4(Salary)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 62.022 617.499 Tm
[(Theresa)-339(Rohr-Kirchgraber)]TJ
6.9735 0 0 6.198 161.348 621.6376 Tm
(1)Tj
9.2982 0 0 9.2982 164.8629 617.499 Tm
[(,)-335.3(Paul)-329.6(Kirchgraber)]TJ
6.9735 0 0 6.198 234.9354 621.6376 Tm
(2)Tj
9.2982 0 0 9.2982 238.4503 617.499 Tm
[(,)-335.3(Tisha)-333.8(Reid)]TJ
6.9735 0 0 6.198 285.3354 621.6376 Tm
(1)Tj
9.2982 0 0 9.2982 288.7936 617.499 Tm
(,)Tj
-24.3888 -1.1219 TD
[(Teri)-337.1(Duell)]TJ
6.9735 0 0 6.198 101.4236 611.2061 Tm
(1)Tj
/F5 1 Tf
-5.6502 -2.6526 TD
(1)Tj
9.2982 0 0 9.2982 65.537 590.6266 Tm
[(IU)-333.1(National)-332.3(Center)-334.8(of)-334.8(Excellence)-336.9(in)-334.8(Womens)-332.6(Health,)]TJ
-.378 -1.128 TD
[(Indianapolis,)-335.1(Indiana)]TJ
6.9735 0 0 6.198 62.022 573.8455 Tm
(2)Tj
9.2982 0 0 9.2982 65.537 569.7069 Tm
[(Covance)-334.3(Central)-336.2(Labs,)-331.2(Indianapolis,)-335.1(Indiana)]TJ
/F3 1 Tf
.6219 -2.3047 TD
(Background:)Tj
/F4 1 Tf
5.9874 0 TD
[(With)-387.2(the)-381.7(passing)-386(of)-386.4(the)-387.8()52.5(Equal)-385.8(Pay)-385(Act)53.5()-386.5(o)0(f)]TJ
-6.9874 -1.128 TD
[(1963,)-451.1(women)-450.2(understood)-450.1(that)-448.2(there)-449.2(would)-452.1(no)-451.1(longer)-451(be)-449.3(two)]TJ
0 -1.1219 TD
[(different)-368(pay)-370(scales)-370.1(for)-370.5(the)-369.5(same)-366.7(job,)-371.3(but)-365.3(alas)-372.8(pay)-370(differences)]TJ
0 -1.128 TD
[(along)-302.4(gender)-297.2(lines)-301(still)-301.9(exists.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.774 0 TD
[(According)-273.8(to)-267.7(the)-265.8(Status)-267.3(of)-270.6(Women)-263.8(report)-270.5(card,)]TJ
-6.774 -1.128 TD
[(Indiana)-315(received)-323.4(a)-315.1()52.5(D)54.8()-313.3(i)0(n)-316.5(employment)-317.1(and)-315.1(earnings.)-320.2(In)-313.3(medi-)]TJ
0 -1.1219 TD
[(cine,)-385.9(the)-381.7(median)-385.3(income)-385.3(of)-386.4(young)-384(female)-385.8(physicians)-383.5(is)-382.7(about)]TJ
0 -1.128 TD
[($18,000/year)-266.1(less)-270.2(than)-271.9(their)-267.6(male)-269.5(counterparts.)-265.2(In)-270.6(one)-266.3(academic)]TJ
0 -1.1219 TD
[(study,)-266.8(a)-260.3(woman)-267.2(physician)-262.4(was)-267(found)-264.4(to)-261.6(earn)-266.8(over)-268.7($360,000)-262(less)]TJ
0 -1.128 TD
[(in)-304.3(her)-305.3(30-year)-311.8(career)-308.1(than)-302.4(a)-309(man)-302.4(working)-308.1(the)-308.5(same)-305.7(hours,)-306.2(with)]TJ
0 -1.1219 TD
[(the)-302.4(same)-299.6(qualications.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Material/Methods:)Tj
/F4 1 Tf
8.5666 0 TD
[(To)-501.8(overcome)-502.1(this)-498(obstacle)-504.5(and)-498(to)-499.4(in-)]TJ
-9.5665 -1.1219 TD
[(crease)-426.8(understanding)-423.2(of)-423(the)-424.3(problem)-426.1(with)-421.1(potential)-426.9(solutions,)]TJ
0 -1.128 TD
[(the)-308.5(IU)-290.4(Na)18.7(t)12.7(i)12.7(o)12.2(na)20.2(l)-298.2(C)0(e)21.6(n)12.2(te)20.7(r)-301.1(o)12.2(f)-301.1(E)0(x)22.6(c)14.1(el)20.7(le)20.7(n)12.2(c)0(e)-288.9(i)0(n)-292.1(W)14.1(o)12.2(m)0(e)20.8(n)12.2(s)-288(He)18.7(al)20.7(t)12.7(h)-298.7(\(I)19.7(UN)21.4(-)]TJ
0 -1.1219 TD
[(CO)18.2(E\))-376.1(al)20.7(o)12.2(n)12.2(g)-390.2(wi)17.3(t)12.7(h)-390.2(t)12.7(h)12.2(e)-394.4(A)0(m)23.5(e)14.1(ri)16.5(c)14.1(a)0(n)-382.2(M)13.1(ed)20.2(i)12.7(c)0(a)16(l)-383.6(Wo)20.2(me)20.7(n)12.2()0(s)-379.5(A)0(s)17.7(s)13.1(o)12.2(c)0(i)20.7(a)0(t)20.7(i)12.7(on)]TJ
0 -1.128 TD
[(\(A)20.6(M)13.1(W)0(A)18.7(\))-313.3(h)12.2(a)0(s)-302.1(t)12.7(ea)16(m)12.8(e)14.1(d)-317(u)12.2(p)-310.9(t)12.7(o)-310.9(c)0(r)17.8(e)0(a)22.1(t)12.7(e)-315.1(a)-315.1(p)12.2(ro)22.1(g)12.2(r)0(a)17.8(m)-310.4(c)14.1(a)0(l)20.7(l)0(e)20.7(d)-317(Ne)24.8(g)12.2(o)0(t)18.8(i)12.7(at)20.7(i)12.7(n)0(g)]TJ
0 -1.1219 TD
[(t)12.7(h)0(e)-339.5(D)0(i)17.3(v)12.2(i)12.7(d)12.2(e:)-345.1(Ge)24.8(nd)18.3(e)14.1(r)-356(a)14.1(n)12.2(d)-353.6(S)15.4(al)20.7(ar)17.8(y)-347.5(\()0(N)20.6(T)0(D)21.1(\))0(.)-343.8(N)0(T)21.1(D)-349(h)12.2(a)0(s)-338.7(b)0(e)20.2(c)0(o)20.2(m)12.8(e)-351.7(a)-351.7(s)13.1(ig)18.8(-)]TJ
0 -1.128 TD
-.0122 Tc
[(na)-12.2(t)8.5(u)0(r)-12.2(e)-335.8(pr)-12.2(o)9.9(g)0(r)-12.2(a)5.6(m)-340.9(w)-12.2(i)11.2(t)-12.2(h)-334.8(t).5(he)-345.6(I)-12.2(U)8.4(N)-12.2(C)12.1(O)-12.2(E)-332.5(a)-12.2(n)8(d)-341.4(t)-12.2(h)6.6(r)-12.2(o)9.9(ugh)-341.4(pa)-12.2(r)5.6(t).5(ne)-12.2(r)5.6(s).9(hi)-12.2(p)-334.8(w)-12.2(i)11.2(t)-12.2(h)]TJ
0 -1.1219 TD
0 Tc
[(AM)23.8(WA)-194.7(i)12.7(s)-200.3(he)20.2(ld)-194.6(a)14.1(c)0(r)17.8(o)12.2(s)13.1(s)-200.3(mu)18.9(l)12.7(t)12.7(i)0(p)18.8(l)12.7(e)-205.4(I)0(n)22.1(d)12.2(i)12.7(a)0(n)20.2(a)-205.4(l)12.7(o)12.2(ca)22.1(ti)19.3(o)12.2(n)12.2(s)-200.3(an)20.2(d)-201.2(b)12.2(ey)20.2(o)12.2(n)0(d)-195.1(s)13.1(t)12.7(a)0(t)20.7(e)]TJ
0 -1.128 TD
[(l)12.7(i)0(n)18.8(e)0(s)-277.7(i)12.7(nc)20.2(lu)18.8(d)12.2(i)12.7(n)12.2(g)-292.6(C)13.6(a)0(l)20.7(i)12.7(fo)16(r)15.9(n)0(i)18.8(a)14.1(.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Results:)Tj
/F4 1 Tf
3.6583 0 TD
[(NTD)-218.2(brings)-220.4(residents,)-221.3(scientists,)-223.1(fellows,)-219.5(physicians,)]TJ
-4.6583 -1.128 TD
[(lawyers,)-462(and)-455.3(other)-457.2(professionals)-460.5(together)-460.8(to)-456.7(discuss)-458.3(pay)-461.4(dis-)]TJ
0 -1.1219 TD
[(crepancies,)-351.1(negotiation)-353.7(skills)-350.3(to)-347(empower)-353.1(female)-349.2(leadership)-354.4(in)]TJ
0 -1.128 TD
[(medicine)-303.6(and)-296.8(science.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Conclusions:)Tj
/F4 1 Tf
5.835 0 TD
[(At)-287.5(n)12.2(o)-298.7(co)20.2(st)-285.2(to)-286(th)18.8(e)-296.9(h)0(o)18.3(s)0(t)19.7(i)12.7(ng)-286.5(in)18.8(st)19.7(it)19.3(ut)18.8(io)18.8(n)12.2(s)-297.9(o)12.2(r)-301.1(g)12.2(r)0(o)22.1(u)0(p)18.3(s)0(,)]TJ
-6.835 -1.128 TD
[(NT)21.1(D)-367.3(h)12.2(as)-357(e)14.1(d)0(u)18.3(c)0(a)16(t)12.7(ed)-351.7(ov)18.3(er)-354.1(3)12.2(0)0(0)-353.6(s)0(t)19.7(u)0(d)18.3(e)0(n)20.2(t)12.7(s,)-358.8(re)23.9(si)19.7(de)20.2(nt)18.8(s)-365(a)0(n)20.2(d)-365.8(p)12.2(h)12.2(y)0(s)19.2(i)0(c)20.7(i)0(a)14.6(n)12.2(s.)]TJ
0 -1.1219 TD
[(Su)21.6(rv)16(e)14.1(y)-182.9(d)12.2(a)0(t)14.6(a)-181(d)12.2(e)0(m)20.8(o)0(n)18.3(s)13.1(tr)16.5(at)20.7(ed)-174.9(t)12.7(h)12.2(at)-174.4(9)12.2(0)0(%)-173(o)12.2(f)-179.2(p)0(a)14.1(r)0(t)22.6(i)0(c)20.7(i)0(p)18.9(a)0(n)20.2(t)0(s)-175.4(w)0(e)24.8(r)0(e)-177.3(e)14.1(xt)18.8(re)17.8(m)12.8(e)0(l)14.6(y)]TJ
0 -1.128 TD
[(o)12.2(r)-270.6(ve)20.2(ry)-264.5(s)13.1(a)0(t)20.7(i)0(s)19.7()0(e)17.3(d)-268.2(wi)17.3(t)12.7(h)-274.3(t)12.7(h)12.2(e)-272.5(p)12.2(ro)16(g)12.2(r)0(a)17.8(m)12.8(;)-273.8(9)12.2(2)12.2(%)-270.6(im)19.4(p)12.2(r)0(o)16(v)12.2(ed)-260.2(i)12.7(n)-274.3(k)12.2(n)12.2(o)0(w)16.8(l)12.7(ed)20.2(ge)20.2(;)]TJ
0 -1.1219 TD
[(an)20.2(d)-207.3(8)0(2)18.3(%)-209.6(d)12.2(o)12.2(c)0(u)14.1(m)12.8(en)20.2(te)20.7(d)-207.3(t)0(h)18.9(a)0(t)-198.8(t)0(h)18.8(e)-211.5(i)12.7(n)12.2(fo)16(rm)22.6(at)14.6(i)12.7(o)12.2(n)-207.3(p)0(r)16(e)0(s)21.1(e)0(n)20.2(t)0(e)14.6(d)-207.3(wa)18.7(s)-206.4(u)12.2(se)15(fu)22.1(l)-206.8(t)0(o)]TJ
0 -1.128 TD
[(th)18.8(ei)20.7(r)-191.4(c)14.1(ar)17.8(ee)16(r.)-179.2(Th)22.6(e)-193.2(p)12.2(u)12.2(r)0(p)16(o)12.2(s)13.1(e)-193.2(o)12.2(f)-191.4(NT)21.1(D)-190.5(i)12.7(s)-188.1(u)12.2(nd)18.3(er)17.8(s)13.1(t)0(a)14.6(n)12.2(d)12.2(i)0(n)18.8(g)-189(th)18.8(e)-187.1(s)0(c)15(o)12.2(p)12.2(e)-193.2(o)12.2(f)-185.3(th)18.8(e)]TJ
0 -1.1219 TD
[(p)12.2(r)0(o)16(b)12.2(le)20.7(m,)-255.5(re)17.8(co)20.2(gn)18.3(i)12.7(z)0(i)14.6(n)12.2(g)-268.2(t)12.7(h)12.2(e)-272.5(g)12.2(a)0(p)-254.2(a)0(n)20.2(d)-268.2(wh)16.8(y)-262.1(i)0(t)-255(e)0(x)20.2(i)0(s)19.7(t)0(s)19.7(;)-267.7(an)20.2(d)-268.2(e)0(m)20.8(p)12.2(ow)16.8(er)17.8(i)12.7(n)0(g)]TJ
0 -1.128 TD
[(wo)16.8(m)12.8(e)0(n)-272.4(t)12.7(o)-280.4(a)0(p)20.2(p)0(r)16(e)14.1(ci)14.6(a)14.1(t)0(e)-271.9(t)0(h)18.8(e)0(i)20.7(r)-282.8(wo)22.9(rt)16.5(h)-280.4(a)14.1(nd)-274.3(e)14.1(n)0(g)18.3(a)0(g)20.2(e)-284.7(i)12.7(n)-280.4(n)12.2(e)0(g)20.2(o)0(t)18.8(i)0(a)20.7(t)0(i)19.3(o)0(n)-274.3(t)12.7(ec)16(h)12.2(-)]TJ
T*
[(n)12.2(i)0(q)18.8(u)0(e)20.2(s)-255.2(t)12.7(h)12.2(at)-241.5(re)17.8(su)19.2(l)12.7(t)-255.6(i)12.7(n)-250(b)12.2(e)0(t)14.6(t)12.7(er)-238.2(sa)15(l)12.7(a)0(r)17.8(y)-250(an)20.2(d)-250(j)0(o)18.8(b)-250(sa)21.1(ti)19.3(sf)16.8(ac)22.1(ti)19.3(on)18.3(.)]TJ
/F3 1 Tf
0 -3.0974 TD
(78.)Tj
9.843 0 0 9.843 82.9417 184.7054 Tm
[(Health)-250.8(Liter)-9(acy)-252.1(and)-250.6(Womens)-252.6(Health:)-257.7(Empowering)]TJ
0 -1.1116 TD
[(Women)-279.4(to)-284.4(Partner)-282.9(in)-278.6(their)-284.2(Healthcare)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 62.022 157.2094 Tm
[(Stacey)-338(E.)-331.1(Rosen)]TJ
/F5 1 Tf
0 -1.7682 TD
[(Northwell)-334.2(Health,)-333.8(Lake)-334.4(Success,)-340(New)-330.6(York)]TJ
/F3 1 Tf
.9999 -2.3047 TD
(Background:)Tj
/F4 1 Tf
5.8167 0 TD
[(The)-170.6(Katz)-174(Institute)-174.2(for)-175.4(Womens)-167.8(Health)-179.5(\(KIWH\))]TJ
-6.8167 -1.128 TD
[(is)-285.2(part)-286.5(of)-288.9(Northwell)-288.3(Health,)-289.2(which)-285.6(serves)-289.4(a)-284.7(geographic)-288.7(area)-289.3(en-)]TJ
0 -1.1219 TD
[(compassing)-353(more)-359.6(than)-351.2(8)-353.6(million)-350.9(people.)-355.3(KIWH)-357(is)-352.2(a)-357.8(dedicated)]TJ
0 -1.128 TD
[(healthcare)-589.3(partner)-585.7(to)-584.8(educate,)-583.2(empower,)-584.7(nurture)-587.5(and)-583.4(guide)]TJ
0 -1.1219 TD
[(women)-261.1(through)-257.8(their)-261.5(healthcare)-266.1(needs)-263.5(at)-259.8(every)-260.7(stage)-263(of)-258.4(life.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.7253 0 TD
[(1.)-213.4(Identify)-215.1(the)-217(importance)-220.6(of)-215.7(low)-214.3(health)-214.6(literacy)]TJ
-6.7252 -1.1219 TD
[(and)-388.3(its)-388.3(impact)-384.8(on)-390.2(patient)-384.8(safety)-393.4(and)-382.2(poor)-392.5(health)-385.3(outcomes.)-390.5(2.)]TJ
26.9984 71.9468 TD
[(Discuss)-551.3(strategies)-548.1(that)-545.8(foster)-550.1(partnerships)-546.7(among)-546.2(healthcare)]TJ
0 -1.128 TD
[(providers)-348.8(and)-351.7(the)-345.1(communities)-352.3(they)-345.1(serve.)-351.3(3.)-347.5(Discuss)-350(how)-349(ap-)]TJ
0 -1.1219 TD
[(plying)-370.8(the)-363.4(NPS)-366.9(to)-365.3(womens)-366.3(health)-367(can)-368.1(be)-370(fundamental)-366.9(to)-365.3(im-)]TJ
0 -1.128 TD
[(proving)-391.9(the)-387.8(nations)-388.7(health.)-385.3(4.)-384.1(Identify)-391.9(the)-387.8(importance)-385.2(of)-392.5(and)]TJ
0 -1.1219 TD
[(strategies)-218.9(to)-212.8(empower)-212.8(patients)-219.3(to)-212.8(make)-209(informed)-215(decisions)-218.9(about)]TJ
0 -1.128 TD
[(their)-304.2(health)-299.9(and)-302.9(wellness.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Material/Methods:)Tj
/F4 1 Tf
8.3471 0 TD
[(KIWH)-277.7(aligned)-275.5(its)-272.4(philosophy,)-272.3(principles)]TJ
-9.347 -1.128 TD
[(and)-638.3(activities)-637.1(with)-634.5(National)-636.3(Prevention)-634.3(Strategy)-640.5(\(NPS\))-633.8(to)]TJ
0 -1.1219 TD
[(maximally)-316.6(improve)-316.3(the)-314.6(health)-318.2(of)-313.3(the)-314.6(populations)-312.5(that)-314.1(it)-316(serves.)]TJ
0 -1.128 TD
[(KIWH)-222.9(focuses)-222.3(on)-219.4(the)-217(need)-221.7(to)-218.9(educate)-223.5(patients,)-219.3(providers)-220.8(and)-223.6(the)]TJ
0 -1.1219 TD
[(public)-253.1(to)-249.4(create)-250.3(a)-248.1(partnership)-248.9(to)-249.4(optimize)-250.1(health)-251.2(though)-243.2(aligning)]TJ
0 -1.128 TD
[(its)-309(efforts)-314.7(with)-305.3(the)-308.5(strategic)-311.2(directions)-313.1(of)-307.2(the)-308.5(NPS:)-311.5(Empowered)]TJ
0 -1.1219 TD
[(People)-303.3(and)-302.9(Elimination)-301.5(of)-295(Health)-307.6(Disparities.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Results:)Tj
/F4 1 Tf
3.89 0 TD
[(Key)-450.7(programs)-452.5(were)-457.3(developed)-450.9(including:)-453.2(1.)-451.1(Wo-)]TJ
-4.8899 -1.128 TD
[(mens)-291.7(Heart)-292.2(Health)-295.4(Program,)-285.5(which)-291.7(provides)-291.6(personalized)-291.5(care)]TJ
0 -1.1219 TD
[(for)-358.3(the)-351.2(prevention,)-357.1(early)-351.6(detection)-358.5(and)-351.7(treatment)-360.3(of)-349.9(cardiovas-)]TJ
0 -1.128 TD
[(cular)-315(disease)-315.2(in)-310.4(women.)-309.9(2.)-310.9(KIWH)-308.2(Wellness)-314.6(Campaigns,)-315.9(which)]TJ
0 -1.1219 TD
[(promotes)-327.7(womens)-329.7(health)-330.4(throughout)-324.3(the)-326.8(year)-327.8(through)-324.8(focused)]TJ
0 -1.128 TD
[(wellness)-360.7(campaigns.)-352(System-wide)-354(activities)-356.6(are)-358.3(coordinated)-355.2(to)]TJ
0 -1.1219 TD
[(educate)-321.1(female)-312.6(employees)-315.4(and)-315.1(community)-312.9(members,)-313.6(including)]TJ
0 -1.128 TD
[(lectures,)-244.7(informational)-248.1(tables,)-244.2(health)-239(screenings)-244.3(and)-241.9(outreach.)-246(3.)]TJ
0 -1.1219 TD
[(KIWH)-387.5(Resource)-390.6(Center,)-386.8(which)-383.1(offers)-388.4(women)-383.1(seamless,)-386.9(coor-)]TJ
0 -1.128 TD
[(dinated)-226.8(access)-228.4(to)-225(all)-228.7(of)-227.9(NSLIJHS)-225.3(clinical)-223.9(programs)-226.9(and)-229.7(services.)]TJ
0 -1.1219 TD
[(In)-301.1(2014,)-298.6(it)-303.8(served)-302.5(over)-299.2(4,500)-298.6(callers.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Conclusions:)Tj
/F4 1 Tf
5.8533 0 TD
[(As)-360.3(healthcare)-363.7(in)-359.2(America)-362.9(moves)-362.5(toward)-361.1(pop-)]TJ
-6.8532 -1.1219 TD
[(ulation)-465.9(health)-464.6(management,)-466.3(wellness)-464.3(and)-461.4(prevention)-466.8(become)]TJ
0 -1.128 TD
[(critically)-219.6(important)-211.6(as)-216.7(we)-213(transition)-210.8(from:)]TJ
/F8 1 Tf
16.7795 0 TD
()Tj
/F4 1 Tf
.5 0 TD
[(Value)-216.6(Blind)-210.9(to)-212.8(Value)]TJ
-17.2794 -1.1219 TD
(Based)Tj
/F8 1 Tf
2.9937 0 TD
()Tj
/F4 1 Tf
.5 0 TD
[(Disease)-554.4(and)-546.8(Treatment)-545.6(to)-548.2(Prevention)-549(and)-546.8(Wellness)]TJ
/F8 1 Tf
-3.4937 -1.128 TD
()Tj
/F4 1 Tf
.5 0 TD
[(Episodic)-302.8(and)-302.9(Fragmented)-303.2(to)-298.2(Seamless)-299.2(and)-302.9(Coordinated.)]TJ
/F3 1 Tf
-.5 -3.0364 TD
(79.)Tj
9.843 0 0 9.843 333.9779 404.3904 Tm
[(The)-281.8(Role)-283(of)-284.4(Maternal)-284.1(Low)-281.7(Birthweight)]TJ
0 -1.1116 TD
[(on)-284.3(Fetal)-278.7(Growth)-286.1(in)-278.6(Virginia)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 313.0582 376.8377 Tm
[(Sylvia)-335.2(Rozario)]TJ
6.9735 0 0 6.198 369.5243 380.9763 Tm
(1)Tj
9.2982 0 0 9.2982 373.0393 376.8377 Tm
[(,)-329.2(Saba)-334.4(Masho)]TJ
6.9735 0 0 6.198 424.9133 380.9763 Tm
(2)Tj
9.2982 0 0 9.2982 428.4282 376.8377 Tm
[(,)-329.2(Derek)-335.3(Chapman)]TJ
6.9735 0 0 6.198 495.4392 380.9763 Tm
(2)Tj
/F5 1 Tf
-26.1534 -2.6526 TD
(1)Tj
9.2982 0 0 9.2982 316.5731 360.4534 Tm
[(Virginia)-334.6(Commonwealth)-332.4(University,)-340(School)-332.8(of)-334.8(Medicine,)]TJ
-.378 -1.128 TD
[(Department)-338.6(of)-334.8(Family)-335.7(Medicine)-330.9(and)-335.3(Population)-335.4(Health,)]TJ
T*
[(Division)-338.5(of)-334.8(Epidemiology,)-333.1(Richmond,)-336.1(Virginia)]TJ
6.9735 0 0 6.198 313.0582 333.1842 Tm
(2)Tj
9.2982 0 0 9.2982 316.5731 329.0456 Tm
[(Virginia)-334.6(Commonwealth)-332.4(University)-340(Department)-332.5(of)-334.8(Family)]TJ
-.378 -1.128 TD
[(Medicine)-337(and)-335.3(Population)-329.3(Health,)-339.9(Division)-332.4(of)-334.8(Epidemiology,)]TJ
0 -1.1219 TD
[(Richmond,)-336.1(Virginia)]TJ
/F3 1 Tf
.9999 -2.3047 TD
(Background:)Tj
/F4 1 Tf
5.9631 0 TD
[(The)-365.7(US)-358(has)-363(a)-363.9(relatively)-366.4(high)-359.1(infant)-359.1(mortality)]TJ
-6.963 -1.1219 TD
[(rate)-467.5(when)-456.8(compared)-465.5(to)-456.7(other)-463.3(developed)-463.1(countries.)-459.9(Small)-462.7(for)]TJ
0 -1.128 TD
[(gestational)-424.1(age)-416.9(\(SGA\))-419(is)-419.3(an)-418.8(important)-419(indicator)-423.7(of)-416.9(poor)-416.9(fetal)]TJ
0 -1.1219 TD
[(growth)-436.1(and)-437(a)-431(major)-432.2(cause)-438.5(of)-435.2(infant)-432.2(mortality)-436.7(and)-430.9(morbidity.)]TJ
0 -1.128 TD
[(Existing)-468.8(literature)-472.4(suggests)-470.5(that)-466.5(intergenerational)-474.1(risk)-470.4(factors)]TJ
0 -1.1219 TD
[(inuence)-289.2(the)-278(occurrence)-287.8(of)-282.8(adverse)-282.3(birth)-281.7(outcomes;)-286.3(but)-279.9(there)-284.6(is)]TJ
0 -1.128 TD
[(paucity)-306(of)-301.1(evidences)-301.9(to)-298.2(back)-301(up)-298.7(this)-302.9(suggestion.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.774 0 TD
[(This)-262.6(study)-260.7(examines)-266.7(the)-259.7(effect)-266.7(of)-264.5(maternal)-263.3(low)]TJ
-6.774 -1.128 TD
[(birthweight)-249.7(\(LBW\))-241(on)-243.8(infants)-244.7(fetal)-247.5(growth)-247.1(in)-243.3(Virginia.)-244.2(In)-240.1(order)]TJ
T*
[(to)-261.6(explore)-254(the)-259.7(possible)-251.3(pathways)-258.4(by)-256(which)-261.2(maternal)-257.2(birthweight)]TJ
0 -1.1219 TD
[(could)-278(be)-272.4(associated)-276.1(with)-274.8(infants)-275.2(fetal)-278(growth,)-271.5(the)-278(current)-274.7(study)]TJ
0 -1.128 TD
[(also)-246.7(assesses)-246(the)-241.4(relationship)-245.5(of)-240.1(maternal)-245(medical)-242.7(complications)]TJ
0 -1.1219 TD
[(with)-305.3(maternal)-299.9(LBW)-303.3(and)-296.8(infant)-304.2(SGA.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Material/Methods:)Tj
/F4 1 Tf
8.4812 0 TD
[(Da)24.8(ta)-387.8(fr)19.7(o)12.2(m)-395.8(a)-400.5(m)12.7(u)12.2(l)0(t)19.3(i)12.7(ge)20.2(n)12.2(e)0(r)17.8(a)0(t)20.7(i)12.7(on)18.3(al)-387.8(b)12.2(i)12.7(rt)22.6(h)-396.3(d)0(a)20.2(-)]TJ
-9.4811 -1.1219 TD
[(ta)14.6(s)13.1(e)0(t)20.7(,)-371.9(c)14.1(r)0(e)17.8(a)14.1(te)14.6(d)-365.8(b)12.2(y)-371.9(l)12.7(in)18.8(k)12.2(i)12.7(ng)-359.7(2)12.2(0)0(0)18.3(5)12.2()12.2(2)0(0)18.3(0)12.2(9)-371.9(V)0(i)23.4(r)0(g)22.1(i)12.7(ni)18.8(a)-370(r)0(e)17.8(s)13.1(i)12.7(d)0(e)20.2(n)0(t)-359.2(l)0(i)19.3(v)12.2(e)-370(b)12.2(ir)16.5(t)12.7(h)]TJ
0 -1.128 TD
-.0127 Tc
[(d)-12.7(a)7.5(t)-12.7(a)-376.1(t)-12.7(o)-378(1960)-12.7(1)5.6(997)-384.6(V)-12.7(i)4.6(r)-12.7(g)9.4(in)-12.7(i)6.1(a)-382.7(m)-12.7(a)8(t)-12.7(e)8(r)-12.7(n)3.3(al)-384.1(l)-12.7(i)6.6(ve)-388.8(bir)-12.7(t)3.8(h)-384.6(d)-.5(a)-12.7(t)8(a)-12.7(,)-376.6(w)-12.7(e)12.1(r)-12.7(e)-379(an)-12.7(a)7.5(-)]TJ
0 -1.1219 TD
0 Tc
[(ly)18.8(ze)22.1(d)-359.7(\()0(n)]TJ
/F2 1 Tf
3.3047 0 TD
(=)Tj
/F4 1 Tf
.5426 0 TD
-.013 Tc
[(159)-13(,)5.3(210\))-13(.)-362.9(T)-13(h)9.6(e)-370.8(o)-13(u)5.3(tc)-13(o)7.2(m)-.2(e)-370.8(v)-13(a)7.2(r)-13(iabl)-13(e,)-366.6(i)-13(n)5.8(f)-13(a)10.9(n)-13(t)-360(S)-13(G)7.1(A)-13(,)-362(w)-13(a)5.7(s)-365.8(d)-13(e)7.2(-)]TJ
-3.8473 -1.128 TD
0 Tc
[(n)21.6(ed)-400.5(a)14.1(s)-407.6(a)-406.6(b)12.2(ir)16.5(t)12.7(h)12.2(we)18.7(i)12.7(g)12.2(ht)]TJ
/F2 1 Tf
8.9629 0 TD
(=<)Tj
/F4 1 Tf
1.0853 0 TD
[(1)12.2(0)12.2(t)12.7(h)-408.5(p)12.2(er)17.8(c)14.1(e)0(n)20.2(t)0(i)19.3(l)12.7(e)-406.6(f)0(o)22.1(r)-410.9(a)-406.6(g)12.2(i)12.7(v)12.2(en)-400.5(g)12.2(e)0(s)21.1(t)12.7(at)20.7(io)18.9(n)12.2(a)0(l)]TJ
-10.0482 -1.1219 TD
[(ag)20.2(e.)-284.7(Th)16.5(e)-290.8(p)12.2(ri)16.5(m)12.8(a)0(r)17.8(y)-292.6(ex)20.2(p)12.2(o)12.2(s)0(u)19.2(r)0(e)-280.9(v)0(a)20.2(r)0(i)16.5(a)14.1(bl)18.8(e,)-284.7(m)12.8(a)0(t)20.7(e)0(r)17.8(n)12.2(al)-284.1(b)12.2(i)0(r)16.5(t)12.7(h)12.2(w)0(e)18.7(i)12.7(g)12.2(h)0(t)-286(\()0(B)23.4(W)0(\))17.9(,)]TJ
0 -1.128 TD
[(wa)18.7(s)-236.9(d)12.2(ic)20.7(ho)18.3(t)12.7(o)12.2(mi)19.4(ze)16(d)-231.7(a)0(s)-228.9(L)0(B)24(W)-241.9(\()]TJ
/F2 1 Tf
11.1822 0 TD
(<)Tj
/F4 1 Tf
.5366 0 TD
-.0122 Tc
[(2)-12.2(,)6.1(500g)-12.2(\))-240.1(a)-12.2(n)8(d)-250(nor)-12.2(m)10.4(a)-12.2(l)-241.5(B)-12.2(W)-240.6(\()-12.2(2)9.9(500)]TJ
/F2 1 Tf
12.231 0 TD
0 Tc
(+)Tj
/F4 1 Tf
.7073 0 TD
-.0122 Tc
[(g\))-12.2(.)]TJ
-24.657 -1.1219 TD
-.0129 Tc
[(A)-12.9(d)3.9(jus)-12.9(t)6.8(e)-12.9(d)-370.7(odds)-384(ra)-12.9(t)7.8(i)-12.9(o)5.9(s)-377.9(\()-12.9(A)7.7(O)-12.9(R)5.3(\))-375(a)-12.9(n)7.3(d)-378.7(95)-12.9(%)-368.8(c)-12.9(o)7.3(n)-.7()-12.9(d)8.7(e)-12.9(n)7.3(c)-12.9(e)-368.8(in)-12.9(t)5.9(e)-12.9(r)5(v)-.7(a)-12.9(l)7.8(s)-377.9(\()-12.9(C)10.6(I)-12.9(\))]TJ
0 -1.128 TD
0 Tc
[(we)18.7(re)-384.6(g)12.2(e)0(n)20.2(e)0(r)17.8(a)14.1(te)20.7(d)-396.3(u)12.2(s)13.1(i)0(n)18.8(g)-390.2(mu)18.9(l)12.7(t)0(i)19.3(p)12.2(l)12.7(e)-394.4(lo)18.8(g)12.2(i)12.7(st)19.7(ic)-381.7(re)17.8(g)12.2(r)0(e)17.8(s)13.1(si)19.7(o)12.2(n)-396.3(m)12.7(o)12.2(d)12.2(e)0(l)20.7(s)0(.)-383.2(S)0(u)21.6(b)12.2(-)]TJ
0 -1.1219 TD
[(po)18.3(p)12.2(u)12.2(l)0(a)20.7(t)0(i)19.3(o)12.2(n)-292.6(a)14.1(na)20.2(ly)18.8(s)13.1(i)0(s)-279.1(w)0(a)18.7(s)-291.8(c)14.1(o)0(n)18.3(d)12.2(u)12.2(c)0(t)20.7(e)0(d)-278.5(s)0(t)19.7(r)0(a)17.8(t)12.7(i)12.7()0(e)17.3(d)-286.5(by)-280.4(ra)17.8(c)14.1(e)0(/)20.7(e)0(t)20.7(h)0(n)18.3(i)12.7(ci)20.7(t)12.7(y)0(.)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 62.022 749.6502 Tm
(A-30)Tj
48.6864 0 TD
(ABSTRACTS)Tj
ET
endstream
endobj
319 0 obj
<>stream
/GS1 gs
BT
/F3 1 Tf
9.2982 0 0 9.2982 69.0519 725.5557 Tm
0 0 0 rg
0 Tc
0 Tw
(Results:)Tj
/F4 1 Tf
3.7254 0 TD
[(The)-286.5(prevalence)-291(of)-282.8(maternal)-287.7(LBW)-285.1(and)-290.7(infants)-287.4(SGA)]TJ
-4.7253 -1.128 TD
[(in)-292.1(Virginia)-293(were)-292.7(7.4%)-288.8(and)-296.8(10.6%,)-288.8(respectively.)-291(Maternal)-293.4(LBW)]TJ
0 -1.1219 TD
[(was)-437.7(associated)-440.7(with)-433.3(increased)-438.4(odds)-431.9(of)-435.2(SGA)-438.7(infants)-431.4(after)-439.4(ad-)]TJ
0 -1.128 TD
[(justing)-631.6(for)-632.7(potential)-634.2(risk)-628.9(factors)-633.6(in)-627.5(the)-631.7(current)-634.4(pregnancy)]TJ
0 -1.1219 TD
(\(AOR)Tj
/F2 1 Tf
2.4389 0 TD
(=)Tj
/F4 1 Tf
.5548 0 TD
[(1.63,)-566.9(95%)-569.3(CI)]TJ
/F2 1 Tf
5.9691 0 TD
(=)Tj
/F4 1 Tf
.5487 0 TD
[(1.52,)-573(1.76\).)-569.3(Maternal)-573.9(medical)-571.9(history)]TJ
-9.5116 -1.128 TD
[(factors,)-609.2(such)-600.8(as)-606.9(respiratory)-604.9(disease,)-607.8(diabetes,)-602(hypertension,)]TJ
0 -1.1219 TD
[(eclampsia,)-410.6(and)-406.6(previous)-401.4(preterm)-408.3(or)-404.7(SGA)-402.1(infant,)-407.8(were)-402.4(signi-)]TJ
0 -1.128 TD
[(cantly)-306(associated)-300.5(with)-299.2(both)-304.3(maternal)-299.9(LBW)-303.3(and)-296.8(infant)-304.2(SGA.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Conclusions:)Tj
/F4 1 Tf
5.8411 0 TD
[(The)-347.4(mothers)-354.4(birthweight)-347.3(may)-351.2(be)-351.7(a)-345.6(useful)-352.6(in-)]TJ
-6.841 -1.128 TD
[(dicator)-296.2(in)-298.2(addressing)-294.9(adverse)-300.6(birth)-293.9(outcomes)-292.9(for)-297.3(infants.)-297.2(Public)]TJ
0 -1.1219 TD
[(health)-275.6(program)-270.4(and)-272.4(policy)-271.3(must)-272.4(focus)-273.9(on)-268.2(factors)-273.8(throughout)-269.4(the)]TJ
0 -1.128 TD
[(life)-261.6(course)-259.8(of)-252.3(women)-261.2(in)-255.5(order)-258.8(to)-255.5(fully)-257.3(address)-258.9(inequities)-261.4(in)-255.5(birth)]TJ
0 -1.1219 TD
(outcomes.)Tj
/F3 1 Tf
0 -3.3839 TD
(80.)Tj
9.843 0 0 9.843 80.674 568.5731 Tm
[(Designing)-282.4(and)-285.2(Validation)-282.6(of)-278.6(a)-277.6(Questionnaire)]TJ
0 -1.1116 TD
[(to)-284.4(Assess)-278.6(Womens)-287.1(Experiences)-283.5(of)-284.4(Menopause)]TJ
0 -1.1174 TD
(\(QAWEM\))Tj
/F4 1 Tf
9.2982 0 0 9.2982 59.7543 531.0991 Tm
[(Masoumeh)-335.2(Simbar)-337.5(Simbar)]TJ
6.9735 0 0 6.198 161.1212 535.2377 Tm
(1)Tj
9.2982 0 0 9.2982 164.6362 531.0991 Tm
[(,)-335.3(Sevil)-329.1(Hakimi)]TJ
6.9735 0 0 6.198 220.3086 535.2377 Tm
(2)Tj
9.2982 0 0 9.2982 223.8235 531.0991 Tm
(,)Tj
-17.6453 -1.128 TD
[(Fahimeh)-339.4(Ramezani)-331.3(Tehrani)]TJ
6.9735 0 0 6.198 165.033 524.7495 Tm
(3)Tj
/F5 1 Tf
-15.0969 -2.6526 TD
(1)Tj
9.2982 0 0 9.2982 63.2693 504.1699 Tm
[(Department)-332.5(of)-334.8(Midwifery)-330(and)-329.2(Reproductive)-333.6(Health,)-333.8(School)-332.8(of)]TJ
-.378 -1.1219 TD
[(Nursing)-319.4(and)-317(Midwifery,)-323.9(Reproductive)-321.4(Endocrinology)-319.1(Research)]TJ
0 -1.128 TD
[(Center,)-334.8(Research)-341.9(Institute)-332.8(for)-333.9(Endocrine)-331.9(Sciences,)-338.5(Shahid)]TJ
0 -1.1219 TD
[(Beheshti)-337.5(University)-340(of)-328.7(Medical)-338.9(Science,)-333.3(Tehran,)-335.3(Iran)]TJ
6.9735 0 0 6.198 59.7543 466.4692 Tm
(2)Tj
9.2982 0 0 9.2982 63.2693 462.3306 Tm
[(Clinical)-336(Psychiatry)-334.7(Research)-335.8(Center,)-334.8(School)-332.8(of)-334.8(Nursing)]TJ
-.378 -1.1219 TD
[(and)-335.3(Midwifery,)-336.1(Tabriz)-329.8(University)-340(of)-334.8(Medical)-332.8(Science,)]TJ
0 -1.128 TD
[(Tabriz,)-335.9(Iran)]TJ
6.9735 0 0 6.198 59.7543 435.118 Tm
(3)Tj
9.2982 0 0 9.2982 63.2693 430.9794 Tm
[(Reproductive)-333.6(Endocrinology)-337.4(Research)-335.8(Center,)-334.8(Research)]TJ
-.378 -1.128 TD
[(Institute)-314.5(for)-315.6(Endocrine)-313.6(Sciences,)-314.1(Shahid)-310.3(Beheshti)-313.1(University)-315.6(of)]TJ
0 -1.1219 TD
[(Medical)-338.9(Sciences,)-332.4(\(Yaman\),)-338.2(Tehran,)-329.2(Iran)]TJ
/F3 1 Tf
.9999 -2.0182 TD
(Background:)Tj
/F4 1 Tf
5.9752 0 TD
[(Contemporary)-370.2(tools)-370(to)-371.4(assess)-370.7(health)-373.1(status)-367.2(of)]TJ
-6.9752 -1.1219 TD
[(menopausal)-376.4(women)-377(concentrate)-375.8(only)-371.3(on)-371.9(physical)-372.2(and)-376.1(psycho-)]TJ
0 -1.128 TD
[(logical)-275(symptoms)-264.8(of)-270.6(menopause)-267.1(while)-272.9(women)-267.2(experience)-272.7(some)]TJ
0 -1.1219 TD
[(complications)-301.6(of)-301.1(other)-304.7(aspects)-303(of)-295(health.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Objective\(s\):)Tj
/F4 1 Tf
6.0484 0 TD
[(This)-543(study)-541.2(aimed)-543.8(to)-542.1(design)-539.3(and)-540.7(validate)-541.4(a)]TJ
-7.0484 -1.1219 TD
[(comprehensive)-309.7(questionnaire)-311.1(to)-304.3(assess)-309.8(womens)-305.3(experiences)-314.5(in)]TJ
0 -1.128 TD
[(all)-301.9(aspects)-303(of)-301.1(health)-300(related)-306.5(to)-298.2(menopause.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Material/Methods:)Tj
/F4 1 Tf
8.4751 0 TD
-.0173 Tc
[(Thi)-4.6(s)-364(was)-364(a)-369(mixed)-364.8(s)1.9(equent)-4.6(ial)-358.2(e)-3.2(xp)-5.1(loratory)]TJ
-9.475 -1.128 TD
[(s)-4.3(t)1.4(udy)-5.2(.)-371(A)-.6(t)-376.6()-2(rst)-376.6(s)1.8(ect)-4.7(i)1.4(on)-377.1(a)-375.2(quali)-4.7(tative)-375.2(p)-5.2(henomenol)-4.7(ogical)-370.5(s)-4.3(t)1.4(udy)-377.1(was)]TJ
0 -1.1219 TD
-.0175 Tc
[(p)-5.3(e)2.7(rformed)-261.4(on)-261.4(18)-261.4(menop)-5.3(aus)-4.4(a)2.7(l)-260.9(w)-.7(o)-5.3(m)1.4(en)-255.3(t)-4.8(o)-261.4(as)-4.4(sess)-260.5(t)-4.8(h).8(ei)-4.8(r)-257.6(h)-5.3(ealth)-261.4(experi-)]TJ
0 -1.128 TD
-.0172 Tc
[(ences)-162.7(in)-163.5(m)-4.4(e)3(n)-5(opause)-167.7(a)-3.1(nd)-163.5(data)-167.7(was)-162.7(a)-3.1(nal)-4.5(y)1.1(zed)-163.5(u)-5(sin)-5(g)-163.5(the)-167.7(s)2(t)-4.5(e)3(p)-5(s)-162.7(described)]TJ
0 -1.1219 TD
[(b)-5.1(y)-157.5(van)-157.5(m)-4.5(ann)-5.1(e)2.9(n)-5.1(.)-157.5(The)-161.7(poo)-5.1(l)-157(o)1(f)-166(items)-162.8(was)-156.7(e)-3.2(xtracted)-157.5(from)-163.1(t)1.5(he)-161.7(quali)-4.6(tative)]TJ
0 -1.128 TD
-.0158 Tc
[(pa)4.4(rt)-362.8(whic)4.4(h)-369.4(w)1(a)4.4(s)-362.5(completed)-363.3(b)2.5(y)-363.3(s)3.4(ome)-361.4(i)-3.1(tems)-362.5(extracted)-363.3(f)6.2(r).1(om)-362.8(a)4.4(n)-363.3(ex-)]TJ
0 -1.1219 TD
-.0176 Tc
[(t)-4.9(e)2.6(n)-5.4(s)1.6(ive)-393.7(l)1.2(i)-4.9(t)1.2(eratu)-5.4(r)4.4(e)-393.7(r)-1.7(ev)-5.4(iew)-384.9(o)-5.4(n)-389.5(t)1.2(he)-393.7(related)-389.5(quest)-4.9(ion)-5.4(n).7(ai)-4.9(res)-4.5(.)-389.5(Face)-387.6(and)]TJ
0 -1.128 TD
-.018 Tc
[(cont)-5.3(en)-5.8(t)-273.6(v)-5.8(al)-5.3(idit)-5.3(y)-280.1(o).3(f)-276.4(t)-5.3(he)-278.3(prelim)-5.2(inar)]TJ
12.8834 0 TD
-.0177 Tc
[(y)-273.8(d)-5.5(es)-4.6(igned)-279.8(quest)-5(ionnaire)-278(w)-17.7(a)13.2(s)-279(as-)]TJ
-12.8834 -1.1219 TD
-.0173 Tc
[(s)-4.2(e)2.9(s)-4.2(s)-168.9(usin)-5.1(g)-163.6(quali)-4.6(tativ)-5.1(e)-167.8(m)1.6(et)-4.6(hods)-168.9(and)-163.6(calculatin)-5.1(g)-163.6(I)-1.4(mpact)-163.1(s)-4.2(c)2.9(o)-5.1(r)4.7(e,)-169.7(con)-5.1(t)1.5(ent)]TJ
0 -1.128 TD
[(v)-5(a)3(l)-4.5(i)1.6(dit)-4.5(y)-230.6(ratio)-236.7(\(CVR\))-232.9(a)-3.1(nd)-230.6(cont)-4.5(en)-5(t)-230.1(v)1.1(ali)-4.5(d)1.1(it)-4.5(y)-230.6(I)-1.3(ndex)-230.6(\()-1.3(CVI\).)-230.6(Exp)-5(l)1.6(oratory)]TJ
0 -1.1219 TD
-.016 Tc
[(Fac)4.2(t)-3.3(or)-262.2(Analysis)-265.1(wa)4.2(s)-265.1(t)2.8(he)4.2(n)-266(p)2.3(e)4.2(rformed)-266(us)3.2(ing)-259.9(V).8(arimax)-259.9(rota)4.2(tion)-259.9(to)-259.9(as)3.2(-)]TJ
0 -1.128 TD
-.0174 Tc
[(s)-4.3(e)2.8(s)-4.3(s)-345.8(con)-5.2(s)1.8(truct)-346.1(v).9(alidi)-4.7(t)1.4(y)-346.6(o).9(f)-342.9(t)1.4(h)-5.2(e)-344.7(questi)-4.7(onnaire.)-340.5(Th)-5.2(e)-344.7(r)4.6(eli)-4.7(a)2.8(b)-5.2(ili)-4.7(ty)-340.5(o)-5.2(f)-342.9(the)]TJ
T*
-.0184 Tc
[(q)-6.2(u)-.1(es)-5.3(tio)-6.2(nnaire)-187.2(w)-1.6(as)-188.2(as)-5.3(sessed)-183(u)-.1(s)-5.3(i).4(ng)-189.1(inte)]TJ
14.1882 0 TD
-.0172 Tc
[(rnal)-181.3(cons)-4.1(ist)-4.5(e)3(ncy)-181.8(a)-3.1(nd)-181.8(t)-4.5(e)3(s)-4.1(t)-181.3(ret)-4.5(e)3(s)-4.1(t)]TJ
-14.1882 -1.1219 TD
-.0167 Tc
[(stability)-260.6(meas)2.5(urement.)-260.6(Data)-258.7(was)-259.7(a)-2.6(nalyze)3.5(d)-260.6(b)1.6(y)-260.6(v)1.6(ers)2.5(i)-4(on)-260.6(22)-260.6(of)-256.8(SPSS)4.8(.)]TJ
/F3 1 Tf
.9999 -1.128 TD
0 Tc
(Results:)Tj
/F4 1 Tf
3.9083 0 TD
[(Th)22.6(e)-418.8(p)12.2(re)17.8(l)12.7(i)0(m)19.4(i)0(n)18.8(a)0(r)17.8(y)-414.6(qu)18.3(es)21.1(ti)19.3(on)18.3(n)12.2(a)0(i)14.6(r)0(e)-402.9(w)0(i)17.3(t)0(h)-408(1)12.2(37)-408.5(i)12.7(t)0(e)14.6(m)12.8(s)-419.8(w)0(a)18.7(s)]TJ
-4.9082 -1.1219 TD
[(de)14.1(s)13.1(i)0(g)18.8(n)12.2(ed)-345.6(b)12.2(y)-353.6(t)12.7(h)0(e)-345.6(q)12.2(ua)20.2(li)19.3(ta)14.6(t)12.7(i)0(v)18.8(e)-351.7(pa)20.2(rt)-343.3(an)20.2(d)-353.6(t)0(h)18.8(e)-351.7(li)19.3(te)20.7(ra)17.8(tu)18.8(re)-341.9(re)17.9(v)12.2(i)0(e)14.6(w)0(.)-342.9(A)0(f)20.6(t)12.7(er)]TJ
0 -1.128 TD
[(qu)18.3(al)20.7(it)19.3(at)14.6(i)12.7(v)12.2(e)-296.9(f)0(a)17.8(c)0(e)-288.9(v)12.2(al)20.7(id)18.8(it)19.3(y)-298.7(a)14.1(ss)13.9(e)14.1(s)0(s)20(m)0(e)14.7(n)12.2(t)-298.2(b)12.2(y)-292.6(2)0(0)-286.5(p)0(a)20.2(r)0(t)16.5(i)12.7(ci)14.6(p)12.2(a)0(n)20.2(t)0(s)-285.2(a)0(s)-289.9(w)0(e)18.7(l)12.7(l)-298.2(a)0(s)]TJ
0 -1.1219 TD
[(ca)16(l)12.7(c)0(u)14.1(l)12.7(at)20.7(in)18.8(g)-310.9(i)12.7(mp)18.9(ac)16(t)-310.4(s)13.1(co)20.2(re)-305.3(o)12.2(f)-307.2(th)18.8(e)-309(i)0(t)19.3(e)0(m)14.7(s)13.1(,)-310.9(1)12.2(31)-298.7(it)19.3(em)14.7(s)-310.1(w)0(e)18.7(r)0(e)-299.2(r)0(e)17.8(m)12.8(ai)20.7(ne)14.1(d)12.2(.)]TJ
0 -1.128 TD
[(Th)16.5(en)-461.5(t)12.7(h)0(e)-461.5(q)0(u)18.3(e)0(s)21.1(t)0(i)19.3(o)0(n)18.3(n)12.2(ai)14.6(re)23.9(s)-464.9(co)20.2(n)12.2(t)0(e)14.6(n)12.2(t)-469(v)0(a)20.2(l)0(i)19.3(d)0(i)18.8(t)0(y)-462.8(w)0(a)18.7(s)-468.6(as)15(s)13.1(e)0(s)21.1(s)0(e)15(d)-469.5(b)12.2(y)-475.5(1)12.2(0)]TJ
0 -1.1219 TD
[(ex)14.1(p)12.2(e)0(r)17.8(t)12.7(s)-675.9(a)0(n)20.2(d)-670.7(av)20.2(er)17.8(ag)20.2(e)-674.9(C)0(V)18.2(R)]TJ
/F2 1 Tf
11.3713 0 TD
(=)Tj
/F4 1 Tf
.5426 0 TD
-.0162 Tc
[(an)-16.2(d)-680.7(S)-16.2(-)3(C)-16.2(VI)]TJ
/F2 1 Tf
4.6522 0 TD
0 Tc
(=)Tj
/F4 1 Tf
.5427 0 TD
[(0)12.2(.)12.2(9)0(8)-664.5(w)0(e)18.7(r)0(e)-665(o)12.2(bt)18.8(ai)20.7(ne)14.1(d)12.2(.)]TJ
-17.1087 -1.128 TD
[(Th)16.5(er)17.8(e)14.1(a)0(f)17.8(t)0(e)14.6(r)0(,)-325.5(q)0(u)18.3(e)0(s)21.1(t)0(i)19.3(o)12.2(nn)18.3(ai)20.7(re)-335.8(wi)23.4(th)]TJ
/F9 1 Tf
12.3895 0 TD
(.)Tj
/F4 1 Tf
1.3414 0 TD
[(i)12.7(t)0(e)14.6(m)12.8(s)-340.6(w)0(e)18.7(r)0(e)-329.7(c)0(o)20.2(m)0(p)18.9(l)0(e)20.7(t)0(e)14.6(d)-335.3(by)-329.2(28)18.3(7)]TJ
-13.7309 -1.1219 TD
[(me)14.7(n)12.2(o)12.2(p)0(a)20.2(u)0(s)19.2(a)0(l)-332.9(w)0(o)16.8(m)12.8(en)-333.4(an)20.2(d)-341.4(t)12.7(he)-333.4(d)12.2(a)0(t)14.6(a)-339.5(we)18.7(re)-329.7(an)20.2(al)14.6(y)12.2(z)0(e)16(d)-335.3(by)-335.3(Ex)22.6(p)12.2(l)0(o)18.9(r)0(a)17.8(t)0(o)18.8(r)0(y)]TJ
0 -1.128 TD
[(Fa)17.3(ct)20.7(or)-166.9(An)16.8(al)20.7(y)12.2(s)0(i)19.7(s)-182(t)12.7(o)-176.8(as)21.1(se)15(s)13.1(s)-175.9(th)18.8(e)-181(c)0(o)20.2(n)12.2(st)19.7(ru)16(c)14.1(t)-176.3(va)14.1(l)12.7(i)0(d)18.8(i)12.7(ty)18.9(.)-176.8(T)0(h)16.5(e)-174.9(v)12.2(a)0(l)14.6(u)12.2(e)-174.9(o)0(f)-166.9(K)0(M)17.7(O)]TJ
0 -1.1219 TD
[(wa)18.7(s)-365(s)0(a)21.1(t)0(i)19.3(s)0(f)16.8(a)0(c)16(t)12.7(o)12.2(r)0(y)-356(\()0(0)22.1(.)0(9)18.3(2)12.2(\))-362.1(a)0(n)14.1(d)-359.7(t)12.7(h)0(e)-357.8(B)13.6(ar)17.8(tl)19.3(et)20.7(t)16.5(s)-365(t)12.7(es)21.1(t)-365.3(o)12.2(f)-368.2(S)0(p)21.6(h)12.2(er)17.9(i)12.7(c)0(i)14.6(t)12.7(y)-365.8(w)0(a)18.7(s)]TJ
0 -1.128 TD
[(si)19.7(gn)18.3(i)22.1(ca)16(n)12.2(t)-170.2(\(P)]TJ
/F2 1 Tf
5.1216 0 TD
(<)Tj
/F4 1 Tf
.5426 0 TD
[(0)12.2(.)0(0)18.3(0)12.2(01)18.3(\).)-160.9(Sc)17.3(re)17.8(e)-168.8(p)12.2(lo)18.8(t)-170.2(i)0(n)18.8(s)13.1(pe)14.1(c)14.1(t)0(i)19.3(o)0(n)-164.6(a)14.1(nd)-164.6(Ka)18.7(i)12.7(s)0(e)21.1(r)0()19.7(s)-175.9(c)14.1(r)0(i)16.5(t)12.7(er)17.8(io)18.8(n)]TJ
-5.6643 -1.1219 TD
[(sh)19.2(ow)16.8(ed)-443.2(6)-457.3(f)0(a)23.9(c)0(t)14.6(o)12.2(rs)-446.6(i)12.7(n)12.2(cl)14.6(u)12.2(d)12.2(i)0(n)18.9(g)-457.3(Ph)21.6(y)12.2(s)0(i)19.7(c)0(a)16(l)-450.7(sy)19.2(mp)18.9(to)18.9(m)12.8(s)0(,)-444.2(P)0(s)16.3(y)12.2(ch)20.2(ol)18.9(o)12.2(g)0(i)18.9(c)0(a)16(l)]TJ
27.0045 71.9468 TD
[(s)13.1(y)0(m)18.9(p)12.2(to)18.8(ms)19.7(,)-414.6(C)0(o)19.7(n)0(c)14.1(e)14.1(r)0(n)16(s)13.1(,)-414.6(A)0(t)17.3(t)0(i)19.3(t)0(u)18.8(d)12.2(e,)-406.6(Fe)17.3(el)20.7(in)18.8(g)12.2(s)-419.8(an)20.2(d)-414.6(A)0(d)16.8(a)14.1(pt)18.8(at)20.7(io)18.9(n)-414.6(w)0(h)16.8(i)12.7(ch)]TJ
0 -1.128 TD
[(ex)20.2(p)12.2(l)0(a)14.6(i)12.7(n)12.2(e)0(d)-174.9(6)12.2(2.)18.3(2)12.2(%)-185.2(o)12.2(f)-185.3(t)12.7(h)0(e)-174.9(t)0(o)18.9(t)12.7(al)-174.4(va)20.2(ri)16.5(an)20.2(ce)16(.)-176.8(R)0(e)15.5(l)12.7(ia)14.6(b)12.2(i)12.7(li)19.3(ty)-176.3(o)12.2(f)-185.3(QA)21.4(WE)18.4(M)-182(w)0(a)18.7(s)]TJ
0 -1.1219 TD
[(ev)20.2(al)20.7(ua)20.2(te)14.6(d)-158.5(a)0(s)-155.8(s)0(a)21.1(t)0(i)19.3(s)0(f)16.8(a)0(c)22.1(t)0(o)18.8(r)0(y)-154.7(b)12.2(y)-164.6(i)12.7(nt)18.8(er)17.8(n)12.2(a)0(l)-156.1(c)0(o)20.2(n)12.2(si)19.7(st)13.6(e)14.1(n)0(c)20.2(y)-164.6(\()]TJ
/F7 1 Tf
18.9745 0 TD
(a)Tj
/F4 1 Tf
.6646 0 TD
[(Ch)19.7(ro)22.1(na)20.2(ch)]TJ
/F2 1 Tf
3.8107 0 TD
(=)Tj
/F4 1 Tf
.7134 0 TD
-.0122 Tc
[(0.7)-12.2(\))]TJ
-24.1632 -1.128 TD
0 Tc
[(an)20.2(d)-317(t)0(h)18.8(e)-321.2(te)20.7(st)19.7(-r)19.7(et)14.6(e)14.1(s)0(t)-315.7(s)13.1(ta)20.7(bi)18.8(li)19.3(ty)-310.4(co)20.2(ef)17.8(c)17.3(i)12.7(e)0(n)20.2(t)-322.6(o)12.2(f)-319.4(0.)18.3(7)12.2(8)0(.)-310.9(F)0(i)22.1(n)0(a)20.2(l)0(l)19.3(y)-323.1(QA)21.4(WE)18.4(M)]TJ
0 -1.1219 TD
[(wa)18.7(s)-261.3(i)12.7(n)12.2(t)0(r)16.5(o)12.2(du)18.3(ce)16(d)-256.1(b)0(y)-249.9(4)0(4)-249.9(i)0(t)19.3(e)0(m)20.8(s)-261.3(sc)15(o)12.2(r)0(i)22.6(n)0(g)-249.9(1)-262.2(to)-249.4(5)-262.1(\()0(n)22.1(e)0(v)20.2(e)0(r)-256.5(t)12.7(o)-262.1(a)14.1(lw)17.3(ay)20.2(s\))-251.5(wi)17.3(t)12.7(h)]TJ
0 -1.128 TD
[(t)12.7(o)0(t)18.8(a)0(l)-320.7(r)0(a)17.8(n)12.2(ge)-327.3(o)12.2(f)-331.6(4)12.2(4)-335.3(t)12.7(o)-329.2(22)18.3(0)-329.2(w)0(h)16.8(i)12.7(ch)-327.3(i)12.7(s)-334.5(c)14.1(a)0(l)14.6(c)14.1(ul)18.8(at)14.6(e)14.1(d)-335.3(a)14.1(s)-334.5(p)12.2(e)0(r)17.9(c)0(e)16(n)12.2(t)-334.8(f)0(o)22.1(r)-331.6(ea)22.1(ch)]TJ
0 -1.1219 TD
[(fa)17.8(c)14.1(t)0(o)18.9(r)-252.3(as)-241.1(we)18.7(l)12.7(l)-249.5(as)-241.1(fo)16(r)-246.2(t)0(o)18.8(t)0(a)20.7(l)-255.6(s)13.1(c)0(o)20.2(r)0(e)17.8(.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Conclusions:)Tj
/F4 1 Tf
5.8167 0 TD
[(QAWEM)-331.2(is)-333.9(a)-327.3(valid)-332.3(and)-333.4(reliable)-330.4(tool)-328.1(to)-334.8(assess)]TJ
-6.8167 -1.1219 TD
[(womens)-402.9(experiences)-406(of)-404.7(menopause.)-407.4(QAWEM)-404.4(with)-408.9(6)-402.4(factors)]TJ
0 -1.128 TD
[(including:)-294.6(concern,)-301.4(attitude,)-298.9(feeling)-302.3(and)-296.8(adaptation)-297.5(experiences)]TJ
0 -1.1219 TD
[(during)-251.7(menopause;)-260.5(is)-254.7(able)-257.8(to)-261.6(evaluate)-259.6(all)-253.1(aspects)-260.3(of)-258.4(menopausal)]TJ
0 -1.128 TD
[(womens)-378.5(experiences)-381.6(of)-380.4(health)-385.3(and)-376.1(so)-383.2(their)-377.4(quality)-380.6(of)-380.4(life.)-383.5(In)]TJ
0 -1.1219 TD
[(compare)-258.2(to)-261.6(other)-256(instruments,)-258.7(QAWEM)-264.1(shows)-255.8(more)-262(acceptable)]TJ
0 -1.128 TD
[(construct)-301.4(validity,)-300.8(reliability)-300.2(and)-302.9(internal)-301.8(consistency.)]TJ
/F3 1 Tf
0 -4.1095 TD
(81.)Tj
9.843 0 0 9.843 331.7668 551.3384 Tm
[(The)-281.8(Impact)-279.2(of)-284.4(the)-280.7(Severity)-282.9(of)-278.6(Menopausal)]TJ
0 -1.1116 TD
[(Symptoms)-281.1(on)-278.5(the)-280.7(Sexual)-284.1(Function)]TJ
0 -1.1174 TD
[(of)-278.6(Post-Menopausal)-285.3(Women)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 310.8472 512.8439 Tm
[(Masoumeh)-335.2(Simbar)]TJ
6.9735 0 0 6.198 382.1668 516.9825 Tm
(1)Tj
9.2982 0 0 9.2982 385.6818 512.8439 Tm
[(,)-335.3(Soheila)-333.3(Nazarpour)]TJ
6.9735 0 0 6.198 461.4802 516.9825 Tm
(2)Tj
9.2982 0 0 9.2982 464.9951 512.8439 Tm
(,)Tj
-16.5783 -1.1219 TD
[(Fahimeh)-333.3(Ramezani)-337.4(Tehrani)]TJ
6.9735 0 0 6.198 416.0692 506.551 Tm
(3)Tj
/F5 1 Tf
-15.0888 -2.6526 TD
(1)Tj
9.2982 0 0 9.2982 314.3054 485.9715 Tm
[(Department)-338.6(of)-328.7(Midwifery)-330(and)-335.3(Reproductive)-333.6(Health,)-327.7(School)-332.8(of)]TJ
-.3719 -1.128 TD
[(Nursing)-319.4(and)-317(Midwifery,)-317.8(Reproductive)-321.4(Endocrinology)-319.1(Research)]TJ
0 -1.1219 TD
[(Center,)-334.8(Research)-335.8(Institute)-332.8(for)-333.9(Endocrine)-338(Sciences,)-332.4(Shahid)]TJ
0 -1.128 TD
[(Beheshti)-331.4(University)-340(of)-334.8(Medical)-332.8(Science,)-333.2(Tehran,)-335.3(Iran)]TJ
6.9735 0 0 6.198 310.8472 448.2708 Tm
(2)Tj
9.2982 0 0 9.2982 314.3054 444.1322 Tm
[(Department)-338.6(of)-328.7(Midwifery)-330(and)-335.3(Reproductive)-333.6(Health,)-327.7(School)-332.8(of)]TJ
-.3719 -1.128 TD
[(Nursing)-307.2(and)-304.8(Midwifery,)-305.6(Shahid)-304.2(Beheshti)-307(University)-309.5(of)-310.4(Medical)]TJ
0 -1.1219 TD
[(Sciences)-332.4(and)-335.3(Health)-333.8(Services,)-337.6(Tehran,)-335.3(Iran)]TJ
6.9735 0 0 6.198 310.8472 416.8629 Tm
(3)Tj
9.2982 0 0 9.2982 314.3054 412.7243 Tm
[(Gynecology,)-340.8(Reproductive)-333.6(Endocrinology)-337.4(Research)-335.8(Center,)]TJ
-.3719 -1.1219 TD
[(Research)-335.8(Institute)-332.8(for)-333.9(Endocrine)-338(Sciences,)-332.4(Shahid)-334.7(Beheshti)]TJ
0 -1.128 TD
[(University)-333.9(of)-334.8(Medical)-332.8(Sciences,)-338.5(Tehran,)-335.3(Iran)]TJ
/F3 1 Tf
.9999 -2.3047 TD
(Background:)Tj
/F4 1 Tf
5.9935 0 TD
-.0234 Tc
[(Menopaus)-4.2(e)-350.7(i)1.5(s)-351.8(a)-356.8(normal)-352.1(e)-3.2(vent)-352.1(in)-352.6(wom)-4.6(e)2.9(n)-5.1()4.7(s)-357.9(lives)]TJ
-6.9935 -1.1219 TD
-.0242 Tc
[(that)-285.9(is)-285.5(of)-282.6(ut)-5.4(mos)-5(t)-279.8(i)-5.4(m).8(port)-5.4(a)2.1(n)-5.9(c)2.1(e)-284.5(a)-4(s)-285.5(one)-284.5(of)-282.6(h)-5.9(e)2.1(alt)-5.4(h)-280.3(i)-5.4(ssu)-5.9(es)-285.5(in)-286.3(the)-284.5(r)-2.2(ange)-284.5(o)-5.9(f)]TJ
0 -1.128 TD
-.0237 Tc
[(rep)-5.4(r)4.4(o)-5.4(ductiv)-5.4(e)-430.3(h).7(eal)-4.9(t)1.2(h.)-432.2(This)-431.3(perio)-5.4(d)-426.1(t)-4.9(ime)-430.3(form)-4.9(s)-425.2(a)-436.4(com)-4.9(p).7(lex)-432.2(s)1.6(tage)-430.3(o)-5.4(f)]TJ
0 -1.1219 TD
[(womens)-205.7(l)-4.9(ife)-210.8(due)-210.8(to)-206.6(ph)-5.4(ysi)-4.9(c)2.6(al)-206.1(and)-206.6(m)-4.8(ent)-4.9(a)2.6(l)-212.2(c)2.6(h)-5.4(a)2.6(n)-5.4(g).7(es)-4.5(.)-206.6(A)-.8(fter)-209(menopaus)-4.5(e,)]TJ
0 -1.128 TD
-.0243 Tc
[(the)-248(ovari)-5.5(es)-242.9(s)-5.1(t).6(op)-243.8(th)-6(e)-241.9(p).1(rodu)-6(ci)-5.5(ng)-243.8(of)-240(cons)-5.1(iderab)-6(le)-241.9(amou)-6(nts)-242.9(o).1(f)-246.1(e)2(s)-5.1(t).6(rogen.)]TJ
0 -1.1219 TD
-.0232 Tc
[(Therefore,)-267.1(th)-4.9(e)-265.2(s)-4(ympt)-4.4(oms)-272.3(a)3.1(n)-4.9(d)-267.1(dis)-4(e)3.1(as)]TJ
13.8223 0 TD
-.0213 Tc
[(es)-270.4(a)5(s)-2.1(s)4(o)3.1(ciated)-265.2(with)-265.2(es)4(tr)6.8(ogen)-265.2(de-)]TJ
-13.8223 -1.128 TD
-.0231 Tc
[(ci)-4.3(e)3.2(ncy)-260.9(s)-3.9(how)-262.4(a)-265.1(g)1.3(rowin)-4.8(g)-260.9(im)-4.3(portance)-259(i)-4.3(n)-260.9(w)-.2(omens)-266.1(healt)-4.3(h)-260.9(\(1\).)-260.9(There-)]TJ
0 -1.1219 TD
-.0237 Tc
[(fore,)-249.3(a)-3.5(ny)-249.3(dis)-4.5(o).7(rder)-245.5(l)-4.9(e)2.6(adi)-4.9(n).7(g)-249.3(t)1.2(o)-249.3(i)1.2(ncons)-4.5(is)-4.5(tency)-5.4(,)-243.2(and)-249.3(t)1.2(h)-5.4(u).7(s,)-249.3(di)-4.9(ssati)-4.9(sfact)-4.9(i)1.2(on)]TJ
0 -1.128 TD
-.0241 Tc
[(of)-258.1(s)-4.9(e)-3.9(xual)-261.4(r)-2.1(el)-5.3(at)-5.3(ions)-261(can)-261.9(be)-260(ass)-4.9(o).3(ci)-5.3(at)-5.3(ed)-261.9(wi)-5.3(th)-261.9(sexual)-261.4(dys)-4.9(functio)-5.8(n)]TJ
/F3 1 Tf
.9999 -1.1219 TD
0 Tc
(Objective\(s\):)Tj
/F4 1 Tf
5.8472 0 TD
[(The)-341.3(purpose)-340.9(of)-343.8(this)-339.5(study)-340(was)-340.1(to)-340.9(examine)-346.8(the)]TJ
-6.8471 -1.128 TD
[(correlation)-351(between)-348.8(the)-345.1(severity)-350.2(of)-349.9(menopausal)-345.9(symptoms)-350.2(and)]TJ
0 -1.1219 TD
[(sexual)-299.6(function.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Material/Methods:)Tj
/F4 1 Tf
8.5422 0 TD
-.0178 Tc
[(This)-437.6(is)-431.5(a)-436.6(c)-3.7(om)7.1(munity-b)6.6(ased,)-438.5(d)6.6(escrip)6.6(tive-)]TJ
-9.5421 -1.1219 TD
[(analytical)-395.3(study)-395.8(of)-398.2(405)-395.8(post-meno)6.6(pau)6.6(s)1.4(al)-395.3(women,)-395.8(ag)6.6(ed)-395.8(40)-395.8(to)-395.8(60)]TJ
0 -1.128 TD
-.019 Tc
[(years.)-159.2(A)-166.8(m)-.1(u)5.4(lti-stage,)-165.3(rand)5.4(om)-164.8(sampling)-159.2(w)-2.2(as)-164.5(conducted.)-165.3(The)-163.4(d)-.7(ata)-163.4(w)-2.2(as)]TJ
0 -1.1219 TD
-.0181 Tc
[(ob)6.3(tained)-280.2(using)-280.2(t).7(he)-284.5(Female)-278.4(Sexual)-279.8(F)-2.7(unction)-280.2(I)3.9(ndex)-280.2(\()3.9(FSFI\),)-280.3(the)-278.4(M)1.1(e-)]TJ
0 -1.128 TD
-.0184 Tc
[(no)6(pause)-205.5(R)1.3(ating)-207.4(S)3.1(cale)-205.5(\(MRS\),)-201.3(and)-201.3(a)-205.5(researcher-made)-205.5(ques)-5.3(tio)6(nnaire.)]TJ
/F3 1 Tf
.9999 -1.128 TD
0 Tc
(Results:)Tj
/F4 1 Tf
3.8046 0 TD
-.018 Tc
[(Sexual)-334.5(dysfunction)-328.9(w)-1.2(as)-328.1(observed)-328.9(i).8(n)-328.9(61%)-331.3(of)-331.3(the)-327.1(s)-4.9(ub-)]TJ
-4.8046 -1.1219 TD
-.0181 Tc
[(jects.)-274.2(The)-266.2(p).2(s)-5(y).2(chologi)-5.4(cal)-267.6(s)1.1(ymp)-5.9(t).7(oms)-267.2(w)-1.3(ere)-266.2(i)-5.4(dentied)-274.2(as)-273.3(the)-272.3(m).7(ost)-273.7(s)1.1(e-)]TJ
0 -1.128 TD
[(vere)-260.1(m)-5.3(e)2.1(nopausal)-261.5(s)-5(y).2(mptoms,)-262(a)-4(nd)-262(the)-266.2(l).7(owest)-261.5(s)-5(core)-260.1(was)-261.1(obtained)-262(b).2(y)]TJ
0 -1.1219 TD
[(uro)-5.9(g).2(enital)-328.5(s)-5(ymptoms.)-335.1(The)-333.3(s)1.1(cores)-328.2(i)-5.4(n)-329(a)-4(ll)-328.5(domains)-334.3(of)-331.4(MRS)-331.9(a)2.1(nd)-335.1(the)]TJ
0 -1.128 TD
-.0187 Tc
[(MRS)-234.9(t)-6(otal)-237.7(sc)-4.6(ores)-237.3(were)-236.3(in)-238.2(a)-236.3(n)-.4(ega)-4.6(tiv)]TJ
13.4321 0 TD
[(e)-236.2(c)-4.5(orrelati)-5.9(on)-232(with)-238.1(the)-236.2(F)-3.2(SFI)-234.3(t)-5.9(otal)]TJ
-13.4321 -1.1219 TD
-.0179 Tc
[(sco)-5.7(r)4.1(e)-3.8(s)-328(\(P)]TJ
/F2 1 Tf
3.573 0 TD
0 Tc
(=)Tj
/F4 1 Tf
.5305 0 TD
-.0181 Tc
[(0.000\).)-329(I)-2.2(n)-335.1(t).7(he)-333.3(women)-335.1(w)4.8(i)-5.4(t).7(h)-329(d).2(im)-5.3(inished)-329(s)1.1(exual)-334.6(r)-2.1(elations)]TJ
-4.1034 -1.128 TD
-.0185 Tc
[(and)-177(s).7(exualit)-5.8(y)-170.9(a)-4.4(ft)-5.8(er)-173.3(menopaus)-5.4(e,)-177(the)-175.1(u)-.2(rogenit)-5.8(a)1.7(l)-176.5(s).7(cores)-176.2(a)1.7(nd)-177(total)-176.5(s).7(cores)]TJ
0 -1.1219 TD
-.0179 Tc
[(of)-319(MRS)-319.5(w)-1.1(ere)-320.9(s)1.3(ignicantly)-322.7(higher,)-322.7(comparing)-316.6(t)-5.2(o)-316.6(o).4(thers)-315.8(\()-2(P)]TJ
/F2 1 Tf
22.773 0 TD
0 Tc
(=)Tj
/F4 1 Tf
.5305 0 TD
-.0183 Tc
(0.000,)Tj
-23.3035 -1.128 TD
0 Tc
(P)Tj
/F2 1 Tf
.5305 0 TD
(=)Tj
/F4 1 Tf
.5365 0 TD
-.0181 Tc
[(0.001\).)-298.6(T)-1.6(he)-302.8(urogeni)-5.4(tal)-304.1(s)1.1(cores)-303.8(\()3.9(r)]TJ
/F2 1 Tf
12.3346 0 TD
0 Tc
(=)Tj
/F4 1 Tf
.5366 0 TD
-.0183 Tc
[(0.283,)-298.8(P)]TJ
/F2 1 Tf
3.2254 0 TD
0 Tc
(=)Tj
/F4 1 Tf
.5305 0 TD
-.0181 Tc
[(0)-5.9(.000\))-300.9(and)-304.6(t).7(he)-302.8(MRS)]TJ
-17.694 -1.1219 TD
-.0173 Tc
[(total)-303.3(s)1.9(cores)-303(\()-1.4(r)]TJ
/F2 1 Tf
5.335 0 TD
0 Tc
(=)Tj
/F4 1 Tf
.5305 0 TD
-.0183 Tc
[(0.116,)-304.9(P)]TJ
/F2 1 Tf
3.2315 0 TD
0 Tc
(=)Tj
/F4 1 Tf
.5366 0 TD
-.0179 Tc
[(0.020\))-300.7(had)-304.4(a)-308.7(signicant,)-304.5(posi)-5.2(tive)-308.7(c)2.3(orrela-)]TJ
-9.6336 -1.128 TD
-.0184 Tc
[(tion)-347.6(w)-1.6(ith)-347.6(dis)-5.3(s).8(at)-5.7(isfaction)-347.6(w)-1.6(ith)-347.6(sexual)-347.1(r)-2.5(elati)-5.7(onship.)-347.6(The)-345.7(s)-5.3(everit)-5.7(y)-347.6(o)-.1(f)]TJ
0 -1.1219 TD
-.018 Tc
[(menopausal)-176(symptoms)-175.7(was)-175.7(a)-174.6(neg)-5.8(a)2.2(tive,)-176.5(prognos)-4.9(tic)-174.6(factor)-178.9(in)-176.5(the)-174.6(F)-2.6(SFI)]TJ
0 -1.128 TD
-.0177 Tc
[(total)-242.8(s)1.5(cores)-248.5(a)2.5(nd)-249.4(the)-247.5(s)1.5(cores)-242.4(i)-5(n)-243.3(a)2.5(l)-5(l)-242.8(domains)-248.5(of)-245.6(sexual)-248.9(f)4.3(unction)-249.4(e)2.5(xcept)]TJ
0 -1.1219 TD
[(sat)-5(i)1.1(sfaction.)-359.1(The)-357.2(M)1.5(R)-4.1(S)-355.9(total)-352.5(s)1.5(core)-351.1(was)-352.2(a)-357.2(predictor)-355.4(f)-1.8(or)-355.4(the)-357.2(r)-1.8(ate)-357.2(o).6(f)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 59.7543 749.7069 Tm
0 Tc
(ABSTRACTS)Tj
52.6193 0 TD
(A-31)Tj
ET
endstream
endobj
324 0 obj
<>stream
/GS1 gs
BT
/F4 1 Tf
9.2982 0 0 9.2982 62.022 725.5557 Tm
0 0 0 rg
-.0179 Tc
0 Tw
[(variation)-243.5(i).9(n)-237.4(s)1.3(exual)-243(r)4.1(elat)-5.2(ions)-236.5(and)-237.4(s)]TJ
12.859 0 TD
-.0182 Tc
[(exuali)-5.5(ty)-237.7(after)-240(m).7(enop)-6(ause,)-237.7(a)2(s)-242.9(w)-1.4(ell)]TJ
-12.859 -1.128 TD
[(as)-255.2(s)-5.2(a)1.9(tis)-5.2(fact)-5.6(ion)-256.1(w)-1.5(it)-5.6(h)-256.1(m).6(arital)-261.7(r)-2.4(el)-5.6(ations)-5.2(hip.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
0 Tc
(Conclusions:)Tj
/F4 1 Tf
5.9082 0 TD
[(The)-420.6(severity)-423.4(of)-423(menopausal)-425.1(symptoms)-417.3(could)]TJ
-6.9081 -1.128 TD
[(have)-215.6(a)-211.5(negative)-212.7(impact)-214.1(on)-207.3(sexual)-214.2(function.)-212.7(Thus)-208.2(these)-214.3(symptoms)]TJ
0 -1.1219 TD
[(need)-368.1(to)-365.3(be)-363.9(taken)-367.5(into)-364.7(consideration)-366(in)-365.3(implementing)-364.8(womens)]TJ
0 -1.128 TD
[(health)-300(initiatives)-303.1(regarding)-305.1(sexual)-299.6(function.)]TJ
/F3 1 Tf
0 -2.9327 TD
(82.)Tj
9.843 0 0 9.843 82.9417 645.9589 Tm
[(Experiences)-289.3(and)-279.4(Perceptions)-282.5(of)-284.4(Gynecologists)]TJ
0 -1.1116 TD
[(and)-279.4(Midwives)-283.7(About)-282.5(Virginity)-282.9(Examination)]TJ
T*
[(and)-279.4(its)-279.7(Consequence)-11.1(s)-277.4(o)0(n)-278.5(Youth)-282.5(Reproductive)]TJ
0 -1.1174 TD
[(Health:)-280.7(A)-284.2(Qualitative)-279.6(Study)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 62.022 596.5227 Tm
[(Masoumeh)-335.2(Simbar)]TJ
6.9735 0 0 6.198 133.3984 600.6613 Tm
(1)Tj
9.2982 0 0 9.2982 136.8567 596.5227 Tm
[(,)-335.3(Fatemeh)-337.5(Rahmanian)]TJ
6.9735 0 0 6.198 220.0251 600.6613 Tm
(2)Tj
9.2982 0 0 9.2982 223.5401 596.5227 Tm
(,)Tj
-17.3709 -1.1219 TD
[(Fahimeh)-333.3(Ramezani)-337.4(Tehrani)]TJ
6.9735 0 0 6.198 167.244 590.2297 Tm
(3)Tj
/F5 1 Tf
-15.0888 -2.6526 TD
(1)Tj
9.2982 0 0 9.2982 65.537 569.6503 Tm
[(Department)-332.5(of)-328.7(Midwifery)-336.1(and)-329.2(Reproductive)-333.6(Health,)-333.8(School)-332.8(of)]TJ
-.378 -1.128 TD
[(Nursing)-319.4(and)-317(Midwifery,)-317.8(Reproductive)-321.4(Endocrinology)-319.1(Research)]TJ
0 -1.1219 TD
[(Center,)-334.8(Research)-335.8(Institute)-338.9(for)-327.8(Endocrine)-338(Sciences,)-338.5(Shahid)]TJ
0 -1.128 TD
[(Beheshti)-337.5(University)-333.9(of)-334.8(Medical)-332.8(Science,)-339.3(Tehran,)-329.2(Iran)]TJ
6.9735 0 0 6.198 62.022 531.9495 Tm
(2)Tj
9.2982 0 0 9.2982 65.537 527.8109 Tm
[(Department)-332.5(of)-334.8(Midwifery,)-336.1(School)-332.8(of)-334.8(Nursing)-331.6(and)-335.3(Midwifery,)]TJ
-.378 -1.128 TD
[(Larestan)-333.9(Azad)-336.2(Islamic)-335.3(University,)-333.9(Fars,)-335.4(Shiraz,)-333(Iran,)]TJ
6.9735 0 0 6.198 62.022 511.0298 Tm
(3)Tj
9.2982 0 0 9.2982 65.537 506.8912 Tm
[(Reproductive)-333.6(Endocrinology)-337.4(Research)-335.8(Center,)-334.8(Research)]TJ
-.378 -1.128 TD
[(Institute)-332.8(for)-333.9(Endocrine)-338(Sciences,)-332.4(Shahid)-334.7(Beheshti)-337.5(University)]TJ
0 -1.1219 TD
[(of)-334.8(Medical)-332.8(Science,)-339.3(Tehran,)-329.2(Iran)]TJ
/F3 1 Tf
.9999 -2.3047 TD
(Background:)Tj
/F4 1 Tf
5.835 0 TD
[(Vi)23.4(rg)16(i)12.7(n)12.2(it)19.3(y)-225.6(e)14.1(xa)20.2(mi)19.4(na)20.2(ti)19.3(on)-213.3(i)12.7(s)-224.7(k)12.2(n)12.2(o)0(w)16.8(n)-219.5(as)-210.6(a)-223.7(c)0(u)20.2(s)13.1(to)18.8(m)-225(a)14.1(nd)]TJ
-6.835 -1.128 TD
[(n)12.2(o)0(r)16(m)-420.1(in)-420.1(s)13.1(o)12.2(me)-418.2(co)20.2(u)12.2(n)0(t)18.8(r)0(i)16.5(e)0(s)-411.8(i)0(n)18.8(c)0(l)20.7(u)0(d)18.3(i)0(n)18.8(g)-420.7(Ir)19.7(an)-418.8(an)20.2(d)-426.8(m)12.8(ed)20.2(ic)20.7(al)-418.3(t)12.7(e)0(a)16(m)0(s)-413.2(a)0(r)17.8(e)]TJ
0 -1.1219 TD
[(in)18.8(v)12.2(o)0(l)18.8(v)12.2(ed)-284.6(i)12.7(n)-292.6(th)18.8(e)-290.8(e)0(x)20.2(a)0(m)14.7(i)12.7(n)12.2(a)0(t)14.6(i)12.7(o)12.2(n)-292.6(an)20.2(d)-292.6(h)12.2(ym)18.9(en)-284.6(re)17.9(p)12.2(a)0(i)20.7(r)0(m)16.5(e)14.1(nt)-286(p)12.2(r)0(o)22.1(c)0(e)16(s)13.1(s.)-285.7(Th)22.6(e)]TJ
0 -1.128 TD
[(ma)20.7(in)-298.2(ai)20.7(ms)-303.4(fo)22.1(r)-307.2(v)12.2(ir)16.5(g)12.2(i)0(n)18.8(i)12.7(ty)-298.2(te)14.6(s)13.1(t)0(i)19.3(n)12.2(g)-310.9(a)0(r)17.8(e)-309.1(m)12.8(e)0(n)20.2(t)0(i)19.3(o)12.2(ne)14.1(d)-304.8(a)0(s)-296()58.6(a)23.9(ss)13.9(e)14.1(s)0(s)20(m)0(e)14.7(n)12.2(t)-310.4(o)12.2(f)]TJ
0 -1.1219 TD
[(ab)20.2(st)19.7(in)18.8(en)20.2(ce)16()64.7()0(,)-587.7()64.7(d)22.1(el)14.6(ay)-583.4(fo)16(r)-593.8(s)0(e)15(x)12.2(u)12.2(a)0(l)-589(r)0(e)17.8(l)12.7(at)14.6(i)12.7(o)0(n)18.3(s)13.1(hi)18.8(p)-597.5(u)12.2(nt)18.8(il)-590.4(m)12.8(a)0(r)17.9(r)0(i)22.6(a)0(g)14.1(e)14.1()58.6(,)]TJ
0 -1.128 TD
[()64.7()0(H)14.5(I)0(V)20.6(/)12.7(AI)20.6(DS)20.1(/S)16(TI)20.2(s)-285.7(p)0(r)16(e)0(v)20.2(e)0(n)20.2(t)0(i)19.3(o)12.2(n)70.8(,)-276.7()58.6()0(k)22.1(e)0(e)22.1(p)0(i)18.8(n)0(g)-280.4(h)12.2(on)18.3(o)12.2(r)-288.9(of)-282.8(fa)23.9(mi)19.4(ly)-279.9(b)12.2(y)-292.6(d)12.2(e)0(-)]TJ
0 -1.1219 TD
[(fe)17.8(n)12.2(d)0(i)18.8(n)12.2(g)-457.3(o)0(f)-447.4(f)0(e)17.8(m)12.8(al)14.6(e)14.1(s)0()-446.6(v)0(i)18.8(r)0(g)16(i)12.7(n)12.2(i)0(t)19.4(y)0()70.8()-453.5(in)-450.6(d)12.2(i)12.7(ff)19.7(er)17.8(en)20.2(t)-456.8(c)0(u)20.2(l)0(t)19.4(u)0(r)16(e)0(s)21.1(.)-457.3(Ho)22.9(we)18.7(ve)14.1(r,)]TJ
0 -1.128 TD
[(ma)20.7(ki)18.8(n)12.2(g)-371.9(a)-363.9(r)0(e)17.8(v)12.2(is)19.7(io)18.8(n)-365.8(i)0(n)-359.2(m)12.8(ed)20.2(ic)14.6(a)14.1(l)-371.4(p)12.2(r)0(a)17.8(c)0(t)20.7(i)0(t)19.3(i)0(o)18.8(n)12.2(er)17.8(s)-355.1(ro)16(l)12.7(e)-370(fo)22.1(r)-368.2(p)12.2(er)17.8(fo)22.1(rm)16.5(i)12.7(n)0(g)]TJ
0 -1.1219 TD
[(th)18.8(i)12.7(s)-316.2(pr)16(o)12.2(c)0(e)16(s)13.1(s)-316.2(i)0(s)-309.6(s)0(e)21.1(e)0(m)14.7(e)14.1(d)-317(e)0(s)15(s)13.1(en)20.2(ti)19.3(al)-308.5(fo)22.1(ll)19.3(ow)16.8(i)12.7(n)0(g)-310.9(d)12.2(i)12.7(f)0(f)13.6(e)14.1(re)17.8(n)12.2(t)-316.5(vi)18.8(ew)18.7(s)-316.2(o)0(f)-307.2(t)0(h)18.8(e)]TJ
0 -1.128 TD
[(p)12.2(r)0(a)17.8(c)0(t)20.7(i)0(t)19.3(i)0(o)18.8(n)0(e)20.2(r)0(s)-233.2(a)0(n)20.2(d)-237.8(to)18.8(wa)18.7(rd)22.1(s)-243(v)12.2(i)12.7(r)0(g)16(i)12.7(n)12.2(i)0(t)19.3(y)-243.9(t)12.7(e)0(s)21.1(t)0(i)19.3(n)0(g)-231.6(a)0(n)20.2(d)-237.8(h)12.2(y)0(m)18.9(e)0(n)-229.8(r)0(e)17.9(p)12.2(ai)14.6(rm)22.6(en)20.2(t.)]TJ
0 -1.1219 TD
[(It)-343.3(s)13.1(e)0(e)16(m)12.8(s)-352.8(n)12.2(ec)16(es)21.1(sa)15(ry)-337.7(to)-340.9(in)18.8(v)12.2(e)0(s)15(t)12.7(ig)18.8(at)20.7(e)-351.7(t)0(h)18.9(e)-351.7(re)17.8(l)12.7(a)0(t)20.7(e)0(d)-345.6(b)12.2(el)20.7(ie)14.6(fs)-336.8(to)-340.9(ma)14.7(k)12.2(e)-351.7(an)]TJ
0 -1.128 TD
[(in)18.8(fo)22.1(rm)16.5(e)14.1(d)-213.4(an)20.2(d)-207.3(r)0(e)17.8(s)0(p)19.2(o)12.2(ns)19.2(ib)18.8(l)12.7(e)-211.5(d)12.2(e)0(c)16(i)12.7(si)19.7(on)-201.2(fo)22.1(r)-209.7(r)0(e)17.8(p)0(r)16(o)12.2(d)12.2(u)0(c)20.2(t)0(i)19.3(v)0(e)-199.3(h)0(e)20.2(a)0(l)14.6(t)12.7(h)-207.3(s)0(y)19.2(s)0(t)19.7(e)0(m)14.6(.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.8106 0 TD
[(This)-262.6(qualitative)-259.9(study)-266.8(aims)-258.3(to)-261.6(explain)-263.3(gynecol-)]TJ
-6.8106 -1.128 TD
[(ogists)-280(and)-278.5(midwives)-279.9(perceptions)-281.2(and)-278.5(experiences)-284(towards)-280.9(vir-)]TJ
0 -1.1219 TD
[(ginity)-211.7(testing)-209(and)-205.4(its)-211.5(effects)-211(on)-213.3(youth)-206.7(sexual-reproductive)-214.4(health.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Material/Methods:)Tj
/F4 1 Tf
8.4263 0 TD
[(This)-360.1(was)-358.4(a)-357.8(qualitative)-363.5(study)-358.3(using)-358.3(con-)]TJ
-9.4263 -1.1219 TD
[(tent)-423.8(analysis)-420.1(approach.)-429.4(Fifteen)-421(participants)-426.5(including)-417.1(7)-426.8(gyne-)]TJ
0 -1.128 TD
[(cologists)-543.4(and)-540.7(8)-542.6(midwives)-539.7(recruited)-540.5(by)-542.6(purposeful)-543.9(sampling)]TJ
0 -1.1219 TD
[(method)-216.4(for)-218.1(beginning)-222.5(and)-217.5(then)-217(snowball)-223.2(sampling)-215(method.)-216.4(They)]TJ
0 -1.128 TD
[(were)-371.9(interviewed)-368.4(by)-365.8(semi-structured)-369.3(in-depth)-371.2(individual)-367.8(inter-)]TJ
0 -1.1219 TD
[(view)-285.6(using)-279(a)-284.7(guide)-278(questions.)-287.9(All)-280.9(interviews)-284.1(were)-280.5(recorded)-285.5(and)]TJ
0 -1.128 TD
[(transcribed)-204.3(verbatim.)-198.1(Transcripts)-207.2(were)-201.2(coded)-203.4(and)-199.3(analyzed)-199.1(using)]TJ
0 -1.1219 TD
[(conventional)-303.5(content)-299.9(analysis)-304.3(method.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Results:)Tj
/F4 1 Tf
3.8107 0 TD
[(Content)-373.6(analysis)-377.5(showed)-376.7(3)-371.9(categories)-376.9()52.5(the)-377.9(exami-)]TJ
-4.8107 -1.1219 TD
[(nations)-699.6(identity)56.6(,)-697.4()52.5(the)-695(examinations)-700.8(requirements)56.1(,)-697.4(and)]TJ
0 -1.128 TD
[()52.5(prevention)-231.4(of)-227.9(negative)-237.1(consequences)-232.5(of)-227.9(the)-235.3(examination)54.4(.)-227.9(The)]TJ
T*
[(category)-246(of)-240.1()52.5(the)-237.7(examination)-242.1(identity)50.5()-240.1(had)-241.9(three)-241.9(sub-categories)]TJ
0 -1.1219 TD
[(including)-234.2(1\))-227.9(the)-229.2(reasons)-234.5(for)-230.3(virginity)-231.8(testing,)-233.4(2\))-227.9(prognostic)-236.2(value)]TJ
0 -1.128 TD
[(of)-362.1(the)-363.4(examination,)-364(and)-363.9(3\))-362.1(expanding)-361.4(unusual)-368.5(sexual)-360.6(relation-)]TJ
0 -1.1219 TD
[(ships)-302.5(and)-309(STIs.)-298.8(T)16.5(h)24.4(e)-284.7(s)19.2(u)24.4(b)18.3(c)20.2(a)20.2(t)18.8(e)20.2(g)24.4(o)18.3(r)22(i)18.8(e)20.2(s)-279.6(o)18.3(f)-282.8()76.9()22(t)18.8(h)24.4(e)-284.7(e)20.2(x)18.3(a)20.2(m)25(i)18.8(n)18.3(a)20.2(t)24.9(i)18.8(o)24.4(n)18.3()22(s)-285.7(r)22(e)20.2(q)18.3(u)24.4(i)18.8(r)22(e)20.2(-)]TJ
0 -1.128 TD
-.0208 Tc
[(ment)56.1()-389(were)-390.8(1\))-389(the)-384.7(n)-2.5(eces)4.5(sity)-380.5(for)-389(p)]TJ
13.7004 0 TD
-.0218 Tc
[(lanning)-387.6(a)-1.6(nd)-387.6(monitoring)-387.6(of)-390(the)]TJ
-13.7004 -1.1219 TD
-.0209 Tc
[(examination)-313.5(p)3.5(rocess)-306.6(a)-.7(nd)-313.5(for)-309.8(t)-2.1(he)-305.6(co)]TJ
13.6943 0 TD
-.0203 Tc
[(nsequences)-306(of)-303.1(negative)-311.1(r)1.7(esults,)]TJ
-13.6943 -1.128 TD
0 Tc
[(2\))-221.8(training,)-224.4(support)-220.3(and)-223.6(safety)-222.7(of)-221.8(medical)-224.4(and)-217.5(midwifery)-228.2(system,)]TJ
0 -1.1219 TD
[(3\))-356(reproductive)-357.5(health)-360.9(rights)-354(and)-357.8(ethics.)-354(The)-359.6(sub-categories)-360(of)]TJ
0 -1.128 TD
[()52.5(prevention)-213.1(of)-209.6(negative)-212.7(consequences)-214.2(of)-209.6(the)-217(examination)54.4()-209.7(were)]TJ
0 -1.1219 TD
[(1\))-435.2(community)-434.8(empowerment)-441.5(and)-430.9(2\))-435.2(prevention)-436.4(strategies)-438.4(for)]TJ
0 -1.128 TD
[(bad)-302.9(consequences)-299.6(of)-301.1(the)-302.4(negative)-298(results.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Conclusions:)Tj
/F4 1 Tf
5.7009 0 TD
-.0186 Tc
[(The)-175.2(r)-2.7(esul)-5.9(ts)-170.2(s)-5.5(howed)-177.1(that)-176.6(planning)-171(on)-177.1(monit)-5.9(o)-.3(ring)-177.1(of)]TJ
-6.7008 -1.128 TD
-.0182 Tc
[(the)-290.7(e)-4.1(xamination)-292.5(p).1(roces)-5.1(s)-285.6(is)-291.7(neces)-5.1(s)1(ary)-286.4(f)-2.3(or)-288.8(preventing)-292.5(o).1(f)-288.8(b).1(ad)-292.5(conse-)]TJ
0 -1.1219 TD
[(quences)-316.2(of)-319.4(the)-315.2(n)0(egati)-5.6(v)0(e)-315.2(r)-2.4(es)-5.2(ults)-316.2(by)-317(the)-321.3(h)0(ealth)-317(s)-5.2(y)0(stem)-5.5(.)-317(C)1.4(ommunit)-5.6(y)]TJ
26.9984 71.9468 TD
[(empowerment)-292(to)-286.4(prevent)-292(v).1(iolence)-290.7(a)-4.1(gai)-5.5(n).1(st)-292(wom)-5.5(e)2(n)-292.5(a)2(nd)-292.5(stigm)-5.4(a)2(tiza-)]TJ
0 -1.128 TD
[(t)-5.4(i).7(on,)-286.4(an)-5.9(d)-286.3(p).2(rofessional)-285.9(t).7(rai)-5.4(n).2(ing)-286.3(f)-2.2(or)-282.6(correct)-291.9(p).2(rognos)-5(is)-285.5(and)-286.3(p).2(roviding)]TJ
0 -1.1219 TD
-.0184 Tc
[(appropri)-5.7(a)1.8(te)-321.4(counseli)-5.7(n)-.1(g)-317.1(f)-2.5(or)-319.5(the)-321.4(n)-.1(eg)]TJ
13.4931 0 TD
-.0178 Tc
[(ative)-320.8(r)4.2(esult)-5.1(s)-315.7(are)-320.8(r)-1.9(ecommended.)]TJ
-13.4931 -1.128 TD
-.0184 Tc
[(Bes)-5.3(i).4(des,)-439.1(emphas)-5.3(i).4(s)-438.2(o)-.1(n)-439.1(hymen)-439.1(virgini)-5.7(t).4(y)-439.1(e)1.8(xaminat)-5.7(ion)-439.1(w)4.5(i)-5.7(t).4(hout)-438.6(ap-)]TJ
0 -1.1219 TD
-.018 Tc
[(p)-5.8(r)4(opriate)-223.4(sexual)-218.7(h).3(ealt)-5.3(h)-219.2(e)-3.9(ducation,)-219.2(le)]TJ
13.8223 0 TD
-.0185 Tc
[(ads)-224.9(t).3(o)-225.8(unusual)-225.3(s).7(exual)-225.3(r)3.5(elat)-5.8(ions,)]TJ
-13.8223 -1.128 TD
-.0182 Tc
[(expanding)-256(STIs)-261.2(and)-262.1(i).6(ncreasing)-262.1(d).1(em)-5.5(and)-262.1(f)3.8(or)-264.4(hymen)-262.1(repairment)-5.5(.)]TJ
/F3 1 Tf
0 -3.201 TD
0 Tc
(83.)Tj
9.843 0 0 9.843 333.9779 643.4644 Tm
[(Impact)-284.9(of)-278.6(a)-283.3(Wellness)-282.7(Coaching)-281.4(Program)]TJ
0 -1.1116 TD
[(for)-280.9(Racial/Ethn)-9.5(ic)-280(Minority)-283(Women)-279.4(on)-284.3(the)-280.7(Health)]TJ
T*
[(Behaviors)-283.8(of)-284.4(their)-278.5(Family)-285.6(Members)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 313.0582 605.0266 Tm
[(Sara)-239.2(Simonsen)]TJ
6.9735 0 0 6.198 368.5605 609.1085 Tm
(1)Tj
9.2982 0 0 9.2982 372.0188 605.0266 Tm
[(,)-237.8(Brenda)-241(Ralls)]TJ
6.9735 0 0 6.198 424.8566 609.1085 Tm
(2)Tj
9.2982 0 0 9.2982 428.3715 605.0266 Tm
[(,)-237.8(Kathleen)-238.6(Digre)]TJ
6.9735 0 0 6.198 489.9967 609.1085 Tm
(3)Tj
9.2982 0 0 9.2982 493.455 605.0266 Tm
[(,)-237.8(Coalition)-238.4(for)-242.5(a)]TJ
-19.4013 -1.128 TD
[(Healthier)-338(Community)-331.7(for)-333.9(Utah)-334.4(Women)-337(and)-333.4(Girls)]TJ
6.9735 0 0 6.198 501.5054 598.677 Tm
(1)Tj
/F5 1 Tf
-27.0233 -2.6526 TD
(1)Tj
9.2982 0 0 9.2982 316.5731 578.0975 Tm
[(University)-340(of)-328.7(Utah,)-336.2(Salt)-334.2(Lake)-334.4(City,)-331(Utah)]TJ
6.9735 0 0 6.198 313.0582 571.7479 Tm
(2)Tj
9.2982 0 0 9.2982 316.5731 567.666 Tm
[(Utah)-336.2(Department)-332.5(of)-334.8(Health,)-333.8(Salt)-334.2(Lake)-334.4(City,)-331(Utah)]TJ
6.9735 0 0 6.198 313.0582 561.3164 Tm
(3)Tj
9.2982 0 0 9.2982 316.5731 557.1778 Tm
[(University)-340(of)-328.7(Utah)-336.2(School)-332.8(of)-334.8(Medicine,)-330.8(Salt)-334.2(Lake)-334.4(City,)-337.1(Utah)]TJ
/F3 1 Tf
.6219 -2.3047 TD
(Background:)Tj
/F4 1 Tf
6.0545 0 TD
[(Gender)-451.2(roles)-450.2(often)-445(ascribe)-452.5(responsibility)-453.2(for)]TJ
-7.0544 -1.1219 TD
[(purchasing)-405.5(and)-406.6(preparing)-402.7(foods)-403.8(and)-406.6(planning)-405.4(leisure-time)-404(ac-)]TJ
0 -1.128 TD
[(tivities)-354.3(to)-347(women,)-346.5(allowing)-351.6(them)-350.6(ample)-348.7(opportunities)-351(to)-347(inu-)]TJ
0 -1.1219 TD
[(ence)-305.2(the)-302.4(health)-299.9(behaviors)-301.9(of)-301.1(family)-297.6(members.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.7131 0 TD
[(We)-209.6(evaluated)-204.7(the)-210.9(impact)-201.9(of)-209.6(a)-205.4(wellness)-208.3(coaching)]TJ
-6.713 -1.1219 TD
[(program)-331.4(targeting)-332.2(women)-334.3(on)-329.2(the)-332.9(diet)-332.4(and)-327.3(physical)-329.5(activity)-335.5(be-)]TJ
0 -1.128 TD
[(haviors)-261.2(of)-252.3(children,)-259.6(spouses/partners,)-256.5(and)-254.1(grandparents)-259.7(living)-254.4(in)]TJ
0 -1.1219 TD
[(the)-302.4(home.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Material/Methods:)Tj
/F4 1 Tf
8.6946 0 TD
[(A)-623.4(community-based)-627.6(participatory)-624.8(re-)]TJ
-9.6945 -1.1219 TD
[(search)-294.5(project)-290.1(was)-291.4(conducted)-286.3(with)-293.1(a)-284.7(coalition)-292.8(including)-289.1(leaders)]TJ
0 -1.128 TD
[(from)-278.5(African)-276.2(American,)-277.5(African)-276.2(Immigrant/Refugee,)-275.7(American)]TJ
0 -1.1219 TD
[(Indian,)-347.4(Latino,)-346.3(and)-345.6(Pacic)-347(Islander)-347(communities.)-346.2(We)-343.7(assessed)]TJ
0 -1.128 TD
[(the)-448.7(impact)-439.7(of)-447.4(a)-443.2(12-month)-440.1(program)-447.3(on)-438.9(changes)-444.5(in)-444.5(health)-446.3(be-)]TJ
0 -1.1219 TD
[(haviors)-230.7(of)-221.8(women)-224.6(and)-223.6(their)-225(family)-224.4(members.)-228.2(We)-221.8(trained)-229.1(women)]TJ
0 -1.128 TD
[(from)-388.2(each)-384.5(community)-380(as)-387.4(wellness)-385.1(coaches.)-387.8(Coaches)-382.2(recruited)]TJ
T*
[(women)-413.6(to)-408(participate)-413.3(and)-406.6(helped)-410.2(them)-411.6(set)-411.3(tailored)-411.5(health)-409.7(be-)]TJ
0 -1.1219 TD
[(havior)-274.2(goals)-271(using)-272.9(Motivational)-273(Interviewing.)-275.1(Participants)-276.9(were)]TJ
0 -1.128 TD
[(randomized)-513.7(to)-511.6(receive)-518.6(either)-509.6(monthly)-510.5(coaching)-511.9(or)-514.5(quarterly)]TJ
0 -1.1219 TD
(coaching.)Tj
/F3 1 Tf
.9999 -1.128 TD
(Results:)Tj
/F4 1 Tf
3.7742 0 TD
[(Data)-338.6(were)-341.5(assessed)-338.3(for)-340(239)-335.3(women;)-339.9(65%)-337.6(had)-339.5(chil-)]TJ
-4.7741 -1.1219 TD
[(dren;)-316.9(49%)-313.2(had)-315.1(a)-315.2(spouse/partner,)-319.2(and)-309(11%)-319.3(had)-309(a)-315.2(grandparent)-315.4(at)]TJ
0 -1.128 TD
[(home.)-229.2(At)-226.5(12)-225.5(months,)-229.7(more)-225.5(than)-229.2(half)-225.5(of)-227.9(the)-229.2(women)-224.6(reported)-232(their)]TJ
0 -1.1219 TD
[(children)-351.1(and/or)-347.4(grandparents)-345(had)-345.6(increased)-353(fruit)-345.1(and)-345.6(vegetable)]TJ
0 -1.128 TD
[(consumption)-227.2(and)-223.6(physical)-225.9(activity.)-225.7(More)-225.1(than)-223.1(half)-225.5(of)-221.8(the)-229.2(women)]TJ
0 -1.1219 TD
[(also)-551.5(reported)-549(that)-545.8(their)-548.1(spouses/partners)-549.2(increased)-548.1(fruit)-552.4(and)]TJ
0 -1.128 TD
[(vegetable)-686.4(consumption.)-678.3(The)-682.8(lowest)-680.5(reported)-677.1(increase)-688.4(was)]TJ
0 -1.1219 TD
[(spouse/partner)-276.5(physical)-274.7(activity,)-274.5(and)-272.4(even)-276.6(that)-271.4(was)-273.1(close)-275.2(to)-273.8(half)]TJ
0 -1.128 TD
[(\(48%\).)-482.5(There)-482(were)-487.8(no)-475.5(differences)-485.8(in)-481.1(family)-486.6(health)-476.8(behavior)]TJ
0 -1.1219 TD
[(changes)-359.2(between)-361(study)-358.3(arms.)-352.6(In)-362.1(multivariable)-353.1(models,)-361.9(women)]TJ
0 -1.128 TD
[(who)-239.2(reported)-238.1(being)-241.4(successful/very)-237.2(successful)-243.4(at)-235.4(achieving)-243.1(their)]TJ
0 -1.1219 TD
[(own)-312.4(goals)-307.6(were)-311(2.6)-310.9(times)-306.6(as)-314.3(likely)-307.4(to)-310.4(report)-307.1(their)-310.3(spouses/part-)]TJ
0 -1.128 TD
[(ners)-304.4(had)-302.9(an)-296.8(increased)-304.3(physical)-299.1(activity)-305(level)-300(\(p)]TJ
/F2 1 Tf
19.1086 0 TD
(=)Tj
/F4 1 Tf
.5487 0 TD
(0.0203\).)Tj
/F3 1 Tf
-18.6574 -1.1219 TD
(Conclusions:)Tj
/F4 1 Tf
5.8167 0 TD
[(Wellness)-326.8(coaching)-329(programs)-324.4(targeting)-332.2(women)]TJ
-6.8167 -1.128 TD
[(may)-314.6(impact)-311.6(health)-318.2(behaviors)-308(of)-313.3(their)-316.4(family)-309.8(members.)-313.6(Women)]TJ
0 -1.1219 TD
[(who)-391.6(are)-394.9(successful)-389.8(at)-387.8(changing)-391.9(their)-389.6(own)-391.6(behaviors)-387.3(are)-394.9(more)]TJ
0 -1.128 TD
[(likely)-325.7(to)-322.6(impact)-317.7(partner)-323.5(behaviors.)-326.3(Future)-319.8(research)-325.4(should)-315.6(cap-)]TJ
0 -1.1219 TD
[(ture)-262.1(the)-253.6(magnitude)-262.8(of)-252.3(this)-260.2(reach)-258.8(by)-256(collecting)-260.4(data)-257.8(directly)-259.1(from)]TJ
0 -1.128 TD
[(children,)-302.3(partners,)-304.3(and)-302.9(other)-298.6(family)-297.6(members.)]TJ
/F3 1 Tf
0 -4.0546 TD
(84.)Tj
9.843 0 0 9.843 333.9779 111.0047 Tm
[(Gender)-287.5(Differences)-283.5(in)-284.4(Burnout)-280.1(and)-279.4(Coping)]TJ
0 -1.1174 TD
[(Mechanisms)-286.8(in)-278.6(Internal)-287.2(Medicine)-285.2(Residents)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 313.0582 83.4519 Tm
[(Brielle)-282.1(Spataro)]TJ
6.9735 0 0 6.198 369.581 87.5905 Tm
(1)Tj
9.2982 0 0 9.2982 373.0393 83.4519 Tm
[(,)-274.4(Sarah)-275.7(Tilstra)]TJ
6.9735 0 0 6.198 426.1038 87.5905 Tm
(2)Tj
9.2982 0 0 9.2982 429.5621 83.4519 Tm
[(,)-274.4(Doris)-276.8(Rubio)]TJ
6.9735 0 0 6.198 480.3589 87.5905 Tm
(1)Tj
9.2982 0 0 9.2982 483.8739 83.4519 Tm
[(,)-274.4(Melissa)-273(McNeil)]TJ
6.9735 0 0 6.198 548.6739 87.5905 Tm
(1)Tj
/F5 1 Tf
-33.7873 -2.6526 TD
(1)Tj
9.2982 0 0 9.2982 316.5731 67.011 Tm
[(University)-340(of)-328.7(Pittsburgh,)-333.7(Pittsburgh,)-333.7(Pennsylvania)]TJ
6.9735 0 0 6.198 313.0582 60.7181 Tm
(2)Tj
9.2982 0 0 9.2982 316.5731 56.5795 Tm
[(UPMC,)-333.5(Pittsburgh,)-333.7(Pennsylvania)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 62.022 749.6502 Tm
(A-32)Tj
48.6864 0 TD
(ABSTRACTS)Tj
ET
endstream
endobj
328 0 obj
<>stream
/GS1 gs
BT
/F3 1 Tf
9.2982 0 0 9.2982 69.0519 725.5557 Tm
0 0 0 rg
0 Tc
0 Tw
(Background:)Tj
/F4 1 Tf
5.835 0 TD
[(Burnout)-232(is)-230.3(a)-235.9(signicant)-228.2(problem)-237.1(facing)-229.7(internal)]TJ
-6.8349 -1.128 TD
[(medicine)-346.3(residents)-343.2(contributing)-339.6(to)-340.9(increased)-340.8(risk)-342.4(of)-337.7(depression)]TJ
0 -1.1219 TD
[(and)-376.1(suicidal)-377.8(ideation.)-372.6(Coping)-376(mechanisms)-375(may)-375.5(affect)-376.5(burnout)]TJ
0 -1.128 TD
[(and)-302.9(may)-302.4(differ)-297.3(based)-306.2(on)-298.7(sex.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.9326 0 TD
[(To)-416.4(determine)-421.8(sex)-424(differences)-424.8(in)-420.1(burnout)-416.3(and)]TJ
-6.9325 -1.128 TD
[(coping)-302.3(in)-298.2(internal)-301.8(medicine)-303.6(residents.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Material/Methods:)Tj
/F4 1 Tf
8.6275 0 TD
[(The)-560.8(study)-559.5(was)-559.6(a)-559(retrospective)-561.6(cross-)]TJ
-9.6275 -1.128 TD
[(sectional)-223.5(study)-211.9(of)-215.7(reported)-219.8(burnout)-215.1(and)-211.4(coping)-217(mechanisms)-216.5(used)]TJ
0 -1.1219 TD
[(by)-280.4(internal)-283.5(medicine)-279.2(residents)-282.3(in)-279.9(June)-283.7(2014)-274.3(at)-284.1(a)-278.6(large)-284.6(academic)]TJ
0 -1.128 TD
[(center)-532.6(and)-534.6(its)-528.5(community)-532.4(afliate.)-534.5(Two-hundred)-530.3(eighty-ve)]TJ
0 -1.1219 TD
[(PGY-1,)-203.2(2,)-201.2(3)-201.2(and)-205.3(4)-201.2(and)-199.3(incoming)-203.7(PGY-1)-203.2(residents)-203(were)-201.2(surveyed.)]TJ
0 -1.128 TD
[(The)-274.3(Maslach)-278.5(Burnout)-274.7(Inventory-General)-276.4(Survey)-271.5(\(MBI-GS\))-279.7(and)]TJ
0 -1.1219 TD
[(Brief)-366.7(COPE)-364.5(were)-359.8(given)-363.3(to)-365.3(measure)-361(levels)-366.2(of)-362.1(burnout)-361.4(and)-357.8(fre-)]TJ
0 -1.128 TD
[(quency)-343.6(of)-337.7(use)-338.6(of)-337.7(coping)-332.8(mechanisms.)-344.5(Percentages)-341.8(of)-337.7(residents)]TJ
T*
[(who)-446.5(met)-442.1(criteria)-448.6(for)-443.7(burnout)-440.7(and)-443.1(high)-444.5(levels)-445.4(on)-445(each)-445.5(of)-441.3(the)]TJ
0 -1.1219 TD
[(subscales)-424(of)-423(emotional)-420.8(exhaustion,)-420.9(cynicism)-426.6(and)-418.8(professional)]TJ
0 -1.128 TD
[(efcacy,)-259.7(were)-262.2(calculated)-257.1(and)-254.1(stratied)-261.1(by)-256(sex.)-253.3(Chi-squared)-260.2(tests)]TJ
0 -1.1219 TD
[(were)-298.8(used)-295.9(for)-297.3(statistical)-294.3(signicance.)-298.1(Average)-296.8(frequency)-297.7(of)-295(use)]TJ
0 -1.128 TD
[(of)-246.2(each)-244.3(coping)-247.5(mechanism)-241.7(by)-243.8(sex)-247.2(was)-242.6(calculated)-251(with)-244.3(statistical)]TJ
0 -1.1219 TD
[(signicance)-304.2(determined)-305.9(by)-298.7(two)-299.7(sided)-301.5(t-tests.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Results:)Tj
/F4 1 Tf
3.7071 0 TD
-.0129 Tc
[(T)-12.9(h)15.8(er)-12.9(e)-257.2(w)-12.9(a)11.9(s)-268.1(a)-267.1(6)-.7(9)5.4(%)-271.3(com)6(p)-.7(letio)5.4(n)-269(r)-12.9(a)11(t)-.2(e)-267.1(\()3(198)5.4(/28)5.4(5)-.7(\))-271.3(w)3.9(ith)-269(1)5.4(0)-.7(0)]TJ
-4.707 -1.1219 TD
[(men)-226.3(a)1.2(nd)-226.3(9)5.4(8)-226.3(w)-12.9(o)16.1(men.)-226.3(Wom)6(a)-12.9(n)-212.2(h)-.7(ad)-226.3(hi)5.9(gher)-222.6(l)-.2(evels)-225.4(o)-.7(f)-222.6(burno)5.4(ut)-225.8(\(30%)-222.5(vs)]TJ
0 -1.128 TD
-.0135 Tc
[(15%,)-287.9(P)]TJ
/F2 1 Tf
2.8535 0 TD
0 Tc
(=)Tj
/F4 1 Tf
.5365 0 TD
-.0126 Tc
[(0.)5.7(014)5.7(\))-289.3(a)1.5(n)5.7(d)-286.9(emo)5.7(tion)5.7(a)-12.6(l)-272.4(e)1.5(xhau)5.7(s).5(tion)-280.8(\()3.3(22%)-283.2(vs)-280(9%,)-287(P)]TJ
/F2 1 Tf
19.0415 0 TD
0 Tc
(=)Tj
/F4 1 Tf
.5366 0 TD
-.0128 Tc
[(0.0)5.5(05\).)]TJ
-22.9681 -1.1219 TD
0 Tc
[(Women)-507.7(used)-509.3(the)-503.6(adaptive)-505.3(coping)-503.5(mechanisms)-509.1(of)-508.4(emotional)]TJ
0 -1.128 TD
[(support)-525.2(\(P)]TJ
/F2 1 Tf
4.4144 0 TD
(=)Tj
/F4 1 Tf
.5487 0 TD
[(0.001\))-526.6(and)-522.4(instrumental)-525.4(support)-525.2(\(P)]TJ
/F2 1 Tf
15.0357 0 TD
(=)Tj
/F4 1 Tf
.5487 0 TD
[(0.018\))-526.6(more)]TJ
-20.5475 -1.1219 TD
[(frequently)-329(but)-322.6(also)-325.9(used)-320.3(the)-326.8(maladaptive)-325.5(coping)-320.6(mechanism)-327.1(of)]TJ
0 -1.128 TD
[(self-blame)-307.4(more)-298.6(frequently)-298.5(\(P)]TJ
/F2 1 Tf
12.2127 0 TD
(=)Tj
/F4 1 Tf
.5487 0 TD
(0.022\).)Tj
/F3 1 Tf
-11.7615 -1.1219 TD
(Conclusions:)Tj
/F4 1 Tf
5.8472 0 TD
[(Greater)-359.7(use)-356.9(of)-356(self-blame)-356.2(as)-357(a)-357.8(coping)-357.2(mecha-)]TJ
-6.8471 -1.128 TD
[(nism)-345.6(may)-339(be)-345.6(a)-339.5(major)-340.8(factor)-347.9(in)-340.9(the)-339(higher)-341.3(rates)-344.7(of)-343.8(burnout)-337(and)]TJ
0 -1.1219 TD
[(emotional)-481.8(exhaustion)-475.8(in)-475(women)-474.6(resident)-478.2(physicians)-475(as)-478.9(com-)]TJ
0 -1.128 TD
[(pared)-266.8(to)-261.6(men.)-259.7(Educators)-267.2(must)-260.2(pay)-260.2(attention)-268.4(to)-261.6(use)-259.4(of)-264.5(self-blame)]TJ
0 -1.1219 TD
[(by)-445(female)-446.8(residents)-446.9(and)-443.1(as)-448.4(it)-444(may)-442.6(be)-443.2(a)-443.2(red)-445.5(ag)-446(for)-443.7(resident)]TJ
0 -1.128 TD
(distress.)Tj
/F3 1 Tf
0 -3.9998 TD
(85.)Tj
9.843 0 0 9.843 80.674 353.5936 Tm
[(Implementation)-284.4(of)-284.4(the)-280.7(Myriad)-280.7(Genetic)]TJ
0 -1.1174 TD
[(Screening)-284.9(Questionnaire)-289.3(and)-279.4(a)-277.6(Multidisciplinary)]TJ
0 -1.1116 TD
[(Team)-284.1(Approach)-282.2(to)-278.6(Improve)-287.2(Early)-278.5(Diagnosis)-287(of)]TJ
T*
[(Hereditary)-287.5(Breast)-280.4(Cance)-8.5(rs)-279.6(in)-278.6(High-Risk)]TJ
T*
[(Populations)-283.6(at)-278.6(a)-283.3(Safety)-284(Net)-281.8(Institution)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 59.7543 293.159 Tm
[(Dimitra)-335.1(Lotakis,)-339.4(Anitha)-333.8(Srinivasan,)-334.7(Anisha)-333.5(Chadda,)]TJ
0 -1.1219 TD
[(Prabhat)-336.2(Bhattarai,)-335.1(Marc)-339.1(Wallack)]TJ
/F5 1 Tf
0 -1.7682 TD
[(Metropolitan)-338.8(Hospital)-334.3(Center,)-334.8(NYMC,)-331.6(New)-336.7(York,)-329.3(New)-336.7(York)]TJ
/F3 1 Tf
.9999 -2.3047 TD
(Background:)Tj
/F4 1 Tf
5.8899 0 TD
[(Studies)-291.6(have)-288.8(shown)-293.2(that)-289.7(as)-289.9(much)-284.1(as)-289.9(510%)-288.8(of)]TJ
-6.8898 -1.1219 TD
[(diagnosed)-262.9(breast)-259.3(cancers)-256(are)-260.7(hereditary)-260(in)-255.5(nature.)-260.1(Multiple)-257.2(gene)]TJ
0 -1.128 TD
[(mutations)-226.7(are)-230.2(responsible)-227.3(for)-230.3(this)-223.6(disease)-229.8(burden,)-225.9(with)-226(only)-225(10%)]TJ
0 -1.1219 TD
[(being)-363.3(BRCA1)-363.1(and)-363.9(BRCA2.)-363.1(With)-362.8(the)-363.4(advent)-361.4(of)-362.1(accessible)-365.7(ge-)]TJ
0 -1.128 TD
[(netic)-324.4(testing,)-318.7(early)-321.1(detection)-321.9(and)-315.1(treatment)-323.7(of)-319.4(patients)-322.9(with)-317.4(he-)]TJ
T*
[(reditary)-268.1(cancers)-262.1(has)-259.4(resulted)-264.8(in)-261.6(overall)-259.6(improvement)-264.6(of)-264.5(survival)]TJ
0 -1.1219 TD
[(rates)-302(and)-302.9(management.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Objective\(s\):)Tj
/F4 1 Tf
6.0179 0 TD
.0133 Tc
[(Th)-5(e)-509.2(p)-5(urp)-5(o)1.1(s)-4.1(e)-509.2(o)-5(f)-507.3(t)-4.5(h)1.1(i)-4.5(s)-510.2(st)-4.5(ud)-5(y)-511(i)1.6(s)-516.3(t)1.6(o)-511(d)1.1(et)-4.5(ermi)-4.5(ne)]TJ
-7.0179 -1.1219 TD
.0156 Tc
[(whether)-553.8(i)-2.2(mplementa)5.3(tion)-551.4(o)-2.7(f)-553.8(t)-2.2(he)-555.6(Myriad)-551.4(Genetic)-555.6(S).6(cree)5.3(ning)]TJ
0 -1.128 TD
.0132 Tc
[(Q)-6.6(u)1(es)-4.2(ti)-4.6(on)-5.1(nai)-4.6(r)-1.3(e)-283.7(a)-3.2(lo)-5.1(ng)-285.5(wi)-4.6(th)-285.5(an)-285.5(im)]TJ
13.1638 0 TD
.0156 Tc
[(proved)-283.1(multidis)4.3(ciplinary)-277(t)-2.2(eam)]TJ
-13.1638 -1.1219 TD
0 Tc
[(app)14.1(roa)11.8(ch)-266.3(to)-273.8(man)14.7(age)16(men)14.7(t)-273.8(dur)16(ing)-267.7(th)12.8(e)-278.6(i)0(n)12.8(iti)13.8(al)-271.9(Br)11.2(eas)10.8(t)-273.8(S)0(u)15.5(rge)11.8(ry)-270.6(cli)15.2(ni)12.7(c)]TJ
0 -1.128 TD
[(vis)13.6(it)-322.1(hav)14.1(e)-327.3(a)-321.2(pos)13.1(iti)13.8(ve)-321.2(ef)11.7(fec)13.6(t)-328.7(o)0(n)-317(ear)13.7(ly)-322.6(re)11.7(cog)14.1(nit)13.3(io)12.8(n)-329.2(for)-315.6(ge)14.1(net)14.6(ic)-320.7(ris)11.2(k)]TJ
0 -1.1219 TD
[(fac)13.7(tors)-269.2(and)-272.4(imp)13.3(rov)16(es)-283.8(acc)17.9(essi)16.4(bi)12.7(lit)13.8(y)-286.5(t)0(o)-273.8(gen)14.1(etic)-269.5(test)16(in)12.8(g.)-280.4(In)-276.7(the)-271.9(past)15.5(,)]TJ
0 -1.128 TD
[(selected)-331.9(high-risk)-319.7(patients)-329(were)-323.2(referred)-326.8(to)-322.6(a)-327.3(genetic)-322.4(counselor)]TJ
0 -1.1219 TD
[(at)-241.5(a)-242(womens)-238.2(health)-239(center)-246.1(for)-236.4(genetic)-243.2(screening)-239.1(and)-241.9(subsequent)]TJ
0 -1.128 TD
(testing.)Tj
/F3 1 Tf
.9999 -1.1219 TD
(Material/Methods:)Tj
/F4 1 Tf
8.5361 0 TD
[(Retrospective)-466.4(case)-469(report)-459.5(examining)-464(a)]TJ
-9.536 -1.128 TD
[(six)-443.7(month)-437.8(period)-438.8(extending)-440.1(from)-437(June)-442.3(to)-438.4(November)-438.4(2015)-438.9(at)]TJ
0 -1.1219 TD
[(Metropolitan)-440.5(Hospital)-436.1(Center,)-435.6(NYC)-434.4(HHC.)-440.5(ANOVA)-434.2(Analysis)]TJ
27.0045 71.9468 TD
[(focused)-595.1(on)-603.6(comparing)-594.9(the)-601.2(three-month)-596.7(period)-597.4(immediately)]TJ
0 -1.128 TD
[(preceding)-313.1(and)-315.1(following)-313.1(implementation)-313.6(of)-313.3(the)-314.6(Myriad)-316(genetic)]TJ
0 -1.1219 TD
[(screening)-592.7(questionnaire)-591.6(and)-589.5(multidisciplinary)-596.9(approach.)-588(All)]TJ
0 -1.128 TD
[(patients)-414.4(presenting)-411.1(to)-408(Surgery)-414.1(clinic)-415.3(with)-408.9(a)-412.7(chief)-412.6(concern)-417.3(in-)]TJ
0 -1.1219 TD
[(volving)-620.7(breast)-631.2(pathology)-624.9(are)-626.6(provided)-627.8(the)-625.6(Myriad)-627(genetic)]TJ
0 -1.128 TD
[(screening)-397.6(questionnaire)-402.6(from)-400.4(the)-400(clerk)-400.4(when)-401.9(registering.)-400.8(This)]TJ
0 -1.1219 TD
[(form)-443.1(is)-443.7(completed)-443.8(in)-444.5(the)-442.6(waiting)-443(room)-446.8(and)-443.1(reviewed)-442.6(by)-445(the)]TJ
0 -1.128 TD
[(provider)-240(during)-239.5(the)-241.4(visit.)-241.4(If)-236.4(signicant)-246.5(risk)-238.7(factors)-243.4(are)-242.4(identied,)]TJ
0 -1.1219 TD
[(the)-235.3(patient)-238.5(is)-236.4(counseled)-236.7(regarding)-238.1(risks)-237.8(and)-235.8(benets)-235.4(of)-234(testing.)-239.5(If)]TJ
0 -1.128 TD
[(the)-393.9(patient)-403.1(chooses)-396.8(to)-395.8(pursue)-401.9(testing,)-398(consent)-397.1(is)-401(obtained)-397.5(and)]TJ
0 -1.1219 TD
[(blood)-365.2(is)-364.4(drawn)-373.8(on)-365.8(site)-368.1(by)-365.8(nursing)-366.7(staff.)-367.2(Patients)-368.5(who)-367.3(undergo)]TJ
0 -1.128 TD
[(testing)-440.7(are)-449.7(then)-442.6(provided)-444.9(a)-443.2(follow)-447.8(up)-438.9(appointment)-445.1(with)-445.5(spe-)]TJ
0 -1.1219 TD
[(cialized)-295.7(geneticist)-290(to)-292.1(discuss)-293.7(their)-292(results.)-290.3(Clinic)-293.9(staff)-294.1(including)]TJ
0 -1.128 TD
[(clerical)-468.8(support,)-464.2(nurses,)-462(PCAs,)-471.5(PAs,)-460.7(Resident)-468.4(and)-467.5(Attending)]TJ
T*
[(Physicians)-581.5(underwent)-584.7(training)-578(on)-579.2(use)-582.5(of)-581.6(questionnaire)-585.5(and)]TJ
0 -1.1219 TD
[(sample)-299.1(collection)-303.1(kit.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Results:)Tj
/F4 1 Tf
3.9388 0 TD
[(Overall)-505(screening)-501.2(and)-504.1(understanding)-502.5(of)-502.3(patients)]TJ
-4.9387 -1.1219 TD
[(cancer)-269.1(related)-269.9(family)-267.1(history)-268.6(improved)-267.5(after)-268.6(implementation.)-270.9(In)]TJ
0 -1.128 TD
[(the)-241.4(three)-241.9(months)-235.8(prior)-241.9(to)-243.3(our)-240.1(protocol,)-237.1(only)-243.3(eleven)-237.6(patients)-243.7(were)]TJ
0 -1.1219 TD
[(provided)-463.2(screening)-464.7(questionnaires.)-462.7(Following)-459.9(implementation)]TJ
0 -1.128 TD
[(over)-524.8(one)-528.5(hundred)-524.7(patients)-530.3(successfully)-529.5(completed)-529.2(screening)]TJ
0 -1.1219 TD
[(questionnaires)-554.1(and)-552.9(were)-554.9(assessed)-557.8(for)-553.4(genetic)-554.1(testing.)-550.4(Com-)]TJ
0 -1.128 TD
[(pliance)-267.6(improved)-273.6(and)-266.3(an)-272.4(increased)-267.7(number)-274.2(of)-264.5(high-risk)-270.9(patients)]TJ
0 -1.1219 TD
[(were)-298.8(successfully)-303.9(identied.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Conclusions:)Tj
/F4 1 Tf
5.7984 0 TD
[(W)14.1(h)0(e)20.2(n)-304.8(c)14.1(a)0(r)17.8(i)0(n)18.8(g)-298.7(fo)16(r)-295(p)0(a)14.1(t)12.7(ie)20.7(nt)18.8(s)-304(a)14.1(t)-304.3(a)-296.9(sa)15(fe)23.9(ty)-292.1(n)12.2(e)0(t)-296.3(i)12.7(n)12.2(s)0(t)19.7(i)0(t)19.3(u)0(-)]TJ
-6.7984 -1.1219 TD
[(t)12.7(i)0(o)18.8(n)12.2(,)-353.6(c)0(o)20.2(n)0(s)19.2(o)0(l)18.8(i)0(d)18.9(a)0(t)20.7(i)0(o)18.8(n)-353.6(o)12.2(f)-356(c)14.1(a)0(r)17.8(e)-351.7(is)-346.1(v)12.2(i)0(t)19.3(a)0(l)-345.1(t)12.7(o)-353.6(o)0(v)18.3(e)0(r)17.8(a)0(l)20.7(l)-353.1(p)12.2(a)0(t)14.6(i)12.7(en)20.2(t)-353.1(h)12.2(ea)16(lt)19.4(h)12.2(.)-353.6(Re)15.5(-)]TJ
0 -1.128 TD
[(d)12.2(u)12.2(c)0(i)14.6(n)12.2(g)-231.7(t)12.7(he)-223.7(n)12.2(u)12.2(m)0(b)18.9(e)0(r)-219.9(o)0(f)-221.8(a)0(p)20.2(p)0(o)18.3(i)12.7(nt)18.8(me)20.7(nt)18.8(s)-230.8(r)0(e)17.8(q)12.2(ui)18.8(re)17.8(d)-231.7(t)12.7(o)-231.7(p)12.2(ro)22.1(vi)18.8(de)-223.7(n)12.2(e)0(c)16(e)14.1(ss)13.9(a)14.1(r)0(y)]TJ
0 -1.1219 TD
[(s)13.1(e)0(r)17.8(v)12.2(ic)14.6(es)-265.5(is)-273(i)12.7(m)0(p)18.9(o)12.2(rt)16.5(an)20.2(t)-279.9(t)12.7(o)-280.4(a)0(i)20.7(d)-280.4(pr)16(o)12.2(v)12.2(i)0(s)19.7(i)0(o)18.8(n)-280.4(o)12.2(f)-282.8(h)12.2(i)12.7(gh)-268.2(qu)18.3(al)20.7(it)19.3(y)-280.4(c)0(a)16(r)0(e)23.9(.)-280.5(In)-270.6(o)12.2(u)0(r)]TJ
0 -1.128 TD
[(ex)20.2(p)12.2(e)0(r)17.8(i)0(e)20.7(n)0(c)20.2(e)-516.4(a)-516.4(m)0(u)18.9(l)12.7(ti)19.3(di)18.8(sc)15(i)12.7(p)12.2(li)19.3(na)20.2(ry)-508.4(ap)20.2(p)12.2(r)0(o)16(a)14.1(ch)-510.2(a)14.1(i)0(m)19.4(e)0(d)-510.2(s)13.1(p)12.2(e)0(c)16(i)0()22.1(c)0(a)16(l)12.7(ly)-505.5(at)]TJ
0 -1.1219 TD
[(s)13.1(c)0(r)17.8(e)0(e)16(n)12.2(in)18.8(g)-310.9(a)0(n)20.2(d)-310.9(id)18.9(en)20.2(ti)19.3(fy)22.1(in)18.8(g)-310.9(h)0(o)18.3(l)0(d)18.8(s)-310.1(th)18.9(e)-315.1(g)12.2(re)17.8(at)20.7(es)21.1(t)-316.5(e)14.1(f)19.2(ca)16(cy)20.2(.)-310.9(F)0(u)21.6(r)0(t)16.5(h)12.2(er)-305.3(i)12.7(n)0(-)]TJ
0 -1.128 TD
[(v)12.2(e)0(s)21.1(t)0(i)19.3(g)0(a)14.1(t)12.7(i)12.7(o)0(n)-286.5(w)0(i)17.3(l)0(l)-285.5(w)0(o)16.8(r)0(k)-288.9(t)12.7(o)-298.7(e)0(x)20.2(t)12.7(en)14.1(d)-292.6(t)0(h)18.8(i)0(s)-285.2(s)0(c)15(r)0(e)17.8(e)14.1(ni)18.8(ng)-286.5(pr)16(o)12.2(c)0(e)22.1(s)0(s)-290.9(t)12.7(o)-298.7(i)0(n)18.8(c)0(l)20.7(u)12.2(de)]TJ
0 -1.1219 TD
[(p)12.2(a)0(t)20.7(i)0(e)14.6(n)12.2(t)12.7(s)-395.4(wi)17.3(th)-383.6(ov)18.3(ar)17.8(i)12.7(a)0(n)-388.3(a)0(n)20.2(d)-396.3(co)20.2(lo)18.8(n)12.2(i)0(c)-387.8(c)0(a)16(n)12.2(ce)16(rs)-385.6(a)14.1(s)-401.5(we)18.7(l)12.7(l)12.7(.)-396.3(Co)19.7(n)21.6(ic)14.6(t)12.7(s)-395.4(of)]TJ
0 -1.128 TD
[(In)22.1(te)20.7(re)17.8(st)19.7(:)-499.4(M)13.1(yr)16(i)12.7(a)0(d)-485.8(c)0(o)14.1(n)12.2(t)12.7(r)0(i)16.5(b)12.2(ut)18.8(ed)-485.8(to)-487.2(th)18.9(e)-498.1(c)0(r)17.9(e)0(a)22.1(t)0(i)19.3(o)0(n)-487.7(o)0(f)-490.1(w)0(o)22.9(r)0(k)16()15.5(ow)-489.2(an)20.2(d)]TJ
0 -1.1219 TD
[(m)12.8(u)0(l)18.8(t)12.7(id)18.8(is)19.7(ci)14.6(p)12.2(l)12.7(in)18.9(ar)17.8(y)-292.6(s)13.1(ta)20.7(ff)-285.2(e)14.1(d)0(u)18.3(c)0(a)16(t)12.7(io)18.8(n)-286.5(d)0(u)18.3(r)0(i)16.5(n)12.2(g)-286.5(t)0(h)18.9(i)0(s)-279.1(i)0(n)18.9(t)0(e)14.6(r)0(v)22.1(e)0(n)20.2(t)12.7(io)18.8(n.)]TJ
/F3 1 Tf
0 -4.1644 TD
(86.)Tj
9.843 0 0 9.843 331.7668 341.6314 Tm
[(Patient-Centered)-284.2(Sexual)-284.1(Function)-281.5(Outcomes)]TJ
0 -1.1116 TD
[(Among)-278(Midlife)-287.8(Women)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 310.8472 314.0786 Tm
[(Holly)-329.6(N.)-336.8(Thomas)]TJ
6.9735 0 0 6.198 377.2345 318.2173 Tm
(1)Tj
9.2982 0 0 9.2982 380.7495 314.0786 Tm
[(,)-335.3(Megan)-330.6(E.)-337.2(Hamm)]TJ
6.9735 0 0 6.198 451.6156 318.2173 Tm
(1)Tj
9.2982 0 0 9.2982 455.1306 314.0786 Tm
[(,)-329.2(Rachel)-339.9(Hess)]TJ
6.9735 0 0 6.198 507.5715 318.2173 Tm
(2)Tj
9.2982 0 0 9.2982 511.0865 314.0786 Tm
(,)Tj
-21.5353 -1.1219 TD
[(Sonya)-330.1(Borrero)]TJ
6.9735 0 0 6.198 366.1227 307.7857 Tm
(1)Tj
9.2982 0 0 9.2982 369.6377 303.6472 Tm
[(,)-329.2(Rebecca)-336.6(C.)-333.9(Thurston)]TJ
6.9735 0 0 6.198 455.0172 307.7857 Tm
(1)Tj
/F5 1 Tf
-20.674 -2.6526 TD
(1)Tj
9.2982 0 0 9.2982 314.3054 287.2062 Tm
[(University)-340(of)-334.8(Pittsburgh,)-333.7(Pittsburgh,)-333.7(Pennsylvania)]TJ
6.9735 0 0 6.198 310.8472 280.8566 Tm
(2)Tj
9.2982 0 0 9.2982 314.3054 276.718 Tm
[(University)-340(of)-334.8(Utah,)-330.1(Salt)-334.2(Lake)-334.4(City,)-337.1(Utah)]TJ
/F3 1 Tf
.628 -2.2986 TD
(Background:)Tj
/F4 1 Tf
5.9692 0 TD
[(Se)17.3(x)12.2(u)12.2(a)0(l)-351.2(d)12.2(ys)19.2(fu)22.1(nc)14.1(t)12.7(i)0(o)18.8(n)-359.7(i)12.7(s)-358.9(co)20.2(mm)19.4(o)12.2(n)-359.7(am)20.7(on)18.3(g)-359.7(m)12.8(id)18.9(l)12.7(i)0(f)16.5(e)]TJ
-6.9691 -1.128 TD
[(wo)22.9(me)14.6(n)-341.4(a)0(n)20.2(d)-347.5(ca)16(n)-341.4(h)0(a)20.2(v)0(e)-339.5(s)0(i)19.7(g)12.2(ni)18.8(c)17.3(an)20.2(t)-347(n)12.2(eg)20.2(at)20.7(iv)18.9(e)-345.6(i)0(m)19.4(p)0(a)14.1(c)14.1(t)0(s)-340(o)12.2(n)-347.5(q)12.2(u)12.2(a)0(l)14.6(i)12.7(ty)-334.8(of)]TJ
0 -1.1219 TD
[(l)12.7(i)0(f)16.5(e)0(.)-217.6(T)0(h)22.6(e)0(r)17.8(e)-223.7(is)-218.1(d)12.2(i)0(s)19.7(a)0(g)14.1(r)0(e)23.9(e)0(m)14.7(e)14.1(nt)-218.9(ab)20.2(o)12.2(u)0(t)-218.9(w)0(h)22.9(i)0(c)14.6(h)-225.6(s)13.1(e)0(x)20.2(u)0(a)14.1(l)-225.1(fu)22.1(n)12.2(c)0(t)14.6(i)12.7(on)-219.4(o)12.2(u)12.2(t)0(c)14.6(o)12.2(m)12.8(e)0(s)]TJ
0 -1.128 TD
[(t)12.7(o)-396.3(t)12.7(a)0(r)17.8(g)0(e)20.2(t)-395.8(in)-383.6(cl)20.7(in)18.8(ic)14.6(a)14.1(l)-395.8(tr)16.5(i)12.7(a)0(l)20.7(s)0(,)-389.3(a)14.1(nd)-384.1(th)18.8(er)17.9(e)-394.4(i)0(s)-382.7(l)0(i)19.4(t)0(t)19.3(l)0(e)-387.8(r)0(e)17.8(s)13.1(ea)16(rc)17.8(h)-390.2(e)0(x)20.2(p)0(l)18.8(o)12.2(ri)16.5(n)12.2(g)]TJ
0 -1.1219 TD
[(t)12.7(r)0(e)17.8(a)0(t)20.7(m)0(e)14.6(n)12.2(t)-292.1(p)12.2(re)17.8(fe)23.9(re)17.8(nc)20.2(es)15(,)-286.6(p)0(a)20.2(r)0(t)16.5(i)12.7(cu)14.1(l)12.7(a)0(r)17.8(l)12.7(y)-292.6(a)0(m)20.8(o)12.2(ng)-280.4(mi)19.4(d)12.2(l)0(i)19.4(f)0(e)-280.9(w)0(o)16.8(m)12.8(en)14.1(.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.9021 0 TD
[(We)-392.5(gathered)-392.4(qualitative)-400.1(data)-392(among)-393.8(sexually)]TJ
-6.902 -1.128 TD
[(active)-450.5(women)-450.2(aged)-447.3(4560)-451.1(to)-444.5(explore)-449.1(patient-centered)-454.5(sexual)]TJ
0 -1.1219 TD
[(function)-298.1(outcomes)-305.1(and)-296.8(treatment)-305.5(preferences.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Material/Methods:)Tj
/F4 1 Tf
8.8226 0 TD
[(Twenty)-763(interviews)-759.7(and)-754.1(three)-760.2(focus)]TJ
-9.8226 -1.1219 TD
[(groups)-220.9(were)-219.5(conducted)-225.3(in)-218.9(person)-225.1(by)-219.4(a)-223.7(trained)-223(facilitator)-221.9(using)-224.1(an)]TJ
0 -1.128 TD
[(interview)-327.6(guide;)-332.3(sessions)-329.4(were)-329.3(audio-recorded)-334.1(and)-327.3(transcribed.)]TJ
0 -1.1219 TD
[(We)-319.3(used)-326.4(a)-321.2(thematic)-327.5(analysis)-322.6(approach)-325.8(for)-321.7(data)-324.9(analysis.)-322.6(Code-)]TJ
0 -1.128 TD
[(book)-347.4(development)-346.2(by)-347.5(two)-348.5(investigators)-348.2(proceeded)-348.3(using)-346.1(an)-345.6(it-)]TJ
0 -1.1219 TD
[(erative)-477.2(process)-478.4(until)-474(a)-473.7(nal)-476(codebook)-477.7(was)-474.3(agreed)-478.3(upon;)-475(the)]TJ
0 -1.128 TD
[(primary)-306.5(investigator)-312.5(then)-308.5(coded)-307.1(all)-314.1(data.)-306.6(Codes)-312.8(relating)-307.9(to)-310.4(out-)]TJ
0 -1.1219 TD
[(comes)-256.9(and)-260.2(treatment)-262.8(preferences)-264.9(were)-262.2(examined)-261.4(to)-261.6(identify)-261(key)]TJ
0 -1.128 TD
(themes.)Tj
/F3 1 Tf
.9999 -1.1219 TD
(Results:)Tj
/F4 1 Tf
3.7193 0 TD
[(Among)-281.3(39)-280.4(total)-283.1(women,)-285.5(the)-284.1(mean)-282.2(age)-282.7(was)-285.3(53;)-286(54%)]TJ
-4.7192 -1.128 TD
[(were)-268.3(White,)-269.5(36%)-270.5(were)-274.4(Black,)-268.6(and)-272.4(10%)-264.4(were)-274.4(other)-268.1(races.)-276.2(When)]TJ
0 -1.1219 TD
[(asked)-257.5(what)-255.1(treatment)-256.7(outcomes)-256.4(they)-253.6(desired,)-259.3(women)-255.1(referenced)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 59.7543 749.7069 Tm
(ABSTRACTS)Tj
52.6193 0 TD
(A-33)Tj
ET
endstream
endobj
332 0 obj
<>stream
/GS1 gs
BT
/F4 1 Tf
9.2982 0 0 9.2982 62.022 725.5557 Tm
0 0 0 rg
0 Tc
0 Tw
[(specic)-343.3(sexual)-342.3(problems:)-345.4(low)-342.4(desire,)-344.7(pain/vaginal)-339.6(dryness,)-346.2(de-)]TJ
0 -1.128 TD
[(creased)-530.4(arousal,)-527.5(and)-528.5(decreased)-534.6(ability)-526.4(to)-529.9(orgasm.)-523.3(However,)]TJ
0 -1.1219 TD
[(when)-414.1(women)-413.6(were)-420.7(asked)-409.9(about)-418.2(the)-412.2(most)-412.6(important)-419(aspect)-413.6(of)]TJ
0 -1.128 TD
[(their)-340.8(sex)-344.7(life,)-346.9(they)-339(discussed)-346.6(emotional)-341.5(as)-344.8(opposed)-338.5(to)-340.9(physical)]TJ
0 -1.1219 TD
[(outcomes.)-232(Emotional)-229.4(outcomes)-232(included)-232.8(enhanced)-230.1(intimacy)-231.8(and)]TJ
0 -1.128 TD
[(connection)-298(with)-299.2(ones)-304.4(partner,)-299.1(mutual)-295.2(pleasure)-300.1(and)-302.9(reciprocity,)]TJ
0 -1.1219 TD
[(and)-370(feeling)-375.5(loved)-375.5(and)-370(desired.)-375.1(Many)-369.1(women)-370.9(preferred)-375.6(behav-)]TJ
0 -1.128 TD
[(ioral)-316.4(over)-317.5(pharmaceutical)-318(treatments,)-316.8(citing)-313.5(concern)-319.7(about)-314.5(side)]TJ
0 -1.1219 TD
[(effects)-265.9(as)-259.4(well)-260.7(as)-259.4(belief)-265.7(that)-259.2(womens)-262.6(sexual)-256.9(problems)-260.6(can)-264.4(have)]TJ
0 -1.128 TD
[(emotional)-329.3(as)-320.4(well)-327.8(physical)-329.5(aspects)-327.3(that)-320.2(are)-327.8(better)-326.7(addressed)-330.2(by)]TJ
0 -1.1219 TD
[(behavioral)-300.4(approaches.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Conclusions:)Tj
/F4 1 Tf
5.6948 0 TD
[(In)-209.6(the)-210.9(development)-212.1(and)-205.4(testing)-215.1(of)-209.6(treatments)-207(for)]TJ
-6.6947 -1.1219 TD
[(sexual)-433.7(dysfunction)-431.3(in)-432.3(women,)-425.8(both)-432.3(more)-432.8(immediate)-430.6(physical)]TJ
0 -1.128 TD
[(outcomes,)-244.1(such)-241.1(as)-241.1(increased)-243.3(desire,)-247.1(as)-241.1(well)-242.4(as)-241.1(more)-243.8(downstream)]TJ
T*
[(emotional)-542.7(outcomes,)-536.8(such)-539.8(as)-539.9(enhanced)-534.9(intimacy,)-542.8(should)-535(be)]TJ
0 -1.1219 TD
[(considered)-287.8(to)-286(ensure)-284.2(that)-289.7(treatments)-286.3(are)-285.1(patient-centered.)-289.8(Many)]TJ
0 -1.128 TD
[(women)-438(prefer)-442.2(behavioral)-440.6(over)-439.4(pharmaceutical)-439.9(treatments;)-444.3(re-)]TJ
0 -1.1219 TD
[(searchers)-306.3(should)-297.3(continue)-306(to)-298.2(develop)-306.5(non-pharmaceutical)-302(treat-)]TJ
0 -1.128 TD
[(ment)-301.9(options)-296.7(for)-303.4(women)-297.7(with)-305.3(sexual)-299.6(dysfunction.)]TJ
/F3 1 Tf
0 -4.1095 TD
(87.)Tj
9.843 0 0 9.843 82.9417 499.0109 Tm
[(Encouraging)-285.8(Diverse)-282.7(Women)-279.4(to)-284.4(Participate)]TJ
0 -1.1116 TD
[(in)-278.6(Clinical)-287.7(Trials:)-280.6(Attitudes,)-285.6(Motivators,)]TJ
T*
[(and)-279.4(Opportunities)-287.9(for)-280.9(Engagement)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 62.022 460.5731 Tm
[(Carley)-338(Thompson)]TJ
/F5 1 Tf
0 -1.7682 TD
[(FDA)-334.4(Ofce)-338.6(of)-328.7(Womens)-338.7(Health,)-333.8(Silver)-335.7(Spring,)-327.7(Maryland)]TJ
/F3 1 Tf
.9999 -2.3047 TD
(Background:)Tj
/F4 1 Tf
5.9082 0 TD
[(Clinical)-315.8(trials)-309(help)-308.5(to)-310.4(advance)-309.4(the)-308.5(understand-)]TJ
-6.9081 -1.128 TD
[(ing)-334.8(of)-337.7(sex)-338.6(differences)-339.4(and)-333.4(health)-342.6(conditions)-337(unique)-332.8(to)-334.8(women.)]TJ
0 -1.1219 TD
[(Changes)-274.3(in)-279.9(government)-271.7(policy,)-277.4(advocacy,)-272.8(and)-278.5(recruitment)-277.3(have)]TJ
0 -1.128 TD
[(helped)-330.9(to)-322.6(increase)-334.8(the)-326.8(inclusion)-324.8(of)-325.5(women)-328.2(in)-328.7(clinical)-327.5(research.)]TJ
0 -1.1219 TD
[(However,)-489.2(there)-491.9(are)-486.3(still)-490.9(opportunities)-485.1(to)-487.2(learn)-491.9(what)-486.8(impacts)]TJ
0 -1.128 TD
[(whether)-231.1(diverse)-234.9(women)-230.7(participate)-236.5(in)-231.1(clinical)-230(trials.)-235.8(In)-227.9(2015,)-231.6(the)]TJ
0 -1.1219 TD
[(FDA)-353.3(Ofce)-350.4(of)-349.9(Womens)-356.8(Health)-350.2(\(OWH\))-353.3(launched)-353.4(the)-351.2(Diverse)]TJ
0 -1.128 TD
[(Women)-410.2(in)-401.9(Clinical)-413.4(Trials)-408.9(Initiative,)-410.5(in)-401.9(collaboration)-409(with)-408.9(the)]TJ
0 -1.1219 TD
[(NIH)-261.4(Ofce)-259(of)-258.4(Research)-260.7(on)-262.1(Womens)-259.2(Health,)-258.8(to)-261.6(raise)-259.3(awareness)]TJ
0 -1.128 TD
[(of)-313.3(the)-308.5(importance)-312(of)-313.3(participation)-311(of)-313.3(diverse)-314.1(women)-309.9(in)-310.4(clinical)]TJ
0 -1.1219 TD
[(trials)-284.6(and)-290.7(to)-286(share)-284.2(clinical)-290.9(research)-288.9(best)-283.2(practices.)-291.5(OWH)-281.5(sought)]TJ
0 -1.128 TD
[(to)-365.3(better)-369.4(understand)-368.9(womens)-366.3(attitudes,)-371.2(motivators)-369.3(for)-364.4(partici-)]TJ
0 -1.1219 TD
[(pation)-301.8(and)-296.8(opportunities)-302.2(for)-303.4(engagement.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Objective\(s\):)Tj
/F4 1 Tf
6.1886 0 TD
[(To)-684.7(understand)-686(womens)-683.3(knowledge)-679.9(about)]TJ
-7.1886 -1.1219 TD
[(clinical)-528.7(trials.)-528.4(To)-532.2(determine)-525.4(motivators,)-527.8(barriers)-532.3(for)-529(diverse)]TJ
0 -1.128 TD
[(women)-303.8(to)-298.2(participate)-303.5(in)-298.2(clinical)-303.1(trials.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Material/Methods:)Tj
/F4 1 Tf
8.3897 0 TD
[(OWH)-324.2(conducted)-322.9(an)-327.3(environmental)-323.6(scan)]TJ
-9.3897 -1.128 TD
[(and)-241.9(literature)-246.9(review)-243.4(to)-243.3(identify)-248.8(existing)-239.5(clinical)-248.2(trials)-241.9(education)]TJ
0 -1.1219 TD
[(projects)-289.2(and)-284.6(research)-288.9(on)-286.5(recruitment,)-289.5(motivators)-283.9(and)-290.7(barriers)-288.4(to)]TJ
0 -1.128 TD
[(participation.)-640.2(OWH)-641.2(also)-643(conducted)-639.9(three)-644.3(qualitative)-637.9(focus)]TJ
0 -1.1219 TD
[(groups)-464.8(with)-463.8(women)-462.4(ages)-464.8(2164)-463.3(in)-462.8(Los)-464.3(Angeles,)-465.7(Dallas)-465.2(and)]TJ
0 -1.128 TD
[(Washington,)-549(DC)-554.9(to)-548.2(learn)-552.8(more)-548.6(about)-552.3(womens)-549.2(knowledge,)]TJ
T*
[(motivators,)-302.2(and)-296.8(barriers)-306.7(to)-298.2(participation.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Results:)Tj
/F4 1 Tf
3.7132 0 TD
[(The)-280.4(research)-282.8(found)-276.6(that)-277.5(women)-279.4(were)-280.5(more)-280.3(likely)-283(to)]TJ
-4.7131 -1.128 TD
[(participate)-358.4(in)-359.2(a)-351.7(clinical)-358(trial)-358.6(if)-355.5(they)-357.3(thought)-358.6(they)-351.2(were)-359.8(helping)]TJ
0 -1.1219 TD
[(their)-225(community,)-227.5(family)-224.4(or)-221.8(friends)-226.9(or)-221.8(were)-225.6(referred)-229.3(to)-225(a)-223.7(study)-224.1(by)]TJ
0 -1.128 TD
[(someone)-415.4(they)-412.1(knew)-414.1(or)-410.8(by)-414.6(their)-414(health)-415.8(care)-417.3(provider.)-410.7(The)-414.5(re-)]TJ
0 -1.1219 TD
[(search)-367.7(also)-368.6(indicated)-364.6(that)-368.9(a)-363.9(common)-362.7(barrier)-368.5(for)-364.4(women)-364.8(is)-370.5(not)]TJ
0 -1.128 TD
[(being)-351.1(asked)-355(to)-353.1(participate.)-358.4(Others)-354.1(included:)-348.2(\(1\))-358.3(lack)-349.3(of)-356(cultur-)]TJ
0 -1.1219 TD
[(ally)-448.2(sensitive)-444(recruitment;)-447.5(\(2\))-443.7(the)-442.6(risk)-446(and)-443.1(unknown)-440.3(side)-447.9(ef-)]TJ
0 -1.128 TD
[(fects;)-460(\(3\))-455.9(possible)-458.6(costs)-459.2(of)-453.5(participation;)-456.8(and)-461.4(\(4\))-455.9(logistics)-457.6(of)]TJ
0 -1.1219 TD
(participating.)Tj
/F3 1 Tf
.9999 -1.128 TD
(Conclusions:)Tj
/F4 1 Tf
5.896 0 TD
[(By)-407.1(tapping)-411.6(into)-407.4(womens)-409(key)-406.6(motivators)-412(the)]TJ
-6.8959 -1.1219 TD
[(initiative)-255.2(can)-252.2(help)-259.7(to)-249.4(encourage)-256.8(greater)-254.5(participation.)-256.1(There)-256.4(also)]TJ
0 -1.128 TD
[(exists)-263.5(an)-254.2(opportunity)-262.8(to)-255.5(provide)-262(health)-257.3(care)-258.8(providers)-263.5(with)-256.5(tools)]TJ
0 -1.1219 TD
[(to)-298.2(educate)-302.8(patients)-304.6(about)-302.4(clinical)-303.1(trial)-297.6(participation.)]TJ
/F3 1 Tf
26.9984 71.9468 TD
(88.)Tj
9.843 0 0 9.843 333.9779 725.5557 Tm
[(WH)46.2(Y)47.7()-277.5(Long-Acting)-285.6(Reversible)-287.2(Contraceptives:)]TJ
0 -1.1174 TD
[(Identifying)-283.5(and)-285.2(Addressing)-284.2(Millennial)]TJ
0 -1.1116 TD
(Misconceptions)Tj
/F4 1 Tf
9.2982 0 0 9.2982 313.0582 687.0613 Tm
[(Pretty)-337.6(Verma)]TJ
6.9735 0 0 6.198 363.7983 691.1998 Tm
(1)Tj
9.2982 0 0 9.2982 367.3133 687.0613 Tm
[(,)-335.3(Vivien)-333.8(Brown)]TJ
6.9735 0 0 6.198 426.444 691.1998 Tm
(2)Tj
9.2982 0 0 9.2982 429.959 687.0613 Tm
[(,)-335.3(Pamela)-331.4(Liao)]TJ
6.9735 0 0 6.198 483.1369 691.1998 Tm
(2)Tj
9.2982 0 0 9.2982 486.5952 687.0613 Tm
(,)Tj
-18.6635 -1.128 TD
[(Elizabeth)-335.9(Chertkow)]TJ
6.9735 0 0 6.198 388.233 680.7117 Tm
(2)Tj
9.2982 0 0 9.2982 391.6912 676.5731 Tm
[(,)-335.3(Christine)-331.9(Palmay)]TJ
6.9735 0 0 6.198 462.3873 680.7117 Tm
(2)Tj
/F5 1 Tf
-21.4138 -2.6526 TD
(1)Tj
9.2982 0 0 9.2982 316.5731 660.1321 Tm
[(University)-327.8(of)-322.6(British)-327.7(Columbia,)-322.1(Vancouver,)-324.4(British)-327.7(Columbia,)]TJ
-.378 -1.1219 TD
(Canada)Tj
6.9735 0 0 6.198 313.0582 643.351 Tm
(2)Tj
9.2982 0 0 9.2982 316.5731 639.2124 Tm
[(Department)-338.6(of)-328.7(Family)-335.7(and)-335.3(Community)-333.9(Medicine,)-336.9(University)]TJ
-.378 -1.1219 TD
[(of)-334.8(Toronto,)-336.7(Toronto,)-330.6(Ontario,)-334.8(Canada)]TJ
/F3 1 Tf
.9999 -2.3047 TD
(Background:)Tj
/F4 1 Tf
5.896 0 TD
[(While)-300(contraceptive)-296(uptake)-294.4(rates)-295.9(in)-298.2(developed)]TJ
-6.8959 -1.1219 TD
[(countries)-368.5(are)-364.4(as)-369.2(high)-359.1(as)-369.2(74%)-362(in)-365.3(developed)-365.6(nations)-361.9(unintended)]TJ
0 -1.128 TD
[(pregnancy)-331.9(rates)-332.5(continue)-330.4(to)-328.7(be)-333.4(upwards)-330.2(of)-325.5(65%.)-331.5(\(1\))-327.8(Although,)]TJ
0 -1.1219 TD
[(long-)-526.1(acting)-525.6(reversible)-533.6(contraceptive)-527.7(devices)-523.3(\(LARCs\))-528.7(have)]TJ
0 -1.128 TD
[(been)-209.6(shown)-201.7(to)-206.7(be)-205.4(highly)-206.1(effective)-209.4(\(1,2,3\))-205.8(in)-200.7(Canada)-212.3(only)-200.6(2.3%)-203.5(of)]TJ
0 -1.1219 TD
[(women)-303.8(use)-302.1(them.)-301.8(\(1\))]TJ
/F3 1 Tf
.9999 -1.128 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.9387 0 TD
[(In)-435.2(t)12.7(h)12.2(is)-413.2(s)13.1(t)0(u)18.8(d)0(y)18.3(,)-420.7(we)-408.1(id)18.9(en)20.2(ti)19.3(e)17.3(d)-420.7(m)12.7(is)19.7(pe)20.2(rc)17.8(ep)20.2(ti)19.4(on)18.3(s)-419.8(o)12.2(f)]TJ
-6.9386 -1.1219 TD
[(LA)15(R)13.6(C)-218.1(u)12.2(s)0(e)-204.5(t)12.7(ha)14.1(t)-212.9(m)12.8(ay)-205.4(d)12.2(e)0(t)20.7(e)0(r)-207.7(u)12.2(se)-204.5(am)20.8(on)18.3(g)-213.4(y)12.2(ou)18.3(n)12.2(g)-213.4(wo)16.8(m)12.7(e)0(n)20.2(,)-213.4(wi)17.3(t)12.7(h)-213.4(th)18.8(e)-211.5(g)0(o)18.3(a)0(l)]TJ
0 -1.128 TD
[(of)-221.8(d)12.2(e)0(v)20.2(e)0(l)20.7(o)0(p)18.3(m)12.8(en)14.1(t)-225.1(o)12.2(f)-227.9(a)-223.7(pa)20.2(ti)19.4(en)20.2(t)-231.2(c)14.1(ou)18.3(n)12.2(s)0(e)15(l)12.7(li)19.3(ng)-219.4(a)14.1(n)0(d)-219.4(e)0(d)20.2(u)12.2(ca)16(t)12.7(i)0(o)18.8(n)12.2(al)-217.1(re)17.9(so)19.2(u)12.2(r)0(c)17.8(e)0(.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Material/Methods:)Tj
/F4 1 Tf
8.7007 0 TD
[(In)-630.3(order)-630.8(to)-627.5(identify)-632.9(determinants)-627.7(of)]TJ
-9.7006 -1.1219 TD
[(IUCD)-320.9(use,)-320.3(a)-315.2(content-based)-321.9(analysis)-316.5(was)-321.9(conducted)-316.8(on)-317(relevant)]TJ
0 -1.128 TD
[(literature.)-332.2(A)-318.5(literature)-326.1(search)-331.1(was)-321.8(performed)-325.8(on)-323.1(PubMed)-323.1(to)-322.6(in-)]TJ
0 -1.1219 TD
[(clude)-452.9(qualitative)-448.9(and)-449.2(quantitative)-455(studies)-446.4(of)-447.4(any)-449.2(design)-447.8(pub-)]TJ
0 -1.128 TD
[(lished)-349.8(in)-340.9(English)-341.3(between)-348.8(20082015)-341.2(whose)-340.1(subjects)-347(included)]TJ
0 -1.1219 TD
[(women)-498.9(aged)-502.2(1635.)-493.7(Content-analysis)-503.4(was)-498.7(conducted)-499.7(on)-493.8(the)]TJ
0 -1.128 TD
[(abstracts)-335.3(of)-331.6(any)-333.4(relevant)-337(studies)-330.6(to)-334.8(distil)-332.3(major)-328.6(themes)-335.7(of)-331.6(mis-)]TJ
0 -1.1219 TD
[(perceptions)-262.9(or)-258.4(barriers)-257.9(to)-255.5(womens)-262.6(use)-253.3(of)-258.4(long-acting)-259(reversible)]TJ
0 -1.128 TD
[(contraceptives.)-289()52.5(Misperceptions)51.8()-282.8(were)-286.6(identied)-284(as)-283.8(such)-283.7(when)]TJ
0 -1.1219 TD
[(primary)-343.1(literature)-350.5(or)-337.7(guidelines)-347.3(refuted)-341.8(the)-345.1(claim)-342.1(or)-343.8(when)-341(evi-)]TJ
0 -1.128 TD
[(dence)-274.7(was)-273.1(inconsistent.)-272.7(These)-271.5(ndings)-269.6(resulted)-270.9(in)-273.8(the)-265.8(basis)-276.3(of)-270.6(a)]TJ
0 -1.1219 TD
[(e-resource)-309.5(for)-297.3(patient)-299.4(education.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Results:)Tj
/F4 1 Tf
3.8717 0 TD
[(Our)-430.6(results)-430.5(identify)-431.7(the)-430.4(specic)-434.7(themes)-433.2(regarding)]TJ
-4.8717 -1.1219 TD
[(perceptions)-598.2(and)-601.7(barriers)-593.3(to)-597(use)-600.8(of)-593.7(Long-Acting)-594(Reversible)]TJ
0 -1.128 TD
[(Contraception)-420.3(\(LARCs\))-412.8(in)-414.1(youth)-407.9(populations.)-416.2(These)-411.7(included)]TJ
0 -1.1219 TD
[(themes)-360.1(such)-356.9(as)-357(1\))-356(reversibility)-357(of)-356(the)-357.3(contraceptive)-357(method)-356.7(2\))]TJ
0 -1.128 TD
[(suitability)-475.7(for)-468.1(use)-466.7(in)-475(nulliparous)-467.4(women,)-468.4(3\))-471.8(discomfort)-469.7(with)]TJ
0 -1.1219 TD
[(LARC)-579.7(placement)-582.2(and)-577.3(removal)-582.8(4\))-575.5(concerns)-581(over)-579.6(menstrual)]TJ
0 -1.128 TD
[(changes,)-310.4(and)-302.9(5\))-307.2(infection)-307.8(risk.)-299.7(We)-307.1(have)-307.1(created)-305.1(a)-309.1(short)-305.8(presen-)]TJ
0 -1.1219 TD
[(tation)-301.3(to)-304.3(address)-301.6(identied)-302.2(misconceptions.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Conclusions:)Tj
/F4 1 Tf
5.7862 0 TD
[(LAR)10.3(C)-291.3(u)0(p)12.2(tak)14.7(e)-296.9(i)0(n)-286(Can)15.5(ada)-282.7(may)-284.1(be)-290.7(im)13.3(ped)14.2(ed)-284.6(by)-292.6(a)]TJ
-6.7862 -1.1219 TD
[(num)12.8(ber)-213.8(of)-215.7(mi)13.3(sco)15(nce)16(pti)13.3(on)12.2(s)-218.6(and)-211.4(bar)11.8(rie)18.4(rs)-221(sp)13.1(eci)16.5(c)-220.4(to)-212.8(you)12.3(ng)-213.3(wom)17.4(en.)]TJ
0 -1.128 TD
[(By)-352.2(dev)14.1(elo)14.7(pi)12.7(ng)-347.5(a)-357.8(d)0(i)12.7(git)13.3(al)-351.2(pa)14.1(tie)15.1(nt)-353.1(ed)14.1(uca)16(tio)13.3(n)-353.6(too)12.8(l,)-347(we)-353.2(ho)12.3(pe)-345.6(to)-353.1(im)13.3(-)]TJ
0 -1.1219 TD
[(pro)16(ve)-321.2(up)12.3(tak)14.7(e)-327.3(o)0(f)-319.4(LAR)16.4(Cs)-320.9(in)-316.5(th)12.8(is)-321.7(po)12.2(pu)12.3(lat)15.1(ion)12.8(.)-323.1(A)0(n)-318.5(edu)14.1(cat)16.5(ion)12.8(al)-314.6(too)12.8(l)]TJ
0 -1.128 TD
[(cre)13.6(ate)10.4(d)-378(i)0(n)-377.5(r)0(e)11.8(s)0(p)13.1(ons)13.1(e)-382.2(t)0(o)-377.5(o)0(u)12.2(r)-380.4(nd)15.5(in)12.8(gs)-377.1(can)-368.1(be)-376.1(fou)16(nd)-378(at)14.6(:)-383.6(www)13.9(.t)12.7(alk)]TJ
0 -1.1219 TD
[(wit)11.8(hy)12.3(ou)12.2(rdo)16(c.c)16(a.)]TJ
/F3 1 Tf
0 -3.7254 TD
(89.)Tj
9.843 0 0 9.843 333.9779 217.0771 Tm
[(Experience,)-286.1(Emotions,)-284.8(Anxiety)-286.1(and)-279.4(Feeling)]TJ
0 -1.1116 TD
[(in)-284.4(Unwanted)-281.9(Pregnancy)-285(a)-277.6(Qualitative)-285.4(Research)]TJ
T*
[(in)-284.4(Women)-279.4(Referring)-286.1(to)-278.6(Maternal)-284.1(Clinic)-285.3(Afliated)]TJ
0 -1.1174 TD
[(to)-284.4(Shiraz)-279.5(University)-284.8(of)-284.4(Medical)-283.1(Sciences,)-281.5(2010)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 313.0582 167.6409 Tm
[(Zahra)-335.7(Yazdanpanahi,)-338.9(Marzieh)-336.6(Akbarzadeh,)-337.6(Ladan)-333.3(Zarshenas,)]TJ
0 -1.1219 TD
[(Farkhondeh)-336.6(Sharif)]TJ
/F5 1 Tf
0 -1.7682 TD
[(Shiraz)-339.1(University)-333.9(of)-334.8(Medical)-332.8(Sciences,)-338.5(Shiraz,)-333(Iran)]TJ
/F3 1 Tf
.9999 -2.3047 TD
(Background:)Tj
/F4 1 Tf
6.1643 0 TD
[(Unwanted)-559.5(pregnancy)-563.6(has)-558.1(affected)-563.6(different)]TJ
-7.1642 -1.128 TD
[(aspects)-418.8(of)-410.8(our)-410.8(life.)-414(Researchers)-412.7(point)-413.5(out)-407.9(if)-416.4(a)-412.7(childs)-407(birth)-415.9(is)]TJ
0 -1.1219 TD
[(unwanted,)-271.4(an)-272.4(increase)-273.8(in)-273.8(maternal)-269.4(issues)-275.4(such)-265.4(as)-271.6(psychological,)]TJ
0 -1.128 TD
[(physical,)-299(social)-299.1(and)-290.7(economic)-298(problems)-297.2(can)-294.9(be)-296.8(observed.)-296.3(Also,)]TJ
0 -1.1219 TD
[(some)-228.3(studies)-220.8(show)-226.1(that)-222.6(unwanted)-222.6(children)-223(have)-227.8(more)-219.4(unsafe)-229.3(and)]TJ
0 -1.128 TD
[(miserable)-323.4(life)-316.4(while)-321.6(being)-320.6(annoyed)-313.1(and)-321.2(neglected)-320.5(by)-317(their)-316.4(par-)]TJ
0 -1.1219 TD
[(ents)-301.5(and)-302.9(are)-303.4(in)-298.2(need)-301(of)-301.1(treatment)-299.4(for)-303.4(their)-298.1(mental)-305.5(problems.)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 62.022 749.6502 Tm
(A-34)Tj
48.6864 0 TD
(ABSTRACTS)Tj
ET
endstream
endobj
336 0 obj
<>stream
/GS1 gs
BT
/F3 1 Tf
9.2982 0 0 9.2982 69.0519 725.5557 Tm
0 0 0 rg
0 Tc
0 Tw
(Objective\(s\):)Tj
/F4 1 Tf
5.8228 0 TD
[(The)-310.9(evaluation)-315.8(of)-313.3(Experience,)-313(emotions,)-312.6(anxi-)]TJ
-6.8228 -1.128 TD
[(ety)-302.4(and)-302.9(feeling)-302.3(in)-298.2(unwanted)-301.9(pregnancy.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Material/Methods:)Tj
/F4 1 Tf
8.341 0 TD
[(This)-268.7(study)-266.8(is)-273(a)-266.4(qualitative)-272.1(method)-271.3(which)]TJ
-9.3409 -1.128 TD
[(is)-309.6(studying)-308.9(a)-309.1(kind)-304.3(of)-307.2(basic)-311.8(theory.)-304.7(An)-306.3(interview)-309.3(was)-309.7(done)-309(with)]TJ
0 -1.1219 TD
[(20)-341.4(women)-340.4(with)-341.8(unwanted)-344.6(pregnancy)-338(who)-342.9(referred)-345.1(to)-340.9(maternal)]TJ
0 -1.128 TD
[(clinic)-494.6(afliated)-491.8(to)-493.3(Shiraz)-488.6(University)-493.3(of)-490.1(Medical)-492.3(Sciences)-493.8(in)]TJ
0 -1.1219 TD
[(2009.)-304.7(They)-304.7(were)-304.9(selected)-307.5(by)-304.8(convenience)-306.9(sampling.)-306.5(Data)-308.1(were)]TJ
0 -1.128 TD
[(gathered)-221.6(through)-221.2(deep)-221.7(and)-217.5(semi-individual)-226.1(structured)-218.4(interviews)]TJ
0 -1.1219 TD
[(with)-372.3(women)-377(who)-367.3(had)-376.1(unwanted)-369(pregnancy.)-374.5(After)-375.7(data)-373.7(collec-)]TJ
0 -1.128 TD
[(tion,)-413.5(all)-405.6(the)-412.2(written)-408.8(content)-409.7(was)-413.3(analyzed)-412.5(through)-410.2(Juorjy)-403.3(and)]TJ
0 -1.1219 TD
[(Colaizzis)-352.5(method.)-344.5(Through)-345.5(this)-339.5(method,)-344.5(description,)-349.6(explana-)]TJ
0 -1.128 TD
[(tion)-248.9(and)-248(categorization)-252.8(of)-252.3(data)-245.6(were)-256.1(done)-248(and)-248(major)-249.3(issues)-251(were)]TJ
0 -1.1219 TD
(obtained.)Tj
/F3 1 Tf
.9999 -1.128 TD
(Results:)Tj
/F4 1 Tf
3.762 0 TD
[(Based)-323.1(on)-323.1(the)-326.8(participants)-325.2(opinion,)-322(unwanted)-326.3(preg-)]TJ
-4.7619 -1.128 TD
[(nancy)-343.7(can)-343.7(be)-339.5(the)-345.1(cause)-340.9(of)-343.8(several)-342.8(problems.)-339.9(The)-341.3(rst)-345.2(problem)]TJ
0 -1.1219 TD
[(arising)-236.3(from)-235.8(this)-229.7(condition)-234.2(is)-230.3(physical)-238.1(problem)-231(And)-233.1(the)-235.3(next)-235.3(one)]TJ
0 -1.128 TD
[(is)-425.4(related)-422.4(to)-420.1(mental)-427.5(reactions)-421.5(such)-424(as)-424(maternal)-421.8(emotions)-422.3(like)]TJ
0 -1.1219 TD
[(embarrassment)-390(for)-382.7(being)-387.7(pregnant,)-388.1(mothers)-384.9(own)-385.5(negative)-383.4(af-)]TJ
0 -1.128 TD
[(fection,)-296.2(being)-290.2(worried)-290.3(about)-290.2(missing)-289.3(family)-291.5(and)-290.7(other)-286.4(children,)]TJ
0 -1.1219 TD
[(and)-272.4(psychological)-278.3(reaction)-269.9(related)-276(to)-273.8(terminating)-270.2(the)-271.9(pregnancy)]TJ
0 -1.128 TD
[(through)-312.6(illegal)-317.2(abortion,)-310.2(and)-309(the)-314.6(husbands)-309.5(disagreement)-315.3(about)]TJ
0 -1.1219 TD
[(the)-558.5(termination.)-556.7(They)-554.7(blame)-562.1(themselves)-557.9(for)-553.4(thinking)-553.1(about)]TJ
0 -1.128 TD
[(abortion)-212.7(or)-209.6(illegal)-213.6(abortion)-206.6(and)-211.4(worry)-213.4(about)-210.9(their)-206.7(doubts)-211.9(for)-212(guilt)]TJ
0 -1.1219 TD
[(feeling.)-436.4(Another)-434.2(problem)-438.3(which)-431.9(results)-436.6(from)-430.9(unwanted)-436(preg-)]TJ
0 -1.128 TD
[(nancy)-319.3(is)-315.6(family)-315.9(problems)-315.5(like)-314.1(husbands)-315.6(behavior)-321.1(and)-315.1(his)-315.6(neg-)]TJ
0 -1.1219 TD
[(ative)-324.4(outlook)-322(towards)-323.6(his)-321.7(child)-320.1(and)-321.2(fetus.)-322.2(4.)-323.1(The)-323(next)-320.7(category)]TJ
0 -1.128 TD
[(belongs)-508.8(to)-499.4(anxiety)-507.2(about)-503.6(the)-503.6(future)-508.3(of)-502.3(their)-505.4(child)-503.1(including)]TJ
0 -1.1219 TD
[(economic,)-224.8(social)-219.8(and)-223.6(relational)-226.2(problems,)-217.9(and)-223.6(suppression)-222.8(of)-215.7(the)]TJ
0 -1.128 TD
[(childrens)-224.5(logical)-226.3(expectations.)-221.5(The)-225.5(last)-221.8(problem)-224.9(is)-218.1(about)-223.1(lack)-221.2(of)]TJ
0 -1.1219 TD
[(maternal)-306(emotional)-298.9(support.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Conclusions:)Tj
/F4 1 Tf
5.9752 0 TD
[(Negative)-494.6(psychological)-491.7(and)-485.8(quantitative)-491.5(im-)]TJ
-6.9752 -1.1219 TD
[(pacts)-525.2(of)-520.6(unwanted)-521.4(pregnancies)-523.7(on)-524.3(the)-521.9(mothers)-522.8(and)-522.4(infants)]TJ
0 -1.128 TD
[(health)-482.9(are)-486.3(considerable.)-480.5(A)-483.1(closer)-484.9(observation)-478.2(by)-481.6(family)-480.5(and)]TJ
0 -1.1219 TD
[(health)-300(care)-295.4(provider)-300.9(for)-291.2(unwanted)-301.9(pregnancies)-298.1(and)-296.8(its)-290.7(results)-302.5(is)]TJ
0 -1.128 TD
[(emphasized;)-276.4(therefore,)-269(they)-265.8(should)-266.8(be)-272.4(taken)-270(care)-271(of)-264.5(as)-271.6(high)-267.7(risk)]TJ
0 -1.1219 TD
[(pregnancies,)-432.2(requiring)-428.4(family)-431.7(support.)-427.6(Keywords:)-428.7(experience,)]TJ
0 -1.128 TD
[(sensation,)-304.3(anxiety,)-299.9(unwanted)-301.9(pregnancy.)]TJ
/F3 1 Tf
0 -3.0425 TD
(90.)Tj
9.843 0 0 9.843 80.674 320.655 Tm
[(Cardiac)-287.3(Resynchronization)-282.8(Therapy)-287.2(in)-278.6(Women:)]TJ
0 -1.1174 TD
[(Meta-Analysis)-289(of)-278.6(Clinical)-281.9(Trials)-285.3(and)-279.4(Post-Market)]TJ
0 -1.1116 TD
[(Comparative)-287(Effectiveness)-284.4(Studies)]TJ
/F4 1 Tf
9.2982 0 0 9.2982 59.7543 282.1606 Tm
[(Robbert)-333.8(Zusterzeel,)-342.1(Kathryn)-330.6(OCallaghan,)-337(William)-335(Sanders,)]TJ
0 -1.128 TD
[(Daniel)-338(Canos,)-331.1(David)-334.3(Strauss)]TJ
/F5 1 Tf
0 -1.7682 TD
[(FDA,)-334.4(Silver)-335.7(Spring,)-333.8(Maryland)]TJ
/F3 1 Tf
.9999 -2.2986 TD
(Background:)Tj
/F4 1 Tf
5.8289 0 TD
[(Wo)20.2(me)20.7(n)-219.5(h)12.2(av)20.2(e)-217.6(b)12.2(ee)16(n)-213.4(h)12.2(is)19.7(to)18.9(ri)22.6(ca)16(ll)19.4(y)-213.4(u)0(n)18.3(d)12.2(er)17.8(re)17.9(p)12.2(r)0(e)17.9(s)0(e)21.1(n)0(t)18.8(e)0(d)]TJ
-6.8289 -1.128 TD
[(in)-286(cl)14.6(i)12.7(n)0(i)18.8(c)0(a)16(l)-292.1(tr)16.5(i)12.7(a)0(l)14.6(s)13.1(.)-298.7(T)0(h)22.6(e)0(r)17.8(e)0(f)17.8(o)12.2(re)17.8(,)-298.7(a)14.1(n)-298.7(i)12.7(nf)16(o)12.2(r)0(m)16.5(a)14.1(ti)19.3(on)-286.5(ga)20.2(p)-298.7(m)12.8(ay)-290.7(ex)20.2(i)12.7(s)0(t)-291.3(o)12.2(n)-298.7(t)12.7(h)12.2(e)]TJ
27.0045 54.0089 TD
[(s)13.1(a)0(f)17.8(e)0(t)20.7(y)-304.8(an)20.2(d)-298.7(e)0(f)17.8(f)0(e)17.8(c)0(t)20.7(i)0(v)18.8(e)0(n)20.2(e)0(s)15(s)-297.9(of)-295(m)12.8(e)0(d)20.2(i)0(c)14.6(a)14.1(l)-304.3(d)12.2(ev)20.2(ic)14.6(es)-289.9(in)-292.1(wo)16.8(m)12.8(e)0(n)20.2(.)-304.8(On)22.9(e)-303(a)0(r)17.8(e)0(a)]TJ
0 -1.128 TD
[(wh)22.9(er)17.8(e)-193.2(w)0(o)16.8(m)12.8(en)-187.1(a)14.1(r)0(e)-183.4(p)0(a)14.1(r)0(t)22.6(i)12.7(cu)14.1(l)12.7(a)0(r)17.8(l)12.7(y)-195.1(u)12.2(nd)18.3(er)17.8(re)17.8(p)12.2(r)0(e)17.8(s)13.1(en)20.2(te)14.6(d)-189(i)0(s)-187.6(i)12.7(n)-195.1(t)12.7(ri)16.5(a)14.1(l)0(s)-187.6(o)12.2(f)-191.4(h)0(e)20.2(a)0(r)17.8(t)]TJ
0 -1.1219 TD
[(fa)17.8(i)12.7(l)0(u)18.8(r)0(e)-232.1(d)0(e)20.2(v)0(i)18.8(c)0(e)16(s)13.1(,)-243.9(s)0(u)19.2(c)0(h)-235.9(a)0(s)-235(c)14.1(ar)17.8(di)18.8(ac)-234(re)17.8(sy)19.2(n)12.2(c)0(h)20.2(r)0(o)16(n)12.2(i)12.7(z)0(a)16(t)0(i)19.3(o)12.2(n)-243.9(t)0(h)18.9(e)0(r)17.8(a)0(p)20.2(y)-243.9(\(C)17.3(R)13.6(T)0(\))20.2(.)]TJ
0 -1.128 TD
[(C)13.6(R)0(T)-372.3(i)12.7(s)-377.2(a)-376.1(pa)14.1(c)14.1(e)0(m)14.7(a)14.1(ke)14.1(r)-374.3(t)12.7(he)14.1(ra)23.9(py)-371.9(fo)22.1(r)-374.3(s)0(e)15(l)12.7(ec)16(t)12.7(e)0(d)-370(p)12.2(at)20.7(ie)14.6(n)12.2(t)0(s)-370.5(w)0(i)23.4(t)0(h)-371.4(c)14.1(hr)16(o)12.2(n)12.2(i)0(c)]TJ
0 -1.1219 TD
[(h)12.2(e)0(a)16(r)0(t)-349.4(f)0(a)17.8(i)0(l)19.3(u)12.2(re)-360.2(a)14.1(n)0(d)-353.6(h)0(a)20.2(s)-365(b)12.2(e)0(e)16(n)-365.8(s)13.1(h)12.2(ow)16.8(n)-365.8(t)12.7(o)-365.8(r)0(e)23.9(d)0(u)18.3(c)0(e)-355.9(h)12.2(ea)16(rt)-355.5(fa)23.9(il)19.3(ur)16(e)-363.9(h)12.2(o)12.2(s)0(p)19.2(i)0(-)]TJ
0 -1.128 TD
[(t)12.7(a)0(l)14.6(i)12.7(za)16(t)12.7(i)0(o)18.9(n)12.2(s)-291.8(a)0(n)20.2(d)-292.6(m)12.7(o)12.2(rt)16.5(al)20.7(it)19.3(y)-292.6(w)0(h)22.9(i)0(l)19.3(e)-290.8(im)19.4(p)12.2(r)0(o)16(v)12.2(i)12.7(n)0(g)-280.4(q)0(u)18.3(a)0(l)20.7(i)0(t)19.3(y)-292.6(o)12.2(f)-288.9(li)19.3(fe)17.8(.)]TJ
/F3 1 Tf
.9999 -1.1219 TD
(Objective\(s\):)Tj
/F4 1 Tf
5.9448 0 TD
[(We)-441.3(assessed)-442(the)-436.5(effectiveness)-443.5(of)-435.2(CRT)-444.1(sepa-)]TJ
-6.9447 -1.128 TD
[(rately)-229.2(in)-225(women)-224.6(and)-229.7(men)-223.1(using)-230.2(pre-market)-225.8(and)-229.7(post-market)-223.9(data)]TJ
0 -1.1219 TD
(sources.)Tj
/F3 1 Tf
.9999 -1.128 TD
(Material/Methods:)Tj
/F4 1 Tf
8.3105 0 TD
[(In)-246.2(3)-243.9(separate)-249.4(studies)-245.2(\(1)-246.2(pre-market)-250.2(meta-)]TJ
-9.3104 -1.1219 TD
[(analysis)-340.9(and)-339.5(2)-341.4(post-market)-339.8(registry)-342.3(studies\))-345.1(we)-341(analyzed)-345.4(long-)]TJ
0 -1.128 TD
[(term)-432.3(mortality)-430.6(outcomes)-433.2(after)-439.4(CRT)-431.9(in)-432.3(subgroups)-433.4(by)-426.7(sex)-436.2(and)]TJ
0 -1.1219 TD
[(electrocardiographic)-369.5(\(ECG\))-366.3(characteristics)-367.4(\(i.e.)-365.7(QRS)-362.7(morphol-)]TJ
0 -1.128 TD
[(ogy)-426.7(and)-430.9(duration\).)-428.4(In)-404.7(th)18.9(e)-418.8(m)0(e)20.7(t)0(a)14.6(-)0(a)23.9(n)0(a)14.1(l)12.7(y)12.2(s)0(i)19.7(s)-419.8(of)-410.8(p)12.2(r)0(e)17.8(-)0(m)22.6(a)0(r)17.8(k)0(e)20.2(t)-420.2(cl)20.7(in)18.9(ic)20.7(al)]TJ
T*
[(t)12.7(r)0(i)16.5(a)0(l)20.7(s)-316.2(we)-304.4(co)14.1(m)12.7(b)12.2(in)18.8(ed)-309(i)12.7(n)0(d)18.3(i)12.7(vi)18.8(d)12.2(u)0(a)14.1(l)12.7(-p)22.1(at)14.6(i)12.7(e)0(n)20.2(t)-316.5(da)20.2(ta)-308.5(fr)19.7(o)12.2(m)-316.5(3)-317(c)0(l)20.7(i)0(n)18.9(i)0(c)20.7(a)0(l)-308.5(C)0(R)15(T)0(-)]TJ
0 -1.1219 TD
-.0242 Tc
[(debrillator)-209.5(\()-2.2(CRT-D\))-209.5(t).7(ri)-5.4(als)-212.3(\()3.9(M)-5(A)-1.3(DIT-CRT,)-213.2(R)1.6(AFT,)-207.1(and)-207.1(R)-4.5(EVERSE;)]TJ
/F2 1 Tf
0 -1.128 TD
0 Tc
(>)Tj
/F4 1 Tf
.6951 0 TD
-.024 Tc
[(4,000)-316.6(p)-5.7(a)2.3(tients)-321.9(t).9(otal\))-319(s)-4.8(ubmitted)-316.6(t)-5.2(o)-316.6(t).9(he)-327(FDA)-324.2(a)2.3(s)-321.9(p).4(art)-322.2(o).4(f)-319(p).4(re-market)]TJ
-.6951 -1.1219 TD
0 Tc
[(approval)-497.9(applications.)-497.3(In)-496.2(the)-497.5(2)-499.9(post-market)-498.3(studies)-495.2(we)-499.5(used)]TJ
0 -1.128 TD
[(data)-373.7(from)-369.9(the)-375.6(National)-374.1(Cardiovascular)-377.8(Data)-375.2(Registry)-375.1(\(NCDR\))]TJ
0 -1.1219 TD
[(Implantable)-415.1(Cardioverter)-419.5(Debrillator)-417.7(Registry)-417.8(\()]TJ
/F2 1 Tf
20.3829 0 TD
(>)Tj
/F4 1 Tf
.7195 0 TD
[(31,000)-414.5(and)]TJ
/F2 1 Tf
-21.1512 -1.128 TD
(>)Tj
/F4 1 Tf
.7195 0 TD
[(75,000)-298.6(patients)-298.6(respectively\).)]TJ
/F3 1 Tf
.3293 -1.1219 TD
(Results:)Tj
/F4 1 Tf
3.8168 0 TD
[(The)-377.9(pre-market)-384.3(meta-analysis)-387.1(showed)-382.7(that)-381.1(women)]TJ
-4.8168 -1.128 TD
[(had)-302.9(a)-303(55%)-301(relative)-306(mortality)-302.6(reduction)-302.3(with)-305.2(CRT-D)-307.7(\(compared)]TJ
0 -1.1219 TD
[(with)-311.4(standard)-320.2(implantable)-314.7(debrillator)-318.6([ICD])-312(alone\))-321.1(while)-315.5(men)]TJ
0 -1.128 TD
[(had)-315.1(a)-321.2(15%)-319.3(reduction.)-320.5(In)-313.3(patients)-322.9(with)-317.5(left)-322.5(bundle)-314.5(branch)-321.6(block)]TJ
0 -1.1219 TD
[(\(LBBB,)-213.4(a)-217.6(block)-217(in)-212.8(the)-217(left-sided)-217.9(conduction)-214.5(system)-214.7(of)-215.7(the)-217(heart\),)]TJ
0 -1.128 TD
[(women)-230.7(beneted)-240.4(even)-233.9(more)-231.6(\(61%)-236.3(relative)-232.8(reduction\))-237.5(while)-236.3(men)]TJ
0 -1.1219 TD
[(beneted)-520.9(to)-517.7(a)-516.4(lesser)-520.6(extent)-519.5(than)-515.8(women)-517.2(\(32%)-522.9(reduction)-515.7(in)]TJ
0 -1.128 TD
[(mortality\).)-402.5(Without)-404.9(LBBB,)-400(neither)-406(women)-401.4(nor)-404.7(men)-399.9(beneted)]TJ
0 -1.1219 TD
[(from)-272.4(CRT-D.)-277.2(In)-276.7(the)-278(rst)-278.2(post-market)-278.8(study)-272.9(of)]TJ
/F2 1 Tf
18.9684 0 TD
(>)Tj
/F4 1 Tf
.7195 0 TD
[(31,000)-274.2(CRT-D)]TJ
-19.6878 -1.128 TD
[(patients,)-322.9(we)-322.7(observed)-326.8(that)-326.3(women)-322.1(had)-327.3(an)-321.2(18%)-325.4(lower)-324.5(mortality)]TJ
0 -1.1219 TD
[(risk)-214.3(than)-210.9(men,)-210.9(while)-218(with)-213.8(LBBB)-211(this)-217.5(difference)-212.3(was)-218.2(even)-215.6(greater)]TJ
0 -1.128 TD
[(\(21%)-291.2(lower)-294(death)-294.4(risk)-293.6(in)-292.1(women)-291.6(than)-290.2(in)-292.1(men\).)-292.5(Among)-293.5(patients)]TJ
0 -1.1219 TD
[(without)-487.6(LBBB,)-491.5(CRT-D)-490.6(was)-492.6(not)-493.3(associated)-489.5(with)-494.3(a)-492(mortality)]TJ
0 -1.128 TD
[(differential)-267.5(by)-268.2(sex.)-265.5(In)-270.6(the)-265.8(second)-269.6(post-market)-266.6(study)-266.8(of)]TJ
/F2 1 Tf
22.2486 0 TD
(>)Tj
/F4 1 Tf
.7134 0 TD
(75,000)Tj
-22.962 -1.1219 TD
[(patients,)-377.8(women)-383.1(had)-382.2(a)-382.2(23%)-380.3(lower)-379.4(mortality)-381.9(risk)-378.9(with)-378.4(CRT-D)]TJ
0 -1.128 TD
[(than)-320.7(those)-319.8(with)-323.5(an)-321.2(ICD)-325.6(while)-321.6(in)-322.6(men)-320.7(this)-321.2(difference)-328.1(was)-321.9(12%.)]TJ
0 -1.1219 TD
[(Both)-351.7(women)-346.5(and)-351.7(men)-351.2(with)-354(a)-351.7(LBBB)-351.3(had)-351.7(lower)-348.9(mortality)-351.4(risks)]TJ
0 -1.128 TD
[(with)-402.8(CRT-D)-405.3(compared)-410.6(to)-401.9(ICD,)-404.8(but)-407.9(again)-404.1(this)-406.6(was)-407.2(more)-402.3(pro-)]TJ
0 -1.1219 TD
[(nounced)-203.4(among)-204.8(women)-206.3(\(26%)-205.8(lower)-202.6(mortality)-205(risk)-208.2(in)-200.7(women)-206.3(and)]TJ
0 -1.128 TD
[(16%)-294.9(lower)-294(risk)-299.7(in)-292.1(men\).)-298.6(Without)-295.2(LBBB,)-296.4(women)-297.7(and)-290.7(men)-296.3(only)]TJ
0 -1.1219 TD
[(had)-296.8(slightly)-301.8(lower)-300.1(mortality)-302.6(risks)-298.8(with)-305.3(CRT-D.)]TJ
/F3 1 Tf
.9999 -1.128 TD
(Conclusions:)Tj
/F4 1 Tf
5.9752 0 TD
[(In)-490.1(both)-493.3(pre-market)-488(and)-491.9(post-market)-492.2(studies,)]TJ
-6.9752 -1.1219 TD
[(CRT-D)-387(was)-395(associated)-392(with)-384.5(a)-394.4(signicantly)-386.2(lower)-391.6(mortality)-388(in)]TJ
0 -1.128 TD
[(women)-291.6(than)-290.2(in)-286(men)-290.2(particularly)-295.6(in)-292.1(the)-290.2(presence)-292.6(of)-288.9(LBBB.)-290.3(This)]TJ
0 -1.1219 TD
[(sex)-552(difference)-553.7(highlights)-557.8(the)-552.4(importance)-555.9(of)-551.1(including)-551.2(more)]TJ
0 -1.128 TD
[(women)-389.2(in)-389.7(clinical)-394.6(trials,)-394.3(and)-388.3(conducting)-391.3(sex-specic)-397.7(analyses)]TJ
0 -1.1219 TD
[(such)-594.7(as)-600.8(these)-598.4(of)-593.8(combined)-598.6(datasets)-601.2(and)-595.6(large)-601.6(post-market)]TJ
0 -1.128 TD
(registries.)Tj
/F3 1 Tf
8.9663 0 0 8.9663 59.7543 749.7069 Tm
(ABSTRACTS)Tj
52.6193 0 TD
(A-35)Tj
ET
endstream
endobj
340 0 obj
<>stream
8;X]O>EqN@%''O_@%e@?J;%+8(9e>X=MR6S?i^YgA3=].HDXF.R$lIL@"pJ+EP(%0
b]6ajmNZn*!='OQZeQ^Y*,=]?C.B+\Ulg9dhD*"iC[;*=3`oP1[!S^)?1)IZ4dup`
E1r!/,*0[*9.aFIR2&b-C#soRZ7Dl%MLY\.?d>Mn
6%Q2oYfNRF$$+ON<+]RUJmC0InDZ4OTs0S!saG>GGKUlQ*Q?45:CI&4J'_2j$XKrcYp0n+Xl_nU*O(
l[$6Nn+Z_Nq0]s7hs]`XX1nZ8&94a\~>
endstream
endobj
342 0 obj
<>stream
htX TWvPTJ
(*(* ȾoM@C;
4*,."M}D1f9֙?9}NSUw}dSSSK-.n[`';29cj=l. ' eTNqSMƘmJ ZgvէוoƫRk{#{bN1Q1>BaaֻֻccDS>XXkkaOLudspD0!~Oߒ`ظ#~>1Sg2Ldbmb1mĞ6 c"1371`2ք4 0yh9j1cy%͆`ڱcO(HMFaKe_[>N;x_`>!x =&%O'N42y}'?2kJԔS^S_~O;2( u܂Zt-*JGO4>G?ePU@O!LJlE 3ތcH lw26#oZ7$f7d5)05(0Cݛ_ vFL{zs,@-`2_OۿFi9 ǂ;'c̱bjW?gPz$$F>Ҳ{ٯP%sf-߮P7{~|;ʏ=⿒qOЖ%qڤ䲃?8g@=%e9Z.[W5j9Ô 7P#XxMtki